https://research-2ry.pages.dev/Concepts/ADC-resistance-mechanisms 2026-07-02T09:20:46.109Z https://research-2ry.pages.dev/Concepts/ALK-G1202R-compound-mutations 2026-07-02T09:20:46.081Z https://research-2ry.pages.dev/Concepts/ALK-TKI-resistance 2026-07-02T09:20:46.122Z https://research-2ry.pages.dev/Concepts/Abscopal-effect 2026-07-02T09:20:46.102Z https://research-2ry.pages.dev/Concepts/Adjuvant-targeted-therapy 2026-07-02T09:20:46.116Z https://research-2ry.pages.dev/Concepts/Avoiding-immune-destruction 2026-07-02T09:20:46.094Z https://research-2ry.pages.dev/Concepts/B-cell-anti-tumor-immunity 2026-07-02T09:20:46.108Z https://research-2ry.pages.dev/Concepts/BBB-disruption-in-brain-metastasis 2026-07-02T09:20:46.113Z https://research-2ry.pages.dev/Concepts/Bispecific-modality-design 2026-07-02T09:20:46.094Z https://research-2ry.pages.dev/Concepts/Bone-metastasis-vicious-cycle 2026-07-02T09:20:46.093Z https://research-2ry.pages.dev/Concepts/Bone-metastasis 2026-07-02T09:20:46.122Z https://research-2ry.pages.dev/Concepts/Brain-met-pre-metastatic-niche 2026-07-02T09:20:46.107Z https://research-2ry.pages.dev/Concepts/Brain-metastasis-clonal-evolution 2026-07-02T09:20:46.118Z https://research-2ry.pages.dev/Concepts/Brain-metastasis-immune-microenvironment 2026-07-02T09:20:46.116Z https://research-2ry.pages.dev/Concepts/CD47-SIRPa-axis 2026-07-02T09:20:46.088Z https://research-2ry.pages.dev/Concepts/CNS-active-TKI-sequencing 2026-07-02T09:20:46.112Z https://research-2ry.pages.dev/Concepts/Cancer-associated-thrombosis 2026-07-02T09:20:46.094Z https://research-2ry.pages.dev/Concepts/Cancer-cachexia 2026-07-02T09:20:46.119Z https://research-2ry.pages.dev/Concepts/Cancer-dormancy 2026-07-02T09:20:46.123Z https://research-2ry.pages.dev/Concepts/Cancer-neuroscience 2026-07-02T09:20:46.099Z https://research-2ry.pages.dev/Concepts/Chromothripsis-ecDNA 2026-07-02T09:20:46.101Z https://research-2ry.pages.dev/Concepts/Clonal-evolution-ITH 2026-07-02T09:20:46.121Z https://research-2ry.pages.dev/Concepts/Compound-mutation-resistance 2026-07-02T09:20:46.116Z https://research-2ry.pages.dev/Concepts/DDR-synthetic-lethality 2026-07-02T09:20:46.103Z https://research-2ry.pages.dev/Concepts/EGFR-C797S-resistance 2026-07-02T09:20:46.085Z https://research-2ry.pages.dev/Concepts/EGFR-T790M-resistance 2026-07-02T09:20:46.089Z https://research-2ry.pages.dev/Concepts/EGFR-exon20-insertion 2026-07-02T09:20:46.103Z https://research-2ry.pages.dev/Concepts/EMT-drug-resistance 2026-07-02T09:20:46.077Z https://research-2ry.pages.dev/Concepts/EMT 2026-07-02T09:20:46.092Z https://research-2ry.pages.dev/Concepts/EV-mediated-intercellular-communication 2026-07-02T09:20:46.093Z https://research-2ry.pages.dev/Concepts/EV-organotropism 2026-07-02T09:20:46.079Z https://research-2ry.pages.dev/Concepts/EV-surface-ligand-signaling 2026-07-02T09:20:46.103Z https://research-2ry.pages.dev/Concepts/Emergency-granulopoiesis 2026-07-02T09:20:46.104Z https://research-2ry.pages.dev/Concepts/Epigenetic-therapy-resistance 2026-07-02T09:20:46.080Z https://research-2ry.pages.dev/Concepts/Exosomal-PD-L1 2026-07-02T09:20:46.084Z https://research-2ry.pages.dev/Concepts/Extracellular-vesicle 2026-07-02T09:20:46.083Z https://research-2ry.pages.dev/Concepts/Ferroptosis-cancer 2026-07-02T09:20:46.120Z https://research-2ry.pages.dev/Concepts/G1202R-solvent-front-resistance 2026-07-02T09:20:46.122Z https://research-2ry.pages.dev/Concepts/Genomic-instability-cancer 2026-07-02T09:20:46.090Z https://research-2ry.pages.dev/Concepts/Granulocytic-MDSC-vs-TAN 2026-07-02T09:20:46.111Z https://research-2ry.pages.dev/Concepts/HLA-system 2026-07-02T09:20:46.114Z https://research-2ry.pages.dev/Concepts/Hallmarks-of-cancer 2026-07-02T09:20:46.080Z https://research-2ry.pages.dev/Concepts/Hypoxia 2026-07-02T09:20:46.119Z https://research-2ry.pages.dev/Concepts/IO-acquired-resistance 2026-07-02T09:20:46.098Z https://research-2ry.pages.dev/Concepts/IO-primary-resistance 2026-07-02T09:20:46.110Z https://research-2ry.pages.dev/Concepts/Immune-checkpoint-beyond-PD1 2026-07-02T09:20:46.099Z https://research-2ry.pages.dev/Concepts/Immunogenic-cell-death 2026-07-02T09:20:46.104Z https://research-2ry.pages.dev/Concepts/Immunosuppressive-myeloid-niche 2026-07-02T09:20:46.125Z https://research-2ry.pages.dev/Concepts/KRAS-co-mutation-landscape 2026-07-02T09:20:46.105Z https://research-2ry.pages.dev/Concepts/Leptomeningeal-metastasis 2026-07-02T09:20:46.111Z https://research-2ry.pages.dev/Concepts/Lineage-plasticity 2026-07-02T09:20:46.095Z https://research-2ry.pages.dev/Concepts/Liquid-biopsy-paradigm 2026-07-02T09:20:46.101Z https://research-2ry.pages.dev/Concepts/MRD-ctDNA-monitoring 2026-07-02T09:20:46.087Z https://research-2ry.pages.dev/Concepts/Metabolic-reprogramming 2026-07-02T09:20:46.096Z https://research-2ry.pages.dev/Concepts/Methylation 2026-07-02T09:20:46.087Z https://research-2ry.pages.dev/Concepts/Microbiome-cancer-immunity 2026-07-02T09:20:46.109Z https://research-2ry.pages.dev/Concepts/NETosis-cancer-metastasis 2026-07-02T09:20:46.083Z https://research-2ry.pages.dev/Concepts/NETosis-thrombosis-axis 2026-07-02T09:20:46.106Z https://research-2ry.pages.dev/Concepts/NK-cell-therapy 2026-07-02T09:20:46.097Z https://research-2ry.pages.dev/Concepts/Neutrophil-EV-cargo-function 2026-07-02T09:20:46.094Z https://research-2ry.pages.dev/Concepts/Neutrophil-IO-biomarker 2026-07-02T09:20:46.111Z https://research-2ry.pages.dev/Concepts/Neutrophil-T-cell-suppression 2026-07-02T09:20:46.119Z https://research-2ry.pages.dev/Concepts/Neutrophil-extracellular-traps 2026-07-02T09:20:46.117Z https://research-2ry.pages.dev/Concepts/Neutrophil-heterogeneity-plasticity 2026-07-02T09:20:46.075Z https://research-2ry.pages.dev/Concepts/Neutrophil-to-lymphocyte-ratio 2026-07-02T09:20:46.078Z https://research-2ry.pages.dev/Concepts/Oligometastatic-disease 2026-07-02T09:20:46.124Z https://research-2ry.pages.dev/Concepts/Oncogene-addiction 2026-07-02T09:20:46.091Z https://research-2ry.pages.dev/Concepts/PM2.5-lung-carcinogenesis 2026-07-02T09:20:46.086Z https://research-2ry.pages.dev/Concepts/Perioperative-IO 2026-07-02T09:20:46.084Z https://research-2ry.pages.dev/Concepts/Peritumor-microenvironment 2026-07-02T09:20:46.103Z https://research-2ry.pages.dev/Concepts/Phenotypic-plasticity-in-cancer 2026-07-02T09:20:46.108Z https://research-2ry.pages.dev/Concepts/Pre-metastatic-niche 2026-07-02T09:20:46.112Z https://research-2ry.pages.dev/Concepts/Precision-oncology 2026-07-02T09:20:46.109Z https://research-2ry.pages.dev/Concepts/Radiation-therapy 2026-07-02T09:20:46.104Z https://research-2ry.pages.dev/Concepts/Reactive-astrocyte-tumor-crosstalk 2026-07-02T09:20:46.120Z https://research-2ry.pages.dev/Concepts/SCLC-molecular-subtypes 2026-07-02T09:20:46.105Z https://research-2ry.pages.dev/Concepts/SRS-ICI-radiation-necrosis 2026-07-02T09:20:46.107Z https://research-2ry.pages.dev/Concepts/Senescence 2026-07-02T09:20:46.106Z https://research-2ry.pages.dev/Concepts/Solvent-front-mutation 2026-07-02T09:20:46.110Z https://research-2ry.pages.dev/Concepts/Spatial-transcriptomics-in-cancer 2026-07-02T09:20:46.106Z https://research-2ry.pages.dev/Concepts/Synthetic-lethality 2026-07-02T09:20:46.088Z https://research-2ry.pages.dev/Concepts/T-cell-exhaustion 2026-07-02T09:20:46.124Z https://research-2ry.pages.dev/Concepts/T790M-mediated-resistance 2026-07-02T09:20:46.100Z https://research-2ry.pages.dev/Concepts/Tertiary-lymphoid-structure 2026-07-02T09:20:46.123Z https://research-2ry.pages.dev/Concepts/Tissue-resident-NK-antitumor 2026-07-02T09:20:46.101Z https://research-2ry.pages.dev/Concepts/Tumor-angiogenesis 2026-07-02T09:20:46.118Z https://research-2ry.pages.dev/Concepts/Tumor-derived-EV-cargo-biology 2026-07-02T09:20:46.121Z https://research-2ry.pages.dev/Concepts/Tumor-immune-microenvironment-classification 2026-07-02T09:20:46.091Z https://research-2ry.pages.dev/Concepts/Tumor-microenvironment 2026-07-02T09:20:46.089Z https://research-2ry.pages.dev/Concepts/Tumor-mutational-burden 2026-07-02T09:20:46.114Z https://research-2ry.pages.dev/Concepts/Tumor-promoting-inflammation 2026-07-02T09:20:46.118Z https://research-2ry.pages.dev/Concepts/Tumor-stroma-interaction 2026-07-02T09:20:46.078Z https://research-2ry.pages.dev/Concepts/Vascular-normalization 2026-07-02T09:20:46.079Z https://research-2ry.pages.dev/Concepts/cancer-immunology 2026-07-02T09:20:46.108Z https://research-2ry.pages.dev/Concepts/irAE-pathophysiology 2026-07-02T09:20:46.081Z https://research-2ry.pages.dev/Entities/CellTypes/AT2-cell 2026-07-02T09:20:46.232Z https://research-2ry.pages.dev/Entities/CellTypes/Aged-neutrophil 2026-07-02T09:20:46.235Z https://research-2ry.pages.dev/Entities/CellTypes/Alveolar-epithelial-cell 2026-07-02T09:20:46.235Z https://research-2ry.pages.dev/Entities/CellTypes/Astrocyte 2026-07-02T09:20:46.216Z https://research-2ry.pages.dev/Entities/CellTypes/B-cell 2026-07-02T09:20:46.229Z https://research-2ry.pages.dev/Entities/CellTypes/Border-associated-macrophage 2026-07-02T09:20:46.219Z https://research-2ry.pages.dev/Entities/CellTypes/CAF 2026-07-02T09:20:46.222Z https://research-2ry.pages.dev/Entities/CellTypes/CAR-T-cell 2026-07-02T09:20:46.227Z https://research-2ry.pages.dev/Entities/CellTypes/CD4-T-helper-cell 2026-07-02T09:20:46.236Z https://research-2ry.pages.dev/Entities/CellTypes/CD8-T-cell 2026-07-02T09:20:46.225Z https://research-2ry.pages.dev/Entities/CellTypes/Cancer-stem-cell 2026-07-02T09:20:46.224Z https://research-2ry.pages.dev/Entities/CellTypes/Choroid-plexus-epithelial-cell 2026-07-02T09:20:46.222Z https://research-2ry.pages.dev/Entities/CellTypes/Circulating-tumor-cell 2026-07-02T09:20:46.237Z https://research-2ry.pages.dev/Entities/CellTypes/Club-cell 2026-07-02T09:20:46.223Z https://research-2ry.pages.dev/Entities/CellTypes/Dendritic-cell 2026-07-02T09:20:46.232Z https://research-2ry.pages.dev/Entities/CellTypes/Drug-tolerant-persister 2026-07-02T09:20:46.230Z https://research-2ry.pages.dev/Entities/CellTypes/Endothelial-cell 2026-07-02T09:20:46.218Z https://research-2ry.pages.dev/Entities/CellTypes/Eosinophil 2026-07-02T09:20:46.228Z https://research-2ry.pages.dev/Entities/CellTypes/Exhausted-CD8-T-cell 2026-07-02T09:20:46.217Z https://research-2ry.pages.dev/Entities/CellTypes/Gamma-delta-T-cell 2026-07-02T09:20:46.231Z https://research-2ry.pages.dev/Entities/CellTypes/Hepatic-stellate-cell 2026-07-02T09:20:46.234Z https://research-2ry.pages.dev/Entities/CellTypes/ILC 2026-07-02T09:20:46.239Z https://research-2ry.pages.dev/Entities/CellTypes/ILC2 2026-07-02T09:20:46.236Z https://research-2ry.pages.dev/Entities/CellTypes/ILC3 2026-07-02T09:20:46.220Z https://research-2ry.pages.dev/Entities/CellTypes/Invariant-NKT-cell 2026-07-02T09:20:46.223Z https://research-2ry.pages.dev/Entities/CellTypes/Kupffer-cell 2026-07-02T09:20:46.240Z https://research-2ry.pages.dev/Entities/CellTypes/Low-density-neutrophil 2026-07-02T09:20:46.240Z https://research-2ry.pages.dev/Entities/CellTypes/MDSC 2026-07-02T09:20:46.229Z https://research-2ry.pages.dev/Entities/CellTypes/Macrophage-TAM 2026-07-02T09:20:46.241Z https://research-2ry.pages.dev/Entities/CellTypes/Mast-cell 2026-07-02T09:20:46.230Z https://research-2ry.pages.dev/Entities/CellTypes/Mesenchymal-stem-cell 2026-07-02T09:20:46.225Z https://research-2ry.pages.dev/Entities/CellTypes/Microglia 2026-07-02T09:20:46.217Z https://research-2ry.pages.dev/Entities/CellTypes/Monocyte 2026-07-02T09:20:46.231Z https://research-2ry.pages.dev/Entities/CellTypes/NK-cell 2026-07-02T09:20:46.215Z https://research-2ry.pages.dev/Entities/CellTypes/Neuroendocrine-cell 2026-07-02T09:20:46.238Z https://research-2ry.pages.dev/Entities/CellTypes/Neutrophil-TAN 2026-07-02T09:20:46.233Z https://research-2ry.pages.dev/Entities/CellTypes/Osteoblast 2026-07-02T09:20:46.228Z https://research-2ry.pages.dev/Entities/CellTypes/Osteoclast 2026-07-02T09:20:46.215Z https://research-2ry.pages.dev/Entities/CellTypes/Pericyte 2026-07-02T09:20:46.237Z https://research-2ry.pages.dev/Entities/CellTypes/Plasma-cell 2026-07-02T09:20:46.220Z https://research-2ry.pages.dev/Entities/CellTypes/Plasmacytoid-dendritic-cell 2026-07-02T09:20:46.213Z https://research-2ry.pages.dev/Entities/CellTypes/Platelet 2026-07-02T09:20:46.224Z https://research-2ry.pages.dev/Entities/CellTypes/Reactive-astrocyte 2026-07-02T09:20:46.221Z https://research-2ry.pages.dev/Entities/CellTypes/Tfh-cell 2026-07-02T09:20:46.218Z https://research-2ry.pages.dev/Entities/CellTypes/Th1-cell 2026-07-02T09:20:46.233Z https://research-2ry.pages.dev/Entities/CellTypes/Th17-cell 2026-07-02T09:20:46.222Z https://research-2ry.pages.dev/Entities/CellTypes/Tpex 2026-07-02T09:20:46.227Z https://research-2ry.pages.dev/Entities/CellTypes/Treg 2026-07-02T09:20:46.241Z https://research-2ry.pages.dev/Entities/CellTypes/Tumor-associated-eosinophil 2026-07-02T09:20:46.216Z https://research-2ry.pages.dev/Entities/CellTypes/Tumor-endothelial-cell 2026-07-02T09:20:46.229Z https://research-2ry.pages.dev/Entities/CellTypes/cDC1 2026-07-02T09:20:46.214Z https://research-2ry.pages.dev/Entities/CellTypes/cDC2 2026-07-02T09:20:46.226Z https://research-2ry.pages.dev/Entities/Cytokines/Arginase-1 2026-07-02T09:20:46.202Z https://research-2ry.pages.dev/Entities/Cytokines/CCL17 2026-07-02T09:20:46.203Z https://research-2ry.pages.dev/Entities/Cytokines/CCL2 2026-07-02T09:20:46.185Z https://research-2ry.pages.dev/Entities/Cytokines/CCL20 2026-07-02T09:20:46.197Z https://research-2ry.pages.dev/Entities/Cytokines/CCL22 2026-07-02T09:20:46.201Z https://research-2ry.pages.dev/Entities/Cytokines/CCL3 2026-07-02T09:20:46.193Z https://research-2ry.pages.dev/Entities/Cytokines/CCL5 2026-07-02T09:20:46.189Z https://research-2ry.pages.dev/Entities/Cytokines/CXCL1 2026-07-02T09:20:46.194Z https://research-2ry.pages.dev/Entities/Cytokines/CXCL12 2026-07-02T09:20:46.196Z https://research-2ry.pages.dev/Entities/Cytokines/CXCL13 2026-07-02T09:20:46.199Z https://research-2ry.pages.dev/Entities/Cytokines/CXCL2 2026-07-02T09:20:46.191Z https://research-2ry.pages.dev/Entities/Cytokines/CXCL5 2026-07-02T09:20:46.206Z https://research-2ry.pages.dev/Entities/Cytokines/CXCL9-10-11 2026-07-02T09:20:46.192Z https://research-2ry.pages.dev/Entities/Cytokines/FasL 2026-07-02T09:20:46.204Z https://research-2ry.pages.dev/Entities/Cytokines/G-CSF 2026-07-02T09:20:50.764Z https://research-2ry.pages.dev/Entities/Cytokines/GM-CSF 2026-07-02T09:20:46.201Z https://research-2ry.pages.dev/Entities/Cytokines/Galectin-9 2026-07-02T09:20:46.211Z https://research-2ry.pages.dev/Entities/Cytokines/Granzyme-B 2026-07-02T09:20:46.186Z https://research-2ry.pages.dev/Entities/Cytokines/HMGB1 2026-07-02T09:20:46.188Z https://research-2ry.pages.dev/Entities/Cytokines/IFN-alpha 2026-07-02T09:20:46.187Z https://research-2ry.pages.dev/Entities/Cytokines/IFN-beta 2026-07-02T09:20:46.188Z https://research-2ry.pages.dev/Entities/Cytokines/IFN-gamma 2026-07-02T09:20:46.207Z https://research-2ry.pages.dev/Entities/Cytokines/IFN-lambda 2026-07-02T09:20:46.211Z https://research-2ry.pages.dev/Entities/Cytokines/IL-1-alpha 2026-07-02T09:20:46.205Z https://research-2ry.pages.dev/Entities/Cytokines/IL-1-beta 2026-07-02T09:20:46.196Z https://research-2ry.pages.dev/Entities/Cytokines/IL-10 2026-07-02T09:20:46.193Z https://research-2ry.pages.dev/Entities/Cytokines/IL-12 2026-07-02T09:20:46.195Z https://research-2ry.pages.dev/Entities/Cytokines/IL-15 2026-07-02T09:20:46.203Z https://research-2ry.pages.dev/Entities/Cytokines/IL-17A 2026-07-02T09:20:46.186Z https://research-2ry.pages.dev/Entities/Cytokines/IL-18 2026-07-02T09:20:46.209Z https://research-2ry.pages.dev/Entities/Cytokines/IL-2 2026-07-02T09:20:46.207Z https://research-2ry.pages.dev/Entities/Cytokines/IL-21 2026-07-02T09:20:46.208Z https://research-2ry.pages.dev/Entities/Cytokines/IL-22 2026-07-02T09:20:46.187Z https://research-2ry.pages.dev/Entities/Cytokines/IL-23 2026-07-02T09:20:46.211Z https://research-2ry.pages.dev/Entities/Cytokines/IL-27 2026-07-02T09:20:46.192Z https://research-2ry.pages.dev/Entities/Cytokines/IL-32 2026-07-02T09:20:46.191Z https://research-2ry.pages.dev/Entities/Cytokines/IL-33 2026-07-02T09:20:46.204Z https://research-2ry.pages.dev/Entities/Cytokines/IL-35 2026-07-02T09:20:46.200Z https://research-2ry.pages.dev/Entities/Cytokines/IL-4 2026-07-02T09:20:46.192Z https://research-2ry.pages.dev/Entities/Cytokines/IL-6-family 2026-07-02T09:20:46.212Z https://research-2ry.pages.dev/Entities/Cytokines/IL-6 2026-07-02T09:20:46.213Z https://research-2ry.pages.dev/Entities/Cytokines/IL-7 2026-07-02T09:20:46.190Z https://research-2ry.pages.dev/Entities/Cytokines/IL-8 2026-07-02T09:20:46.197Z https://research-2ry.pages.dev/Entities/Cytokines/M-CSF 2026-07-02T09:20:46.199Z https://research-2ry.pages.dev/Entities/Cytokines/MIF 2026-07-02T09:20:46.201Z https://research-2ry.pages.dev/Entities/Cytokines/Neutrophil-elastase 2026-07-02T09:20:46.205Z https://research-2ry.pages.dev/Entities/Cytokines/OX40L 2026-07-02T09:20:46.198Z https://research-2ry.pages.dev/Entities/Cytokines/PGE2 2026-07-02T09:20:46.185Z https://research-2ry.pages.dev/Entities/Cytokines/Perforin 2026-07-02T09:20:46.190Z https://research-2ry.pages.dev/Entities/Cytokines/S100A8-A9 2026-07-02T09:20:46.206Z https://research-2ry.pages.dev/Entities/Cytokines/TGF-beta 2026-07-02T09:20:46.209Z https://research-2ry.pages.dev/Entities/Cytokines/TNF-alpha 2026-07-02T09:20:46.189Z https://research-2ry.pages.dev/Entities/Cytokines/TRAIL 2026-07-02T09:20:46.205Z https://research-2ry.pages.dev/Entities/Cytokines/VEGF 2026-07-02T09:20:46.198Z https://research-2ry.pages.dev/Entities/Cytokines/XCL1 2026-07-02T09:20:46.191Z https://research-2ry.pages.dev/Entities/Drugs/ADC 2026-07-02T09:20:46.348Z https://research-2ry.pages.dev/Entities/Drugs/ALK-TKI 2026-07-02T09:20:46.342Z https://research-2ry.pages.dev/Entities/Drugs/AURK-inhibitor 2026-07-02T09:20:46.324Z https://research-2ry.pages.dev/Entities/Drugs/Amivantamab 2026-07-02T09:20:46.347Z https://research-2ry.pages.dev/Entities/Drugs/Anakinra 2026-07-02T09:20:46.326Z https://research-2ry.pages.dev/Entities/Drugs/Antibody-drug-conjugate 2026-07-02T09:20:46.351Z https://research-2ry.pages.dev/Entities/Drugs/Aurora-kinase-inhibitor 2026-07-02T09:20:46.331Z https://research-2ry.pages.dev/Entities/Drugs/BCL-2-inhibitor 2026-07-02T09:20:46.350Z https://research-2ry.pages.dev/Entities/Drugs/BET-inhibitor 2026-07-02T09:20:46.352Z https://research-2ry.pages.dev/Entities/Drugs/BRAF-MEK-inhibitor 2026-07-02T09:20:46.353Z https://research-2ry.pages.dev/Entities/Drugs/Belzutifan 2026-07-02T09:20:46.340Z https://research-2ry.pages.dev/Entities/Drugs/BiTE-bispecific 2026-07-02T09:20:46.345Z https://research-2ry.pages.dev/Entities/Drugs/Bispecific-antibody 2026-07-02T09:20:46.325Z https://research-2ry.pages.dev/Entities/Drugs/CAR-T-therapy 2026-07-02T09:20:46.364Z https://research-2ry.pages.dev/Entities/Drugs/CDK4-6-inhibitor 2026-07-02T09:20:46.340Z https://research-2ry.pages.dev/Entities/Drugs/CTLA-4-inhibitor 2026-07-02T09:20:46.363Z https://research-2ry.pages.dev/Entities/Drugs/Canakinumab 2026-07-02T09:20:46.325Z https://research-2ry.pages.dev/Entities/Drugs/Cancer-vaccine 2026-07-02T09:20:46.343Z https://research-2ry.pages.dev/Entities/Drugs/Corticosteroid 2026-07-02T09:20:46.358Z https://research-2ry.pages.dev/Entities/Drugs/DLL3-targeted-therapy 2026-07-02T09:20:46.327Z https://research-2ry.pages.dev/Entities/Drugs/Datopotamab-deruxtecan 2026-07-02T09:20:46.326Z https://research-2ry.pages.dev/Entities/Drugs/Docetaxel 2026-07-02T09:20:46.343Z https://research-2ry.pages.dev/Entities/Drugs/Durvalumab 2026-07-02T09:20:46.341Z https://research-2ry.pages.dev/Entities/Drugs/EGFR-MET-bispecific 2026-07-02T09:20:46.354Z https://research-2ry.pages.dev/Entities/Drugs/EGFR-TKI 2026-07-02T09:20:46.365Z https://research-2ry.pages.dev/Entities/Drugs/EZH2-inhibitor 2026-07-02T09:20:46.325Z https://research-2ry.pages.dev/Entities/Drugs/Etoposide 2026-07-02T09:20:46.357Z https://research-2ry.pages.dev/Entities/Drugs/FGFR-inhibitor 2026-07-02T09:20:46.364Z https://research-2ry.pages.dev/Entities/Drugs/Gemcitabine 2026-07-02T09:20:50.860Z https://research-2ry.pages.dev/Entities/Drugs/HDAC-inhibitor 2026-07-02T09:20:46.341Z https://research-2ry.pages.dev/Entities/Drugs/HER2-directed-therapy 2026-07-02T09:20:46.334Z https://research-2ry.pages.dev/Entities/Drugs/HER3-directed-therapy 2026-07-02T09:20:46.345Z https://research-2ry.pages.dev/Entities/Drugs/Hypomethylating-agent 2026-07-02T09:20:46.327Z https://research-2ry.pages.dev/Entities/Drugs/Immune-checkpoint-inhibitor 2026-07-02T09:20:46.342Z https://research-2ry.pages.dev/Entities/Drugs/Irinotecan-Topotecan 2026-07-02T09:20:50.868Z https://research-2ry.pages.dev/Entities/Drugs/Ivonescimab 2026-07-02T09:20:46.326Z https://research-2ry.pages.dev/Entities/Drugs/KRAS-G12C-CRISPR-modality 2026-07-02T09:20:46.344Z https://research-2ry.pages.dev/Entities/Drugs/KRAS-G12C-inhibitor 2026-07-02T09:20:46.335Z https://research-2ry.pages.dev/Entities/Drugs/KRAS-G12Ci 2026-07-02T09:20:46.326Z https://research-2ry.pages.dev/Entities/Drugs/LAG-3-inhibitor 2026-07-02T09:20:46.357Z https://research-2ry.pages.dev/Entities/Drugs/Lorlatinib 2026-07-02T09:20:50.876Z https://research-2ry.pages.dev/Entities/Drugs/Lurbinectedin 2026-07-02T09:20:46.356Z https://research-2ry.pages.dev/Entities/Drugs/MET-TKI 2026-07-02T09:20:46.348Z https://research-2ry.pages.dev/Entities/Drugs/Mogamulizumab 2026-07-02T09:20:46.355Z https://research-2ry.pages.dev/Entities/Drugs/NTRK-inhibitor 2026-07-02T09:20:46.337Z https://research-2ry.pages.dev/Entities/Drugs/OX40-agonist 2026-07-02T09:20:46.360Z https://research-2ry.pages.dev/Entities/Drugs/Osimertinib 2026-07-02T09:20:46.360Z https://research-2ry.pages.dev/Entities/Drugs/PARP-inhibitor 2026-07-02T09:20:46.325Z https://research-2ry.pages.dev/Entities/Drugs/PD-1-inhibitor 2026-07-02T09:20:46.346Z https://research-2ry.pages.dev/Entities/Drugs/PD-L1-inhibitor 2026-07-02T09:20:46.366Z https://research-2ry.pages.dev/Entities/Drugs/PI3K-AKT-mTOR-inhibitor 2026-07-02T09:20:46.338Z https://research-2ry.pages.dev/Entities/Drugs/Pemetrexed 2026-07-02T09:20:46.349Z https://research-2ry.pages.dev/Entities/Drugs/Platinum-chemotherapy 2026-07-02T09:20:46.337Z https://research-2ry.pages.dev/Entities/Drugs/RET-inhibitor 2026-07-02T09:20:46.352Z https://research-2ry.pages.dev/Entities/Drugs/ROS1-TKI 2026-07-02T09:20:46.362Z https://research-2ry.pages.dev/Entities/Drugs/Repotrectinib 2026-07-02T09:20:46.355Z https://research-2ry.pages.dev/Entities/Drugs/SHP2-inhibitor 2026-07-02T09:20:46.353Z https://research-2ry.pages.dev/Entities/Drugs/Selpercatinib 2026-07-02T09:20:46.334Z https://research-2ry.pages.dev/Entities/Drugs/TCR-T-therapy 2026-07-02T09:20:46.354Z https://research-2ry.pages.dev/Entities/Drugs/TIGIT-inhibitor 2026-07-02T09:20:46.324Z https://research-2ry.pages.dev/Entities/Drugs/TIL-therapy 2026-07-02T09:20:50.912Z https://research-2ry.pages.dev/Entities/Drugs/Tarlatamab 2026-07-02T09:20:46.356Z https://research-2ry.pages.dev/Entities/Drugs/Taxane 2026-07-02T09:20:46.362Z https://research-2ry.pages.dev/Entities/Drugs/Tucatinib 2026-07-02T09:20:46.345Z https://research-2ry.pages.dev/Entities/Drugs/VEGFR-TKI 2026-07-02T09:20:50.917Z https://research-2ry.pages.dev/Entities/Drugs/Vinorelbine 2026-07-02T09:20:46.358Z https://research-2ry.pages.dev/Entities/Drugs/anti-EGFR-antibody 2026-07-02T09:20:50.923Z https://research-2ry.pages.dev/Entities/Drugs/anti-VEGF-antibody 2026-07-02T09:20:46.359Z https://research-2ry.pages.dev/Entities/Drugs/anti-VEGFR2-antibody 2026-07-02T09:20:46.351Z https://research-2ry.pages.dev/Entities/Drugs/cGAS-STING-agonist 2026-07-02T09:20:46.346Z https://research-2ry.pages.dev/Entities/Drugs/mRNA-vaccine 2026-07-02T09:20:46.361Z https://research-2ry.pages.dev/Entities/Genes/ACKR3 2026-07-02T09:20:46.255Z https://research-2ry.pages.dev/Entities/Genes/ACSS2 2026-07-02T09:20:46.287Z https://research-2ry.pages.dev/Entities/Genes/ADAR1 2026-07-02T09:20:46.279Z https://research-2ry.pages.dev/Entities/Genes/AKT1 2026-07-02T09:20:46.280Z https://research-2ry.pages.dev/Entities/Genes/ALIX 2026-07-02T09:20:46.293Z https://research-2ry.pages.dev/Entities/Genes/ALK 2026-07-02T09:20:46.290Z https://research-2ry.pages.dev/Entities/Genes/APOBEC3B 2026-07-02T09:20:46.256Z https://research-2ry.pages.dev/Entities/Genes/ARID1A 2026-07-02T09:20:46.267Z https://research-2ry.pages.dev/Entities/Genes/ASCL1 2026-07-02T09:20:46.281Z https://research-2ry.pages.dev/Entities/Genes/ATM 2026-07-02T09:20:46.250Z https://research-2ry.pages.dev/Entities/Genes/AXL 2026-07-02T09:20:46.288Z https://research-2ry.pages.dev/Entities/Genes/B2M 2026-07-02T09:20:46.265Z https://research-2ry.pages.dev/Entities/Genes/BAP1 2026-07-02T09:20:46.281Z https://research-2ry.pages.dev/Entities/Genes/BCL2 2026-07-02T09:20:46.291Z https://research-2ry.pages.dev/Entities/Genes/BECN1 2026-07-02T09:20:46.292Z https://research-2ry.pages.dev/Entities/Genes/BRAF 2026-07-02T09:20:46.278Z https://research-2ry.pages.dev/Entities/Genes/BRCA1 2026-07-02T09:20:46.254Z https://research-2ry.pages.dev/Entities/Genes/BRCA2 2026-07-02T09:20:46.266Z https://research-2ry.pages.dev/Entities/Genes/BRD4 2026-07-02T09:20:46.277Z https://research-2ry.pages.dev/Entities/Genes/CASP8 2026-07-02T09:20:46.261Z https://research-2ry.pages.dev/Entities/Genes/CCND1 2026-07-02T09:20:46.293Z https://research-2ry.pages.dev/Entities/Genes/CD44 2026-07-02T09:20:46.257Z https://research-2ry.pages.dev/Entities/Genes/CD63 2026-07-02T09:20:46.281Z https://research-2ry.pages.dev/Entities/Genes/CD81 2026-07-02T09:20:46.255Z https://research-2ry.pages.dev/Entities/Genes/CD9 2026-07-02T09:20:46.275Z https://research-2ry.pages.dev/Entities/Genes/CDH1 2026-07-02T09:20:46.250Z https://research-2ry.pages.dev/Entities/Genes/CDK4 2026-07-02T09:20:46.255Z https://research-2ry.pages.dev/Entities/Genes/CDKN2A 2026-07-02T09:20:46.243Z https://research-2ry.pages.dev/Entities/Genes/CHEK2 2026-07-02T09:20:46.278Z https://research-2ry.pages.dev/Entities/Genes/CREBBP 2026-07-02T09:20:46.291Z https://research-2ry.pages.dev/Entities/Genes/CSF1R 2026-07-02T09:20:46.289Z https://research-2ry.pages.dev/Entities/Genes/CTNNB1 2026-07-02T09:20:46.279Z https://research-2ry.pages.dev/Entities/Genes/CXCR4 2026-07-02T09:20:46.271Z https://research-2ry.pages.dev/Entities/Genes/CXCR5 2026-07-02T09:20:46.261Z https://research-2ry.pages.dev/Entities/Genes/CXCR7 2026-07-02T09:20:46.278Z https://research-2ry.pages.dev/Entities/Genes/DLL3 2026-07-02T09:20:46.281Z https://research-2ry.pages.dev/Entities/Genes/EGFR 2026-07-02T09:20:46.275Z https://research-2ry.pages.dev/Entities/Genes/ERBB3 2026-07-02T09:20:46.273Z https://research-2ry.pages.dev/Entities/Genes/EZH2 2026-07-02T09:20:46.286Z https://research-2ry.pages.dev/Entities/Genes/FGFR1 2026-07-02T09:20:46.290Z https://research-2ry.pages.dev/Entities/Genes/FOXA1 2026-07-02T09:20:46.284Z https://research-2ry.pages.dev/Entities/Genes/FOXP3 2026-07-02T09:20:46.271Z https://research-2ry.pages.dev/Entities/Genes/GPX4 2026-07-02T09:20:46.268Z https://research-2ry.pages.dev/Entities/Genes/HAVCR2 2026-07-02T09:20:46.242Z https://research-2ry.pages.dev/Entities/Genes/HER2 2026-07-02T09:20:46.284Z https://research-2ry.pages.dev/Entities/Genes/HIF1A 2026-07-02T09:20:46.270Z https://research-2ry.pages.dev/Entities/Genes/HLA-A 2026-07-02T09:20:46.261Z https://research-2ry.pages.dev/Entities/Genes/IFNGR1 2026-07-02T09:20:46.294Z https://research-2ry.pages.dev/Entities/Genes/IGF1R 2026-07-02T09:20:46.258Z https://research-2ry.pages.dev/Entities/Genes/JAK1 2026-07-02T09:20:46.252Z https://research-2ry.pages.dev/Entities/Genes/KDM5A 2026-07-02T09:20:46.249Z https://research-2ry.pages.dev/Entities/Genes/KDM6A 2026-07-02T09:20:46.277Z https://research-2ry.pages.dev/Entities/Genes/KEAP1 2026-07-02T09:20:46.244Z https://research-2ry.pages.dev/Entities/Genes/KIT 2026-07-02T09:20:46.268Z https://research-2ry.pages.dev/Entities/Genes/KRAS 2026-07-02T09:20:46.256Z https://research-2ry.pages.dev/Entities/Genes/LAG3 2026-07-02T09:20:46.283Z https://research-2ry.pages.dev/Entities/Genes/LIF 2026-07-02T09:20:46.286Z https://research-2ry.pages.dev/Entities/Genes/MCL1 2026-07-02T09:20:46.270Z https://research-2ry.pages.dev/Entities/Genes/MDM2 2026-07-02T09:20:46.286Z https://research-2ry.pages.dev/Entities/Genes/MER 2026-07-02T09:20:46.281Z https://research-2ry.pages.dev/Entities/Genes/MET 2026-07-02T09:20:46.276Z https://research-2ry.pages.dev/Entities/Genes/MMP9 2026-07-02T09:20:46.243Z https://research-2ry.pages.dev/Entities/Genes/MPO 2026-07-02T09:20:46.283Z https://research-2ry.pages.dev/Entities/Genes/MTAP 2026-07-02T09:20:46.285Z https://research-2ry.pages.dev/Entities/Genes/MUC1 2026-07-02T09:20:46.259Z https://research-2ry.pages.dev/Entities/Genes/MYC 2026-07-02T09:20:46.275Z https://research-2ry.pages.dev/Entities/Genes/MYCN 2026-07-02T09:20:46.249Z https://research-2ry.pages.dev/Entities/Genes/NEUROD1 2026-07-02T09:20:46.257Z https://research-2ry.pages.dev/Entities/Genes/NF1 2026-07-02T09:20:46.282Z https://research-2ry.pages.dev/Entities/Genes/NFE2L2 2026-07-02T09:20:46.284Z https://research-2ry.pages.dev/Entities/Genes/NKX2-1 2026-07-02T09:20:46.248Z https://research-2ry.pages.dev/Entities/Genes/NOTCH1 2026-07-02T09:20:46.272Z https://research-2ry.pages.dev/Entities/Genes/NRAS 2026-07-02T09:20:46.247Z https://research-2ry.pages.dev/Entities/Genes/NRG1 2026-07-02T09:20:46.267Z https://research-2ry.pages.dev/Entities/Genes/NSD3 2026-07-02T09:20:46.264Z https://research-2ry.pages.dev/Entities/Genes/NTRK 2026-07-02T09:20:46.269Z https://research-2ry.pages.dev/Entities/Genes/PAD4 2026-07-02T09:20:46.245Z https://research-2ry.pages.dev/Entities/Genes/PBRM1 2026-07-02T09:20:46.274Z https://research-2ry.pages.dev/Entities/Genes/PD-L1 2026-07-02T09:20:46.244Z https://research-2ry.pages.dev/Entities/Genes/PDGFRA 2026-07-02T09:20:46.260Z https://research-2ry.pages.dev/Entities/Genes/PIK3CA 2026-07-02T09:20:46.268Z https://research-2ry.pages.dev/Entities/Genes/POU2F3 2026-07-02T09:20:46.289Z https://research-2ry.pages.dev/Entities/Genes/PTEN 2026-07-02T09:20:46.287Z https://research-2ry.pages.dev/Entities/Genes/RAGE 2026-07-02T09:20:46.259Z https://research-2ry.pages.dev/Entities/Genes/RB1 2026-07-02T09:20:46.260Z https://research-2ry.pages.dev/Entities/Genes/RET 2026-07-02T09:20:46.261Z https://research-2ry.pages.dev/Entities/Genes/ROS1 2026-07-02T09:20:51.036Z https://research-2ry.pages.dev/Entities/Genes/Rab27 2026-07-02T09:20:46.262Z https://research-2ry.pages.dev/Entities/Genes/SETD2 2026-07-02T09:20:46.279Z https://research-2ry.pages.dev/Entities/Genes/SLC7A11 2026-07-02T09:20:46.243Z https://research-2ry.pages.dev/Entities/Genes/SLFN11 2026-07-02T09:20:46.247Z https://research-2ry.pages.dev/Entities/Genes/SMAD4 2026-07-02T09:20:46.245Z https://research-2ry.pages.dev/Entities/Genes/SMARCA2 2026-07-02T09:20:46.277Z https://research-2ry.pages.dev/Entities/Genes/SMARCA4 2026-07-02T09:20:46.245Z https://research-2ry.pages.dev/Entities/Genes/SMARCB1 2026-07-02T09:20:46.264Z https://research-2ry.pages.dev/Entities/Genes/SOS1 2026-07-02T09:20:46.284Z https://research-2ry.pages.dev/Entities/Genes/SOX2 2026-07-02T09:20:46.262Z https://research-2ry.pages.dev/Entities/Genes/SPP1 2026-07-02T09:20:46.265Z https://research-2ry.pages.dev/Entities/Genes/STAT1 2026-07-02T09:20:46.287Z https://research-2ry.pages.dev/Entities/Genes/STAT3 2026-07-02T09:20:46.251Z https://research-2ry.pages.dev/Entities/Genes/STAT6 2026-07-02T09:20:46.259Z https://research-2ry.pages.dev/Entities/Genes/STK11 2026-07-02T09:20:46.283Z https://research-2ry.pages.dev/Entities/Genes/SUZ12 2026-07-02T09:20:46.295Z https://research-2ry.pages.dev/Entities/Genes/Syntenin 2026-07-02T09:20:46.271Z https://research-2ry.pages.dev/Entities/Genes/TAP1 2026-07-02T09:20:46.294Z https://research-2ry.pages.dev/Entities/Genes/TERT 2026-07-02T09:20:46.259Z https://research-2ry.pages.dev/Entities/Genes/TET2 2026-07-02T09:20:46.254Z https://research-2ry.pages.dev/Entities/Genes/TGFB1 2026-07-02T09:20:46.251Z https://research-2ry.pages.dev/Entities/Genes/TLR4 2026-07-02T09:20:46.280Z https://research-2ry.pages.dev/Entities/Genes/TNFRSF1A 2026-07-02T09:20:46.248Z https://research-2ry.pages.dev/Entities/Genes/TNFRSF4 2026-07-02T09:20:46.278Z https://research-2ry.pages.dev/Entities/Genes/TP53 2026-07-02T09:20:46.294Z https://research-2ry.pages.dev/Entities/Genes/TREM2 2026-07-02T09:20:46.288Z https://research-2ry.pages.dev/Entities/Genes/TROP2 2026-07-02T09:20:46.246Z https://research-2ry.pages.dev/Entities/Genes/TSG101 2026-07-02T09:20:46.264Z https://research-2ry.pages.dev/Entities/Genes/TSPAN8 2026-07-02T09:20:46.258Z https://research-2ry.pages.dev/Entities/Genes/TYRO3 2026-07-02T09:20:46.248Z https://research-2ry.pages.dev/Entities/Genes/Tissue-factor 2026-07-02T09:20:46.249Z https://research-2ry.pages.dev/Entities/Genes/VEGFA 2026-07-02T09:20:46.295Z https://research-2ry.pages.dev/Entities/Methods/ATAC-seq 2026-07-02T09:20:46.154Z https://research-2ry.pages.dev/Entities/Methods/Base-editing 2026-07-02T09:20:46.170Z https://research-2ry.pages.dev/Entities/Methods/Basket-umbrella-platform-trial 2026-07-02T09:20:46.180Z https://research-2ry.pages.dev/Entities/Methods/Bayesian-adaptive-trial-design 2026-07-02T09:20:46.158Z https://research-2ry.pages.dev/Entities/Methods/Bulk-RNA-seq 2026-07-02T09:20:46.155Z https://research-2ry.pages.dev/Entities/Methods/CITE-seq 2026-07-02T09:20:46.184Z https://research-2ry.pages.dev/Entities/Methods/CODEX-PhenoCycler 2026-07-02T09:20:46.182Z https://research-2ry.pages.dev/Entities/Methods/CRISPR-screen 2026-07-02T09:20:46.173Z https://research-2ry.pages.dev/Entities/Methods/ChIP-seq 2026-07-02T09:20:46.160Z https://research-2ry.pages.dev/Entities/Methods/Clinical-trial-design 2026-07-02T09:20:46.154Z https://research-2ry.pages.dev/Entities/Methods/Cryo-EM 2026-07-02T09:20:46.177Z https://research-2ry.pages.dev/Entities/Methods/Cut-and-Tag 2026-07-02T09:20:46.161Z https://research-2ry.pages.dev/Entities/Methods/DNase-I 2026-07-02T09:20:46.169Z https://research-2ry.pages.dev/Entities/Methods/Digital-pathology 2026-07-02T09:20:46.176Z https://research-2ry.pages.dev/Entities/Methods/ELISpot-functional-T-cell-assay 2026-07-02T09:20:46.179Z https://research-2ry.pages.dev/Entities/Methods/EV-isolation-characterization 2026-07-02T09:20:46.163Z https://research-2ry.pages.dev/Entities/Methods/EV-proteomics-cargo-analysis 2026-07-02T09:20:46.158Z https://research-2ry.pages.dev/Entities/Methods/FISH 2026-07-02T09:20:46.170Z https://research-2ry.pages.dev/Entities/Methods/Flow-cytometry-CyTOF 2026-07-02T09:20:46.176Z https://research-2ry.pages.dev/Entities/Methods/Flow-cytometry 2026-07-02T09:20:46.183Z https://research-2ry.pages.dev/Entities/Methods/Foundation-model-pathology 2026-07-02T09:20:46.184Z https://research-2ry.pages.dev/Entities/Methods/GEMM 2026-07-02T09:20:51.100Z https://research-2ry.pages.dev/Entities/Methods/GeoMx-DSP 2026-07-02T09:20:46.167Z https://research-2ry.pages.dev/Entities/Methods/Hi-C-3D-genome 2026-07-02T09:20:46.156Z https://research-2ry.pages.dev/Entities/Methods/Humanized-mouse 2026-07-02T09:20:46.172Z https://research-2ry.pages.dev/Entities/Methods/IMC 2026-07-02T09:20:46.176Z https://research-2ry.pages.dev/Entities/Methods/In-situ-hybridization 2026-07-02T09:20:46.183Z https://research-2ry.pages.dev/Entities/Methods/Lineage-tracing 2026-07-02T09:20:46.174Z https://research-2ry.pages.dev/Entities/Methods/Long-read-RNA-seq 2026-07-02T09:20:46.177Z https://research-2ry.pages.dev/Entities/Methods/Machine-learning-AI 2026-07-02T09:20:46.173Z https://research-2ry.pages.dev/Entities/Methods/Mass-cytometry 2026-07-02T09:20:46.172Z https://research-2ry.pages.dev/Entities/Methods/Mendelian-randomization 2026-07-02T09:20:46.182Z https://research-2ry.pages.dev/Entities/Methods/Metabolomics-LC-MS 2026-07-02T09:20:46.160Z https://research-2ry.pages.dev/Entities/Methods/Methylation-profiling 2026-07-02T09:20:46.178Z https://research-2ry.pages.dev/Entities/Methods/Microfluidic-organ-on-chip 2026-07-02T09:20:46.161Z https://research-2ry.pages.dev/Entities/Methods/Multiome 2026-07-02T09:20:46.157Z https://research-2ry.pages.dev/Entities/Methods/Multiplex-IF-imaging 2026-07-02T09:20:46.178Z https://research-2ry.pages.dev/Entities/Methods/NGS-panel 2026-07-02T09:20:46.168Z https://research-2ry.pages.dev/Entities/Methods/Nanoparticle-LNP 2026-07-02T09:20:46.168Z https://research-2ry.pages.dev/Entities/Methods/Nanoparticle-tracking-analysis 2026-07-02T09:20:46.175Z https://research-2ry.pages.dev/Entities/Methods/Nanopore-long-read 2026-07-02T09:20:46.166Z https://research-2ry.pages.dev/Entities/Methods/Organoid 2026-07-02T09:20:46.155Z https://research-2ry.pages.dev/Entities/Methods/PDX 2026-07-02T09:20:46.171Z https://research-2ry.pages.dev/Entities/Methods/Patient-derived-tumor-fragment 2026-07-02T09:20:46.170Z https://research-2ry.pages.dev/Entities/Methods/Prime-editing 2026-07-02T09:20:46.166Z https://research-2ry.pages.dev/Entities/Methods/Proteomics-mass-spec 2026-07-02T09:20:46.162Z https://research-2ry.pages.dev/Entities/Methods/Proximity-labeling-BioID-APEX 2026-07-02T09:20:46.174Z https://research-2ry.pages.dev/Entities/Methods/Radiomics 2026-07-02T09:20:46.165Z https://research-2ry.pages.dev/Entities/Methods/Real-world-data-analysis 2026-07-02T09:20:46.164Z https://research-2ry.pages.dev/Entities/Methods/Spatial-transcriptomics 2026-07-02T09:20:46.159Z https://research-2ry.pages.dev/Entities/Methods/Syngeneic-model 2026-07-02T09:20:46.175Z https://research-2ry.pages.dev/Entities/Methods/TCR-seq 2026-07-02T09:20:46.181Z https://research-2ry.pages.dev/Entities/Methods/Tissue-clearing-3D-imaging 2026-07-02T09:20:46.173Z https://research-2ry.pages.dev/Entities/Methods/WES-WGS 2026-07-02T09:20:46.180Z https://research-2ry.pages.dev/Entities/Methods/ctDNA-liquid-biopsy 2026-07-02T09:20:46.164Z https://research-2ry.pages.dev/Entities/Methods/ddPCR 2026-07-02T09:20:51.156Z https://research-2ry.pages.dev/Entities/Methods/scATAC-seq 2026-07-02T09:20:46.179Z https://research-2ry.pages.dev/Entities/Methods/scRNA-seq 2026-07-02T09:20:46.162Z https://research-2ry.pages.dev/Entities/Pathways/ALK-ROS1-signaling-pathway 2026-07-02T09:20:46.297Z https://research-2ry.pages.dev/Entities/Pathways/AMPK-LKB1-pathway 2026-07-02T09:20:46.306Z https://research-2ry.pages.dev/Entities/Pathways/Antigen-presentation-pathway 2026-07-02T09:20:46.310Z https://research-2ry.pages.dev/Entities/Pathways/Apoptosis-pathway 2026-07-02T09:20:46.296Z https://research-2ry.pages.dev/Entities/Pathways/Autophagy-pathway 2026-07-02T09:20:46.312Z https://research-2ry.pages.dev/Entities/Pathways/BBB-neurovascular-unit-pathway 2026-07-02T09:20:46.301Z https://research-2ry.pages.dev/Entities/Pathways/COX2-PGE2-pathway 2026-07-02T09:20:46.313Z https://research-2ry.pages.dev/Entities/Pathways/CTLA-4-B7-signaling-pathway 2026-07-02T09:20:46.316Z https://research-2ry.pages.dev/Entities/Pathways/Complement-pathway 2026-07-02T09:20:46.318Z https://research-2ry.pages.dev/Entities/Pathways/DDR-pathway 2026-07-02T09:20:46.306Z https://research-2ry.pages.dev/Entities/Pathways/EGFR-signaling-pathway 2026-07-02T09:20:46.310Z https://research-2ry.pages.dev/Entities/Pathways/Epigenetic-chromatin-remodeling-pathway 2026-07-02T09:20:46.319Z https://research-2ry.pages.dev/Entities/Pathways/Exosome-biogenesis-pathway 2026-07-02T09:20:46.311Z https://research-2ry.pages.dev/Entities/Pathways/Ferroptosis-pathway 2026-07-02T09:20:46.310Z https://research-2ry.pages.dev/Entities/Pathways/HGF-MET-pathway 2026-07-02T09:20:46.321Z https://research-2ry.pages.dev/Entities/Pathways/Hedgehog-pathway 2026-07-02T09:20:46.315Z https://research-2ry.pages.dev/Entities/Pathways/Hippo-Merlin-NF2-pathway 2026-07-02T09:20:46.321Z https://research-2ry.pages.dev/Entities/Pathways/Hippo-YAP-drug-resistance-pathway 2026-07-02T09:20:46.303Z https://research-2ry.pages.dev/Entities/Pathways/Hippo-YAP-pathway 2026-07-02T09:20:46.315Z https://research-2ry.pages.dev/Entities/Pathways/Homologous-recombination-repair-pathway 2026-07-02T09:20:46.316Z https://research-2ry.pages.dev/Entities/Pathways/IL-8-CXCR1-CXCR2-pathway 2026-07-02T09:20:46.299Z https://research-2ry.pages.dev/Entities/Pathways/Interferon-pathway 2026-07-02T09:20:46.304Z https://research-2ry.pages.dev/Entities/Pathways/Itaconate-immunometabolism-pathway 2026-07-02T09:20:46.309Z https://research-2ry.pages.dev/Entities/Pathways/JAK-STAT-pathway 2026-07-02T09:20:46.298Z https://research-2ry.pages.dev/Entities/Pathways/MAPK-RAS-ERK-pathway 2026-07-02T09:20:46.314Z https://research-2ry.pages.dev/Entities/Pathways/MAPK-pathway-resistance 2026-07-02T09:20:46.314Z https://research-2ry.pages.dev/Entities/Pathways/MHC-I-antigen-processing-pathway 2026-07-02T09:20:46.312Z https://research-2ry.pages.dev/Entities/Pathways/Metabolic-reprogramming-pathway 2026-07-02T09:20:46.319Z https://research-2ry.pages.dev/Entities/Pathways/Mismatch-repair-pathway 2026-07-02T09:20:46.322Z https://research-2ry.pages.dev/Entities/Pathways/NF-kB-pathway 2026-07-02T09:20:46.303Z https://research-2ry.pages.dev/Entities/Pathways/NKG2D-MICA-MICB-pathway 2026-07-02T09:20:46.311Z https://research-2ry.pages.dev/Entities/Pathways/NLRP3-inflammasome-pathway 2026-07-02T09:20:46.305Z https://research-2ry.pages.dev/Entities/Pathways/NRF2-KEAP1-pathway 2026-07-02T09:20:46.318Z https://research-2ry.pages.dev/Entities/Pathways/NRF2-pathway 2026-07-02T09:20:46.308Z https://research-2ry.pages.dev/Entities/Pathways/Necroptosis-pathway 2026-07-02T09:20:46.323Z https://research-2ry.pages.dev/Entities/Pathways/Neutrophil-recruitment-activation-pathway 2026-07-02T09:20:46.320Z https://research-2ry.pages.dev/Entities/Pathways/Notch-pathway 2026-07-02T09:20:46.320Z https://research-2ry.pages.dev/Entities/Pathways/Oxidative-phosphorylation-pathway 2026-07-02T09:20:46.317Z https://research-2ry.pages.dev/Entities/Pathways/PD-1-PD-L1-signaling-pathway 2026-07-02T09:20:46.299Z https://research-2ry.pages.dev/Entities/Pathways/PI3K-AKT-mTOR-pathway 2026-07-02T09:20:46.322Z https://research-2ry.pages.dev/Entities/Pathways/PI3K-AKT-pathway 2026-07-02T09:20:46.302Z https://research-2ry.pages.dev/Entities/Pathways/Phagocytosis-checkpoint-pathway 2026-07-02T09:20:46.304Z https://research-2ry.pages.dev/Entities/Pathways/Pyroptosis-inflammasome-pathway 2026-07-02T09:20:46.305Z https://research-2ry.pages.dev/Entities/Pathways/RANK-RANKL-OPG-pathway 2026-07-02T09:20:46.309Z https://research-2ry.pages.dev/Entities/Pathways/RAS-GTPase-cycle-pathway 2026-07-02T09:20:46.296Z https://research-2ry.pages.dev/Entities/Pathways/Rb-E2F-cell-cycle-pathway 2026-07-02T09:20:46.308Z https://research-2ry.pages.dev/Entities/Pathways/Rho-ROCK 2026-07-02T09:20:46.314Z https://research-2ry.pages.dev/Entities/Pathways/Senescence-SASP-pathway 2026-07-02T09:20:46.314Z https://research-2ry.pages.dev/Entities/Pathways/Sphingolipid-S1P-pathway 2026-07-02T09:20:46.301Z https://research-2ry.pages.dev/Entities/Pathways/TGF-beta-pathway 2026-07-02T09:20:46.297Z https://research-2ry.pages.dev/Entities/Pathways/Toll-like-receptor-pathway 2026-07-02T09:20:46.300Z https://research-2ry.pages.dev/Entities/Pathways/Ubiquitin-proteasome-pathway 2026-07-02T09:20:46.295Z https://research-2ry.pages.dev/Entities/Pathways/Unfolded-protein-response-pathway 2026-07-02T09:20:46.299Z https://research-2ry.pages.dev/Entities/Pathways/VEGF-angiogenesis-pathway 2026-07-02T09:20:46.318Z https://research-2ry.pages.dev/Entities/Pathways/WNT-beta-catenin-pathway 2026-07-02T09:20:46.308Z https://research-2ry.pages.dev/Entities/Pathways/Wnt-pathway 2026-07-02T09:20:46.317Z https://research-2ry.pages.dev/Entities/Pathways/cGAMP-intercellular-signaling-pathway 2026-07-02T09:20:46.303Z https://research-2ry.pages.dev/Entities/Pathways/cGAS-STING-pathway 2026-07-02T09:20:46.307Z https://research-2ry.pages.dev/Entities/Pathways/p53-pathway 2026-07-02T09:20:46.307Z https://research-2ry.pages.dev/Entities/Trials/ADAURA 2026-07-02T09:20:46.140Z https://research-2ry.pages.dev/Entities/Trials/ADRIATIC 2026-07-02T09:20:46.146Z https://research-2ry.pages.dev/Entities/Trials/AEGEAN 2026-07-02T09:20:46.132Z https://research-2ry.pages.dev/Entities/Trials/ALEX 2026-07-02T09:20:46.133Z https://research-2ry.pages.dev/Entities/Trials/ALINA 2026-07-02T09:20:46.134Z https://research-2ry.pages.dev/Entities/Trials/ALTA-1L 2026-07-02T09:20:46.128Z https://research-2ry.pages.dev/Entities/Trials/ARROW 2026-07-02T09:20:46.131Z https://research-2ry.pages.dev/Entities/Trials/ASCEND-4 2026-07-02T09:20:46.135Z https://research-2ry.pages.dev/Entities/Trials/AURA3 2026-07-02T09:20:46.144Z https://research-2ry.pages.dev/Entities/Trials/CASPIAN 2026-07-02T09:20:46.136Z https://research-2ry.pages.dev/Entities/Trials/CAURAL 2026-07-02T09:20:46.131Z https://research-2ry.pages.dev/Entities/Trials/CROWN 2026-07-02T09:20:46.153Z https://research-2ry.pages.dev/Entities/Trials/CheckMate-017 2026-07-02T09:20:46.145Z https://research-2ry.pages.dev/Entities/Trials/CheckMate-057 2026-07-02T09:20:46.141Z https://research-2ry.pages.dev/Entities/Trials/CheckMate-227 2026-07-02T09:20:46.134Z https://research-2ry.pages.dev/Entities/Trials/CheckMate-816 2026-07-02T09:20:46.127Z https://research-2ry.pages.dev/Entities/Trials/CheckMate-9LA 2026-07-02T09:20:46.136Z https://research-2ry.pages.dev/Entities/Trials/CodeBreaK-200 2026-07-02T09:20:46.150Z https://research-2ry.pages.dev/Entities/Trials/DESTINY-Lung02 2026-07-02T09:20:46.130Z https://research-2ry.pages.dev/Entities/Trials/DeLLphi-301 2026-07-02T09:20:46.130Z https://research-2ry.pages.dev/Entities/Trials/DeLLphi-304 2026-07-02T09:20:46.146Z https://research-2ry.pages.dev/Entities/Trials/EURTAC 2026-07-02T09:20:46.135Z https://research-2ry.pages.dev/Entities/Trials/FLAURA 2026-07-02T09:20:46.148Z https://research-2ry.pages.dev/Entities/Trials/FLAURA2 2026-07-02T09:20:46.138Z https://research-2ry.pages.dev/Entities/Trials/FLOWERS 2026-07-02T09:20:46.148Z https://research-2ry.pages.dev/Entities/Trials/GEOMETRY-mono-1 2026-07-02T09:20:46.141Z https://research-2ry.pages.dev/Entities/Trials/HARMONi-2 2026-07-02T09:20:46.152Z https://research-2ry.pages.dev/Entities/Trials/IMpower010 2026-07-02T09:20:46.142Z https://research-2ry.pages.dev/Entities/Trials/IMpower133 2026-07-02T09:20:46.147Z https://research-2ry.pages.dev/Entities/Trials/IMpower150 2026-07-02T09:20:46.133Z https://research-2ry.pages.dev/Entities/Trials/IPASS 2026-07-02T09:20:46.128Z https://research-2ry.pages.dev/Entities/Trials/J-ALEX 2026-07-02T09:20:46.150Z https://research-2ry.pages.dev/Entities/Trials/JBR10 2026-07-02T09:20:46.143Z https://research-2ry.pages.dev/Entities/Trials/KEYNOTE-010 2026-07-02T09:20:46.131Z https://research-2ry.pages.dev/Entities/Trials/KEYNOTE-024 2026-07-02T09:20:46.131Z https://research-2ry.pages.dev/Entities/Trials/KEYNOTE-042 2026-07-02T09:20:46.142Z https://research-2ry.pages.dev/Entities/Trials/KEYNOTE-091 2026-07-02T09:20:46.126Z https://research-2ry.pages.dev/Entities/Trials/KEYNOTE-189 2026-07-02T09:20:46.126Z https://research-2ry.pages.dev/Entities/Trials/KEYNOTE-407 2026-07-02T09:20:46.129Z https://research-2ry.pages.dev/Entities/Trials/KEYNOTE-604 2026-07-02T09:20:46.127Z https://research-2ry.pages.dev/Entities/Trials/KEYNOTE-671 2026-07-02T09:20:46.144Z https://research-2ry.pages.dev/Entities/Trials/LACE 2026-07-02T09:20:46.152Z https://research-2ry.pages.dev/Entities/Trials/LAURA 2026-07-02T09:20:46.148Z https://research-2ry.pages.dev/Entities/Trials/LIBRETTO-001 2026-07-02T09:20:46.129Z https://research-2ry.pages.dev/Entities/Trials/LIBRETTO-431 2026-07-02T09:20:46.139Z https://research-2ry.pages.dev/Entities/Trials/LUME-Lung-1 2026-07-02T09:20:46.137Z https://research-2ry.pages.dev/Entities/Trials/LUX-Lung-3 2026-07-02T09:20:46.138Z https://research-2ry.pages.dev/Entities/Trials/LUX-Lung-7 2026-07-02T09:20:46.135Z https://research-2ry.pages.dev/Entities/Trials/MARIPOSA-2 2026-07-02T09:20:46.138Z https://research-2ry.pages.dev/Entities/Trials/MARIPOSA 2026-07-02T09:20:46.149Z https://research-2ry.pages.dev/Entities/Trials/MYSTIC 2026-07-02T09:20:46.147Z https://research-2ry.pages.dev/Entities/Trials/NEJ002-updated-OS 2026-07-02T09:20:46.130Z https://research-2ry.pages.dev/Entities/Trials/NEJ002 2026-07-02T09:20:46.151Z https://research-2ry.pages.dev/Entities/Trials/OAK 2026-07-02T09:20:46.143Z https://research-2ry.pages.dev/Entities/Trials/PACIFIC 2026-07-02T09:20:46.145Z https://research-2ry.pages.dev/Entities/Trials/PAPILLON 2026-07-02T09:20:46.151Z https://research-2ry.pages.dev/Entities/Trials/PARAMOUNT 2026-07-02T09:20:46.153Z https://research-2ry.pages.dev/Entities/Trials/PROFILE-1014 2026-07-02T09:20:46.139Z https://research-2ry.pages.dev/Entities/Trials/RELATIVITY-047 2026-07-02T09:20:46.129Z https://research-2ry.pages.dev/Entities/Trials/RELAY 2026-07-02T09:20:46.132Z https://research-2ry.pages.dev/Entities/Trials/REVEL 2026-07-02T09:20:46.139Z https://research-2ry.pages.dev/Entities/Trials/SAVANNAH 2026-07-02T09:20:46.140Z https://research-2ry.pages.dev/Entities/Trials/TATTON 2026-07-02T09:20:46.127Z https://research-2ry.pages.dev/Entities/Trials/TRACERx 2026-07-02T09:20:46.146Z https://research-2ry.pages.dev/Entities/Trials/TRIDENT-1 2026-07-02T09:20:46.139Z https://research-2ry.pages.dev/Entities/Trials/WJTOG3405 2026-07-02T09:20:46.132Z https://research-2ry.pages.dev/MOCs/cancer-biology 2026-07-02T09:20:46.367Z https://research-2ry.pages.dev/MOCs/cancer-brain-metastasis 2026-07-02T09:20:46.435Z https://research-2ry.pages.dev/MOCs/cancer-extracellular-vesicles 2026-07-02T09:20:46.391Z https://research-2ry.pages.dev/MOCs/cancer-neutrophils 2026-07-02T09:20:46.403Z https://research-2ry.pages.dev/MOCs/lung-cancer-biology 2026-07-02T09:20:46.371Z https://research-2ry.pages.dev/MOCs/lung-cancer-treatment 2026-07-02T09:20:46.415Z https://research-2ry.pages.dev/MOCs/novel-cancer-modalities 2026-07-02T09:20:46.379Z https://research-2ry.pages.dev/MOCs/respiratory-diseases 2026-07-02T09:20:46.411Z https://research-2ry.pages.dev/Outputs/README 2026-07-02T09:20:46.463Z https://research-2ry.pages.dev/Outputs/adc-her2-nsclc-paradigm 2026-07-02T09:20:46.467Z https://research-2ry.pages.dev/Outputs/adc-payload-diversity-ild-management 2026-07-02T09:20:46.467Z https://research-2ry.pages.dev/Outputs/alk-g1202r-compound-mutation-sequencing 2026-07-02T09:20:46.462Z https://research-2ry.pages.dev/Outputs/antigen-presenting-tan-endogenous-t-cell-response 2026-07-02T09:20:46.464Z https://research-2ry.pages.dev/Outputs/bbb-permeability-cns-drug-selection 2026-07-02T09:20:46.466Z https://research-2ry.pages.dev/Outputs/bbb-permeability-prediction-imaging-liquid-biopsy 2026-07-02T09:20:46.461Z https://research-2ry.pages.dev/Outputs/brain-metastasis-srs-io-sequencing 2026-07-02T09:20:46.465Z https://research-2ry.pages.dev/Outputs/car-cell-tme-resilience-engineering 2026-07-02T09:20:46.462Z https://research-2ry.pages.dev/Outputs/egfr-osimertinib-post-resistance-strategy 2026-07-02T09:20:46.464Z https://research-2ry.pages.dev/Outputs/egfr-uncommon-mutation-treatment-selection 2026-07-02T09:20:46.463Z https://research-2ry.pages.dev/Outputs/ev-liquid-biopsy-clinical-implementation 2026-07-02T09:20:46.467Z https://research-2ry.pages.dev/Outputs/hallmarks-of-cancer-overview 2026-07-02T09:20:46.461Z https://research-2ry.pages.dev/Outputs/hpcs-plasticity-hub-preemptive-targeting-translation 2026-07-02T09:20:46.464Z https://research-2ry.pages.dev/Outputs/immunosuppressive-niche-single-target-phase1 2026-07-02T09:20:46.462Z https://research-2ry.pages.dev/Outputs/kl-mutant-io-resistance-combination 2026-07-02T09:20:46.465Z https://research-2ry.pages.dev/Outputs/kras-g12c-crispr-modality-synthesis 2026-07-02T09:20:46.466Z https://research-2ry.pages.dev/Outputs/kras-g12d-druggability-io-resistance 2026-07-02T09:20:46.463Z https://research-2ry.pages.dev/Outputs/lineage-plasticity-pharmacological-lock 2026-07-02T09:20:46.466Z https://research-2ry.pages.dev/Outputs/neoantigen-vaccine-io-clinical-translation 2026-07-02T09:20:46.464Z https://research-2ry.pages.dev/Outputs/net-targeting-anti-metastatic-benefit-risk 2026-07-02T09:20:46.465Z https://research-2ry.pages.dev/Outputs/net-targeting-clinical-translation 2026-07-02T09:20:46.461Z https://research-2ry.pages.dev/Outputs/nets-neutrophil-extracellular-traps-overview 2026-07-02T09:20:46.466Z https://research-2ry.pages.dev/Outputs/neutrophil-ev-overview 2026-07-02T09:20:46.467Z https://research-2ry.pages.dev/Outputs/novel-modality-sequencing-driver-resistance 2026-07-02T09:20:46.463Z https://research-2ry.pages.dev/Outputs/pm2-5-il-1beta-lung-carcinogenesis 2026-07-02T09:20:46.461Z https://research-2ry.pages.dev/Outputs/pmn-ml-signature-liquid-biopsy-prediction 2026-07-02T09:20:46.462Z https://research-2ry.pages.dev/Outputs/sclc-molecular-subtype-treatment-selection 2026-07-02T09:20:46.463Z https://research-2ry.pages.dev/Outputs/tex-hierarchy-citraconate-rescue 2026-07-02T09:20:46.461Z https://research-2ry.pages.dev/Outputs/tumor-neuro-crosstalk-therapeutic-targeting 2026-07-02T09:20:46.464Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/AnnOncol-2012-Brodowicz-Bone-matters-in-lung-cancer 2026-07-02T09:20:49.432Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/AnnOncol-2016-Mansfield-Temporal-and-spatial-discordance-of-programmed-cell-death-ligand-1-expression-and-lymphocyte-tumor-infiltration-between 2026-07-02T09:20:49.443Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/AnnOncol-2019-Kudo-Suppressed-immune-microenvironment-and-repertoire-in-brain-metastases-from-patients-with-resected-NSCLC 2026-07-02T09:20:49.437Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/AnnOncol-2026-Mavrikios-Lung-cancer-brain-metastases-management-at-the-dawn-of-personalized-medicine-are-we-ready-to-break-the-barriers 2026-07-02T09:20:49.445Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/BrJCancer-2026-Skribek-The-brain-lung-immunotherapy-prognostic-(BLIP)-score-a-novel-robust-tool-for-prognostication-in-non-small-cell-lung 2026-07-02T09:20:49.429Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/Cancer-2004-Rosen-Long-term-efficacy-and-safety-of-zoledronic-acid-in-the-treatment-of-skeletal-metastases-in-patients-with-nonsmall-cell 2026-07-02T09:20:49.435Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/CancerCell-2017-Quail-The-microenvironmental-landscape-of-brain-tumors 2026-07-02T09:20:49.427Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/CancerCell-2023-Huang-CD44+-lung-cancer-stem-cell-derived-pericyte-like-cells-cause-brain-metastases-through-GPR124-enhanced 2026-07-02T09:20:49.428Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/CancerCell-2023-Sanchez-Aguilera-Machine-learning-identifies-experimental-brain-metastasis-subtypes-based-on-their-influence-on-neural-circuits 2026-07-02T09:20:49.423Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/CancerCell-2024-Fu-Overcoming-tyrosine-kinase-inhibitor-resistance-in-lung-cancer-brain-metastasis-with-CTLA4-blockade 2026-07-02T09:20:49.440Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/CancerCell-2025-Rodriguez-Baena-Microglial-reprogramming-enhances-antitumor-immunity-and-immunotherapy-response-in-melanoma-brain-metastases 2026-07-02T09:20:49.449Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/CancerCell-2026-Jassowicz-Dissecting-the-cellular-architecture-of-breast-cancer-brain-metastases-reveals-prognostically-distinct-immune-landscapes 2026-07-02T09:20:49.450Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/CancerCell-2026-Yuan-Rethinking-immune-states-in-brain-metastasis 2026-07-02T09:20:49.425Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/CancerDiscov-2026-Ding-Glioblastoma-Secreted-C1QL1-orchestrates-Tumor-microtube-expansion-and-Neural-synaptic-pruning-to-drive-malignant-synapse-Formation-and-recurrence 2026-07-02T09:20:49.436Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/CancerDiscov-2026-Liu-GPNMB-drives-brain-metastasis-by-sculpting-a-pathological-endothelial-immune-interactome 2026-07-02T09:20:49.452Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/CancerDiscov-2026-Liu-Targeting-the-lipid-metabolism-proteins-FASN-and-GPAM-in-alveolar-type-II-cells-decreases-lung-metastasis 2026-07-02T09:20:49.426Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/CancerLett-2013-GarciaRoman-Vascular-permeability-changes-involved-in-tumor-metastasis 2026-07-02T09:20:49.445Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/CancerPathogTher-2024-Liu-Experimental-models-for-cancer-brain-metastasis 2026-07-02T09:20:49.444Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/CancerRes-2009-Yoshimura-Integrin-alpha2-mediates-selective-metastasis-to-the-liver 2026-07-02T09:20:49.435Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/CancerRes-2026-Wang-VGF-Mediated-mitochondrial-remodeling-fuels-lung-adenocarcinoma-brain-metastasis 2026-07-02T09:20:49.448Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/CancerRes-2026-Young-ACSS2-Suppresses-Ferroptosis-to-Drive-Breast-Cancer-Brain-Metastasis 2026-07-02T09:20:49.452Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/Cell-2009-Nguyen-WNTTCF-signaling-through-LEF1-and-HOXB9-mediates-lung-adenocarcinoma-metastasis 2026-07-02T09:20:49.429Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/Cell-2020-Guldner-CNS-native-myeloid-cells-drive-immune-suppression-in-the-brain-metastatic-niche-through-Cxcl10 2026-07-02T09:20:49.450Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/Cell-2022-Biermann-Dissecting-the-treatment-naive-ecosystem-of-human-melanoma-brain-metastasis 2026-07-02T09:20:49.434Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/Cell-2026-Gao-Meningeal-blood-vessel-blockage-enhances-anti-glioblastoma-immunity 2026-07-02T09:20:49.424Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/Cell-2026-Xu-Unbiased-niche-labeling-maps-immune-excluded-niche-in-bone-metastasis 2026-07-02T09:20:49.447Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/CellOncol(Dordr)-2023-Huang-Involvement-of-ACACA-(acetyl-CoA-carboxylase-alpha)-in-the-lung-pre-metastatic-niche-formation-in-breast-cancer-by 2026-07-02T09:20:49.450Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/ClinCancerRes-2020-Eguren-Santamaria-PD-1pd-L1-blockers-in-NSCLC-brain-metastases-challenging-paradigms-and-clinical-practice 2026-07-02T09:20:49.434Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/ClinLungCancer-2020-Karacz-Timing,-sites,-and-correlates-of-lung-cancer-recurrence 2026-07-02T09:20:49.437Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/EBioMedicine-2026-Yu-Tcf1+cd4+-t-cells-and-microglia-co-orchestrate-tertiary-lymphoid-structures-to-enhance-prognosis-and-immunotherapy-in 2026-07-02T09:20:49.442Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/EMBOJ-2023-She-Immune-surveillance-of-brain-metastatic-cancer-cells-is-mediated-by-IFITM1 2026-07-02T09:20:49.453Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/EurJCancer-2020-Page-Systemic-treatment-of-brain-metastases-in-non-small-cell-lung-cancer 2026-07-02T09:20:49.449Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/FEBSJ-2015-Keaney-The-dynamic-blood-brain-barrier 2026-07-02T09:20:49.425Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/FrontCellDevBiol-2020-Gan-Lung-cancer-cells-controlled-dkk-1-production-in-brain-metastatic-cascade-drive-microglia-to-acquire-a-pro-tumorigenic 2026-07-02T09:20:49.439Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/FrontCellNeurosci-2022-Srakocic-Proposed-practical-protocol-for-flow-cytometry-analysis-of-microglia-from-the-healthy-adult-mouse-brain 2026-07-02T09:20:49.430Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/FrontImmunol-2021-Bongiovanni-Immune-checkpoint-inhibitors-with-or-without-bone-targeted-therapy-in-NSCLC-patients-with-bone-metastases-and 2026-07-02T09:20:49.446Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/FrontImmunol-2026-Cai-Mechanistic-and-functional-characterization-of-NETsIL-17-as-a-therapeutic-target-in-EMT-and-brain-metastasis-of-lung 2026-07-02T09:20:49.440Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/FrontOncol-2022-Aili-Tumor-microenvironment-and-exosomes-in-brain-metastasis-molecular-mechanisms-and-clinical-application 2026-07-02T09:20:49.434Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/FrontOncol-2026-Chen-Stereotactic-radiotherapy-for-brain-metastases-indications,-dose-fractionation,-technological-innovations,-and-evolving 2026-07-02T09:20:49.430Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/FrontOncol-2026-Jiang-Advances-in-ommaya-reservoir-based-intrathecal-therapy-for-leptomeningeal-metastasis-from-non-small-cell-lung-cancer-a 2026-07-02T09:20:49.432Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/FrontOncol-2026-Weng-Assessment-of-real-world-surveillance-strategies-for-patients-undergoing-systemic-therapy-for-brain-metastases 2026-07-02T09:20:49.423Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/IntJBiolSci-2026-Wang-USP33-promotes-lung-adenocarcinoma-brain-metastasis-by-inhibiting-the-K48-linked-ubiquitination-and-degradation-of 2026-07-02T09:20:49.444Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/JCIInsight-2026-Maritan-Distinct-immune-landscapes-characterize-highly-versus-minimally-invasive-brain-metastases 2026-07-02T09:20:49.441Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/JCerebBloodFlowMetab-2012-Pardridge-Drug-transport-across-the-blood-brain-barrier 2026-07-02T09:20:49.431Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/JClinOncol-2003-Rosen-Zoledronic-acid-versus-placebo-in-the-treatment-of-skeletal-metastases-in-patients-with-lung-cancer-and-other-solid 2026-07-02T09:20:49.441Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/JClinOncol-2018-Kayama-Effects-of-surgery-with-salvage-stereotactic-radiosurgery-versus-surgery-with-whole-brain-radiation-therapy-in-patients 2026-07-02T09:20:49.427Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/JClinOncol-2020-Brown-Hippocampal-avoidance-during-whole-brain-radiotherapy-plus-memantine-for-patients-with-brain-metastases-phase-III-trial 2026-07-02T09:20:49.440Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/JClinOncol-2026-Lu-Multicenter-cohort-study-of-original-or-substitute-systemic-therapy-with-or-without-brain-radiotherapy-for 2026-07-02T09:20:49.428Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/JImmunotherCancer-2019-Landi-Bone-metastases-and-immunotherapy-in-patients-with-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:49.446Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/JImmunotherCancer-2026-Kojundzic-Targeting-B7-H3-in-patients-with-metastatic-triple-negative-breast-cancer-and-brain-metastases-an-opportunity-to-revive 2026-07-02T09:20:49.439Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/JImmunotherCancer-2026-Zhu-Spatial-immune-atlas-of-breast-cancer-brain-metastasis-reveals-CD163 2026-07-02T09:20:49.438Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/JNatlCancerInst-2026-Dee-Brain-metastases-among-older-people-with-cancer 2026-07-02T09:20:49.447Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/LancetOncol-2016-Goldberg-Pembrolizumab-for-patients-with-melanoma-or-non-small-cell-lung-cancer-and-untreated-brain-metastases-early-analysis-of 2026-07-02T09:20:49.426Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/LancetOncol-2018-Long-Combination-nivolumab-and-ipilimumab-or-nivolumab-alone-in-melanoma-brain-metastases-a-multicentre-randomised-phase-2 2026-07-02T09:20:49.453Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/LungCancer-2019-Gadgeel-Atezolizumab-in-patients-with-advanced-non-small-cell-lung-cancer-and-history-of-asymptomatic,-treated-brain-metastases 2026-07-02T09:20:49.442Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/LungCancer-2022-Friese-Hamim-Brain-penetration-and-efficacy-of-tepotinib-in-orthotopic-patient-derived-xenograft-models-of-MET-driven-non-small-cell 2026-07-02T09:20:49.435Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/MolCancer-2026-Vilarino-NSCLC-brain-metastases-exhibit-reduced-HLA-I-antigen-presentation-machinery-and-immune-evasion-independent-of-IFNgamma 2026-07-02T09:20:49.430Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/NatCancer-2023-Wischnewski-Phenotypic-diversity-of-T-cells-in-human-primary-and-metastatic-brain-tumors-revealed-by-multiomic-interrogation 2026-07-02T09:20:49.438Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/NatCancer-2024-Jakab-Lung-endothelium-exploits-susceptible-tumor-cell-states-to-instruct-metastatic-latency 2026-07-02T09:20:49.446Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/NatCancer-2026-Huang-Leptomeningeal-metastatic-cancer-cells-induce-a-permissive-choroid-plexus-vasculature-through 2026-07-02T09:20:49.427Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/NatCommun-2022-Zhang-The-spatial-transcriptomic-landscape-of-non-small-cell-lung-cancer-brain-metastasis 2026-07-02T09:20:49.433Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/NatCommun-2023-Skakodub-Genomic-analysis-and-clinical-correlations-of-non-small-cell-lung-cancer-brain-metastasis 2026-07-02T09:20:49.427Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/NatCommun-2025-Hill-Molecular-profiling-of-brain-endothelial-cell-to-astrocyte-endfoot-communication-in-mouse-and-human 2026-07-02T09:20:49.433Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/NatCommun-2026-Fox-Brain-FGF2-and-NCAM1-contribute-to-FGFR1-dependent-progression-of-estrogen-receptor-positive-breast-cancer-brain 2026-07-02T09:20:49.436Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/NatCommun-2026-Lin-Complex-i-protein-NDUFB9-is-a-metabolic-vulnerability-in-triple-negative-breast-cancer-brain-metastases 2026-07-02T09:20:49.438Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/NatImmunol-2026-Faust-Astrocyte-driven-immunosuppression-in-the-brain-tumor-microenvironment 2026-07-02T09:20:49.443Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/NatMed-2022-Monteiro-Stratification-of-radiosensitive-brain-metastases-based-on-an-actionable-S100A9RAGE-resistance-mechanism 2026-07-02T09:20:49.432Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/NatMed-2025-Tagore-Single-cell-and-spatial-genomic-landscape-of-non-small-cell-lung-cancer-brain-metastases 2026-07-02T09:20:49.448Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/NatRevCancer-2017-Dewhirst-Transport-of-drugs-from-blood-vessels-to-tumour-tissue 2026-07-02T09:20:49.439Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/NatRevCancer-2017-Peinado-Pre-metastatic-niches-organ-specific-homes-for-metastases 2026-07-02T09:20:49.441Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/NatRevCancer-2020-Boire-Brain-metastasis 2026-07-02T09:20:49.442Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/NatRevCancer-2020-Follain-Fluids-and-their-mechanics-in-tumour-transit-shaping-metastasis 2026-07-02T09:20:49.430Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/NatRevCancer-2021-Bergers-The-metabolism-of-cancer-cells-during-metastasis 2026-07-02T09:20:49.444Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/NatRevCancer-2022-Satcher-Evolving-cancer-niche-interactions-and-therapeutic-targets-during-bone-metastasis 2026-07-02T09:20:49.440Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/NatRevCancer-2024-Rabas-Cancer-induced-systemic-pre-conditioning-of-distant-organs-building-a-niche-for-metastatic-cells 2026-07-02T09:20:49.431Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/NatRevDisPrimers-2019-Achrol-Brain-metastases 2026-07-02T09:20:49.443Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/NatRevImmunol-2025-Kovacs-Immune-control-of-brain-physiology 2026-07-02T09:20:49.433Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/Nature-2009-Bos-Genes-that-mediate-breast-cancer-metastasis-to-the-brain 2026-07-02T09:20:49.439Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/Nature-2025-Doglioni-Aspartate-signalling-drives-lung-metastasis-via-alternative-translation 2026-07-02T09:20:49.423Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/Nature-2026-Wei-Tumour-brain-crosstalk-restrains-cancer-immunity-via-a-sensory-sympathetic-axis 2026-07-02T09:20:49.425Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/NeuroOncol-2026-Voglis-Spatially-resolved-single-cell-imaging-of-melanoma-brain-metastases-identifies-localized-immune-1 2026-07-02T09:20:49.453Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/OncolLett-2026-Li-Advances-in-cerebrospinal-fluid-biomarkers-for-the-diagnosis,-treatment-and-monitoring-of-leptomeningeal-metastases-(Review) 2026-07-02T09:20:49.451Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/ProcNatlAcadSciUSA-2018-Taggart-Anti-PD-1anti-CTLA-4-efficacy-in-melanoma-brain-metastases-depends-on-extracranial-disease-and-augmentation-of-CD8+-T 2026-07-02T09:20:49.424Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/STARProtoc-2025-Wang-Protocol-for-generating-brain-metastatic-tumor-cells-through-repeated-intracardiac-injections-in-mice 2026-07-02T09:20:49.449Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/SciAdv-2026-Yang-Glycerol-mediated-nose-to-brain-codelivery-of-anti-IL-17-and-anti-CD73-antibodies-enhances-immunotherapy-for-melanoma 2026-07-02T09:20:49.447Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/SciSignal-2026-Chafe-Emerging-paradigms-in-the-study-of-brain-metastases 2026-07-02T09:20:49.435Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/SciTranslMed-2021-Singhal-Temporal-multi-omics-identifies-LRG1-as-a-vascular-niche-instructor-of-metastasis 2026-07-02T09:20:51.528Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/Science-2018-Brown-Lymph-node-blood-vessels-provide-exit-routes-for-metastatic-tumor-cell-dissemination-in-mice 2026-07-02T09:20:49.449Z https://research-2ry.pages.dev/Summary/Basic-Brain-metastasis/TrendsCancer-2025-Dunbar-Regulation-of-metastatic-organotropism 2026-07-02T09:20:49.451Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/ACSApplMaterInterfaces-2016-Chen-Imaging-and-intracellular-tracking-of-cancer-derived-exosomes-using-single-molecule-localization-based-super-resolution 2026-07-02T09:20:49.668Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/ACSApplMaterInterfaces-2017-Han-Real-time-imaging-of-endocytosis-and-intracellular-trafficking-of-semiconducting-polymer-dots 2026-07-02T09:20:49.645Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/ACSApplMaterInterfaces-2024-Liu-Cell-specific-impacts-of-surface-coating-composition-on-extracellular-vesicle-secretion 2026-07-02T09:20:49.708Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/ACSNano-2018-Tian-Protein-profiling-and-sizing-of-extracellular-vesicles-from-colorectal-cancer-patients-via-flow-cytometry 2026-07-02T09:20:49.782Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/ACSSens-2026-Jung-Wash-free-digital-detection-of-tumor-extracellular-vesicles-via-plasmonic-droplet-microfluidics 2026-07-02T09:20:49.646Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/AdvSci-2026-Feng-S100A14-in-tumor-derived-evs-targets-PIAS3-to-reprogram-astrocytes-and-induce-immunosuppressive-microenvironment 2026-07-02T09:20:49.803Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/AmJPathol-2012-Deng-Tumor-cell-cross-talk-with-tumor-associated-leukocytes-leads-to-induction-of-tumor-exosomal-fibronectin-and-promotes 2026-07-02T09:20:49.787Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/AmJPathol-2012-DiVizio-Large-oncosomes-in-human-prostate-cancer-tissues-and-in-the-circulation-of-mice-with-metastatic-disease 2026-07-02T09:20:49.776Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/AmJPhysiolCellPhysiol-2023-Wight-V3-An-enigmatic-isoform-of-the-proteoglycan-versican 2026-07-02T09:20:49.737Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/AmJPhysiolCellPhysiol-2026-Schmidt-Extracellular-vesicles-in-exhaled-breath-condensate-as-emerging-biomarkers-in-lung-cancer 2026-07-02T09:20:49.752Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/AmJPhysiolLungCellMolPhysiol-2016-Veerappan-Mast-cells-and-exosomes-in-hyperoxia-induced-neonatal-lung-disease 2026-07-02T09:20:49.809Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/AnalChem-2017-Carney-Multispectral-optical-tweezers-for-biochemical-fingerprinting-of-CD9-positive-exosome-subpopulations 2026-07-02T09:20:49.745Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/AnnOncol-2016-Lucas-Minimally-invasive-genomic-and-transcriptomic-profiling-of-visceral-cancers-by-next-generation-sequencing-of-circulating-exosomes 2026-07-02T09:20:49.665Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/AnnOncol-2018-Castillo-Surfaceome-profiling-enables-isolation-of-cancer-specific-exosomal-cargo-in-liquid-biopsies-from-pancreatic-cancer 2026-07-02T09:20:49.689Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/AnnOncol-2021-Yu-Exosome-based-liquid-biopsies-in-cancer-opportunities-and-challenges 2026-07-02T09:20:49.762Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/AnnuRevBiochem-2019-Pegtel-Exosomes 2026-07-02T09:20:49.696Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/AnnuRevCellDevBiol-2014-Colombo-Biogenesis,-secretion,-and-intercellular-interactions-of-exosomes-and-other-extracellular-vesicles 2026-07-02T09:20:49.686Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/AnnuRevCellDevBiol-2019-Thottacherry-Spoiled-for-choice-diverse-endocytic-pathways-function-at-the-cell-surface 2026-07-02T09:20:49.726Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/AnnuRevPathol-2023-Clancy-Tumor-derived-extracellular-vesicles-multifunctional-entities-in-the-tumor-microenvironment 2026-07-02T09:20:49.653Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/BMCBioinformatics-2023-Jones-Tidyproteomics-An-open-source-R-package-and-data-object-for-quantitative-proteomics-post-analysis-and-visualization 2026-07-02T09:20:49.710Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/BiochemBiophysResCommun-2024-Esmaeili-Metabolically-healthy-unhealthy-obesity-and-breast-cancer 2026-07-02T09:20:49.736Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/BiochemSocTrans-2009-Saksena-ESCRTs-and-human-disease 2026-07-02T09:20:49.696Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/BiochimBiophysActa-1981-Trams-Exfoliation-of-membrane-ecto-enzymes-in-the-form-of-micro-vesicles 2026-07-02T09:20:49.705Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Bioengineering(Basel)-2023-Patel-Extracellular-vesicles-as-regulators-of-the-extracellular-matrix 2026-07-02T09:20:49.797Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/BioinformAdv-2023-Ranathunge-promor-A-comprehensive-R-package-for-label-free-proteomics-data-analysis-and-predictive-modeling 2026-07-02T09:20:49.778Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Biomaterials-2014-Tian-A-doxorubicin-delivery-platform-using-engineered-natural-membrane-vesicle-exosomes-for-targeted-tumor-therapy 2026-07-02T09:20:49.777Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Biomaterials-2022-Shin-Novel-antitumor-therapeutic-strategy-using-CD4+-T-cell-derived-extracellular-vesicles 2026-07-02T09:20:49.699Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/BiomedPharmacother-2024-Zhongyu-Review-of-pre-metastatic-niches-induced-by-osteosarcoma-derived-extracellular-vesicles-in-lung-metastasis-A-potential 2026-07-02T09:20:49.808Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Blood-2004-Morelli-Endocytosis,-intracellular-sorting,-and-processing-of-exosomes-by-dendritic-cells 2026-07-02T09:20:49.802Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/BrJAnaesth-2025-Stephens-Human-neutrophil-derived-extracellular-vesicles-induce-renal-endothelial-inflammation-in-critical-illness-an-ex-vivo 2026-07-02T09:20:49.677Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/BrainRes-2023-Tang-Activated-neutrophil-derived-exosomes-contribute-to-blood-brain-barrier-damage-and-hemorrhagic-transformation-after 2026-07-02T09:20:49.673Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerBiolTher-2017-Yang-Detection-of-mutant-KRAS-and-TP53-DNA-in-circulating-exosomes-from-healthy-individuals-and-patients-with-pancreatic 2026-07-02T09:20:49.735Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerCell-2014-Melo-Cancer-exosomes-perform-cell-independent-microRNA-biogenesis-and-promote-tumorigenesis 2026-07-02T09:20:49.797Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerCell-2014-Zhou-Cancer-secreted-miR-105-destroys-vascular-endothelial-barriers-to-promote-metastasis 2026-07-02T09:20:49.796Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerCell-2016-Becker-Extracellular-vesicles-in-cancer-cell-to-cell-mediators-of-metastasis 2026-07-02T09:20:49.664Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerCell-2016-Liu-Tumor-exosomal-RNAs-promote-lung-pre-metastatic-niche-formation-by-activating-alveolar-epithelial-TLR3-to-recruit 2026-07-02T09:20:49.648Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerCell-2018-Pavlyukov-Apoptotic-cell-derived-extracellular-vesicles-promote-malignancy-of-glioblastoma-via-intercellular-transfer-of-splicing 2026-07-02T09:20:49.721Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerCell-2019-Cooper-Integrin-signaling-in-cancer-Mechanotransduction,-stemness,-epithelial-plasticity,-and-therapeutic-resistance 2026-07-02T09:20:49.794Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerCell-2019-Ortiz-An-interferon-driven-oxysterol-based-defense-against-tumor-derived-extracellular-vesicles 2026-07-02T09:20:49.665Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerCell-2023-Patras-Immune-determinants-of-the-pre-metastatic-niche 2026-07-02T09:20:49.807Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerCell-2024-Casanova-Salas-Circulating-tumor-extracellular-vesicles-to-monitor-metastatic-prostate-cancer-genomics-and-transcriptomic-evolution 2026-07-02T09:20:49.751Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerCell-2026-Dumontet-When-more-target-antigen-expression-is-less 2026-07-02T09:20:49.669Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerCell-2026-Fan-Cancer-stem-cells-orchestrate-immune-evasion-through-extracellular-vesicle-mediated-non-canonical-signaling-pathways 2026-07-02T09:20:49.740Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerCell-2026-Hendrix-Extracellular-vesicles-whisperers-of-tumor-immune-evasion 2026-07-02T09:20:49.700Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerCell-2026-Hu-Activated-T-cell-extracellular-vesicle-DNA-transfer-enhances-antigen-presentation-and-anti-tumor-immunity 2026-07-02T09:20:49.790Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerCell-2026-Ji-T-cell-extracellular-vesicles-go-nuclear-to-turn-cold-tumors-hot 2026-07-02T09:20:49.684Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerCell-2026-Wang-Endocytic-evasion-confers-resistance-to-antibody-drug-conjugates-therapy-in-cancer 2026-07-02T09:20:49.645Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerCellInt-2026-Xue-Tissue-derived-extracellular-vesicles-comparing-ts-EVs-and-te-EVs-in-extraction,-characteristics-and-research-trends 2026-07-02T09:20:49.752Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerImmunolImmunother-2022-Wang-Tumor-derived-exosomes-drive-pre-metastatic-niche-formation-in-lung-via-modulating-CCL1-fibroblast-and-CCR8-Treg-cell-interactions 2026-07-02T09:20:49.740Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerLett-2009-Lima-Tumor-derived-microvesicles-modulate-the-establishment-of-metastatic-melanoma-in-a-phosphatidylserine-dependent-manner 2026-07-02T09:20:49.661Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerLett-2018-Fan-The-emerging-role-of-exosome-derived-non-coding-RNAs-in-cancer-biology 2026-07-02T09:20:49.760Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerLett-2023-Garcia-Fernandez-Exosome-like-systems-Nanotechnology-to-overcome-challenges-for-targeted-cancer-therapies 2026-07-02T09:20:49.690Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerLett-2026-Hudson-Human-neural-stem-cell-derived-extracellular-vesicles-improve-cognitive-function-following-glioma-chemoradiation-therapy 2026-07-02T09:20:49.687Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerRes-2009-DiVizio-Oncosome-formation-in-prostate-cancer-association-with-a-region-of-frequent-chromosomal-deletion-in-metastatic-disease 2026-07-02T09:20:49.784Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerRes-2011-Hood-Exosomes-released-by-melanoma-cells-prepare-sentinel-lymph-nodes-for-tumor-metastasis 2026-07-02T09:20:49.681Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerRes-2012-Bobrie-Rab27a-supports-exosome-dependent-and-independent-mechanisms-that-modify-the-tumor-microenvironment-and-can-promote 2026-07-02T09:20:49.648Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerRes-2017-Minciacchi-MYC-mediates-large-oncosome-induced-fibroblast-reprogramming-in-prostate-cancer 2026-07-02T09:20:49.809Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CancerRes-2017-Ruivo-The-biology-of-cancer-exosomes-insights-and-new-perspectives 2026-07-02T09:20:49.686Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cancers-2020-Park-Detection-of-EGFR-mutations-using-bronchial-washing-derived-extracellular-vesicles-in-patients-with-non-small-cell-lung 2026-07-02T09:20:49.801Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cancers-2020-Semba-Lung-adenocarcinoma-mouse-models-based-on-orthotopic-transplantation-of-syngeneic-tumor-initiating-cells-expressing 2026-07-02T09:20:49.788Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cancers-2020-Wong-Exosomal-microRNAs-and-organotropism-in-breast-cancer-metastasis 2026-07-02T09:20:49.702Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cell-1987-Salminen-A-ras-like-protein-is-required-for-a-post-Golgi-event-in-yeast-secretion 2026-07-02T09:20:49.671Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cell-2001-Katzmann-Ubiquitin-dependent-sorting-into-the-multivesicular-body-pathway-requires-the-function-of-a-conserved-endosomal-protein-sorting-complex-ESCRT-I 2026-07-02T09:20:49.739Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cell-2010-Hurley-Membrane-budding 2026-07-02T09:20:49.676Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cell-2012-Luga-Exosomes-mediate-stromal-mobilization-of-autocrine-Wnt-PCP-signaling-in-breast-cancer-cell-migration 2026-07-02T09:20:49.646Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cell-2014-Boelens-Exosome-transfer-from-stromal-to-breast-cancer-cells-regulates-therapy-resistance-pathways 2026-07-02T09:20:49.658Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cell-2015-Zomer-In-vivo-imaging-reveals-extracellular-vesicle-mediated-phenocopying-of-metastatic-behavior 2026-07-02T09:20:49.757Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cell-2016-Tkach-Communication-by-extracellular-vesicles-where-we-are-and-where-we-need-to-go 2026-07-02T09:20:49.802Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cell-2017-Nabet-Exosome-RNA-unshielding-couples-stromal-activation-to-pattern-recognition-receptor-signaling-in-cancer 2026-07-02T09:20:49.682Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cell-2017-Nager-An-actin-network-dispatches-ciliary-GPCRs-into-extracellular-vesicles-to-modulate-signaling 2026-07-02T09:20:49.654Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cell-2019-Genschmer-Activated-PMN-exosomes-Pathogenic-entities-causing-matrix-destruction-and-disease-in-the-lung 2026-07-02T09:20:49.774Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cell-2019-Jeppesen-Reassessment-of-exosome-composition 2026-07-02T09:20:49.730Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cell-2019-Murillo-exRNA-atlas-analysis-reveals-distinct-extracellular-RNA-cargo-types-and-their-carriers-present-across-human-biofluids 2026-07-02T09:20:49.692Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cell-2019-Poggio-Suppression-of-exosomal-PD-L1-induces-systemic-anti-tumor-immunity-and-memory 2026-07-02T09:20:49.698Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cell-2019-Shurer-Physical-principles-of-membrane-shape-regulation-by-the-glycocalyx 2026-07-02T09:20:49.796Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cell-2020-Cocozza-SnapShot-Extracellular-vesicles 2026-07-02T09:20:49.667Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cell-2020-Hoshino-Suppl1-Extracellular-vesicle-and-particle-biomarkers-define-multiple-human-cancers 2026-07-02T09:20:49.743Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cell-2023-Chhabra-Fibroblasts-in-cancer-Unity-in-heterogeneity 2026-07-02T09:20:49.787Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cell-2023-Kalluri-The-role-of-extracellular-vesicles-in-cancer 2026-07-02T09:20:49.763Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cell-2024-Swanton-Embracing-cancer-complexity-Hallmarks-of-systemic-disease 2026-07-02T09:20:49.781Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cell-2025-Lucotti-Extracellular-vesicles-from-the-lung-pro-thrombotic-niche-drive-cancer-associated-thrombosis-and-metastasis-via 2026-07-02T09:20:49.699Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cell-2026-Chayama-Physiological-brain-clearance-architecture-revealed-by-neuronal-protein-tracing 2026-07-02T09:20:49.778Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CellCommunSignal-2019-Rahbarghazi-Tumor-derived-extracellular-vesicles-Reliable-tools-for-cancer-diagnosis-and-clinical-applications 2026-07-02T09:20:49.767Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CellCommunSignal-2021-Gurung-The-exosome-journey-from-biogenesis-to-uptake-and-intracellular-signalling 2026-07-02T09:20:49.650Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CellDeathDis-2020-Malkin-Bioactive-DNA-from-extracellular-vesicles-and-particles 2026-07-02T09:20:49.695Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CellDeathDis-2021-Wu-TGFb1-mediated-exosomal-lnc-MMP2-2-increases-blood-brain-barrier-permeability-via-the-miRNA-1207-5p-EPB41L5-axis-to-promote-non-small-celllung-cancer-brain-metastasis 2026-07-02T09:20:49.724Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CellDeathDis-2024-Tsering-Extracellular-vesicle-associated-DNA-ten-years-since-its-discovery-in-human-blood 2026-07-02T09:20:49.751Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CellMetab-2019-Goossens-Membrane-cholesterol-efflux-drives-tumor-associated-macrophage-reprogramming-and-tumor-progression 2026-07-02T09:20:49.695Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CellMetab-2021-Crewe-Extracellular-vesicle-based-interorgan-transport-of-mitochondria-from-energetically-stressed-adipocytes 2026-07-02T09:20:49.785Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CellMetab-2021-Isaac-Exosomes-as-mediators-of-intercellular-crosstalk-in-metabolism 2026-07-02T09:20:49.675Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CellMetab-2021-Morrissey-Tumor-derived-exosomes-drive-immunosuppressive-macrophages-in-a-pre-metastatic-niche-through-glycolytic-dominant 2026-07-02T09:20:49.656Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CellMetab-2022-Kudo-Secreted-phospholipase-A2-modifies-extracellular-vesicles-and-accelerates-B-cell-lymphoma 2026-07-02T09:20:49.760Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CellMetab-2023-Wang-Extracellular-vesicles-in-fatty-liver-promote-a-metastatic-tumor-microenvironment 2026-07-02T09:20:49.723Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CellMetab-2025-Li-Liver-breast-communication-of-adipocyte-oriented-exosomes-drives-primary-mammary-cancer-progression 2026-07-02T09:20:49.666Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CellMetab-2025-Xue-Extracellular-vesicles-from-obese-visceral-adipose-promote-pancreatic-cancer-development-and-resistance-to-immune 2026-07-02T09:20:49.690Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CellMolBiolLett-2026-Peng-Lactate-activated-astrocytes-promote-NSCLC-brain-metastasis-through-extracellular-vesicle-mediated-miR-8085trim67elk1 2026-07-02T09:20:49.786Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CellMolLifeSci-2020-Sun-The-SF3b-complex-Splicing-and-beyond 2026-07-02T09:20:49.656Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CellRep-2013-Hoshino-Exosome-secretion-is-enhanced-by-invadopodia-and-drives-invasive-behavior 2026-07-02T09:20:49.764Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CellRep-2014-Squadrito-Endogenous-RNAs-modulate-microRNA-sorting-to-exosomes-and-transfer-to-acceptor-cells 2026-07-02T09:20:49.773Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CellRep-2019-Zhang-Transfer-of-functional-cargo-in-exomeres 2026-07-02T09:20:49.677Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CellRep-2022-Clancy-Recruitment-of-DNA-to-tumor-derived-microvesicles 2026-07-02T09:20:49.652Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CellRep-2024-Deng-Extracellular-vesicle-packaged-S100A11-from-osteosarcoma-cells-mediates-lung-premetastatic-niche-formation-by 2026-07-02T09:20:49.689Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CellRepMed-2026-Zhang-Artificial-exosomes-synergistically-reshape-sepsis-immune-homeostasis-by-modulating-neutrophil-fate-and-blocking 2026-07-02T09:20:49.792Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CellRepMethods-2021-Fitzgerald-A-mouse-model-for-the-study-of-anti-tumor-T-cell-responses-in-Kras-driven-lung-adenocarcinoma 2026-07-02T09:20:49.806Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CellRes-2014-Thakur-Double-stranded-DNA-in-exosomes-a-novel-biomarker-in-cancer-detection 2026-07-02T09:20:49.695Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CellSignal-2025-Tang-N2-neutrophils-induce-cell-stemness-reprogramming-to-promote-gastric-cancer-progression-via-exosomal-miRNAs 2026-07-02T09:20:49.683Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cells-2021-Mosbach-Molecular-determinants-for-RNA-release-into-extracellular-vesicles 2026-07-02T09:20:49.652Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cells-2022-Amorim-Extracellular-vesicles-derived-from-MDA-MB-231-cells-trigger-neutrophils-to-a-pro-tumor-profile 2026-07-02T09:20:49.713Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Cells-2022-Moon-Exosome-as-a-delivery-vehicle-for-cancer-therapy 2026-07-02T09:20:49.696Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/ClinCancerRes-2005-Gutwein-Cleavage-of-L1-in-exosomes-and-apoptotic-membrane-vesicles-released-from-ovarian-carcinoma-cells 2026-07-02T09:20:49.750Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/ClinCancerRes-2015-Javeed-Pancreatic-cancer-derived-exosomes-cause-paraneoplastic-beta-cell-dysfunction 2026-07-02T09:20:49.804Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CommunBiol-2022-Doulabi-Surface-protein-profiling-of-prostate-derived-extracellular-vesicles-by-mass-spectrometry-and-proximity-assays 2026-07-02T09:20:49.692Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CritRevImmunol-2005-Taieb-Dendritic-cell-derived-exosomes-as-cell-free-peptide-based-vaccines 2026-07-02T09:20:49.706Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CurrBiol-2009-Muralidharan-Chari-ARF6-regulated-shedding-of-tumor-cell-derived-plasma-membrane-microvesicles 2026-07-02T09:20:49.780Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CurrOpinCellBiol-2008-Ross-Cargo-transport-Molecular-motors-navigate-a-complex-cytoskeleton 2026-07-02T09:20:49.725Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CurrOpinCellBiol-2009-Simons-Exosomes-vesicular-carriers-for-intercellular-communication 2026-07-02T09:20:49.709Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CurrProtoc-2021-Ma-Characterization-and-functional-analysis-of-tumor-derived-microparticles 2026-07-02T09:20:49.794Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/CurrProtocCellBiol-2006-Thery-Isolation-and-characterization-of-exosomes-from-cell-culture-supernatants-and-biological-fluids 2026-07-02T09:20:49.753Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/DevCell-2002-Babst-ESCRT-III-An-endosome-associated-heterooligomeric-protein-complex-required-for-MVB-sorting 2026-07-02T09:20:49.737Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/DevCell-2008-Teis-Ordered-assembly-of-the-ESCRT-III-complex-on-endosomes-is-required-to-sequester-cargo-during-MVB-formation 2026-07-02T09:20:49.654Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/DevCell-2011-vanNiel-The-tetraspanin-CD63-regulates-ESCRT-independent-and-dependent-endosomal-sorting-during-melanogenesis 2026-07-02T09:20:49.768Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/DevCell-2012-Dowlatshahi-ALIX-is-a-Lys63-specific-polyubiquitin-binding-protein-that-functions-in-retrovirus-budding 2026-07-02T09:20:49.777Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/DevCell-2019-Hyenne-Studying-the-fate-of-tumor-extracellular-vesicles-at-high-spatiotemporal-resolution-using-the-Zebrafish-embryo 2026-07-02T09:20:49.788Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/DevCell-2019-Verweij-Live-tracking-of-inter-organ-communication-by-endogenous-exosomes-in-vivo 2026-07-02T09:20:49.700Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/DevCell-2019-Wortzel-Exosome-mediated-metastasis-Communication-from-a-distance 2026-07-02T09:20:49.645Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/EMBOJ-2000-Gillooly-Localization-of-phosphatidylinositol-3-phosphate-in-yeast-and-mammalian-cells 2026-07-02T09:20:49.782Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/EMBOJ-2001-Raiborg-Hrs-recruits-clathrin-to-early-endosomes 2026-07-02T09:20:49.673Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/EMBOJ-2022-Lucotti-Extracellular-vesicles-and-particles-impact-the-systemic-landscape-of-cancer 2026-07-02T09:20:49.747Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/EMBOJ-2023-Cocozza-Extracellular-vesicles-and-co-isolated-endogenous-retroviruses-from-murine-cancer-cells-differentially-affect-dendritic 2026-07-02T09:20:49.785Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/EMBORep-2021-Matsui-ALIX-and-ceramide-differentially-control-polarized-small-extracellular-vesicle-release-from-epithelial-cells 2026-07-02T09:20:49.675Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/EMBORep-2022-Leger-Functional-platelet-derived-mitochondria-induce-the-release-of-human-neutrophil-microvesicles 2026-07-02T09:20:49.769Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/EurRespirJ-2021-Lucchetti-Detection-and-characterisation-of-extracellular-vesicles-in-exhaled-breath-condensate-and-sputum-of-COPD-and-severe 2026-07-02T09:20:49.774Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/ExpMolMed-2020-Kakarla-Apoptotic-cell-derived-exosomes-Messages-from-dying-cells 2026-07-02T09:20:49.800Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/ExtracellVesiclesCircNuclAcids-2023-Asao-Extracellular-vesicles-and-particles-as-mediators-of-long-range-communication-in-cancer-connecting-biological-function 2026-07-02T09:20:49.682Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/FASEBBioadv-2021-Clancy-The-ins-and-outs-of-microvesicles 2026-07-02T09:20:49.705Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/FluidsBarriersCNS-2022-Ramos-Zaldivar-Extracellular-vesicles-through-the-blood-brain-barrier-a-review 2026-07-02T09:20:49.808Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/FrontCellDevBiol-2021-Jin-Rab-GTPases-Central-coordinators-of-membrane-trafficking-in-cancer 2026-07-02T09:20:49.771Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/FrontImmunol-2022-Allen-Extracellular-vesicles-from-A23187-treated-neutrophils-cause-cGAS-STING-dependent-IL-6-production-by-macrophages 2026-07-02T09:20:49.799Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/FrontImmunol-2026-Chen-Exosomal-POSTN-from-cancer-associated-fibroblasts-drives-progression-of-microinvasive-lung-adenocarcinoma-insights-from 2026-07-02T09:20:49.789Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Gastroenterology-2019-Bernard-Circulating-nucleic-acids-are-associated-with-outcomes-of-patients-with-pancreatic-cancer 2026-07-02T09:20:49.744Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/GenomicsProteomicsBioinformatics-2023-Cun-Specific-regulation-of-m6A-by-SRSF7-promotes-the-progression-of-glioblastoma 2026-07-02T09:20:49.799Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/IntImmunol-2005-Caby-Exosomal-like-vesicles-are-present-in-human-blood-plasma 2026-07-02T09:20:49.673Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/IntImmunopharmacol-2025-Xie-Neutrophil-derived-exosomes-promote-sepsis-related-multiple-organ-dysfunction-through-the-induction-of-neutrophil 2026-07-02T09:20:49.759Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/IntJCancer-2005-Cho-Exosomes-A-new-delivery-system-for-tumor-antigens-in-cancer-immunotherapy 2026-07-02T09:20:49.764Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/IntJMolSci-2020-Kogure-Extracellular-vesicles-in-cancer-metastasis-potential-as-therapeutic-targets-and-materials 2026-07-02T09:20:49.772Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/IntJMolSci-2021-Esposti-Exosomes-from-plasma-of-neuroblastoma-patients-contain-doublestranded-DNA-reflecting-the-muational-status-of-parental-tumor-cells 2026-07-02T09:20:49.791Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/IntJMolSci-2022-Aimaletdinov-Tracking-of-extracellular-vesicles'-biodistribution-new-methods-and-approaches 2026-07-02T09:20:49.731Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/IntJMolSci-2022-Breitwieser-Detailed-characterization-of-small-extracellular-vesicles-from-different-cell-types-based-on-tetraspanin-composition-by 2026-07-02T09:20:49.693Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/IntJMolSci-2023-Ochkasova-Two-edges-in-our-knowledge-on-the-functions-of-ribosomal-proteins-the-revealed-contributions-of-their-regions-to 2026-07-02T09:20:49.806Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JAutoimmun-2022-Glemain-Neutrophil-derived-extracellular-vesicles-induce-endothelial-inflammation-and-damage-through-the-transfer-of-miRNAs 2026-07-02T09:20:49.715Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JBiolChem-1998-Escola-Selective-enrichment-of-tetraspan-proteins-on-the-internal-vesicles-of-multivesicular-endosomes-and-on-exosomes 2026-07-02T09:20:49.697Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JBiolChem-2002-Hales-Rab11-family-interacting-protein-2-associates-with-myosin-Vb-and-regulates-plasma-membrane-recycling 2026-07-02T09:20:49.710Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JBiolChem-2009-Parolini-Microenvironmental-pH-is-a-key-factor-for-exosome-traffic-in-tumor-cells 2026-07-02T09:20:49.800Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JBiolChem-2010-Kosaka-Secretory-mechanisms-and-intercellular-transfer-of-microRNAs-in-living-cells 2026-07-02T09:20:49.694Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JBiolChem-2011-Mayers-ESCRT-0-assembles-as-a-heterotetrameric-complex-on-membranes-and-binds-multiple-ubiquitinylated-cargoes-simultaneously 2026-07-02T09:20:49.693Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JBiolChem-2011-Shen-Protein-targeting-to-exosomesmicrovesicles-by-plasma-membrane-anchors 2026-07-02T09:20:49.761Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JBiolChem-2014-Tian-Exosome-uptake-through-clathrin-mediated-endocytosis-and-macropinocytosis-and-mediating-miR-21-delivery 2026-07-02T09:20:49.734Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JBiolChem-2016-Purushothaman-Fibronectin-on-the-surface-of-myeloma-cell-derived-exosomes-mediates-exosome-cell-interactions 2026-07-02T09:20:49.727Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JCIInsight-2018-Mendt-Generation-and-testing-of-clinical-grade-exosomes-for-pancreatic-cancer 2026-07-02T09:20:49.725Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JCellBiochem-2021-Gorji-Bahri-RAB5A-is-associated-with-genes-involved-in-exosome-secretion-integration-of-bioinformatics-analysis-and-experimental 2026-07-02T09:20:49.728Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JCellBiol-1985-Pan-Electron-microscopic-evidence-for-externalization-of-the-transferrin-receptor-in-vesicular-form-in-sheep-reticulocytes 2026-07-02T09:20:49.659Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JCellBiol-2001-Futter-Human-VPS34-is-required-for-internal-vesicle-formation-within-multivesicular-endosomes 2026-07-02T09:20:49.678Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JCellBiol-2010-Hsu-Regulation-of-exosome-secretion-by-rab35-and-its-GTPase-activating-proteins-TBC1D10A-C 2026-07-02T09:20:49.734Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JCellBiol-2013-Harding-Exosomes-looking-back-three-decades-and-into-the-future 2026-07-02T09:20:49.788Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JCellBiol-2013-Raposo-Extracellular-vesicles-exosomes,-microvesicles,-and-friends 2026-07-02T09:20:49.670Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JCellBiol-2016-Heusermann-Exosomes-surf-on-filopodia-to-enter-cells-at-endocytic-hot-spots,-traffic-within-endosomes,-and-are-targeted-to-the-ER 2026-07-02T09:20:49.799Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JCellBiol-2016-Sinha-Cortactin-promotes-exosome-secretion-by-controlling-branched-actin-dynamics 2026-07-02T09:20:49.688Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JCellBiol-2020-Larios-ALIX-and-ESCRT-III-dependent-sorting-of-tetraspanins-to-exosomes 2026-07-02T09:20:49.698Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JCellPhysiol-2013-Tian-Dynamics-of-exosome-internalization-and-trafficking 2026-07-02T09:20:49.776Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JCellSci-2001-Raiborg-FYVE-and-coiled-coil-domains-determine-the-specific-localisation-of-Hrs-to-early-endosomes 2026-07-02T09:20:49.746Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JCellSci-2006-Raiborg-Flat-clathrin-coats-on-endosomes-mediate-degradative-protein-sorting-by-scaffolding-Hrs-in-dynamic-microdomains 2026-07-02T09:20:49.739Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JCellSci-2013-Colombo-Analysis-of-ESCRT-functions-in-exosome-biogenesis,-composition-and-secretion-highlights-the-heterogeneity-of 2026-07-02T09:20:49.739Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JCellSci-2019-Kim-Deficiency-of-Fhl2-leads-to-delayed-neuronal-cell-migration-and-premature-astrocyte-differentiation 2026-07-02T09:20:49.803Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JCircBiomark-2015-McKelvey-Exosomes-mechanisms-of-uptake 2026-07-02T09:20:49.773Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JClinInvest-2020-Chen-Exosomal-long-noncoding-RNA-LNMAT2-promotes-lymphatic-metastasis-in-bladder-cancer 2026-07-02T09:20:49.774Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JClinInvest-2025-Yang-HIF-1-promotes-murine-breast-cancer-brain-metastasis-by-increasing-production-of-integrin-beta3-containing 2026-07-02T09:20:49.738Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JControlRelease-2015-Saari-Microvesicle-and-exosome-mediated-drug-delivery-enhances-the-cytotoxicity-of-paclitaxel-in-autologous-prostate-cancer-cells 2026-07-02T09:20:49.792Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JControlRelease-2015-Smyth-Biodistribution-and-delivery-efficiency-of-unmodified-tumor-derived-exosomes 2026-07-02T09:20:49.796Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExpClinCancerRes-2026-Pontis-Circulating-extracellular-vesicles-from-early-stage-lung-cancer-patients-trigger-endothelial-activation-to-drive 2026-07-02T09:20:51.748Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExpMed-1996-Raposo-B-lymphocytes-secrete-antigen-presenting-vesicles 2026-07-02T09:20:49.808Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExpMed-2019-Lee-Caveolin-1-selectively-regulates-microRNA-sorting-into-microvesicles-after-noxious-stimuli 2026-07-02T09:20:49.650Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellBiol-2023-Mugoni-Integrating-extracellular-vesicle-and-circulating-cell-free-DNA-analysis-using-a-single-plasma-aliquot-improves-the 2026-07-02T09:20:49.686Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2012-Bobrie-Diverse-subpopulations-of-vesicles-secreted-by-different-intracellular-mechanisms-are-present-in-exosome-preparations 2026-07-02T09:20:49.672Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2012-Choi-Quantitative-proteomics-of-extracellular-vesicles-derived-from-human-primary-and-metastatic-colorectal-cancer-cells 2026-07-02T09:20:49.744Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2013-Bijnsdorp-Exosomal-ITGA3-interferes-with-non-cancerous-prostate-cell-functions-and-is-increased-in-urine-exosomes-of-metastatic 2026-07-02T09:20:49.690Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2013-Yoshioka-Comparative-marker-analysis-of-extracellular-vesicles-in-different-human-cancer-types 2026-07-02T09:20:49.750Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2014-Inder-Cavin-1ptrf-alters-prostate-cancer-cell-derived-extracellular-vesicle-content-and-internalization-to-attenuate 2026-07-02T09:20:49.726Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2014-Mulcahy-Routes-and-mechanisms-of-extracellular-vesicle-uptake 2026-07-02T09:20:49.770Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2015-Aliotta-Lung-derived-exosome-uptake-into-and-epigenetic-modulation-of-marrow-progenitorstem-and-differentiated-cells 2026-07-02T09:20:49.701Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2015-Smith-Single-exosome-study-reveals-subpopulations-distributed-among-cell-lines-with-variability-related-to-membrane-content 2026-07-02T09:20:49.754Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2016-Haraszti-High-resolution-proteomic-and-lipidomic-analysis-of-exosomes-and-microvesicles-from-different-cell-sources 2026-07-02T09:20:49.665Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2018-Guo-Microfluidics-based-on-a-chip-systems-for-isolating-and-analysing-extracellular-vesicles 2026-07-02T09:20:49.698Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2018-Thery-Minimal-information-for-studies-of-extracellular-vesicles-2018-(MISEV2018)-a-position-statement-of-the-international 2026-07-02T09:20:49.681Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2018-Vagner-Large-extracellular-vesicles-carry-most-of-the-tumour-DNA-circulating-in-prostate-cancer-patient-plasma 2026-07-02T09:20:49.795Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2019-Lazaro-Ibanez-DNA-analysis-of-low-and-high-density-fractions-defines-heterogeneous-subpopulations-of-small-extracellular-vesicles 2026-07-02T09:20:49.729Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2020-Fabbiano-RNA-packaging-into-extracellular-vesicles-an-orchestra-of-RNA-binding-proteins 2026-07-02T09:20:49.799Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2020-Mariscal-Comprehensive-palmitoyl-proteomic-analysis-identifies-distinct-protein-signatures-for-large-and-small-cancer-derived 2026-07-02T09:20:49.712Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2021-Kadota-Human-bronchial-epithelial-cell-derived-extracellular-vesicle-therapy-for-pulmonary-fibrosis-via-inhibition-of 2026-07-02T09:20:49.805Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2021-Veerman-Molecular-evaluation-of-five-different-isolation-methods-for-extracellular-vesicles-reveals-different-clinical 2026-07-02T09:20:49.805Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2022-Almeida-Urinary-extracellular-vesicles-contain-mature-transcriptome-enriched-in-circular-and-long-noncoding-RNAs-with 2026-07-02T09:20:49.694Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2022-Jung-Reprogramming-of-T-cell-derived-small-extracellular-vesicles-using-IL2-surface-engineering-induces-potent-anti-cancer 2026-07-02T09:20:49.779Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2022-Leary-Melanoma-derived-extracellular-vesicles-mediate-lymphatic-remodelling-and-impair-tumour-immunity-in-draining-lymph-nodes 2026-07-02T09:20:49.726Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2022-Liu-Extracellular-vesicles-from-lung-tissue-drive-bone-marrow-neutrophil-recruitment-in-inflammation 2026-07-02T09:20:49.655Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2022-Yates-In-sickness-and-in-health-the-functional-role-of-extracellular-vesicles-in-physiology-and-pathology-in-vivo-part-I 2026-07-02T09:20:49.730Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2022-Yates-In-sickness-and-in-health-the-functional-role-of-extracellular-vesicles-in-physiology-and-pathology-in-vivo-part-II 2026-07-02T09:20:49.684Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2023-Blavier-The-capture-of-extracellular-vesicles-endogenously-released-by-xenotransplanted-tumours-induces-an-inflammatory 2026-07-02T09:20:49.663Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2023-Sriwastva-An-extracellular-vesicular-mutant-KRAS-associated-protein-complex-promotes-lung-inflammation-and-tumor-growth 2026-07-02T09:20:49.651Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2023-Su-Tumour-extracellular-vesicles-induce-neutrophil-extracellular-traps-to-promote-lymph-node-metastasis 2026-07-02T09:20:49.731Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2025-Crescitelli-Recommendations-for-studying-in-situ-extracellular-vesicles-from-solid-tissue 2026-07-02T09:20:49.806Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2026-De-Characterizing-the-fate-of-anti-CS1-nanobody-displaying-extracellular-vesicles-in-multiple-myeloma 2026-07-02T09:20:49.678Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2026-Lee-Systemic-propagation-of-STING-signalling-via-generation-of-large-extracellular-vesicles 2026-07-02T09:20:49.798Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2026-Li-Exosomal-oleic-acid-promotes-lymphangiogenesis-and-nodal-metastasis-in-cervical-cancer-via-the-AKTmTOR-pathway 2026-07-02T09:20:49.706Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2026-Ma-Enterococcus-faecalis-extracellular-vesicles-deliver-the-bacterial-GTPase-obg-to-hijack-mTOR-signalling-in 2026-07-02T09:20:49.793Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2026-Seo-Proteomic-profiling-of-human-extracellular-vesicles-reveals-diagnostic-biomarkers-for-colon-adenocarcinoma 2026-07-02T09:20:49.748Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2026-Walther-Therapeutic-poxviruses-induce-the-secretion-of-immunostimulating-and-anti-tumoral-extracellular-vesicles 2026-07-02T09:20:49.681Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2026-Xie-Predictor-a-non-enzymatic-catalytic-cascade-tool-for-in-situ-visualization-of-small-extracellular-vesicle-surface 2026-07-02T09:20:49.793Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JExtracellVesicles-2026-Zhang-In-situ-engineered-cascade-amplified-drug-loaded-vesicles-for-enhanced-cancer-stem-cell-therapy 2026-07-02T09:20:49.798Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JImmunol-2001-Thery-Proteomic-analysis-of-dendritic-cell-derived-exosomes-a-secreted-subcellular-compartment-distinct-from-apoptotic 2026-07-02T09:20:49.809Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JImmunol-2017-Kitai-DNA-containing-exosomes-derived-from-cancer-cells-treated-with-topotecan-activate-a-STING-dependent-pathway-and-reinforce-antitumor-immunity 2026-07-02T09:20:49.786Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JLeukocBiol-2022-Guimaraes-Bastos-Melanoma-derived-extracellular-vesicles-skew-neutrophils-into-a-pro-tumor-phenotype 2026-07-02T09:20:49.759Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JLipidRes-2019-Skotland-Exosomal-lipid-composition-and-the-role-of-ether-lipids-and-phosphoinositides-in-exosome-biology 2026-07-02T09:20:49.652Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JNanobiotechnology-2026-Du-Plant-derived-nanovesicles-the-intelligent-nanoplatforms-for-therapeutics-and-drug-delivery 2026-07-02T09:20:49.755Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JNanobiotechnology-2026-Liu-Overcoming-blood-brain-barrier-and-chemoresistance-in-glioblastoma-by-angiopep-2-modified-NK-cell-derived-extracellular 2026-07-02T09:20:49.750Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JVirol-2009-Tumne-Noncytotoxic-suppression-of-human-immunodeficiency-virus-type-1-transcription-by-exosomes-secreted-from-CD8+-T-cells 2026-07-02T09:20:49.672Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JVisExp-2017-Menck-Isolation-and-characterization-of-microvesicles-from-peripheral-blood 2026-07-02T09:20:49.765Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/JVisExp-2019-Hurwitz-Extraction-of-extracellular-vesicles-from-whole-tissue 2026-07-02T09:20:49.773Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Keire-2017-Versican-Role-in-cancer-tumorigenesis 2026-07-02T09:20:49.770Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Leukemia-2006-Ratajczak-Membrane-derived-microvesicles-Important-and-underappreciated-mediators-of-cell-to-cell-communication 2026-07-02T09:20:49.759Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/MethodMolBiol-2016-Valencia-Microvesicles-isolation,-characterization-for-in-vitro-and-in-vivo-procedures 2026-07-02T09:20:49.649Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/MethodMolBiol-2019-Kuo-Extracellular-Vesicles 2026-07-02T09:20:49.786Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Methods-2020-Mohammadi-Isolation-and-characterization-of-microvesicles-from-mesenchymal-stem-cells 2026-07-02T09:20:49.651Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/MethodsMolBiol-Extracellular-vesicles 2026-07-02T09:20:49.749Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/MolCancer-2022-Han-Exosome-biogenesis-machinery,-regulation,-and-therapeutic-implications-in-cancer 2026-07-02T09:20:49.789Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/MolCancer-2026-Cai-Extracellular-vesicles-in-solid-tumors-from-tumor-ecology-to-engineered-therapeutics 2026-07-02T09:20:49.792Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/MolCancerRes-2021-Xiao-Exosomal-delivery-of-FTO-confers-gefitinib-resistance-to-recipient-cells-through-ABCC10-regulation-in-an-m6a-dependent 2026-07-02T09:20:49.719Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/MolCancerRes-2025-Qiu-Insulin-resistance-increases-TNBC-aggressiveness-and-brain-metastasis-via-adipocyte-derived-exosomes 2026-07-02T09:20:49.706Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/MolCell-2014-Dustin-What-counts-in-the-immunological-synapse 2026-07-02T09:20:49.731Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/MolCell-2019-Tu-PD-L1-(B7-H1)-competes-with-the-RNA-exosome-to-regulate-the-DNA-damage-response-and-can-be-targeted-to-sensitize-to 2026-07-02T09:20:49.775Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/MolTher-2016-Wang-Mesenchymal-stem-cells-deliver-exogenous-microRNA-let7c-via-exosomes-to-attenuate-renal-fibrosis 2026-07-02T09:20:49.664Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/MolTher-2021-Aday-Bioinspired-artificial-exosomes-based-on-lipid-nanoparticles-carrying-let-7b-5p-promote-angiogenesis-in-vitro-and-in 2026-07-02T09:20:49.707Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/MolTher-2023-Frederickson-Extracellular-vesicles-Expanding-the-landscape-for-next-generation-delivery-strategies-in-gene-and-cell-therapy 2026-07-02T09:20:49.738Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/MolTher-2023-Radler-Exploiting-the-biogenesis-of-extracellular-vesicles-for-bioengineering-and-therapeutic-cargo-loading 2026-07-02T09:20:49.757Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NEnglJMed-2015-ODriscoll-Expanding-on-exosomes-and-ectosomes-in-cancer 2026-07-02T09:20:49.748Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Nanomedicine-2011-Dragovic-Sizing-and-phenotyping-of-cellular-vesicles-using-nanoparticle-tracking-analysis 2026-07-02T09:20:49.759Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Nanomedicine-2017-Caponnetto-Size-dependent-cellular-uptake-of-exosomes 2026-07-02T09:20:49.780Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatAging-2026-You-Brain-endothelial-cell-derived-extracellular-vesicles-(c-beevs)-as-a-promising-biomarker-for-brain-vascular-pathology 2026-07-02T09:20:49.722Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatBiomedEng-2026-Tian-Skeletal-muscle-targeted-non-viral-delivery-of-full-length-DMD-mRNA-for-duchenne-muscular-dystrophy 2026-07-02T09:20:49.733Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatBiotechnol-2011-Alvarez-Erviti-Delivery-of-siRNA-to-the-mouse-brain-by-systemic-injection-of-targeted-exosomes 2026-07-02T09:20:51.832Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatBiotechnol-2014-Im-Label-free-detection-and-molecular-profiling-of-exosomes-with-a-nano-plasmonic-sensor 2026-07-02T09:20:49.649Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatBiotechnol-2026-Wen-Spatially-resolved-profiling-of-extracellular-vesicles-in-tissues-with-spatial-EV-seq 2026-07-02T09:20:49.667Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCancer-2021-Garcia-Silva-Melanoma-derived-small-extracellular-vesicles-induce-lymphangiogenesis-and-metastasis-through-an-NGFR-dependent 2026-07-02T09:20:49.779Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCellBiol-2002-Wu-Identification-of-an-organelle-receptor-for-myosin-Va 2026-07-02T09:20:49.783Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCellBiol-2004-Kuroda-Rab27A-binding-protein-Slp2-a-is-required-for-peripheral-melanosome-distribution-and-elongated-cell-shape-in-melanocytes 2026-07-02T09:20:49.797Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCellBiol-2007-Valadi-Exosome-mediated-transfer-of-mRNAs-and-microRNAs-is-a-novel-mechanism-of-genetic-exchange-between-cells 2026-07-02T09:20:49.795Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCellBiol-2008-Al-Nedawi-Intercellular-transfer-of-the-oncogenic-receptor-EGFRvIII-by-microvesicles-derived-from-tumour-cells 2026-07-02T09:20:49.717Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCellBiol-2008-Skog-Glioblastoma-microvesicles-transport-RNA-and-proteins-that-promote-tumour-growth-and-provide-diagnostic-biomarkers 2026-07-02T09:20:49.767Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCellBiol-2010-Ostrowski-Rab27a-and-Rab27b-control-different-steps-of-the-exosome-secretion-pathway 2026-07-02T09:20:49.676Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCellBiol-2012-Baietti-Syndecan-syntenin-ALIX-regulates-the-biogenesis-of-exosomes 2026-07-02T09:20:49.693Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCellBiol-2015-Costa-Silva-Pancreatic-cancer-exosomes-initiate-pre-metastatic-niche-formation-in-the-liver 2026-07-02T09:20:49.688Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCellBiol-2015-Fong-Breast-cancer-secreted-miR-122-reprograms-glucose-metabolism-in-premetastatic-niche-to-promote-metastasis 2026-07-02T09:20:49.670Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCellBiol-2018-Yan-Cancer-cell-secreted-exosomal-miR-105-promotes-tumour-growth-through-the-MYC-dependent-metabolic-reprogramming-of 2026-07-02T09:20:49.657Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCellBiol-2018-Zhang-Identification-of-distinct-nanoparticles-and-subsets-of-extracellular-vesicles-by-asymmetric-flow-field-flow 2026-07-02T09:20:49.802Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCellBiol-2018-Zijlstra-Size-matters-in-nanoscale-communication 2026-07-02T09:20:49.676Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCellBiol-2019-Chen-Extracellular-vesicle-packaged-HIF-1alpha-stabilizing-lncRNA-from-tumour-associated-macrophages-regulates-aerobic 2026-07-02T09:20:49.766Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCellBiol-2019-Clancy-An-ARF6-Exportin-5-axis-delivers-pre-miRNA-cargo-to-tumour-microvesicles 2026-07-02T09:20:49.811Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCellBiol-2019-Keklikoglou-Chemotherapy-elicits-pro-metastatic-extracellular-vesicles-in-breast-cancer-models 2026-07-02T09:20:49.658Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCellBiol-2019-Mathieu-Specificities-of-secretion-and-uptake-of-exosomes-and-other-extracellular-vesicles-for-cell-to-cell-communication 2026-07-02T09:20:49.703Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCellBiol-2019-Rodrigues-Tumour-exosomal-CEMIP-protein-promotes-cancer-cell-colonization-in-brain-metastasis 2026-07-02T09:20:49.722Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCellBiol-2020-Leidal-The-LC3-conjugation-machinery-specifies-the-loading-of-RNA-binding-proteins-into-extracellular-vesicles 2026-07-02T09:20:49.682Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCellBiol-2020-Rak-L(C3)icensing-of-exosomes-for-RNA-export 2026-07-02T09:20:49.786Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCellBiol-2021-Clancy-Profiling-and-promise-of-supermeres 2026-07-02T09:20:49.760Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCellBiol-2021-Kugeratski-Quantitative-proteomics-identifies-the-core-proteome-of-exosomes-with-syntenin-1-as-the-highest-abundant-protein-and-a 2026-07-02T09:20:49.743Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCellBiol-2021-Zhang-Supermeres-are-functional-extracellular-nanoparticles-replete-with-disease-biomarkers-and-therapeutic-targets 2026-07-02T09:20:49.732Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCellBiol-2022-Arya-Ceramide-rich-microdomains-facilitate-nuclear-envelope-budding-for-non-conventional-exosome-formation 2026-07-02T09:20:49.701Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCellBiol-2024-Palmulli-CD63-sorts-cholesterol-into-endosomes-for-storage-and-distribution-via-exosomes 2026-07-02T09:20:49.735Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCellBiol-2025-Arya-Neutrophils-secrete-exosome-associated-DNA-to-resolve-sterile-acute-inflammation 2026-07-02T09:20:49.801Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2011-Mittelbrunn-Unidirectional-transfer-of-microRNA-loaded-exosomes-from-T-cells-to-antigen-presenting-cells 2026-07-02T09:20:49.687Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2013-Villarroya-Beltri-Sumoylated-hnRNPA2B1-controls-the-sorting-of-miRNAs-into-exosomes-through-binding-to-specific-motifs 2026-07-02T09:20:49.758Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2015-Clancy-Regulated-delivery-of-molecular-cargo-to-invasive-tumour-derived-microvesicles 2026-07-02T09:20:49.805Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2015-Tominaga-Brain-metastatic-cancer-cells-release-microRNA-181c-containing-extracellular-vesicles-capable-of-destructing 2026-07-02T09:20:49.761Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2016-Yim-Exosome-engineering-for-efficient-intracellular-delivery-of-soluble-proteins-using-optically-reversible-protein-protein 2026-07-02T09:20:49.700Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2017-Takahashi-Exosomes-maintain-cellular-homeostasis-by-excreting-harmful-DNA-from-cells 2026-07-02T09:20:49.777Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2017-Wang-Plasma-membrane-derived-extracellular-microvesicles-mediate-non-canonical-intercellular-NOTCH-signaling 2026-07-02T09:20:49.648Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2017-Wei-Coding-and-noncoding-landscape-of-extracellular-RNA-released-by-human-glioma-stem-cells 2026-07-02T09:20:49.732Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2017-Zhang-Exosome-delivered-EGFR-regulates-liver-microenvironment-to-promote-gastric-cancer-liver-metastasis 2026-07-02T09:20:49.659Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2018-Cooks-Mutant-p53-cancers-reprogram-macrophages-to-tumor-supporting-macrophages-via-exosomal-miR-1246 2026-07-02T09:20:49.755Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2018-Kojima-Designer-exosomes-produced-by-implanted-cells-intracerebrally-deliver-therapeutic-cargo-for-parkinson's-disease 2026-07-02T09:20:49.737Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2018-Madeo-Cancer-exosomes-induce-tumor-innervation 2026-07-02T09:20:49.756Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2018-Wenzel-Concerted-ESCRT-and-clathrin-recruitment-waves-define-the-timing-and-morphology-of-intraluminal-vesicle-formation 2026-07-02T09:20:49.689Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2018-Zeng-Cancer-derived-exosomal-miR-25-3p-promotes-pre-metastatic-niche-formation-by-inducing-vascular-permeability-and-angiogenetis 2026-07-02T09:20:49.684Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2019-Song-KIBRA-controls-exosome-secretion-via-inhibiting-the-proteasomal-degradation-of-Rab27a 2026-07-02T09:20:49.692Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2019-Wu-Profiling-surface-proteins-on-individual-exosomes-using-a-proximity-barcoding-assay 2026-07-02T09:20:49.732Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2020-Bertin-Human-ESCRT-III-polymers-assemble-on-positively-curved-membranes-and-induce-helical-membrane-tube-formation 2026-07-02T09:20:49.748Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2020-Ji-Primary-tumors-release-ITGBL1-rich-extracellular-vesicles-to-promote-distal-metastatic-tumor-growth-through 2026-07-02T09:20:49.742Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2021-An-An-active-tethering-mechanism-controls-the-fate-of-vesicles 2026-07-02T09:20:51.888Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2021-Lima-Tumor-microenvironmental-cytokines-bound-to-cancer-exosomes-determine-uptake-by-cytokine-receptor-expressing-cells-and 2026-07-02T09:20:49.810Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2021-Mathieu-Specificities-of-exosome-versus-small-ectosome-secretion-revealed-by-live-intracellular-tracking-of-CD63-and-CD9 2026-07-02T09:20:49.705Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2022-El-Shennawy-Circulating-ACE2-expressing-extracellular-vesicles-block-broad-strains-of-SARS-CoV-2 2026-07-02T09:20:49.799Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2022-Qi-Lin28B-high-breast-cancer-cells-promote-immune-suppression-in-the-lung-pre-metastatic-niche-via-exosomes-and-support 2026-07-02T09:20:49.807Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2022-Wedge-Virally-programmed-extracellular-vesicles-sensitize-cancer-cells-to-oncolytic-virus-and-small-molecule-therapy 2026-07-02T09:20:49.766Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2022-Xie-Breast-cancer-cell-derived-extracellular-vesicles-promote-CD8+-T-cell-exhaustion-via-TGF-beta-type-II-receptor-signaling 2026-07-02T09:20:49.662Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2025-Son-Fusogenic-lipid-nanoparticles-for-rapid-delivery-of-large-therapeutic-molecules-to-exosomes 2026-07-02T09:20:49.747Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2025-Yu-Defective-neutrophil-derived-exosomes-facilitate-macrophage-activation-through-miR-122-5p-in-Behcet's-disease 2026-07-02T09:20:49.804Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2026-Goh-Sarcopenia-promotes-tumorigenesis-by-disrupting-NOTCH-SDC2-regulated-biogenesis-of-muscle-derived-extracellular-vesicles 2026-07-02T09:20:49.744Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatCommun-2026-Shen-Co-enrichment-of-proteins-in-extracellular-vesicles 2026-07-02T09:20:49.790Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatMater-2023-Shin-Curvature-sensing-peptide-inhibits-tumour-derived-exosomes-for-enhanced-cancer-immunotherapy 2026-07-02T09:20:49.762Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatMater-2024-Gong-Tumour-derived-small-extracellular-vesicles-act-as-a-barrier-to-therapeutic-nanoparticle-delivery 2026-07-02T09:20:49.708Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatMed-1998-Zitvogel-Eradication-of-established-murine-tumors-using-a-novel-cell-free-vaccine-dendritic-cell-derived-exosomes 2026-07-02T09:20:49.666Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatMed-2001-Wolfers-Tumor-derived-exosomes-are-a-source-of-shared-tumor-rejection-antigens-for-CTL-cross-priming 2026-07-02T09:20:49.749Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatMed-2012-Peinado-Melanoma-exosomes-educate-bone-marrow-progenitor-cells-toward-a-pro-metastatic-phenotype-through-MET 2026-07-02T09:20:49.763Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatMed-2017-Romero-Keap1-loss-promotes-Kras-driven-lung-cancer-and-results-in-dependence-on-glutaminolysis 2026-07-02T09:20:49.758Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatMethods-2017-VanDeun-EV-TRACK-transparent-reporting-and-centralizing-knowledge-in-extracellular-vesicle-research 2026-07-02T09:20:49.670Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatMethods-2019-Gupta-Non-reversible-tissue-fixation-retains-extracellular-vesicles-for-in-situ-imaging 2026-07-02T09:20:49.790Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatMethods-2021-Verweij-The-power-of-imaging-to-understand-extracellular-vesicle-biology-in-vivo 2026-07-02T09:20:49.666Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatMethods-2022-Spackova-Label-free-nanofluidic-scattering-microscopy-of-size-and-mass-of-single-diffusing-molecules-and-nanoparticles 2026-07-02T09:20:49.646Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatNanotechnol-2021-Herrmann-Extracellular-vesicles-as-a-next-generation-drug-delivery-platform 2026-07-02T09:20:49.746Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatNeurosci-2026-Liang-Microglial-mitochondria-transfer-to-astrocytes-via-GPNMB-enriched-extracellular-vesicles-alleviates-cognitive-deficits 2026-07-02T09:20:49.654Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatProtoc-2019-Zhang-Asymmetric-flow-field-flow-fractionation-technology-for-exomere-and-small-extracellular-vesicle-separation-and 2026-07-02T09:20:49.789Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatProtoc-2020-Bebelman-Real-time-imaging-of-multivesicular-body-plasma-membrane-fusion-to-quantify-exosome-release-from-single-cells 2026-07-02T09:20:49.723Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatProtoc-2020-Sponsini-Imaging-endocytic-vesicle-formation-at-high-spatial-and-temporal-resolutions-with-the-pulsed-pH-protocol 2026-07-02T09:20:49.710Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatProtoc-2021-Bordanaba-Florit-Using-single-vesicle-technologies-to-unravel-the-heterogeneity-of-extracellular-vesicles 2026-07-02T09:20:49.803Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatProtoc-2021-Crescitelli-Isolation-and-characterization-of-extracellular-vesicle-subpopulations-from-tissues 2026-07-02T09:20:49.768Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatRevBioeng-2026-Chaudhari-The-status-of-extracellular-vesicles-a-drug-carriers-and-therapeutics 2026-07-02T09:20:49.769Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatRevCancer-2009-Psaila-The-metastatic-niche-Adapting-the-foreign-soil 2026-07-02T09:20:49.663Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatRevCancer-2020-Moller-The-evolving-translational-potential-of-small-extracellular-vesicles-in-cancer 2026-07-02T09:20:49.699Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatRevClinOncol-2018-Xu-Extracellular-vesicles-in-cancer-implications-for-future-improvements-in-cancer-care 2026-07-02T09:20:49.810Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatRevClinOncol-2025-Greening-Clinical-relevance-of-extracellular-vesicles-in-cancer-therapeutic-and-diagnostic-potential 2026-07-02T09:20:49.714Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatRevDrugDiscov-2013-Andaloussi-Extracellular-vesicles-biology-and-emerging-therapeutic-opportunities 2026-07-02T09:20:49.742Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatRevDrugDiscov-2022-Cheng-Therapeutically-harnessing-extracellular-vesicles 2026-07-02T09:20:49.647Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatRevImmunol-2002-Thery-Exosomes-composition,-biogenesis-and-function 2026-07-02T09:20:49.804Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatRevImmunol-2009-Thery-Membrane-vesicles-as-conveyors-of-immune-responses 2026-07-02T09:20:49.678Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatRevImmunol-2014-Robbins-Regulation-of-immune-responses-by-extracellular-vesicles 2026-07-02T09:20:49.735Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatRevImmunol-2023-Buzas-The-roles-of-extracellular-vesicles-in-the-immune-system 2026-07-02T09:20:49.679Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatRevMolCellBiol-2009-Stenmark-Rab-GTPases-as-coordinators-of-vesicle-traffic 2026-07-02T09:20:49.680Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatRevMolCellBiol-2017-Schoneberg-Reverse-topology-membrane-scission-by-the-ESCRT-proteins 2026-07-02T09:20:49.647Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatRevMolCellBiol-2018-vanNiel-Shedding-light-on-the-cell-biology-of-extracellular-vesicles 2026-07-02T09:20:49.660Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatRevMolCellBiol-2020-OBrien-RNA-delivery-by-extracellular-vesicles-in-mammalian-cells-and-its-applications 2026-07-02T09:20:49.683Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatRevMolCellBiol-2020-Vietri-The-many-functions-of-ESCRTs 2026-07-02T09:20:49.661Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatRevMolCellBiol-2022-vanNiel-Challenges-and-directions-in-studying-cell-cell-communication-by-extracellular-vesicles 2026-07-02T09:20:49.707Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatRevMolCellBiol-2023-Dixson-Context-specific-regulation-of-extracellular-vesicle-biogenesis-and-cargo-selection 2026-07-02T09:20:49.794Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatRevMolCellBiol-2023-Kozlov-Generation-of-nanoscopic-membrane-curvature-for-membrane-trafficking 2026-07-02T09:20:49.716Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NatRevMolCellBiol-2026-Ripoll-Biology-and-therapeutic-potential-of-extracellular-vesicle-targeting-and-uptake 2026-07-02T09:20:49.672Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Nature-2009-Wollert-Membrane-scission-by-the-ESCRT-III-complex 2026-07-02T09:20:49.685Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Nature-2010-Wollert-Molecular-mechanism-of-multivesicular-body-biogenesis-by-ESCRT-complexes 2026-07-02T09:20:49.797Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Nature-2015-Hoshino-Tumour-exosome-integrins-determine-organotropic-metastasis 2026-07-02T09:20:49.764Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Nature-2015-Melo-Glypican-1-identifies-cancer-exosomes-and-detects-early-pancreatic-cancer 2026-07-02T09:20:49.765Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Nature-2015-Zhang-Microenvironment-induced-PTEN-loss-by-exosomal-microRNA-primes-brain-metastasis-outgrowth 2026-07-02T09:20:49.771Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Nature-2016-Votteler-Designed-proteins-induce-the-formation-of-nanocage-containing-extracellular-vesicles 2026-07-02T09:20:49.761Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Nature-2017-Kamerkar-Exosomes-facilitate-therapeutic-targeting-of-oncogenic-KRAS-in-pancreatic-cancer 2026-07-02T09:20:49.697Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Nature-2017-Melentijevic-C.-elegans-neurons-jettison-protein-aggregates-and-mitochondria-under-neurotoxic-stress 2026-07-02T09:20:49.709Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Nature-2018-Chen-Exosomal-PD-L1-contributes-to-immunosuppression-and-is-associated-with-anti-PD-1-response 2026-07-02T09:20:49.775Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Nature-2023-Wang-Tumour-extracellular-vesicles-and-particles-induce-liver-metabolic-dysfunction 2026-07-02T09:20:49.787Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NeuroOncol-2016-vanderVos-Directly-visualized-glioblastoma-derived-extracellular-vesicles-transfer-RNA-to-microgliamacrophages-in-the-brain 2026-07-02T09:20:49.781Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NucleicAcidsRes-2012-Palma-MicroRNAs-are-exported-from-malignant-cells-in-customized-particles 2026-07-02T09:20:49.685Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/NucleicAcidsRes-2026-Wei-SVAtlas-a-comprehensive-single-extracellular-vesicle-omics-resource 2026-07-02T09:20:49.671Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Oncogene-2019-Li-Glioma-associated-human-endothelial-cell-derived-extracellular-vesicles-specifically-promote-the-tumourigenicity-of 2026-07-02T09:20:49.703Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Oncogene-2022-Bertolini-NFkappaB-activation-by-hypoxic-small-extracellular-vesicles-drives-oncogenic-reprogramming-in-a-breast-cancer 2026-07-02T09:20:49.711Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Oncogene-2022-Tyagi-Exosomal-miR-4466-from-nicotine-activated-neutrophils-promotes-tumor-cell-stemness-and-metabolism-in-lung-cancer 2026-07-02T09:20:49.741Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Oncotarget-2016-Hurwitz-Proteomic-profiling-of-NCI-60-extracellular-vesicles-uncovers-common-protein-cargo-and-cancer-type-specific-biomarkers 2026-07-02T09:20:49.718Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Oncotarget-2016-Sanchez-Exosomes-from-bulk-and-stem-cells-from-human-prostate-cancer-have-a-differential-microRNA-content-that-contributes 2026-07-02T09:20:49.660Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/PLoSONE-2008-Hunter-Detection-of-microRNA-expression-in-human-peripheral-blood-microvesicles 2026-07-02T09:20:49.728Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/PLoSONE-2020-Domenis-Circulating-exosomes-express-alpha4beta7-integrin-and-compete-with-CD4+-T-cells-for-the-binding-to-vedolizumab 2026-07-02T09:20:49.770Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/PhysiolRev-2011-Hutagalung-Role-of-Rab-GTPases-in-membrane-traffic-and-cell-physiology 2026-07-02T09:20:49.787Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/ProcNatlAcadSciUSA-2010-Pegtel-Functional-delivery-of-viral-miRNAs-via-exosomes 2026-07-02T09:20:49.724Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/ProcNatlAcadSciUSA-2011-Antonyak-Cancer-cell-derived-microvesicles-induce-transformation-by-transferring-tissue-transglutaminase-and-fibronectin-to 2026-07-02T09:20:49.739Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/ProcNatlAcadSciUSA-2012-Nabhan-Formation-and-release-of-arrestin-domain-containing-protein-1-mediated-microvesicles-(ARMMs)-at-plasma-membrane-by 2026-07-02T09:20:49.810Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/ProcNatlAcadSciUSA-2013-Christianson-Cancer-cell-exosomes-depend-on-cell-surface-heparan-sulfate-proteoglycans-for-their-internalization-and-functional 2026-07-02T09:20:49.661Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/ProcNatlAcadSciUSA-2014-Chevillet-Quantitative-and-stoichiometric-analysis-of-the-microRNA-content-of-exosomes 2026-07-02T09:20:49.720Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/ProcNatlAcadSciUSA-2016-Kowal-Proteomic-comparison-defines-novel-markers-to-characterize-heterogeneous-populations-of-extracellular-vesicle-subtypes 2026-07-02T09:20:49.658Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/ProcNatlAcadSciUSA-2017-Chen-Phosphoproteins-in-extracellular-vesicles-as-candidate-markers-for-breast-cancer 2026-07-02T09:20:49.762Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/ProcNatlAcadSciUSA-2017-Sansone-Packaging-and-transfer-of-mitochondrial-DNA-via-exosomes-regulate-escape-from-dormancy-in-hormonal-therapy-resistant 2026-07-02T09:20:49.674Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/ProcNatlAcadSciUSA-2022-Wang-Tumor-polarized-GPX3+-AT2-lung-epithelial-cells-promote-premetastatic-niche-formation 2026-07-02T09:20:49.753Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/ProcNatlAcadSciUSA-2023-Chung-Viral-nanoparticle-vaccines-against-S100A9-reduce-lung-tumor-seeding-and-metastasis 2026-07-02T09:20:49.784Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/ProcNatlAcadSciUSA-2024-Arvanitaki-Microglia-derived-extracellular-vesicles-trigger-age-related-neurodegeneration-upon-DNA-damage 2026-07-02T09:20:49.662Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/ProgLipidRes-2017-Skotland-Lipids-in-exosomes-current-knowledge-and-the-way-forward 2026-07-02T09:20:49.771Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Prostate-2014-Lazaro-Ibanez-Different-gDNA-content-in-the-subpopulations-of-prostate-cancer-extracellular-vesicles-apoptotic-bodies,-microvesicles, 2026-07-02T09:20:49.807Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Proteomics-2004-Mears-Proteomic-analysis-of-melanoma-derived-exosomes-by-two-dimensional-polyacrylamide-gel-electrophoresis-and-mass 2026-07-02T09:20:49.763Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/ResSq-2024-Dror-Tumour-derived-extracellular-vesicle-and-particle-reprogramming-of-interstitial-macrophages-in-the-lung-pre-metastatic-niche-enhances-vascular-permeability-and-metastatic-potential 2026-07-02T09:20:49.727Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/STARProtoc-2021-Bojmar-Extracellular-vesicle-and-particle-isolation-from-human-and-murine-cell-lines,-tissues,-and-bodily-fluids 2026-07-02T09:20:49.704Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/STARProtoc-2021-Wang-Isolation-and-characterization-of-extracellular-vesicles-produced-by-cell-lines 2026-07-02T09:20:49.801Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/STARProtoc-2024-Bojmar-Protocol-for-cross-platform-characterization-of-human-and-murine-extracellular-vesicles-and-particles 2026-07-02T09:20:49.767Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/STARProtoc-2025-Richter-Protocol-for-the-isolation-of-human-neutrophil-derived-extracellular-vesicles-for-characterization-and-functional 2026-07-02T09:20:49.702Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/SciAdv-2019-Yokoi-Mechanisms-of-nuclear-content-loading-to-exosomes 2026-07-02T09:20:49.756Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/SciAdv-2021-DAcunzo-Mitovesicles-are-a-novel-population-of-extracellular-vesicles-of-mitochondrial-origin-altered-in-down-syndrome 2026-07-02T09:20:49.783Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/SciAdv-2022-Zhang-Engineered-neutrophil-derived-exosome-like-vesicles-for-targeted-cancer-therapy 2026-07-02T09:20:49.697Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/SciAdv-2026-Guo-Helper-lipid-engineered-extracellular-vesicles-enable-PET-imaging-guided-pulmonary-siRNA-delivery-to-treat-lung 2026-07-02T09:20:49.769Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/SciImmunol-2017-Haderk-Tumor-derived-exosomes-modulate-PD-L1-expression-in-monocytes 2026-07-02T09:20:49.736Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/SciImmunol-2023-Merlotti-Noncanonical-splicing-junctions-between-exons-and-transposable-elements-represent-a-source-of-immunogenic-recurrent 2026-07-02T09:20:49.766Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/SciRep-2015-Bala-Biodistribution-and-function-of-extracellular-miRNA-155-in-mice 2026-07-02T09:20:49.711Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/SciRep-2015-Plebanek-Nanoparticle-targeting-and-cholesterol-flux-through-scavenger-receptor-type-B-1-inhibits-cellular-exosome-uptake 2026-07-02T09:20:49.776Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/SciRep-2015-Sedgwick-Extracellular-microvesicles-and-invadopodia-mediate-non-overlapping-modes-of-tumor-cell-invasion 2026-07-02T09:20:49.738Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/SciRep-2016-Nakase-Vectorization-of-biomacromolecules-into-cells-using-extracellular-vesicles-with-enhanced-internalization-induced-by 2026-07-02T09:20:49.649Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/SciRep-2016-Srinivasan-Lymphatic-transport-of-exosomes-as-a-rapid-route-of-information-dissemination-to-the-lymph-node 2026-07-02T09:20:49.747Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/SciRep-2016-Willms-Cells-release-subpopulations-of-exosomes-with-distinct-molecular-and-biological-properties 2026-07-02T09:20:49.729Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/SciRep-2017-Bonjoch-REG3beta-modifies-cell-tumor-function-by-impairing-extracellular-vesicle-uptake 2026-07-02T09:20:49.752Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/SciRep-2024-Ortmann-Large-extracellular-vesicle-(EV)-and-neutrophil-extracellular-trap-(NET)-interaction-captured-in-vivo-during-systemic 2026-07-02T09:20:49.674Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/SciSignal-2021-Jafari-Adipocyte-derived-exosomes-may-promote-breast-cancer-progression-in-type-2-diabetes 2026-07-02T09:20:49.730Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/SciTranslMed-2019-Wiklander-Advances-in-therapeutic-applications-of-extracellular-vesicles 2026-07-02T09:20:49.657Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/SciTranslMed-2021-Wang-Macrophage-tumor-chimeric-exosomes-accumulate-in-lymph-node-and-tumor-to-activate-the-immune-response-and-the-tumor 2026-07-02T09:20:49.803Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/SciTranslMed-2024-Sleeboom-The-extracellular-matrix-as-hallmark-of-cancer-and-metastasis-From-biomechanics-to-therapeutic-targets 2026-07-02T09:20:49.655Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/SciTranslMed-2025-Giudice-Target-antigen-displaying-extracellular-vesicles-boost-CAR-T-cell-efficacy-in-cell-and-mouse-models-of-neuroblastoma 2026-07-02T09:20:52.012Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/SciTranslMed-2025-Ma-Tumor-extracellular-vesicle-derived-PD-L1-promotes-T-cell-senescence-through-lipid-metabolism-reprogramming 2026-07-02T09:20:49.718Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Science-1998-Echard-Interaction-of-a-Golgi-associated-kinesin-like-protein-with-Rab6 2026-07-02T09:20:49.800Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Science-2008-Trajkovic-Ceramide-triggers-budding-of-exosome-vesicles-into-multivesicular-endosomes 2026-07-02T09:20:49.756Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Science-2014-Anastasiadou-Cancer.-malicious-exosomes 2026-07-02T09:20:49.761Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Science-2020-Kalluri-The-biology,-function,-and-biomedical-applications-of-exosomes 2026-07-02T09:20:49.758Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/SemCancerBiol-2023-Hu-Tumor-derived-nanoseeds-condition-the-soil-for-metastatic-organotropism 2026-07-02T09:20:49.765Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Small-2016-Chiu-A-single-cell-assay-for-time-lapse-studies-of-exosome-secretion-and-cell-behaviors 2026-07-02T09:20:49.745Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Thorax-2016-Soni-Alveolar-macrophage-derived-microvesicles-mediate-acute-lung-injury 2026-07-02T09:20:49.753Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Traffic-2004-Seabra-Rab-GTPases-and-myosin-motors-in-organelle-motility 2026-07-02T09:20:49.707Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Traffic-2010-Feng-Cellular-internalization-of-exosomes-occurs-through-phagocytosis 2026-07-02T09:20:49.745Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Traffic-2014-Mageswaran-Binding-to-any-ESCRT-can-mediate-ubiquitin-independent-cargo-sorting 2026-07-02T09:20:49.754Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Traffic-2018-Sedgwick-The-biology-of-extracellular-microvesicles 2026-07-02T09:20:49.669Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/TranslLungCancerRes-2022-Bao-Proteomic-analysis-of-plasma-exosomes-in-patients-with-non-small-cell-lung-cancer 2026-07-02T09:20:49.781Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/TrendsCellBiol-2009-Cocucci-Shedding-microvesicles-artefacts-no-more 2026-07-02T09:20:49.711Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/TrendsCellBiol-2014-Bissig-ALIX-and-the-multivesicular-endosome-ALIX-in-wonderland 2026-07-02T09:20:49.653Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/TrendsCellBiol-2023-Jeppesen-Extracellular-vesicles-and-nanoparticles-emerging-complexities 2026-07-02T09:20:49.772Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Viruses-2021-Kaddour-The-past,-the-present,-and-the-future-of-the-size-exclusion-chromatography-in-extracellular-vesicles-separation 2026-07-02T09:20:49.653Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/Wang-2022-Systemic-regulation-of-metastatic-disease-by-extracellular-vesicles-and-particles 2026-07-02T09:20:49.800Z https://research-2ry.pages.dev/Summary/Basic-Extracellular-vesicles/eLife-2016-Shurtleff-Y-box-protein-1-is-required-to-sort-microRNAs-into-exosomes-in-cells-and-in-a-cell-free-reaction 2026-07-02T09:20:49.704Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/AdvImmunol-2012-Serbina-Monocyte-mediated-immune-defense-against-murine-Listeria-monocytogenes-infection 2026-07-02T09:20:48.982Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/AmJSurgPathol-2016-Inaguma-Comprehensive-immunohistochemical-study-of-programmed-cell-death-ligand-1-(PD-L1)-analysis-in-5536-cases-revealed 2026-07-02T09:20:48.973Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/AnnuRevImmunol-2002-Janeway-Innate-immune-recognition 2026-07-02T09:20:48.926Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/AnnuRevImmunol-2006-Boon-Human-T-cell-responses-against-melanoma 2026-07-02T09:20:48.985Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/AnnuRevImmunol-2008-Stavnezer-Mechanism-and-regulation-of-class-switch-recombination 2026-07-02T09:20:49.025Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/AnnuRevImmunol-2012-Bilate-Induced-CD4+Foxp3+-regulatory-T-cells-in-immune-tolerance 2026-07-02T09:20:49.016Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/AnnuRevImmunol-2019-Hammer-Origin,-organization,-dynamics,-and-function-of-actin-and-actomyosin-networks-at-the-T-cell-immunological-synapse 2026-07-02T09:20:48.911Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/AnticancerRes-2017-Konagai-Correlation-between-NKG2DL-expression-and-antitumor-effect-of-protein-bound-polysaccharide-K-in-tumor-bearing-mouse 2026-07-02T09:20:48.903Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ArchSurg-2012-Olino-Glycolipid-antigens-for-treating-hepatic-colorectal-cancer-metastases-and-their-effect-on-the-therapeutic-efficacy-of 2026-07-02T09:20:48.870Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/BMCCancer-2014-Cho-MICAB-and-ULBP1-NKG2D-ligands-are-independent-predictors-of-good-prognosis-in-cervical-cancer 2026-07-02T09:20:48.962Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/BioProtocol-2013-Li-Generation-of-mouse-iNKT-cell-lines 2026-07-02T09:20:49.012Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/BiochemBiophysResCommun-2012-Bera-POTE-protein,-a-cancer-testis-antigen,-is-highly-expressed-in-spermatids-in-human-testis-and-is-associated-with 2026-07-02T09:20:48.976Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/BiolMethodsProtoc-2025-Kundu-Protocol-for-isolation-and-expansion-of-natural-killer-cells-from-human-peripheral-blood-scalable-for-clinical-applications 2026-07-02T09:20:48.918Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/BloodCancerDiscov-2021-Koya-Single-cell-analysis-of-the-multicellular-ecosystem-in-viral-carcinogenesis-by-HTLV-1 2026-07-02T09:20:49.011Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/BrJCancer-2016-Kim-Characterisation-of-PD-L1-positive-subsets-of-microsatellite-unstable-colorectal-cancers 2026-07-02T09:20:48.997Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/BrJCancer-2026-Wiest-Differential-effects-of-prior-versus-concomitant-steroid-and-antibiotic-treatment-on-immunotherapy-efficacy-A-pooled 2026-07-02T09:20:48.943Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerCell-2015-Topalian-Immune-checkpoint-blockade-a-common-denominator-approach-to-cancer-therapy 2026-07-02T09:20:48.889Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerCell-2018-Hellmann-Genomic-features-of-response-to-combination-immunotherapy-in-patients-with-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:49.001Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerCell-2018-Kitajima-Overcoming-resistance-to-dual-innate-immune-and-MEK-inhibition-downstream-of-KRAS 2026-07-02T09:20:49.015Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerCell-2018-Zappasodi-Non-conventional-inhibitory-CD4+Foxp3-PD-1hi-T-cells-as-a-biomarker-of-immune-checkpoint-blockade-activity 2026-07-02T09:20:48.915Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerCell-2019-Burr-An-evolutionarily-conserved-function-of-polycomb-silences-the-MHC-class-I-antigen-presentation-pathway-and-enables-immune-evasion-in-cancer 2026-07-02T09:20:48.873Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerCell-2020-Leko-Identifying-and-targeting-human-tumor-antigens-for-T-cell-based-immunotherapy-of-solid-tumors 2026-07-02T09:20:49.004Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerCell-2020-Motzer-Molecular-subsets-in-renal-cancer-determine-outcome-to-checkpoint-and-angiogenesis-blockade 2026-07-02T09:20:48.946Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerCell-2020-Schoenfeld-Acquired-resistance-to-immune-checkpoint-inhibitors 2026-07-02T09:20:48.968Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerCell-2021-Bagati-Integrin-avb6-TGFb-SOX4-pathway-drives-immne-evasion-in-TNBC 2026-07-02T09:20:48.980Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerCell-2021-Chow-Tim-4+-cavity-resident-macrophages-impair-anti-tumor-CD8+-T-cell-immunity 2026-07-02T09:20:48.885Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerCell-2021-Lin-Stanniocalcin-1-is-a-phagocytosis-checkpoint-driving-tumor-immune-resistance 2026-07-02T09:20:48.966Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerCell-2022-Kitajima-MPS1-inhibition-primes-immunogenicity-of-KRAS-LKB1-mutant-lung-cancer 2026-07-02T09:20:49.010Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerCell-2022-Nassar-Ancestry-driven-recalibration-of-tumor-mutational-burden-and-disparate-clinical-outcomes-in-response-to-immune 2026-07-02T09:20:48.919Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerCell-2023-Vennin-Taxanes-trigger-cancer-cell-killing-in-vivo-by-inducing-non-canonical-T-cell-cytotoxicity 2026-07-02T09:20:48.967Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerCell-2023-Zhu-Loss-of-p53-and-mutational-heterogeneity-drives-immune-resistance-in-an-autochthonous-mouse-lung-cancer-model-with-high 2026-07-02T09:20:48.905Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerCell-2024-Galassi-The-hallmarks-of-cancer-immune-evasion 2026-07-02T09:20:48.894Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerCell-2024-McGinnis-The-temporal-progression-of-lung-immune-remodeling-during-breast-cancer-metastasis 2026-07-02T09:20:48.921Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerCell-2026-Foidart-Whole-genome-doubling-drives-immune-evasion-by-silencing-antigen-presentation 2026-07-02T09:20:49.024Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerCell-2026-Karakousi-IFNgamma-dependent-metabolic-reprogramming-restrains-an-immature,-pro-metastatic-lymphatic-state-in-melanoma 2026-07-02T09:20:48.986Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerCell-2026-Kureshi-Dendritic-cell-redundancy-enables-priming-of-anti-tumor-cd4+-t-cells-in-pancreatic-cancer 2026-07-02T09:20:48.903Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerCell-2026-Liu-Clonal-lineage-tracing-of-innate-immune-cells-in-human-cancer 2026-07-02T09:20:48.997Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerDiscov-2013-Rech-Dynamic-interplay-of-oncogenes-and-T-cells-induces-PD-L1-in-the-tumor-microenvironment 2026-07-02T09:20:48.944Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerDiscov-2016-Liu-Improved-efficacy-of-neoadjuvant-compared-to-adjuvant-immunotherapy-to-eradicate-metastatic-disease 2026-07-02T09:20:48.907Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerDiscov-2016-Peng-Loss-of-PTEN-promotes-resistance-to-T-cell-mediated-immunotherapy 2026-07-02T09:20:48.969Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerDiscov-2017-Gettinger-Impaired-HLA-class-I-antigen-processing-and-presentation-as-a-mechanism-of-acquired-resistance-to-immune-checkpoint 2026-07-02T09:20:48.956Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerDiscov-2017-Reuben-TCR-repertoire-intratumor-heterogeneity-in-localized-lung-adenocarcinomas-an-association-with-predicted-neoantigen 2026-07-02T09:20:48.880Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerDiscov-2017-Shin-Primary-resistance-to-PD-1-blockade-mediated-by-JAK12-mutations 2026-07-02T09:20:48.932Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerDiscov-2021-Kumar-CARM1-inhibition-enables-immunotherapy-of-resistant-tumors-by-dual-action-on-tumor-cells-and-T-cells 2026-07-02T09:20:48.995Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerDiscov-2021-Mahadevan-Intrinsic-immunogenicity-of-small-cell-lung-carcinoma-revealed-by-its-cellular-plasticity 2026-07-02T09:20:48.978Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerDiscov-2021-Montesion-Somatic-HLA-class-I-loss-is-a-widespread-mechanism-of-immune-evasion-which-refines-the-use-of-tumor-mutational-burden 2026-07-02T09:20:48.951Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerDiscov-2021-Pore-Resistance-to-durvalumab-and-durvalumab-plus-tremelimumab-is-associated-with-functional-STK11-mutations-in-patients 2026-07-02T09:20:48.909Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerDiscov-2022-Tang-Combined-inhibition-of-SHP2-and-CXCR12-promotes-antitumor-T-cell-response-in-NSCLC 2026-07-02T09:20:49.014Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerDiscov-2026-Molina-Arcas-Sensitizing-lung-cancer-to-immunotherapy-with-a-RAS(ON)-inhibitor-doublet 2026-07-02T09:20:48.874Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerGeneTher-2026-Pinto-Preclinical-development-of-a-mutant-KRAS-targeting-therapeutic-cancer-vaccine 2026-07-02T09:20:48.929Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerImmunolImmunother-2026-Kamigaichi-Immunological-impact-of-tumor-draining-lymph-node-dissection-on-systemic-th1-like-CD4+-T-cells-in-patients-with 2026-07-02T09:20:48.967Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerImmunolRes-2014-Dustin-The-immunological-synapse 2026-07-02T09:20:48.884Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerImmunolRes-2015-Lanier-NKG2D-receptor-and-its-ligands-in-host-defense 2026-07-02T09:20:48.918Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerImmunolRes-2015-Liadi-Individual-motile-CD4(+)-T-cells-can-participate-in-efficient-multikilling-through-conjugation-to-multiple-tumor-cells 2026-07-02T09:20:48.963Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerImmunolRes-2015-Severson-PD-1+tim-3+-CD8+-T-lymphocytes-display-varied-degrees-of-functional-exhaustion-in-patients-with-regionally-metastatic 2026-07-02T09:20:48.953Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerImmunolRes-2015-Srivastava-STAT1-induced-HLA-class-I-upregulation-enhances-immunogenicity-and-clinical-response-to-anti-EGFR-mAb-cetuximab-therapy 2026-07-02T09:20:48.900Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerImmunolRes-2016-Zah-T-cells-expressing-CD19CD20-bispecific-chimeric-antigen-receptors-prevent-antigen-escape-by-malignant-B-cells 2026-07-02T09:20:48.904Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerImmunolRes-2017-Scharping-Efficacy-of-PD-1-blockade-is-potentiated-by-metformin-induced-reduction-of-tumor-hypoxia 2026-07-02T09:20:48.895Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerImmunolRes-2018-Chapman-Hallmarks-of-T-cell-exit-from-quiescence 2026-07-02T09:20:48.906Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerImmunolRes-2020-Hakozaki-The-gut-microbiome-associates-with-immune-checkpoint-inhibition-outcomes-in-patients-with-advanced-non-small-cell-lung 2026-07-02T09:20:48.923Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerImmunolRes-2020-Kortekaas-CD39-identifies-the-CD4+-tumor-specific-T-cell-population-in-human-cancer 2026-07-02T09:20:52.112Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerImmunolRes-2020-Kotanides-Bispecific-targeting-of-PD-1-and-PD-L1-enhances-T-cell-activation-and-antitumor-immunity 2026-07-02T09:20:48.934Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerImmunolRes-2021-Veneziani-Nutlin-3a-enhances-natural-killer-cell-mediated-killing-of-neuroblastoma-by-restoring-p53-dependent-expression-of 2026-07-02T09:20:49.005Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerImmunolRes-2021-Yang-Targeted-deletion-of-CXCR2-in-myeloid-cells-alters-the-tumor-immune-environment-to-improve-antitumor-immunity 2026-07-02T09:20:48.899Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerRes-1988-Berd-Effect-of-low-dose-cyclophosphamide-on-the-immune-system-of-cancer-patients-depletion-of-CD4+,-2h4+-suppressor-inducer 2026-07-02T09:20:48.872Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerRes-2006-Bera-POTE-paralogs-are-induced-and-differentially-expressed-in-many-cancers 2026-07-02T09:20:48.957Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerRes-2006-Yoshimura-Selective-targeting-of-antitumor-immune-responses-with-engineered-live-attenuated-listeria-monocytogenes 2026-07-02T09:20:52.120Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerRes-2007-Yoshimura-Live-attenuated-listeria-monocytogenes-effectively-treats-hepatic-colorectal-cancer-metastases-and-is-strongly-enhanced 2026-07-02T09:20:48.993Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerRes-2010-Shrimali-Antiangiogenic-agents-can-increase-lymphocyte-infiltration-into-tumor-and-enhance-the-effectiveness-of-adoptive 2026-07-02T09:20:48.879Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerRes-2015-Donia-Aberrant-expression-of-MHC-class-II-in-melanoma-attracts-inflammatory-tumor-specific-CD4+-T-cells,-which-dampen-CD8+ 2026-07-02T09:20:49.023Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerRes-2016-Housseau-Redundant-innate-and-adaptive-sources-of-IL17-production-drive-colon-tumorigenesis 2026-07-02T09:20:48.920Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerRes-2017-Prat-Immune-related-gene-expression-profiling-after-PD-1-blockade-in-non-small-cell-lung-carcinoma,-head-and-neck-squamous 2026-07-02T09:20:48.879Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerRes-2026-George-Immune-checkpoint-blockade-augments-lymphodepleting-chemotherapy-induced-antitumor-immunity-by-expanding-effector-CD8-T-cell-clones 2026-07-02T09:20:52.128Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CancerSci-2017-Inoue-Cetuximab-strongly-enhances-immune-cell-infiltration-into-liver-metastatic-sites-in-colorectal-cancer 2026-07-02T09:20:48.913Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2015-Chiappinelli-Inhibiting-DNA-methylation-causes-an-interferon-response-in-cancer-via-dsRNA-including-endogenous-retroviruses 2026-07-02T09:20:49.011Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2015-Rooney-Molecular-and-genetic-properties-of-tumors-associated-with-local-immune-cytolytic-activity 2026-07-02T09:20:48.883Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2016-Gao-Loss-of-IFN-pathway-genes-in-tumor-cells-as-a-mechanism-of-resistance-to-anti-ctla-4-therapy 2026-07-02T09:20:48.910Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2016-Hugo-Genomic-and-transcriptomic-features-of-response-to-anti-PD-1-therapy-in-metastatic-melanoma 2026-07-02T09:20:49.004Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2016-Malladi-Metastatic-latency-and-immune-evasion-through-autocrine-inhibition-of-WNT 2026-07-02T09:20:49.022Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2016-Minn-Combination-cancer-therapies-with-immune-checkpoint-blockade-convergence-on-interferon-signaling 2026-07-02T09:20:48.909Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2016-Palucka-The-basis-of-oncoimmunology 2026-07-02T09:20:48.936Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2017-Lavin-Innate-immune-landscape-in-early-lung-adenocarcinoma-by-paired-single-cell-analyses 2026-07-02T09:20:48.934Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2017-Marty-MHC-I-genotype-restricts-the-oncogenic-mutational-landscape 2026-07-02T09:20:48.976Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2017-McGranahan-Allele-specific-HLA-loss-and-immune-escape-in-lung-cancer-evolution 2026-07-02T09:20:48.943Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2017-Nissim-Synthetic-RNA-based-immunomodulatory-gene-circuits-for-cancer-immunotherapy 2026-07-02T09:20:48.894Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2017-Riaz-Tumor-and-microenvironment-evolution-during-immunotherapy-with-nivolumab 2026-07-02T09:20:48.870Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2017-Sharma-Primary,-adaptive,-and-acquired-resistance-to-cancer-immunotherapy 2026-07-02T09:20:48.923Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2017-Spitzer-Systemic-immunity-is-required-for-effective-cancer-immunotherapy 2026-07-02T09:20:48.906Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2017-Topper-Epigenetic-therapy-ties-MYC-depletion-to-reversing-immune-evasion-and-treating-lung-cancer 2026-07-02T09:20:48.992Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2018-Andre-Anti-NKG2A-mAb-Is-a-Checkpoint-Inhibitor-that-Promotes-Anti-tumor-Immunity-by-Unleashing-Both-T-and-NK-Cells 2026-07-02T09:20:48.969Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2018-Azizi-Single-cell-map-of-diverse-immune-phenotypes-in-the-breast-tumor-microenvironment 2026-07-02T09:20:48.982Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2018-Jerby-Arnon-A-cancer-cell-program-promotes-T-cell-exclusion-and-resistance-to-checkpoint-blockade 2026-07-02T09:20:48.949Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2018-Mitroulis-Modulation-of-myelopoiesis-progenitors-is-an-integral-component-of-trained-immunity 2026-07-02T09:20:48.888Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2018-Neal-Organoid-Modeling-of-the-Tumor-Immune-Microenvironment 2026-07-02T09:20:48.927Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2018-Pyke-Evolutionary-Pressure-against-MHC-Class-II-Binding-Cancer-Mutations 2026-07-02T09:20:49.021Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2018-Sade-Feldman-Defining-T-cell-states-associated-with-response-to-checkpoint-immunotherapy-in-melanoma 2026-07-02T09:20:49.008Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2019-Wang-Fibrinogen-like-Protein-1-Is-a-Major-Immune-Inhibitory-Ligand-of-LAG-3 2026-07-02T09:20:48.923Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2020-Buggert-The-identity-of-human-tissue-emigrant-CD8+-T-cells 2026-07-02T09:20:52.156Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2020-Jiang-Direct-tumor-killing-and-immunotherapy-through-anti-serpinB9-therapy 2026-07-02T09:20:48.964Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2020-Liu-Detecting-tumor-antigen-specific-T-cells-via-interaction-dependent-fucosyl-biotinylation 2026-07-02T09:20:49.022Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2020-Ringel-Obesity-shapes-metabolism-in-the-tumor-microenvironment-to-suppress-anti-tumor-immunity 2026-07-02T09:20:48.987Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2020-Wells-Key-parameters-of-tumor-epitope-immunogenicity-revealed-through-a-consortium-approach-improve-neoantigen-prediction 2026-07-02T09:20:48.933Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2021-Burger-Antigen-dominance-hierarchies-shape-TCF1+-progenitor-CD8-T-cell-phenotypes-in-tumors 2026-07-02T09:20:48.932Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2021-DiPilato-CXCR6-positions-cytotoxic-T-cells-to-receive-critical-survival-signals-in-the-tumor-microenvironment 2026-07-02T09:20:49.004Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2021-Litchfield-Meta-analysis-of-tumor-and-T-cell-intrinsic-mechanisms-of-sensitization-to-checkpoint-inhibition 2026-07-02T09:20:48.883Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2022-Combes-Discovering-dominant-tumor-immune-archetypes-in-a-pan-cancer-census 2026-07-02T09:20:48.919Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2022-Luoma-Tissue-resident-memory-and-circulating-T-cells-are-early-responders-to-pre-surgical-cancer-immunotherapy 2026-07-02T09:20:48.947Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2022-Marzio-EMSY-inhibits-homologous-recombination-repair-and-the-interferon-response,-promoting-lung-cancer-immune-evasion 2026-07-02T09:20:48.937Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2022-Sellars-Cancer-vaccines-Building-a-bridge-over-troubled-waters 2026-07-02T09:20:48.910Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2023-Sharma-Immune-checkpoint-therapy-current-perspectives-and-future-directions 2026-07-02T09:20:48.914Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2024-Petralia-Pan-cancer-proteogenomics-characterization-of-tumor-immunity 2026-07-02T09:20:49.013Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2024-Pozniak-A-TCF4-dependent-gene-regulatory-network-confers-resistance-to-immunotherapy-in-melanoma 2026-07-02T09:20:48.959Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2025-Zhang-Cancer-cells-co-opt-an-inter-organ-neuroimmune-circuit-to-escape-immune-surveillance 2026-07-02T09:20:49.017Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2026-Brown-Gut-microbiota-promotes-immune-tolerance-at-the-maternal-fetal-interface 2026-07-02T09:20:48.945Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2026-Chemla-HLA-export-by-melanoma-cells-decoys-cytotoxic-T-cells-to-promote-immune-evasion 2026-07-02T09:20:48.938Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2026-Davar-Improving-immunotherapy-in-solid-tumors-using-FMT 2026-07-02T09:20:48.917Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2026-Heieis-O-glcnacylation-drives-macrophage-IL-4-responsiveness-and-tissue-residency-through-metabolic-and-cell-cycle-calibration 2026-07-02T09:20:48.931Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2026-Marine-Mapping-intratumor-heterogeneity-across-layers-for-advancing-immunotherapy 2026-07-02T09:20:48.977Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2026-Scharping-Proteostasis-sustains-t-cell-differentiation-potential-and-tumor-infiltrating-lymphocyte-function 2026-07-02T09:20:48.981Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2026-Wang-A-blood-brain-barrier-like-vascular-gate-limits-immunotherapy-efficacy-in-neuroendocrine-cancers 2026-07-02T09:20:48.986Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2026-Wang-CLIM-TIME-identifies-metastatic-microenvironment-modulators-for-T-cell-therapy-response 2026-07-02T09:20:48.917Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2026-Yue-Expansion-and-CAR-engineering-of-granulocyte-monocyte-progenitors-for-cellular-immunotherapy 2026-07-02T09:20:48.895Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cell-2026-Zhang-A-convergent-uPAR-positive-tumor-ecosystem-creates-broad-vulnerability-to-CAR-t-cell-therapy 2026-07-02T09:20:48.927Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CellDeathDis-2015-Jiang-T-cell-exhaustion-in-the-tumor-microenvironment 2026-07-02T09:20:48.885Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CellMetab-2022-Best-Glutaminase-inhibition-impairs-CD8-T-cell-activation-in-STK11-lkb1-deficient-lung-cancer 2026-07-02T09:20:48.886Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CellMetab-2026-Chen-16-h-fasting-optimizes-cancer-immunotherapy-in-mice-and-humans 2026-07-02T09:20:48.975Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CellMolImmunol-2026-Nutt-Defining-the-rules-of-engagement-b-cells,-antibodies-and-cancer-control 2026-07-02T09:20:48.970Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CellRep-2016-Giannakis-Genomic-correlates-of-immune-cell-infiltrates-in-colorectal-carcinoma 2026-07-02T09:20:48.897Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CellRep-2017-Garcia-Diaz-Interferon-receptor-signaling-pathways-regulating-PD-L1-and-PD-L2-expression 2026-07-02T09:20:48.928Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CellRep-2022-Kos-Tumor-educated-tregs-drive-organ-specific-metastasis-in-breast-cancer-by-impairing-NK-cells-in-the-lymph-node-niche 2026-07-02T09:20:48.920Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CellRep-2026-Cremasco-Natural-killer-cells-swarm-and-cross-recruit-cytotoxic-T-cells-via-CCR5 2026-07-02T09:20:48.996Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CellRep-2026-Ma-Multivalent-nanoparticles-activate-t-dependent-antibody-response-via-antigen-presentation-by-both-b-cells-and-dendritic 2026-07-02T09:20:48.940Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/CellRepMed-2026-Brennan-Circulating-natural-killer-cells-are-phenotypically-and-functionally-altered-in-age-related-macular-degeneration 2026-07-02T09:20:48.954Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Cells-2019-Cassioli-A-ciliary-view-of-the-immunological-synapse 2026-07-02T09:20:48.924Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ClinCancerRes-2013-John-Anti-PD-1-antibody-therapy-potently-enhances-the-eradication-of-established-tumors-by-gene-modified-T-cells 2026-07-02T09:20:48.900Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ClinCancerRes-2013-Melief-License-to-kill-reflects-joint-action-of-CD4-and-CD8-T-cells 2026-07-02T09:20:49.006Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ClinCancerRes-2014-Taube-Association-of-PD-1,-PD-1-ligands,-and-other-features-of-the-tumor-immune-microenvironment-with-response-to-anti-PD-1 2026-07-02T09:20:48.900Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ClinCancerRes-2015-Zhai-Molecular-pathways-targeting-IDO1-and-other-tryptophan-dioxygenases-for-cancer-immunotherapy 2026-07-02T09:20:48.987Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ClinCancerRes-2016-Maus-Making-better-chimeric-antigen-receptors-for-adoptive-T-cell-therapy 2026-07-02T09:20:48.902Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ClinCancerRes-2018-Mazzaschi-Low-PD-1-expression-in-cytotoxic-CD8+-tumor-infiltrating-lymphocytes-confers-an-immune-privileged-tissue 2026-07-02T09:20:48.868Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ClinCancerRes-2018-Niknam-Radiation-followed-by-OX40-stimulation-drives-local-and-abscopal-antitumor-effects-in-an-anti-PD1-resistant-lung-tumor 2026-07-02T09:20:48.902Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ClinCancerRes-2019-Costa-Nunes-High-throughput-screening-of-human-tumor-antigen-specific-CD4-T-cells,-including-neoantigen-reactive-T-cells 2026-07-02T09:20:48.881Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ClinCancerRes-2019-Luke-WNT-beta-catenin-pathway-activation-correlates-with-immune-exclusion-across-human-cancers 2026-07-02T09:20:48.950Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ClinCancerRes-2019-Viitala-Immunotherapeutic-blockade-of-macrophage-clever-1-reactivates-the-CD8+-T-cell-response-against-immunosuppressive-tumors 2026-07-02T09:20:48.930Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ClinCancerRes-2020-Malekzadeh-Antigen-experienced-T-cells-from-peripheral-blood-recognize-p53-neoantigens 2026-07-02T09:20:48.971Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ClinCancerRes-2020-Olivera-Exploiting-TCR-recognition-of-shared-hotspot-oncogene-encoded-neoantigens 2026-07-02T09:20:48.912Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ClinCancerRes-2020-Proia-STAT3-antisense-oligonucleotide-remodels-the-suppressive-tumor-microenvironment-to-enhance-immune-activation-in 2026-07-02T09:20:48.936Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ClinCancerRes-2020-Zugazagoitia-Biomarkers-associated-with-beneficial-PD-1-checkpoint-blockade-in-non-small-cell-lung-cancer-(NSCLC)-identified-using 2026-07-02T09:20:48.884Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ClinCancerRes-2021-Chalfin-Circulating-tumor-cell-subtypes-and-T-cell-populations-as-prognostic-biomarkers-to-combination-immunotherapy-in 2026-07-02T09:20:48.898Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ClinCancerRes-2021-Datar-Spatial-analysis-and-clinical-significance-of-HLA-class-I-and-class-II-subunit-expression-in-non-small-cell-lung-cancer 2026-07-02T09:20:48.901Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ClinCancerRes-2021-Jou-The-changing-landscape-of-therapeutic-cancer-vaccines-novel-platforms-and-neoantigen-identification 2026-07-02T09:20:48.992Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ClinCancerRes-2021-Virtakoivu-Systemic-blockade-of-clever-1-elicits-lymphocyte-activation-alongside-checkpoint-molecule-downregulation-in-patients 2026-07-02T09:20:49.022Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ClinExpImmunol-2015-Attaf-The-T-cell-antigen-receptor-the-swiss-army-knife-of-the-immune-system 2026-07-02T09:20:48.996Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ClinLungCancer-2015-Kitazono-Reliability-of-small-biopsy-samples-compared-with-resected-specimens-for-the-determination-of-programmed-death-ligand-1 2026-07-02T09:20:48.880Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/EurJCancer-2017-Kim-Comparative-analysis-of-PD-L1-expression-between-primary-and-metastatic-pulmonary-adenocarcinomas 2026-07-02T09:20:48.966Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/FrontImmunol-2014-Fooksman-Organizing-MHC-class-II-presentation 2026-07-02T09:20:48.984Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/FrontImmunol-2015-Zhang-NKG2D-ligands-in-tumor-immunity-two-sides-of-a-coin 2026-07-02T09:20:48.948Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/FrontImmunol-2020-Binder-CD2-immunobiology 2026-07-02T09:20:48.988Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/FrontImmunol-2026-Jung-ATG5-mediated-inducible-autophagy-sustains-CAR-T-cell-durability-under-solid-tumor-stress 2026-07-02T09:20:48.906Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/FrontImmunol-2026-Mao-MicroRNA-targeted-reprogramming-of-CD8+-T-cells-against-cancer 2026-07-02T09:20:49.006Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/FrontMed(Lausanne)-2026-Smesseim-Defining-the-abscopal-effect-in-non-small-cell-lung-cancer-in-the-era-of-immunotherapy-and-lung-ablation-treatment-a 2026-07-02T09:20:48.871Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/FrontPharmacol-2017-Garrido-Upregulation-of-HLA-class-I-expression-on-tumor-cells-by-the-anti-EGFR-antibody-nimotuzumab 2026-07-02T09:20:48.878Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/FrontPharmacol-2017-Mazorra-Nimotuzumab-induces-NK-cell-activation,-cytotoxicity,-dendritic-cell-maturation-and-expansion-of-EGFR-specific-T-cells 2026-07-02T09:20:48.970Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Immunity-1999-Nishimura-Development-of-lupus-like-autoimmune-diseases-by-disruption-of-the-PD-1-gene-encoding-an-ITIM-motif-carrying 2026-07-02T09:20:48.869Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Immunity-2013-Chen-Oncology-meets-immunology-the-cancer-immunity-cycle 2026-07-02T09:20:48.965Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Immunity-2016-Anderson-Lag-3,-tim-3,-and-TIGIT-co-inhibitory-receptors-with-specialized-functions-in-immune-regulation 2026-07-02T09:20:48.890Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Immunity-2016-Mlecnik-Integrative-analyses-of-colorectal-cancer-show-immunoscore-is-a-stronger-predictor-of-patient-survival-than 2026-07-02T09:20:49.020Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Immunity-2016-Pitt-Resistance-mechanisms-to-immune-checkpoint-blockade-in-cancer-tumor-intrinsic-and-extrinsic-factors 2026-07-02T09:20:48.873Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Immunity-2018-Garris-Successful-anti-PD-1-cancer-immunotherapy-requires-T-cell-dendritic-cell-crosstalk-involving-the-cytokines-IFN-gamma 2026-07-02T09:20:48.993Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Immunity-2018-Patel-Combination-cancer-therapy-with-immune-checkpoint-blockade-mechanisms-and-strategies 2026-07-02T09:20:48.903Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Immunity-2018-Sun-Regulation-and-function-of-the-PD-L1-checkpoint 2026-07-02T09:20:48.941Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Immunity-2018-Thorsson-The-immune-landscape-of-cancer 2026-07-02T09:20:48.946Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Immunity-2019-Abelin-Defining-HLA-II-ligand-processing-and-binding-rules-with-mass-spectrometry-enhances-cancer-epitope-prediction 2026-07-02T09:20:48.949Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Immunity-2019-VanDerVeeken-Natural-genetic-variation-reveals-key-features-of-epigenetic-and-transcriptional-memory-in-virus-specific-CD8-T-cells 2026-07-02T09:20:48.884Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Immunity-2020-Beltra-Developmental-relationships-of-four-exhausted-CD8+-T-cell-subsets-reveals-underlying-transcriptional-and-epigenetic 2026-07-02T09:20:48.922Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Immunity-2020-Bilate-T-cell-receptor-is-required-for-differentiation,-but-not-maintenance,-of-intestinal-CD4+-intraepithelial-lymphocytes 2026-07-02T09:20:48.921Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Immunity-2020-Braun-CD155-on-tumor-cells-drives-resistance-to-immunotherapy-by-inducing-the-degradation-of-the-activating-receptor-CD226-in 2026-07-02T09:20:48.941Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Immunity-2020-Weulersse-Eomes-dependent-loss-of-the-co-activating-receptor-CD226-restrains-CD8+-T-cell-anti-tumor-functions-and-limits-the 2026-07-02T09:20:48.998Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Immunity-2021-Ozga-Chemokines-and-the-immune-response-to-cancer 2026-07-02T09:20:48.877Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Immunity-2026-Pei-Neutrophil-regulation-of-immunotherapy-for-cancer-is-controlled-by-type-II-interferon 2026-07-02T09:20:48.890Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ImmunolCellBiol-2026-Aires-Lopes-Highlights-of-2025-advancements-in-natural-killer-cell-biology 2026-07-02T09:20:48.882Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ImmunolRes-2008-Burgess-The-NKG2D-receptor-immunobiology-and-clinical-implications 2026-07-02T09:20:48.974Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ImmunolRev-2001-Sutherland-The-UL16-binding-proteins,-a-novel-family-of-MHC-class-I-related-ligands-for-NKG2D,-activate-natural-killer-cell 2026-07-02T09:20:48.980Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JAMAOncol-2015-Demaria-Role-of-local-radiation-therapy-in-cancer-immunotherapy 2026-07-02T09:20:48.944Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JAMAOncol-2016-McLaughlin-Quantitative-assessment-of-the-heterogeneity-of-PD-L1-expression-in-non-small-cell-lung-cancer 2026-07-02T09:20:48.891Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JCIInsight-2016-Lizotte-Multiparametric-profiling-of-non-small-cell-lung-cancers-reveals-distinct-immunophenotypes 2026-07-02T09:20:48.949Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JCOPrecisOncol-2026-Bansal-Immunotherapy-response-and-survival-outcome-by-immunophenotypic-signature-in-non-small-cell-lung-cancer 2026-07-02T09:20:48.914Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JCellBiol-2007-Vascotto-The-actin-based-motor-protein-myosin-II-regulates-MHC-class-II-trafficking-and-BCR-driven-antigen-presentation 2026-07-02T09:20:48.939Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JCellSci-2019-Goyette-How-does-T-cell-receptor-clustering-impact-on-signal-transduction 2026-07-02T09:20:48.957Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JClinInvest-2010-Ramakrishnan-Chemotherapy-enhances-tumor-cell-susceptibility-to-CTL-mediated-killing-during-cancer-immunotherapy-in-mice 2026-07-02T09:20:48.989Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JClinInvest-2015-Chen-Anti-PD-1pd-L1-therapy-of-human-cancer-past,-present,-and-future 2026-07-02T09:20:48.956Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JClinInvest-2015-Melief-Therapeutic-cancer-vaccines 2026-07-02T09:20:48.968Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JClinInvest-2017-Ayers-IFN-gamma-related-mRNA-profile-predicts-clinical-response-to-PD-1-blockade 2026-07-02T09:20:49.000Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JClinInvest-2019-Kamiya-Blocking-expression-of-inhibitory-receptor-NKG2A-overcomes-tumor-resistance-to-NK-cells 2026-07-02T09:20:48.957Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JClinInvest-2019-Nambiar-Galectin-1-driven-T-cell-exclusion-in-the-tumor-endothelium-promotes-immunotherapy-resistance 2026-07-02T09:20:49.002Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JClinInvest-2020-Li-Epigenetic-driver-mutations-in-ARID1A-shape-cancer-immune-phenotype-and-immunotherapy 2026-07-02T09:20:48.961Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JClinInvest-2020-Theivanthiran-A-tumor-intrinsic-PD-L1-LLRP3-inflamasome-signaling-pathway-drives-resistance-to-anti-PD-1-immunotherapy 2026-07-02T09:20:48.932Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JClinInvest-2021-Baretti-Epigenetic-modifiers-synergize-with-immune-checkpoint-blockade-to-enhance-long-lasting-antitumor-efficacy 2026-07-02T09:20:48.958Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JClinInvest-2021-Lhuillier-Radiotherapy-exposed-CD8+-and-CD4+-neoantigens-enhance-tumor-control 2026-07-02T09:20:48.976Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JClinInvest-2021-Sehgal-Dynamic-single-cell-RNA-sequencing-identifies-immunotherapy-persister-cells-following-PD-1-blockade 2026-07-02T09:20:48.963Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JClinInvest-2025-Pitter-Citrullination-in-tumor-immunity-and-therapy 2026-07-02T09:20:49.000Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JClinInvest-2026-Lopez-Janeiro-Conventional-type-1-DC-density-is-associated-with-checkpoint-inhibitor-response-across-multiple-types-of-cancer 2026-07-02T09:20:49.007Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JClinOncol-2010-Brahmer-Phase-I-study-of-single-agent-anti-programmed-death-1-(MDX-1106)-in-refractory-solid-tumors-safety,-clinical-activity, 2026-07-02T09:20:48.894Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JClinOncol-2013-vanRooij-Tumor-exome-analysis-reveals-neoantigen-specific-T-cell-reactivity-in-an-ipilimumab-responsive-melanoma 2026-07-02T09:20:48.974Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JClinOncol-2021-Olson-Pembrolizumab-plus-ipilimumab-following-anti-PD-1l1-failure-in-melanoma 2026-07-02T09:20:48.994Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JExpMed-1982-North-Cyclophosphamide-facilitated-adoptive-immunotherapy-of-an-established-tumor-depends-on-elimination-of-tumor-induced 2026-07-02T09:20:48.979Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JExpMed-1991-Houchins-DNA-sequence-analysis-of-NKG2,-a-family-of-related-cDNA-clones-encoding-type-II-integral-membrane-proteins-on-human 2026-07-02T09:20:48.869Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JExpMed-2000-Freeman-Engagement-of-the-PD-1-immunoinhibitory-receptor-by-a-novel-B7-family-member-leads-to-negative-regulation-of-lymphocyte 2026-07-02T09:20:48.896Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JExpMed-2005-Campi-Actin-and-agonist-MHC-peptide-complex-dependent-T-cell-receptor-microclusters-as-scaffolds-for-signaling 2026-07-02T09:20:48.908Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JExpMed-2010-Sakuishi-Targeting-Tim-3-and-PD-1-pathway-to-restore-anti-tumor-immunity 2026-07-02T09:20:48.931Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JExpMed-2020-Tanaka-Tyrosine-kinase-inhibitor-imatinib-augments-tumor-immunity-by-depleting-effector-regulatory-T-cells 2026-07-02T09:20:48.935Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JHepatol-2014-Koh-Cancer-immunotherapy-targeting-the-difference 2026-07-02T09:20:48.952Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JImmunol-2009-Zhao-A-herceptin-based-chimeric-antigen-receptor-with-modified-signaling-domains-leads-to-enhanced-survival-of-transduced-T 2026-07-02T09:20:52.292Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JImmunol-2013-Goding-Restoring-immune-function-of-tumor-specific-CD4+-T-cells-during-recurrence-of-melanoma 2026-07-02T09:20:48.867Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JImmunol-2014-Gorman-Tim-3-directly-enhances-CD8-T-cell-responses-to-acute-listeria-monocytogenes-infection 2026-07-02T09:20:49.007Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JImmunol-2015-Ilyas-Landscape-of-tumor-antigens-in-T-cell-immunotherapy 2026-07-02T09:20:48.911Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JImmunol-2018-Blery-NKG2D-MICA-interaction-A-paradigm-shift-in-innate-recognition 2026-07-02T09:20:48.922Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JImmunol-2026-Akbar-Myelin-antigen-specific-effector-CD8+-T-cells-induce-chronic-CNS-autoimmunity-in-a-CD4+-T-cell-dependent-manner 2026-07-02T09:20:48.964Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JImmunother-2013-Maiti-Sleeping-beauty-system-to-redirect-T-cell-specificity-for-human-applications 2026-07-02T09:20:48.991Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JImmunotherCancer-2013-Mkrtichyan-Anti-PD-1-antibody-significantly-increases-therapeutic-efficacy-of-listeria-monocytogenes-(lm)-LLO-immunotherapy 2026-07-02T09:20:48.955Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JImmunotherCancer-2026-Carreira-CXCR3-signaling-promotes-delta-one-T-cell-recruitment-and-antitumor-efficacy-in-colorectal-cancer 2026-07-02T09:20:48.973Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JImmunotherCancer-2026-Gonzalez-Morning-versus-afternoon-administration-of-immune-checkpoint-inhibitors-in-metastatic-non-small-cell-lung-cancer 2026-07-02T09:20:49.018Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JImmunotherCancer-2026-Keddar-Pan-cancer-analysis-in-the-real-world-setting-uncovers-immunogenomic-drivers-of-acquired-resistance-post-immunotherapy 2026-07-02T09:20:48.972Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JImmunotherCancer-2026-Wu-Sequential-involvement-of-hypoxia-and-anti-PD-1-treatment-in-shaping-tumor-regional-CD39 2026-07-02T09:20:48.900Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JNanobiotechnology-2026-Zhang-Apigenin-based-nanoplatform-achieves-non-small-cell-lung-cancer-immunotherapy-through-glycolysis-inhibition-and 2026-07-02T09:20:49.015Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JNatlCancerInst-2015-Schalper-Objective-measurement-and-clinical-significance-of-TILs-in-non-small-cell-lung-cancer 2026-07-02T09:20:48.893Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JThoracOncol-2016-Yu-PD-L1-expression-in-lung-cancer 2026-07-02T09:20:48.914Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JThoracOncol-2017-Faruki-Lung-adenocarcinoma-and-squamous-cell-carcinoma-gene-expression-subtypes-demonstrate-significant-differences-in-tumor 2026-07-02T09:20:48.961Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/JpnJCancerRes-1997-Yoshino-The-induction-of-cytotoxic-T-lymphocytes-against-HLA-A-locus-matched-lung-adenocarcinoma-in-patients-with-non-small 2026-07-02T09:20:48.888Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/LabInvest-2014-Velcheti-Programmed-death-ligand-1-expression-in-non-small-cell-lung-cancer 2026-07-02T09:20:48.963Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Lancet-2021-Meric-Bernstam-Enhancing-anti-tumour-efficacy-with-immunotherapy-combinations 2026-07-02T09:20:48.887Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/LancetOncol-2017-Turajlic-Insertion-and-deletion-derived-tumour-specific-neoantigens-and-the-immunogenic-phenotype-a-pan-cancer-analysis 2026-07-02T09:20:48.923Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ModPathol-2016-Rosenbaum-PD-L1-expression-in-colorectal-cancer-is-associated-with-microsatellite-instability,-BRAF-mutation,-medullary 2026-07-02T09:20:48.981Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/MolCancer-2019-Duan-Natural-killer-group-2d-receptor-and-its-ligands-in-cancer-immune-escape 2026-07-02T09:20:48.994Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/MolCancerTher-2022-Hollmen-Nonclinical-characterization-of-bexmarilimab,-a-clever-1-targeting-antibody-for-supporting-immune-defense-against 2026-07-02T09:20:48.875Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/MolTher-2009-Ahmed-Immunotherapy-for-osteosarcoma-genetic-modification-of-T-cells-overcomes-low-levels-of-tumor-antigen-expression 2026-07-02T09:20:48.875Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/MolTher-2020-Honda-Sustainable-tumor-suppressive-effect-of-iPSC-derived-rejuvenated-T-cells-targeting-cervical-cancers 2026-07-02T09:20:48.922Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NEnglJMed-2012-Ribas-Tumor-immunotherapy-directed-at-PD-1 2026-07-02T09:20:48.926Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NEnglJMed-2014-Snyder-Genetic-basis-for-clinical-response-to-CTLA-4-blockade-in-melanoma 2026-07-02T09:20:48.939Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NEnglJMed-2015-Ansell-PD-1-blockade-with-nivolumab-in-relapsed-or-refractory-hodgkin's-lymphoma 2026-07-02T09:20:48.966Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NEnglJMed-2016-Zaretsky-Mutations-associated-with-acquired-resistance-to-PD-1-blockade-in-melanoma 2026-07-02T09:20:49.020Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatBiomedEng-2026-Huang-Programmable-mRNA-3utr-engineering-restores-MHC-I-and-overcomes-immune-evasion-in-prostate-cancer 2026-07-02T09:20:48.942Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatBiotechnol-2013-Kloss-Combinatorial-antigen-recognition-with-balanced-signaling-promotes-selective-tumor-eradication-by-engineered-T-cells 2026-07-02T09:20:48.978Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatBiotechnol-2018-Bentzen-T-cell-receptor-fingerprinting-enables-in-depth-characterization-of-the-interactions-governing-recognition-of 2026-07-02T09:20:49.015Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatBiotechnol-2020-Dolgin-Antibody-engineers-seek-optimal-drug-targeting-TIGIT-checkpoint 2026-07-02T09:20:48.918Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatBiotechnol-2021-Dileepan-MHC-class-II-tetramers-engineered-for-enhanced-binding-to-CD4-improve-detection-of-antigen-specific-T-cells 2026-07-02T09:20:49.007Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatBiotechnol-2021-Sugata-Affinity-matured-HLA-class-II-dimers-for-robust-staining-of-antigen-specific-CD4+-T-cells 2026-07-02T09:20:48.946Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatBiotechnol-2022-Chong-Identification-of-tumor-antigens-with-immunopeptidomics 2026-07-02T09:20:48.932Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatBiotechnol-2026-Gupta-Immune-remodeling-mRNAs-expressing-IRF8-or-NIK-generate-durable-antitumor-immunity-in-multiple-cancer-models 2026-07-02T09:20:49.016Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatCancer-2022-Nishiga-Radiotherapy-in-combination-with-CD47-blockade-elicits-a-macrophage-mediated-abscopal-effect 2026-07-02T09:20:48.891Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatCancer-2023-Lerner-CD8+-T-cells-maintain-killing-of-MHC-I-negative-tumor-cells-through-the-NKG2D-NKG2DL-axis 2026-07-02T09:20:49.005Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatCancer-2026-Bernstock-Oncolytic-viruses-and-cytokine-based-gene-therapies-reprogram-the-tumor-microenvironment 2026-07-02T09:20:48.907Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatCancer-2026-Melero-Safety-and-activity-of-ro7300490,-a-bispecific-CD40-agonist-targeted-to-fibroblast-activation-protein,-in-patients-with 2026-07-02T09:20:48.972Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatCancer-2026-Steeghs-Tumor-localized-CD40-agonism-with-mp0317,-a-FAP-x-CD40-darpin,-reprograms-the-tumor-microenvironment-in-patients-with 2026-07-02T09:20:48.947Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatCellBiol-2026-Wang-Slc2a1+-tumour-associated-macrophages-spatially-control-cd8+-t-cell-function-and-drive-resistance-to-immunotherapy-in 2026-07-02T09:20:48.978Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatCommun-2013-Yoshihara-Inferring-tumour-purity-and-stromal-and-immune-cell-admixture-from-expression-data 2026-07-02T09:20:48.869Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatCommun-2016-Koyama-Adaptive-resistance-to-therapeutic-PD-1-blockade-is-associated-with-upregulation-of-alternative-immune-checkpoints 2026-07-02T09:20:48.941Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatCommun-2017-Sade-Feldman-Resistance-to-checkpoint-blockade-therapy-through-inactivation-of-antigen-presentation 2026-07-02T09:20:48.950Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatCommun-2018-Gettinger-A-dormant-TIL-phenotype-defines-non-small-cell-lung-carcinomas-sensitive-to-immune-checkpoint-blockers 2026-07-02T09:20:48.905Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatCommun-2020-Reuben-Comprehensive-T-cell-repertoire-characterization-of-non-small-cell-lung-cancer 2026-07-02T09:20:48.999Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatCommun-2021-Kim-CD177-modulates-the-function-and-homeostasis-of-tumor-infiltrating-regulatory-t-cells 2026-07-02T09:20:48.916Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatCommun-2021-Valpione-The-T-cell-receptor-repertoire-of-tumor-infiltrating-T-cells-is-predictive-and-prognostic-for-cancer-survival 2026-07-02T09:20:48.891Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatCommun-2026-Ito-Phenotype-of-circulating-tumor-reactive-t-cells-predicts-immune-checkpoint-inhibitor-response-in-non-small-cell-lung 2026-07-02T09:20:48.874Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatGenet-2016-Riaz-Recurrent-SERPINB3-and-SERPINB4-mutations-in-patients-who-respond-to-anti-CTLA4-immunotherapy 2026-07-02T09:20:48.901Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatGenet-2020-Lakatos-Evolutionary-dynamics-of-neoantigens-in-growing-tumors 2026-07-02T09:20:48.935Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatGenet-2023-Ravi-Genomic-and-transcriptomic-analysis-of-checkpoint-blockade-response-in-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:48.925Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatImmunol-2000-Diefenbach-Ligands-for-the-murine-NKG2D-receptor-expression-by-tumor-cells-and-activation-of-NK-cells-and-macrophages 2026-07-02T09:20:48.939Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatImmunol-2002-Dunn-The-three-Es-of-cancer-immunoediting 2026-07-02T09:20:48.908Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatImmunol-2002-Freiberg-Staging-and-resetting-T-cell-activation-in-SMACs 2026-07-02T09:20:48.905Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatImmunol-2010-Goodnow-Control-systems-and-decision-making-for-antibody-production 2026-07-02T09:20:49.026Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatImmunol-2010-Mueller-Mechanisms-maintaining-peripheral-tolerance 2026-07-02T09:20:48.974Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatImmunol-2011-Wherry-T-cell-exhaustion 2026-07-02T09:20:48.954Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatImmunol-2013-Okazaki-A-rheostat-for-immune-responses-the-unique-properties-of-PD-1-and-their-advantages-for-clinical-application 2026-07-02T09:20:48.907Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatImmunol-2016-Moro-Interferon-and-IL-27-antagonize-the-function-of-group-2-innate-lymphoid-cells-and-type-2-innate-immune-responses 2026-07-02T09:20:48.971Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatImmunol-2018-Brameshuber-Monomeric-TCRs-drive-T-cell-antigen-recognition 2026-07-02T09:20:48.975Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatImmunol-2019-Mann-Tick-TOX,-it's-time-for-T-cell-exhaustion 2026-07-02T09:20:48.930Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatImmunol-2020-Aksoylar-PD-1+-treg-cells-a-foe-in-cancer-immunotherapy 2026-07-02T09:20:48.913Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatImmunol-2020-Bonaguro-CRELD1-modulates-homeostasis-of-the-immune-system-in-mice-and-humans 2026-07-02T09:20:48.886Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatImmunol-2020-Kumagai-The-PD-1-expression-balance-between-effector-and-regulatory-T-cells-predicts-the-clinical-efficacy-of-PD-1-blockade 2026-07-02T09:20:49.020Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatImmunol-2021-Labarta-Bajo-BAtCHing-stem-like-T-cells-during-exhaustion 2026-07-02T09:20:48.895Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatImmunol-2021-Liu-Mitochondria-orchestrate-T-cell-fate-and-function 2026-07-02T09:20:48.971Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatImmunol-2021-Lopes-Distinct-metabolic-programs-established-in-the-thymus-control-effector-functions-of-gammadelta-T-cell-subsets-in-tumor 2026-07-02T09:20:48.874Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatImmunol-2022-Lee-Significance-of-bystander-T-cell-activation-in-microbial-infection 2026-07-02T09:20:52.368Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatImmunol-2022-Liu-tRNA-m1A-modification-promotes-T-cell-expansion-via-efficient-MYC-protein-synthesis 2026-07-02T09:20:48.925Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatImmunol-2026-Kim-Engineering-NK-and-T-cells-with-metabolite-sensing-receptors-to-target-solid-tumors 2026-07-02T09:20:48.912Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatMater-2026-Pires-IL-12-releasing-nanoparticles-for-effective-immunotherapy-of-metastatic-ovarian-cancer 2026-07-02T09:20:48.888Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatMed-1998-Rosenberg-Immunologic-and-therapeutic-evaluation-of-a-synthetic-peptide-vaccine-for-the-treatment-of-patients-with-metastatic 2026-07-02T09:20:48.905Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatMed-1999-Dong-B7-H1,-a-third-member-of-the-B7-family,-co-stimulates-T-cell-proliferation-and-interleukin-10-secretion 2026-07-02T09:20:48.892Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatMed-2002-Dong-Tumor-associated-B7-H1-promotes-T-cell-apoptosis-a-potential-mechanism-of-immune-evasion 2026-07-02T09:20:48.970Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatMed-2007-Parsa-Loss-of-tumor-suppressor-PTEN-function-increases-B7-H1-expression-and-immunoresistance-in-glioma 2026-07-02T09:20:48.882Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatMed-2013-Robbins-Mining-exomic-sequencing-data-to-identify-mutated-antigens-recognized-by-adoptively-transferred-tumor-reactive-T-cells 2026-07-02T09:20:48.960Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatMed-2015-Gentles-The-prognostic-landscape-of-genes-and-infiltrating-immune-cells-across-human-cancers 2026-07-02T09:20:48.954Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatMed-2016-Moynihan-Eradication-of-large-established-tumors-in-mice-by-combination-immunotherapy-that-engages-innate-and-adaptive-immune 2026-07-02T09:20:49.019Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatMed-2016-Pozzi-The-EGFR-specific-antibody-cetuximab-combined-with-chemotherapy-triggers-immunogenic-cell-death 2026-07-02T09:20:48.990Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatMed-2016-Saito-Two-FOXP3(+)CD4(+)-T-cell-subpopulations-distinctly-control-the-prognosis-of-colorectal-cancers 2026-07-02T09:20:48.980Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatMed-2018-Barry-A-natural-killer-dendritic-cell-axis-defines-checkpoint-therapy-responsive-tumor-microenvironments 2026-07-02T09:20:52.388Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatMed-2018-Binnewies-Understanding-the-tumor-immune-microenvironment-(TIME)-for-effective-therapy 2026-07-02T09:20:48.965Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatMed-2018-Formenti-Radiotherapy-induces-responses-of-lung-cancer-to-CTLA-4-blockade 2026-07-02T09:20:48.943Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatMed-2018-Krieg-High-dimensional-single-cell-analysis-predicts-response-to-anti-PD-1-immunotherapy 2026-07-02T09:20:49.006Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatMed-2018-Savas-Single-cell-profiling-of-breast-cancer-T-cells-reveals-a-tissue-resident-memory-subset-associated-with-improved-prognosis 2026-07-02T09:20:48.977Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatMed-2018-Thommen-A-transcriptionally-and-functionally-distinct-PD-1+-CD8+-T-cell-pool-with-predictive-potential-in-non-small-cell-lung 2026-07-02T09:20:48.929Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatMed-2019-Chowdhury-Programmable-bacteria-induce-durable-tumor-regression-and-systemic-antitumor-immunity 2026-07-02T09:20:48.876Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatMed-2019-Yost-Clonal-replacement-of-tumor-specific-T-cells-following-PD-1-blockade 2026-07-02T09:20:48.987Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatMed-2020-Fairfax-Peripheral-CD8+-T-cell-characteristics-associated-with-durable-responses-to-immune-checkpoint-blockade-in-patients-with 2026-07-02T09:20:48.893Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatMed-2020-Laughney-Regenerative-lineages-and-immune-mediated-pruning-in-lung-cancer-metastasis 2026-07-02T09:20:49.002Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatMed-2020-Yofe-Single-cell-genomic-approaches-for-developing-the-next-generation-of-immunotherapies 2026-07-02T09:20:48.899Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatMed-2021-Liu-Evolution-of-delayed-resistance-to-immunotherapy-in-a-melanoma-responder 2026-07-02T09:20:49.021Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatMed-2021-Powles-An-adaptive,-biomarker-directed-platform-study-of-durvalumab-in-combination-with-targeted-therapies-in-advanced 2026-07-02T09:20:48.924Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatMed-2023-Chu-Pan-cancer-T-cell-atlas-links-a-cellular-stress-response-state-to-immunotherapy-resistance 2026-07-02T09:20:48.875Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatMed-2026-Gonzalez-Kozlova-Humoral-IgG1-responses-to-tumor-antigens-underpin-clinical-outcomes-in-immune-checkpoint-blockade 2026-07-02T09:20:48.876Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatMetab-2024-Wang-Acetate-reprogrammes-tumour-metabolism-and-promotes-PD-l1-expression-and-immune-evasion-by-upregulating-c-Myc 2026-07-02T09:20:49.009Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevCancer-2012-Fridman-The-immune-contexture-in-human-tumours-impact-on-clinical-outcome 2026-07-02T09:20:48.969Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevCancer-2012-Pardoll-The-blockade-of-immune-checkpoints-in-cancer-immunotherapy 2026-07-02T09:20:48.925Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevCancer-2016-Topalian-Mechanism-driven-biomarkers-to-guide-immune-checkpoint-blockade-in-cancer-therapy 2026-07-02T09:20:48.990Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevCancer-2019-Feng-Phagocytosis-checkpoints-as-new-targets-for-cancer-immunotherapy 2026-07-02T09:20:48.997Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevCancer-2019-Havel-The-evolving-landscape-of-biomarkers-for-checkpoint-inhibitor-immunotherapy 2026-07-02T09:20:48.913Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevCancer-2020-Bruni-The-immune-contexture-and-immunoscore-in-cancer-prognosis-and-therapeutic-efficacy 2026-07-02T09:20:49.026Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevCancer-2020-vanDerLeun-CD8+-T-cell-states-in-human-cancer-insights-from-single-cell-analysis 2026-07-02T09:20:48.887Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevCancer-2021-Bayik-Cancer-stem-cell-immune-cell-crosstalk-in-tumour-progression 2026-07-02T09:20:48.993Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevCancer-2021-Chabanon-Targeting-the-DNA-damage-response-in-immuno-oncology-developments-and-opportunities 2026-07-02T09:20:49.001Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevCancer-2021-Jhunjhunwala-Antigen-presentation-in-cancer-insights-into-tumour-immunogenicity-and-immune-evasion 2026-07-02T09:20:48.977Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevCancer-2026-Lu-Opportunities-and-challenges-of-targeting-cGAS-STING-in-cancer 2026-07-02T09:20:48.955Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevClinOncol-2016-Romero-Immunotherapy-PD-1-says-goodbye,-TIM-3-says-hello 2026-07-02T09:20:48.961Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevClinOncol-2017-Weichselbaum-Radiotherapy-and-immunotherapy-a-beneficial-liaison 2026-07-02T09:20:48.933Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevClinOncol-2021-Hou-Targeting-cancer-promoting-inflammation-have-anti-inflammatory-therapies-come-of-age 2026-07-02T09:20:48.940Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevClinOncol-2021-LopezDeRodas-Tumour-antigen-induced-T-cell-exhaustion-the-archenemy-of-immune-hot-malignancies 2026-07-02T09:20:48.938Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevClinOncol-2022-Kraehenbuehl-Enhancing-immunotherapy-in-cancer-by-targeting-emerging-immunomodulatory-pathways 2026-07-02T09:20:49.009Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevDrugDiscov-2020-Hogg-Targeting-the-epigenetic-regulation-of-antitumour-immunity 2026-07-02T09:20:48.877Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevImmunol-2002-Murphy-The-lineage-decisions-of-helper-T-cells 2026-07-02T09:20:48.871Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevImmunol-2003-Raulet-Roles-of-the-NKG2D-immunoreceptor-and-its-ligands 2026-07-02T09:20:49.025Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevImmunol-2008-Zou-Inhibitory-B7-family-molecules-in-the-tumour-microenvironment 2026-07-02T09:20:49.009Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevImmunol-2009-Wilson-Epigenetic-control-of-T-helper-cell-differentiation 2026-07-02T09:20:48.983Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevImmunol-2012-Maecker-Standardizing-immunophenotyping-for-the-human-immunology-project 2026-07-02T09:20:48.912Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevImmunol-2013-Chen-Molecular-mechanisms-of-T-cell-co-stimulation-and-co-inhibition 2026-07-02T09:20:52.432Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevImmunol-2014-Farber-Human-memory-T-cells-generation,-compartmentalization-and-homeostasis 2026-07-02T09:20:49.003Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevImmunol-2014-Speiser-T-cell-differentiation-in-chronic-infection-and-cancer-functional-adaptation-or-exhaustion 2026-07-02T09:20:48.877Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevImmunol-2015-Wherry-Molecular-and-cellular-insights-into-T-cell-exhaustion 2026-07-02T09:20:49.013Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevImmunol-2026-Bianca-CRISPR-screen-reveals-regulators-of-age-associated-cd8+-t-cell-dysfunction-in-cancer 2026-07-02T09:20:48.873Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevImmunol-2026-Elahi-Immune-regulation-by-erythroid-cells-how-erythroid-progenitor-cells-and-mature-red-blood-cells-shape-immunity 2026-07-02T09:20:48.921Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/NatRevImmunol-2026-Sinha-O-glcnacylation-shapes-macrophage-tissue-residency-and-alternative-activation 2026-07-02T09:20:49.012Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-1991-Peters-Segregation-of-MHC-class-II-molecules-from-MHC-class-I-molecules-in-the-golgi-complex-for-transport-to-lysosomal 2026-07-02T09:20:48.883Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2001-Shankaran-IFNgamma-and-lymphocytes-prevent-primary-tumour-development-and-shape-tumour-immunogenicity 2026-07-02T09:20:48.942Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2005-Goodnow-Cellular-and-genetic-mechanisms-of-self-tolerance-and-autoimmunity 2026-07-02T09:20:48.998Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2006-Barber-Restoring-function-in-exhausted-CD8-T-cells-during-chronic-viral-infection 2026-07-02T09:20:48.927Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2009-Ishikawa-STING-regulates-intracellular-DNA-mediated,-type-I-interferon-dependent-innate-immunity 2026-07-02T09:20:48.942Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2010-Moro-Innate-production-of-T(H)2-cytokines-by-adipose-tissue-associated-c-Kit(+)Sca-1(+)-lymphoid-cells 2026-07-02T09:20:48.889Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2011-Mellman-Cancer-immunotherapy-comes-of-age 2026-07-02T09:20:48.931Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2012-Matsushita-Cancer-exome-analysis-reveals-a-T-cell-dependent-mechanism-of-cancer-immunoediting 2026-07-02T09:20:48.890Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2014-Gubin-Checkpoint-blockade-cancer-immunotherapy-targets-tumour-specific-mutant-antigens 2026-07-02T09:20:48.990Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2014-Herbst-Predictive-correlates-of-response-to-the-anti-PD-L1-antibody-MPDL3280A-in-cancer-patients 2026-07-02T09:20:48.934Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2014-Nogrady-Immunotherapy-chemical-tricks 2026-07-02T09:20:48.887Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2014-Powles-MPDL3280A-(anti-PD-L1)-treatment-leads-to-clinical-activity-in-metastatic-bladder-cancer 2026-07-02T09:20:48.872Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2014-Tumeh-PD-1-blockade-induces-responses-by-inhibiting-adaptive-immune-resistance 2026-07-02T09:20:48.915Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2015-Kreiter-Mutant-MHC-class-II-epitopes-drive-therapeutic-immune-responses-to-cancer 2026-07-02T09:20:48.944Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2015-Sabado-Cancer-immunotherapy-dendritic-cell-vaccines-on-the-move 2026-07-02T09:20:48.965Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2016-Im-Defining-CD8+-T-cells-that-provide-the-proliferative-burst-after-PD-1-therapy 2026-07-02T09:20:48.885Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2016-Yang-Potentiating-the-antitumour-response-of-CD8(+)-T-cells-by-modulating-cholesterol-metabolism 2026-07-02T09:20:48.994Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2017-Burr-CMTM6-maintains-the-expression-of-PD-L1-and-regulates-anti-tumour-immunity 2026-07-02T09:20:52.460Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2017-Chen-Elements-of-cancer-immunity-and-the-cancer-immune-set-point 2026-07-02T09:20:49.005Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2017-Huang-T-cell-invigoration-to-tumour-burden-ratio-associated-with-anti-PD-1-response 2026-07-02T09:20:48.894Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2017-Luksza-A-neoantigen-fitness-model-predicts-tumour-response-to-checkpoint-blockade-immunotherapy 2026-07-02T09:20:48.916Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2017-Manguso-In-vivo-CRISPR-screening-identifies-ptpn2-as-a-cancer-immunotherapy-target 2026-07-02T09:20:48.951Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2017-Patel-Identification-of-essential-genes-for-cancer-immunotherapy 2026-07-02T09:20:48.887Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2017-Sahin-Personalized-RNA-mutanome-vaccines-mobilize-poly-specific-therapeutic-immunity-against-cancer 2026-07-02T09:20:48.891Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2018-Haag-Targeting-STING-with-covalent-small-molecule-inhibitors 2026-07-02T09:20:48.908Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2018-Mariathasan-TGFbeta-attenuates-tumour-response-to-PD-L1-blockade-by-contributing-to-exclusion-of-T-cells 2026-07-02T09:20:49.027Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2019-Esterhazy-Compartmentalized-gut-lymph-node-drainage-dictates-adaptive-immune-responses 2026-07-02T09:20:48.949Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2019-Ishizuka-Loss-of-ADAR1-in-tumours-overcomes-resistance-to-immune-checkpoint-blockade 2026-07-02T09:20:48.882Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2019-Khan-TOX-transcriptionally-and-epigenetically-programs-CD8-T-cell-exhaustion 2026-07-02T09:20:48.898Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2019-Rosenthal-Neoantigen-directed-immune-escape-in-lung-cancer-evolution 2026-07-02T09:20:49.010Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2019-Tanoue-A-defined-commensal-consortium-elicits-CD8-T-cells-and-anti-cancer-immunity 2026-07-02T09:20:48.903Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2020-Lawson-Functional-genomic-landscape-of-cancer-intrinsic-evasion-of-killing-by-T-cells 2026-07-02T09:20:48.891Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2021-Caushi-Transcriptional-programs-of-neoantigen-specific-TIL-in-anti-PD-1-treated-lung-cancers 2026-07-02T09:20:49.003Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2022-Hong-Immune-tolerance-of-food-is-mediated-by-layers-of-CD4+-T-cell-dysfunction 2026-07-02T09:20:48.992Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2022-Legut-A-genome-scale-screen-for-synthetic-drivers-of-T-cell-proliferation 2026-07-02T09:20:48.988Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2023-Puig-Saus-Neoantigen-targeted-CD8+-T-cell-responses-with-PD-1-blockade-therapy 2026-07-02T09:20:49.017Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2023-Reina-Campos-Metabolic-programs-of-T-cell-tissue-residency-empower-tumour-immunity 2026-07-02T09:20:48.925Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2023-Rojas-Personalized-RNA-neoantigen-vaccines-stimulate-t-cells-in-pancreatic-cancer 2026-07-02T09:20:48.889Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2024-Goto-SOX17-enables-immune-evasion-of-early-colorectal-adenomas-and-cancers 2026-07-02T09:20:48.930Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2025-Gong-Multi-omic-profiling-reveals-age-related-immune-dynamics-in-healthy-adults 2026-07-02T09:20:48.945Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2025-Ikeda-Immune-evasion-through-mitochondrial-transfer-in-the-tumour-microenvironment 2026-07-02T09:20:48.958Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2026-Cassandras-A-glucocorticoid-FAS-axis-controls-immune-evasion-during-metastatic-seeding 2026-07-02T09:20:48.965Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2026-Kumar-Postprandial-lipid-metabolism-durably-enhances-t-cell-immunity 2026-07-02T09:20:48.958Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2026-Li-SLAMF6-as-a-drug-targetable-suppressor-of-t-cell-immunity-against-cancer 2026-07-02T09:20:49.024Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2026-Medina-Exposed-phosphatidylserine-is-an-inhibitory-molecule-in-T-cell-exhaustion 2026-07-02T09:20:48.955Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Nature-2026-Nicola-Polyclonal-selection-of-immune-checkpoint-mutations-in-thyroid-autoimmunity 2026-07-02T09:20:48.979Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Oncogene-2016-Hernandez-Damage-associated-molecular-patterns-in-cancer-a-double-edged-sword 2026-07-02T09:20:48.869Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Oncogene-2017-Wang-BIN1-reverses-PD-L1-mediated-immune-escape-by-inactivating-the-c-MYC-and-EGFRMAPK-signaling-pathways-in-non-small-cell 2026-07-02T09:20:48.960Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Oncotarget-2016-Lin-The-prevalence-and-clinicopathological-features-of-programmed-death-ligand-1-(PD-L1)-expression-a-pooled-analysis-of 2026-07-02T09:20:48.963Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Oncotarget-2017-Chen-Differentiated-regulation-of-immune-response-related-genes-between-LUAD-and-LUSC-subtypes-of-lung-cancers 2026-07-02T09:20:48.937Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ProcNatlAcadSciUSA-1996-Groh-Cell-stress-regulated-human-major-histocompatibility-complex-class-I-gene-expressed-in-gastrointestinal-epithelium 2026-07-02T09:20:48.902Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ProcNatlAcadSciUSA-1999-Groh-Broad-tumor-associated-expression-and-recognition-by-tumor-derived-gamma-delta-T-cells-of-MICA-and-MICB 2026-07-02T09:20:48.918Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ProcNatlAcadSciUSA-2000-Johnson-A-supramolecular-basis-for-CD45-tyrosine-phosphatase-regulation-in-sustained-T-cell-activation 2026-07-02T09:20:48.950Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ProcNatlAcadSciUSA-2002-Iwai-Involvement-of-PD-L1-on-tumor-cells-in-the-escape-from-host-immune-system-and-tumor-immunotherapy-by-PD-L1-blockade 2026-07-02T09:20:48.935Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ProcNatlAcadSciUSA-2010-Curran-PD-1-and-CTLA-4-combination-blockade-expands-infiltrating-T-cells-and-reduces-regulatory-T-and-myeloid-cells-within-B16 2026-07-02T09:20:48.951Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ProcNatlAcadSciUSA-2014-Qi-Diversity-and-clonal-selection-in-the-human-T-cell-repertoire 2026-07-02T09:20:48.968Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ProcNatlAcadSciUSA-2018-Chen-B7-H1-maintains-the-polyclonal-T-cell-response-by-protecting-dendritic-cells-from-cytotoxic-T-lymphocyte-destruction 2026-07-02T09:20:48.937Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ProcNatlAcadSciUSA-2018-Wang-Adjuvant-effect-of-the-novel-TLR1TLR2-agonist-diprovocim-synergizes-with-anti-PD-L1-to-eliminate-melanoma-in-mice 2026-07-02T09:20:48.947Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ProcNatlAcadSciUSA-2019-Kamada-PD-1+-regulatory-T-cells-amplified-by-PD-1-blockade-promote-hyperprogression-of-cancer 2026-07-02T09:20:48.953Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ProcNatlAcadSciUSA-2021-Hellmeier-DNA-origami-demonstrate-the-unique-stimulatory-power-of-single-pMHCs-as-T-cell-antigens 2026-07-02T09:20:48.924Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ProcNatlAcadSciUSA-2023-Sender-The-total-mass,-number,-and-distribution-of-immune-cells-in-the-human-body 2026-07-02T09:20:48.909Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ProcNatlAcadSciUSA-2026-Robay-Targeting-CRTC2-reverses-STK11-mutant-NSCLC-tumor-resistance-to-immunotherapy 2026-07-02T09:20:48.954Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ProcNatlAcadSciUSA-2026-Yuan-Targeting-XIAP-coordinated-PKC-signaling-resensitizes-PD-1-refractory-tumors-for-rechallenge 2026-07-02T09:20:48.974Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/STARProtoc-2023-Quigley-Protocol-for-investigating-tertiary-lymphoid-structures-in-human-and-murine-fixed-tissue-sections-using-Opal-TSA-multiplex-immunohistochemistry 2026-07-02T09:20:48.914Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/STARProtoc-2025-Chang-Protocol-for-a-patient-derived-preclinical-platform-to-model-tumor-immune-interactions-and-evaluate-therapeutic-efficacy 2026-07-02T09:20:48.907Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/ScandJImmunol-2012-Donia-Characterization-and-comparison-of-'standard'-and-'young'-tumour-infiltrating-lymphocytes-for-adoptive-cell-therapy-at 2026-07-02T09:20:49.014Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/SciAdv-2021-Han-Weighting-tumor-specific-TCR-repertoires-as-a-classifier-to-stratify-the-immunotherapy-delivery-in-non-small-cell-lung 2026-07-02T09:20:48.929Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/SciImmunol-2020-Lee-Regulatory-T-cell-control-of-systemic-immunity-and-immunotherapy-response-in-liver-metastasis 2026-07-02T09:20:48.915Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/SciImmunol-2021-Watson-Immune-checkpoint-blockade-sensitivity-and-progression-free-survival-associates-with-baseline-CD8+-T-cell-clone-size 2026-07-02T09:20:48.939Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/SciImmunol-2022-Kvedaraite-Human-dendritic-cells-in-cancer 2026-07-02T09:20:48.962Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/SciImmunol-2022-Oja-Two-sides-of-the-same-coin-protective-versus-pathogenic-CD4+-resident-memory-T-cells 2026-07-02T09:20:48.880Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/SciImmunol-2026-Corrigan-In-vivo-reprogramming-of-cytotoxic-effector-CD8-T-cells-via-fractalkine-conjugated-mRNA-LNPs 2026-07-02T09:20:48.896Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/SciImmunol-2026-Li-Citraconate-preserves-T-cell-stemness-and-antitumor-immunity 2026-07-02T09:20:48.962Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/SciImmunol-2026-Wei-Foxp3-drives-context-dependent-epigenetic-programs-that-define-regulatory-t-cell-molecular-identity-and-function 2026-07-02T09:20:48.910Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/SciSignal-2020-Ambler-PD-1-suppresses-the-maintenance-of-cell-couples-between-cytotoxic-T-cells-and-target-tumor-cells-within-the-tumor 2026-07-02T09:20:49.023Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/SciTranslMed-2012-Taube-Colocalization-of-inflammatory-response-with-B7-h1-expression-in-human-melanocytic-lesions-supports-an-adaptive 2026-07-02T09:20:48.928Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/SciTranslMed-2013-Spranger-Up-regulation-of-PD-L1,-IDO,-and-t(regs)-in-the-melanoma-tumor-microenvironment-is-driven-by-CD8(+)-T-cells 2026-07-02T09:20:49.001Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/SciTranslMed-2014-Kvistborg-Anti-CTLA-4-therapy-broadens-the-melanoma-reactive-CD8+-T-cell-response 2026-07-02T09:20:48.958Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/SciTranslMed-2014-Vantourout-Immunological-Visibility-Posttranscriptional-regulation-of-human-NKG2DL-by-the-EGFR-receptor-pathway 2026-07-02T09:20:48.945Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/SciTranslMed-2015-Fu-STING-agonist-formulated-cancer-vaccines-can-cure-established-tumors-resistant-to-PD-1-blockade 2026-07-02T09:20:48.926Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/SciTranslMed-2017-Allen-Combined-antiangiogenic-and-anti-PD-L1-therapy-stimulates-tumor-immunity-through-HEV-formation 2026-07-02T09:20:48.977Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/SciTranslMed-2019-Ishihara-Targeted-antibody-and-cytokine-cancer-immunotherapies-through-collagen-affinity 2026-07-02T09:20:48.886Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/SciTranslMed-2020-Hao-Combination-of-metabolic-intervention-and-T-cell-therapy-enhances-solid-tumor-immunotherapy 2026-07-02T09:20:48.988Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/SciTranslMed-2020-Kalbasi-Uncoupling-interferon-signaling-and-antigen-presentation-to-overcome-immunotherapy-resistance-due-to-JAK1-loss-in 2026-07-02T09:20:48.860Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/SciTranslMed-2021-Foord-Characterization-of-ascites-and-tumor-infiltrating-gammadelta-T-cells-reveals-distinct-repertoires-and-a-beneficial 2026-07-02T09:20:49.015Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/SciTranslMed-2021-Shen-LAG-3-expression-on-peripheral-blood-cells-identifies-patients-with-poorer-outcomes-after-immune-checkpoint-blockade 2026-07-02T09:20:48.959Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/SciTranslMed-2026-Cohen-Chimeric-antigen-receptor-T-cells-against-the-IGHV4-34-B-cell-receptor-specifically-eliminate-neoplastic-and-autoimmune 2026-07-02T09:20:48.943Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/SciTranslMed-2026-Merkt-Natural-killer-cell-immunotherapy-reverses-lung-fibrosis-by-eliminating-senescent-fibroblasts 2026-07-02T09:20:48.953Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-1996-Leach-Enhancement-of-antitumor-immunity-by-CTLA-4-blockade 2026-07-02T09:20:48.956Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2001-Nishimura-Autoimmune-dilated-cardiomyopathy-in-PD-1-receptor-deficient-mice 2026-07-02T09:20:48.985Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2006-Galon-Type,-density,-and-location-of-immune-cells-within-human-colorectal-tumors-predict-clinical-outcome 2026-07-02T09:20:48.989Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2011-Schreiber-Cancer-immunoediting-integrating-immunity's-roles-in-cancer-suppression-and-promotion 2026-07-02T09:20:48.960Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2013-delaRoche-Hedgehog-signaling-controls-T-cell-killing-at-the-immunological-synapse 2026-07-02T09:20:48.998Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2014-Kuehn-Immune-dysregulation-in-human-subjects-with-heterozygous-germline-mutations-in-CTLA4 2026-07-02T09:20:48.919Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2014-Maeda-Detection-of-self-reactive-CD8+-T-cells-with-an-anergic-phenotype-in-healthy-individuals 2026-07-02T09:20:48.959Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2014-Tran-Cancer-immunotherapy-based-on-mutation-specific-CD4+-T-cells-in-a-patient-with-epithelial-cancer 2026-07-02T09:20:49.019Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2015-Joyce-T-cell-exclusion,-immune-privilege,-and-the-tumor-microenvironment 2026-07-02T09:20:48.876Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2015-Rizvi-Cancer-immunology.-mutational-landscape-determines-sensitivity-to-PD-1-blockade-in-non-small-cell-lung-cancer 2026-07-02T09:20:48.898Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2015-Schumacher-Neoantigens-in-cancer-immunotherapy 2026-07-02T09:20:52.556Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2015-Sharma-The-future-of-immune-checkpoint-therapy 2026-07-02T09:20:48.899Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2015-Steinle-Immunology.-MULT1plying-cancer-immunity 2026-07-02T09:20:48.989Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2015-Tran-Immunogenicity-of-somatic-mutations-in-human-gastrointestinal-cancers 2026-07-02T09:20:48.975Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2015-VanAllen-Genomic-correlates-of-response-to-CTLA-4-blockade-in-metastatic-melanoma 2026-07-02T09:20:48.938Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2016-Blank-CANCER-IMMUNOLOGY.-the-cancer-immunogram 2026-07-02T09:20:48.926Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2016-McGranahan-Clonal-neoantigens-elicit-T-cell-immunoreactivity-and-sensitivity-to-immune-checkpoint-blockade 2026-07-02T09:20:48.936Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2016-Stronen-Targeting-of-cancer-neoantigens-with-donor-derived-T-cell-receptor-repertoires 2026-07-02T09:20:48.967Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2017-Davoli-Tumor-aneuploidy-correlates-with-markers-of-immune-evasion-and-with-reduced-response-to-immunotherapy 2026-07-02T09:20:48.952Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2017-Hui-T-cell-costimulatory-receptor-CD28-is-a-primary-target-for-PD-1-mediated-inhibition 2026-07-02T09:20:48.917Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2017-LeDung-Mismatch-repair-deficiency-predicts-response-of-solid-tumors-to-PD-1-blockade 2026-07-02T09:20:48.870Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2017-Stubbington-Single-cell-transcriptomics-to-explore-the-immune-system-in-health-and-disease 2026-07-02T09:20:48.897Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2018-Chowell-Patient-HLA-class-I-genotype-influences-cancer-response-to-checkpoint-blockade-immunotherapy 2026-07-02T09:20:48.893Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2018-Ribas-Cancer-immunotherapy-using-checkpoint-blockade 2026-07-02T09:20:48.980Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2018-Routy-Gut-microbiome-influences-efficacy-of-PD-1-based-immunotherapy-against-epithelial-tumors 2026-07-02T09:20:48.889Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2018-Ruscetti-NK-cell-mediated-cytotoxicity-contributes-to-tumor-control-by-a-cytostatic-drug-combination 2026-07-02T09:20:48.979Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2019-Vodnala-T-cell-stemness-and-dysfunction-in-tumors-are-triggered-by-a-common-mechanism 2026-07-02T09:20:49.008Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2020-Balint-Supramolecular-attack-particles-are-autonomous-killing-entities-released-from-cytotoxic-T-cells 2026-07-02T09:20:49.021Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2020-Topalian-Neoadjuvant-checkpoint-blockade-for-cancer-immunotherapy 2026-07-02T09:20:48.933Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2021-Davar-Fecal-microbiota-transplant-overcomes-resistance-to-anti-PD-1-therapy-in-melanoma-patients 2026-07-02T09:20:48.999Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2021-Hsiue-Targeting-a-neoantigen-derived-from-a-common-TP53-mutation 2026-07-02T09:20:48.985Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2021-Spencer-Dietary-fiber-and-probiotics-influence-the-gut-microbiome-and-melanoma-immunotherapy-response 2026-07-02T09:20:49.024Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2021-Xu-Glycolysis-fuels-phosphoinositide-3-kinase-signaling-to-bolster-T-cell-immunity 2026-07-02T09:20:48.911Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2021-Zheng-Pan-cancer-single-cell-landscape-of-tumor-infiltrating-T-cells 2026-07-02T09:20:48.973Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2022-Lowery-Molecular-signatures-of-antitumor-neoantigen-reactive-T-cells-from-metastatic-human-cancers 2026-07-02T09:20:48.896Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2022-Ritter-ESCRT-mediated-membrane-repair-protects-tumor-derived-cells-against-T-cell-attack 2026-07-02T09:20:48.940Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2024-Ascic-In-vivo-dendritic-cell-reprogramming-for-cancer-immunotherapy 2026-07-02T09:20:48.937Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/Science-2026-Zhou-Intermetallic-nanoassemblies-potentiate-systemic-STING-activation 2026-07-02T09:20:49.013Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/SignalTransductTargetTher-2026-Chakraborty-Cortisol-resistant-CAR-NK-cells-overcome-steroid-induced-immunosuppression-in-lung-cancer 2026-07-02T09:20:48.920Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/SignalTransductTargetTher-2026-Chung-Rapid-CAR-screening-and-circRNA-driven-CAR-NK-cells-for-persistent-shed-resistant-immunotherapy 2026-07-02T09:20:48.892Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/SignalTransductTargetTher-2026-Dietze-Preventing-trogocytosis-by-cathepsin-b-inhibition-augments-CAR-t-cell-function 2026-07-02T09:20:48.999Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/TransplInt-2019-Minervina-T-cell-receptor-and-B-cell-receptor-repertoire-profiling-in-adaptive-immunity 2026-07-02T09:20:48.881Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/TrendsCancer-2026-Slater-Epigenetic,-epitranscriptomic,-and-metabolic-control-of-t-cell-exhaustion 2026-07-02T09:20:48.878Z https://research-2ry.pages.dev/Summary/Basic-Immunotherapy/eLife-2018-Morrissey-Chimeric-antigen-receptors-that-trigger-phagocytosis 2026-07-02T09:20:48.995Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/AnnOncol-2019-Hannigan-Liquid-biopsy-assay-for-lung-carcinoma-using-centrifuged-supernatants-from-fine-needle-aspiration-speecimens 2026-07-02T09:20:49.947Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/AnnOncol-2019-Zugazagoitia-Clinical-utility-of-plasma-based-digital-next-generation-sequencing-in-patients-with-advance-stage-lung-adenocarcinomas 2026-07-02T09:20:49.975Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/AnnOncol-2020-Liu-Sensitive-and-specific-multi-cancer-detection-and-localization-using-methylation-signatures-in-cell-free-DNA 2026-07-02T09:20:49.971Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/AnnOncol-2021-Klein-Clinical-validation-of-a-targeted-methylation-based-multi-cancer-early-detection-test-using-an-independent-validation 2026-07-02T09:20:49.948Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/AnnOncol-2022-Gale-Residual-ctDNA-after-treatment-predicts-early-relapse-in-patients-with-early-stage-non-small-cell-lung-cancer 2026-07-02T09:20:49.965Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/BMJOncol-2024-Yang-Circulating-tumour-cell-clusters-isolation,-biological-significance-and-therapeutic-implications 2026-07-02T09:20:49.947Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/BiochemCellBiol-2024-Penny-Chromatin-and-nucleosome-associated-features-in-liquid-biopsy-implications-for-cancer-biomarker-discovery 2026-07-02T09:20:49.954Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/BiopreservBiobank-2020-Heatlie-Specialized-cell-free-DNA-blood-collection-tubes-can-be-repurposed-for-extracellular-vesicle-isolation-A-pilot-study 2026-07-02T09:20:49.949Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/BrJCancer-2022-Zhang-Utility-of-cell-free-DNA-from-bronchial-washing-fluid-in-diagnosis-and-genomic-determination-for-radiology-suspected 2026-07-02T09:20:49.978Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/BrJCancer-2026-Lalchungnunga-Deconvolution-of-haematological-cancer-methylation-patterns-reveals-a-predominantly-non-disease-related-proliferation 2026-07-02T09:20:49.962Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/CancerCell-2019-vanDerPol-Toward-the-early-detection-of-cancer-by-decoding-the-epitgenetic-and-environmental-fingerprints-of-cell-free-DNA 2026-07-02T09:20:49.951Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/CancerCell-2020-Kilgour-Liquid-biopsy-based-biomarkers-of-treatment-response-and-resistance 2026-07-02T09:20:49.971Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/CancerCell-2024-Heeke-Tumor-and-circulating-free-DNA-methylation-identifies-clinically-relevant-small-cell-lung-cancer-subtypes 2026-07-02T09:20:49.954Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/CancerCell-2025-Dai-Circulating-tumor-cells-blood-based-detection,-molecular-biology,-and-clinical-applications 2026-07-02T09:20:49.971Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/CancerCell-2025-Tsui-Cell-free-DNA-fragmentomics-in-cancer 2026-07-02T09:20:49.963Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/CancerDiscov-2018-OLeary-The-genetic-landscape-and-clonal-evolution-of-breast-cancer-resistance-to-palbociclib-plus-fulvestrant-in-the-PALOMA-3 2026-07-02T09:20:49.979Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/CancerDiscov-2020-Zhang-Prognostic-and-predictive-impact-of-circulating-tumor-DNA-in-patients-with-advanced-cancers-treated-with-immune 2026-07-02T09:20:49.980Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/CancerGeneTher-2022-Shimizu-Pan-cancer-methylome-analysis-for-cancer-diagnosis-and-classification-of-cancer-cell-of-origin 2026-07-02T09:20:49.957Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/Cell-2016-Snyder-Cell-free-DNA-comprises-an-in-vivo-nucleosome-footprint-that-informs-its-tissues-of-origin 2026-07-02T09:20:49.952Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/Cell-2025-Black-Longitudinal-ultrasensitive-ctDNA-monitoring-for-high-resolution-lung-cancer-risk-prediction 2026-07-02T09:20:49.976Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/CellRepMed-2023-Batool-Extrinsic-and-intrinsic-preanalytical-variables-affecting-liquid-biopsy-in-cancer 2026-07-02T09:20:49.949Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/ClinCancerRes-2017-Sperger-Integrated-analysis-of-multiple-biomarkers-from-circulating-tumor-cells-enabled-by-exclusion-based-analyte-isolation 2026-07-02T09:20:49.973Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/ClinCancerRes-2018-Mohrmann-Liquid-biopsies-using-plasma-exosomal-nucleic-acids-and-plasma-cell-free-DNA-compared-with-clinical-outcomes-of 2026-07-02T09:20:49.953Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/ClinCancerRes-2019-Leighl-Clinical-utility-of-comprehensive-cell-free-DNA-analysis-to-identify-genomic-biomarkers-in-patients-with-newly 2026-07-02T09:20:49.979Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/ClinCancerRes-2020-Hellmann-Circulating-tumor-DNA-analysis-to-assess-risk-of-progression-after-long-term-response-to-PD-(l)1-blockade-in-NSCLC 2026-07-02T09:20:49.977Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/ClinCancerRes-2021-Si-A-blood-based-assay-for-assessment-of-tumor-mutational-burden-in-first-line-metastatic-NSCLC-treatment-Results-from-the-MYSTIC-study 2026-07-02T09:20:49.967Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/ClinCancerRes-2022-Xia-Perioperative-ctDNA-based-molecular-residual-disease-detection-for-non-small-cell-lung-cancer-A-prospective-multicenter 2026-07-02T09:20:49.952Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/ClinCancerRes-2024-Nakamura-Colorectal-cancer-recurrence-prediction-using-a-tissue-free-epigenomic-minimal-residual-disease-assay 2026-07-02T09:20:49.953Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/ClinChem-2022-Choy-Single-molecule-sequencing-enables-long-cell-free-DNA-detection-and-direct-methylation-analysis-for-cancer-patients 2026-07-02T09:20:49.972Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/ClinLungCancer-2021-DallOlio-PD-L1-expression-in-circulating-tumor-cells-as-a-promising-prognostic-biomarker-in-advanced-NSCLC-treated-with-immune-checkpoint-inhibitors 2026-07-02T09:20:49.971Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/ClinTranslMed-2025-Wang-Cell-free-epigenomes-enhanced-fragmentomics-based-model-for-early-detection-of-lung-cancer 2026-07-02T09:20:49.960Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/Cytopathology-2026-Leporati-From-tumour-to-bloodstream-advancing-PD-L1-testing-with-liquid-biopsies-in-non-small-cell-lung-cancer 2026-07-02T09:20:49.962Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/EurRespirJ-2021-Gaga-Validation-of-lung-EpiCheck,-a-novel-methylation-based-blood-assay,-for-the-detection-of-lung-cancer-in-European-and-Chinese-high-risk-individuals 2026-07-02T09:20:49.957Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/FrontMolBiosci-2026-Cao-Research-progress-of-surface-enhanced-raman-scattering-technology-in-tumor-liquid-biopsy 2026-07-02T09:20:49.969Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/FrontOncol-2024-Cheng-A-review-on-the-impact-of-single-stranded-library-preparation-on-plasma-cell-free-diversity-for-cancer-detection 2026-07-02T09:20:49.955Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/GenomeRes-2024-Muller-A-novel-approach-for-in-vivo-DNA-footprinting-using-short-double-stranded-cell-free-DNA-from-plasma 2026-07-02T09:20:49.962Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/JAMAOncol-2019-Tie-Circulating-tumor-DNA-analyses-as-markers-of-recurrence-risk-and-benefit-of-adjuvant-therapy-for-stage-III-colon-cancer 2026-07-02T09:20:49.968Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/JAMAOncol-2019-Wang-Assessment-of-blood-tumor-mutational-burden-as-a-potential-biomarker-for-immunotherapy-in-patients-with-non-small-cell 2026-07-02T09:20:49.948Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/JAMAOncol-2023-Mo-Early-detection-of-molecular-residual-disease-and-risk-stratification-for-stage-I-to-III-colorectal-cancer-via 2026-07-02T09:20:49.962Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/JCOPrecisOncol-2022-Moran-Monitoring-PD-L1-expression-on-circulating-tumor-associated-cells-in-recurrent-metastatic-non-small-cell-lung-carcinoma 2026-07-02T09:20:49.961Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/JCOPrecisOncol-2025-Ajay-Comprehensive-analysis-of-the-value-of-dynamic-changes-in-circulating-tumor-DNA-in-small-cell-lung-cancer 2026-07-02T09:20:49.955Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/JCOPrecisOncol-2025-Samol-Prospective-multicenter-study-evaluating-a-combined-circulating-tumor-DNA-and-circulating-tumor-RNA-liquid-biopsy-in 2026-07-02T09:20:49.958Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/JClinOncol-2014-Smerage-Circulating-tumor-cells-and-response-to-chemotherapy-in-metastatic-breast-cancer-SWOG-S0500 2026-07-02T09:20:49.973Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/JClinOncol-2018-Merker-Circulating-tumor-DNA-analysis-in-patients-with-cancer-american-society-of-clinical-oncology-and-college-of-american 2026-07-02T09:20:49.980Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/JClinOncol-2022-Bootsma-Longitudinal-molecular-profiling-of-circulating-tumor-cells-in-metastatic-renal-cell-carcinoma 2026-07-02T09:20:49.949Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/JClinOncol-2026-Sinicrope-Tissue-free-circulating-tumor-DNA-assay-and-patient-outcome-in-a-phase-III-trial-of-FOLFOX-based-adjuvant-chemotherapy-Alliance-N0147 2026-07-02T09:20:49.970Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/JImmunotherCancer-2026-Cai-Neoadjuvant-camrelizumab-plus-chemotherapy-in-resectable-stage-IIIA-IIIB-non-small-cell-lung-cancer-integrated 2026-07-02T09:20:49.968Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/JMolDiagn-2024-Terp-Extraction-of-cell-free-DNA-evaluation-of-efficiency,-quantity,-and-quality 2026-07-02T09:20:49.959Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/JThoracOncol-2018-Almodovar-Longitudinal-cell-free-DNA-analysis-in-patients-with-small-cell-lung-cancer-reveals-dynamic-insights-into-treatment 2026-07-02T09:20:49.974Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/JThoracOncol-2020-Aldea-Circulating-tumor-DNA-analysis-for-patients-with-oncogene-addicted-NSCLC-with-isolated-central-nervous-system 2026-07-02T09:20:49.950Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/JThoracOncol-2020-Mohan-Profiling-of-circulating-free-DNA-using-targeted-and-genome-wide-sequencing-in-patients-with-SCLC 2026-07-02T09:20:49.948Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/JThoracOncol-2021-Lam-Genotype-specific-differences-in-circulating-tumor-DNA-levels-in-advanced-NSCLC 2026-07-02T09:20:49.950Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/JThoracOncol-2026-Horndalsveen-ctDNA-based-MRD-detection-in-stage-III-NSCLC-treated-with-chemoradiotherapy-and-durvalumab 2026-07-02T09:20:49.961Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/LancetOncol-2016-Moran-Epigenetic-profiling-to-classify-cancer-of-unknown-primary-a-multicentre,-retrospective-analysis 2026-07-02T09:20:49.978Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/LancetOncol-2018-Blackhall-Will-liquid-biopsies-improve-outcomes-for-patients-with-small-cell-lung-cancer 2026-07-02T09:20:49.951Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/LancetOncol-2021-Syeda-Circulating-tumour-DNA-in-patients-with-advanced-melanoma-treated-with-dabrafenib-or-dabrafenib-plus-trametinib-a 2026-07-02T09:20:49.976Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/LancetRespirMed-2020-Marquette-Circulating-tumour-cells-as-a-potential-biomarker-for-lung-cancer-screening-a-prospective-cohort-study 2026-07-02T09:20:49.953Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/MolOncol-2012-Henry-Cancer-biomarkers 2026-07-02T09:20:49.969Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NARCancer-2024-Yasumizu-Neural-net-based-cell-deconvolution-from-DNA-methylation-reveals-tumor-microenvironment-associated-with-cancer-prognosis 2026-07-02T09:20:49.956Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NEnglJMed-2013-Dawson-Analysis-of-circulating-tumor-DNA-to-monitor-metastatic-breast-cancer 2026-07-02T09:20:49.969Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NEnglJMed-2018-Corcoran-Application-of-cell-free-DNA-analysis-to-cancer-treatment 2026-07-02T09:20:49.950Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NEnglJMed-2022-Tie-Circulating-tumor-DNA-analysis-guiding-adjuvant-therapy-in-stage-II-colon-cancer 2026-07-02T09:20:52.660Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatAging-2026-Hartono-Urinary-detection-of-therapy-induced-senescence-and-fibrosis-using-an-injectable-albumin-based-nanoprobe 2026-07-02T09:20:49.958Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatBiomedEng-2022-Song-Limitations-and-opportunities-of-technologies-for-the-analysis-of-cell-free-DNA-in-cancer-diagnostics 2026-07-02T09:20:49.966Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatBiotechnol-2022-Esfahani-Inferring-gene-expression-from-cell-free-DNA-fragmentation-profiles 2026-07-02T09:20:49.977Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatCancer-2020-Moding-Circulating-tumor-DNA-dynamics-predict-benefit-from-consolidation-immunotherapy-in-locally-advanced-non-small-cell-lung 2026-07-02T09:20:49.956Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatCancer-2026-Fang-Decoding-pediatric-brain-tumors-via-CSF-derived-methylomes 2026-07-02T09:20:49.977Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatCommun-2011-Balaj-Tumour-microvesicles-contain-retrotransposon-elements-and-amplified-oncogene-sequences 2026-07-02T09:20:49.954Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatCommun-2017-Shin-Prevalence-and-detection-of-low-allele-fraction-variants-in-clinical-cancer-samples 2026-07-02T09:20:49.979Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatCommun-2018-Chakravarthy-Pan-cancer-deconvolution-of-tumour-composition-using-DNA-methylation 2026-07-02T09:20:49.973Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatCommun-2018-Nong-Circulating-tumor-DNA-analysis-depicts-subclonal-architecture-and-genomic-evolution-of-small-cell-lung-cancer 2026-07-02T09:20:49.974Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatCommun-2021-Mathios-Detection-and-characterization-of-lung-cancer-using-cell-free-DNA-fragmentomes 2026-07-02T09:20:49.953Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatCommun-2023-Zhang-Single-cell-metabolic-fingerprints-discover-a-cluster-of-circulating-tumor-cells-with-distinct-metastatic-potential 2026-07-02T09:20:49.978Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatCommun-2024-Conway-A-cfDNA-methylation-based-tissue-of-origin-classifier-for-cancers-of-unknown-primary 2026-07-02T09:20:49.963Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatCommun-2024-Noe-DNA-methylation-and-gene-expression-as-determinants-of-genome-wide-cell-free-DNA-fragmentation 2026-07-02T09:20:49.960Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatCommun-2024-Stanley-Cell-type-signatures-in-cell-free-DNA-fragmentation-profiles-reveal-disease-biology 2026-07-02T09:20:49.957Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatMed-1996-Chen-Microsatellite-alterations-in-plasma-DNA-of-small-cell-lung-cancer-patients 2026-07-02T09:20:49.972Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatMed-2008-Diehl-Circulating-mutant-DNA-to-assess-tumor-dynamics 2026-07-02T09:20:49.970Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatMed-2014-Newman-An-ultrasensitive-method-for-quantitating-circulating-tumor-DNA-with-broad-patient-coverage 2026-07-02T09:20:49.964Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatMed-2018-Gandara-Blood-based-tumor-mutational-burden-as-a-predictor-of-clinical-benefit-in-non-small-cell-lung-cancer-patients-treated 2026-07-02T09:20:49.961Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatMed-2020-Nakamura-Clinical-utility-of-circulating-tumor-DNA-sequencing-in-advanced-gastrointestinal-cancer-SCRUM-japan-GI-SCREEN-and 2026-07-02T09:20:49.968Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatMed-2022-Jee-Overall-survival-with-circulating-tumor-DNA-guided-therapy-in-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:49.965Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatMed-2023-Baca-Liquid-biopsy-epigenomic-profiling-for-cancer-subtyping 2026-07-02T09:20:49.956Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatMed-2023-Kotani-Molecular-residual-disease-and-efficacy-of-adjuvant-chemotherapy-in-patients-with-colorectal-cancer 2026-07-02T09:20:49.965Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatProtoc-2019-Shen-Preparation-of-cfMeDIP-seq-libraries-for-methylome-profiling-of-plasma-cell-free-DNA 2026-07-02T09:20:49.954Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatRevCancer-2019-Keller-Unravelling-tumour-heterogeneity-by-single-cell-profiling-of-circulating-tumour-cells 2026-07-02T09:20:49.977Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatRevCancer-2021-Kwong-Synthetic-biomarkers-a-twenty-first-century-path-to-early-cancer-detection 2026-07-02T09:20:49.955Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatRevCancer-2023-Ring-Biology,-vulnerabilities-and-clinical-applications-of-circulating-tumour-cells 2026-07-02T09:20:49.962Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatRevCancer-2025-Bruhm-Genomic-and-fragmentomic-landscapes-of-cell-free-DNA-for-early-cancer-detection 2026-07-02T09:20:49.949Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatRevClinOncol-2014-Krebs-Molecular-analysis-of-circulating-tumour-cells-biology-and-biomarkers 2026-07-02T09:20:49.968Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/NatRevClinOncol-2021-Aggarwal-Strategies-for-the-successful-implementation-of-plasma-based-NSCLC-genotyping-in-clinical-practice 2026-07-02T09:20:49.980Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/Nature-2013-Murtaza-Non-invasive-analysis-of-acquired-resistance-to-cancer-therapy-by-sequencing-of-plasma-DNA 2026-07-02T09:20:49.976Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/Nature-2016-Massague-Metastatic-colonization-by-circulating-tumour-cells 2026-07-02T09:20:49.947Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/Nature-2017-Abbosh-Phylogenetic-ctDNA-analysis-depicts-early-stage-lung-cancer-evolution 2026-07-02T09:20:49.972Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/Nature-2019-Cristiano-Genome-wide-cell-free-DNA-fragmentation-in-patients-with-cancer 2026-07-02T09:20:49.967Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/Nature-2020-Chabon-Integrating-genomic-features-for-non-invasive-early-lung-cancer-detection 2026-07-02T09:20:49.964Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/Nature-2021-Powles-ctDNA-guiding-adjuvant-immunotherapy-in-urothelial-carcinoma 2026-07-02T09:20:52.708Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/Nature-2022-Herberts-Deep-whole-genome-ctDNA-chronology-of-treatment-resistant-prostate-cancer 2026-07-02T09:20:49.958Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/Nature-2023-Abbosh-Tracking-early-lung-cancer-metastatic-dissemination-in-TRACERx-using-ctDNA 2026-07-02T09:20:49.964Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/Nature-2026-Chen-Cell-free-chromatin-state-tracing-reveals-disease-origin-and-therapy-responses 2026-07-02T09:20:49.974Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/ProcNatlAcadSciUSA-2022-Zhou-Epigenetic-analysis-of-cell-free-DNA-by-fragmentomic-profiling 2026-07-02T09:20:49.979Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/ProcNatlAcadSciUSA-2023-Zhou-Fragmentation-landscape-of-cell-free-DNA-revealed-by-deconvolutional-analysis-of-end-motifs 2026-07-02T09:20:49.966Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/SciRep-2025-Andersson-Evaluation-of-automatic-cell-free-DNA-extraction-metrics-using-different-blood-collection-tubes 2026-07-02T09:20:49.951Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/SciTranslMed-2014-Bettegowda-Detection-of-circulating-tumor-DNA-in-early-and-late-stage-human-malignancies 2026-07-02T09:20:49.960Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/SciTranslMed-2023-Budhraja-Genome-wide-analysis-of-aberrant-position-and-sequence-of-plasma-DNA-fragment-ends-in-patients-with-cancer 2026-07-02T09:20:49.966Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/SciTranslMed-2024-Annapragada-Genome-wide-repeat-landscapes-in-cancer-and-cell-free-DNA 2026-07-02T09:20:49.967Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/Science-2021-Lo-Epigenetics,-fragmentomics,-and-topology-of-cell-free-DNA-in-liquid-biopsies 2026-07-02T09:20:49.969Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/TrendsCancer-2025-Gvozdenovic-A-growing-entourage-for-heterotypic-circulating-tumor-cell-clusters 2026-07-02T09:20:49.967Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/TrendsGenet-2023-Moser-Bridging-biological-cfDNA-features-and-machine-learning-approaches 2026-07-02T09:20:49.951Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/TrendsMolMed-2025-Behrouzi-Cell-free-and-extrachromosomal-DNA-profiling-of-small-cell-lung-cancer 2026-07-02T09:20:49.970Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/iScience-2022-Cheng-Plasma-contains-ultrashort-single-stranded-DNA-in-addition-to-nucleosomal-cell-free-DNA 2026-07-02T09:20:49.963Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/iScience-2022-Haq-Cell-free-DNA-methylation-defined-prognostic-subgroups-in-small-cell-lung-cancer-identified-by-leukocyte-methylation-subtraction 2026-07-02T09:20:49.957Z https://research-2ry.pages.dev/Summary/Basic-Liquid-biopsy/npjPrecisOncol-2025-Osawa-Genomic-alteration-and-clinical-significance-of-circulating-tumor-DNA-in-patients-with-advanced-urothelial-cancer 2026-07-02T09:20:49.961Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/ACSApplMaterInterfaces-2025-Wang-Neutrophil-mediated-tumor-discrimination-biomimetic-nanodevice-for-precise-tumor-eradication-and-metastasis-cascade 2026-07-02T09:20:50.242Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/ACSNano-2017-Kang-Nanoparticles-coated-with-neutrophil-membranes-can-effectively-treat-cancer-metastasis 2026-07-02T09:20:50.183Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/ACSNano-2024-Zeng-Neutrophil-nanodecoys-inhibit-tumor-metastasis-by-blocking-the-interaction-between-tumor-cells-and-neutrophils 2026-07-02T09:20:50.212Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/AdvSci-2025-Guan-Engineered-bacterial-outer-membrane-vesicles-hitchhiking-on-neutrophils-for-antibody-drug-delivery-to-enhance 2026-07-02T09:20:50.219Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/AmJHematol-2015-Gavillet-Flow-cytometric-assay-for-direct-quantification-of-neutrophil-extracellular-traps-in 2026-07-02T09:20:50.258Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/AmJHematol-2017-Teng-Heterogeneity-of-neutrophil-spontaneous-death 2026-07-02T09:20:50.224Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/AmJRespirCellMolBiol-2017-Gibbings-Three-unique-interstitial-macrophages-in-the-murine-lung-at-steady-state 2026-07-02T09:20:50.222Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/AnnAmThoracSoc-2016-Russell-Neutrophil-fates-in-bronchiectasis-and-alpha-1-antitrypsin-deficiency 2026-07-02T09:20:50.172Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/AnnuIntConfIEEEEngMedBiolSoc-2011-Ivan-Estimation-of-the-population-of-neutrophils-induced-to-differentiate-from-the-MPRO-mouse-promyelocytic-cell-line 2026-07-02T09:20:50.168Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/AnnuRevCancerBiol-2022-He-Caught-in-a-web-Emerging-roles-of-neutrophil-extracellular-traps-in-cancer 2026-07-02T09:20:50.256Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/ArteriosclerThrombVascBiol-2019-Thalin-Neutrophil-extracellular-traps-villains-and-targets-in-arterial,-venous,-and-cancer-associated-thrombosis 2026-07-02T09:20:50.239Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Biomaterials-2020-Okeke-Inhibition-of-neutrophil-elastase-prevents-neutrophil-extracellular-trap-formation-and-rescues-mice-from-endotoxic-shock 2026-07-02T09:20:50.170Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Blood-1999-Weiler-D3-a-gene-induced-during-myeloid-cell-differentiation-of-linlo-c-kit+-sca-1(+)-progenitor-cells 2026-07-02T09:20:50.221Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Blood-2002-Genomic-and-proteomic-analysis-of-the-myeloid-differentiation-program-Global-analysis-of-gene-expression-during-induced-differentiation-in-the-MPRO-cell-line 2026-07-02T09:20:50.221Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Blood-2014-Rossaint-Synchronized-integrin-engagement-and-chemokine-activation-is-crucial-in-neutrophil-extracellular-trap-mediated-sterile 2026-07-02T09:20:50.222Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Blood-2017-Noubouossie-In-vitro-activation-of-coagulation-by-human-neutrophil-DNA-and-histone-proteins-but-not-neutrophil-extracellular-traps 2026-07-02T09:20:50.206Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Blood-2019-Giese-Neutrophil-plasticity-in-the-tumor-microenvironment 2026-07-02T09:20:50.169Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerCell-2009-Fridlender-Polarization-of-tumor-associated-neutrophil-phenotype-by-TGF-beta-N1-versus-N2-TAN 2026-07-02T09:20:50.251Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerCell-2011-Granot-Tumor-entrained-neutrophils-inhibit-seeding-in-the-premetastatic-lung 2026-07-02T09:20:50.187Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerCell-2016-Singhal-Origin-and-role-of-a-subset-of-tumor-associated-neutrophils-with-antigen-presenting-cell-features-in-early-stage-human 2026-07-02T09:20:50.252Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerCell-2021-Xiao-Cathepsin-C-promotes-breast-cancer-lung-metastasis-by-modulating-neutrophil-infiltration-and-neutrophil-extracellular 2026-07-02T09:20:50.271Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerCell-2022-Salcher-High-resolution-single-cell-atlas-reveals-diversity-and-plasticity-of-tissue-resident-neutrophils-in-non-small-cell 2026-07-02T09:20:50.199Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerCell-2023-Adrover-NETworking-with-cancer-The-bidirectional-interplay-between-cancer-and-neutrophil-extracellular-traps 2026-07-02T09:20:50.210Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerCell-2023-Haston-Clearance-of-senescent-macrophages-ameliorates-tumorigenesis-in-KRAS-driven-lung-cancer 2026-07-02T09:20:50.177Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerCell-2023-Mousset-Neutrophil-extracellular-traps-formed-during-chemotherapy-confer-treatment-resistance-via-TGF-beta-activation 2026-07-02T09:20:50.263Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerCell-2024-Benguigui-Interferon-stimulated-neutrophils-as-a-predictor-of-immunotherapy-response 2026-07-02T09:20:50.226Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerCell-2024-He-Chronic-stress-increases-metastasis-via-neutrophil-mediated-changes-to-the-microenvironment 2026-07-02T09:20:50.240Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerCell-2025-Chen-DNASE1L3-expressing-dendritic-cells-promote-CD8+-T-cell-function-and-anti-PD-(l)1-therapy-efficacy-by-degrading 2026-07-02T09:20:50.210Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerCell-2025-He-Chemotherapy-awakens-dormant-cancer-cells-in-lung-by-inducing-neutrophil-extracellular-traps 2026-07-02T09:20:50.233Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerCell-2025-Lee-Neutrophil-extracellular-traps-promote-pre-metastatic-niche-formation-in-the-omentum-by-expanding-innate-like-B-cells 2026-07-02T09:20:50.264Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerCell-2025-Qian-A-CXCR4-partial-agonist-improves-immunotherapy-by-targeting-immunosuppressive-neutrophils-and-cancer-driven 2026-07-02T09:20:50.245Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerCell-2025-Shi-CHI3L3+-immature-neutrophils-inhibit-anti-tumor-immunity-and-impede-immune-checkpoint-blockade-therapy-in-bone 2026-07-02T09:20:50.243Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerCell-2025-Zhu-Cancer-cell-derived-arginine-fuels-polyamine-biosynthesis-in-tumor-associated-macrophages-to-promote-immune-evasion 2026-07-02T09:20:50.195Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerCell-2026-Bolli-CCL3-is-produced-by-aged-neutrophils-across-cancers-and-promotes-tumor-growth 2026-07-02T09:20:50.224Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerCell-2026-Guo-Tumor-initiating-stem-cells-fine-tune-the-plasticity-of-neutrophils-to-sculpt-a-protective-niche 2026-07-02T09:20:50.226Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerCell-2026-Haist-Lymph-node-colonization-induces-tissue-remodeling-via-immunosuppressive-fibroblast-myeloid-cell-niches-supporting 2026-07-02T09:20:50.218Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerCell-2026-Hayward-Tissue-tension-fosters-macrophage-driven-lipid-peroxidation-induced-DNA-damage 2026-07-02T09:20:50.198Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerCell-2026-Marteau-Single-cell-integration-and-multi-modal-profiling-reveals-phenotypes-and-spatial-organization-of-neutrophils-in 2026-07-02T09:20:50.231Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerCell-2026-Shi-Tumor-immune-neural-circuit-disrupts-energy-homeostasis-in-cancer-cachexia 2026-07-02T09:20:50.181Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerCell-2026-Zuo-IL-36gamma-armored-CAR-T-cells-reprogram-neutrophils-to-induce-endogenous-antitumor-immunity 2026-07-02T09:20:50.265Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerDiscov-2023-Goldman-Early-infiltration-of-innate-immune-cells-to-the-liver-depletes-HNF4alpha-and-promotes-extrahepatic-carcinogenesis 2026-07-02T09:20:50.220Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerDiscov-2024-Enfield-Spatial-architecture-of-myeloid-and-T-cells-orchestrates-immune-evasion-and-clinical-outcome-in-lung-cancer 2026-07-02T09:20:50.242Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerDiscov-2026-Lin-Arachidonic-acid-metabolism-in-PMN-MDSCs-suppresses-antitumor-capacity-of-T-cells-in-KRAS-mutant-cholangiocarcinoma 2026-07-02T09:20:50.260Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerDiscov-2026-Pillai-LIF-Induced-Tumor-Plasticity-Establishes-an-Immunosuppressive-Myeloid-Niche-in-LKB1-Mutant-Lung-Cancer 2026-07-02T09:20:50.191Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerImmunolRes-2020-Xu-Chemotherapeutic-tumor-microparticles-elicit-a-neutrophil-response-targeting-malignant-pleural-effusions 2026-07-02T09:20:50.243Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerImmunolRes-2023-Fu-Syntaphilin-regulates-neutrophil-migration-in-cancer 2026-07-02T09:20:50.179Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerRes-2016-Koyama-STK11LKB1-deficiency-promotes-neutrophil-recruitment-and-proinflammatory-cytokine-production-to-suppress-T-cell 2026-07-02T09:20:50.174Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerRes-2016-Tohme-Neutrophil-extracellular-traps-promote-the-development-and-progression-of-liver-metastases-after-surgical-stress 2026-07-02T09:20:50.249Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CancerRes-2019-Yazdani-Neutrophil-extracellular-traps-drive-mitochondrial-homeostasis-in-tumors-to-augment-growth 2026-07-02T09:20:50.223Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Cancers-2020-Wu-Breast-cancer-cell-neutrophil-interactions-enhance-neutrophil-survival-and-pro-tumorigenic-activities 2026-07-02T09:20:50.163Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Cancers-2022-Ozel-The-good,-the-bad,-and-the-ugly-neutrophils,-angiogenesis,-and-cancer 2026-07-02T09:20:50.239Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Cancers-2025-Sturgeon-Neutrophil-dynamics-contribute-to-disease-progression-and-poor-survival-in-pancreatic-cancer 2026-07-02T09:20:50.202Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Cell-2020-Ballesteros-Co-option-of-neutrophil-fates-by-tissue-environments 2026-07-02T09:20:50.189Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Cell-2021-Cheng-A-pan-cancer-single-cell-transcriptional-atlas-of-tumor-infiltrating-myeloid-cells 2026-07-02T09:20:50.232Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Cell-2023-Gungabeesoon-A-neutrophil-response-linked-to-tumor-control-in-immunotherapy 2026-07-02T09:20:50.245Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Cell-2023-Hirschhorn-T-cell-immunotherapies-engage-neutrophils-to-eliminate-tumor-antigen-escape-variants 2026-07-02T09:20:50.254Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Cell-2023-Kloosterman-Macrophages-at-the-interface-of-the-co-evolving-cancer-ecosystem 2026-07-02T09:20:50.254Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Cell-2023-Maas-The-local-microenvironment-drives-activation-of-neutrophils-in-human-brain-tumors 2026-07-02T09:20:50.165Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Cell-2024-Mihlan-Neutrophil-trapping-and-nexocytosis,-mast-cell-mediated-processes-for-inflammatory-signal-relay 2026-07-02T09:20:50.182Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Cell-2024-Wu-Neutrophil-profiling-illuminates-anti-tumor-antigen-presenting-potency 2026-07-02T09:20:50.271Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Cell-2024-Zhang-Cell-surface-RNAs-control-neutrophil-recruitment 2026-07-02T09:20:50.183Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Cell-2025-Ballesteros-The-neutrophil-collective 2026-07-02T09:20:50.234Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Cell-2025-Han-Tumors-hijack-macrophages-for-iron-supply-to-promote-bone-metastasis-and-anemia 2026-07-02T09:20:50.269Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Cell-2025-Hsu-Neutrophil-derived-vesicles-control-complement-activation-to-facilitate-inflammation-resolution 2026-07-02T09:20:50.184Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Cell-2026-Qian-Respiratory-viral-infections-prime-accelerated-lung-cancer-growth 2026-07-02T09:20:50.211Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CellDeathDis-2024-Ji-Chemerin-attracts-neutrophil-reverse-migration-by-interacting-with-C-C-motif-chemokine-receptor-like-2 2026-07-02T09:20:50.211Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CellMetab-2026-Gao-Restricting-lipid-accumulation-in-tumor-infiltrating-neutrophils-mediates-caloric-restriction-induced-anti-cancer 2026-07-02T09:20:50.248Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CellMolImmunol-2020-Metzemaekers-Neutrophil-chemoattractant-receptors-in-health-and-disease-Double-edged-swords 2026-07-02T09:20:50.259Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CellMolImmunol-2025-Koenderman-Neutrophils-in-cancer-from-biology-to-therapy 2026-07-02T09:20:50.238Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CellRep-2015-Sagiv-Phenotypic-diversity-and-plasticity-in-circulating-neutrophil-subpopulations-in-cancer 2026-07-02T09:20:50.256Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CellRep-2019-Hoogendijk-Dynamic-transcriptome-proteome-correlation-networks-reveal-human-myeloid-differentiation-and-neutrophil-specific 2026-07-02T09:20:50.167Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CellRep-2020-Pfirschke-Tumor-promoting-ly-6g+-SiglecFhigh-cells-are-mature-and-long-lived-neutrophils 2026-07-02T09:20:50.212Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CellRep-2020-Tsourouktsoglou-Histones,-DNA,-and-citrullination-promote-neutrophil-extracellular-trap-inflammation-by-regulating-the-localization-and 2026-07-02T09:20:50.235Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CellRep-2022-Neuenfeldt-Inflammation-induces-pro-NETotic-neutrophils-via-TNFR2-signaling 2026-07-02T09:20:50.225Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CellRep-2023-Kapellos-Systemic-alterations-in-neutrophils-and-their-precursors-in-early-stage-chronic-obstructive-pulmonary-disease 2026-07-02T09:20:50.224Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CellRep-2026-Lim-Neutrophil-derived-itaconate-facilitates-tiered-pulmonary-inflammation-via-kdm5b-associated-epigenetic-remodeling-in 2026-07-02T09:20:50.267Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CellRep-2026-Meng-Nociceptive-neurons-inhibit-neutrophil-extracellular-trap-formation-via-MLKL-licensed-histone-release 2026-07-02T09:20:50.202Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CellRep-2026-Ponessa-Alveolar-macrophages-inhibit-emphysematous-pathology-via-expression-of-carbonic-anhydrase-4 2026-07-02T09:20:50.186Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CellRepMed-2026-Hao-Non-genetically-reprogrammed-meta-neutrophils-potentiate-chemo-immunotherapy-against-lung-metastatic-triple-negative 2026-07-02T09:20:50.270Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CellRepMed-2026-Mestrallet-Reprogramming-t-cell-myeloid-crosstalk-overcomes-immune-resistance-in-colorectal-cancer 2026-07-02T09:20:50.166Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Cells-2020-Kolonics-The-functional-heterogeneity-of-neutrophil-derived-extracellular-vesicles-reflects-the-status-of-the-parent-cell 2026-07-02T09:20:50.204Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Cells-2022-Gutierrez-Human-neutrophils-generate-extracellular-vesicles-that-modulate-their-functional-responses 2026-07-02T09:20:50.171Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Cells-2022-Zhou-Neutrophil-extracellular-vesicles-A-delicate-balance-between-pro-inflammatory-responses-and-anti-inflammatory-therapies 2026-07-02T09:20:50.174Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/ChinMed-2026-He-Shuangshen-granules-enhance-anti-PD1-therapy-effectiveness-in-lung-adenocarcinoma-by-modulating-myeloid-derived 2026-07-02T09:20:50.176Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/ClinCancerRes-2019-LoRusso-Antibody-FcFcR-interaction-on-macrophages-as-a-mechanism-for-hyperprogressive-disease-in-non-small-cell-lung-cancer 2026-07-02T09:20:50.225Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/ClinCancerRes-2021-Teijeira-IL8,-neutrophils,-and-NETs-in-a-collusion-against-cancer-immunity-and-immunotherapy 2026-07-02T09:20:50.204Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/ClinCancerRes-2026-Chen-CCL3+-neutrophil-signature-predicts-response-to-neoadjuvant-toripalimab-plus-chemotherapy-in-patients-with 2026-07-02T09:20:50.233Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/ClinTranslMed-2023-Zhang-Neutrophil,-neutrophil-extracellular-traps-and-endothelial-cell-dysfunction-in-sepsis 2026-07-02T09:20:50.262Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/ClinTranslOncol-2026-Nemilostiva-CAR-engineered-neutrophils-derived-from-induced-pluripotent-stem-cells-a-new-frontier-in-cellular-immunotherapy 2026-07-02T09:20:50.200Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CommunBiol-2025-McDonald-Neutrophil-extracellular-trap-gene-expression-signatures-identify-prognostic-and-targetable-signaling-axes-for 2026-07-02T09:20:50.255Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CommunBiol-2025-Zaranski-NLRP3-inflammasome-promotes-PAD2-PAD4-release-and-protein-citrullination-in-rheumatoid-arthritis 2026-07-02T09:20:50.237Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CurrProtoc-2023-Wishart-Isolation-of-mouse-neutrophils 2026-07-02T09:20:50.249Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CurrProtocImmunol-2005-Gaines-Differentiation-and-characterization-of-myeloid-cells 2026-07-02T09:20:50.261Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/CurrProtocImmunol-2015-Swamydas-Isolation-of-mouse-neutrophils 2026-07-02T09:20:50.175Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Diagnostics-2022-Pfister-Neutrophil-extracellular-traps-and-neutrophil-derived-extracellular-vesicles-common-players-in-neutrophil-effector 2026-07-02T09:20:50.245Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/EurRespirJ-2014-Hamaguchi-Neutrophil-extracellular-traps-in-bronchial-aspirates-a-quantitative-analysis 2026-07-02T09:20:50.263Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/ExpHematolOncol-2024-Xie-Targeting-SPP1-orchestrated-neutrophil-extracellular-traps-dominant-pre-metastatic-niche-reduced-HCC-lung-metastasis 2026-07-02T09:20:50.164Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/FASEBJ-2022-Iqbal-Galectin-9-mediates-neutrophil-capture-and-adhesion-in-a-CD44-and-beta2-integrin-dependent-manner 2026-07-02T09:20:50.169Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/FrontCellDevBiol-2021-Tokuhiro-Oxidized-phospholipids-and-neutrophil-elastase-coordinately-play-critical-roles-in-NET-formation 2026-07-02T09:20:50.227Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/FrontImmunol-2020-Masucci-The-emerging-role-of-neutrophil-extracellular-traps-(NETs)-in-tumor-progression-and-metastasis 2026-07-02T09:20:50.175Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/FrontImmunol-2020-Ohms-An-attempt-to-polarize-human-neutrophils-toward-N1-and-N2-phenotypes-in-vitro 2026-07-02T09:20:50.229Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/FrontImmunol-2021-Hardisty-High-purity-isolation-of-low-density-neutrophils-casts-doubt-on-their-exceptionality-in-health-and-disease 2026-07-02T09:20:50.180Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/FrontImmunol-2022-Abbas-Conventional-therapies-deplete-brain-infiltrating-adaptive-immune-cells-in-a-mouse-model-of-group-3-medulloblastoma 2026-07-02T09:20:50.218Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/FrontImmunol-2022-Chen-Roles-of-the-exosomes-derived-from-myeloid-derived-suppressor-cells-in-tumor-immunity-and-cancer-progression 2026-07-02T09:20:50.251Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/FrontImmunol-2022-Wang-Neutrophil-extracellular-traps-promote-non-small-cell-lung-cancer-metastasis-by-suppressing-lncRNA-MIR503HG-to-activate-the-NF-kappaB-NLRP3-inflammasome-pathway 2026-07-02T09:20:50.196Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/FrontImmunol-2025-Yang-Unveiling-cd177-a-key-player-in-tumors,-autoimmune-diseases,-and-inflammatory-disorders 2026-07-02T09:20:50.213Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/FrontImmunol-2026-McGarrity-Cottrell-Physiological,-patho-physiological,-and-potential-therapeutic-roles-for-neutrophils-in-cancer--and--beyond 2026-07-02T09:20:50.169Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/FrontImmunol-2026-Wu-Tumor-associated-neutrophils-in-pancreatic-ductal-adenocarcinoma-mechanisms-and-therapeutic-targeting 2026-07-02T09:20:50.185Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/FrontOncol-2025-Baron-Neutrophil-extracellular-traps-are-associated-with-poor-response-to-neoadjuvant-therapy-and-poor-survival-in-pediatric 2026-07-02T09:20:50.227Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Heliyon-2024-Malavez-Cajigas-HL-60-cells-as-a-valuable-model-to-study-LPS-induced-neutrophil-extracellular-traps-release 2026-07-02T09:20:50.191Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Heliyon-2024-Sun-Neutrophil-extracellular-trap-genes-predict-immunotherapy-response-in-gastric-cancer 2026-07-02T09:20:50.207Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Immunity-2017-Sabatel-Exposure-to-bacterial-CpG-DNA-protects-from-airway-allergic-inflammation-by-expanding-regulatory-lung-interstitial 2026-07-02T09:20:50.184Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Immunity-2018-Evrard-Developmental-analysis-of-bone-marrow-neutrophils-reveals-populations-specialized-in-expansion,-trafficking,-and 2026-07-02T09:20:50.258Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Immunity-2019-Adrover-A-neutrophil-timer-coordinates-immune-defense-and-vascular-protection 2026-07-02T09:20:50.196Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Immunity-2019-Zilionis-Single-cell-transcriptomics-of-human-and-mouse-lung-cancers-reveals-conserved-myeloid-populations-across-individuals 2026-07-02T09:20:50.212Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Immunity-2020-Teijeira-CXCR1-and-CXCR2-chemokine-receptor-agonists-produced-by-tumors-induce-neutrophil-extracellular-traps-that-interfere 2026-07-02T09:20:50.167Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Immunity-2021-Burn-The-neutrophil 2026-07-02T09:20:50.209Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Immunity-2022-Aegerter-Biology-of-lung-macrophages-in-health-and-disease 2026-07-02T09:20:50.250Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Immunity-2023-Taifour-The-tumor-derived-cytokine-chi3l1-induces-neutrophil-extracellular-traps-that-promote-T-cell-exclusion-in 2026-07-02T09:20:50.238Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Immunity-2025-Ng-From-complexity-to-consensus-A-roadmap-for-neutrophil-classification 2026-07-02T09:20:50.188Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Immunity-2026-Huang-Macrophage-metabolic-exhaustion-and-PANoptotic-cell-death-drive-chronic-tissue-inflammation-in-rheumatoid-arthritis 2026-07-02T09:20:50.192Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Immunity-2026-Pires-Innate-lymphoid-cells-activated-by-the-cytokine-TL1A-link-colitis-to-emergency-granulopoiesis-and-the-recruitment-of 2026-07-02T09:20:50.250Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/ImmunolRev-2022-Marki-The-expanding-family-of-neutrophil-derived-extracellular-vesicles 2026-07-02T09:20:50.165Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Inflammation-2022-Pan-The-effect-and-mechanism-of-lipoxin-A4-on-neutrophil-function-in-LPS-induced-lung-injury 2026-07-02T09:20:50.226Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/IntJMolMed-2021-Zhu-Neutrophil-extracellular-traps-promote-gastric-cancer-metastasis-by-inducing-epithelial-mesenchymal-transition 2026-07-02T09:20:50.237Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/IntJMolSci-2021-Kato-Effects-of-thrombomodulin-in-reducing-lethality-and-suppressing-neutrophil-extracellular-trap-formation-in-the-lungs 2026-07-02T09:20:50.273Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/IntJMolSci-2023-Sounbuli-A-comparative-study-of-different-protocols-for-isolation-of-murine-neutrophils-from-bone-marrow-and-spleen 2026-07-02T09:20:50.178Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JCIInsight-2019-Rayes-Primary-tumors-induce-neutrophil-extracellular-traps-with-targetable-metastasis-promoting-effects 2026-07-02T09:20:50.197Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JCIInsight-2022-Song-PTP1B-inhibitors-protect-against-acute-lung-injury-and-regulate-CXCR4-signaling-in-neutrophils 2026-07-02T09:20:50.205Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JCellBiol-2007-Fuchs-Novel-cell-death-program-leads-to-neutrophil-extracellular-traps 2026-07-02T09:20:50.177Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JCellBiol-2018-Condon-Macropinosome-formation-by-tent-pole-ruffling-in-macrophages 2026-07-02T09:20:50.197Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JClinInvest-2013-Cools-Lartigue-Neutrophil-extracellular-traps-sequester-circulating-tumor-cells-and-promote-metastasis 2026-07-02T09:20:50.274Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JClinInvest-2014-Eruslanov-Tumor-associated-neutrophils-stimulate-T-cell-responses-in-early-stage-human-lung-cancer 2026-07-02T09:20:50.230Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JClinInvest-2026-Wang-A-CD138+-tumor-associated-macrophagesiglec-f+-neutrophil-feed-forward-loop-promotes-immune-evasion-in-pancreatic-cancer 2026-07-02T09:20:50.206Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JExpMed-2019-Lee-Neutrophils-facilitate-ovarian-cancer-premetastatic-niche-formation-in-the-omentum 2026-07-02T09:20:50.180Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JExpMed-2021-Nogales-Pons-Myeloid-diversity-in-tumors-shaped-by-genes,-location,-and-time 2026-07-02T09:20:50.271Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JExpMed-2021-Veglia-Analysis-of-classical-neutrophils-and-polymorphonuclear-myeloid-derived-suppressor-cells-in-cancer-patients-and 2026-07-02T09:20:52.880Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JExpMed-2026-Bub-Sensing-of-metabolic-signals-via-GPR183-promotes-occupation-of-lung-macrophage-niches-by-monocytes 2026-07-02T09:20:50.168Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JImmunol-2019-Tong-Lipopolysaccharide-stimulated-human-fetal-membranes-induce-neutrophil-activation-and-release-of-vital-neutrophil 2026-07-02T09:20:50.184Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JImmunol-2022-Wigerblad-Single-cell-analysis-reveals-the-range-of-transcriptional-states-of-circulating-human-neutrophils 2026-07-02T09:20:50.172Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JImmunol-2026-Smith-The-paracrine-factor-myeloid-derived-growth-factor-regulates-the-inflammatory-fate-and-motility-of-human-induced 2026-07-02T09:20:50.187Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JImmunolRes-2016-deBuhr-How-neutrophil-extracellular-traps-become-visible 2026-07-02T09:20:52.888Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JImmunotherCancer-2020-Lecoultre-Phagocytic-function-of-tumor-associated-macrophages-as-a-key-determinant-of-tumor-progression-control-a-review 2026-07-02T09:20:50.244Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JImmunotherCancer-2021-Yang-Aged-neutrophils-form-mitochondria-dependent-vital-NETs-to-promote-breast-cancer-lung-metastasis 2026-07-02T09:20:50.205Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JImmunotherCancer-2026-Lin-Integrin-CD11bCD18-reprograms-macrophage-polarization-by-suppressing-ERKSTAT3-signaling-to-enhance-antitumor-immunity 2026-07-02T09:20:50.185Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JImmunotherCancer-2026-Redavid-Targeting-macrophage-driven-NK-cell-immunosuppression-to-improve-cancer-immunotherapy 2026-07-02T09:20:50.173Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JInflammRes-2023-Luan-Identification-and-analysis-of-neutrophil-extracellular-trap-related-genes-in-osteoarthritis-by-bioinformatics-and 2026-07-02T09:20:50.266Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JInvestDermatol-2017-Kim-Phenformin-inhibits-myeloid-derived-suppressor-cells-and-enhances-the-anti-tumor-activity-of-PD-1-blockade-in-melanoma 2026-07-02T09:20:50.257Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JLeukocBiol-2024-Madison-In-a-sticky-situation-Pro-coagulant-properties-expand-the-importance-of-neutrophil-EVs-in-driving-tissue-injury 2026-07-02T09:20:50.237Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JTranslMed-2024-Naveh-Correction-to-neutrophils-cultured-ex-vivo-from-CD34-+-stem-cells-are-immature-and-genetically-tractable 2026-07-02T09:20:50.246Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JTranslMed-2024-Naveh-Neutrophils-cultured-ex-vivo-from-CD34+-stem-cells-are-immature-and-genetically-tractable 2026-07-02T09:20:50.206Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JVisExp-2010-Brinkmann-Neutrophil-extracellular-traps-how-to-generate-and-visualize-them 2026-07-02T09:20:52.904Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JVisExp-2010-Ray-Isolation-of-mouse-peritoneal-cavity-cells 2026-07-02T09:20:50.213Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JVisExp-2013-Swamydas-Isolation,-purification-and-labeling-of-mouse-bone-marrow-neutrophils-for-functional-studies-and-adoptive-transfer 2026-07-02T09:20:50.239Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/JVisExp-2019-Abu-Immunofluorescence-labelling-of-human-and-murine-neutrophil-extracellular-traps-in-paraffin-embedded-tissue 2026-07-02T09:20:52.908Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/LungCancer-2018-Sekine-Change-in-the-lymphocyte-to-monocyte-ratio-is-an-early-surrogate-marker-of-the-efficacy-of-nivolumab-monotherapy-in 2026-07-02T09:20:50.267Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/MethodMolBiol-2019-Rada-Neutrophil-extracellular-traps 2026-07-02T09:20:50.164Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/MethodMolBiol-2020-Quinn-Neutrophil 2026-07-02T09:20:50.230Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/MethodMolBiol-2021-Brandau-Myeloid-derived-suppressor-cells-methods-and-protocols 2026-07-02T09:20:50.234Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/MolCancer-2018-Zhang-Tumor-derived-exosomes-induce-N2-polarization-of-neutrophils-to-promote-gastric-cancer-cell-migration 2026-07-02T09:20:50.219Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/MolCell-2010-Heinz-Simple-combinations-of-lineage-determining-transcription-factors-prime-cis-regulatory-elements-required-for-macrophage 2026-07-02T09:20:50.231Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/MolImmunol-2025-Li-Neutrophil-derived-exosomal-S100A8-aggravates-lung-injury-in-sepsis-by-inducing-pyroptosis 2026-07-02T09:20:50.255Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/MolTher-2021-Chen-Microglial-lnc-U90926-facilitates-neutrophil-infiltration-in-ischemic-stroke-via-MDH2CXCL2-axis 2026-07-02T09:20:50.243Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatAging-2026-Salladay-Perez-P21+trem2+-senescent-macrophages-fuel-inflammaging-and-metabolic-dysfunction-associated-steatotic-liver-disease 2026-07-02T09:20:50.203Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatBiomedEng-2026-Chang-CAR-neutrophils-produced-in-vivo-to-treat-glioma 2026-07-02T09:20:50.267Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatBiotechnol-2022-Pisaneschi-Imaging-of-innate-immunity-activation-in-vivo-with-a-redox-tuned-PET-reporter 2026-07-02T09:20:50.223Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatBiotechnol-2026-Zhao-A-logic-gated-trispecific-engager-enhances-macrophage-killing-of-cancer-cells-in-solid-tumors 2026-07-02T09:20:50.233Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatCancer-2024-Zheng-Targeting-PID1-generates-oxysterols-to-switch-macrophage-cell-fates-for-improved-antitumor-immunity 2026-07-02T09:20:50.251Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatCancer-2026-Wang-CD300ld-on-pathologically-activated-neutrophils-promotes-tumor-immune-suppression-by-binding-phosphatidylserine-on-CD8 2026-07-02T09:20:50.210Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatCardiovascRes-2022-Su-Gasdermin-D-dependent-platelet-pyroptosis-exacerbates-NET-formation-and-inflammation-in-severe-sepsis 2026-07-02T09:20:50.236Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatCellBiol-2026-Wan-Thy1+-cancer-stem-cells-drive-metastasis-through-a-pseudohypoxic-state-shaped-by-neutrophil-derived-mitochondria 2026-07-02T09:20:50.195Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatCommun-2016-Bronte-Recommendations-for-myeloid-derived-suppressor-cell-nomenclature-and-characterization-standards 2026-07-02T09:20:50.244Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatCommun-2018-Inoue-Plasma-redox-imbalance-caused-by-albumin-oxidation-promotes-lung-predominant-NETosis-and-pulmonary-cancer-metastasis 2026-07-02T09:20:50.178Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatCommun-2021-Grieshaber-Bouyer-The-neutrotime-transcriptional-signature-defines-a-single-continuum-of-neutrophils-across-biological-compartments 2026-07-02T09:20:50.272Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatCommun-2021-Valero-Pretreatment-neutrophil-to-lymphocyte-ratio-and-mutational-burden-as-biomarkers-of-tumor-response-to-immune-checkpoint 2026-07-02T09:20:50.208Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatCommun-2022-Chen-Cancer-co-opts-differentiation-of-b-cell-precursors-into-macrophage-like-cells 2026-07-02T09:20:50.213Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatCommun-2023-Chang-CAR-neutrophil-mediated-delivery-of-tumor-microenvironment-responsive-nanodrugs-for-glioblastoma-chemo-immunotherapy 2026-07-02T09:20:50.225Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatCommun-2023-Puttock-Extracellular-matrix-educates-an-immunoregulatory-tumor-macrophage-phenotype-found-in-ovarian-cancer-metastasis 2026-07-02T09:20:50.261Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatCommun-2023-Taniguchi-In-vivo-induction-of-activin-A-producing-alveolar-macrophages-supports-the-progression-of-lung-cell-carcinoma 2026-07-02T09:20:50.201Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatCommun-2025-Yang-Extracellular-matrix-anchored-neutrophils-drive-pulmonary-fibrosis-in-mice 2026-07-02T09:20:50.209Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatCommun-2026-Li-Macrophage-derived-fibronectin-suppresses-antitumor-immunity-via-tissue-stiffening-and-immunosuppressive-cell-induction 2026-07-02T09:20:50.215Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatGenet-2026-Boesch-Integrated-multi-omics-identifies-distinct-macrophage-alterations-during-progression-of-metabolic 2026-07-02T09:20:50.218Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatImmunol-2015-Kopf-The-development-and-function-of-lung-resident-macrophages-and-dendritic-cells 2026-07-02T09:20:50.165Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatImmunol-2017-Piccolo-Opposing-macrophage-polarization-programs-show-extensive-epigenomic-and-transcriptional-cross-talk 2026-07-02T09:20:50.228Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatImmunol-2018-Patin-Natural-variation-in-the-parameters-of-innate-immune-cells-is-preferentially-driven-by-genetic-factors 2026-07-02T09:20:50.208Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatImmunol-2019-Aran-Reference-based-analysis-of-lung-single-cell-sequencing-reveals-a-transitional-profibrotic-macrophage 2026-07-02T09:20:50.194Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatImmunol-2019-Radermecker-Locally-instructed-CXCR4hi-neutrophils-trigger-environment-driven-allergic-asthma-through-the-release-of-neutrophil 2026-07-02T09:20:50.192Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatImmunol-2020-Li-Lung-mesenchymal-cells-elicit-lipid-storage-in-neutrophils-that-fuel-breast-cancer-lung-metastasis 2026-07-02T09:20:50.217Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatImmunol-2020-Xie-Single-cell-transcriptome-profiling-reveals-neutrophil-heterogeneity-in-homeostasis-and-infection 2026-07-02T09:20:50.203Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatImmunol-2021-Li-Targeting-resident-macrophages-in-cancer 2026-07-02T09:20:50.198Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatImmunol-2024-Li-Coordinated-chemokine-expression-defines-macrophage-subsets-across-tissues 2026-07-02T09:20:50.262Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatImmunol-2025-Sanchez-Garcia-Hypoxia-induces-histone-clipping-and-H3K4me3-loss-in-neutrophil-progenitors-resulting-in-long-term-impairment-of 2026-07-02T09:20:50.202Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatImmunol-2026-Ghosh-Chemokine-defined-macrophage-niches-establish-spatial-organization-of-tumor-immunity 2026-07-02T09:20:50.220Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatImmunol-2026-Kerndl-Monocyte-infiltration-induces-CNS-arginine-catabolism-to-fuel-neuroinflammation 2026-07-02T09:20:50.259Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatMed-2009-Kessenbrock-Netting-neutrophils-in-autoimmune-small-vessel-vasculitis 2026-07-02T09:20:50.215Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatMed-2020-Schalper-Elevated-serum-interleukin-8-is-associated-with-enhanced-intratumor-neutrophils-and-reduced-clinical-benefit-of 2026-07-02T09:20:50.261Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatNanotechnol-2017-Xue-Neutrophil-mediated-anticancer-drug-delivery-for-suppression-of-postoperative-malignant-glioma-recurrence 2026-07-02T09:20:50.191Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatRevCancer-2016-Coffelt-Neutrophils-in-cancer-neutral-no-more 2026-07-02T09:20:50.220Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatRevCancer-2020-Jaillon-Neutrophil-diversity-and-plasticity-in-tumour-progression-and-therapy 2026-07-02T09:20:50.179Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatRevCancer-2023-Barry-Therapeutic-targeting-of-tumour-myeloid-cells 2026-07-02T09:20:50.177Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatRevCancer-2026-Shahzad-Neutrophil-extracellular-traps-in-cancer 2026-07-02T09:20:50.247Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatRevClinOncol-2024-Lasser-Myeloid-derived-suppressor-cells-in-cancer-and-cancer-therapy 2026-07-02T09:20:50.215Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatRevDrugDiscov-2020-Nemeth-Neutrophils-as-emerging-therapeutic-targets 2026-07-02T09:20:50.241Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatRevImmunol-2009-Gabrilovich-Myeloid-derived-suppressor-cells-as-regulators-of-the-immune-system 2026-07-02T09:20:50.207Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatRevImmunol-2012-Gabrilovich-Coordinated-regulation-of-myeloid-cells-by-tumours 2026-07-02T09:20:50.207Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatRevImmunol-2018-Papayannopoulos-Neutrophil-extracellular-traps-in-immunity-and-disease 2026-07-02T09:20:50.228Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatRevImmunol-2019-Ng-Heterogeneity-of-neutrophils 2026-07-02T09:20:50.241Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatRevImmunol-2020-Flemming-Tumours-use-NETs-as-physical-shields 2026-07-02T09:20:50.201Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatRevImmunol-2021-Veglia-Myeloid-derived-suppressor-cells-in-the-era-of-increasing-myeloid-cell-diversity 2026-07-02T09:20:50.260Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/NatRevImmunol-2022-Hedrick-Neutrophils-in-cancer-heterogeneous-and-multifaceted 2026-07-02T09:20:50.247Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Nature-2009-Kim-Carcinoma-produced-factors-activate-myeloid-cells-through-TLR2-to-stimulate-metastasis 2026-07-02T09:20:50.166Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Nature-2011-Qian-CCL2-recruits-inflammatory-monocytes-to-facilitate-breast-tumour-metastasis 2026-07-02T09:20:50.269Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Nature-2015-Coffelt-IL-17-producing-gammadelta-T-cells-and-neutrophils-conspire-to-promote-breast-cancer-metastasis 2026-07-02T09:20:50.186Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Nature-2015-Wculek-Neutrophils-support-lung-colonization-of-metastasis-initiating-breast-cancer-cells 2026-07-02T09:20:50.171Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Nature-2016-DeHenau-Overcoming-resistance-to-checkpoint-blockade-therapy-by-targeting-PI3Kgamma-in-myeloid-cells 2026-07-02T09:20:50.262Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Nature-2017-Gordon-PD-1-expression-by-tumour-associated-macrophages-inhibits-phagocytosis-and-tumour-immunity 2026-07-02T09:20:50.179Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Nature-2019-Szczerba-Neutrophils-escort-circulating-tumour-cells-to-enable-cell-cycle-progression 2026-07-02T09:20:50.175Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Nature-2019-Veglia-Fatty-acid-transport-protein-2-reprograms-neutrophils-in-cancer 2026-07-02T09:20:50.168Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Nature-2020-Yang-DNA-of-neutrophil-extracellular-traps-promotes-cancer-metastasis-via-CCDC25 2026-07-02T09:20:50.182Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Nature-2022-Kim-Ferroptosis-of-tumour-neutrophils-causes-immune-suppression-in-cancer 2026-07-02T09:20:50.273Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Nature-2022-Xue-Liver-tumour-immune-microenvironment-subtypes-and-neutrophil-heterogeneity 2026-07-02T09:20:50.248Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Nature-2023-Wang-CD300ld-on-neutrophils-is-required-for-tumour-driven-immune-suppression 2026-07-02T09:20:50.218Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Nature-2025-Adrover-Neutrophils-drive-vascular-occlusion,-tumour-necrosis-and-metastasis 2026-07-02T09:20:50.227Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Nature-2025-Burn-Myeloperoxidase-transforms-chromatin-into-neutrophil-extracellular-traps 2026-07-02T09:20:50.197Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Nature-2026-Cerezo-Wallis-Architecture-of-the-neutrophil-compartment 2026-07-02T09:20:50.194Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Nature-2026-Fan-Submicrometre-sampling-of-living-cells-by-macrophages 2026-07-02T09:20:50.193Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Nature-2026-Son-Neutrophils-preserve-energy-storage-in-sympathetically-activated-adipocytes 2026-07-02T09:20:50.207Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Neuron-2025-Liu-Lcn2-from-neutrophil-extracellular-traps-induces-astrogliosis-and-post-stroke-emotional-disorders 2026-07-02T09:20:50.231Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/OncoImmunology-2016-Demers-Priming-of-neutrophils-toward-NETosis-promotes-tumor-growth 2026-07-02T09:20:50.172Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Oncogene-2024-Yu-Neutrophils-in-cancer-dual-roles-through-intercellular-interactions 2026-07-02T09:20:50.174Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Oncogenesis-2022-Raskov-Neutrophils-and-polymorphonuclear-myeloid-derived-suppressor-cells-an-emerging-battleground-in-cancer-therapy 2026-07-02T09:20:50.180Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Oncotarget-2018-Zou-Neutrophil-extracellular-traps-promote-lipopolysaccharide-induced-airway-inflammation-and-mucus-hypersecretion-in-mice 2026-07-02T09:20:50.223Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Poster-2024-Meyerson-Serine-Protease-Inhibitors-Enhance-Neutrophil-Survival 2026-07-02T09:20:50.186Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/ProcNatlAcadSciUSA-1993-Tsai-A-dominant-negative-retinoic-acid-receptor-blocks-neutrophil-differentiation-at-the-promyelocyte-stage 2026-07-02T09:20:50.188Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/ProcNatlAcadSciUSA-2010-Fuchs-Extracellular-DNA-traps-promote-thrombosis 2026-07-02T09:20:50.236Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/ProcNatlAcadSciUSA-2012-Cortez-Retamozo-Origins-of-tumor-associated-macrophages-and-neutrophils 2026-07-02T09:20:50.221Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/ProcNatlAcadSciUSA-2015-Casbon-Invasive-breast-cancer-reprograms-early-myeloid-differentiation-in-the-bone-marrow-to-generate-immunosuppressive 2026-07-02T09:20:50.216Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/ProcNatlAcadSciUSA-2021-Carminita-DNase-dependent-NET-indepenedent-pathway-of-thrombus-formation-in-vivo 2026-07-02T09:20:50.238Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/ProcNatlAcadSciUSA-2026-Kalinowski-Peripheral-complement-C4-protein-in-schizophrenia-association-with-gene-copy-number-and-immune-cell-subtypes 2026-07-02T09:20:50.189Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/SSRN-2024-Chen-Circulating-cell-in-cell-tumor-cells-with-neutrophils-signature-are-hematogenous-metastasis-initiating-cells 2026-07-02T09:20:50.166Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/STARProtoc-2020-Liu-Analysis-of-myeloid-cells-in-mouse-tissues-with-flow-cytometry 2026-07-02T09:20:50.167Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/STARProtoc-2021-Cui-Isolation-of-polymorphonuclear-neutrophils-and-monocytes-from-a-single-sample-of-human-peripheral-blood 2026-07-02T09:20:50.232Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/STARProtoc-2021-McGill-Protocol-for-analysis-of-mouse-neutrophil-NETosis-by-flow-cytometry 2026-07-02T09:20:53.004Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/STARProtoc-2023-Kuang-Protocol-for-density-gradient-neutrophil-isolation-and-flow-cytometry-based-characterization-from-human-peripheral-blood 2026-07-02T09:20:50.270Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/STARProtoc-2023-Poli-Quantitative-cytofluorimetric-analysis-of-mouse-neutrophil-extracellular-traps 2026-07-02T09:20:50.209Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/SciAdv-2022-Tang-Single-cell-RNA-sequencing-uncovers-a-neuron-like-macrophage-subset-associated-with-cancer-pain 2026-07-02T09:20:50.240Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/SciAdv-2023-Youn-Neutrophil-intrinsic-TNF-receptor-signaling-orchestrates-host-defense-against-staphylococcus-aureus 2026-07-02T09:20:50.171Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/SciData-2022-Scieszka-NETome-A-model-to-decode-the-human-genome-and-proteome-of-neutrophil-extracellular-traps 2026-07-02T09:20:53.012Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/SciImmunol-2016-Condamine-Lectin-type-oxidized-LDL-receptor-1-distinguishes-population-of-human-polymorphonuclear-myeloid-derived-suppressor 2026-07-02T09:20:50.173Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/SciImmunol-2018-Krishnamoorthy-Neutrophil-cytoplasts-induce-TH17-differentiation-and-skew-inflammation-toward-neutrophilia-in-severe-asthma 2026-07-02T09:20:50.198Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/SciImmunol-2018-Sollberger-Gasdermin-D-plays-a-vital-role-in-the-generation-of-neutrophil-extracellular-traps 2026-07-02T09:20:50.253Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/SciImmunol-2022-Muendlein-Neutrophils-and-macrophages-drive-TNF-induced-lethality-via-TRIF-CD14-mediated-responses 2026-07-02T09:20:50.265Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/SciImmunol-2023-Gong-Immunosuppressive-reprogramming-of-neutrophils-by-lung-mesenchymal-cells-promotes-breast-cancer-metastasis 2026-07-02T09:20:50.257Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/SciImmunol-2024-Ruscitti-Recruited-atypical-Ly6G+-macrophages-license-alveolar-regeneration-after-lung-injury 2026-07-02T09:20:50.222Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/SciImmunol-2025-Tavares-SiglecF-neutrophils 2026-07-02T09:20:50.254Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/SciRep-2016-Liu-Neutrophil-extracellular-traps-are-indirectly-triggered-by-lipopolysaccharide-and-contribute-to-acute-lung-injury 2026-07-02T09:20:50.247Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/SciRep-2017-Leal-Tumor-derived-exosomes-induce-the-formation-of-neutrophil-extracellular-traps-implications-for-the-establishment-of 2026-07-02T09:20:50.162Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/SciRep-2022-Nakamura-Mycobacterium-avium-intracellulare-complex-promote-release-of-pro-inflammatory-enzymes-matrix-metalloproteinases-by-inducing-neutrophil-extracellular-trap-formation 2026-07-02T09:20:50.188Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/SciTranslMed-2016-Park-Cancer-cells-induce-metastasis-supporting-neutrophil-extracellular-DNA-traps 2026-07-02T09:20:50.181Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/SciTranslMed-2021-Fan-Targeting-multiple-cell-death-pathways-extends-the-shelf-life-and-preserves-the-function-of-human-and-mouse-neutrophils 2026-07-02T09:20:50.248Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Science-2004-Brinkmann-Neutrophil-extracellular-traps-kill-bacteria 2026-07-02T09:20:50.193Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Science-2015-Warnatsch-Inflammation.-neutrophil-extracellular-traps-license-macrophages-for-cytokine-production-in-atherosclerosis 2026-07-02T09:20:50.266Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Science-2017-Engblom-Osteoblasts-remotely-supply-lung-tumors-with-cancer-promoting-SiglecFhigh-neutrophils 2026-07-02T09:20:50.264Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Science-2018-Albrengues-Neutrophil-extracellular-traps-produced-during-inflammation-awaken-dormant-cancer-cells-in-mice 2026-07-02T09:20:50.232Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Science-2019-Chakarov-Two-distinct-interstitial-macrophage-populations-coexist-across-tissues-in-specific-subtissular-niches 2026-07-02T09:20:50.179Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Science-2024-Ng-Deterministic-reprogramming-of-neutrophils-within-tumors 2026-07-02T09:20:50.214Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Science-2026-Kusch-Platelet-derived-integrin-and-tetraspanin-enriched-tethers-exacerbate-severe-inflammation 2026-07-02T09:20:50.195Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/SignalTransductTargetTher-2025-Zhou-Therapeutic-potential-of-tumor-associated-neutrophils-dual-role-and-phenotypic-plasticity 2026-07-02T09:20:50.229Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/Thorax-2019-Rocks-Ozone-primed-neutrophils-promote-early-steps-of-tumour-cell-metastasis-to-lungs-by-enhancing-their-NET-production 2026-07-02T09:20:50.176Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/TranslLungCancerRes-2021-Aloe-Emerging-and-multifaceted-role-of-neutrophils-in-lung-cancer 2026-07-02T09:20:50.170Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/TrendsCancer-2024-Horvath-Beyond-binary-bridging-neutrophil-diversity-to-new-therapeutic-approaches-in-NSCLC 2026-07-02T09:20:50.183Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/TrendsCellBiol-2025-Rys-Senescent-neutrophils-a-hidden-role-in-cancer-progression 2026-07-02T09:20:50.241Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/TrendsImmunol-2019-Cassatella-Biological-roles-of-neutrophil-derived-granule-proteins-and-cytokines 2026-07-02T09:20:50.173Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/TrendsImmunol-2026-Henne-TGF-beta-A-master-regulator-of-tissue-resident-macrophage-identity-and-function 2026-07-02T09:20:50.214Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/TrendsImmunol-2026-Zheng-Bioelectric-signaling-as-an-emerging-layer-of-macrophage-communication 2026-07-02T09:20:50.190Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/bioRxiv-2024-Rabas-Cancer-driven-neutrophil-priming-couples-systemic-epithelial-regenerative-programs-with-pre-metastatic-niche-formation 2026-07-02T09:20:50.214Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/bioRxiv-2026-Alkan-S100A9-dependent-CXCR2hi-neutrophils-mediate-systemic-immune-suppression-and 2026-07-02T09:20:50.200Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/bioRxiv-2026-Xu-Neutrophils-repurpose-the-nucleolus-as-a-cytokine-reservoir-and-secretory-organelle 2026-07-02T09:20:50.181Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/eLife-2020-Sollberger-Linker-histone-H1.2-and-H1.4-affect-the-neutrophil-lineage-determination 2026-07-02T09:20:50.274Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/iScience-2023-Strickland-Alternatively-activated-lung-alveolar-and-interstitial-macrophages-promote-fungal-growth 2026-07-02T09:20:50.217Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/%E8%A1%80%E6%A0%93%E6%AD%A2%E8%A1%80%E8%AA%8C-2021-%E5%A4%A7%E5%9D%82-NETs%E3%81%A8%E7%99%8C 2026-07-02T09:20:50.178Z https://research-2ry.pages.dev/Summary/Basic-Neutrophil-and-myeloid-cell/%E8%A1%80%E6%A0%93%E6%AD%A2%E8%A1%80%E8%AA%8C-2022-%E4%B8%89%E5%A5%BD-NETs%E3%81%AE%E6%B8%AC%E5%AE%9A%E6%96%B9%E6%B3%95%E3%81%A8%E8%87%A8%E5%BA%8A%E7%9A%84%E6%84%8F%E7%BE%A9 2026-07-02T09:20:50.246Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/AnnOncol-2015-Heuckmann-A-new-generation-of-cancer-genome-diagnostics-for-routine-clinical-use-overcoming-the-roadblocks-to-personalized-cancer 2026-07-02T09:20:49.562Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/AnnOncol-2020-Bailey-Extrachromosomal-DNA-relieving-heredity-constraints,-accelerating-tumour-evolution 2026-07-02T09:20:49.498Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/AnnOncol-2021-McGrail-High-tumor-mutation-burden-fails-to-predict-immune-checkpoint-blockade-response-across-all-cancer-types 2026-07-02T09:20:53.056Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/BMCPulmMed-2021-Wang-The-pattern-of-alternative-splicing-in-lung-adenocarcinoma-shows-novel-events-correlated-with-tumorigenesis-and-immune 2026-07-02T09:20:49.509Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cancer-2014-Serizawa-Assessment-of-mutational-profile-of-japanese-lung-adenocarcinoma-patients-by-multitarget-assays-a-prospective, 2026-07-02T09:20:49.532Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerCell-2011-Sutherland-Cell-of-origin-of-small-cell-lung-cancer-inactivation-of-trp53-and-rb1-in-distinct-cell-types-of-adult-mouse-lung 2026-07-02T09:20:49.471Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerCell-2012-Mitsuishi-Nrf2-redirects-glucose-and-glutamine-into-anabolic-pathways-in-metabolic-reprogramming 2026-07-02T09:20:49.505Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerCell-2017-Mollaoglu-MYC-drives-progression-of-small-cell-lung-cancer-to-a-variant-neuroendocrine-subtype-with-vulnerability-to-aurora 2026-07-02T09:20:49.559Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerCell-2017-Zhang-A-pan-cancer-proteogenomic-atlas-of-PI3K-AKT-mTOR-pathway-alterations 2026-07-02T09:20:49.486Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerCell-2018-Kahles-Comprehensive-analysis-of-alternative-splicing-across-tumors-from-8,705-patients 2026-07-02T09:20:53.064Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerCell-2018-Li-Loss-of-the-FAT1-Tumor-Suppressor-Promotes-Resistance-to-CDK4-6-Inhibitors-via-the-Hippo-Pathway 2026-07-02T09:20:49.485Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerCell-2018-Razavi-The-genomic-landscape-of-endocrine-resistant-advanced-breast-cancers 2026-07-02T09:20:49.478Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerCell-2018-RojoDeLaVega-NRF2-and-the-hallmarks-of-cancer 2026-07-02T09:20:49.494Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerCell-2020-Ireland-MYC-drives-temporal-evolution-of-small-cell-lung-cancer-subtypes-by-reprogramming-neuroendocrine-fate 2026-07-02T09:20:49.520Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerCell-2020-LaFave-Epigenomic-state-transitions-characterize-tumor-progression-in-mouse-lung-adenocarcinoma 2026-07-02T09:20:49.472Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerCell-2020-Lim-Advancing-cancer-research-and-medicine-with-single-cell-genomics 2026-07-02T09:20:49.464Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerCell-2020-Marjanovic-Emergence-of-a-high-plasticity-cell-state-during-lung-cancer-evolution 2026-07-02T09:20:49.545Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerCell-2020-Salvador-Barbero-CDK46-inhibitors-impair-recovery-from-cytotoxic-chemotherapy-in-pancreatic-adenocarcinoma 2026-07-02T09:20:49.492Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerCell-2021-Ghosh-Mutant-p53-suppresses-innate-immune-signaling-to-promote-tumorigenesis 2026-07-02T09:20:49.556Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerCell-2021-Leader-Single-cell-analysis-of-human-non-small-cell-lung-cancer-lesions-refines-tumor-classification-and-patient-stratification 2026-07-02T09:20:49.547Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerCell-2021-Sanclemente-RAF1-kinase-activity-is-dispensable-for-KRASp53-mutant-lung-tumor-progression 2026-07-02T09:20:49.520Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerCell-2023-Lengel-Genomic-mapping-of-metastatic-organotropism-in-lung-adenocarcinoma 2026-07-02T09:20:49.474Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerCell-2026-Bandlamudi-Cancer-type-specific-variation-in-patterns-of-driver-alterations-across-50,000-tumors 2026-07-02T09:20:49.548Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerCell-2026-Liao-Targeting-TROP2-in-drug-tolerant-persister-cells-delays-EGFR-tyrosine-kinase-inhibitor-resistance-in-non-small-cell 2026-07-02T09:20:49.536Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerCell-2026-Sill-Advancing-CNS-tumor-diagnostics-with-expanded-DNA-methylation-based-classification 2026-07-02T09:20:49.546Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerChemotherPharmacol-2023-Ning-The-role-of-alternative-splicing-in-lung-cancer 2026-07-02T09:20:49.461Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerDiscov-2018-Wang-A-secondary-mutation-in-BRAF-confers-resistance-to-RAF-inhibition-in-a-BRAFV600E-mutant-brain-tumor 2026-07-02T09:20:49.555Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerDiscov-2020-Binkley-KEAP1NFE2L2-mutations-predict-lung-cancer-radiation-resistance-that-can-be-targeted-by-glutaminase-inhibition 2026-07-02T09:20:49.527Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerDiscov-2021-Quintanal-Villalonga-Multiomic-analysis-of-lung-tumors-defines-pathways-activated-in-neuroendocrine-transformation 2026-07-02T09:20:49.484Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerDiscov-2022-Concepcion-Smarca4-inactivation-promotes-lineage-specific-transformation-and-early-metastatic-features-in-the-lung 2026-07-02T09:20:49.504Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerDiscov-2022-Johnson-Classification-of-KRAS-activating-mutations-and-the-implications-for-therapeutic-intervention 2026-07-02T09:20:49.533Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerDiscov-2022-Myer-The-genomics-of-colorectal-cancer-in-populations-with-African-and-European-ancestry 2026-07-02T09:20:49.523Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerDiscov-2022-Yi-Live-cell-imaging-shows-uneven-segregation-of-extrachromosomal-DNA-elements-and-transcriptionally-active 2026-07-02T09:20:49.513Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerDiscov-2023-Stein-LKB1-dependent-regulation-of-TPI1-creates-a-divergent-metabolic-liability-between-human-and-mouse-lung-adenocarcinoma 2026-07-02T09:20:49.510Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerDiscov-2026-Scaparone-EML4-ALK-mediates-resistance-to-KRAS-G12C-inhibition-and-induces-an 2026-07-02T09:20:49.509Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerDiscov-2026-Wei-Abrogation-of-oncogenic-RAS-signaling 2026-07-02T09:20:49.466Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerGeneTher-2026-Sarkar-TP53-mutation-at-codon-179-metabolically-reprograms-cancer-cells-to-promote-invasion 2026-07-02T09:20:49.542Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerLett-2022-Hareendran-Carboxypeptidase-E-and-its-splice-variants-Key-regulators-of-growth-and-metastasis-in-multiple-cancer-types 2026-07-02T09:20:49.543Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerPrevRes(Phila)-2012-Rizzo-Key-principles-and-clinical-applications-of-next-generation-DNA-sequencing 2026-07-02T09:20:49.469Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerRes-2015-Saito-Development-of-lung-adenocarcinomas-with-exclusive-dependence-on-oncogene-fusions 2026-07-02T09:20:49.476Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerRes-2015-Schott-Genome-medicine-in-cancer-what's-in-a-name 2026-07-02T09:20:49.498Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerRes-2017-Udyavar-Novel-hybrid-phenotype-revealed-in-small-cell-lung-cancer-by-a-transcription-factor-network-model-that-can-explain 2026-07-02T09:20:49.493Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerRes-2026-Gu-EGFR-N-glycosylation-catalyzed-by-NDST2-promotes-lenvatinib-resistance-in-hepatocellular-carcinoma 2026-07-02T09:20:49.473Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerResCommun-2023-Chaudhary-Activation-of-KrasG12D-in-subset-of-alveolar-type-II-cells-enhances-cellular-plasticity-in-lung-adenocarcinoma 2026-07-02T09:20:49.507Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CancerSci-2021-Saito-Multiple-mutations-within-individual-oncogenes 2026-07-02T09:20:53.104Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cancers-2022-Cui-Dynamic-expression-of-epcam-in-primary-and-metastatic-lung-cancer-is-controlled-by-both-genetic-and-epigenetic 2026-07-02T09:20:49.505Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-1999-Kornberg-Twenty-five-years-of-the-nucleosome,-fundamental-particle-of-the-eukaryote-chromosome 2026-07-02T09:20:49.477Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2000-Cheung-Signaling-to-chromatin-through-histone-modifications 2026-07-02T09:20:49.541Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2006-Zhang-An-allosteric-mechanism-for-activation-of-the-kinase-domain-of-epidermal-growth-factor-receptor 2026-07-02T09:20:49.484Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2007-Rikova-Global-survey-of-phosphotyrosine-signaling-identifies-oncogenic-kinases-in-lung-cancer 2026-07-02T09:20:49.554Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2009-Vousden-Blinded-by-the-light-The-growing-complexity-of-p53 2026-07-02T09:20:49.496Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2010-Sharma-A-chromatin-mediated-reversible-drug-tolerant-state-in-cancer-cell-subpopulations 2026-07-02T09:20:49.543Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2011-Hanahan-Hallmarks-of-cancer-the-next-generation 2026-07-02T09:20:49.554Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2012-Dawson-Cancer-epigenetics-From-mechanism-to-therapy 2026-07-02T09:20:49.541Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2012-Govindan-Genomic-landscape-of-non-small-cell-lung-cancer-in-smokers-and-never-smokers 2026-07-02T09:20:49.536Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2012-Huang-MED12-controls-the-response-to-multiple-cancer-drugs-through-regulation-of-TGF-beta-receptor-signaling 2026-07-02T09:20:49.465Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2012-Imielinski-Mapping-the-hallmarks-of-lung-adenocarcinoma-with-massively-parallel-sequencing 2026-07-02T09:20:49.493Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2012-Nik-Zainal-The-life-history-of-21-breast-cancers 2026-07-02T09:20:49.529Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2013-Koboldt-The-next-generation-sequencing-revolution-and-its-impact-on-genomics 2026-07-02T09:20:49.489Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2014-McFadden-Genetic-and-clonal-dissection-of-murine-small-cell-lung-carcinoma-progression-by-genome-sequencing 2026-07-02T09:20:49.509Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2015-Pefanis-RNA-exosome-regulated-long-non-coding-RNA-transcription-controls-super-enhancer-activity 2026-07-02T09:20:49.464Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2017-Imielinski-Insertions-and-deletions-target-lineage-defining-genes-in-human-cancers 2026-07-02T09:20:49.496Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2017-McGranahan-Clonal-heterogeneity-and-tumor-evolution-past,-present,-and-the-future 2026-07-02T09:20:49.491Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2018-Huang-Pathogenic-germline-variants-in-10,389-adult-cancers 2026-07-02T09:20:49.543Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2018-Sanchez-Vega-Oncogenic-signaling-pathways-in-the-cancer-genome-atlas 2026-07-02T09:20:49.541Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2018-Wang-An-acquired-vulnerability-of-drug-resistant-melanoma-with-therapeutic-potential 2026-07-02T09:20:49.471Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2018-Zhang-Targeting-CDK9-reactivates-epigenetically-silenced-genes-in-Cancer 2026-07-02T09:20:49.461Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2018-janes-Targeting-KRAS-mutant-cancers-with-a-covalent-G12C-specific-inhibitor 2026-07-02T09:20:49.517Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2019-Kucab-A-compendium-of-mutational-signatures-of-environmental-agents 2026-07-02T09:20:49.533Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2019-Morton-Functional-enhancers-shape-extrachromosomal-oncogene-amplifications 2026-07-02T09:20:49.494Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2020-Gillette-Proteogenomic-characterization-reveals-therapeutic-vulnerabilities-in-lung-adenocarcinoma 2026-07-02T09:20:49.512Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2020-Kumar-Passenger-mutations-in-more-than-2,500-cancer-genomes-overall-molecular-functional-impact-and-consequences 2026-07-02T09:20:49.538Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2020-Xu-Integrative-proteomic-characterization-of-human-lung-adenocarcinoma 2026-07-02T09:20:49.461Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2021-Hahn-An-expanded-universe-of-cancer-targets 2026-07-02T09:20:49.519Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2021-Satpathy-A-proteogenomic-portrait-of-lung-squamous-cell-carcinoma 2026-07-02T09:20:49.480Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2022-Nguyen-Genomic-characterization-of-metastatic-patterns-from-prospective-clinical-sequencing-of-25,000-patients 2026-07-02T09:20:49.464Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2022-he-A-human-fetal-lung-cell-atlas-uncovers-proximal-distal-gradients-of-differentiation-and-key-regulators-of-epithelial 2026-07-02T09:20:49.526Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2024-You-Disruption-of-cellular-plasticity-by-repeat-RNAs-in-human-pancreatic-cancer 2026-07-02T09:20:49.521Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2026-Maurais-Genome-instability-triggers-intercellular-DNA-transfer-between-human-cells 2026-07-02T09:20:49.487Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2026-Wong-A-recipe-for-chaos-extrachromosomal-DNA-and-the-hallmarks-of-cancer 2026-07-02T09:20:49.550Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Cell-2026-Yap-Targeting-genomic-instability-in-cancer 2026-07-02T09:20:49.487Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CellDeathDis-2023-Xu-SRSF3AMOTL1-splicing-axis-promotes-the-tumorigenesis-of-nasopharyngeal-carcinoma-through-regulating-the-nucleus 2026-07-02T09:20:49.515Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CellDeathDiscov-2025-Sui-Lactylation-in-cancer-metabolic-mechanism-and-therapeutic-strategies 2026-07-02T09:20:49.554Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CellRep-2018-Seiler-Somatic-mutational-landscape-of-splicing-factor-genes-and-their-functional-consequences-across-33-cancer-types 2026-07-02T09:20:49.540Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CellRep-2018-Smith-A-human-adult-stem-cell-signature-marks-aggressive-variants-across-epithelial-cancers 2026-07-02T09:20:49.482Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CellRep-2019-Donehower-Integrated-analysis-of-TP53-gene-and-pathway-alterations-in-the-cancer-genome-atlas 2026-07-02T09:20:49.499Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CellRep-2022-Reggiardo-Mutant-KRAS-regulates-transposable-element-RNA-and-innate-immunity-via-KRAB-zinc-finger-genes 2026-07-02T09:20:49.487Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CellRep-2026-Yang-Pan-cancer-evolution-signatures-link-clonal-expansion-to-dynamic-changes-in-the-tumor-immune-microenvironment 2026-07-02T09:20:49.490Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/CellStemCell-2020-Dost-Organoids-model-transcriptional-hallmarks-of-oncogenic-KRAS-activation-in-lung-epithelial-progenitor-cells 2026-07-02T09:20:49.506Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/ClinCancerRes-2002-Chen-Proteomic-analysis-of-lung-adenocarcinoma-identification-of-a-highly-expressed-set-of-proteins-in-tumors 2026-07-02T09:20:49.464Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/ClinCancerRes-2014-Stintzing-Molecular-pathways-turning-proteasomal-protein-degradation-into-a-unique-treatment-approach 2026-07-02T09:20:49.545Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/ClinCancerRes-2018-Frank-Clinical-and-pathological-characteristics-of-KEAP1-and-NFE2L2-mutated-non-small-cell-lung-carcinoma-(NSCLC) 2026-07-02T09:20:49.547Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/ClinCancerRes-2020-Adachi-Epithelial-to-mesenchymal-transition-is-a-cause-of-both-intrinsic-and-acquired-resistance-to-KRAS-G12C-inhibitor-in 2026-07-02T09:20:49.559Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/ClinCancerRes-2020-Schoenfeld-The-genomic-landscape-of-SMARCA4-alterations-and-associations-with-outcomes-in-patients-with-lung-cancer 2026-07-02T09:20:49.523Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/ClinCancerRes-2021-Singh-NRF2-activation-promotes-aggressive-lung-cancer-and-associates-with-poor-clinical-outcomes 2026-07-02T09:20:49.495Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/ClinCancerRes-2021-Sitthideatphaiboon-STK11LKB1-mutations-in-NSCLC-are-associated-with-KEAP1NRF2-dependent-radiotherapy-resistance-targetable-by-glutaminase 2026-07-02T09:20:49.483Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/FrontImmunol-2026-Liu-Pan-cancer-analysis-of-OSR2-with-a-focus-on-underlying-mechanisms-and-therapeutic-implications-in-lung-adenocarcinoma 2026-07-02T09:20:49.531Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/GenesDev-2018-Huang-POU2F3-is-a-master-regulator-of-a-tuft-cell-like-variant-of-small-cell-lung-cancer 2026-07-02T09:20:49.552Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/GenomeBiol-2011-Mermel-GISTIC2.0-facilitates-sensitive-and-confident-localization-of-the-targets-of-focal-somatic-copy-number-alteration-in 2026-07-02T09:20:49.479Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/GenomeMed-2017-Chalmers-Analysis-of-100,000-human-cancer-genomes-reveals-the-landscape-of-tumor-mutational-burden 2026-07-02T09:20:49.560Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/GenomeRes-2018-Houle-Aberrant-PRDM9-expression-impacts-the-pan-cancer-genomic-landscape 2026-07-02T09:20:49.557Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/GenomeRes-2020-Sakamoto-Long-read-sequencing-for-non-small-cell-lung-cancer-genomes 2026-07-02T09:20:49.465Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/HumMolGenet-2015-Matsuda-Genome-wide-association-study-identified-SNP-on-15q24-associated-with-bladder-cancer-risk-in-japanese-population 2026-07-02T09:20:49.547Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/JCOPrecisOncol-2018-Honda-Deleterious-pulmonary-surfactant-system-gene-mutations-in-lung-adenocarcinomas-associated-with-usual-interstitial 2026-07-02T09:20:49.466Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/JClinInvest-2019-LaCanna-YapTaz-regulate-alveolar-regeneration-and-resolution-of-lung-inflammation 2026-07-02T09:20:49.455Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/JClinOncol-2013-Li-Genotyping-and-genomic-profiling-of-non-small-cell-lung-cancer-implications-for-current-and-future-therapies 2026-07-02T09:20:49.524Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/JClinOncol-2013-Oxnard-New-targetable-oncogenes-in-non-small-cell-lung-cancer 2026-07-02T09:20:49.511Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/JClinOncol-2015-Lopez-Chavez-Molecular-profiling-and-targeted-therapy-for-advanced-thoracic-malignancies-a-biomarker-derived,-multiarm, 2026-07-02T09:20:49.520Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/JClinOncol-2015-Meric-Bernstam-Feasibility-of-large-scale-genomic-testing-to-facilitate-enrollment-onto-genomically-matched-clinical-trials 2026-07-02T09:20:49.537Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/JClinOncol-2020-Flaherty-Molecular-landscape-and-actionable-alterations-in-a-genomically-guided-cancer-clinical-trial-national-cancer-institute 2026-07-02T09:20:49.474Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/JImmunotherCancer-2022-Wong-Rolle-Spatial-meta-transcriptomics-reveal-associations-of-intratumor-bacteria-burden-with-lung-cancer-cells-showing-a 2026-07-02T09:20:49.497Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/JThoracOncol-2019-Murphy-Using-genomics-to-differentiate-multiple-primaries-from-metastatic-lung-cancer 2026-07-02T09:20:49.458Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/JThoracOncol-2021-Li-Potential-unreliability-of-uncommon-ALK,-ROS1,-and-RET-genomic-breakpoints-in-predicting-the-efficacy-of-targeted 2026-07-02T09:20:49.528Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/JThoracOncol-2021-Mikubo-Mechanism-of-drug-tolerant-persister-cancer-cells-the-landscape-and-clinical-implication-for-therapy 2026-07-02T09:20:49.514Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/JThoracOncol-2021-Tang-Timing-and-origins-of-local-and-distant-metastases-in-lung-cancer 2026-07-02T09:20:49.493Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/LancetOncol-2011-Pao-New-driver-mutations-in-non-small-cell-lung-cancer 2026-07-02T09:20:49.507Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/MicrobiolMolBiolRev-2015-Fraser-An-overview-of-genome-organization-and-how-we-got-there-from-FISH-to-hi-C 2026-07-02T09:20:49.516Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/ModPathol-2026-Pineda-A-comprehensive-mutational-and-histopathological-analysis-of-STK11-mutant-non-small-cell-lung-carcinomas 2026-07-02T09:20:49.518Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/MolCancer-2018-Du-Mechanisms-of-receptor-tyrosine-kinase-activation-in-cancer 2026-07-02T09:20:49.471Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/MolCancerTher-2007-Christensen-Cytoreductive-antitumor-activity-of-PF-2341066,-a-novel-inhibitor-of-anaplastic-lymphoma-kinase-and-c-met,-in 2026-07-02T09:20:49.492Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/MolCancerTher-2017-Fuse-Mechanisms-of-resistance-to-NTRK-inhibitors-and-therapeutic-strategies-in-NTRK1-rearranged-cancers 2026-07-02T09:20:49.523Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/MolCell-2023-Keun-RBM39-A-druggable-metabolic-sensor-linking-RNA-splicing,-transcriptional-regulation,-and-metabolic-reprogramming-in 2026-07-02T09:20:49.515Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/MolCell-2023-Ma-SRSF2-plays-an-unexpected-role-as-reader-of-m5c-on-mRNA,-linking-epitranscriptomics-to-cancer 2026-07-02T09:20:49.531Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/MolOncol-2012-Hoelder-Discovery-of-small-molecule-cancer-drugs-successes,-challenges-and-opportunities 2026-07-02T09:20:49.477Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/MolTher-2022-Peng-Impacts-and-mechanisms-of-alternative-mRNA-splicing-in-cancer-metabolism,-immune-response,-and-therapeutics 2026-07-02T09:20:49.525Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NEnglJMed-2012-Gerlinger-Intratumor-heterogeneity-and-branched-evolution-revealed-by-multiregion-sequencing 2026-07-02T09:20:49.479Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NEnglJMed-2017-Jamal-Hanjani-Tracking-the-evolution-of-non-small-cell-lung-cancer 2026-07-02T09:20:49.490Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NEnglJMed-2025-Pich-Tumor-infiltrating-clonal-hematopoiesis 2026-07-02T09:20:49.545Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatBiotechnol-2008-Karaman-A-quantitative-analysis-of-kinase-inhibitor-selectivity 2026-07-02T09:20:49.489Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatBiotechnol-2012-Carter-Absolute-quantification-of-somatic-DNA-alterations-in-human-cancer 2026-07-02T09:20:49.542Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatBiotechnol-2013-Cibulskis-Sensitive-detection-of-somatic-point-mutations-in-impure-and-heterogeneous-cancer-samples 2026-07-02T09:20:49.561Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatBiotechnol-2021-Argelaguet-Computational-principles-and-challenges-in-single-cell-data-integration 2026-07-02T09:20:49.547Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatBiotechnol-2021-Prensner-Noncanonical-open-reading-frames-encode-functional-proteins-essential-for-cancer-cell-survival 2026-07-02T09:20:49.459Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatBiotechnol-2024-AlKhafaji-High-throughput-RNA-isoform-sequencing-using-programmed-cDNA-concatenation 2026-07-02T09:20:49.531Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatCancer-2021-Lehtio-Proteogenomics-of-non-small-cell-lung-cancer-reveals-molecular-subtypes-associated-with-specific-therapeutic-targets 2026-07-02T09:20:49.505Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatCommun-2014-Stransky-The-landscape-of-kinase-fusions-in-cancer 2026-07-02T09:20:49.495Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatCommun-2017-Vannini-Transcribed-ultraconserved-region-339-promotes-carcinogenesis-by-modulating-tumor-suppressor-microRNAs 2026-07-02T09:20:49.490Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatCommun-2018-Grzeskowiak-In-vivo-screening-identifies-GATAD2B-as-a-metastasis-driver-in-KRAS-driven-lung-cancer 2026-07-02T09:20:49.514Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatCommun-2018-Su-SHQ1-regulation-of-RNA-splicing-is-required-for-T-lymphoblastic-leukemia-cell-survival 2026-07-02T09:20:49.508Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatCommun-2018-Wagner-Recurrent-WNT-pathway-alterations-are-frequent-in-relapsed-SCLC 2026-07-02T09:20:49.454Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatCommun-2018-Wang-Whole-genome-sequencing-reveals-genomic-signatures-associated-with-the-inflammatory-microenvironments-in-chinese-NSCLC 2026-07-02T09:20:49.507Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatCommun-2026-Klink-Targeted-degradation-of-USP7-in-solid-cancer-cells-reveals-distinct-effects-of-deubiquitinase-degraders-and-inhibitors 2026-07-02T09:20:49.480Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatCommun-2026-Li-Molecular-glue-that-stabilizes-the-LRPPRC-MET-G4-interaction-complex-to-drive-MET-downregulation 2026-07-02T09:20:49.530Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatGenet-2011-DePristo-A-framework-for-variation-discovery-and-genotyping-using-next-generation-DNA-sequencing-data 2026-07-02T09:20:49.475Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatGenet-2012-Peifer-Integrative-genome-analyses-identify-key-somatic-driver-mutations-of-small-cell-lung-cancer 2026-07-02T09:20:49.515Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatGenet-2013-Weinstein-The-cancer-genome-atlas-pan-cancer-analysis-project 2026-07-02T09:20:49.475Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatGenet-2015-DeNicola-NRF2-regulates-serine-biosynthesis-in-non-small-cell-lung-cancer 2026-07-02T09:20:49.486Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatGenet-2016-Campbell-Distinct-patterns-of-somatic-genome-alterations-in-lung-adenocarcinomas-and-squamous-cell-carcinomas 2026-07-02T09:20:49.516Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatGenet-2016-Williams-Identification-of-neutral-tumor-evolution-across-cancer-types 2026-07-02T09:20:49.492Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatGenet-2017-Okimoto-Inactivation-of-Capicua-drives-cancer-metastasis 2026-07-02T09:20:49.484Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatGenet-2018-deCarvalho-Discordant-inheritance-of-chromosomal-and-extrachromosomal-DNA-elements-contributes-to-dynamic-disease-evolution-in 2026-07-02T09:20:49.510Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatGenet-2019-Jang-Transposable-elements-drive-widespread-expression-of-oncogenes-in-human-cancers 2026-07-02T09:20:49.534Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatGenet-2020-Akdemir-Disruption-of-chromatin-folding-domains-by-somatic-genomic-rearrangements-in-human-cancer 2026-07-02T09:20:49.496Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatGenet-2020-Akdemir-Somatic-mutation-distributions-in-cancer-genomes-vary-with-three-dimensional-chromatin-structure 2026-07-02T09:20:49.482Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatGenet-2020-Balmain-The-critical-roles-of-somatic-mutations-and-environmental-tumor-promoting-agents-in-cancer-risk 2026-07-02T09:20:49.517Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatGenet-2020-Cortes-Ciriano-Comprehensive-analysis-of-chromothripsis-in-2,658-human-cancers-using-whole-genome-sequencing 2026-07-02T09:20:49.455Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatGenet-2020-Dietlein-Identification-of-cancer-driver-genes-based-on-nucleotide-context 2026-07-02T09:20:49.485Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatGenet-2020-Kim-Extrachromosomal-DNA-is-associated-with-oncogene-amplification-and-poor-outcome-across-multiple-cancers 2026-07-02T09:20:49.561Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatGenet-2020-Mina-Discovering-functional-evolutionary-dependencies-in-human-cancers 2026-07-02T09:20:49.548Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatGenet-2020-Yuan-Comprehensive-molecular-characterization-of-mitochondrial-genomes-in-human-cancers 2026-07-02T09:20:49.546Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatGenet-2020-Zapatka-The-landscape-of-viral-associations-in-human-cancers 2026-07-02T09:20:49.535Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatGenet-2021-Avsec-Base-resolution-models-of-transcription-factor-binding-reveal-soft-motif-syntax 2026-07-02T09:20:49.463Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatGenet-2021-Hargreaves-Chromatin-openness-requires-continuous-SWISNF-activity 2026-07-02T09:20:49.557Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatGenet-2021-Rosswog-Chromothripsis-followed-by-circular-recombination-drives-oncogene-amplification-in-human-cancer 2026-07-02T09:20:49.511Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatGenet-2022-vanLeen-The-genomic-and-spatial-mobility-of-extrachromosomal-DNA-and-its-implications-for-cancer-therapy 2026-07-02T09:20:49.553Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatGenet-2026-Cheek-Age-distinguishes-selection-from-causation-in-cancer-genomes 2026-07-02T09:20:49.539Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatMed-2011-Chin-Cancer-genomics-from-discovery-science-to-personalized-medicine 2026-07-02T09:20:49.455Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatMed-2012-Pao-Chipping-away-at-the-lung-cancer-genome 2026-07-02T09:20:49.553Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatMed-2015-Bhang-Studying-clonal-dynamics-in-response-to-cancer-therapy-using-high-complexity-barcoding 2026-07-02T09:20:49.467Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatMed-2016-Andor-Pan-cancer-analysis-of-the-extent-and-consequences-of-intratumor-heterogeneity 2026-07-02T09:20:53.252Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatMed-2018-Deribe-Mutations-in-the-SWI-SNF-coplex-induce-a-targetable-dependence-on-oxidative-phosphorylation-in-lung-cancer 2026-07-02T09:20:53.258Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatMed-2020-Milanez-Almeida-Cancer-prognosis-with-shallow-tumor-RNA-sequencing 2026-07-02T09:20:49.552Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatProtoc-2017-Mardis-DNA-sequencing-technologies-2006-2016 2026-07-02T09:20:49.528Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatProtoc-2022-Doman-Designing-and-executing-prime-editing-experiments-in-mammalian-cells 2026-07-02T09:20:49.491Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevCancer-2003-Liang-Analysing-differential-gene-expression-in-cancer 2026-07-02T09:20:49.473Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevCancer-2009-Brown-Awakening-guardian-angels-drugging-the-p53-pathway 2026-07-02T09:20:49.459Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevCancer-2015-Friedman-Precision-medicine-for-cancer-with-next-generation-functional-diagnostics 2026-07-02T09:20:49.457Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevCancer-2017-Rotow-Understanding-and-targeting-resistance-mechanisms-in-NSCLC 2026-07-02T09:20:49.528Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevCancer-2019-Reiter-An-analysis-of-genetic-heterogeneity-in-untreated-cancers 2026-07-02T09:20:49.468Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevCancer-2019-Verhaak-Extrachromosomal-oncogene-amplification-in-tumour-pathogenesis-and-evolution 2026-07-02T09:20:49.533Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevCancer-2020-Hausser-Tumour-heterogeneity-and-the-evolutionary-trade-offs-of-cancer 2026-07-02T09:20:49.454Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevCancer-2020-Marine-Non-genetic-mechanisms-of-therapeutic-resistance-in-cancer 2026-07-02T09:20:49.478Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevCancer-2021-Black-Genetic-and-non-genetic-clonal-diversity-in-cancer-evolution 2026-07-02T09:20:49.507Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevCancer-2021-Bugter-Mutations-and-mechanisms-of-WNT-pathway-tumour-suppressor-in-cancer 2026-07-02T09:20:49.532Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevCancer-2021-Ghiraldini-Solid-tumours-hijack-the-histone-variant-network 2026-07-02T09:20:49.476Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevCancer-2021-Goodall-RNA-in-cancer 2026-07-02T09:20:49.526Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevCancer-2021-Kakiuchi-Clonal-expansion-in-non-cancer-tissues 2026-07-02T09:20:49.540Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevClinOncol-2010-Harris-The-molecular-pathology-of-cancer 2026-07-02T09:20:49.457Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevClinOncol-2012-Collisson-What-are-we-learning-from-the-cancer-genome 2026-07-02T09:20:49.468Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevClinOncol-2018-Dagogo-Jack-Tumour-heterogeneity-and-resistance-to-cancer-therapies 2026-07-02T09:20:49.526Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevClinOncol-2020-Bonnal-Roles-and-mechanisms-of-alternative-splicing-in-cancer-implications-for-care 2026-07-02T09:20:49.508Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevClinOncol-2020-Mittal-The-SWISNF-complex-in-cancer-biology,-biomarkers-and-therapy 2026-07-02T09:20:49.458Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevGenet-2001-Stein-Genome-annotation-from-sequence-to-biology 2026-07-02T09:20:49.517Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevGenet-2009-Segal-From-DNA-sequence-to-transcriptional-behaviour-a-quantitative-approach 2026-07-02T09:20:49.499Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevGenet-2010-Hawkins-Next-generation-genomics-an-integrative-approach 2026-07-02T09:20:49.536Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevGenet-2010-Metzker-Sequencing-technologies-the-next-generation 2026-07-02T09:20:49.558Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevGenet-2010-Meyerson-Advances-in-understanding-cancer-genomes-through-second-generation-sequencing 2026-07-02T09:20:49.534Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevGenet-2011-Alkan-Genome-structural-variation-discovery-and-genotyping 2026-07-02T09:20:49.544Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevGenet-2011-Bamshad-Exome-sequencing-as-a-tool-for-mendelian-disease-gene-discovery 2026-07-02T09:20:49.525Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevGenet-2012-Yates-Evolution-of-the-cancer-genome 2026-07-02T09:20:49.470Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevGenet-2013-Mwenifumbo-Cancer-genome-sequencing-study-design 2026-07-02T09:20:49.457Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevGenet-2013-Watson-Emerging-patterns-of-somatic-mutations-in-cancer 2026-07-02T09:20:49.557Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevGenet-2014-Helleday-Mechanisms-underlying-mutational-signatures-in-human-cancers 2026-07-02T09:20:49.523Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevGenet-2015-Henn-Estimating-the-mutation-load-in-human-genomes 2026-07-02T09:20:49.465Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevGenet-2016-Gawad-Single-cell-genome-sequencing-current-state-of-the-science 2026-07-02T09:20:49.513Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevGenet-2017-Schwartz-The-evolution-of-tumour-phylogenetics-principles-and-practice 2026-07-02T09:20:49.473Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevGenet-2021-Nam-Integrating-genetic-and-non-genetic-determinants-of-cancer-evolution-by-single-cell-multi-omics 2026-07-02T09:20:49.511Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevGenet-2022-Yi-Extrachromosomal-DNA-amplifications-in-cancer 2026-07-02T09:20:49.560Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevMolCellBiol-2019-Marchal-Control-of-DNA-replication-timing-in-the-3D-genome 2026-07-02T09:20:53.300Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevMolCellBiol-2019-Michalak-The-roles-of-DNA,-RNA-and-histone-methylation-in-ageing-and-cancer 2026-07-02T09:20:49.462Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/NatRevMolCellBiol-2019-Treiber-Regulation-of-microRNA-biogenesis-and-its-crosstalk-with-other-cellular-pathways 2026-07-02T09:20:49.554Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2001-Blume-Jensen-Oncogenic-kinase-signalling 2026-07-02T09:20:49.518Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2001-Lander-Initial-sequencing-and-analysis-of-the-human-genome 2026-07-02T09:20:49.529Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2002-Davies-Mutations-of-the-BRAF-gene-in-human-cancer 2026-07-02T09:20:49.557Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2004-International-human-genome-sequencing-consortium-Finishing-the-euchromatic-sequence-of-the-human-genome 2026-07-02T09:20:49.548Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2005-Bryant-Specific-killing-of-BRCA2-deficient-tumours-with-inhibitors-of-poly(adp-ribose)-polymerase 2026-07-02T09:20:49.460Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2005-Farmer-Targeting-the-DNA-repair-defect-in-BRCA-mutant-cells-as-a-therapeutic-strategy 2026-07-02T09:20:49.558Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2008-Bentley-Accurate-whole-human-genome-sequencing-using-reversible-terminator-chemistry 2026-07-02T09:20:49.467Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2008-Ding-Somatic-mutations-affect-key-pathways-in-lung-adenocarcinoma 2026-07-02T09:20:49.478Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2008-TCGA-Comprehensive-genomic-characterization-defines-human-glioblastoma-genes-and-core-pathways 2026-07-02T09:20:49.458Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2009-Stratton-The-cancer-genome 2026-07-02T09:20:49.475Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2009-Zhou-Novel-mutant-selective-EGFR-kinase-inhibitors-against-EGFR-T790M 2026-07-02T09:20:49.469Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2010-Filippakopoulos-Selective-inhibition-of-BET-bromodomains 2026-07-02T09:20:49.483Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2010-Lee-The-mutation-spectrum-revealed-by-paired-genome-sequences-from-a-lung-cancer-patient 2026-07-02T09:20:49.528Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2010-Pleasance-A-comprehensive-catalogue-of-somatic-mutations-from-a-human-cancer-genome 2026-07-02T09:20:49.477Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2011-Navin-Tumour-evolution-inferred-by-single-cell-sequencing 2026-07-02T09:20:49.453Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2012-An-integrated-map-of-genetic-variation-from-1092-human-genomes 2026-07-02T09:20:49.474Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2012-TCGA-Comprehensive-genomic-characterization-of-squamous-cell-lung-cancers 2026-07-02T09:20:49.460Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2013-Lawrence-Mutational-heterogeneity-in-cancer-and-the-search-for-new-cancer-associated-genes 2026-07-02T09:20:49.485Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2014-Cancer-Comprehensive-molecular-profiling-of-lung-adenocarcinoma 2026-07-02T09:20:49.486Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2014-Lawrence-Discovery-and-saturation-analysis-of-cancer-genes-across-21-tumour-types 2026-07-02T09:20:49.470Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2017-Neri-Intragenic-DNA-methylation-prevents-spurious-transcription-initiation 2026-07-02T09:20:49.466Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2017-Shendure-DNA-sequencing-at-40-past,-present-and-future 2026-07-02T09:20:49.495Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2017-Tanay-Scaling-single-cell-genomics-from-phenomenology-to-mechanism 2026-07-02T09:20:49.518Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2017-Turner-Extrachromosomal-oncogene-amplification-drives-tumour-evolution-and-genetic-heterogeneity 2026-07-02T09:20:49.529Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2017-Yao-Tumours-with-class-3-BRAF-mutants-are-sensitive-to-the-inhibition-of-activated-RAS 2026-07-02T09:20:49.480Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2018-Bakhoum-Chromosomal-instability-drives-metastasis-through-a-cytosolic-DNA-response 2026-07-02T09:20:49.499Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2018-Roerink-Intra-tumour-diversification-in-colorectal-cancer-at-the-single-cell-level 2026-07-02T09:20:49.498Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2019-Anzalone-Search-and-replace-genome-editing-without-double-strand-breaks-or-donor-DNA 2026-07-02T09:20:49.559Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2019-Behan-Prioritization-of-cancer-therapeutic-targets-using-CRISPR-Cas9-screens 2026-07-02T09:20:49.456Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2019-Wu-Circular-ecDNA-promotes-accessible-chromatin-and-high-oncogene-expression 2026-07-02T09:20:49.560Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2020-Alexandrov-The-repertoire-of-mutational-signatures-in-human-cancer 2026-07-02T09:20:49.538Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2020-ICGCTCGA-Pan-cancer-analysis-of-whole-genomes 2026-07-02T09:20:49.524Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2020-Jayavelu-Splicing-factor-YBX1-mediates-persistence-of-JAK2-mutated-neoplasms 2026-07-02T09:20:49.534Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2020-PCAWG-Genomic-basis-for-RNA-alterations-in-cancer 2026-07-02T09:20:49.513Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2020-Watkins-Pervasive-chromosomal-instability-and-karyotype-order-in-tumour-evolution 2026-07-02T09:20:49.522Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2021-Hung-ecDNA-hubs-drive-cooperative-intermolecular-oncogene-expression 2026-07-02T09:20:49.556Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2021-Sroka-An-epigenetic-fulcrum-tipped-in-cancer 2026-07-02T09:20:49.551Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2021-Vassiliadis-Mutation-alters-chromatin-changes-during-injury-response-to-drive-cancer 2026-07-02T09:20:49.472Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2021-Yuan-Elevated-NSD3-histone-methylation-activity-drives-squamous-cell-lung-cancer 2026-07-02T09:20:49.491Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2021-Yum-Tracing-oncogene-driven-remodelling-of-the-intestinal-stem-cell-niche 2026-07-02T09:20:49.535Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2022-Fennell-Non-genetic-determinants-of-malignant-clonal-fitness-at-single-cell-resolution 2026-07-02T09:20:49.531Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2022-Funnell-Single-cell-genomic-variation-induced-by-mutational-processes-in-cancer 2026-07-02T09:20:49.551Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2023-Li-Non-cell-autonomous-cancer-progression-from-chromosomal-instability 2026-07-02T09:20:49.488Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2026-Chan-Critical-role-for-a-high-plasticity-cell-state-in-lung-cancer 2026-07-02T09:20:49.519Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2026-Franca-A-mechanism-for-adaptive-genome-regulation-in-cancer 2026-07-02T09:20:49.537Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2026-Hessey-Evolutionary-characterization-of-lung-cancer-metastasis 2026-07-02T09:20:49.530Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2026-Lopez-Bigas-Tumour-promotion-through-the-lens-of-evolution 2026-07-02T09:20:49.555Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2026-Pich-Somatic-evolution-following-cancer-treatment-in-normal-tissue 2026-07-02T09:20:49.561Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Nature-2026-Sankar-Genetic-elements-promote-retention-of-extrachromosomal-DNA-in-cancer-cells 2026-07-02T09:20:49.462Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Oncotarget-2014-Cummings-Mer590,-a-novel-monoclonal-antibody-targeting-MER-receptor-tyrosine-kinase,-decreases-colony-formation-and-increases 2026-07-02T09:20:49.546Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/ProcNatlAcadSciUSA-2008-Shibata-Cancer-related-mutations-in-NRF2-impair-its-recognition-by-keap1-cul3-E3-ligase-and-promote-malignancy 2026-07-02T09:20:49.460Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/ProcNatlAcadSciUSA-2008-Yun-The-T790M-mutation-in-EGFR-kinase-causes-drug-resistance-by-increasing-the-affinity-for-ATP 2026-07-02T09:20:49.482Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/ProcNatlAcadSciUSA-2016-McFadden-Mutational-landscape-of-EGFR-,-MYC-,-and-kras-driven-genetically-engineered-mouse-models-of-lung-adenocarcinoma 2026-07-02T09:20:49.551Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/ProcNatlAcadSciUSA-2019-Miranda-Cancer-stemness,-intratumoral-heterogeneity,-and-immune-response-across-cancers 2026-07-02T09:20:49.454Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/ProcNatlAcadSciUSA-2020-Benisty-Mutation-bias-within-oncogene-families-is-related-to-proliferation-specific-codon-usage 2026-07-02T09:20:49.515Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/ProcNatlAcadSciUSA-2020-Mayrhofer-Mutation-oriented-profiling-of-autoinhibitory-kinase-conformations-predicts-RAF-inhibitor-efficacies 2026-07-02T09:20:49.468Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/ProteinCell-2022-Yang-Emerging-roles-of-spliceosome-in-cancer-and-immunity 2026-07-02T09:20:49.537Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/SciRep-2015-Cao-Genome-wide-association-study-on-platinum-induced-hepatotoxicity-in-non-small-cell-lung-cancer-patients 2026-07-02T09:20:49.511Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/SciRep-2020-Anusewicz-Lung-squamous-cell-carcinoma-and-lung-adenocarcinoma-differential-gene-expression-regulation-through-pathways-of-notch, 2026-07-02T09:20:49.460Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/SciSignal-2019-Augert-Targeting-NOTCH-activation-in-small-cell-lung-cancer-through-LSD1-inhibition 2026-07-02T09:20:49.471Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/SciTranslMed-2015-McGranahan-Clonal-status-of-actionable-driver-events-and-the-timing-of-mutational-processes-in-cancer-evolution 2026-07-02T09:20:49.524Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/SciTranslMed-2022-Liu-A-germline-SNP-in-BRMS1-predisposes-patients-with-lung-adenocarcinoma-to-metastasis-and-can-be-ameliorated-by-targeting 2026-07-02T09:20:49.522Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Science-2002-Manning-The-protein-kinase-complement-of-the-human-genome 2026-07-02T09:20:49.500Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Science-2002-Weinstein-Cancer.-addiction-to-oncogenes-the-achilles-heal-of-cancer 2026-07-02T09:20:49.497Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Science-2004-Schlessinger-Common-and-distinct-elements-in-cellular-signaling-via-EGF-and-FGF-receptors 2026-07-02T09:20:49.539Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Science-2014-Crystal-Patient-derived-models-of-acquired-resistance-can-identify-effective-drug-combinations-for-cancer 2026-07-02T09:20:49.466Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Science-2014-Nathanson-Targeted-therapy-resistance-mediated-by-dynamic-regulation-of-extrachromosomal-mutant-EGFR-DNA 2026-07-02T09:20:49.529Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Science-2014-deBruin-Spatial-and-temporal-diversity-in-genomic-instability-processes-defines-lung-cancer-evolution 2026-07-02T09:20:49.520Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Science-2017-Dawson-The-cancer-epigenome-Concepts,-challenges,-and-therapeutic-opportunities 2026-07-02T09:20:49.481Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Science-2018-Park-Reprogramming-normal-human-epithelial-tissues-to-a-common,-lethal-neuroendocrine-cancer-lineage 2026-07-02T09:20:49.532Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Science-2018-Reiter-Minimal-functional-driver-gene-heterogeneity-among-untreated-metastases 2026-07-02T09:20:49.456Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Science-2021-Payne-In-situ-genome-sequencing-resolves-DNA-sequence-and-structure-in-intact-biological-samples 2026-07-02T09:20:49.508Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Science-2021-Quinn-Single-cell-lineages-reveal-the-rates,-routes,-and-drivers-of-metastasis-in-cancer-xenografts 2026-07-02T09:20:49.527Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Science-2022-Altemose-Complete-genomic-and-epigenetic-maps-of-human-centromeres 2026-07-02T09:20:49.538Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Science-2022-Church-A-next-generation-human-genome-sequence 2026-07-02T09:20:49.500Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Science-2023-Girish-Oncogene-like-addiction-to-aneuploidy-in-human-cancers 2026-07-02T09:20:49.549Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Science-2024-Gardner-Lineage-specific-intolerance-to-oncogenic-drivers-restricts-histological-transformation 2026-07-02T09:20:49.552Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/Science-2026-Zhang-Stem-cell-control-in-the-lung-by-an-autocrine-injury-activated-igf-complex 2026-07-02T09:20:49.549Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/SemCancerBiol-2018-Duruisseaux-Lung-cancer-epigenetics-from-knowledge-to-applications 2026-07-02T09:20:49.494Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/SeminOncol-2014-Berge-Targeted-therapies-in-non-small-cell-lung-cancer-emerging-oncogene-targets-following-the-success-of-epidermal-growth 2026-07-02T09:20:49.516Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/SignalTransductTargetTher-2021-Zhang-Alternative-splicing-and-cancer-a-systematic-review 2026-07-02T09:20:49.538Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/SignalTransductTargetTher-2022-Wu-Multi-omics-analysis-reveals-RNA-splicing-alterations-and-their-biological-and-clinical-implications-in-lung 2026-07-02T09:20:49.550Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/SignalTransductTargetTher-2026-Wang-Disrupting-SOX2-self-association-and-condensate-formation-to-overcome-chemotherapeutic-drug-resistance-in-lung-squamous 2026-07-02T09:20:49.512Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/TrendsCancer-2026-Attardi-P53-defender-of-lineage-fidelity-and-foe-of-plasticity-in-cancer-and-regeneration 2026-07-02T09:20:49.556Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/TrendsCancer-2026-Tan-Targeting-cyclin-dependent-kinases-in-cancer-emerging-therapeutics-and-clinical-strategies 2026-07-02T09:20:49.548Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/TrendsGenet-2021-Nesta-Hotspots-of-human-mutation 2026-07-02T09:20:49.558Z https://research-2ry.pages.dev/Summary/Basic-Oncogene-and-genetics/TrendsGenet-2022-Noer-Extrachromosomal-circular-DNA-in-cancer-History,-current-knowledge,-and-methods 2026-07-02T09:20:49.522Z https://research-2ry.pages.dev/Summary/Basic-Others/ACSOmega-2020-Graw-proteiNorm-A-user-friendly-tool-for-normalization-and-analysis-of-TMT-and-label-free-protein-quantification 2026-07-02T09:20:49.295Z https://research-2ry.pages.dev/Summary/Basic-Others/AdvSci-2026-Gan-Single-cell-reveal-GALNT7-dependent-ferroptosis-suppression-as-a-mechanism-of-immunotherapy-resistance-in-non-small 2026-07-02T09:20:49.249Z https://research-2ry.pages.dev/Summary/Basic-Others/AmJTranslRes-2014-Zhang-Comparative-membrane-proteomic-analysis-between-lung-adenocarcinoma-and-normal-tissue-by-iTRAQ-labeling-mass 2026-07-02T09:20:49.211Z https://research-2ry.pages.dev/Summary/Basic-Others/AmSocClinOncolEducBook-2026-Osarogiagbon-Optimal-use-of-targeted-therapy-and-immunotherapy-in-early-stage,-resectable-non-small-cell-lung-cancer 2026-07-02T09:20:49.216Z https://research-2ry.pages.dev/Summary/Basic-Others/AnnOncol-2011-Cahu-18f-fluorodeoxyglucose-positron-emission-tomography-before,-during-and-after-treatment-in-mature-TNK-lymphomas-a-study 2026-07-02T09:20:49.287Z https://research-2ry.pages.dev/Summary/Basic-Others/AnnOncol-2015-Ali-PD-L1-protein-expression-in-breast-cancer-is-rare,-enriched-in-basal-like-tumours-and-associated-with-infiltrating 2026-07-02T09:20:49.282Z https://research-2ry.pages.dev/Summary/Basic-Others/AnnOncol-2017-Izumchenko-Patient-derived-xenografts-effectively-capture-responses-to-oncology-therapy-in-a-heterogeneous-cohort-of-patients-with 2026-07-02T09:20:49.276Z https://research-2ry.pages.dev/Summary/Basic-Others/AnnThoracSurg-2014-Nakajima-Orthotopic-lung-cancer-murine-model-by-nonoperative-transbronchial-approach 2026-07-02T09:20:49.251Z https://research-2ry.pages.dev/Summary/Basic-Others/AnnuRevBiochem-2020-Wilkinson-RNA-splicing-by-the-spliceosome 2026-07-02T09:20:49.170Z https://research-2ry.pages.dev/Summary/Basic-Others/BMCBioinformatics-2011-Li-RSEM-accurate-transcript-quantification-from-RNA-seq-data-with-or-without-a-reference-genome 2026-07-02T09:20:49.223Z https://research-2ry.pages.dev/Summary/Basic-Others/BMCBioinformatics-2013-Hanzelmann-GSVA-gene-set-variation-analysis-for-microarray-and-RNA-seq-data 2026-07-02T09:20:49.204Z https://research-2ry.pages.dev/Summary/Basic-Others/BMJOncol-2026-ODwyer-Treatment-of-oligometastatic-lung-cancers-new-data,-new-drivers,-new-approaches 2026-07-02T09:20:49.232Z https://research-2ry.pages.dev/Summary/Basic-Others/BioProtocol-2016-Sinha-Isolation-of-highly-pure-primary-mouse-alveolar-epithelial-type-II-cells-by-flow-cytometric-cell-sorting 2026-07-02T09:20:49.226Z https://research-2ry.pages.dev/Summary/Basic-Others/Biochemist-2020-Sinha-A-beginner's-guide-to-mass-spectrometry-based-proteomics 2026-07-02T09:20:49.231Z https://research-2ry.pages.dev/Summary/Basic-Others/Bioinformatics-2009-Li-Fast-and-accurate-short-read-alignment-with-burrows-wheeler-transform 2026-07-02T09:20:49.277Z https://research-2ry.pages.dev/Summary/Basic-Others/Bioinformatics-2009-Li-The-sequence-AlignmentMap-format-and-SAMtools 2026-07-02T09:20:49.307Z https://research-2ry.pages.dev/Summary/Basic-Others/Bioinformatics-2010-Quinlan-BEDTools-a-flexible-suite-of-utilities-for-comparing-genomic-features 2026-07-02T09:20:49.206Z https://research-2ry.pages.dev/Summary/Basic-Others/Bioinformatics-2010-Robinson-edgeR-a-bioconductor-package-for-differential-expression-analysis-of-digital-gene-expression-data 2026-07-02T09:20:49.175Z https://research-2ry.pages.dev/Summary/Basic-Others/Bioinformatics-2010-Wilkerson-ConsensusClusterPlus-a-class-discovery-tool-with-confidence-assessments-and-item-tracking 2026-07-02T09:20:49.223Z https://research-2ry.pages.dev/Summary/Basic-Others/Bioinformatics-2012-Saunders-Strelka-accurate-somatic-small-variant-calling-from-sequenced-tumor-normal-sample-pairs 2026-07-02T09:20:49.308Z https://research-2ry.pages.dev/Summary/Basic-Others/Bioinformatics-2013-Dobin-STAR-ultrafast-universal-RNA-seq-aligner 2026-07-02T09:20:49.192Z https://research-2ry.pages.dev/Summary/Basic-Others/Bioinformatics-2014-Bolger-Trimmomatic-a-flexible-trimmer-for-illumina-sequence-data 2026-07-02T09:20:49.234Z https://research-2ry.pages.dev/Summary/Basic-Others/Bioinformatics-2014-Liao-featureCounts-an-efficient-general-purpose-program-for-assigning-sequence-reads-to-genomic-features 2026-07-02T09:20:49.276Z https://research-2ry.pages.dev/Summary/Basic-Others/Bioinformatics-2015-Anders-HTSeq-a-python-framework-to-work-with-high-throughput-sequencing-data 2026-07-02T09:20:49.190Z https://research-2ry.pages.dev/Summary/Basic-Others/BiomedPharmacother-2022-Chen-Integrin-mediated-cancer-progression-as-a-specific-target-in-clinical-therapy 2026-07-02T09:20:49.260Z https://research-2ry.pages.dev/Summary/Basic-Others/Blood-2010-Jena-Redirecting-T-cell-specificity-by-introducing-a-tumor-specific-chimeric-antigen-receptor 2026-07-02T09:20:49.221Z https://research-2ry.pages.dev/Summary/Basic-Others/Blood-2022-Heazlewood-The-RNA-binding-protein-SRSF3-has-an-essential-role-in-megakaryocyte-maturation-and-platelet-production 2026-07-02T09:20:49.242Z https://research-2ry.pages.dev/Summary/Basic-Others/Blood-2022-Wen-Molecular-mechanisms-of-leukocyte-beta2-integrin-activation 2026-07-02T09:20:49.181Z https://research-2ry.pages.dev/Summary/Basic-Others/Blood-2025-Conrad-Decoding-functional-hematopoietic-progenitor-cells-in-the-adult-human-lung 2026-07-02T09:20:49.264Z https://research-2ry.pages.dev/Summary/Basic-Others/BrJCancer-1999-Doki-Mediastinal-lymph-node-metastasis-model-by-orthotopic-intrapulmonary-implantation-of-Lewis-lung-carcinoma-cells-in-mice 2026-07-02T09:20:49.300Z https://research-2ry.pages.dev/Summary/Basic-Others/BreastCancerRes-2014-Sun-Construction-and-evaluation-of-a-novel-humanized-HER2-specific-chimeric-receptor 2026-07-02T09:20:49.284Z https://research-2ry.pages.dev/Summary/Basic-Others/CancerBiolTher-2008-Karanikas-Co-expression-patterns-of-tumor-associated-antigen-genes-by-non-small-cell-lung-carcinomas-implications-for 2026-07-02T09:20:49.199Z https://research-2ry.pages.dev/Summary/Basic-Others/CancerCell-2009-Sugahara-Tissue-penetrating-delivery-of-compounds-and-nanoparticles-into-tumors 2026-07-02T09:20:49.202Z https://research-2ry.pages.dev/Summary/Basic-Others/CancerCell-2020-Zhao-Large-scale-characterization-of-drug-responses-of-clinically-relevant-proteins-in-cancer-cell-lines 2026-07-02T09:20:49.308Z https://research-2ry.pages.dev/Summary/Basic-Others/CancerCell-2021-Zhu-Oncogenic-extrachromosomal-DNA-functions-as-mobile-enhancers-to-globally-amplify-chromosomal-transcription 2026-07-02T09:20:49.246Z https://research-2ry.pages.dev/Summary/Basic-Others/CancerCell-2022-Newell-Multiomic-profiling-of-checkpoint-inhibitor-treated-melanoma-identifying-predictors-of-response-and-resistance,-and 2026-07-02T09:20:49.215Z https://research-2ry.pages.dev/Summary/Basic-Others/CancerCell-2026-Enssle-Pathogenesis-of-diffuse-large-B-cell-lymphoma-proteogenotypes 2026-07-02T09:20:49.236Z https://research-2ry.pages.dev/Summary/Basic-Others/CancerCell-2026-Liang-Spatial-biomarker-discovery-via-interpretable-semantic-learning-in-histopathology 2026-07-02T09:20:49.194Z https://research-2ry.pages.dev/Summary/Basic-Others/CancerCell-2026-Richter-A-closed-tumor-immune-brain-circuit-in-cancer-cachexia 2026-07-02T09:20:49.211Z https://research-2ry.pages.dev/Summary/Basic-Others/CancerCell-2026-Tang-Mapping-cell-type-resolved-transcriptomic-profiles-to-patient-survival-in-pancreatic-cancer 2026-07-02T09:20:49.166Z https://research-2ry.pages.dev/Summary/Basic-Others/CancerCell-2026-Xu-Received-24-february-2026 2026-07-02T09:20:49.223Z https://research-2ry.pages.dev/Summary/Basic-Others/CancerCell-2026-Zhang-Cancer-cachexia-a-tumor-driven-disorder-of-whole-body-homeostasis 2026-07-02T09:20:49.192Z https://research-2ry.pages.dev/Summary/Basic-Others/CancerCellInt-2020-Nolan-Development-of-syngeneic-murine-cell-lines-for-use-in-immunocompetent-orthotopic-lung-cancer-models 2026-07-02T09:20:49.196Z https://research-2ry.pages.dev/Summary/Basic-Others/CancerChemotherPharmacol-2014-Doi-Phase-I-dose-escalation-study-of-the-HSP90-inhibitor-AUY922-in-japanese-patients-with-advanced-solid-tumors 2026-07-02T09:20:49.222Z https://research-2ry.pages.dev/Summary/Basic-Others/CancerDiscov-2012-Cerami-The-cBio-cancer-genomics-portal-an-open-platform-for-exploring-multidimensional-cancer-genomics-data 2026-07-02T09:20:49.204Z https://research-2ry.pages.dev/Summary/Basic-Others/CancerDiscov-2022-Garciaz-Pharmacologic-reduction-of-mitochondrial-iron-triggers-a-noncanonical-BAXBAK-dependent-cell-death 2026-07-02T09:20:49.197Z https://research-2ry.pages.dev/Summary/Basic-Others/CancerDiscov-2026-Marinello-Approaches-in-non-small-cell-lung-cancer-2 2026-07-02T09:20:49.221Z https://research-2ry.pages.dev/Summary/Basic-Others/CancerDiscov-2026-Winslow-A-roadmap-to-transform-lung-cancer-outcomes-priorities-in-biology,-therapeutic-innovation,-early-detection,-prevention 2026-07-02T09:20:49.244Z https://research-2ry.pages.dev/Summary/Basic-Others/CancerDiscov-2026-Yiu-Same-slide-spatial-multiomics-integration 2026-07-02T09:20:49.301Z https://research-2ry.pages.dev/Summary/Basic-Others/CancerImmunolImmunother-2009-DiGiacomo-Therapeutic-efficacy-of-ipilimumab,-an-anti-CTLA-4-monoclonal-antibody,-in-patients-with-metastatic-melanoma 2026-07-02T09:20:49.170Z https://research-2ry.pages.dev/Summary/Basic-Others/CancerImmunolRes-2014-Wang-Targeting-fibroblast-activation-protein-in-tumor-stroma-with-chimeric-antigen-receptor-T-cells-can-inhibit-tumor-growth 2026-07-02T09:20:49.167Z https://research-2ry.pages.dev/Summary/Basic-Others/CancerImmunolRes-2015-Davenport-CAR-T-cells-inflict-sequential-killing-of-multiple-tumor-target-cells 2026-07-02T09:20:49.318Z https://research-2ry.pages.dev/Summary/Basic-Others/CancerImmunolRes-2026-Li-Peripheral-th17-immune-signature-associates-with-excellent-response-to-anti-PD1anti-PD-L1-therapy-across-solid-tumors 2026-07-02T09:20:49.283Z https://research-2ry.pages.dev/Summary/Basic-Others/CancerLett-2026-Muneer-Deep-learning-of-CT-imaging-predicts-PD-L1-expression-and-immunotherapy-response-in-metastatic-NSCLC-A-multi-center 2026-07-02T09:20:49.202Z https://research-2ry.pages.dev/Summary/Basic-Others/CancerMed-2026-Zhu-Harnessing-gut-microbiota-to-enhance-immunotherapy-in-NSCLC-from-mechanisms-to-translational-applications 2026-07-02T09:20:49.318Z https://research-2ry.pages.dev/Summary/Basic-Others/CancerRes-2009-Okamoto-Improved-expression-and-reactivity-of-transduced-tumor-specific-TCRs-in-human-lymphocytes-by-specific-silencing-of 2026-07-02T09:20:49.299Z https://research-2ry.pages.dev/Summary/Basic-Others/CancerRes-2026-Clarke-Virtual-tumors-enable-prediction-of-personalized-therapeutic-combinations-for-non-small-cell-lung-cancer 2026-07-02T09:20:49.178Z https://research-2ry.pages.dev/Summary/Basic-Others/Cancers-2026-Jiang-Selective-inhibition-of-KRASG13C-reveals-an-increased-dependence-on-wild-type-RAS 2026-07-02T09:20:49.187Z https://research-2ry.pages.dev/Summary/Basic-Others/Carcinogenesis-2026-Wang-Camrelizumab,-apatinib-and-radiotherapy-in-locally-advanced,-unresectable 2026-07-02T09:20:49.210Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2000-Hanahan-The-hallmarks-of-cancer 2026-07-02T09:20:49.285Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2005-Hoepfner-Modulation-of-receptor-recycling-and-degradation-by-the-endosomal-kinesin-KIF16B 2026-07-02T09:20:49.308Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2012-Glickman-Converting-cancer-therapies-into-cures-lessons-from-infectious-diseases 2026-07-02T09:20:49.274Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2012-Nik-Zainal-Mutational-processes-molding-the-genomes-of-21-breast-cancers 2026-07-02T09:20:53.469Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2013-Rivera-Mapping-human-epigenomes 2026-07-02T09:20:49.228Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2014-Gao-Organoid-cultures-derived-from-patients-with-advanced-prostate-cancer 2026-07-02T09:20:49.273Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2014-Lee-Lung-stem-cell-differentiation-in-mice-directed-by-endothelial-cells-via-a-BMP4-NFATc1-thrombospondin-1-axis 2026-07-02T09:20:49.230Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2015-Macosko-Highly-parallel-genome-wide-expression-profiling-of-individual-cells-using-nanoliter-droplets 2026-07-02T09:20:49.300Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2015-Network-Genomic-classification-of-cutaneous-melanoma 2026-07-02T09:20:49.193Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2017-Lee-Anatomically-and-functionally-distinct-lung-mesenchymal-populations-marked-by-Lgr5-and-Lgr6 2026-07-02T09:20:49.288Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2017-Lim-The-principles-of-engineering-immune-cells-to-treat-cancer 2026-07-02T09:20:49.262Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2018-Lee-Tumor-evolution-and-drug-response-in-patient-derived-organoid-models-of-bladder-cancer 2026-07-02T09:20:49.226Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2018-Stillman-Histone-modifications-insights-into-their-influence-on-gene-expression 2026-07-02T09:20:49.233Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2019-Stuart-Comprehensive-integration-of-single-cell-data 2026-07-02T09:20:49.214Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2019-Wagner-A-single-cell-atlas-of-the-tumor-and-immune-ecosystem-of-human-breast-cancer 2026-07-02T09:20:49.172Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2021-Hao-Integrated-analysis-of-multimodal-single-cell-data 2026-07-02T09:20:49.249Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2021-Schreiber-The-rise-of-molecular-glues 2026-07-02T09:20:49.302Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2023-Falzone-Cancer-chemotherapy 2026-07-02T09:20:49.168Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2023-Finley-What-is-cancer-metabolism 2026-07-02T09:20:49.174Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2023-Horns-Engineering-RNA-export-for-measurement-and-manipulation-of-living-cells 2026-07-02T09:20:49.309Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2023-Shiraishi-Biophysical-forces-mediated-by-respiration-maintain-lung-alveolar-epithelial-cell-fate 2026-07-02T09:20:49.245Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2026-Aggarwal-Engineered-commensals-for-metabolic-modulation-of-the-gut-liver-brain-axis 2026-07-02T09:20:49.298Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2026-Conard-Tackling-the-complexity-of-cancer-with-generative-models 2026-07-02T09:20:49.169Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2026-Conrad-Cell-death-in-cancer 2026-07-02T09:20:49.175Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2026-Dohlman-Biodiversity-and-biogeography-of-the-multi-kingdom-cancer-microbiome 2026-07-02T09:20:49.265Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2026-Gao-Nanoparticles-hijack-calvarial-immune-cells-for-CNS-drug-delivery-and-stroke-therapy 2026-07-02T09:20:49.302Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2026-Hanahan-Hallmarks-of-cancer-then-and-now,-and-beyond 2026-07-02T09:20:49.182Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2026-Hinterleitner-Senescence-in-cancer-hallmarks,-paradoxes,-and-therapeutic-promise 2026-07-02T09:20:49.250Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2026-Ho-Transposable-element-DNA-and-RNA-drivers-of-gene-expression,-evolution,-and-disease 2026-07-02T09:20:49.294Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2026-Li-Cellular-architecture-and-neighborhood-informed-virtual-spatial-tumor-profiling-from-histopathology 2026-07-02T09:20:49.303Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2026-Li-Multimodal-clocks-of-human-aging 2026-07-02T09:20:49.279Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2026-Quail-Cancer-ecosystems-a-dynamic-interplay-across-scales 2026-07-02T09:20:49.162Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2026-Song-Hijacking-ERAD-for-targeted-degradation-of-transmembrane-proteins 2026-07-02T09:20:49.263Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2026-Tzouanas-Hepatic-adaptation-to-chronic-metabolic-stress-primes-tumorigenesis 2026-07-02T09:20:49.195Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2026-Ueki-A-CRISPR-knockout-mouse-library-for-functional-genomics-in-influenza-research 2026-07-02T09:20:49.247Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2026-Winkler-Cancer-neuroscience-the-past,-the-present,-and-the-road-ahead 2026-07-02T09:20:49.196Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2026-Xing-Deep-learning-based-de-novo-discovery-and-design-of-therapeutics-that-reverse-disease-associated-transcriptional 2026-07-02T09:20:49.309Z https://research-2ry.pages.dev/Summary/Basic-Others/Cell-2026-deLaunoit-The-spatiotemporal-dynamics-of-postnatal-vascularization-in-the-mouse-brain 2026-07-02T09:20:49.207Z https://research-2ry.pages.dev/Summary/Basic-Others/CellDeathDis-2021-Flamini-Glucocorticoid-induced-leucine-zipper-regulates-liver-fibrosis-by-suppressing-CCL2-mediated-leukocyte-recruitment 2026-07-02T09:20:49.272Z https://research-2ry.pages.dev/Summary/Basic-Others/CellDeathDiscov-2023-Wang-Role-of-ADAM-and-ADAMTS-proteases-in-pathological-tissue-remodeling 2026-07-02T09:20:49.309Z https://research-2ry.pages.dev/Summary/Basic-Others/CellMetab-2026-Gao-The-s100a8a9-complex-promotes-food-intake-and-prevents-adipose-tissue-loss-during-cancer-cachexia-in-mice 2026-07-02T09:20:49.228Z https://research-2ry.pages.dev/Summary/Basic-Others/CellMetab-2026-Jia-Plasma-proteomic-signature-of-frailty-in-50,506-adults 2026-07-02T09:20:49.271Z https://research-2ry.pages.dev/Summary/Basic-Others/CellMetab-2026-Liang-Large-scale-metaproteomics-of-human-gut-microbiota-reveals-microbial-functions-in-metabolic-diseases-and-aging 2026-07-02T09:20:49.296Z https://research-2ry.pages.dev/Summary/Basic-Others/CellMolLifeSci-2006-Johannessen-The-multifunctional-roles-of-the-four-and-a-half-LIM-only-protein-FHL2 2026-07-02T09:20:49.237Z https://research-2ry.pages.dev/Summary/Basic-Others/CellRep-2017-Kodack-Primary-patient-derived-cancer-cells-and-their-potential-for-personalized-cancer-patient-care 2026-07-02T09:20:49.169Z https://research-2ry.pages.dev/Summary/Basic-Others/CellRep-2020-Dijkstra-Challenges-in-establishing-pure-lung-cancer-organoids-limit-their-utility-for-personalized-medicine 2026-07-02T09:20:49.208Z https://research-2ry.pages.dev/Summary/Basic-Others/CellRep-2021-Yang-Dimensionality-reduction-by-UMAP-reinforces-sample-heterogeneity-analysis-in-bulk-transcriptomic-data 2026-07-02T09:20:49.286Z https://research-2ry.pages.dev/Summary/Basic-Others/CellRep-2026-Tiwari-An-orally-active-dual-CBPp300-degrader-targets-core-dependencies-of-multiple-myeloma 2026-07-02T09:20:49.294Z https://research-2ry.pages.dev/Summary/Basic-Others/CellRes-2017-Johnson-Driving-gene-engineered-T-cell-immunotherapy-of-cancer 2026-07-02T09:20:49.219Z https://research-2ry.pages.dev/Summary/Basic-Others/CellStemCell-2020-Choi-Inflammatory-signals-induce-AT2-cell-derived-damage-associated-transient-progenitors-that-mediate-alveolar-regeneration 2026-07-02T09:20:49.293Z https://research-2ry.pages.dev/Summary/Basic-Others/CellStemCell-2020-Yao-Patient-derived-organoids-predict-chemoradiation-responses-of-locally-advanced-rectal-cancer 2026-07-02T09:20:49.259Z https://research-2ry.pages.dev/Summary/Basic-Others/CellSyst-2015-Liberzon-The-molecular-signatures-database-(MSigDB)-hallmark-gene-set-collection 2026-07-02T09:20:49.171Z https://research-2ry.pages.dev/Summary/Basic-Others/Cells-2020-Miklavc-Actin-and-myosin-in-non-neuronal-exocytosis 2026-07-02T09:20:49.218Z https://research-2ry.pages.dev/Summary/Basic-Others/Cells-2022-Mirzalieva-ISG15-and-ISGylation-in-human-diseases 2026-07-02T09:20:49.218Z https://research-2ry.pages.dev/Summary/Basic-Others/CellsDev-2021-Kay-Macropinocytosis-biology-and-mechanisms 2026-07-02T09:20:49.165Z https://research-2ry.pages.dev/Summary/Basic-Others/ClinCancerRes-1999-Hirata-Pharmacokinetic-study-of-S-1,-a-novel-oral-fluorouracil-antitumor-drug 2026-07-02T09:20:49.249Z https://research-2ry.pages.dev/Summary/Basic-Others/ClinCancerRes-2002-Ibrahim-Phase-I-and-pharmacokinetic-study-of-ABI-007,-a-cremophor-free,-protein-stabilized,-nanoparticle-formulation-of 2026-07-02T09:20:49.299Z https://research-2ry.pages.dev/Summary/Basic-Others/ClinCancerRes-2009-Yvon-Immunotherapy-of-metastatic-melanoma-using-genetically-engineered-GD2-specific-T-cells 2026-07-02T09:20:49.279Z https://research-2ry.pages.dev/Summary/Basic-Others/ClinCancerRes-2014-Heiss-The-role-of-relative-lymphocyte-count-as-a-biomarker-for-the-effect-of-catumaxomab-on-survival-in-malignant-ascites 2026-07-02T09:20:49.161Z https://research-2ry.pages.dev/Summary/Basic-Others/ClinCancerRes-2015-Casak-FDA-approval-summary-ramucirumab-for-gastric-cancer 2026-07-02T09:20:53.529Z https://research-2ry.pages.dev/Summary/Basic-Others/ClinCancerRes-2015-Lum-Targeted-T-cell-therapy-in-stage-IV-breast-cancer-A-phase-I-clinical-trial 2026-07-02T09:20:49.271Z https://research-2ry.pages.dev/Summary/Basic-Others/ClinCancerRes-2017-Gupta-Whole-genomic-copy-number-alterations-in-circulating-tumor-cells-from-men-with-abiraterone-or-enzalutamide-resistant 2026-07-02T09:20:49.244Z https://research-2ry.pages.dev/Summary/Basic-Others/ClinCancerRes-2018-Atkins-Pembrolizumab-plus-pegylated-interferon-alfa-2b-or-ipilimumab-for-advanced-melanoma-or-renal-cell-carcinoma 2026-07-02T09:20:49.302Z https://research-2ry.pages.dev/Summary/Basic-Others/ClinCancerRes-2019-Li-The-immune-subtypes-and-landscape-of-squamous-cell-carcinoma 2026-07-02T09:20:49.269Z https://research-2ry.pages.dev/Summary/Basic-Others/ClinCancerRes-2026-Chae-Mitochondrial-imaging-detects-early-cardiac-changes-following-cancer-immunotherapy 2026-07-02T09:20:49.238Z https://research-2ry.pages.dev/Summary/Basic-Others/ClinCancerRes-2026-Repetto-The-genomic-landscape-of-MYC,-MYCL,-and-MYCN-amplified-solid-tumors 2026-07-02T09:20:49.257Z https://research-2ry.pages.dev/Summary/Basic-Others/ClinOrthopRelatRes-2018-Maloney-Intratibial-injection-causes-direct-pulmonary-seeding-of-osteosarcoma-cells-and-is-not-a-spontaneous-model-of 2026-07-02T09:20:49.197Z https://research-2ry.pages.dev/Summary/Basic-Others/ColdSpringHarbPerspectBiol-2019-Yan-Molecular-mechanisms-of-pre-mRNA-splicing-through-structural-biology-of-the-spliceosome 2026-07-02T09:20:49.291Z https://research-2ry.pages.dev/Summary/Basic-Others/CurrBiol-2001-Jordens-The-rab7-effector-protein-RILP-controls-lysosomal-transport-by-inducing-the-recruitment-of-dynein-dynactin-motors 2026-07-02T09:20:49.260Z https://research-2ry.pages.dev/Summary/Basic-Others/CurrBiol-2008-Arai-Ypt11-functions-in-bud-directed-transport-of-the-golgi-by-linking-myo2-to-the-coatomer-subunit-ret2 2026-07-02T09:20:49.293Z https://research-2ry.pages.dev/Summary/Basic-Others/CurrBiol-2015-Chen-Spliceosomes 2026-07-02T09:20:49.222Z https://research-2ry.pages.dev/Summary/Basic-Others/CurrOpinCellBiol-2000-Herrmann-Intermediate-filaments-and-their-associates-multi-talented-structural-elements-specifying-cytoarchitecture-and 2026-07-02T09:20:49.274Z https://research-2ry.pages.dev/Summary/Basic-Others/CurrOpinCellBiol-2013-Barlan-The-journey-of-the-organelle-teamwork-and-regulation-in-intracellular-transport 2026-07-02T09:20:49.197Z https://research-2ry.pages.dev/Summary/Basic-Others/DevCell-2010-Madsen-Cancer-dissemination-lessons-from-leukocytes 2026-07-02T09:20:49.234Z https://research-2ry.pages.dev/Summary/Basic-Others/DevCell-2010-Morrisey-Preparing-for-the-first-breath-genetic-and-cellular-mechanisms-in-lung-development 2026-07-02T09:20:49.274Z https://research-2ry.pages.dev/Summary/Basic-Others/DevCell-2015-Wang-Formin-like-2-promotes-beta1-integrin-trafficking-and-invasive-motility-downstream-of-PKCalpha 2026-07-02T09:20:49.280Z https://research-2ry.pages.dev/Summary/Basic-Others/DrugDesDevelTher-2015-Kundranda-Albumin-bound-paclitaxel-in-solid-tumors-clinical-development-and-future-directions 2026-07-02T09:20:49.199Z https://research-2ry.pages.dev/Summary/Basic-Others/ExpMolMed-2022-Kang-The-diverse-repertoire-of-ISG15-more-intricate-than-initially-thought 2026-07-02T09:20:49.225Z https://research-2ry.pages.dev/Summary/Basic-Others/FASEBJ-2013-Tirino-Cancer-stem-cells-in-solid-tumors-an-overview-and-new-approaches-for-their-isolation-and-characterization 2026-07-02T09:20:49.177Z https://research-2ry.pages.dev/Summary/Basic-Others/FEBSJ-2010-Chen-Comparison-of-membrane-fraction-proteomic-profiles-of-normal-and-cancerous-human-colorectal-tissues-with-gel-assisted 2026-07-02T09:20:49.293Z https://research-2ry.pages.dev/Summary/Basic-Others/FEBSLett-2014-Ahmed-Engineering-anti-GD2-monoclonal-antibodies-for-cancer-immunotherapy 2026-07-02T09:20:49.266Z https://research-2ry.pages.dev/Summary/Basic-Others/FEBSOpenBio-2023-Tanaka-A-mouse-model-of-lung-cancer-induced-via-intranasal-injection-for-anticancer-drug-screening-and-evaluation-of-pathology 2026-07-02T09:20:49.307Z https://research-2ry.pages.dev/Summary/Basic-Others/FrontCellDevBiol-2020-Schioppa-Molecular-basis-for-CCRL2-regulation-of-leukocyte-migration 2026-07-02T09:20:49.160Z https://research-2ry.pages.dev/Summary/Basic-Others/FrontImmunol-2023-Sharp-Experimental-procedures-for-flow-cytometry-of-wild-type-mouse-brain-a-systematic-review 2026-07-02T09:20:49.227Z https://research-2ry.pages.dev/Summary/Basic-Others/FrontOncol-2020-Lucotti-Platelets-and-metastasis-New-implications-of-an-old-interplay 2026-07-02T09:20:49.165Z https://research-2ry.pages.dev/Summary/Basic-Others/Gene-2004-Bera-Five-POTE-paralogs-and-their-splice-variants-are-expressed-in-human-prostate-and-encode-proteins-of-different-lengths 2026-07-02T09:20:49.200Z https://research-2ry.pages.dev/Summary/Basic-Others/GenomeBiol-2008-Zhang-Model-based-analysis-of-ChIP-Seq-(MACS) 2026-07-02T09:20:49.284Z https://research-2ry.pages.dev/Summary/Basic-Others/GenomeBiol-2009-Langmead-Ultrafast-and-memory-efficient-alignment-of-short-DNA-sequences-to-the-human-genome 2026-07-02T09:20:49.179Z https://research-2ry.pages.dev/Summary/Basic-Others/GenomeBiol-2014-Love-Moderated-estimation-of-fold-change-and-dispersion-for-RNA-seq-data-with-DESeq2 2026-07-02T09:20:49.283Z https://research-2ry.pages.dev/Summary/Basic-Others/GenomeBiol-2018-Wolf-SCANPY-large-scale-single-cell-gene-expression-data-analysis 2026-07-02T09:20:49.164Z https://research-2ry.pages.dev/Summary/Basic-Others/GenomeBiol-2019-Hafemeister-Normalization-and-variance-stabilization-of-single-cell-RNA-seq-data-using-regularized-negative-binomial-regression 2026-07-02T09:20:49.235Z https://research-2ry.pages.dev/Summary/Basic-Others/GenomeMed-2015-Pongor-A-genome-wide-approach-to-link-genotype-to-clinical-outcome-by-utilizing-next-generation-sequencing-and-gene-chip-data 2026-07-02T09:20:49.239Z https://research-2ry.pages.dev/Summary/Basic-Others/IBRORep-2020-Calvo-Dissociation-of-neonatal-and-adult-mice-brain-for-simultaneous-analysis-of-microglia,-astrocytes-and-infiltrating 2026-07-02T09:20:49.202Z https://research-2ry.pages.dev/Summary/Basic-Others/Immunity-2007-Wherry-Molecular-signature-of-CD8-T-cell-exhaustion-during-chronic-viral-infection 2026-07-02T09:20:49.191Z https://research-2ry.pages.dev/Summary/Basic-Others/InVivo-2023-Aoki-Precise-and-facile-endotracheal-lung-tumor-implantation-mouse-model-visualized-by-GFP-expression 2026-07-02T09:20:49.207Z https://research-2ry.pages.dev/Summary/Basic-Others/Innovation(Camb)-2021-Wu-clusterProfiler-4.0-A-universal-enrichment-tool-for-interpreting-omics-data 2026-07-02T09:20:49.313Z https://research-2ry.pages.dev/Summary/Basic-Others/IntJMolSci-2021-Martinez-Arroyo-Small-rab-GTPases-in-intracellular-vesicle-trafficking-the-case-of-Rab3ARaphillin-3a-complex-in-the-kidney 2026-07-02T09:20:49.233Z https://research-2ry.pages.dev/Summary/Basic-Others/IntJOncol-2014-Watanabe-A-stem-cell-medium-containing-neural-stimulating-factor-induces-a-pancreatic-cancer-stem-like-cell-enriched-population 2026-07-02T09:20:49.240Z https://research-2ry.pages.dev/Summary/Basic-Others/JAMA-2026-Zhang-An-AI-based-OCT-system-to-detect-diabetic-macular-edema 2026-07-02T09:20:49.237Z https://research-2ry.pages.dev/Summary/Basic-Others/JCOOncolPract-2026-Strohbehn-Maintenance-PemetrexedPembrolizumab-versus-pembrolizumab-in-non-small-cell-lung-cancer-A-propensity-score-weighted 2026-07-02T09:20:49.314Z https://research-2ry.pages.dev/Summary/Basic-Others/JCOPrecisOncol-2017-Chakravarty-OncoKB-A-precision-oncology-knowledge-base 2026-07-02T09:20:49.183Z https://research-2ry.pages.dev/Summary/Basic-Others/JCellBiol-1983-Harding-Receptor-mediated-endocytosis-of-transferrin-and-recycling-of-the-transferrin-receptor-in-rat-reticulocytes 2026-07-02T09:20:49.198Z https://research-2ry.pages.dev/Summary/Basic-Others/JCellBiol-2021-Borchers-Who's-in-control-principles-of-rab-GTPase-activation-in-endolysosomal-membrane-trafficking-and-beyond 2026-07-02T09:20:49.281Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinInvest-2011-Savoldo-CD28-costimulation-improves-expansion-and-persistence-of-chimeric-antigen-receptor-modified-T-cells-in-lymphoma-patients 2026-07-02T09:20:49.302Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinInvest-2016-Kebriaei-Phase-I-trials-using-sleeping-beauty-to-generate-CD19-specific-CAR-T-cells 2026-07-02T09:20:49.275Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinInvest-2016-Ruella-Dual-CD19-and-CD123-targeting-prevents-antigen-loss-relapses-after-CD19-directed-immunotherapies 2026-07-02T09:20:49.177Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinInvest-2016-Turtle-CD19-CAR-T-cells-of-defined-CD4+-CD8+-composition-in-adult-B-cell-ALL-patients 2026-07-02T09:20:49.216Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinInvest-2026-Morigny-Inhibition-of-ceramide-synthesis-ameliorates-body-wasting-in-a-cancer-cachexia-model 2026-07-02T09:20:49.267Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinInvest-2026-Rochelle-Leveraging-factors-that-control-alveolar-epithelial-cell-fate-enables-large-scale-expansion-for-lung-tissue-engineering 2026-07-02T09:20:49.203Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinInvest-2026-Ruggero-Rewriting-the-cancer-proteome-targeting-selective-translation-as-a 2026-07-02T09:20:49.189Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinOncol-1987-Motzer-Residual-mass-an-indication-for-further-therapy-in-patients-with-advanced-seminoma-following-systemic-chemotherapy 2026-07-02T09:20:49.191Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinOncol-1992-Jodrell-Relationships-between-carboplatin-exposure-and-tumor-response-and-toxicity-in-patients-with-ovarian-cancer 2026-07-02T09:20:49.260Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinOncol-1995-Cortes-Docetaxel 2026-07-02T09:20:49.252Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinOncol-1997-Horwich-Randomized-trial-of-bleomycin,-etoposide,-and-cisplatin-compared-with-bleomycin,-etoposide,-and-carboplatin-in 2026-07-02T09:20:49.297Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinOncol-1998-Al-Sarraf-Chemoradiotherapy-versus-radiotherapy-in-patients-with-advanced-nasopharyngeal-cancer-phase-III-randomized-intergroup 2026-07-02T09:20:49.304Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinOncol-1999-Chapman-Phase-III-multicenter-randomized-trial-of-the-dartmouth-regimen-versus-dacarbazine-in-patients-with-metastatic-melanoma 2026-07-02T09:20:49.159Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinOncol-2006-Lamers-Treatment-of-metastatic-renal-cell-carcinoma-with-autologous-T-lymphocytes-genetically-retargeted-against-carbonic 2026-07-02T09:20:49.206Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinOncol-2011-Robbins-Tumor-regression-in-patients-with-metastatic-synovial-cell-sarcoma-and-melanoma-using-genetically-engineered 2026-07-02T09:20:49.254Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinOncol-2014-Barrington-Role-of-imaging-in-the-staging-and-response-assessment-of-lymphoma-consensus-of-the-international-conference-on 2026-07-02T09:20:49.295Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinOncol-2014-Topalian-Survival,-durable-tumor-remission,-and-long-term-safety-in-patients-with-advanced-melanoma-receiving-nivolumab 2026-07-02T09:20:53.593Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinOncol-2015-Ahmed-Human-epidermal-growth-factor-receptor-2-(HER2)-specific-chimeric-antigen-receptor-modified-T-cells-for-the 2026-07-02T09:20:49.258Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinOncol-2015-Awad-Durable-responses-with-PD-1-inhibition-in-lung-and-kidney-cancer-and-the-ongoing-search-for-predictive-biomarkers 2026-07-02T09:20:49.201Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinOncol-2015-Cohen-Controversies-in-the-treatment-of-local-and-locally-advanced-gastric-and-esophageal-cancers 2026-07-02T09:20:49.229Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinOncol-2015-Hamanishi-Safety-and-antitumor-activity-of-anti-PD-1-antibody,-nivolumab,-in-patients-with-platinum-resistant-ovarian-cancer 2026-07-02T09:20:49.290Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinOncol-2015-Maio-Five-year-survival-rates-for-treatment-naive-patients-with-advanced-melanoma-who-received-ipilimumab-plus-dacarbazine 2026-07-02T09:20:49.225Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinOncol-2015-Park-Efficacy-and-safety-of-CD19-targeted-CAR-T-for-B-ALL 2026-07-02T09:20:49.220Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinOncol-2015-Schadendorf-Pooled-analysis-of-long-term-survival-data-from-phase-II-and-phase-III-trials-of-ipilimumab-in-unresectable-or 2026-07-02T09:20:49.167Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinOncol-2015-Wang-Immune-therapy-in-GI-malignancies-A-review 2026-07-02T09:20:49.199Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinOncol-2020-Kojima-Randomized-phase-III-KEYNOTE-181-study-of-pembrolizumab-versus-chemotherapy-in-advanced-esophageal-cancer 2026-07-02T09:20:49.233Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinOncol-2021-Kanemitsu-Primary-tumor-resection-plus-chemotherapy-versus-chemotherapy-alone-for-colorectal-cancer-patients-with-asymptomatic, 2026-07-02T09:20:49.300Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinOncol-2022-Rugo-Sacituzumab-govitecan-in-hormone-receptor-PositiveHuman-epidermal-growth-factor-receptor-2-negative-metastatic-breast 2026-07-02T09:20:49.291Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinOncol-2023-Atkins-Combination-dabrafenib-and-trametinib-versus-combination-nivolumab-and-ipilimumab-for-patients-with-advanced 2026-07-02T09:20:49.316Z https://research-2ry.pages.dev/Summary/Basic-Others/JClinOncol-2026-Oberstein-Amivantamab-monotherapy-in-chemorefractory-RASBRAF-wild-type-metastatic-colorectal-cancer-results-from-OrigAMI-1,-an 2026-07-02T09:20:49.255Z https://research-2ry.pages.dev/Summary/Basic-Others/JExpMed-1993-Hwu-Lysis-of-ovarian-cancer-cells-by-human-lymphocytes-redirected-with-a-chimeric-gene-composed-of-an-antibody-variable 2026-07-02T09:20:49.261Z https://research-2ry.pages.dev/Summary/Basic-Others/JImmunolMethods-2013-Iglesias-Ussel-Isolation-of-microarray-quality-RNA-from-primary-human-cells-after-intracellular-immunostaining-and 2026-07-02T09:20:49.307Z https://research-2ry.pages.dev/Summary/Basic-Others/JImmunotherCancer-2026-Abascal-FLT3L-secreting-cDC1-in-situ-vaccination-enhances-antitumor-immunity-and-synergizes-with-PD-1-blockade-in-murine 2026-07-02T09:20:49.292Z https://research-2ry.pages.dev/Summary/Basic-Others/JImmunotherCancer-2026-Chen-Targeting-CD74-may-mitigate-immune-escape-features-and-enhance-BCMA-CAR-T-activity-in-preclinical-models-of 2026-07-02T09:20:49.255Z https://research-2ry.pages.dev/Summary/Basic-Others/JImmunotherCancer-2026-Jong-Lenalidomide-boosts-CD1d-vdelta2-bispecific-antibody-engaged-Vgamma9Vdelta2-T-cell-effector-functions-via-CD28,-notch 2026-07-02T09:20:49.253Z https://research-2ry.pages.dev/Summary/Basic-Others/JImmunotherCancer-2026-Zhang-HDAC-inhibitors-reverse-YAP-driven-immune-resistance-in-NSCLC-mechanistic-and-translational-evidence 2026-07-02T09:20:49.252Z https://research-2ry.pages.dev/Summary/Basic-Others/JMedChem-2020-Ernst-Design-of-development-candidate-eFT226,-a-first-in-class-inhibitor-of-eukaryotic-initiation-factor-4a-RNA-helicase 2026-07-02T09:20:49.213Z https://research-2ry.pages.dev/Summary/Basic-Others/JNatlCancerInst-2011-Chen-Concurrent-chemoradiotherapy-vs-radiotherapy-alone-in-stage-II-nasopharyngeal-carcinoma-phase-III-randomized-trial 2026-07-02T09:20:49.242Z https://research-2ry.pages.dev/Summary/Basic-Others/JNuclMed-2010-Weiler-Sagie-(18)f-FDG-avidity-in-lymphoma-readdressed-a-study-of-766-patients 2026-07-02T09:20:49.253Z https://research-2ry.pages.dev/Summary/Basic-Others/JThoracOncol-2009-Pio-Alternative-splicing-in-lung-cancer 2026-07-02T09:20:49.270Z https://research-2ry.pages.dev/Summary/Basic-Others/JThoracOncol-2012-Weickhardt-Local-ablative-therapy-of-oligoprogressive-disease-prolongs-disease-control-by-tyrosine-kinase-inhibitors-in 2026-07-02T09:20:49.300Z https://research-2ry.pages.dev/Summary/Basic-Others/JVisExp-2009-Adenocarcinoma-engraftment-A-method-to-implant-cancer-cells-into-the-murine-lungs 2026-07-02T09:20:49.297Z https://research-2ry.pages.dev/Summary/Basic-Others/JVisExp-2011-Opitz-Araya-Organotypic-hippocampal-slice-cultures 2026-07-02T09:20:49.209Z https://research-2ry.pages.dev/Summary/Basic-Others/Lancet-2016-Rosenberg-Atezolizumab-in-patients-with-locally-advanced-and-metastatic-urothelial-carcinoma-who-have-progressed-following 2026-07-02T09:20:49.200Z https://research-2ry.pages.dev/Summary/Basic-Others/LancetOncol-2015-Ribas-Pembrolizumab-versus-investigator-choice-chemotherapy-for-ipilimumab-refractory-melanoma-(KEYNOTE-002)-a-randomised, 2026-07-02T09:20:49.316Z https://research-2ry.pages.dev/Summary/Basic-Others/LancetOncol-2020-Elsallab-CAR-T-cell-product-performance-in-haematological-malignancies-before-and-after-marketing-authorisation 2026-07-02T09:20:49.176Z https://research-2ry.pages.dev/Summary/Basic-Others/LancetOncol-2020-Powles-Pembrolizumab-plus-axitinib-versus-sunitinib-monotherapy-as-first-line-treatment-of-advanced-renal-cell-carcinoma 2026-07-02T09:20:49.168Z https://research-2ry.pages.dev/Summary/Basic-Others/LancetOncol-2021-Winer-Pembrolizumab-versus-investigator-choice-chemotherapy-for-metastatic-triple-negative-breast-cancer-(KEYNOTE-119)-a 2026-07-02T09:20:49.253Z https://research-2ry.pages.dev/Summary/Basic-Others/Leukemia-2015-Pegram-IL-12-secreting-CD19-targeted-cord-blood-derived-T-cells-for-the-immunotherapy-of-B-cell-acute-lymphoblastic-leukemia 2026-07-02T09:20:49.176Z https://research-2ry.pages.dev/Summary/Basic-Others/MethodMolBiol-2021-Alvero-Detection-of-cell-death-mechanisms 2026-07-02T09:20:49.247Z https://research-2ry.pages.dev/Summary/Basic-Others/MethodMolBiol-2022-Christian-Cancer-cell-biology 2026-07-02T09:20:49.303Z https://research-2ry.pages.dev/Summary/Basic-Others/ModRheumatol-2014-Yamanaka-Estimates-of-the-prevalence-of-and-current-treatment-practices-for-rheumatoid-arthritis-in-japan-using-reimbursement 2026-07-02T09:20:49.236Z https://research-2ry.pages.dev/Summary/Basic-Others/MolBiolCell-2007-Roland-Myosin-vb-interacts-with-rab8a-on-a-tubular-network-containing-EHD1-and-EHD3 2026-07-02T09:20:49.215Z https://research-2ry.pages.dev/Summary/Basic-Others/MolBiolCell-2012-Cheng-Myosin-1e-coordinates-actin-assembly-and-cargo-trafficking-during-clathrin-mediated-endocytosis 2026-07-02T09:20:49.190Z https://research-2ry.pages.dev/Summary/Basic-Others/MolBiolCell-2014-Weaver-How-taxolpaclitaxel-kills-cancer-cells 2026-07-02T09:20:53.629Z https://research-2ry.pages.dev/Summary/Basic-Others/MolCell-2026-Zhang-PKCalpha-mediated-nuclear-translocation-of-cGAS-stabilizes-beta-catenin-and-drives-metastasis 2026-07-02T09:20:49.201Z https://research-2ry.pages.dev/Summary/Basic-Others/MolCell-2026-Zhu-Mitochondrial-glutamine-import-sustains-electron-transport-chain-integrity-independently-of-glutaminolysis-in-cancer 2026-07-02T09:20:49.163Z https://research-2ry.pages.dev/Summary/Basic-Others/MolCellBiol-2001-Fontijn-The-human-kinesin-like-protein-RB6K-is-under-tight-cell-cycle-control-and-is-essential-for-cytokinesis 2026-07-02T09:20:49.283Z https://research-2ry.pages.dev/Summary/Basic-Others/MolOmics-2020-Aguilan-Guide-for-protein-fold-change-and-p-value-calculation-for-non-experts-in-proteomics 2026-07-02T09:20:49.286Z https://research-2ry.pages.dev/Summary/Basic-Others/MolOncol-2025-Maltseva-Interplay-of-integrins-and-selectins-in-metastasis 2026-07-02T09:20:49.262Z https://research-2ry.pages.dev/Summary/Basic-Others/MolSystBiol-2021-Cuklina-Diagnostics-and-correction-of-batch-effects-in-large-scale-proteomic-studies-a-tutorial 2026-07-02T09:20:49.209Z https://research-2ry.pages.dev/Summary/Basic-Others/NARCancer-2021-Vancura-Cancer-LncRNA-census-2-(CLC2)-an-enhanced-resource-reveals-clinical-features-of-cancer-lncRNAs 2026-07-02T09:20:49.302Z https://research-2ry.pages.dev/Summary/Basic-Others/NEnglJMed-2010-Hodi-Improved-survival-with-ipilimumab-in-patients-with-metastatic-melanoma 2026-07-02T09:20:49.241Z https://research-2ry.pages.dev/Summary/Basic-Others/NEnglJMed-2011-Chapman-Improved-survival-with-vemurafenib-in-melanoma-with-BRAF-V600E-mutation 2026-07-02T09:20:49.285Z https://research-2ry.pages.dev/Summary/Basic-Others/NEnglJMed-2011-Robert-Ipilimumab-plus-dacarbazine-for-previously-untreated-metastatic-melanoma 2026-07-02T09:20:49.248Z https://research-2ry.pages.dev/Summary/Basic-Others/NEnglJMed-2012-Topalian-Safety,-activity,-and-immune-correlates-of-anti-PD-1-antibody-in-cancer 2026-07-02T09:20:49.193Z https://research-2ry.pages.dev/Summary/Basic-Others/NEnglJMed-2013-Hamid-Safety-and-tumor-responses-with-lambrolizumab-(anti-PD-1)-in-melanoma 2026-07-02T09:20:49.207Z https://research-2ry.pages.dev/Summary/Basic-Others/NEnglJMed-2013-Wolchok-Nivolumab-plus-ipilimumab-in-advanced-melanoma 2026-07-02T09:20:49.194Z https://research-2ry.pages.dev/Summary/Basic-Others/NEnglJMed-2015-Chapman-Rapid-eradication-of-a-bulky-melanoma-mass-with-one-dose-of-immunotherapy 2026-07-02T09:20:49.315Z https://research-2ry.pages.dev/Summary/Basic-Others/NEnglJMed-2015-Motzer-Nivolumab-versus-everolimus-in-advanced-renal-cell-carcinoma 2026-07-02T09:20:49.277Z https://research-2ry.pages.dev/Summary/Basic-Others/NEnglJMed-2015-Postow-Nivolumab-and-ipilimumab-versus-ipilimumab-in-untreated-melanoma 2026-07-02T09:20:49.242Z https://research-2ry.pages.dev/Summary/Basic-Others/NEnglJMed-2015-Robert-Nivolumab-in-previously-untreated-melanoma-without-BRAF-mutation 2026-07-02T09:20:49.221Z https://research-2ry.pages.dev/Summary/Basic-Others/NEnglJMed-2015-Robert-Pembrolizumab-versus-ipilimumab-in-advanced-melanoma 2026-07-02T09:20:49.219Z https://research-2ry.pages.dev/Summary/Basic-Others/NEnglJMed-2017-Wolchok-Overall-survival-with-combined-nivolumab-and-ipilimumab-in-advanced-melanoma 2026-07-02T09:20:49.193Z https://research-2ry.pages.dev/Summary/Basic-Others/NEnglJMed-2018-DiNardo-Durable-remissions-with-ivosidenib-in-IDH1-mutated-relapsed-or-refractory-AML 2026-07-02T09:20:49.261Z https://research-2ry.pages.dev/Summary/Basic-Others/NEnglJMed-2018-Mejean-Sunitinib-alone-or-nephrectomy-for-advanced-RCC 2026-07-02T09:20:49.253Z https://research-2ry.pages.dev/Summary/Basic-Others/NEnglJMed-2018-Migden-PD-1-blockade-with-cemiplimab-in-advanced-cutaneous-squamous-cell-carcinoma 2026-07-02T09:20:49.196Z https://research-2ry.pages.dev/Summary/Basic-Others/NEnglJMed-2018-Park-Long-term-follow-up-of-CD19-CAR-therapy-in-acute-lymphoblastic-leukemia 2026-07-02T09:20:49.316Z https://research-2ry.pages.dev/Summary/Basic-Others/NEnglJMed-2021-Burley-Predicting-proteome-scale-protein-structure-with-artificial-intelligence 2026-07-02T09:20:49.173Z https://research-2ry.pages.dev/Summary/Basic-Others/NEnglJMed-2021-Choueiri-Nivolumab-plus-cabozantinib-versus-sunitinib-for-advanced-renal-cell-carcinoma 2026-07-02T09:20:49.171Z https://research-2ry.pages.dev/Summary/Basic-Others/NEnglJMed-2021-Motzer-Lenvatinib-plus-pembrolizumab-or-everolimus-for-advanced-renal-cell-carcinoma 2026-07-02T09:20:49.217Z https://research-2ry.pages.dev/Summary/Basic-Others/NEnglJMed-2023-Hadoux-Phase-3-trial-of-selpercatinib-in-advanced-RET-mutant-medullary-thyroid-cancer 2026-07-02T09:20:49.292Z https://research-2ry.pages.dev/Summary/Basic-Others/NEnglJMed-2026-Centre-Sodium-bicarbonate-for-critically-ill-adults-with-metabolic-acidosis-and-shock 2026-07-02T09:20:49.281Z https://research-2ry.pages.dev/Summary/Basic-Others/NEnglJMed-2026-Cohn-Lonvoguran-ziclumeran-in-vivo-CRISPR-gene-editing-in-hereditary-angioedema 2026-07-02T09:20:49.171Z https://research-2ry.pages.dev/Summary/Basic-Others/NEnglJMed-2026-Haber-Altering-the-diet-to-rewire-cancer 2026-07-02T09:20:49.258Z https://research-2ry.pages.dev/Summary/Basic-Others/NEnglJMed-2026-OReilly-Daraxonrasib-or-chemotherapy-in-previously-treated-metastatic-pancreatic-cancer 2026-07-02T09:20:49.198Z https://research-2ry.pages.dev/Summary/Basic-Others/NatAging-2026-Lu-Proteomic-signatures-of-the-APOE-epsilon4-and-APOE-epsilon2-genetic-variants-and-alzheimer's-disease 2026-07-02T09:20:49.240Z https://research-2ry.pages.dev/Summary/Basic-Others/NatBiotechnol-2011-Robinson-Integrative-genomics-viewer 2026-07-02T09:20:49.248Z https://research-2ry.pages.dev/Summary/Basic-Others/NatBiotechnol-2013-Frampton-Development-and-validation-of-a-clinical-cancer-genomic-profiling-test-based-on-massively-parallel-DNA-sequencing 2026-07-02T09:20:49.165Z https://research-2ry.pages.dev/Summary/Basic-Others/NatBiotechnol-2013-Themeli-Generation-of-tumor-targeted-human-T-lymphocytes-from-induced-pluripotent-stem-cells-for-cancer-therapy 2026-07-02T09:20:49.224Z https://research-2ry.pages.dev/Summary/Basic-Others/NatBiotechnol-2014-Trapnell-The-dynamics-and-regulators-of-cell-fate-decisions-are-revealed-by-pseudotemporal-ordering-of-single-cells 2026-07-02T09:20:49.173Z https://research-2ry.pages.dev/Summary/Basic-Others/NatBiotechnol-2015-Satija-Spatial-reconstruction-of-single-cell-gene-expression-data 2026-07-02T09:20:49.205Z https://research-2ry.pages.dev/Summary/Basic-Others/NatBiotechnol-2015-Shukla-Comprehensive-analysis-of-cancer-associated-somatic-mutations-in-class-I-HLA-genes 2026-07-02T09:20:49.298Z https://research-2ry.pages.dev/Summary/Basic-Others/NatBiotechnol-2016-Bray-Near-optimal-probabilistic-RNA-seq-quantification 2026-07-02T09:20:49.273Z https://research-2ry.pages.dev/Summary/Basic-Others/NatBiotechnol-2018-Butler-Integrating-single-cell-transcriptomic-data-across-different-conditions,-technologies,-and-species 2026-07-02T09:20:49.212Z https://research-2ry.pages.dev/Summary/Basic-Others/NatBiotechnol-2026-Zhou-Digital-twins-of-ex-vivo-human-lungs-enable-accurate-and-personalized-evaluation-of-therapeutic-efficacy 2026-07-02T09:20:49.276Z https://research-2ry.pages.dev/Summary/Basic-Others/NatCancer-2021-Tanaka-Multi-omic-profiling-of-peritoneal-metastases-in-gastric-cancer-identifies-molecular-subtypes-and-therapeutic 2026-07-02T09:20:49.181Z https://research-2ry.pages.dev/Summary/Basic-Others/NatCancer-2023-Goswami-Myeloid-specific-KDM6B-inhibition-sensitizes-glioblastoma-to-PD1-blockade 2026-07-02T09:20:49.166Z https://research-2ry.pages.dev/Summary/Basic-Others/NatCancer-2026-Frangieh-Single-cell-and-spatial-profiling-in-cancer-biology-and-clinical-oncology 2026-07-02T09:20:49.217Z https://research-2ry.pages.dev/Summary/Basic-Others/NatCancer-2026-Gfeller-Advances-in-predicting-t-cell-epitope-recognition-for-cancer-immunotherapy 2026-07-02T09:20:49.257Z https://research-2ry.pages.dev/Summary/Basic-Others/NatCancer-2026-Jimenez-Castano-Epithelial-to-mesenchymal-transition-as-a-central-driver-of-tumor-cell-plasticity 2026-07-02T09:20:49.295Z https://research-2ry.pages.dev/Summary/Basic-Others/NatCellBiol-2021-Choi-Release-of-notch-activity-coordinated-by-IL-1beta-signalling-confers-differentiation-plasticity-of-airway-progenitors 2026-07-02T09:20:49.209Z https://research-2ry.pages.dev/Summary/Basic-Others/NatCellBiol-2026-Ge-Stress-granules-restrain-ferroptosis-by-sequestering-ferritin 2026-07-02T09:20:49.304Z https://research-2ry.pages.dev/Summary/Basic-Others/NatCommun-2017-Zheng-Massively-parallel-digital-transcriptional-profiling-of-single-cells 2026-07-02T09:20:49.220Z https://research-2ry.pages.dev/Summary/Basic-Others/NatCommun-2019-Xue-CDK46-inhibitors-target-SMARCA4-determined-cyclin-D1-deficiency-in-hypercalcemic-small-cell-carcinoma-of-the-ovary 2026-07-02T09:20:49.229Z https://research-2ry.pages.dev/Summary/Basic-Others/NatCommun-2020-Alzahofi-Rab27a-co-ordinates-actin-dependent-transport-by-controlling-organelle-associated-motors-and-track-assembly-proteins 2026-07-02T09:20:49.203Z https://research-2ry.pages.dev/Summary/Basic-Others/NatCommun-2022-Ferguson-The-surfaceome-of-multiple-myeloma-cells-suggests-potential-immunotherapeutic-strategies-and-protein-markers-of-drug 2026-07-02T09:20:49.224Z https://research-2ry.pages.dev/Summary/Basic-Others/NatCommun-2022-Mirhadi-Integrative-analysis-of-non-small-cell-lung-cancer-patient-derived-xenografts-identifies-distinct-proteotypes 2026-07-02T09:20:49.288Z https://research-2ry.pages.dev/Summary/Basic-Others/NatCommun-2022-Song-Proteomic-analysis-reveals-key-differences-between-squamous-cell-carcinomas-and-adenocarcinomas-across-multiple-tissues 2026-07-02T09:20:49.172Z https://research-2ry.pages.dev/Summary/Basic-Others/NatCommun-2026-Krey-The-ISG-atlas-a-loss-of-function-analysis-characterizes-antiviral-properties-of-interferon-stimulated-genes 2026-07-02T09:20:49.317Z https://research-2ry.pages.dev/Summary/Basic-Others/NatCommun-2026-Radke-RBM20-isoform-regulation-by-independent-transcription-start-sites-adapts-alternative-splicing-in-development-and-disease 2026-07-02T09:20:49.275Z https://research-2ry.pages.dev/Summary/Basic-Others/NatGenet-2026-Cheruiyot-Inflammatory-cytokines-induce-new-cancer-dependencies 2026-07-02T09:20:49.162Z https://research-2ry.pages.dev/Summary/Basic-Others/NatGenet-2026-Sarni-A-progeria-syndrome-links-DNA-hypermethylation-to-age-related-pathology 2026-07-02T09:20:49.312Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMater-2022-LeSavage-Next-generation-cancer-organoids 2026-07-02T09:20:49.286Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMed-2006-Roeder-Dynamic-modeling-of-imatinib-treated-chronic-myeloid-leukemia-functional-insights-and-clinical-implications 2026-07-02T09:20:49.196Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMed-2014-Zheng-Anchored-multiplex-PCR-for-targeted-next-generation-sequencing 2026-07-02T09:20:49.256Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMed-2015-Cristescu-Molecular-analysis-of-gastric-cancer-identifies-subtypes-associated-with-distinct-clinical-outcomes 2026-07-02T09:20:49.176Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMed-2015-Gao-High-throughput-screening-using-patient-derived-tumor-xenografts-to-predict-clinical-trial-drug-response 2026-07-02T09:20:49.301Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMed-2015-Long-4-1bb-costimulation-ameliorates-T-cell-exhaustion-induced-by-tonic-signaling-of-chimeric-antigen-receptors 2026-07-02T09:20:49.214Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMed-2017-Batlle-Cancer-stem-cells-revisited 2026-07-02T09:20:49.180Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMed-2017-Cramer-Systemic-depletion-of-L-cyst(e)ine-with-cyst(e)inase-increases-reactive-oxygen-species-and-suppresses-tumor-growth 2026-07-02T09:20:49.177Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMed-2017-Furman-Expression-of-specific-inflammasome-gene-modules-stratifies-older-individuals-into-two-extreme-clinical-and 2026-07-02T09:20:49.191Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMed-2018-Wang-Metastatic-cancers-promote-cachexia-through-ZIP14-upregulation-in-skeletal-muscle 2026-07-02T09:20:49.270Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMed-2020-Algazi-Continuous-versus-intermittent-BRAF-and-MEK-inhibition-in-patients-with-BRAF-mutated-melanoma-a-randomized-phase-2-trial 2026-07-02T09:20:49.248Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMed-2020-Deng-Characteristics-of-anti-CD19-CAR-T-cell-infusion-products-associated-with-efficacy-and-toxicity-in-patients-with-large 2026-07-02T09:20:49.306Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMed-2020-Slyper-A-single-cell-and-single-nucleus-RNA-Seq-toolbox-for-fresh-and-frozen-human-tumors 2026-07-02T09:20:49.314Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMed-2021-Rozeman-Survival-and-biomarker-analyses-from-the-OpACIN-neo-and-OpACIN-neoadjuvant-immunotherapy-trials-in-stage-III-melanoma 2026-07-02T09:20:49.161Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMed-2023-Sikkema-An-integrated-cell-atlas-of-the-lung-in-health-and-disease 2026-07-02T09:20:49.263Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMed-2024-Bojmar-Multi-parametric-atlas-of-the-pre-metastatic-liver-for-prediction-of-metastatic-outcome-in-early-stage-pancreatic-cancer 2026-07-02T09:20:49.313Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMed-2025-DeMichele-Targeting-dormant-tumor-cells-to-prevent-recurrent-breast-cancer-a-randomized-phase-2-trial 2026-07-02T09:20:49.189Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMed-2026-De-Neoadjuvant-stereotactic-body-radiation-therapy-with-durvalumab-and-oleclumab-in-ER 2026-07-02T09:20:49.319Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMed-2026-Ding-Plasma-proteomic-signatures-of-cellular-aging-predict-human-disease 2026-07-02T09:20:49.214Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMed-2026-Gentner-Tumor-targeted-interferon-alpha-gene-therapy-for-glioblastoma-a-phase-1-trial 2026-07-02T09:20:49.268Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMed-2026-Ke-AI-induced-never-skilling-in-medical-education 2026-07-02T09:20:49.226Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMed-2026-Peng-Savolitinib-in-MET-amplified-gastric-or-gastroesophageal-junction-adenocarcinoma-a-phase-2-trial 2026-07-02T09:20:49.317Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMethods-2012-Langmead-Fast-gapped-read-alignment-with-Bowtie-2 2026-07-02T09:20:49.216Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMethods-2012-Schindelin-Fiji-an-open-source-platform-for-biological-image-analysis 2026-07-02T09:20:49.289Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMethods-2015-Newman-Robust-enumeration-of-cell-subsets-from-tissue-expression-profiles 2026-07-02T09:20:49.251Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMethods-2016-Uhlen-A-proposal-for-validation-of-antibodies 2026-07-02T09:20:49.174Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMethods-2017-Aibar-SCENIC-single-cell-regulatory-network-inference-and-clustering 2026-07-02T09:20:49.314Z https://research-2ry.pages.dev/Summary/Basic-Others/NatMethods-2019-Korsunsky-Fast,-sensitive-and-accurate-integration-of-single-cell-data-with-harmony 2026-07-02T09:20:49.235Z https://research-2ry.pages.dev/Summary/Basic-Others/NatNanotechnol-2021-Rennick-Key-principles-and-methods-for-studying-the-endocytosis-of-biological-and-nanoparticle-therapeutics 2026-07-02T09:20:49.247Z https://research-2ry.pages.dev/Summary/Basic-Others/NatNanotechnol-2026-Jiang-Efficient-prime-editing-in-vivo-and-in-vitro-using-lipid-nanoparticles 2026-07-02T09:20:49.287Z https://research-2ry.pages.dev/Summary/Basic-Others/NatNeurosci-2026-Sanchez-Molina-Spatial-proteomic-analysis-in-human-alzheimer's-disease-brains-enables-identification-of-microenvironment-dependent 2026-07-02T09:20:49.245Z https://research-2ry.pages.dev/Summary/Basic-Others/NatProtoc-2009-DuPage-Conditional-mouse-lung-cancer-models-using-adenoviral-or-lentiviral-delivery-of-cre-recombinase 2026-07-02T09:20:49.307Z https://research-2ry.pages.dev/Summary/Basic-Others/NatProtoc-2009-Huang-Systematic-and-integrative-analysis-of-large-gene-lists-using-DAVID-bioinformatics-resources 2026-07-02T09:20:49.315Z https://research-2ry.pages.dev/Summary/Basic-Others/NatProtoc-2016-Broutier-Culture-and-establishment-of-self-renewing-human-and-mouse-adult-liver-and-pancreas-3d-organoids-and-their-genetic 2026-07-02T09:20:49.190Z https://research-2ry.pages.dev/Summary/Basic-Others/NatProtoc-2020-Driehuis-Establishment-of-patient-derived-cancer-organoids-for-drug-screening-applications 2026-07-02T09:20:49.179Z https://research-2ry.pages.dev/Summary/Basic-Others/NatProtoc-2026-Zhu-Differential-protein-expression-analysis-of-quantitative-mass-spectrometry-data-using-deqms 2026-07-02T09:20:49.254Z https://research-2ry.pages.dev/Summary/Basic-Others/NatRevCancer-2015-Bachireddy-Haematological-malignancies-at-the-forefront-of-immunotherapeutic-innovation 2026-07-02T09:20:49.288Z https://research-2ry.pages.dev/Summary/Basic-Others/NatRevCancer-2018-Hamidi-Every-step-of-the-way-integrins-in-cancer-progression-and-metastasis 2026-07-02T09:20:49.271Z https://research-2ry.pages.dev/Summary/Basic-Others/NatRevCancer-2018-Lytle-Stem-cell-fate-in-cancer-growth,-progression-and-therapy-resistance 2026-07-02T09:20:49.280Z https://research-2ry.pages.dev/Summary/Basic-Others/NatRevCancer-2021-Rottenberg-The-rediscovery-of-platinum-based-cancer-therapy 2026-07-02T09:20:49.317Z https://research-2ry.pages.dev/Summary/Basic-Others/NatRevCancer-2025-Laisne-Epigenomic-heterogeneity-as-a-source-of-tumour-evolution 2026-07-02T09:20:49.205Z https://research-2ry.pages.dev/Summary/Basic-Others/NatRevCancer-2026-Rowles-Decoding-cancer-across-scales-with-metabolomics 2026-07-02T09:20:49.294Z https://research-2ry.pages.dev/Summary/Basic-Others/NatRevCancer-2026-Saviano-Claudin-proteins-as-emerging-therapeutic-targets-for-solid-tumours 2026-07-02T09:20:49.306Z https://research-2ry.pages.dev/Summary/Basic-Others/NatRevChem-2026-Pike-Lessons-learned-in-linking-PROTACs-from-discovery-to-the-clinic 2026-07-02T09:20:49.282Z https://research-2ry.pages.dev/Summary/Basic-Others/NatRevClinOncol-2016-OLeary-Treating-cancer-with-selective-CDK46-inhibitors 2026-07-02T09:20:49.180Z https://research-2ry.pages.dev/Summary/Basic-Others/NatRevClinOncol-2020-Rohatgi-Cancer-vaccine-induces-potent-T-cell-responses-but-is-it-enough 2026-07-02T09:20:49.252Z https://research-2ry.pages.dev/Summary/Basic-Others/NatRevClinOncol-2026-Chen-Engineering-platelets-as-cancer-therapeutics 2026-07-02T09:20:49.248Z https://research-2ry.pages.dev/Summary/Basic-Others/NatRevClinOncol-2026-Kang-Translating-ferroptosis-into-oncology-challenges,-opportunities-and-future-directions 2026-07-02T09:20:49.188Z https://research-2ry.pages.dev/Summary/Basic-Others/NatRevDisPrimers-2023-Malfertheiner-Helicobacter-pylori-infection 2026-07-02T09:20:49.263Z https://research-2ry.pages.dev/Summary/Basic-Others/NatRevDrugDiscov-2004-Ferrara-Discovery-and-development-of-bevacizumab,-an-anti-VEGF-antibody-for-treating-cancer 2026-07-02T09:20:49.310Z https://research-2ry.pages.dev/Summary/Basic-Others/NatRevDrugDiscov-2018-Ferguson-Kinase-inhibitors-the-road-ahead 2026-07-02T09:20:49.262Z https://research-2ry.pages.dev/Summary/Basic-Others/NatRevDrugDiscov-2026-Guilbaud-Autophagy-modulation-in-cancer 2026-07-02T09:20:49.172Z https://research-2ry.pages.dev/Summary/Basic-Others/NatRevDrugDiscov-2026-Monroe-Therapeutic-targeting-of-neuroimmune-mechanisms-in-neurodegeneration 2026-07-02T09:20:49.235Z https://research-2ry.pages.dev/Summary/Basic-Others/NatRevGenet-2011-Martin-Next-generation-transcriptome-assembly 2026-07-02T09:20:49.167Z https://research-2ry.pages.dev/Summary/Basic-Others/NatRevGenet-2016-Goodwin-Coming-of-age-ten-years-of-next-generation-sequencing-technologies 2026-07-02T09:20:49.198Z https://research-2ry.pages.dev/Summary/Basic-Others/NatRevGenet-2019-Stuart-Integrative-single-cell-analysis 2026-07-02T09:20:49.243Z https://research-2ry.pages.dev/Summary/Basic-Others/NatRevImmunol-2025-Leunig-Connection-and-communication-between-the-nervous-and-immune-systems 2026-07-02T09:20:49.312Z https://research-2ry.pages.dev/Summary/Basic-Others/NatRevImmunol-2026-Lee-Glial-cells-in-chronic-inflammation-diversity,-dysfunction-and-therapeutic-targeting 2026-07-02T09:20:49.230Z https://research-2ry.pages.dev/Summary/Basic-Others/NatRevImmunol-2026-Turner-RNA-binding-proteins-and-ribonucleoproteins-as-determinants-of-immunity 2026-07-02T09:20:49.169Z https://research-2ry.pages.dev/Summary/Basic-Others/NatRevMolCellBiol-2008-vanMeer-Membrane-lipids-where-they-are-and-how-they-behave 2026-07-02T09:20:49.290Z https://research-2ry.pages.dev/Summary/Basic-Others/NatRevNeurosci-2026-Ehlers-Wired-for-immunity-neuroimmune-control-of-the-lung-by-sensory-neurons 2026-07-02T09:20:49.164Z https://research-2ry.pages.dev/Summary/Basic-Others/NatStructMolBiol-2018-McMahon-Yeast-surface-display-platform-for-rapid-discovery-of-conformationally-selective-nanobodies 2026-07-02T09:20:49.311Z https://research-2ry.pages.dev/Summary/Basic-Others/NatStructMolBiol-2020-Konigs-SRSF7-maintains-its-homeostasis-through-the-expression-of-split-ORFs-and-nuclear-body-assembly 2026-07-02T09:20:49.230Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2005-Michor-Dynamics-of-chronic-myeloid-leukaemia 2026-07-02T09:20:49.189Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2011-Network-Integrated-genomic-analyses-of-ovarian-carcinoma 2026-07-02T09:20:49.237Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2012-Barretina-The-cancer-cell-line-encyclopedia-enables-predictive-modelling-of-anticancer-drug-sensitivity 2026-07-02T09:20:49.208Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2012-ENCODE-An-integrated-encyclopedia-of-DNA-elements-in-the-human-genome 2026-07-02T09:20:53.773Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2012-Network-Comprehensive-molecular-characterization-of-human-colon-and-rectal-cancer 2026-07-02T09:20:49.255Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2012-Network-Comprehensive-molecular-portraits-of-human-breast-tumours 2026-07-02T09:20:49.310Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2013-Alexandrov-Signatures-of-mutational-processes-in-human-cancer 2026-07-02T09:20:49.243Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2014-Cancer-Comprehensive-molecular-characterization-of-gastric-adenocarcinoma 2026-07-02T09:20:49.281Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2015-Bertotti-The-genomic-landscape-of-response-to-EGFR-blockade-in-colorectal-cancer 2026-07-02T09:20:49.198Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2015-DeLosAngeles-Hallmarks-of-pluripotency 2026-07-02T09:20:49.241Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2015-Spranger-Melanoma-intrinsic-beta-catenin-signalling-prevents-anti-tumour-immunity 2026-07-02T09:20:49.227Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2017-Lefrancais-The-lung-is-a-site-of-platelet-biogenesis-and-a-reservoir-for-haematopoietic-progenitors 2026-07-02T09:20:49.166Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2017-Ott-An-immunogenic-personal-neoantigen-vaccine-for-patients-with-melanoma 2026-07-02T09:20:49.194Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2018-La-RNA-velocity-of-single-cells 2026-07-02T09:20:49.289Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2018-Sun-Genomic-atlas-of-the-human-plasma-proteome 2026-07-02T09:20:49.183Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2019-Chan-Molecular-recording-of-mammalian-embryogenesis 2026-07-02T09:20:49.209Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2019-Tikhonova-The-bone-marrow-microenvironment-at-single-cell-resolution 2026-07-02T09:20:49.246Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2025-Hoover-Nerve-to-cancer-transfer-of-mitochondria-during-cancer-metastasis 2026-07-02T09:20:49.298Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2025-Li-SPP1-is-required-for-maintaining-mesenchymal-cell-fate-in-pancreatic-cancer 2026-07-02T09:20:49.310Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2026-Brixi-Genome-modelling-and-design-across-all-domains-of-life-with-evo-2 2026-07-02T09:20:49.296Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2026-Davis-25-years-of-chemistry-that-simply-clicks 2026-07-02T09:20:49.265Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2026-Gerhardt-Mutation-dependent-responses-to-sleep-and-exercise-in-clonal-haematopoiesis 2026-07-02T09:20:49.264Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2026-Li-Spermine-is-an-endogenous-iron-chelator-that-inhibits-ferroptosis 2026-07-02T09:20:49.219Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2026-Lu-Molecular-glue-degraders-of-HuR-suppress-BRAF-mutant-colorectal-cancer 2026-07-02T09:20:49.242Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2026-Menendez-Montes-Mitochondria-directly-interact-with-the-nuclear-pore-complex 2026-07-02T09:20:49.231Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2026-Scholz-RNA-triggered-cell-killing-with-crispr-cas12a2 2026-07-02T09:20:49.238Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2026-Yan-Ecotypes-of-triple-negative-breast-cancer-in-response-to-chemotherapy 2026-07-02T09:20:49.278Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2026-Yue-Spatial-distribution-of-the-proteome-in-the-human-body-and-in-cancers 2026-07-02T09:20:49.289Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2026-Zeng-Human-haematopoietic-stem-cells-remember-inflammatory-stress 2026-07-02T09:20:49.267Z https://research-2ry.pages.dev/Summary/Basic-Others/Nature-2026-Zhang-The-mutational-landscape-of-STING-induced-immunity 2026-07-02T09:20:49.218Z https://research-2ry.pages.dev/Summary/Basic-Others/Neuron-2026-Lee-Immune-brain-plasticity-underpins-stress-and-affective-behaviors 2026-07-02T09:20:49.272Z https://research-2ry.pages.dev/Summary/Basic-Others/NucleicAcidsRes-2010-Wang-ANNOVAR-functional-annotation-of-genetic-variants-from-high-throughput-sequencing-data 2026-07-02T09:20:49.299Z https://research-2ry.pages.dev/Summary/Basic-Others/NucleicAcidsRes-2015-Ritchie-Limma-powers-differential-expression-analyses-for-RNA-sequencing-and-microarray-studies 2026-07-02T09:20:49.239Z https://research-2ry.pages.dev/Summary/Basic-Others/OncolRev-2026-Liu-Progress-in-the-application-of-68ga-pentixafor-petct-in-lung-cancer-a-review 2026-07-02T09:20:49.260Z https://research-2ry.pages.dev/Summary/Basic-Others/Oncologist-2014-Pellegrini-Prognostic-value-of-interim-positron-emission-tomography-in-patients-with-peripheral-T-cell-lymphoma 2026-07-02T09:20:49.275Z https://research-2ry.pages.dev/Summary/Basic-Others/PigmentCellMelanomaRes-2015-Madore-PD-L1-expression-in-melanoma-shows-marked-heterogeneity-within-and-between-patients-implications-for-anti-PD-1pd-L1 2026-07-02T09:20:49.211Z https://research-2ry.pages.dev/Summary/Basic-Others/ProcNatlAcadSciUSA-2005-Subramanian-Gene-set-enrichment-analysis-a-knowledge-based-approach-for-interpreting-genome-wide-expression-profiles 2026-07-02T09:20:49.282Z https://research-2ry.pages.dev/Summary/Basic-Others/ProcNatlAcadSciUSA-2006-Lee-Evolution-and-expression-of-chimeric-POTE-actin-genes-in-the-human-genome 2026-07-02T09:20:49.253Z https://research-2ry.pages.dev/Summary/Basic-Others/ProcNatlAcadSciUSA-2009-Carpenito-Control-of-large,-established-tumor-xenografts-with-genetically-retargeted-human-T-cells-containing-CD28-and-CD137 2026-07-02T09:20:49.278Z https://research-2ry.pages.dev/Summary/Basic-Others/ProcNatlAcadSciUSA-2012-Bustos-Rab27-and-rab3-sequentially-regulate-human-sperm-dense-core-granule-exocytosis 2026-07-02T09:20:49.266Z https://research-2ry.pages.dev/Summary/Basic-Others/ProcNatlAcadSciUSA-2021-Koh-A-short-ORF-encoded-transcriptional-regulator 2026-07-02T09:20:49.244Z https://research-2ry.pages.dev/Summary/Basic-Others/ProcNatlAcadSciUSA-2023-Zhang-Integrin-alpha5beta1-contributes-to-cell-fusion-and-inflammation-mediated-by-SARS-CoV-2-spike-via-RGD-independent 2026-07-02T09:20:49.312Z https://research-2ry.pages.dev/Summary/Basic-Others/ProcNatlAcadSciUSA-2025-Li-Targeting-orthotopic-and-metastatic-pancreatic-cancer-with-allogeneic-stem-cell-engineered-mesothelin-redirected 2026-07-02T09:20:49.178Z https://research-2ry.pages.dev/Summary/Basic-Others/ProcNatlAcadSciUSA-2025-Liaki-A-targeted-combination-therapy-achieves-effective-pancreatic-cancer-regression-and-prevents-tumor-resistance 2026-07-02T09:20:49.282Z https://research-2ry.pages.dev/Summary/Basic-Others/STARProtoc-2021-Rosin-Live-cell-imaging-of-microglial-interactions-with-radial-glia-in-transgenic-embryonic-mouse-brains-using-slice-culture 2026-07-02T09:20:49.211Z https://research-2ry.pages.dev/Summary/Basic-Others/STARProtoc-2023-Pennitz-Protocol-to-dissociate-healthy-and-infected-murine-and-hamster-derived-lung-tissue-for-single-cell-transcriptome-analysis 2026-07-02T09:20:49.306Z https://research-2ry.pages.dev/Summary/Basic-Others/SciRep-2016-Walsh-Drug-response-in-organoids-generated-from-frozen-primary-tumor-tissues 2026-07-02T09:20:53.829Z https://research-2ry.pages.dev/Summary/Basic-Others/SciRep-2016-Wang-THBS2-is-a-potential-prognostic-biomarker-in-colorectal-cancer 2026-07-02T09:20:49.268Z https://research-2ry.pages.dev/Summary/Basic-Others/SciRep-2017-Bankhead-QuPath-open-source-software-for-digital-pathology-image-analysis 2026-07-02T09:20:49.293Z https://research-2ry.pages.dev/Summary/Basic-Others/SciSignal-2013-Gao-Integrative-analysis-of-complex-cancer-genomics-and-clinical-profiles-using-the-cBioPortal 2026-07-02T09:20:53.834Z https://research-2ry.pages.dev/Summary/Basic-Others/SciTranslMed-2012-Scholler-Decade-long-safety-and-function-of-retroviral-modified-chimeric-antigen-receptor-T-cells 2026-07-02T09:20:49.161Z https://research-2ry.pages.dev/Summary/Basic-Others/SciTranslMed-2026-Dymun-Clinicogenomic-analysis-of 2026-07-02T09:20:49.192Z https://research-2ry.pages.dev/Summary/Basic-Others/SciTranslMed-2026-Western-Low-overlap-of-plasma-and-CSF-protein-quantitative-trait-loci-affects-protein-discovery-for-neurological-disease 2026-07-02T09:20:49.256Z https://research-2ry.pages.dev/Summary/Basic-Others/Science-2001-Venter-The-sequence-of-the-human-genome 2026-07-02T09:20:49.174Z https://research-2ry.pages.dev/Summary/Basic-Others/Science-2002-Dudley-Cancer-regression-and-autoimmunity-in-patients-after-clonal-repopulation-with-antitumor-lymphocytes 2026-07-02T09:20:49.298Z https://research-2ry.pages.dev/Summary/Basic-Others/Science-2013-Vogelstein-Cancer-genome-landscapes 2026-07-02T09:20:49.250Z https://research-2ry.pages.dev/Summary/Basic-Others/Science-2015-Garrett-Cancer-and-the-microbiota 2026-07-02T09:20:49.265Z https://research-2ry.pages.dev/Summary/Basic-Others/Science-2015-Rosenberg-Adoptive-cell-transfer-as-personalized-immunotherapy-for-human-cancer 2026-07-02T09:20:49.311Z https://research-2ry.pages.dev/Summary/Basic-Others/Science-2015-Wu-Remote-control-of-therapeutic-T-cells-through-a-small-molecule-gated-chimeric-receptor 2026-07-02T09:20:49.269Z https://research-2ry.pages.dev/Summary/Basic-Others/Science-2016-Tirosh-Dissecting-the-multicellular-ecosystem-of-metastatic-melanoma-by-single-cell-RNA-seq 2026-07-02T09:20:49.179Z https://research-2ry.pages.dev/Summary/Basic-Others/Science-2018-Cohen-Detection-and-localization-of-surgically-resectable-cancers-with-a-multi-analyte-blood-test 2026-07-02T09:20:49.254Z https://research-2ry.pages.dev/Summary/Basic-Others/Science-2018-Pereira-Lymph-node-metastases-can-invade-local-blood-vessels,-exit-the-node,-and-colonize-distant-organs-in-mice 2026-07-02T09:20:49.225Z https://research-2ry.pages.dev/Summary/Basic-Others/Science-2020-Gilan-Selective-targeting-of-BD1-and-BD2-of-the-BET-proteins-in-cancer-and-immunoinflammation 2026-07-02T09:20:49.194Z https://research-2ry.pages.dev/Summary/Basic-Others/Science-2021-Altae-Tran-The-widespread-IS200IS605-transposon-family-encodes-diverse-programmable-RNA-guided-endonucleases 2026-07-02T09:20:49.259Z https://research-2ry.pages.dev/Summary/Basic-Others/Science-2022-Nurk-The-complete-sequence-of-a-human-genome 2026-07-02T09:20:49.160Z https://research-2ry.pages.dev/Summary/Basic-Others/Science-2026-Kim-Complex-interplay-of-neuronal-and-hormonal-gut-brain-responses-to-essential-amino-acid-deficit 2026-07-02T09:20:49.287Z https://research-2ry.pages.dev/Summary/Basic-Others/Science-2026-Lin-Antifibrotic-drug-finerenone-restores-fertility-in-premature-ovarian-insufficiency 2026-07-02T09:20:49.222Z https://research-2ry.pages.dev/Summary/Basic-Others/Science-2026-Pearce-Transcriptformer-a-generative-cell-atlas-across-1.5-billion-years-of-evolution 2026-07-02T09:20:49.305Z https://research-2ry.pages.dev/Summary/Basic-Others/SeminOncol-2006-Rowinsky-Novel-agents-that-target-tublin-and-related-elements 2026-07-02T09:20:49.297Z https://research-2ry.pages.dev/Summary/Basic-Others/TranslLungCancerRes-2021-Ishiwata-A-preclinical-research-platform-to-evaluate-photosensitizers-for-transbronchial-localization-and-phototherapy-of-lung 2026-07-02T09:20:49.259Z https://research-2ry.pages.dev/Summary/Basic-Others/TrendsCancer-2026-Davalos-How-DNA-methylation-predicts-response-to-cancer-therapies 2026-07-02T09:20:49.277Z https://research-2ry.pages.dev/Summary/Basic-Others/TrendsCancer-2026-Janiak-Platelets-the-next-generation-ovarian-cancer-biomarker 2026-07-02T09:20:49.234Z https://research-2ry.pages.dev/Summary/Basic-Others/TrendsGenet-2022-Hollox-Genome-structural-variation-in-human-evolution 2026-07-02T09:20:49.213Z https://research-2ry.pages.dev/Summary/Basic-Others/iScience-2024-Chen-Translating-CD47-targeted-therapy-in-gastrointestinal-cancers-insights-from-preclinical-to-clinical-studies 2026-07-02T09:20:49.182Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/CancerCell-2002-Hiratsuka-MMP9-induction-by-vascular-endothelial-growth-factor-receptor-1-is-involved-in-lung-specific-metastasis 2026-07-02T09:20:50.150Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/CancerCell-2017-Roberts-The-stromal-niche-for-epithelial-stem-cells-A-template-for-regeneration-and-a-brake-on-malignancy 2026-07-02T09:20:50.156Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/CancerCell-2020-Zhou-Single-cell-multiomics-sequencing-reveals-prevalent-genomic-alterations-in-tumor-stromal-cells-of-human-colorectal 2026-07-02T09:20:50.141Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/CancerCell-2021-Hu-Three-subtypes-of-lung-cancer-fibroblasts-define-distinct-therapeutic-paradigms 2026-07-02T09:20:50.146Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/CancerCell-2026-Bashir-Chronic-stress-unleashes-an-intratumor-phage-fibroblast-B-cell-circuit-to-promote-tumor-growth 2026-07-02T09:20:50.160Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/CancerCell-2026-Cruz-Reyes-When-tissue-tension-creates-a-mutagenic-niche 2026-07-02T09:20:50.125Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/CancerCell-2026-Kirschstein-Myofibroblast-programming-blocks-differentiation-of-TLS-organizing-fibroblastic-reticular-cells-in-pancreatic-cancer 2026-07-02T09:20:50.143Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/CancerCell-2026-Liu-Molecular-phenotypes-and-spatial-archetypes-A-new-framework-for-cancer-associated-fibroblasts 2026-07-02T09:20:50.162Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/CancerCell-2026-Mahadevan-Tumor-restraining-fibroblasts-emerge-after-chemotherapy-specifically-in-responders 2026-07-02T09:20:50.158Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/CancerCell-2026-Zhuo-A-conserved-re-epithelialization-program-underlies-malignancy-in-pancreatic-ductal-adenocarcinoma 2026-07-02T09:20:50.158Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/CancerCellInt-2022-Liao-Thrombospondin-2-acts-as-a-bridge-between-tumor-extracellular-matrix-and-immune-infiltration-in-pancreatic-and-stomach 2026-07-02T09:20:50.159Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/CancerDiscov-2022-Grout-Spatial-positioning-and-matrix-programs-of-cancer-associated-fibroblasts-promote-T-cell-exclusion-in-human-lung-tumors 2026-07-02T09:20:50.120Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/CancerDiscov-2026-Elhossiny-Asynchronous-evolution-of-epithelium-and-stroma-differentiates-precursor-lesions-from-pancreatic-cancer 2026-07-02T09:20:50.154Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/CancerDiscov-2026-Nigri-Myofibroblasts-induce-neuroplasticity-to-promote-pancreatic-inflammation-and-cancer-progression 2026-07-02T09:20:50.161Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/CancerLett-2022-Chen-Sulfonylurea-receptor-1-expressing-cancer-cells-induce-cancer-associated-fibroblasts-to-promote-non-small-cell-lung 2026-07-02T09:20:50.132Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/CancerRes-2015-Bertolini-Microenvironment-modulated-metastatic-CD133+CXCR4+EpCAM-lung-cancer-initiating-cells-sustain-tumor-dissemination-and 2026-07-02T09:20:50.129Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/CancerRes-2015-Teng-Classifying-cancers-based-on-T-cell-infiltration-and-PD-L1 2026-07-02T09:20:50.161Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/CancerRes-2025-Eigenbrood-Spatial-profiling-identifies-regionally-distinct-microenvironments-and-targetable-immunosuppressive-mechanisms-in 2026-07-02T09:20:50.155Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/CancerRes-2025-Reinecke-Metastasis-initiating-osteosarcoma-subpopulations-establish-paracrine-interactions-with-lung-and-tumor-cells-to-create 2026-07-02T09:20:50.121Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/Cell-2020-Maynard-Therapy-induced-evolution-of-human-lung-cancer-revealed-by-single-cell-RNA-sequencing 2026-07-02T09:20:50.150Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/Cell-2026-Ho-Nociceptive-innervation-limits-tertiary-lymphoid-structures-to-promote-lung-cancer 2026-07-02T09:20:50.156Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/Cell-2026-Reyes-Oncogenic-and-tumor-suppressive-forces-converge-on-a-progenitor-niche-at-the-benign-to-malignant-transition 2026-07-02T09:20:50.122Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/Cell-2026-Subudhi-Targeting-angiogenesis-lessons-from-25-years-of-normalizing-tumor-vasculature 2026-07-02T09:20:53.881Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/Cell-2026-Zhang-Sensory-neurons-drive-immune-exclusion-by-stimulating-a-dense-extracellular-matrix-in-the-breast-cancer-tumor 2026-07-02T09:20:50.127Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/Cell-2026-Zhang-Uncovering-spatially-resolved-functional-genomics-with-CRISPR-screen-sequencing 2026-07-02T09:20:50.120Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/CellMolImmunol-2022-Kim-Reprogramming-of-cancer-associated-fibroblasts-by-apoptotic-cancer-cells-inhibits-lung-metastasis-via-notch1-WISP-1 2026-07-02T09:20:50.124Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/CellRepMethods-2026-Podaza-Tumor-immune-microenvironment-reconstitution-in-patient-derived-organoids-enables-therapy-modeling-for-NSCLC 2026-07-02T09:20:50.145Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/ClinCancerRes-2019-Rahma-The-intersection-between-tumor-angiogenesis-and-immune-suppression 2026-07-02T09:20:50.123Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/ClinCancerRes-2021-Galbo-Molecular-features-of-cancer-associated-fibroblast-subtypes-and-their-implication-on-cancer-pathogenesis,-prognosis, 2026-07-02T09:20:50.141Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/CurrBiol-2011-Sung-Cortactin-controls-cell-motility-and-lamellipodial-dynamics-by-regulating-ECM-secretion 2026-07-02T09:20:50.154Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/DevCell-2016-Ye-The-complexity-of-translating-anti-angiogenesis-therapy-from-basic-science-to-the-clinic 2026-07-02T09:20:50.130Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/DevCell-2022-Sun-A-census-of-the-lung-CellCards-from-LungMAP 2026-07-02T09:20:50.153Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/FrontImmunol-2022-Song-Versican-enrichment-predicts-poor-prognosis-and-response-to-adjuvant-therapy-and-immunotherapy-in-gastric-cancer 2026-07-02T09:20:50.119Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/FrontImmunol-2026-Bain-Tumor-draining-lymph-nodes-in-non-small-cell-lung-cancer 2026-07-02T09:20:50.162Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/FrontOncol-2014-Voron-Control-of-the-immune-response-by-pro-angiogenic-factors 2026-07-02T09:20:50.153Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/Immunity-2022-Gong-Lung-fibroblasts-facilitate-pre-metastatic-niche-formation-by-remodeling-the-local-immune-microenvironment 2026-07-02T09:20:50.161Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/IntJMolSci-2017-LaFoya-Beyond-the-matrix-the-many-non-ECM-ligands-for-integrins 2026-07-02T09:20:50.123Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/JClinInvest-2019-Lucotti-Aspirin-blocks-formation-of-metastatic-intravascular-niches-by-inhibiting-platelet-derived-COX-1thromboxane-A2 2026-07-02T09:20:50.144Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/JClinInvest-2026-Isomoto-Spatial-single-cell-proteotyping-reveals-immunotherapy-resistant-features-within-the-complex-tumor-microenvironment-of 2026-07-02T09:20:50.134Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/JClinOncol-2012-Pajares-Expression-of-tumor-derived-vascular-endothelial-growth-factor-and-its-receptors-is-associated-with-outcome-in-early 2026-07-02T09:20:50.143Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/JExpMed-2015-Voron-VEGF-A-modulates-expression-of-inhibitory-checkpoints-on-CD8+-T-cells-in-tumors 2026-07-02T09:20:50.157Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/JImmunotherCancer-2026-Garate-Soraluze-Cancer-associated-fibroblast-targeting-therapies-as-a-tool-to-enhance-responses-to-radiotherapy-and-immunotherapy 2026-07-02T09:20:50.133Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/JImmunotherCancer-2026-Wu-Sensory-neuron-derived-CCL5-orchestrates-an-immunosuppressive-niche-via-regulatory-T-cells-to-fuel-head-and-neck-tumor 2026-07-02T09:20:50.138Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/JThoracOncol-2017-Manegold-The-potential-of-combined-immunotherapy-and-antiangiogenesis-for-the-synergistic-treatment-of-advanced-NSCLC 2026-07-02T09:20:50.149Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/LifeSciAlliance-2019-Bullock-Tumor-intrinsic-response-to-IFNgamma-shapes-the-tumor-microenvironment-and-anti-PD-1-response-in-NSCLC 2026-07-02T09:20:50.137Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/MatrixBiol-2014-Wight-Versican-and-the-control-of-inflammation 2026-07-02T09:20:50.140Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/ModPathol-2010-Gorter-Versican-expression-is-associated-with-tumor-infiltrating-CD8-positive-T-cells-and-infiltration-depth-in-cervical-cancer 2026-07-02T09:20:50.143Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/MolOncol-2021-Iwai-Cancer-associated-fibroblast-migration-in-non-small-cell-lung-cancers-is-modulated-by-increased-integrin-alpha11 2026-07-02T09:20:50.148Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/NatBiotechnol-2026-Lu-Single-cell-spatial-pharmacobiology-identifies-conserved-stromal-barriers-to-therapeutic-antibody-delivery-in-human 2026-07-02T09:20:50.125Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/NatCancer-2020-Gui-Activation-of-p38alpha-stress-activated-protein-kinase-drives-the-formation-of-the-pre-metastatic-niche-in-the-lungs 2026-07-02T09:20:50.131Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/NatCancer-2025-Zhao-A-cellular-and-spatial-atlas-of-TP53-associated-tissue-remodeling-defines-a-multicellular-tumor-ecosystem-in-lung 2026-07-02T09:20:50.127Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/NatCancer-2026-Lichun-Cellular-neighborhoods-in-cancer 2026-07-02T09:20:50.140Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/NatCancer-2026-Pramod-Heterogeneity-and-plasticity-of-cancer-associated-fibroblasts 2026-07-02T09:20:50.129Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/NatCancer-2026-Wang-TGFbeta-induces-an-atypical-EMT-to-evade-immune-mechanosurveillance-in-lung-adenocarcinoma-dormant-metastasis 2026-07-02T09:20:50.135Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/NatCellBiol-2026-Bang-Rudenstam-Tumour-acidosis-remodels-the-glycocalyx-to-control-lipid-scavenging-and-ferroptosis 2026-07-02T09:20:50.138Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/NatCommun-2024-DeZuani-Single-cell-and-spatial-transcriptomics-analysis-of-non-small-cell-lung-cancer 2026-07-02T09:20:50.129Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/NatCommun-2025-Desharnais-Spatially-mapping-the-tumour-immune-microenvironments-of-non-small-cell-lung-cancer 2026-07-02T09:20:50.139Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/NatGenet-2023-Madissoon-A-spatially-resolved-atlas-of-the-human-lung-characterizes-a-gland-associated-immune-niche 2026-07-02T09:20:50.142Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/NatMed-2003-Ferrara-The-biology-of-VEGF-and-its-receptors 2026-07-02T09:20:50.142Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/NatMed-2013-Quail-Microenvironmental-regulation-of-tumor-progression-and-metastasis 2026-07-02T09:20:50.134Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/NatMed-2018-Lambrechts-Phenotype-molding-of-stromal-cells-in-the-lung-tumor-microenvironment 2026-07-02T09:20:50.128Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/NatRevCancer-2021-Cox-The-matrix-in-cancer 2026-07-02T09:20:50.121Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/NatRevClinOncol-2020-Martin-Improving-cancer-immunotherapy-using-nanomedicines-progress,-opportunities-and-challenges 2026-07-02T09:20:50.152Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/NatRevDrugDiscov-2016-Ferrara-Ten-years-of-anti-vascular-endothelial-growth-factor-therapy 2026-07-02T09:20:50.122Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/Nature-2005-Kaplan-VEGFR1-positive-haematopoietic-bone-marrow-progenitors-initiate-the-pre-metastatic-niche 2026-07-02T09:20:50.160Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/Nature-2019-Ombrato-Metastatic-niche-labelling-reveals-parenchymal-cells-with-stem-features 2026-07-02T09:20:50.158Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/Nature-2020-Travaglini-A-molecular-cell-atlas-of-the-human-lung-from-single-cell-RNA-sequencing 2026-07-02T09:20:50.146Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/Nature-2023-Karimi-Single-cell-spatial-immune-landscapes-of-primary-and-metastatic-brain-tumours 2026-07-02T09:20:50.153Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/Nature-2023-Sorin-Single-cell-spatial-landscapes-of-the-lung-tumour-immune-microenvironment 2026-07-02T09:20:50.148Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/Nature-2026-Buissant-Emergence-of-oncofetal-plasticity-is-ubiquitous-in-early-colorectal-cancers 2026-07-02T09:20:50.151Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/Nature-2026-Cardoso-Early-fibrotic-niches-establish-tumour-permissive-microenvironments 2026-07-02T09:20:50.130Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/Nature-2026-Chai-GlycoRNA-complexed-with-heparan-sulfate-regulates-VEGF-A-signalling 2026-07-02T09:20:50.159Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/Nature-2026-Skrupskelyte-Precancerous-niche-remodelling-dictates-nascent-tumour-persistence 2026-07-02T09:20:50.150Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/Nature-2026-Zhang-Non-invasive-profiling-of-the-tumour-microenvironment-with-spatial-ecotypes 2026-07-02T09:20:50.144Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/Neuron-2026-Zhang-A-peritumoral-microenvironment-engaged-by-reg-extl3-axis-fosters-nerve-cancer-interactions-in-pancreatic-ductal 2026-07-02T09:20:50.131Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/Oncotarget-2017-Wang-Cancer-associated-fibroblasts-enhance-metastatic-potential-of-lung-cancer-cells-through-IL-6-STAT3-signaling-pathway 2026-07-02T09:20:50.155Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/STARProtoc-2021-Yasuda-Protocol-to-establish-cancer-associated-fibroblasts-from-surgically-resected-tissues-and-generate-senescent-fibroblasts 2026-07-02T09:20:50.155Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/SciRep-2017-Asano-Stromal-versican-regulates-tumor-growth-by-promoting-angiogenesis 2026-07-02T09:20:50.141Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/SciSignal-2022-Remsing-IGF-binding-proteins-secreted-by-cancer-associated-fibroblasts-induce-context-dependent-drug-sensitization-of-lung 2026-07-02T09:20:50.146Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/Science-2005-Jain-Normalization-of-tumor-vasculature-an-emerging-concept-in-antiangiogenic-therapy 2026-07-02T09:20:50.120Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/TrendsCancer-2020-Chakraborty-Agrin-mediates-angiogenesis-in-the-tumor-microenvironment 2026-07-02T09:20:50.136Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/TrendsCancer-2026-Papavassiliou-Neural-circuits-in-lung-adenocarcinoma-modulate-immunosurveillance 2026-07-02T09:20:50.151Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/bioRxiv-2026-Risom-A-spatial-proteomic-atlas-of-tertiary-lymphoid-structures-in-non-small-cell-lung-cancer-identifies-a-novel-predictive 2026-07-02T09:20:50.137Z https://research-2ry.pages.dev/Summary/Basic-Tumor-microenvironment/npjPrecisOncol-2026-Zhang-Multi-omics-profiling-reveals-tumor-microenvironment-characteristics-linked-to-immunotherapy-response-and-prognosis-in 2026-07-02T09:20:50.133Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/AmJRespirCritCareMed-2013-Powell-Update-in-lung-cancer-and-mesothelioma-2012 2026-07-02T09:20:49.939Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/AnnOncol-2012-Inoue-Attributable-causes-of-cancer-in-japan-in-2005-systematic-assessment-to-estimate-current-burden-of-cancer-attributable 2026-07-02T09:20:49.941Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/AnnThoracSurg-2007-Sugimura-Survival-after-recurrent-nonsmall-cell-lung-cancer-after-complete-pulmonary-resection 2026-07-02T09:20:49.938Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/AnnThoracSurg-2012-Nwogu-Number-of-lymph-nodes-and-metastatic-lymph-node-ratio-are-associated-with-survival-in-lung-cancer 2026-07-02T09:20:49.943Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/AnnThoracSurg-2013-Taylor-Lymph-node-ratio-predicts-recurrence-and-survival-after-R0-resection-for-non-small-cell-lung-cancer 2026-07-02T09:20:49.944Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/AnnThoracSurg-2023-Potter-Recurrence-after-complete-resection-for-non-small-cell-lung-cancer-in-the-national-lung-screening-trial 2026-07-02T09:20:49.942Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/CACancerJClin-2011-Jemal-Global-cancer-statistics 2026-07-02T09:20:49.941Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/CACancerJClin-2012-Siegel-Cancer-treatment-and-survivorship-statistics,-2012 2026-07-02T09:20:49.944Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/CACancerJClin-2018-Bray-Global-cancer-statistics-2018-GLOBOCAN-estimates-of-incidence-and-mortality-worldwide-for-36-cancers-in-185-countries 2026-07-02T09:20:49.946Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/CACancerJClin-2021-Sung-Global-cancer-statistics-2020-GLOBOCAN-estimates-of-incidence-and-mortality-worldwide-for-36-cancers-in-185-countries 2026-07-02T09:20:49.941Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/Cancer-2016-Behera-Trends,-predictors,-and-impact-of-systemic-chemotherapy-in-small-cell-lung-cancer-patients-between-1985-and-2005 2026-07-02T09:20:49.938Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/Cell-2026-Pandya-Plasma-signals-of-lung-tumor-promotion-for-molecular-cancer-prevention 2026-07-02T09:20:49.941Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/Cell-2026-Shi-Accelerating-discovery-of-cancer-causes-for-prevention-in-the-era-of-rising-early-onset-cancers 2026-07-02T09:20:49.940Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/EurJCancer-2026-Corre-Real-life-management-and-outcomes-of-octogenarians-with-non-small-cell-lung-cancer-A-10-year-evolution 2026-07-02T09:20:49.938Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/GenThoracCardiovascSurg-2016-Committee-Thoracic-and-cardiovascular-surgery-in-japan-during-2014-annual-report-by-the-japanese-association-for-thoracic-surgery 2026-07-02T09:20:49.946Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/IntJCancer-2005-Devesa-International-lung-cancer-trends-by-histologic-type-male-female-differences-diminishing-and-adenocarcinoma-rates-rising 2026-07-02T09:20:49.943Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/JAMA-2019-Singal-Association-of-patient-characteristics-and-tumor-genomics-with-clinical-outcomes-among-patients-with-non-small-cell 2026-07-02T09:20:49.940Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/JAMAOncol-2021-Ganti-Update-of-incidence,-prevalence,-survival,-and-initial-treatment-in-patients-with-non-small-cell-lung-cancer-in-the-US 2026-07-02T09:20:53.973Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/JAMAOncol-2022-Global-Burden-of-Disease-2019-Cancer-Collaboration-Cancer-incidence,-moratlity,-years-of-life-lost,-years-live-with-disability,-and-disability-adjusted-life-years-for-29-cancer-groups-from-2010-to-2019 2026-07-02T09:20:53.978Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/JClinOncol-2006-Govindan-Changing-epidemiology-of-small-cell-lung-cancer-in-the-united-states-over-the-last-30-years-analysis-of-the 2026-07-02T09:20:53.981Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/JClinOncol-2008-Asmis-Age-and-comorbidity-as-independent-prognostic-factors-in-the-treatment-of-non-small-cell-lung-cancer-a-review-of 2026-07-02T09:20:49.942Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/JClinOncol-2012-Cuffe-Adjuvant-chemotherapy-for-non-small-cell-lung-cancer-in-the-elderly-a-population-based-study-in-ontario,-canada 2026-07-02T09:20:49.945Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/JThoracCardiovascSurg-1994-Yano-The-first-site-of-recurrence-after-complete-resection-in-non-small-cell-carcinoma-of-the-lung.-comparison-between-pN0 2026-07-02T09:20:49.942Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/JThoracCardiovascSurg-2025-Fick-Late-recurrence-of-completely-resected-stage-I-to-IIIA-lung-adenocarcinoma 2026-07-02T09:20:49.946Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/JThoracOncol-2010-Subramanian-Distinctive-characteristics-of-non-small-cell-lung-cancer-(NSCLC)-in-the-young-a-surveillance,-epidemiology,-and-end 2026-07-02T09:20:49.945Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/JThoracOncol-2011-Sawabata-Japanese-lung-cancer-registry-study-of-11,663-surgical-cases-in-2004-demographic-and-prognosis-changes-over-decade 2026-07-02T09:20:49.944Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/JpnJClinOncol-2015-Katanoda-An-updated-report-on-the-trends-in-cancer-incidence-and-mortality-in-japan,-1958-2013 2026-07-02T09:20:49.939Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/Lancet-2011-Goldstraw-Non-small-cell-lung-cancer 2026-07-02T09:20:49.944Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/Lancet-2013-Reck-Management-of-NSCLC 2026-07-02T09:20:49.947Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/Lancet-2021-Thai-Lung-Cancer 2026-07-02T09:20:49.941Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/Lancet-2023-Adams-Lung-cancer-screening 2026-07-02T09:20:49.940Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/Lancet-2024-GBD-Global-fertility-in-204-countries-and-territories,-1950-2021,-with-forecasts-to-2100-a-comprehensive-demographic 2026-07-02T09:20:49.939Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/LungCancer-2013-Tsuta-The-utility-of-the-proposed-IASLCATSERS-lung-adenocarcinoma-subtypes-for-disease-prognosis-and-correlation-of-driver 2026-07-02T09:20:49.940Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/NEnglJMed-2020-Howlader-The-effect-of-advances-in-lung-cancer-treatment-on-population-mortality 2026-07-02T09:20:49.943Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/NatMed-2026-Maas-Epigenetic-fingerprints-link-early-onset-colon-and-rectal-cancer-to-pesticide-exposure 2026-07-02T09:20:49.945Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/NatRevClinOncol-2026-Zhang-Innovative-approaches-for-lung-cancer-screening-and-interception 2026-07-02T09:20:49.945Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/Oncotarget-2015-Liu-Clinical-significance-of-age-at-diagnosis-among-young-non-small-cell-lung-cancer-patients-under-40-years-old-a 2026-07-02T09:20:49.943Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/Thorax-2019-Mets-Primary-lung-cancer-in-patients-with-previous-malignancies-a-nationwide-study 2026-07-02T09:20:54.001Z https://research-2ry.pages.dev/Summary/Clinical-Epidemiology/WHO-2004-Travis-Classification-of-tumours-pathology-and-genetics-of-tumours-of-the-lung-pleura-thymus-and-heart 2026-07-02T09:20:49.946Z https://research-2ry.pages.dev/Summary/Clinical-Mesothelioma/AnnOncol-2014-Suraokar-Expression-profiling-stratifies-mesothelioma-tumors-and-signifies-deregulation-of-spindle-checkpoint-pathway-and 2026-07-02T09:20:50.069Z https://research-2ry.pages.dev/Summary/Clinical-Mesothelioma/AnnOncol-2015-Baas-Malignant-pleural-mesothelioma-ESMO-Clinical-Practice-Guidelines-for-diagnosis,-treatment-and-follow-up 2026-07-02T09:20:50.067Z https://research-2ry.pages.dev/Summary/Clinical-Mesothelioma/ArchPatholLabMed-2013-Husain-Guidelines-for-pathologic-diagnosis-of-malignant-mesothelioma-2012-update-of-the-consensus-statement-from-the 2026-07-02T09:20:50.067Z https://research-2ry.pages.dev/Summary/Clinical-Mesothelioma/BMCCancer-2012-Petrausch-Re-directed-T-cells-for-the-treatment-of-fibroblast-activation-protein-(FAP)-positive-malignant-pleural-mesothelioma 2026-07-02T09:20:50.071Z https://research-2ry.pages.dev/Summary/Clinical-Mesothelioma/CancerRes-2010-Zhao-Multiple-injections-of-electroporated-autologous-T-cells-expressing-a-chimeric-antigen-receptor-mediate-regression-of 2026-07-02T09:20:50.070Z https://research-2ry.pages.dev/Summary/Clinical-Mesothelioma/CancerRes-2015-Yamada-Akt-kinase-interacting-protein-1-signals-through-CREB-to-drive-diffuse-malignant-mesothelioma 2026-07-02T09:20:50.068Z https://research-2ry.pages.dev/Summary/Clinical-Mesothelioma/CancerSci-2015-Li-Therapeutic-activity-of-glycoengineered-anti-GM2-antibodies-against-malignant-pleural-mesothelioma 2026-07-02T09:20:50.069Z https://research-2ry.pages.dev/Summary/Clinical-Mesothelioma/ClinCancerRes-2021-Oehl-Alterations-in-BAP1-are-associated-with-cisplatin-resistance-through-inhibition-of-apoptosis-in-malignant-pleural 2026-07-02T09:20:50.069Z https://research-2ry.pages.dev/Summary/Clinical-Mesothelioma/JCancerMetastasisTreat-2023-Offin-The-past,-present,-and-future-of-targeted-therapeutic-approaches-in-patients-with-diffuse-pleural-mesotheliomas 2026-07-02T09:20:50.072Z https://research-2ry.pages.dev/Summary/Clinical-Mesothelioma/JClinOncol-2023-Vogelzang-Phase-III-study-of-pemetrexed-in-combination-with-cisplatin-versus-cisplatin-alone-in-patients-with-malignant-pleural 2026-07-02T09:20:50.070Z https://research-2ry.pages.dev/Summary/Clinical-Mesothelioma/JImmunotherCancer-2020-Vroman-T-cell-receptor-repertoire-characteristics-both-before-and-following-immunotherapy-correlate-with-clinical-response-in 2026-07-02T09:20:50.070Z https://research-2ry.pages.dev/Summary/Clinical-Mesothelioma/JThoracOncol-2014-Riquelme-Frequent-coamplification-and-cooperation-between-C-MYC-and-PVT1-oncogenes-promote-malignant-pleural-mesothelioma 2026-07-02T09:20:50.068Z https://research-2ry.pages.dev/Summary/Clinical-Mesothelioma/Lancet-2021-Baas-First-line-nivolumab-plus-ipilimumab-in-unresectable-malignant-pleural-mesothelioma-(CheckMate-743)-a-multicentre, 2026-07-02T09:20:50.066Z https://research-2ry.pages.dev/Summary/Clinical-Mesothelioma/LancetOncol-2017-vanZandwijk-Safety-and-activity-of-microRNA-loaded-minicells-in-patients-with-recurrent-malignant-pleural-mesothelioma-a 2026-07-02T09:20:50.066Z https://research-2ry.pages.dev/Summary/Clinical-Mesothelioma/Med-2026-Lopez-Lago-Loss-of-tumor-suppressor-NF2-mediates-resistance-to-CAR-T-cell-and-anti-PD-1-therapy-strategies-to-restore 2026-07-02T09:20:50.072Z https://research-2ry.pages.dev/Summary/Clinical-Mesothelioma/NatCommun-2019-Blum-Dissecting-heterogeneity-in-malignant-pleural-mesothelioma-through-histo-molecular-gradients-for-clinical-applications 2026-07-02T09:20:50.067Z https://research-2ry.pages.dev/Summary/Clinical-Mesothelioma/NatGenet-2011-Bott-The-nuclear-deubiquitinase-BAP1-is-commonly-inactivated-by-somatic-mutations-and-3p21.1-losses-in-malignant-pleural 2026-07-02T09:20:50.073Z https://research-2ry.pages.dev/Summary/Clinical-Mesothelioma/NatGenet-2011-Testa-Germline-BAP1-mutations-predispose-to-malignant-mesothelioma 2026-07-02T09:20:50.073Z https://research-2ry.pages.dev/Summary/Clinical-Mesothelioma/NatGenet-2016-Bueno-Comprehensive-genomic-analysis-of-malignant-pleural-mesothelioma-identifies-recurrent-mutations,-gene-fusions-and 2026-07-02T09:20:54.025Z https://research-2ry.pages.dev/Summary/Clinical-Mesothelioma/NatRevDrugDiscov-2004-Muhsin-Pemetrexed-disodium 2026-07-02T09:20:50.072Z https://research-2ry.pages.dev/Summary/Clinical-Mesothelioma/TrendsCancer-2026-Dungey-Mesothelioma-a-systemic-therapy-clinical-trials-snapshot 2026-07-02T09:20:54.030Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/AnnOncol-2014-Moran-Two-biomarker-directed-randomized-trials-in-European-and-Chinese-patients-with-NSCLC-The-BRCA1-RAP80-expression-customizatin-(BREC)-studies 2026-07-02T09:20:50.089Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/AnnOncol-2016-Postel-Vinay-Challenges-of-phase-1-clinical-trials-evaluating-immune-checkpoint-targeted-antibodies 2026-07-02T09:20:50.074Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/AnnOncol-2018-Yan-Phase-I-II-clinical-trial-design-A-state-of-the-art-paradigm-for-dose-finding 2026-07-02T09:20:50.096Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/AnnSurg-2022-Famularo-Hepatectomy-versus-sorafenib-in-advanced-nonmetastatic-hepatocellular-carcinoma-A-real-life-multicentric-weighted 2026-07-02T09:20:50.090Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/AnnThoracSurg-2006-Williams-Predicting-postrecurrence-survival-among-completely-resected-nonsmall-cell-lung-cancer-patients 2026-07-02T09:20:50.083Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/Bioinformatics-2016-Gu-Complex-heatmaps-reveal-patterns-and-correlations-in-multidimensional-genomic-data 2026-07-02T09:20:50.097Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/Biometrics-2017-Morita-Bayesian-population-finding-with-biomarkers-in-a-randomized-clinical-trial 2026-07-02T09:20:50.086Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/BrJCancer-2023-Bruno-Support-to-early-clinical-decisions-in-drug-development-and-personalised-medicine-with-checkpoint-inhibitors-using 2026-07-02T09:20:50.084Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/Cancer-1981-Miller-Reporting-results-of-cancer-treatment 2026-07-02T09:20:50.081Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/CancerDiscov-2021-Spreafico-The-future-of-clinical-trial-design-in-oncology 2026-07-02T09:20:50.081Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/CancerSci-2018-Sunami-Clinical-practice-guidance-for-next-generation-sequencing-in-cancer-diagnosis-and-treatment-(edition-1.0) 2026-07-02T09:20:50.087Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/CancerSci-2019-Sunami-Feasibility-and-utility-of-a-panel-testing-for-114-cancer-associated-genes-in-a-clinical-setting-A-hospital-based-study 2026-07-02T09:20:50.093Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/CancerSci-2020-Udagawa-Feasibility-and-utility-of-transbronchial-cryobiopsy-in-precision-medicine-for-lung-cancer-prospective-single-arm-study 2026-07-02T09:20:50.087Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/ClinCancerRes-2009-Wolchok-Guidelines-for-the-evaluation-of-immune-therapy-activity-in-solid-tumors-immune-related-response-criteria 2026-07-02T09:20:50.077Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/ClinCancerRes-2021-Rahma-Early-3+3-trial-dose-escalation-phase-I-clinical-trial-design-and-suitability-for-immune-checkpoint-inhibitors 2026-07-02T09:20:50.085Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/ClinCancerRes-2023-Bruno-Tumor-dynamic-model-based-decision-support-for-phase-IbII-combination-studies-A-retrospective-assessment-based-on 2026-07-02T09:20:50.094Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/ClinPharmTher-2001-BiomarkersDefinitionsWorkingGroup-Biomarkers-and-surrogate-endpoints-preferred-definitions-and-conceptual-framework 2026-07-02T09:20:50.094Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/ClinPharmTher-2023-Lemaire-From-cold-to-hot-changing-perceptions-and-future-opportunities-for-quantitative-systems-pharmacology-modeling-in-cancer 2026-07-02T09:20:54.053Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/ClinTranslSci-2016-Morrissey-Immunotherapy-and-novel-combinations-in-oncology-current-landscape,-challenges,-and-opportunities 2026-07-02T09:20:50.080Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/ClinTranslSci-2021-Weddell-Mechanistic-modeling-of-intra-tumor-spatial-distribution-of-antibody-drug-conjugates-insights-into-dosing-strategies-in 2026-07-02T09:20:50.085Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/ClinTranslSci-2022-Ji-Model-based-dose-selection-to-inform-translational-clinical-oncology-development-of-WNT974,-a-first-in-class-porcupine 2026-07-02T09:20:50.089Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/DrugDiscovTodayTechnol-2016-Kamath-Translational-pharmacokinetics-and-pharmacodynamics-of-monoclonal-antibodies 2026-07-02T09:20:50.089Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/EurJCancer-2009-Eisenhauer-New-response-evaluation-criteria-in-solid-tumours-revised-RECIST-guideline-(version-1.1) 2026-07-02T09:20:50.090Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/EurUrolFocus-2021-Seisen-Prognostic-impact-of-pT3-subclassification-in-a-multicentre-cohort-of-patients-with-urothelial-carcinoma-of-the-renal 2026-07-02T09:20:50.077Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/FDA-2011-Guidance-for-industry-Clinical-trial-endpoints-for-the-approval-of-NSCLC 2026-07-02T09:20:50.093Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/FrontOncol-2020-Wang-Patterns-of-extrathoracic-metastases-in-different-histological-types-of-lung-cancer 2026-07-02T09:20:50.095Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JAMA-2018-Presley-Association-of-broad-based-genomic-sequencing-with-survival-among-patients-with-advanced-non-small-cell-lung-cancer-in 2026-07-02T09:20:50.091Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JAMA-2018-Woloshin-Characteristics-of-interim-publications-of-randomized-clinical-trials-and-comparison-with-final-publications 2026-07-02T09:20:50.078Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JClinOncol-2003-Johnson-End-points-and-united-states-food-and-drug-administration-approval-of-oncology-drugs 2026-07-02T09:20:54.065Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JClinOncol-2011-Chibaudel-Alternative-end-points-to-evaluate-a-therapeutic-strategy-in-advanced-colorectal-cancer-evaluation-of-progression-free 2026-07-02T09:20:50.081Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JClinOncol-2014-Cheson-Recommendations-for-initial-evaluation,-staging,-and-response-assessment-of-hodgkin-and-non-hodgkin-lymphoma-the-lugano 2026-07-02T09:20:50.078Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JClinOncol-2014-Ellis-American-society-of-clinical-oncology-perspective-raising-the-bar-for-clinical-trials-by-defining-clinically-meaningful 2026-07-02T09:20:50.092Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JClinOncol-2014-Sacher-Shifting-patterns-in-the-interpretation-of-phase-III-clinical-trial-outcomes-in-advanced-non-small-cell-lung-cancer-the 2026-07-02T09:20:50.083Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JClinOncol-2014-Uno-Moving-beyond-the-hazard-ratio-in-quantifying-the-between-group-difference-in-survival-analysis 2026-07-02T09:20:50.074Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JClinOncol-2015-Blumenthal-Overall-response-rate,-progression-free-survival,-and-overall-survival-with-targeted-and-standard-therapies-in-advanced 2026-07-02T09:20:50.077Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JClinOncol-2015-Mizugaki-Current-status-of-single-agent-phase-I-trials-in-japan-toward-globalization 2026-07-02T09:20:50.096Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JClinOncol-2015-Tosi-Clinical-development-strategies-and-outcomes-in-first-in-human-trials-of-monoclonal-antibodies 2026-07-02T09:20:50.091Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JClinOncol-2015-Zhang-Subgroup-analyses-in-reporting-of-phase-III-clinical-trials-in-solid-tumors 2026-07-02T09:20:54.081Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JClinPharmacol-2017-Sheng-Clinical-pharmacology-considerations-for-the-development-of-immune-checkpoint-inhibitors 2026-07-02T09:20:50.092Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JClinPharmacol-2020-An-Concept-of-pharmacologic-target-mediated-drug-disposition-in-large-molecule-and-small-molecule-compounds 2026-07-02T09:20:50.093Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JMolDiagn-2015-Cheng-Memorial-sloan-kettering-integrated-mutation-profiling-of-actionable-cancer-targets-(MSK-IMPACT)-A-hybridization 2026-07-02T09:20:50.088Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JNatlCancerInst-2009-Broglio-Detecting-an-overall-survival-benefit-that-is-derived-from-progression-free-survival 2026-07-02T09:20:50.082Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JThoracOncol-2007-Goldstraw-The-IASLC-lung-cancer-staging-project-proposals-for-the-revision-of-the-TNM-stage-groupings-in-the-forthcoming 2026-07-02T09:20:50.075Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JThoracOncol-2007-Rusch-The-IASLC-lung-cancer-staging-project-proposals-for-the-revision-of-the-N-descriptors-in-the-forthcoming-seventh 2026-07-02T09:20:50.080Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JThoracOncol-2009-Rusch-The-IASLC-lung-cancer-staging-project-a-proposal-for-a-new-international-lymph-node-map-in-the-forthcoming-seventh 2026-07-02T09:20:50.088Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JThoracOncol-2011-Travis-International-association-for-the-study-of-lung-canceramerican-thoracic-societyeuropean-respiratory-society 2026-07-02T09:20:50.091Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JThoracOncol-2015-Asamura-The-international-association-for-the-study-of-lung-cancer-lung-cancer-staging-project-proposals-for-the-revision-of 2026-07-02T09:20:50.079Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JThoracOncol-2015-Travis-The-2015-world-health-organization-classification-of-lung-tumors-impact-of-genetic,-clinical-and-radiologic-advances 2026-07-02T09:20:50.074Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JThoracOncol-2016-Travis-The-IASLC-lung-cancer-staging-project-proposals-for-coding-T-categories-for-subsolid-nodules-and-assessment-of-tumor 2026-07-02T09:20:50.096Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JThoracOncol-2017-Chansky-The-IASLC-lung-cancer-staging-project-external-validation-of-the-revision-of-the-TNM-stage-groupings-in-the-eighth 2026-07-02T09:20:50.088Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JThoracOncol-2019-Kratz-Incorporation-of-a-molecular-prognostic-classifier-improves-conventional-non-small-cell-lung-cancer-staging 2026-07-02T09:20:50.083Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JThoracOncol-2019-Okami-Demographics,-safety-and-quality,-and-prognostic-information-in-both-the-seventh-and-eighth-editions-of-the-TNM 2026-07-02T09:20:50.084Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/JThoracOncol-2021-Mino-Kenudson-The-international-association-for-the-study-of-lung-cancer-global-survey-on-programmed-death-ligand-1-testing-for-NSCLC 2026-07-02T09:20:50.084Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/LancetOncol-2017-Seymour-iRECIST-guidelines-for-response-criteria-for-use-in-trials-testing-immunotherapeutics 2026-07-02T09:20:50.075Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/NEnglJMed-2019-Harrington-New-guidelines-for-statistical-reporting-in-the-journal 2026-07-02T09:20:50.094Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/NatCommun-2016-Yu-Predicting-non-small-cell-lung-cancer-prognosis-by-fully-automated-microscopic-pathology-image-features 2026-07-02T09:20:50.076Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/NatMed-2019-Sicklick-Molecular-profiling-of-cancer-patients-enables-personalized-combination-therapy-the-I-PREDICT-study 2026-07-02T09:20:50.082Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/NatRevCancer-2015-Weiner-Building-better-monoclonal-antibody-based-therapeutics 2026-07-02T09:20:54.105Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/NatRevCancer-2026-Liu-Advancing-AI-for-multi-omics-and-clinical-data-integration-in-basic-and-translational-cancer-research 2026-07-02T09:20:50.078Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/NatRevClinOncol-2013-Doebele-Targeted-therapies-time-to-shift-the-burden-of-proof-for-oncogene-positive-cancer 2026-07-02T09:20:50.097Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/NatRevClinOncol-2016-Wong-The-changing-landscape-of-phase-I-trials-in-oncology 2026-07-02T09:20:50.076Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/NatRevClinOncol-2020-Kurzrock-New-drug-approvals-in-oncology 2026-07-02T09:20:50.083Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/Pharmacogenomics-2010-Fujiwara-An-overview-of-the-recent-progress-in-irinotecan-pharmacogenetics 2026-07-02T09:20:50.079Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/RadiotherOncol-2004-Rodrigues-Prediction-of-radiation-pneumonitis-by-dose-volume-histogram-parameters-in-lung-cancer-a-systematic-review 2026-07-02T09:20:50.097Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/SciRep-2020-Chatton-G-computation,-propensity-score-based-methods,-and-targeted-maximum-likelihood-estimator-for-causal-inference-with 2026-07-02T09:20:50.095Z https://research-2ry.pages.dev/Summary/Clinical-Methodology/UrolOncol-2021-Reitblat-Radical-prostatectomy-versus-external-beam-radiation-therapy-for-high-grade,-clinically-localized-prostate-cancer 2026-07-02T09:20:50.087Z https://research-2ry.pages.dev/Summary/Clinical-NEC/AnnOncol-2013-LeTreut-Multicentre-phase-II-study-of-cisplatin-etoposide-chemotherapy-for-advanced-large-cell-neuroendocrine-lung-carcinoma 2026-07-02T09:20:49.412Z https://research-2ry.pages.dev/Summary/Clinical-NEC/AnnOncol-2017-Christopoulos-Everolimus-with-paclitaxel-and-carboplatin-as-first-line-treatment-for-metastatic-large-cell-neuroendocrine-lung 2026-07-02T09:20:49.423Z https://research-2ry.pages.dev/Summary/Clinical-NEC/AnnSurgOncol-2024-Fujiwara-Clinical-and-pathologic-differences-between-small-cell-carcinoma-and-large-cell-neuroendocrine-carcinoma-of-the-lung 2026-07-02T09:20:49.417Z https://research-2ry.pages.dev/Summary/Clinical-NEC/BrJCancer-2021-Lindsay-Large-cell-neuroendocrine-lung-carcinoma-consensus-statement-from-the-british-thoracic-oncology-group-and-the 2026-07-02T09:20:49.416Z https://research-2ry.pages.dev/Summary/Clinical-NEC/Cancer-2001-Iyoda-Clinical-characterization-of-pulmonary-large-cell-neuroendocrine-carcinoma-and-large-cell-carcinoma-with-neuroendocrine 2026-07-02T09:20:49.415Z https://research-2ry.pages.dev/Summary/Clinical-NEC/Cell-2020-Kawasaki-An-organoid-biobank-of-neuroendocrine-neoplasms-enables-genotype-phenotype-mapping 2026-07-02T09:20:49.421Z https://research-2ry.pages.dev/Summary/Clinical-NEC/ClinCancerRes-2016-Rekhtman-Next-generation-sequencing-of-pulmonary-large-cell-neuroendocrine-carcinoma-reveals-small-cell-carcinoma-like-and 2026-07-02T09:20:49.418Z https://research-2ry.pages.dev/Summary/Clinical-NEC/ClinCancerRes-2017-Miyoshi-Genomic-profiling-of-large-cell-neuroendocrine-carcinoma-of-the-lung 2026-07-02T09:20:49.415Z https://research-2ry.pages.dev/Summary/Clinical-NEC/ClinCancerRes-2018-Derks-Molecular-subtypes-of-pulmonary-large-cell-neuroendocrine-carcinoma-predict-chemotherapy-treatment-outcome 2026-07-02T09:20:49.419Z https://research-2ry.pages.dev/Summary/Clinical-NEC/ClinCancerRes-2020-Zhuo-The-prognostic-and-therapeutic-role-of-genomic-subtyping-by-sequencing-tumor-or-cell-free-DNA-in-pulmonary-large-cell 2026-07-02T09:20:49.416Z https://research-2ry.pages.dev/Summary/Clinical-NEC/ClinLungCancer-2016-Naidoo-LCNEC-of-the-lung 2026-07-02T09:20:49.419Z https://research-2ry.pages.dev/Summary/Clinical-NEC/EurRespirJ-2016-Derks-Clinical-features-of-large-cell-neuroendocrine-carcinoma-a-population-based-overview 2026-07-02T09:20:49.414Z https://research-2ry.pages.dev/Summary/Clinical-NEC/EurRespirJ-2017-Derks-Chemotherapy-for-pulmonary-large-cell-neuroendocrine-carcinomas-does-the-regimen-matter 2026-07-02T09:20:49.419Z https://research-2ry.pages.dev/Summary/Clinical-NEC/FrontOncol-2021-Fisch-Comprehensive-dissection-of-treatment-patterns-and-outcome-for-patients-with-metastatic-large-cell-neuroendocrine-lung 2026-07-02T09:20:49.422Z https://research-2ry.pages.dev/Summary/Clinical-NEC/IntJMolSci-2020-Tashiro-Heterogeneous-tumor-immune-microenvironments-between-primary-and-metastatic-tumors-in-a-patient-with-ALK 2026-07-02T09:20:49.416Z https://research-2ry.pages.dev/Summary/Clinical-NEC/JCOPrecisOncol-2025-Heijboer-Actionable-genomic-alterations-in-large-cell-neuroendocrine-carcinoma-A-european-case-series-of-patients-treated-with-a 2026-07-02T09:20:49.421Z https://research-2ry.pages.dev/Summary/Clinical-NEC/JClinOncol-2015-Kunz-Carcinoid-and-neuroendocrine-tumors-building-on-success 2026-07-02T09:20:49.414Z https://research-2ry.pages.dev/Summary/Clinical-NEC/JClinOncol-2020-Kenmotsu-Randomized-phase-III-study-of-irinotecan-plus-cisplatin-versus-etoposide-plus-cisplatin-for-completely-resected 2026-07-02T09:20:49.413Z https://research-2ry.pages.dev/Summary/Clinical-NEC/JImmunotherCancer-2021-Dudnik-Real-world-survival-outcomes-with-immune-checkpoint-inhibitors-in-large-cell-neuroendocrine-tumors-of-lung 2026-07-02T09:20:49.421Z https://research-2ry.pages.dev/Summary/Clinical-NEC/JNatlComprCancNetw-2006-Chen-Pulmonary-neuroendocrine-tumors-what-(little)-do-we-know 2026-07-02T09:20:49.422Z https://research-2ry.pages.dev/Summary/Clinical-NEC/JThoracOncol-2013-Niho-Combination-chemotherapy-with-irinotecan-and-cisplatin-for-large-cell-neuroendocrine-carcinoma-of-the-lung-a 2026-07-02T09:20:49.415Z https://research-2ry.pages.dev/Summary/Clinical-NEC/JThoracOncol-2015-Steuer-Atypical-carcinoid-tumor-of-the-lung-a-surveillance,-epidemiology,-and-end-results-database-analysis 2026-07-02T09:20:49.419Z https://research-2ry.pages.dev/Summary/Clinical-NEC/JThoracOncol-2022-Nicholson-The-2021-WHO-classification-of-lung-tumors-impact-of-advances-since-2015 2026-07-02T09:20:49.417Z https://research-2ry.pages.dev/Summary/Clinical-NEC/JpnJClinOncol-2014-Eba-A-phase-III-trial-comparing-irinotecan-and-cisplatin-with-etoposide-and-cisplatin-in-adjuvant-chemotherapy-for 2026-07-02T09:20:54.153Z https://research-2ry.pages.dev/Summary/Clinical-NEC/Lancet-2004-Jones-Two-prognostically-significant-subtypes-of-high-grade-lung-neuroendocrine-tumours-independent-of-small-cell-and 2026-07-02T09:20:49.413Z https://research-2ry.pages.dev/Summary/Clinical-NEC/LancetOncol-2025-Sen-Pulmonary-neuroendocrine-neoplasms-the-molecular-landscape,-therapeutic-challenges,-and-diagnosis-and-management 2026-07-02T09:20:49.414Z https://research-2ry.pages.dev/Summary/Clinical-NEC/LungCancer-2018-Christopoulos-Large-cell-neuroendocrine-lung-carcinoma-induces-peripheral-T-cell-repertoire-alterations-with-predictive-and 2026-07-02T09:20:49.422Z https://research-2ry.pages.dev/Summary/Clinical-NEC/LungCancer-2019-Hermans-Prevalence-and-prognostic-value-of-PD-L1-expression-in-molecular-subtypes-of-metastatic-large-cell-neuroendocrine-carcinoma-LCNEC 2026-07-02T09:20:49.417Z https://research-2ry.pages.dev/Summary/Clinical-NEC/LungCancer-2020-Hermans-Exploring-imaging-features-of-molecular-subtypes-of-large-cell-neuroendocrine-carcinoma-(LCNEC) 2026-07-02T09:20:49.416Z https://research-2ry.pages.dev/Summary/Clinical-NEC/LungCancer-2020-Sherman-Efficacy-of-immune-check-point-inhibitors-(ICPi)-in-large-cell-neuroendocrine-tumors-of-lung-(LCNEC) 2026-07-02T09:20:49.422Z https://research-2ry.pages.dev/Summary/Clinical-NEC/LungCancer-2025-Heijboer-Treatment-outcomes-in-patients-with-stage-IV-large-cell-neuroendocrine-carcinoma-a-nationwide-registry-study 2026-07-02T09:20:49.413Z https://research-2ry.pages.dev/Summary/Clinical-NEC/LungCancer-2025-Shirai-Epidemiology-and-clinical-course-of-large-cell-neuroendocrine-carcinoma-of-the-lung-the-japanese-lung-cancer-registry 2026-07-02T09:20:49.417Z https://research-2ry.pages.dev/Summary/Clinical-NEC/MedSciMonit-2019-Deng-Lung-large-cell-neuroendocrine-carcinoma-an-analysis-of-patients-from-the-surveillance,-epidemiology,-and-end-results 2026-07-02T09:20:49.421Z https://research-2ry.pages.dev/Summary/Clinical-NEC/ModPathol-2022-Rekhtman-Lung-neuroendocrine-neoplasms-recent-progress-and-persistent-challenges 2026-07-02T09:20:49.420Z https://research-2ry.pages.dev/Summary/Clinical-NEC/NatCommun-2018-George-Integrative-genomic-profiling-of-large-cell-neuroendocrine-carcinomas-reveals-distinct-subtypes-of-high-grade 2026-07-02T09:20:49.415Z https://research-2ry.pages.dev/Summary/Clinical-NEC/NatCommun-2025-Nassar-Integrated-molecular-and-clinical-characterization-of-pulmonary-large-cell-neuroendocrine-carcinoma 2026-07-02T09:20:49.420Z https://research-2ry.pages.dev/Summary/Clinical-NEC/NatGenet-2018-Alvarez-A-precision-oncology-approach-to-the-pharmacological-targeting-of-mechanistic-dependencies-in-neuroendocrine 2026-07-02T09:20:49.418Z https://research-2ry.pages.dev/Summary/Clinical-NEC/TranslLungCancerRes-2017-Hiroshima-Update-on-large-cell-neuroendocrine-carcinoma 2026-07-02T09:20:49.412Z https://research-2ry.pages.dev/Summary/Clinical-NEC/TranslLungCancerRes-2020-Lantuejoul-New-molecular-classification-of-large-cell-neuroendocrine-carcinoma-and-small-cell-lung-carcinoma-with-potential 2026-07-02T09:20:49.420Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/AmSocClinOncolEducBook-2017-Lovly-Managing-resistance-to-EFGR-and-ALK-targeted-therapies 2026-07-02T09:20:49.991Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/AnnOncol-2013-Shaw-Pemetrexed-based-chemotherapy-in-patients-with-advanced,-ALK-positive-non-small-cell-lung-cancer 2026-07-02T09:20:49.983Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/AnnOncol-2013-Ying-Diagnostic-value-of-a-novel-fully-automated-immunochimistry-assay-for-detection-of-ALK-rearrangement-in-primary-lung-adenocarcinoma 2026-07-02T09:20:49.990Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/AnnOncol-2014-Ou-Clinical-benefit-of-continuing-ALK-inhibition-with-crizotinib-beyond-initial-disease-progression-in-patients-with 2026-07-02T09:20:50.016Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/AnnOncol-2017-Woo-Differential-protein-stability-and-clinical-responses-of-EML4-ALK-fusion-variants-to-various-ALK-inhibitors-in-advanced 2026-07-02T09:20:49.994Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/AnnOncol-2018-Gadgeel-Alectinib-versus-crizotinib-in-treatment-naive-anaplastic-lymphoma-kinase-positive-(ALK+)-non-small-cell-lung-cancer 2026-07-02T09:20:50.009Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/AnnOncol-2018-Novello-Alectinib-versus-chemotherapy-in-crizotinib-pretreated-anaplastic-lymphoma-kinase-(ALK)-positive-non-small-cell-lung 2026-07-02T09:20:50.014Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/AnnOncol-2018-Soria-Correlation-of-extent-of-ALK-FISH-positivity-and-crizotinib-efficacy-in-three-prospective-studies-of-ALK-positive-patients-with-non-small-cell-lung-cancer 2026-07-02T09:20:50.008Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/AnnOncol-2020-Mok-Updated-overall-survival-and-final-progression-free-survival-data-for-patients-with-treatment-naive-advanced 2026-07-02T09:20:49.998Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/AnnOncol-2021-Felip-Intracranial-and-extracranial-efficacy-of-lorlatinib-in-patients-with-ALK-positive-non-small-cell-lung-cancer 2026-07-02T09:20:50.006Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/Cancer-2009-Wong-The-EML4-ALK-fusion-gene-is-involved-in-various-histologic-types-of-lung-cancers-from-nonsmokers-with-wild-type-EGFR 2026-07-02T09:20:49.981Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/Cancer-2012-Lee-Comparative-analyses-of-overall-survival-in-patients-with-anaplastic-lymphoma-kinase-positive-and-matched-wild-type 2026-07-02T09:20:50.011Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/CancerCell-2011-Sakamoto-CH5424802,-a-selective-ALK-inhibitor-capable-of-blocking-the-resistant-gatekeeper-mutant 2026-07-02T09:20:49.995Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/CancerCell-2015-Wilson-A-functional-landscape-of-resistance-to-ALK-inhibition-in-lung-cancer 2026-07-02T09:20:50.005Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/CancerCell-2015-Zou-PF-06463922,-an-ALKROS1-inhibitor,-overcomes-resistance-to-first-and-second-generation-ALK-inhibitors-in-preclinical 2026-07-02T09:20:49.986Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/CancerDiscov-2014-Friboulet-The-ALK-inhibitor-ceritinib-overcomes-crizotinib-resistance-in-non-small-cell-lung-cancer 2026-07-02T09:20:49.987Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/CancerDiscov-2016-Gainor-Molecular-mechanisms-of-resistance-to-first-and-second-generation-ALK-inhibitors-in-ALK-rearranged-lung-cancer 2026-07-02T09:20:49.999Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/CancerDiscov-2016-Infarinato-The-ALKROS1-inhibitor-PF-06463922-overcomes-primary-resistance-to-crizotinib-in-ALK-driven-neuroblastoma 2026-07-02T09:20:50.011Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/CancerDiscov-2017-Lin-Targeting-ALK-Precision-medicine-takes-on-drug-resistance 2026-07-02T09:20:49.985Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/CancerDiscov-2018-Yoda-Sequential-ALK-inhibitors-can-select-for-lorlatinib-resistant-compound-ALK-mutations-in-ALK-positive-lung-cancer 2026-07-02T09:20:50.000Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/CancerMetastasisRev-2015-Toyokawa-Insights-into-brain-metastasis-in-patients-with-ALK+-lung-cancer-is-the-brain-truly-a-sanctuary 2026-07-02T09:20:50.002Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/CancerRes-2007-Zou-An-orally-available-small-molecule-inhibitor-of-c-met,-PF-2341066,-exhibits-cytoreductive-antitumor-efficacy-through 2026-07-02T09:20:50.015Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/CancerRes-2008-Choi-Identification-of-novel-isoforms-of-the-EML4-ALK-transforming-gene-in-non-small-cell-lung-cancer 2026-07-02T09:20:49.987Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/CancerRes-2008-McDermott-Genomic-alterations-of-anaplastic-lymphoma-kinase-may-sensitize-tumors-to-anaplastic-lymphoma-kinase-inhibitors 2026-07-02T09:20:50.010Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/CancerRes-2018-Redaelli-Lorlatinib-treatment-elicits-multiple-on-and-off-target-mechanisms-of-resistance-in-ALK-driven-cancer 2026-07-02T09:20:50.007Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/CancerRes-2019-Fukuda-Epithelial-to-mesenchymal-transition-is-a-mechanism-of-ALK-inhibitor-resistance-in-lung-cancer-independent-of-ALK 2026-07-02T09:20:50.014Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/CancerSci-2008-Mano-Non-solid-oncogenes-in-solid-tumors-EML4-ALK-fusion-genes-in-lung-cancer 2026-07-02T09:20:50.015Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/CancerSci-2018-Hida-Phase-II-study-of-ceritinib-in-alectinib-pretreated-patients-with-anaplastic-lymphoma-kinase-rearranged-metastatic 2026-07-02T09:20:50.010Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/CancerSci-2018-Katayama-Drug-resistance-in-anaplastic-lymphoma-kinase-rearranged-lung-cancer 2026-07-02T09:20:49.989Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/CancerTreatRev-2014-Gridelli-ALK-inhibitors-in-the-treatment-of-advanced-NSCLC 2026-07-02T09:20:50.004Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/Cancers-2020-Ando-Brigatinib-and-alectinib-for-ALK-rearrangement-positive-NSCLC-with-or-without-CNS-metastasis 2026-07-02T09:20:49.998Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/ClinCancerRes-2008-Koivunen-EML4-ALK-fusion-gene-and-efficacy-of-an-ALK-kinase-inhibitor-in-lung-cancer 2026-07-02T09:20:49.993Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/ClinCancerRes-2008-Takeuchi-Multiplex-reverse-transcription-PCR-screening-for-EML4-ALK-fusion-transcripts 2026-07-02T09:20:49.984Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/ClinCancerRes-2009-Takeuchi-KIF5B-ALK,-a-Novel-Fusion-Oncokinase-Identified-by-an-Immunohistochemistry-based-Diagnostic-System-for-ALK-positive-Lung-Cancer 2026-07-02T09:20:49.984Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/ClinCancerRes-2010-Camidge-Optimizing-the-detection-of-lung-cancer-patients-harboring-anaplastic-lymphoma-kinase-(ALK)-gene-rearrangements 2026-07-02T09:20:49.987Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/ClinCancerRes-2011-Shaw-Targeting-anaplastic-lymphoma-kinase-in-lung-cancer 2026-07-02T09:20:50.004Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/ClinCancerRes-2012-Doebele-Mechanisms-of-resistance-to-crizotinib-in-patients-with-ALK-gene-rearranged-non-small-cell-lung-cancer 2026-07-02T09:20:50.009Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/ClinCancerRes-2013-Gainor-ALK-rearrangements-are-mutually-exclusive-with-mutations-in-EGFR-or-KRAS-an-analysis-of-1,683-patients-with-non-small 2026-07-02T09:20:49.997Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/ClinCancerRes-2014-Katayama-Two-novel-ALK-mutations-mediate-acquired-resistance-to-the-next-generation-ALK-inhibitor-alectinib 2026-07-02T09:20:49.985Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/ClinCancerRes-2015-Gainor-Progression-free-and-overall-survival-in-ALK-positive-NSCLC-patients-treated-with-sequential-crizotinib-and-ceritinib 2026-07-02T09:20:49.988Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/ClinCancerRes-2016-Zhang-The-potent-ALK-inhibitor-brigatinib-(AP26113)-overcomes-mechanisms-of-resistance-to-first-and-second-generation-ALK 2026-07-02T09:20:49.989Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/ClinCancerRes-2018-McCoach-Clinical-utility-of-cell-free-DNA-for-the-detection-of-ALK-fusions-and-genomic-mechanisms-of-ALK-inhibitor-resistance 2026-07-02T09:20:49.992Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/ClinCancerRes-2018-McCoach-Resistance-mechanisms-to-targeted-therapies-in-ROS1+-and-ALK+-non-small-cell-lung-cancer 2026-07-02T09:20:50.005Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/ClinCancerRes-2019-Pailler-Acquired-resistance-mutations-to-ALK-inhibitors-identified-by-single-circulating-tumor-cell-sequencing-in 2026-07-02T09:20:49.997Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/ClinCancerRes-2020-Dagogo-Jack-MET-alterations-are-a-recurring-and-actionable-resistance-mechanism-in-ALK-positive-lung-cancer 2026-07-02T09:20:50.012Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/ClinCancerRes-2020-Recondo-Diverse-resistance-mechanisms-to-the-third-generation-ALK-inhibitor-lorlatinib-in-ALK-rearranged-lung-cancer 2026-07-02T09:20:50.013Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/ClinCancerRes-2021-Tanimoto-Proteasome-inhibition-overcomes-ALK-TKI-resistance-in-ALK-RearrangedTP53-mutant-NSCLC-via-noxa-expression 2026-07-02T09:20:49.992Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/ClinLungCancer-2016-Matikas-Management-of-resistance-to-crizotinib-in-anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer 2026-07-02T09:20:50.016Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/ClinLungCancer-2016-Watanabe-Progression-free-and-overall-survival-of-patients-with-ALK-rearrangement-positive-non-small-cell-lung-cancer-treated 2026-07-02T09:20:50.003Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/ClinLungCancer-2017-Asao-Sequential-use-of-anaplastic-lymphoma-kinase-inhibitors-in-japanese-patients-with-ALK-rearranged-non-small-cell-lung 2026-07-02T09:20:50.015Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/ERJOpenRes-2018-Cadranel-Real-life-experience-of-ceritinib-in-crizotinib-pretreated-ALK+-advanced-non-small-cell-lung-cancer-patients 2026-07-02T09:20:49.985Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/EurJCancer-2021-Ito-Sequential-therapy-of-crizotinib-followed-by-alectinib-for-non-small-cell-lung-cancer-harbouring-anaplastic-lymphoma 2026-07-02T09:20:49.998Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/ExpertOpinInvestigDrugs-2014-Jhaveri-Heat-shock-protein-90-inhibitors-in-the-treatment-of-cancer-current-status-and-future-directions 2026-07-02T09:20:50.011Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/FutureOncol-2020-Lin-Real-world-treatment-duration-in-ALK-positive-non-small-cell-lung-cancer-patients-receiving-brigatinib-through-the 2026-07-02T09:20:49.995Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/FutureOncol-2021-Kim-ALTA-2-phase-II-study-of-brigatinib-in-patients-with-ALK-positive,-advanced-non-small-cell-lung-cancer-who-progressed 2026-07-02T09:20:49.982Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/IASLC-2016-Tsao-Atlas-of-ALK-and-ROS1-Testing-in-Lung-Cancer-Second-Edition 2026-07-02T09:20:50.017Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JCOGlobOncol-2026-Mascarenhas-Current-access-to-anaplastic-lymphoma-kinase-testing-and-targeted-therapies-for-non-small-cell-lung-cancer-in-brazil 2026-07-02T09:20:50.010Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JClinOncol-2009-Horn-EML4-ALK-honing-in-on-a-new-target-in-non-small-cell-lung-cancer 2026-07-02T09:20:49.992Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JClinOncol-2009-Shaw-Clinical-features-and-outcome-of-patients-with-non-small-cell-lung-cancer-who-harbor-EML4-ALK 2026-07-02T09:20:49.996Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JClinOncol-2011-Costa-CSF-concentration-of-the-anaplastic-lymphoma-kinase-inhibitor-crizotinib 2026-07-02T09:20:50.005Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JClinOncol-2015-Costa-Clinical-experience-with-crizotinib-in-patients-with-advanced-ALK-rearranged-non-small-cell-lung-cancer-and-brain 2026-07-02T09:20:49.982Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JClinOncol-2016-Crino-Multicenter-phase-II-study-of-whole-body-and-intracranial-activity-with-ceritinib-in-patients-with-ALK-rearranged 2026-07-02T09:20:49.987Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JClinOncol-2016-Johung-Extended-survival-and-prognostic-factors-for-patients-with-ALK-rearranged-non-small-cell-lung-cancer-and-brain 2026-07-02T09:20:50.018Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JClinOncol-2016-Ou-Alectinib-in-crizotinib-refractory-ALK-rearranged-non-small-cell-lung-cancer-A-phase-II-global-study 2026-07-02T09:20:49.995Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JClinOncol-2016-Yoshida-Differential-crizotinib-response-duration-among-ALK-fusion-variants-in-ALK-positive-non-small-cell-lung-cancer 2026-07-02T09:20:50.013Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JClinOncol-2017-Kim-Brigatinib-in-patients-with-crizotinib-refractory-anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer-A 2026-07-02T09:20:49.997Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JClinOncol-2017-Tamura-Three-year-follow-up-of-an-alectinib-phase-III-study-in-ALK-positive-non-small-cell-lung-cancer-AF-001jp 2026-07-02T09:20:50.008Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JClinOncol-2018-Lin-Impact-of-EML4-ALK-variant-on-resistance-mechanisms-and-clinical-outcomes-in-ALK-positive-lung-cancer 2026-07-02T09:20:49.983Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JClinOncol-2018-Solomon-Final-overall-survival-analysis-from-a-study-comparing-first-line-crizotinib-versus-chemotherapy-in 2026-07-02T09:20:50.004Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JClinOncol-2019-Shaw-ALK-resistance-mutations-and-efficacy-of-lorlatinib-in-advanced-anaplastic-lymphoma-kinase-positive-non-small-cell-lung 2026-07-02T09:20:49.991Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JClinOncol-2020-Camidge-Brigatinib-versus-crizotinib-in-advanced-ALK-inhibitor-naive-ALK-positive-non-small-cell-lung-cancer-second-interim 2026-07-02T09:20:49.984Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JClinOncol-2024-Solomon-Lorlatinib-versus-crizotinib-in-patients-with-advanced-ALK-positive-non-small-cell-lung-cancer-5-year-outcomes-from-the 2026-07-02T09:20:50.000Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JMedChem-2011-Cui-Structure-based-drug-design-of-crizotinib-(PF-02341066),-a-potent-and-selective-dual-inhibitor-of 2026-07-02T09:20:49.989Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JThoracOncol-2008-Inamura-EML4-ALK-fusion-is-linked-to-histological-characteristics-in-a-subset-of-lung-cancers 2026-07-02T09:20:49.990Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JThoracOncol-2010-Ou-Rapid-and-dramatic-radiographic-and-clinical-response-to-an-ALK-inhibitor-(crizotinib,-PF02341066)-in-an-ALK 2026-07-02T09:20:50.002Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JThoracOncol-2011-Camidge-Anaplastic-lymphoma-kinase-gene-rearrangements-in-non-small-cell-lung-cancer-are-associated-with-prolonged 2026-07-02T09:20:49.992Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JThoracOncol-2013-Conklin-Immunohistochemistry-is-a-reliable-screening-tool-for-identification-of-ALK-rearrangement-in-non-small-cell-lung 2026-07-02T09:20:49.981Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JThoracOncol-2013-Srivastava-Esophagitis-a-novel-adverse-event-of-crizotinib-in-a-patient-with-ALK-positive-non-small-cell-lung-cancer 2026-07-02T09:20:49.986Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JThoracOncol-2015-Nishio-Phase-I-study-of-ceritinib-(LDK378)-in-japanese-patients-with-advanced,-anaplastic-lymphoma-kinase-rearranged 2026-07-02T09:20:49.985Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JThoracOncol-2016-Janne-Combined-pan-HER-and-ALKROS1MET-inhibition-with-dacomitinib-and-crizotinib-in-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:49.994Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JThoracOncol-2017-Cho-ASCEND-8-A-randomized-phase-1-study-of-ceritinib,-450-mg-or-600-mg,-taken-with-a-low-fat-meal-versus-750-mg-in-fasted 2026-07-02T09:20:50.002Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JThoracOncol-2017-Ito-Sequential-therapy-with-crizotinib-and-alectinib-in-ALK-rearranged-non-small-cell-lung-cancer-A-multicenter 2026-07-02T09:20:49.993Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JThoracOncol-2019-Camidge-Management-strategies-for-early-onset-pulmonary-events-associated-with-brigatinib 2026-07-02T09:20:49.983Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JThoracOncol-2019-Camidge-Updated-efficacy-and-safety-data-and-impact-of-the-EML4-ALK-fusion-variant-on-the-efficacy-of-alectinib-in-untreated 2026-07-02T09:20:50.004Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JThoracOncol-2019-Cho-Efficacy-and-safety-of-ceritinib-(450-mgd-or-600-mgd)-with-food-versus-750-mgd-fasted-in-patients-with-ALK-receptor 2026-07-02T09:20:50.003Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JThoracOncol-2019-Gemma-Interstitial-lung-disease-onset-and-its-risk-factors-in-japanese-patients-with-ALK-positive-NSCLC-after-treatment-with 2026-07-02T09:20:49.999Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JThoracOncol-2019-Makimoto-Rapid-acquisition-of-alectinib-resistance-in-ALK-positive-lung-cancer-with-high-tumor-mutation-burden 2026-07-02T09:20:50.006Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JThoracOncol-2020-Arai-Osimertinib-overcomes-alectinib-resistance-caused-by-amphiregulin-in-a-leptomeningeal-carcinomatosis-model-of 2026-07-02T09:20:50.005Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JThoracOncol-2020-Felip-Ceritinib-plus-nivolumab-in-patients-with-advanced-ALK-rearranged-non-small-cell-lung-cancer-results-of-an-open-label, 2026-07-02T09:20:49.994Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JThoracOncol-2020-Huber-Brigatinib-in-crizotinib-refractory-ALK+-NSCLC-2-year-follow-up-on-systemic-and-intracranial-outcomes-in-the-phase-2 2026-07-02T09:20:50.000Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JThoracOncol-2020-Lin-Efficacy-of-PlatinumPemetrexed-combination-chemotherapy-in-ALK-positive-NSCLC-refractory-to-second-generation-ALK 2026-07-02T09:20:50.008Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JThoracOncol-2020-Ng-Early-onset-pulmonary-events-associated-with-brigatinib-use-in-advanced-NSCLC 2026-07-02T09:20:50.013Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JThoracOncol-2020-Nishio-Final-overall-survival-and-other-efficacy-and-safety-results-from-ASCEND-3-phase-II-study-of-ceritinib-in-ALKi-naive 2026-07-02T09:20:50.011Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JThoracOncol-2021-Camidge-Brigatinib-versus-crizotinib-in-ALK-inhibitor-naive-advanced-ALK-positive-NSCLC-final-results-of-phase-3-ALTA-1l-trial 2026-07-02T09:20:49.990Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JThoracOncol-2021-Nishio-Brigatinib-in-japanese-patients-with-ALK-positive-NSCLC-previously-treated-with-alectinib-and-other-tyrosine-kinase 2026-07-02T09:20:50.016Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JpnJClinOncol-2018-Kiura-Phase-3-study-of-ceritinib-vs-chemotherapy-in-ALK-rearranged-NSCLC-patients-previously-treated-with-chemotherapy-and 2026-07-02T09:20:50.003Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/JpnJClinOncol-2021-Naito-Brigatinib-and-lorlatinib-their-effect-on-ALK-inhibitors-in-NSCLC-focusing-on-resistant-mutations-and-central-nervous 2026-07-02T09:20:50.009Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/Lancet-2017-Hida-Alectinib-versus-crizotinib-in-patients-with-ALK-positive-non-small-cell-lung-cancer-(J-ALEX)-an-open-label,-randomised 2026-07-02T09:20:50.012Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/Lancet-2017-Soria-First-line-ceritinib-versus-platinum-based-chemotherapy-in-advanced-ALK-rearranged-non-small-cell-lung-cancer 2026-07-02T09:20:49.996Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/LancetOncol-2011-Shaw-Effect-of-crizotinib-on-overall-survival-in-patients-with-advanced-non-small-cell-lung-cancer-harbouring-ALK-gene 2026-07-02T09:20:49.999Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/LancetOncol-2012-Camidge-Activity-and-safety-of-crizotinib-in-patients-with-ALK-positive-non-small-cell-lung-cancer-updated-results-from-a-phase 2026-07-02T09:20:49.991Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/LancetOncol-2013-Seto-CH5424802-(RO5424802)-for-patients-with-ALK-rearranged-advanced-non-small-cell-lung-cancer-(AF-001jp-study)-a 2026-07-02T09:20:50.006Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/LancetOncol-2013-Yang-A-selective-ALK-inhibitor-in-ALK-rearranged-patients 2026-07-02T09:20:50.007Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/LancetOncol-2014-Gadgeel-Safety-and-activity-of-alectinib-against-systemic-disease-and-brain-metastases-in-patients-with-crizotinib-resistant 2026-07-02T09:20:49.988Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/LancetOncol-2016-Gettinger-Activity-and-safety-of-brigatinib-in-ALK-rearranged-non-small-cell-lung-cancer-and-other-malignancies-a-single-arm, 2026-07-02T09:20:49.982Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/LancetOncol-2016-Kim-Activity-and-safety-of-ceritinib-in-patients-with-ALK-rearranged-non-small-cell-lung-cancer-(ASCEND-1)-updated-results 2026-07-02T09:20:50.008Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/LancetOncol-2016-Shaw-Alectinib-in-ALK-positive,-crizotinib-resistant,-non-small-cell-lung-cancer-a-single-group,-multicentre,-phase-2-trial 2026-07-02T09:20:54.301Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/LancetOncol-2017-Shaw-Ceritinib-versus-chemotherapy-in-patients-with-ALK-rearranged-non-small-cell-lung-cancer-previously-given-chemotherapy 2026-07-02T09:20:49.991Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/LancetOncol-2017-Shaw-Lorlatinib-in-non-small-cell-lung-cancer-with-ALK-or-ROS1-rearrangement-an-international,-multicentre,-open-label, 2026-07-02T09:20:54.305Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/LancetRespirMed-2019-Zhou-Alectinib-versus-crizotinib-in-untreated-asian-patients-with-anaplastic-lymphoma-kinase-positive-non-small-cell-lung 2026-07-02T09:20:49.996Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/LancetRespirMed-2020-Yang-Efficacy,-safety,-and-biomarker-analysis-of-ensartinib-in-crizotinib-resistant,-ALK-positive-non-small-cell-lung-cancer 2026-07-02T09:20:50.001Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/LungCancer-2015-Chiari-Clinical-impact-of-sequential-treatment-with-ALK-TKIs-in-patients-with-advanced-ALK-positive-non-small-cell-lung-cancer 2026-07-02T09:20:50.012Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/LungCancer-2015-Chino-Successful-treatment-with-alectinib-after-crizotinib-induced-ILD 2026-07-02T09:20:50.017Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/LungCancer-2016-Yoshida-Clinical-impact-of-crizotinib-on-central-nervous-system-progression-in-ALK-positive-non-small-lung-cancer 2026-07-02T09:20:49.996Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/LungCancer-2017-Califano-Management-of-ceritinib-therapy-and-adverse-events-in-patients-with-ALK-rearranged-non-small-cell-lung-cancer 2026-07-02T09:20:54.309Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/LungCancer-2018-Nishio-Analysis-of-central-nervous-system-efficacy-in-the-J-ALEX-study-of-alectinib-versus-crizotinib-in-ALK-positive 2026-07-02T09:20:50.011Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/LungCancer-2019-Descourt-Brigatinib-in-patients-with-ALK-positive-advanced-non-small-cell-lung-cancer-pretreated-with-sequential-ALK-inhibitors 2026-07-02T09:20:49.988Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/LungCancer-2020-Nakagawa-Final-progression-free-survival-results-from-the-J-ALEX-study-of-alectinib-versus-crizotinib-in-ALK-positive 2026-07-02T09:20:49.991Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/ModPathol-2013-Selinger-Testing-for-ALK-rearrangement-in-lung-adenocarcinoma-a-multicenter-comparison-of-immunohistochemistry-and-fluorescent 2026-07-02T09:20:50.002Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/NEnglJMed-2010-Choi-EML4-ALK-mutations-in-lung-cancer-that-confer-resistance-to-ALK-inhibitors 2026-07-02T09:20:50.010Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/NEnglJMed-2010-Kwak-Anaplastic-lymphoma-kinase-inhibition-in-non-small-cell-lung-cancer 2026-07-02T09:20:49.982Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/NEnglJMed-2013-Shaw-Crizotinib-versus-chemotherapy-in-advanced-ALK-positive-lung-cancer 2026-07-02T09:20:50.016Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/NEnglJMed-2014-Shaw-Ceritinib-in-ALK-rearranged-non-small-cell-lung-cancer 2026-07-02T09:20:54.321Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/NEnglJMed-2014-Solomon-First-line-crizotinib-versus-chemotherapy-in-ALK-positive-lung-cancer 2026-07-02T09:20:49.994Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/NEnglJMed-2016-Shaw-Resensitization-to-crizotinib-by-the-lorlatinib-ALK-resistance-mutation-L1198F 2026-07-02T09:20:50.001Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/NEnglJMed-2017-Peters-Alectinib-versus-crizotinib-in-untreated-ALK-positive-non-small-cell-lung-cancer 2026-07-02T09:20:50.014Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/NEnglJMed-2018-Camidge-Brigatinib-versus-crizotinib-in-ALK-positive-non-small-cell-lung-cancer 2026-07-02T09:20:49.983Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/NEnglJMed-2020-Shaw-First-line-lorlatinib-or-crizotinib-in-advanced-ALK-positive-lung-cancer 2026-07-02T09:20:50.009Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/NatCommun-2019-Trigg-The-targetable-kinase-PIM1-drives-ALK-inhibitor-resistance-in-high-risk-neuroblastoma-independent-of-MYCN-status 2026-07-02T09:20:50.013Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/NatMed-2014-Lovly-Rationale-for-co-targeting-IGF-1R-and-ALK-in-ALK-fusion-positive-lung-cancer 2026-07-02T09:20:50.007Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/NatMed-2018-Dardaei-SHP2-inhibition-restores-sensitivity-in-ALK-rearranged-non-small-cell-lung-cancer-resistant-to-ALK-inhibitors 2026-07-02T09:20:49.990Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/Nature-2007-Soda-Identification-of-the-transforming-EML4-ALK-fusion-gene-in-non-small-cell-lung-cancer 2026-07-02T09:20:50.008Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/OncoImmunology-2016-Hong-Upregulation-of-PD-L1-by-EML4-ALK-fusion-protein-mediates-the-immune-escape-in-ALK-positive-NSCLC-implication-for 2026-07-02T09:20:49.981Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/OncoImmunology-2016-Koh-EML4-ALK-enhances-programmed-cell-death-ligand-1-expression-in-pulmonary-adenocarcinoma-via-hypoxia-inducible-factor 2026-07-02T09:20:49.993Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/Oncologist-2020-Jahanzeb-Real-world-treatment-patterns-and-progression-free-survival-associated-with-anaplastic-lymphoma-kinase-(ALK)-tyrosine 2026-07-02T09:20:49.998Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/Oncotarget-2017-Duruisseaux-Overall-survival-with-crizotinib-and-next-generation-ALK-inhibitors-in-ALK-positive-non-small-cell-lung-cancer 2026-07-02T09:20:50.017Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/ProcNatlAcadSciUSA-2011-Katayama-Therapeutic-strategies-to-overcome-crizotinib-resistance-in-non-small-cell-lung-cancers-harboring-the-fusion-oncogene 2026-07-02T09:20:49.993Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/SciRep-2020-Kaneda-Ceritinib-in-japanese-patients-with-anaplastic-lymphoma-kinase-(ALK)+-non-small-cell-lung-cancer-interim-analysis 2026-07-02T09:20:50.001Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ALK/SciTranslMed-2012-Katayama-Mechanisms-of-acquired-crizotinib-resistance-in-ALK-rearranged-lung-cancers 2026-07-02T09:20:49.986Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/AnnOncol-2002-Rosell-Phase-III-randomised-trial-comparing-paclitaxelcarboplatin-with-paclitaxelcisplatin-in-patients-with-advanced 2026-07-02T09:20:49.881Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/AnnOncol-2004-Gridelli-Treatment-of-advanced-non-small-cell-lung-cancer-patients-with-ECOG-performance-status-2-results-of-an-european-experts 2026-07-02T09:20:49.890Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/AnnOncol-2005-Nakagawa-A-randomized-phase-III-trial-of-adjuvant-chemotherapy-with-UFT-for-completely-resected-pathological-stage-I 2026-07-02T09:20:54.345Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/AnnOncol-2006-Gridelli-Chemotherapy-of-advanced-NSCLC-in-special-patient-population 2026-07-02T09:20:49.851Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/AnnOncol-2007-Ohe-Randomized-phase-III-study-of-cisplatin-plus-irinotecan-versus-carboplatin-plus-paclitaxel,-cisplatin-plus-gemcitabine, 2026-07-02T09:20:49.881Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/AnnOncol-2010-Reck-Overall-survival-with-cisplatin-gemcitabine-and-bevacizumab-or-placebo-as-first-line-therapy-for-nonsquamous 2026-07-02T09:20:49.860Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/AnnOncol-2013-Socinski-Safety-and-efficacy-analysis-by-histology-of-weekly-nab-paclitaxel-in-combination-with-carboplatin-as-first-line 2026-07-02T09:20:49.879Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/AnnOncol-2013-Yoshioka-Efficacy-and-safety-analysis-according-to-histology-for-S-1-in-combination-with-carboplatin-as-first-line-chemotherapy 2026-07-02T09:20:49.896Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/AnnOncol-2014-Rotolo-Adjuvant-cisplatin-based-chemotherapy-in-nonsmall-cell-lung-cancer-new-insights-into-the-effect-on-failure-type-via-a 2026-07-02T09:20:49.841Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/AnnOncol-2015-Eberhardt-2nd-ESMO-consensus-conference-in-lung-cancer-locally-advanced-stage-III-non-small-cell-lung-cancer 2026-07-02T09:20:54.353Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/AnnOncol-2015-Kubota-A-randomized-phase-III-trial-of-oral-S-1-plus-cisplatin-versus-docetaxel-plus-cisplatin-in-japanese-patients-with 2026-07-02T09:20:49.907Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/AnnOncol-2015-Li-Randomized-phase-III-trial-of-prophylactic-cranial-irradiation-versus-observation-in-patients-with-fully-resected-stage 2026-07-02T09:20:49.906Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/AnnOncol-2015-Malhotra-Adjuvant-chemotherapy-for-elderly-patients-with-stage-I-non-small-cell-lung-cancer-4-cm-in-size-an-SEER-medicare 2026-07-02T09:20:49.876Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/AnnOncol-2016-Chatterjee-Systematic-evaluation-of-pembrolizumab-dosing-in-patients-with-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:49.865Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/AnnOncol-2016-Kanda-Safety-and-efficacy-of-nivolumab-and-standard-chemotherapy-drug-combination-in-patients-with-advanced-non-small-cell 2026-07-02T09:20:49.855Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/AnnOncol-2016-Paz-Ares-Correlation-of-EGFR-expression-with-safety-and-efficacy-outcomes-in-SQUIRE-a-randomized,-multicenter,-open-label,-phase 2026-07-02T09:20:49.842Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/AnnOncol-2017-Nokihara-Randomized-controlled-trial-of-S-1-versus-docetaxel-in-patients-with-non-small-cell-lung-cancer-previously-treated-with 2026-07-02T09:20:49.937Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/AnnOncol-2017-Tang-Comprehensive-evaluation-of-published-gene-expression-prognostic-signatures-for-biomarker-based-lung-cancer-clinical 2026-07-02T09:20:49.894Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/AnnOncol-2018-Planchard-Metastatic-non-small-cell-lung-cancer-ESMO-clinical-practice-guidelines-for-diagnosis,-treatment-and-follow-up 2026-07-02T09:20:49.852Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/AnnOncol-2021-Rodriguez-Abreu-Pemetrexed-plus-platinum-with-or-without-pembrolizumab-in-patients-with-previously-untreated-metastatic-nonsquamous 2026-07-02T09:20:49.904Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/AnnSurgOncol-2015-Berry-Benefit-of-adjuvant-chemotherapy-after-resection-of-stage-II-(T1-2n1m0)-non-small-cell-lung-cancer-in-elderly-patients 2026-07-02T09:20:49.892Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/AnnThoracSurg-2012-Taylor-Tumor-recurrence-after-complete-resection-for-non-small-cell-lung-cancer 2026-07-02T09:20:49.893Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/AnnThoracSurg-2017-Chaft-Initial-experience-with-lung-cancer-resection-after-treatment-with-T-cell-checkpoint-inhibitors 2026-07-02T09:20:49.899Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/AnnThoracSurg-2018-Tanaka-Induction-chemoradiotherapy-(50-gy),-followed-by-resection,-for-stage-IIIA-N2-non-small-cell-lung-cancer 2026-07-02T09:20:54.377Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/AnnThoracSurg-2019-Spicer-Multimodality-therapy-for-N2-non-small-cell-lung-cancer-an-evolving-paradigm 2026-07-02T09:20:49.870Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/AnticancerRes-2019-Harada-Previous-immune-checkpoint-inhibitor-treatment-to-increase-the-efficacy-of-docetaxel-and-ramucirumab-combination 2026-07-02T09:20:49.907Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/BMCCancer-2020-Kaira-A-phase-II-study-of-daily-carboplatin-plus-irradiation-followed-by-durvalumab-for-stage-III-non-small-cell-lung-cancer 2026-07-02T09:20:49.937Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/BMCResNotes-2015-Tamura-Retrospective-analysis-of-the-efficacy-of-chemotherapy-and-molecular-targeted-therapy-for-advanced-pulmonary 2026-07-02T09:20:49.843Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/BMJ-1995-NSCLCMetaAnalyses-Chemotherapy-in-non-small-cell-lung-cancer-a-meta-analysis-using-updated-data-on-individual-patients 2026-07-02T09:20:49.842Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/BMJ-2011-Wisnivesky-Survival-and-risk-of-adverse-events-in-older-patients-receiving-postoperative-adjuvant-chemotherapy-for-resected-stages 2026-07-02T09:20:49.842Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/BrJCancer-2000-Anderson-Gemcitabine-plus-best-supportive-care-(BSC)-vs-BSC-in-inoperable-non-small-cell-lung-cancer-a-randomized-trial-with 2026-07-02T09:20:49.885Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/BrJCancer-2000-Gregory-Vinorelbine-a-clinical-review 2026-07-02T09:20:49.874Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/Cancer-2001-Sweeney-Outcome-of-patients-with-a-performance-status-of-2-in-eastern-cooperative-oncology-group-study-E1594-a-phase-II-trial 2026-07-02T09:20:49.918Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/Cancer-2012-Katakami-A-phase-3-study-of-induction-treatment-with-concurrent-chemoradiotherapy-versus-chemotherapy-before-surgery-in-patients 2026-07-02T09:20:49.861Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/Cancer-2026-Kim-Fianlimab,-a-human-lymphocyte-activation-gene-3-monoclonal-antibody,-in-combination-with-cemiplimab-tumor-specific 2026-07-02T09:20:49.845Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/CancerCell-2019-Trinh-Tumor-neoantigens-When-too-much-of-a-good-thing-is-bad 2026-07-02T09:20:49.936Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/CancerDiscov-2017-Anagnostou-Evolution-of-neoantigen-landscape-during-immune-checkpoint-blockade-in-non-small-cell-lung-cancer 2026-07-02T09:20:49.880Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/CancerDiscov-2018-Skoulidis-STK11LKB1-mutations-and-PD-1-inhibitor-resistance-in-KRAS-mutant-lung-adenocarcinoma 2026-07-02T09:20:54.397Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/CancerDiscov-2020-Sha-Tumor-mutational-burden-as-a-predictive-biomarker-in-solid-tumors 2026-07-02T09:20:49.883Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/CancerDiscov-2022-Hanahan-Hallmarks-of-cancer-New-Dimensions 2026-07-02T09:20:49.893Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/CancerImmunolImmunother-2020-Ozaki-Tumor-mutation-burden-and-immunological,-genomic,-and-clinicopathological-factors-as-biomarkers-for-checkpoint 2026-07-02T09:20:49.897Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/CancerImmunolImmunother-2021-Amrein-Chemotherapy-negatively-impacts-the-tumor-immune-microenvironment-in-NSCLC-SAKK19-09-study 2026-07-02T09:20:49.841Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/CancerImmunolImmunother-2026-Chien-Smoking-associated-modulation-of-gut-microbiota-shapes-response-to-immune-checkpoint-inhibitors-in-non-small-cell-lung-cancer 2026-07-02T09:20:49.853Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/CancerImmunolRes-2014-Ayyoub-Assessment-of-MAGE-A-expression-in-resected-non-small-cell-lung-cancer-in-relation-to-clinicopathologic-features-and 2026-07-02T09:20:49.934Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/CancerSci-2004-Sekine-Phase-I-study-of-cisplatin,-vinorelbine,-and-concurrent-thoracic-radiotherapy-for-unresectable-stage-III-non-small-cell 2026-07-02T09:20:49.868Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/CancerSci-2021-Nishio-IMpower132-Atezolizumab-plus-platinum-based-chemotherapy-vs-chemotherapy-for-advanced-NSCLC-in-Japanese-patients 2026-07-02T09:20:49.901Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/CancerSci-2021-Sakai-Tumor-mutation-burden-as-a-biomarker-for-lung-cancer-patients-treated-with-pemetrexed-and-cisplatin-(the-JIPANG-TR) 2026-07-02T09:20:49.931Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/CancerSci-2021-Satouchi-First-line-pembrolizumab-vs-chemotherapy-in-metastatic-non-small-cell-lung-cancer-KEYNOTE-024-japan-subset 2026-07-02T09:20:49.910Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/CancerSci-2026-Shimizu-Atezolizumab-+-chemotherapy-in-older-patients-with-lung-cancer-in-japan 2026-07-02T09:20:49.917Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/CancerTreatRev-2026-Marinelli-PD-(l)1-containing-rechallenge-strategies-in-patients-with-advanced-NSCLC-previously-treated-with-immunotherapy-A 2026-07-02T09:20:49.885Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/CellRepMed-2024-Altorki-A-signature-of-enhanced-proliferation-associated-with-response-and-survival-to-anti-PD-L1-therapy-in-early-stage 2026-07-02T09:20:49.867Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ClinCancerRes-2006-Desai-Increased-antitumor-activity,-intratumor-paclitaxel-concentrations,-and-endothelial-cell-transport-of-cremophor-free, 2026-07-02T09:20:49.858Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ClinCancerRes-2015-Anagnostou-Cancer-immunotherapy-a-future-paradigm-shift-in-the-treatment-of-non-small-cell-lung-cancer 2026-07-02T09:20:49.887Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ClinCancerRes-2015-vanElsas-Translating-pembrolizumab-to-clinical-practice-speak-immunology-and-learn-fast! 2026-07-02T09:20:49.917Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ClinCancerRes-2017-Ratcliffe-Agreement-between-programmed-cell-death-ligand-1-diagnostic-assays-across-multiple-protein-expression-cutoffs-in 2026-07-02T09:20:49.916Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ClinCancerRes-2018-Biton-TP53,-STK11,-and-EGFR-mutations-predict-tumor-immune-profile-and-the-response-to-anti-PD-1-in-lung-adenocarcinoma 2026-07-02T09:20:49.882Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ClinCancerRes-2018-Kim-Abemaciclib-in-combination-with-single-agent-options-in-patients-with-stage-IV-non-small-cell-lung-cancer-A-phase-ib 2026-07-02T09:20:49.892Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ClinCancerRes-2018-McCall-Beyond-concurrent-chemoradiation-the-emerging-role-of-PD-1pd-L1-inhibitors-in-stage-III-lung-cancer 2026-07-02T09:20:49.882Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ClinCancerRes-2019-Doroshow-Immunotherapy-in-non-small-cell-lung-cancer-facts-and-hopes 2026-07-02T09:20:49.933Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ClinCancerRes-2021-Harding-Blocking-TIM-3-in-treatment-refractory-advanced-solid-tumors-A-phase-iab-study-of-LY3321367-with-or-without-an 2026-07-02T09:20:49.903Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ClinCancerRes-2021-Hellmann-Entinostat-plus-pembrolizumab-in-patients-with-metastatic-NSCLC-previously-treated-with-anti-PD-(l)1-therapy 2026-07-02T09:20:49.856Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ClinCancerRes-2022-Hummelink-PD-1t-TILs-as-a-predictive-biomarker-for-clinical-benefit-to-PD-1-blockade-in-patients-with-advanced-NSCLC 2026-07-02T09:20:49.916Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ClinCancerRes-2022-Rocha-Distinct-immune-gene-programs-associated-with-host-tumor-immunity,-neoadjuvant-chemotherapy,-and-chemoimmunotherapy-in 2026-07-02T09:20:49.919Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ClinCancerRes-2026-Borghaei-Early-detriment-analysis-of-first-line-nivolumab-plus-ipilimumab-based-therapy-in-patients-with-metastatic-non-small 2026-07-02T09:20:49.866Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ClinCancerRes-2026-Vujanovic-Tumoral-and-systemic-immune-correlates-of-response-to-concurrent-pembrolizumab-and-chemoradiotherapy-in-patients-with 2026-07-02T09:20:49.878Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ClinCancerRes-2026-Zamulko-A-phase-2-feasibility-study-combining-pembrolizumab-and-metformin-in-patients-with-metastatic-head-and-neck-cancer 2026-07-02T09:20:49.841Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ClinLungCancer-2011-Galetta-Induction-pemetrexed-and-cisplatin-followed-by-maintenance-pemetrexed-versus-carboplatin-plus-paclitaxel-plus 2026-07-02T09:20:49.879Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ClinLungCancer-2013-Paramanathan-Patients-treated-with-platinum-doublet-chemotherapy-for-advanced-non-small-cell-lung-cancer-have-inferior-outcomes-if 2026-07-02T09:20:49.915Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ClinLungCancer-2015-Galetta-CisplatinPemetrexed-followed-by-maintenance-pemetrexed-versus-CarboplatinPaclitaxelBevacizumab-followed-by-maintenance 2026-07-02T09:20:49.882Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ClinLungCancer-2017-Nakamichi-Comparison-of-radiotherapy-and-chemoradiotherapy-for-locoregional-recurrence-of-non-small-cell-lung-cancer-developing 2026-07-02T09:20:49.855Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ClinLungCancer-2017-Shiran-Non-small-cell-lung-cancer-patients-with-adenocarcinoma-morphology-have-a-better-outcome-compared-with-patients 2026-07-02T09:20:49.856Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ClinLungCancer-2018-Atagi-Chemoradiotherapy-in-elderly-patients-with-non-small-cell-lung-cancer-long-term-follow-up-of-a-randomized-trial 2026-07-02T09:20:49.917Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ClinLungCancer-2018-Ciuleanu-Efficacy-and-safety-of-necitumumab-continuation-therapy-in-the-phase-III-SQUIRE-study-of-patients-with-stage-IV 2026-07-02T09:20:49.908Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ClinLungCancer-2018-Ramalingam-Efficacy-and-safety-of-ramucirumab-with-docetaxel-versus-placebo-with-docetaxel-as-second-line-treatment-of-advanced 2026-07-02T09:20:49.868Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ClinLungCancer-2020-Frost-Pemetrexed-based-chemotherapy-is-inferior-to-pemetrexed-free-regimens-in-thyroid-transcription-factor-1 2026-07-02T09:20:49.927Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ClinLungCancer-2022-Gadgeel-Comparison-of-SP142-and-22c3-immunohistochemistry-PD-L1-assays-for-clinical-efficacy-of-atezolizumab-in-non-small-cell 2026-07-02T09:20:49.908Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ClinLungCancer-2025-Peruzzo-Chemotherapy-plus-anti-PD-1-or-anti-PD-L1-in-advanced-PD-L1-negative-squamous-cell-lung-carcinoma-A-systematic-review 2026-07-02T09:20:49.906Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/CochraneDatabaseSystRev-2005-Manser-Surgery-for-early-stage-non-small-cell-lung-cancer 2026-07-02T09:20:49.918Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/CochraneDatabaseSystRev-2010-Non-Small-Chemotherapy-and-supportive-care-versus-supportive-care-alone-for-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:49.892Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/CochraneDatabaseSystRev-2013-deCastria-Cisplatin-versus-carboplatin-in-combination-with-third-generation-drugs-for-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:49.845Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/CritRevOncolHematol-2014-Viudez-Nab-paclitaxel-A-flattering-facelift 2026-07-02T09:20:49.843Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ESMOOpen-2016-Nishio-Multicentre-phase-II-study-of-nivolumab-in-japanese-patients-with-advanced-or-recurrent-non-squamous-non-small-cell 2026-07-02T09:20:49.924Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ESMOOpen-2020-Garon-Exploratory-analysis-of-front-line-therapies-in-REVEL-a-randomised-phase-3-study-of-ramucirumab-plus-docetaxel-versus 2026-07-02T09:20:49.870Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ESMOOpen-2021-Reck-First-line-nivolumab-plus-ipilimumab-with-two-cycles-of-chemotherapy-versus-chemotherapy-alone-(four-cycles)-in 2026-07-02T09:20:49.935Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ESMOOpen-2022-Gridelli-First-line-immunotherapy-in-advanced-NSCLC-patients-with-ECOG-PS-2-results-of-an-international-expert-Panel-meeting-by-the-italian-association-of-thoracic-oncology 2026-07-02T09:20:49.905Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ESMOOpen-2025-Carbone-Nivolumab-plus-ipilimumab-with-chemotherapy-as-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung 2026-07-02T09:20:49.913Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ESMOOpen-2025-Rossi-Immunotherapy-for-resectable-NSCLC-neoadjuvantperioperative-followed-by-surgery-over-surgery-followed-by-adjuvant 2026-07-02T09:20:49.912Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/EurJCancer-2017-Su-Treatment-of-elderly-patients-or-patients-who-are-performance-status-2-(PS2)-with-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:49.848Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/EurJCancer-2018-Horn-Safety-and-clinical-activity-of-atezolizumab-monotherapy-in-metastatic-non-small-cell-lung-cancer-final-results-from-a 2026-07-02T09:20:49.924Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/EurJCancer-2019-Basak-Correlation-between-nivolumab-exposure-and-treatment-outcomes-in-non-small-cell-lung-cancer 2026-07-02T09:20:49.875Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/EurJCancer-2020-Facchinetti-First-line-pembrolizumab-in-advanced-non-small-cell-lung-cancer-patients-with-poor-performance-status 2026-07-02T09:20:49.875Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/EurJCancer-2020-Felip-CheckMate-171-A-phase-2-trial-of-nivolumab-in-patients-with-previously-treated-advanced-squamous-non-small-cell-lung 2026-07-02T09:20:49.863Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/EurJCancer-2020-Lala-A-six-weekly-dosing-schedule-for-pembrolizumab-in-patients-with-cancer-based-on-evaluation-using-modelling-and 2026-07-02T09:20:49.895Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/EurJCancer-2020-Wiesweg-Machine-learning-reveals-a-PD-L1-independent-prediction-of-response-to-immunotherapy-of-non-small-cell-lung-cancer-by 2026-07-02T09:20:49.853Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/EurJCancer-2021-Kim-Dynamic-changes-in-circulating-PD-1+cd8+-T-lymphocytes-for-predicting-treatment-response-to-PD-1-blockade-in-patients 2026-07-02T09:20:49.935Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/EurJCardiothoracSurg-1999-Wada-Postoperative-adjuvant-chemotherapy-with-PVM-(cisplatin-+-vindesine-+-mitomycin-C)-and-UFT-(uracil-+-tegaful)-in 2026-07-02T09:20:49.844Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/EurJCardiothoracSurg-2015-Speicher-Outcomes-after-treatment-of-17,378-patients-with-locally-advanced-(T3N0-2)-non-small-cell-lung-cancer 2026-07-02T09:20:49.888Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/FrontImmunol-2026-Li-The-application-and-challenges-of-immune-checkpoint-inhibitors-in-lung-cancer-therapy 2026-07-02T09:20:49.866Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/FrontOncol-2017-Tabchi-Antiangiogenesis-for-advanced-non-small-cell-lung-cancer-in-the-era-of-immunotherapy-and-personalized-medicine 2026-07-02T09:20:49.917Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/FrontOncol-2026-Han-Efficacy-and-safety-of-local-consolidative-therapy-combined-with-systemic-therapy-in-driver-negative-oligometastatic 2026-07-02T09:20:49.898Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/GanToKagakuRyoho-1994-Taguchi-Late-phase-II-clinical-study-of-RP56976-(docetaxel)-in-patients-with-advancedrecurrent-breast-cancer 2026-07-02T09:20:49.867Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/IntJClinOncol-2000-Okamoto-Phase-II-study-of-cisplatin-and-docetaxel-combination-chemotherapy-in-untreated-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:49.908Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/IntJClinOncol-2019-Sugawara-Japanese-subgroup-analysis-of-a-phase-III-study-of-S-1-versus-docetaxel-in-non-small-cell-lung-cancer-patients-after 2026-07-02T09:20:49.934Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/IntJClinOncol-2022-Hosokawa-Pembrolizumab-in-advanced-NSCLC-patients-with-poor-performance-status-and-high-PD-L1-expression-OLCSG-1801 2026-07-02T09:20:54.481Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/IntJRadiatOncolBiolPhys-2003-Tsujino-Predictive-value-of-dose-volume-histogram-parameters-for-predicting-radiation-pneumonitis-after-concurrent 2026-07-02T09:20:54.485Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/IntJRadiatOncolBiolPhys-2015-Nagata-Prospective-trial-of-stereotactic-body-radiation-therapy-for-both-operable-and-inoperable-T1N0M0-non-small-cell-lung 2026-07-02T09:20:49.936Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/InvestNewDrugs-2005-Sugiura-Phase-III-study-of-amrubicin,-a-novel-9-aminoanthracycline,-in-patients-with-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:49.907Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JAMA-2012-Zhu-Carboplatin-and-paclitaxel-with-vs-without-bevacizumab-in-older-patients-with-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:49.895Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JAMA-2026-Chaft-Adjuvant-nivolumab-vs-observation-in-resected-Non-Small-cell-lung-cancer 2026-07-02T09:20:49.896Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JAMAOncol-2017-Salazar-Association-of-delayed-adjuvant-chemotherapy-with-survival-after-lung-cancer-surgery 2026-07-02T09:20:49.859Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JAMAOncol-2018-Gridelli-Safety-and-efficacy-of-bevacizumab-plus-standard-of-care-treatment-beyond-disease-progression-in-patients-with-advanced 2026-07-02T09:20:49.893Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JAMAOncol-2019-Salem-Association-of-chemoradiotherapy-with-outcomes-among-patients-with-stage-I-to-II-vs-stage-III-Small-Cell-Lung-Cancer 2026-07-02T09:20:49.856Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JAMAOncol-2019-Theelen-Effect-of-pembrolizumab-after-stereotactic-body-radiotherapy-vs-pembrolizumab-alone-on-tumor-response-in-patients-with 2026-07-02T09:20:49.920Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JAMAOncol-2020-Duan-Use-of-immunotherapy-with-programmed-cell-death-1-vs-programmed-cell-death-ligand-1-inhibitors-in-patients-with-cancer 2026-07-02T09:20:49.928Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JAMAOncol-2020-Dummer-Rationale-for-immune-checkpoint-inhibitors-plus-targeted-therapy-in-metastatic-melanoma-A-review 2026-07-02T09:20:49.864Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JAMAOncol-2020-Jabbour-Phase-1-trial-of-pembrolizumab-administered-concurrently-with-chemoradiotherapy-for-locally-advanced-non-small-cell 2026-07-02T09:20:49.922Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JAMAOncol-2020-Pathak-Association-of-survival-with-adjuvant-chemotherapy-among-patients-with-early-stage-non-small-cell-lung-cancer-with-vs 2026-07-02T09:20:49.848Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JAMAOncol-2020-Rizvi-Durvalumab-with-or-without-tremelimumab-vs-standard-chemotherapy-in-first-line-treatment-of-metastatic-non-small-cell 2026-07-02T09:20:49.929Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JAMAOncol-2021-Gettinger-Nivolumab-plus-ipilimumab-vs-nivolumab-for-previously-treated-patients-with-stage-IV-squamous-cell-lung-cancer-the 2026-07-02T09:20:49.883Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JAMAOncol-2021-Jabbour-Pembrolizumab-plus-concurrent-chemoradiation-therapy-in-patients-with-unresectable,-locally-advanced,-stage-III 2026-07-02T09:20:49.894Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JAMAOncol-2021-Skinner-Addition-of-metformin-to-concurrent-chemoradiation-in-patients-with-locally-advanced-non-small-cell-lung-cancer-the 2026-07-02T09:20:49.931Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JAMAOncol-2021-Zenke-Effect-of-second-generation-vs-third-generation-chemotherapy-regimens-with-thoracic-radiotherapy-on-unresectable-stage 2026-07-02T09:20:49.936Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JAMAOncol-2022-Ricciuti-Association-of-high-tumor-mutation-burden-in-non-small-cell-lung-cancers-with-increased-immune-infiltration-and 2026-07-02T09:20:49.872Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JAMAOncol-2026-DiFederico-PD-(l)1-inhibitor-monotherapy-vs-chemoimmunotherapy 2026-07-02T09:20:49.857Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JAMAOncol-2026-Socinski-Tiragolumab-plus-atezolizumab-and-chemotherapy-for-advanced-nonsquamous-non-small-cell-lung-cancer-the-phase-3 2026-07-02T09:20:49.847Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JCOPrecisOncol-2021-Schlauch-Tumor-specific-and-tumor-agnostic-molecular-signatures-associated-with-response-to-immune-checkpoint-inhibitors 2026-07-02T09:20:49.884Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-1988-Rapp-Chemotherapy-can-prolong-survival-in-patients-with-advanced-non-small-cell-lung-cancer-report-of-a-canadian-multicenter 2026-07-02T09:20:49.850Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-1989-Bonomi-Combination-chemotherapy-versus-single-agents-followed-by-combination-chemotherapy-in-stage-IV-non-small-cell-lung 2026-07-02T09:20:49.852Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-1991-Albain-Survival-determinants-in-extensive-stage-non-small-cell-lung-cancer-the-southwest-oncology-group-experience 2026-07-02T09:20:49.903Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-1996-Crawford-Randomized-trial-of-vinorelbine-compared-with-fluorouracil-plus-leucovorin-in-patients-with-stage-IV-non-small-cell 2026-07-02T09:20:49.889Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-1996-Kunitoh-Phase-II-trial-of-docetaxel-in-previously-untreated-advanced-non-small-cell-lung-cancer-a-japanese-cooperative-study 2026-07-02T09:20:49.920Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-1996-Wada-Adjuvant-chemotherapy-after-complete-resection-in-non-small-cell-lung-cancer.-west-japan-study-group-for-lung-cancer 2026-07-02T09:20:49.885Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-1999-Cullen-Mitomycin,-ifosfamide,-and-cisplatin-in-unresectable-non-small-cell-lung-cancer-effects-on-survival-and-quality-of-life 2026-07-02T09:20:49.911Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2000-Fossella-Randomized-phase-III-trial-of-docetaxel-versus-vinorelbine-or-ifosfamide-in-patients-with-advanced-non-small-cell-lung 2026-07-02T09:20:49.930Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2000-Shepherd-Prospective-randomized-trial-of-docetaxel-versus-best-supportive-care-in-patients-with-non-small-cell-lung-cancer 2026-07-02T09:20:49.920Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2001-Kelly-Randomized-phase-III-trial-of-paclitaxel-plus-carboplatin-versus-vinorelbine-plus-cisplatin-in-the-treatment-of 2026-07-02T09:20:49.926Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2004-Hanna-Randomized-phase-III-trial-of-pemetrexed-versus-docetaxel-in-patients-with-non-small-cell-lung-cancer-previously 2026-07-02T09:20:49.886Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2004-Johnson-Randomized-phase-II-trial-comparing-bevacizumab-plus-carboplatin-and-paclitaxel-with-carboplatin-and-paclitaxel-alone 2026-07-02T09:20:49.905Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2005-Belani-Combined-chemoradiotherapy-regimens-of-paclitaxel-and-carboplatin-for-locally-advanced-non-small-cell-lung-cancer-a 2026-07-02T09:20:49.861Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2005-Hamada-Meta-analysis-of-postoperative-adjuvant-chemotherapy-with-tegafur-uracil-in-non-small-cell-lung-cancer 2026-07-02T09:20:49.869Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2005-Hoang-Clinical-model-to-predict-survival-in-chemonaive-patients-with-advanced-non-small-cell-lung-cancer-treated-with 2026-07-02T09:20:49.851Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2005-Lilenbaum-Single-agent-versus-combination-chemotherapy-in-advanced-non-small-cell-lung-cancer-the-cancer-and-leukemia-group-B 2026-07-02T09:20:49.902Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2007-Gridelli-Lung-cancer-in-the-elderly 2026-07-02T09:20:49.873Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2007-Langer-Randomized-phase-II-trial-of-paclitaxel-plus-carboplatin-or-gemcitabine-plus-cisplatin-in-eastern-cooperative-oncology 2026-07-02T09:20:49.856Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2007-Park-Phase-III-trial-of-two-versus-four-additional-cycles-in-patients-who-are-nonprogressive-after-two-cycles-of 2026-07-02T09:20:49.930Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2007-Pepe-Adjuvant-vinorelbine-and-cisplatin-in-elderly-patients-national-cancer-institute-of-canada-and-intergroup-study-JBR.10 2026-07-02T09:20:49.902Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2008-NSCLC-Chemotherapy-in-addition-to-supportive-care-improves-survival-in-advanced-non-small-cell-lung-cancer-a-systematic 2026-07-02T09:20:49.861Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2008-Pignon-Lung-adjuvant-cisplatin-evaluation-a-pooled-analysis-by-the-LACE-collaborative-group 2026-07-02T09:20:49.876Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2008-Ramalingam-Outcomes-for-elderly,-advanced-stage-non-small-cell-lung-cancer-patients-treated-with-bevacizumab-in-combination-with 2026-07-02T09:20:49.927Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2008-Scagliotti-Phase-III-study-comparing-cisplatin-plus-gemcitabine-with-cisplatin-plus-pemetrexed-in-chemotherapy-naive-patients-with 2026-07-02T09:20:49.862Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2008-Strauss-Adjuvant-paclitaxel-plus-carboplatin-compared-with-observation-in-stage-IB-non-small-cell-lung-cancer-CALGB-9633-with 2026-07-02T09:20:49.883Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2009-Gronberg-Phase-III-study-by-the-norwegian-lung-cancer-study-group-pemetrexed-plus-carboplatin-compared-with-gemcitabine-plus 2026-07-02T09:20:49.932Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2009-Patel-Phase-II-study-of-pemetrexed-and-carboplatin-plus-bevacizumab-with-maintenance-pemetrexed-and-bevacizumab-as-first-line 2026-07-02T09:20:49.901Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2009-Reck-Phase-III-trial-of-cisplatin-plus-gemcitabine-with-either-placebo-or-bevacizumab-as-first-line-therapy-for-nonsquamous 2026-07-02T09:20:49.917Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2009-Smit-Randomized-phase-II-and-pharmacogenetic-study-of-pemetrexed-compared-with-pemetrexed-plus-carboplatin-in-pretreated 2026-07-02T09:20:49.858Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2010-Arriagada-Long-term-results-of-the-international-adjuvant-lung-cancer-trial-evaluating-adjuvant-cisplatin-based-chemotherapy-in 2026-07-02T09:20:49.914Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2010-Butts-Randomized-phase-III-trial-of-vinorelbine-plus-cisplatin-compared-with-observation-in-completely-resected-stage-IB-and 2026-07-02T09:20:49.909Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2010-Dahlberg-Clinical-course-of-advanced-non-small-cell-lung-cancer-patients-experiencing-hypertension-during-treatment-with 2026-07-02T09:20:49.848Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2010-Felip-Preoperative-chemotherapy-plus-surgery-versus-surgery-plus-adjuvant-chemotherapy-versus-surgery-alone-in-early-stage 2026-07-02T09:20:49.870Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2010-Okamoto-Phase-III-trial-comparing-oral-S-1-plus-carboplatin-with-paclitaxel-plus-carboplatin-in-chemotherapy-naive-patients 2026-07-02T09:20:49.899Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2010-Yamamoto-Phase-III-study-comparing-second-and-third-generation-regimens-with-concurrent-thoracic-radiotherapy-in-patients-with 2026-07-02T09:20:49.905Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2012-Ardizzoni-Pemetrexed-versus-pemetrexed-and-carboplatin-as-second-line-chemotherapy-in-advanced-non-small-cell-lung-cancer-results 2026-07-02T09:20:49.929Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2012-Socinski-Weekly-nab-paclitaxel-in-combination-with-carboplatin-versus-solvent-based-paclitaxel-plus-carboplatin-as-first-line 2026-07-02T09:20:49.927Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2013-Barlesi-Randomized-phase-III-trial-of-maintenance-bevacizumab-with-or-without-pemetrexed-after-first-line-induction-with 2026-07-02T09:20:49.911Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2013-Patel-PointBreak-a-randomized-phase-III-study-of-pemetrexed-plus-carboplatin-and-bevacizumab-followed-by-maintenance 2026-07-02T09:20:49.910Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2013-Paz-Ares-PARAMOUNT-final-overall-survival-results-of-the-phase-III-study-of-maintenance-pemetrexed-versus-placebo-immediately 2026-07-02T09:20:49.926Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2013-Zukin-Randomized-phase-III-trial-of-single-agent-pemetrexed-versus-carboplatin-and-pemetrexed-in-patients-with-advanced 2026-07-02T09:20:49.927Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2014-Hung-Predictive-value-of-the-international-association-for-the-study-of-lung-canceramerican-thoracic-SocietyEuropean 2026-07-02T09:20:49.874Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2014-Langer-Randomized,-phase-III-trial-of-first-line-figitumumab-in-combination-with-paclitaxel-and-carboplatin-versus-paclitaxel 2026-07-02T09:20:49.884Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2015-Abe-Randomized-phase-III-trial-comparing-weekly-docetaxel-plus-cisplatin-versus-docetaxel-monotherapy-every-3-weeks-in 2026-07-02T09:20:49.926Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2015-Eberhardt-Phase-III-study-of-surgery-versus-definitive-concurrent-chemoradiotherapy-boost-in-patients-with-resectable-stage 2026-07-02T09:20:49.877Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2015-Gettinger-Overall-survival-and-long-term-safety-of-nivolumab-(anti-programmed-death-1-antibody,-BMS-936558,-ONO-4538)-in-patients 2026-07-02T09:20:49.889Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2015-Postow-Immune-checkpoint-blockade-in-cancer-therapy 2026-07-02T09:20:49.846Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2015-Robinson-Postoperative-radiotherapy-for-pathologic-N2-non-small-cell-lung-cancer-treated-with-adjuvant-chemotherapy-a-review-of 2026-07-02T09:20:49.898Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2015-Santana-Davila-Cisplatin-and-etoposide-versus-carboplatin-and-paclitaxel-with-concurrent-radiotherapy-for-stage-III-non-small-cell 2026-07-02T09:20:49.889Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2015-Tsao-Subtype-classification-of-lung-adenocarcinoma-predicts-benefit-from-adjuvant-chemotherapy-in-patients-undergoing 2026-07-02T09:20:49.928Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2016-Gettinger-Nivolumab-monotherapy-for-first-line-treatment-of-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:49.848Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2016-Rizvi-Nivolumab-in-combination-with-platinum-based-doublet-chemotherapy-for-first-line-treatment-of-advanced-non-small-cell 2026-07-02T09:20:49.874Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2017-Hanna-Systemic-therapy-for-stage-IV-non-small-cell-lung-cancer-american-society-of-clinical-oncology-clinical-practice 2026-07-02T09:20:49.935Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2017-Horn-Nivolumab-versus-docetaxel-in-previously-treated-patients-with-advanced-non-small-cell-lung-cancer-two-year-outcomes 2026-07-02T09:20:49.865Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2017-Peters-Phase-II-trial-of-atezolizumab-as-first-line-or-subsequent-therapy-for-patients-with-programmed-death-ligand-1-selected 2026-07-02T09:20:49.938Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2018-Gettinger-Five-year-follow-up-of-nivolumab-in-previously-treated-advanced-non-small-cell-lung-cancer-results-from-the-CA209-003 2026-07-02T09:20:49.891Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2018-Rizvi-Molecular-determinants-of-response-to-anti-programmed-cell-death-(PD)-1-and-anti-programmed-death-ligand-1-(PD-L1) 2026-07-02T09:20:49.930Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2019-Garon-Five-year-overall-survival-for-patients-with-advanced-Non-Small-cell-lung-cancer-treated-with-pembrolizumab-results 2026-07-02T09:20:49.860Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2019-Passaro-Immunotherapy-in-non-small-cell-lung-cancer-patients-with-performance-status-2-clinical-decision-making-with-scant 2026-07-02T09:20:49.866Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2019-Ramalingam-Pemetrexed,-bevacizumab,-or-the-combination-as-maintenance-therapy-for-advanced-nonsquamous-non-small-cell-lung-cancer 2026-07-02T09:20:49.912Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2019-Ready-First-line-nivolumab-plus-ipilimumab-in-advanced-non-small-cell-lung-cancer-(CheckMate-568)-outcomes-by-programmed 2026-07-02T09:20:49.862Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2019-Reck-Updated-analysis-of-KEYNOTE-024-pembrolizumab-versus-platinum-based-chemotherapy-for-advanced-non-small-cell-lung 2026-07-02T09:20:49.863Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2020-Gadgeel-Updated-analysis-from-KEYNOTE-189-pembrolizumab-or-placebo-plus-pemetrexed-and-platinum-for-previously-untreated 2026-07-02T09:20:49.849Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2020-Kenmotsu-Randomized-phase-III-study-of-pemetrexed-plus-cisplatin-versus-vinorelbine-plus-cisplatin-for-completely-resected-stage 2026-07-02T09:20:49.900Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2020-Waterhouse-Continuous-versus-1-year-fixed-duration-nivolumab-in-previously-treated-advanced-non-small-cell-lung-cancer-CheckMate 2026-07-02T09:20:49.906Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2021-Borghaei-Five-year-outcomes-from-the-randomized,-phase-III-trials-CheckMate-017-and-057-nivolumab-versus-docetaxel-in-previously 2026-07-02T09:20:49.873Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2021-Boyer-Pembrolizumab-plus-ipilimumab-or-placebo-for-metastatic-non-small-cell-lung-cancer-with-PD-L1-tumor-proportion-score 2026-07-02T09:20:49.931Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2021-Reck-Five-year-outcomes-with-pembrolizumab-versus-chemotherapy-for-metastatic-non-small-cell-lung-cancer-with-PD-L1-tumor 2026-07-02T09:20:49.857Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2022-Provencio-Overall-survival-and-biomarker-analysis-of-neoadjuvant-nivolumab-plus-chemotherapy-in-operable-stage-IIIA 2026-07-02T09:20:49.855Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JClinOncol-2026-Willmann-Metastatic-trajectories-in-non-small-cell-lung-cancer-guide-local-and-systemic-therapies 2026-07-02T09:20:49.892Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JImmunotherCancer-2020-Kato-Propensity-score-weighted-analysis-of-chemotherapy-after-PD-1-inhibitors-versus-chemotherapy-alone-in-patients-with 2026-07-02T09:20:49.900Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JImmunotherCancer-2020-Reuss-Neoadjuvant-nivolumab-plus-ipilimumab-in-resectable-non-small-cell-lung-cancer 2026-07-02T09:20:49.921Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JImmunotherCancer-2021-Hu-Genomic-profiles-and-their-associations-with-TMB,-PD-L1-expression,-and-immune-cell-infiltration-landscapes-in 2026-07-02T09:20:49.843Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JImmunotherCancer-2021-Negrao-Oncogene-specific-differences-in-tumor-mutational-burden,-PD-L1-expression,-and-outcomes-from-immunotherapy-in 2026-07-02T09:20:49.911Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JImmunotherCancer-2022-Casarrubios-Tumor-microenvironment-gene-expression-profiles-associated-to-complete-pathological-response-and-disease-progression-in 2026-07-02T09:20:49.925Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JImmunotherCancer-2026-Lee-Phase-I-trial-of-CJRB-101-plus-pembrolizumab-in-patients-with-metastatic-non-small-cell-lung-cancer,-head-and-neck 2026-07-02T09:20:49.854Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JImmunotherCancer-2026-Ulas-Rescue-by-radiotherapy-and-anti-CTLA4PD-1-after-failure-of-anti-PD-1-therapy-in-patients-with-metastatic-NSCLC-the 2026-07-02T09:20:49.873Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JNatlCancerInst-2002-Langer-Cisplatin-based-therapy-for-elderly-patients-with-advanced-non-small-cell-lung-cancer-implications-of-eastern 2026-07-02T09:20:49.875Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JNatlCancerInst-2007-Ardizzoni-Cisplatin-versus-carboplatin-based-chemotherapy-in-first-line-treatment-of-advanced-non-small-cell-lung-cancer-an 2026-07-02T09:20:49.910Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JNatlCancerInst-2007-vanMeerbeeck-Randomized-controlled-trial-of-resection-versus-radiotherapy-after-induction-chemotherapy-in-stage-IIIA-N2 2026-07-02T09:20:49.914Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JTOClinResRep-2020-Miyawaki-Desensitizing-effect-of-cancer-cachexia-on-immune-checkpoint-inhibitors-in-patients-with-advanced-NSCLC 2026-07-02T09:20:54.617Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JTOClinResRep-2023-Garassino-Associations-of-tissue-tumor-mutational-burden-and-mutational-status-with-clinical-outcomes-with-pembrolizumab-plus 2026-07-02T09:20:49.862Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracCardiovascSurg-2025-Fick-High-risk-features-associated-with-recurrence-in-stage-I-lung-adenocarcinoma 2026-07-02T09:20:49.864Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2006-Sekine-Docetaxel-consolidation-therapy-following-cisplatin,-vinorelbine,-and-concurrent-thoracic-radiotherapy-in-patients-with 2026-07-02T09:20:49.872Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2008-Naito-Concurrent-chemoradiotherapy-with-cisplatin-and-vinorelbine-for-stage-III-non-small-cell-lung-cancer 2026-07-02T09:20:49.908Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2009-Hamada-UFT-on-stage-IA-NSCLC 2026-07-02T09:20:49.905Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2010-Clement-Duchene-A-phase-II-first-line-study-of-gemcitabine,-carboplatin,-and-bevacizumab-in-advanced-stage-nonsquamous-non-small-cell 2026-07-02T09:20:49.932Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2010-Douillard-Adjuvant-cisplatin-and-vinorelbine-for-completely-resected-non-small-cell-lung-cancer-subgroup-analysis-of-the-lung 2026-07-02T09:20:49.925Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2010-Leighl-Efficacy-and-safety-of-bevacizumab-based-therapy-in-elderly-patients-with-advanced-or-recurrent-nonsquamous-non-small 2026-07-02T09:20:49.860Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2010-Sandler-Histology-subset-of-ECOG4599 2026-07-02T09:20:49.881Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2012-Spigel-A-randomized-phase-II-trial-of-pemetrexedgemcitabinebevacizumab-or-pemetrexedcarboplatinbevacizumab-in-the-first-line 2026-07-02T09:20:49.921Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2012-Wakelee-A-Double-Blind-Randomized-Discontinuation-Phase-II-Trial-of-sorafenib-(BAY-43-9006) 2026-07-02T09:20:49.877Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2015-Hung-Prognostic-factors-of-survival-after-recurrence-in-patients-with-resected-lung-adenocarcinoma 2026-07-02T09:20:49.864Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2015-Noonan-The-influence-of-the-evolution-of-first-line-chemotherapy-on-steadily-improving-survival-in-advanced-non-small-cell 2026-07-02T09:20:49.850Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2015-Zinner-PRONOUNCE-randomized,-open-label,-phase-III-study-of-first-line-pemetrexed-+-carboplatin-followed-by-maintenance 2026-07-02T09:20:49.853Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2016-Shukuya-Predictive-markers-for-the-efficacy-of-anti-PD-1pd-L1-antibodies-in-lung-cancer 2026-07-02T09:20:49.846Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2017-Evison-Resectable-clinical-N2-non-small-cell-lung-cancer;-what-is-the-optimal-treatment-strategy-an-update-by-the-british 2026-07-02T09:20:49.932Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2017-Marchetti-Multicenter-comparison-of-22c3-PharmDx-(agilent)-and-SP263-(ventana)-assays-to-test-PD-L1-expression-for-NSCLC-patients 2026-07-02T09:20:49.861Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2018-Fehrenbacher-Updated-efficacy-analysis-including-secondary-population-results-for-OAK-A-randomized-phase-III-study-of-atezolizumab 2026-07-02T09:20:49.865Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2018-Genova-EGFR-gene-copy-number-by-FISH-may-predict-outcome-of-necitumumab-in-squamous-lung-carcinomas-analysis-from-the-SQUIRE 2026-07-02T09:20:49.856Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2018-Tsao-PD-L1-immunohistochemistry-comparability-study-in-real-life-clinical-samples-results-of-blueprint-phase-2-project 2026-07-02T09:20:49.850Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2019-Jin-The-diversity-of-gut-microbiome-is-associated-with-favorable-responses-to-anti-programmed-death-1-immunotherapy-in 2026-07-02T09:20:49.891Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2019-Spigel-Safety,-efficacy,-and-patient-reported-health-related-quality-of-life-and-symptom-burden-with-nivolumab-in-patients 2026-07-02T09:20:49.923Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2020-Gray-Three-year-overall-survival-with-durvalumab-after-chemoradiotherapy-in-stage-III-NSCLC-update-from-PACIFIC 2026-07-02T09:20:49.871Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2020-Jotte-Atezolizumab-in-combination-with-carboplatin-and-nab-paclitaxel-in-advanced-squamous-NSCLC-(IMpower131)-results-from-a 2026-07-02T09:20:49.890Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2020-Lantuejoul-Interobserver-reliability-of-programmed-cell-death-ligand-1-scoring-using-the-VENTANA-PD-L1-(SP263)-assay-in-NSCLC 2026-07-02T09:20:49.896Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2020-Paz-Ares-A-randomized,-placebo-controlled-trial-of-pembrolizumab-plus-chemotherapy-in-patients-with-metastatic-squamous-NSCLC 2026-07-02T09:20:49.928Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2021-Awad-Long-term-overall-survival-from-KEYNOTE-021-cohort-G-pemetrexed-and-carboplatin-with-or-without-pembrolizumab-as 2026-07-02T09:20:49.909Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2021-Doroshow-Programmed-death-ligand-1-tumor-proportion-score-and-overall-survival-from-first-line-pembrolizumab-in-patients-with 2026-07-02T09:20:49.915Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2021-Faivre-Finn-Four-year-survival-with-durvalumab-after-chemoradiotherapy-in-stage-III-NSCLC-an-update-from-the-PACIFIC-trial 2026-07-02T09:20:49.900Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2021-Hellyer-Role-of-consolidation-durvalumab-in-patients-with-EGFR-and-HER2-mutant-unresectable-stage-III-NSCLC 2026-07-02T09:20:49.868Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2021-Leighl-Meeting-immunotherapy-resistance-in-lung-cancer 2026-07-02T09:20:49.927Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2021-Mazieres-Atezolizumab-versus-docetaxel-in-pretreated-patients-with-NSCLC-final-results-from-the-randomized-phase-2-POPLAR-and 2026-07-02T09:20:49.920Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2021-Nishio-Atezolizumab-plus-chemotherapy-for-first-line-treatment-of-nonsquamous-NSCLC-results-from-the-randomized-phase-3 2026-07-02T09:20:49.917Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2021-Powell-Outcomes-with-pembrolizumab-plus-platinum-based-chemotherapy-for-patients-with-NSCLC-and-stable-brain-metastases-pooled 2026-07-02T09:20:54.665Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2021-Shirasawa-Differential-immune-related-microenvironment-determines-programmed-cell-death-protein-1programmed-death-ligand-1 2026-07-02T09:20:49.918Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2021-Socinski-IMpower150-final-overall-survival-analyses-for-atezolizumab-plus-bevacizumab-and-chemotherapy-in-first-line-metastatic 2026-07-02T09:20:49.847Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2021-Yoneshima-Phase-3-trial-comparing-nanoparticle-albumin-bound-paclitaxel-with-docetaxel-for-previously-treated-advanced-NSCLC 2026-07-02T09:20:49.895Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JThoracOncol-2025-Peters-Durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-nsclc-five-year 2026-07-02T09:20:49.888Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JpnJClinOncol-2005-Okamoto-Phase-II-study-of-carboplatin-paclitaxel-combination-chemotherapy-in-elderly-patients-with-advanced-non-small-cell-lung 2026-07-02T09:20:54.670Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/JpnJClinOncol-2017-Watanabe-Neoadjuvant-and-adjuvant-therapy-for-stage-III-non-small-cell-lung-cancer 2026-07-02T09:20:49.858Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/Lancet-2009-Albain-Radiotherapy-plus-chemotherapy-with-or-without-surgical-resection-for-stage-III-non-small-cell-lung-cancer-a-phase-III 2026-07-02T09:20:49.859Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/Lancet-2009-Ciuleanu-Maintenance-pemetrexed-plus-best-supportive-care-versus-placebo-plus-best-supportive-care-for-non-small-cell-lung 2026-07-02T09:20:49.871Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/Lancet-2011-Quoix-Carboplatin-and-weekly-paclitaxel-doublet-chemotherapy-compared-with-monotherapy-in-elderly-patients-with-advanced 2026-07-02T09:20:49.916Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/Lancet-2014-Garon-Ramucirumab-plus-docetaxel-versus-placebo-plus-docetaxel-for-second-line-treatment-of-stage-IV-non-small-cell-lung 2026-07-02T09:20:49.879Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/Lancet-2014-Mok-A-REVELation-in-non-small-cell-lung-cancer-treatment 2026-07-02T09:20:49.852Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/Lancet-2014-NSCLC-Preoperative-chemotherapy-for-NSCLC-A-systematic-review-and-meta-analysis-of-individual-participant-data 2026-07-02T09:20:49.869Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/Lancet-2015-Pless-Induction-chemoradiation-in-stage-IIIAN2-non-small-cell-lung-cancer-a-phase-3-randomised-trial 2026-07-02T09:20:49.909Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/Lancet-2016-Fehrenbacher-Atezolizumab-versus-docetaxel-for-patients-with-previously-treated-non-small-cell-lung-cancer-(POPLAR)-a-multicentre, 2026-07-02T09:20:49.842Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/Lancet-2016-Herbst-Pembrolizumab-versus-docetaxel-for-previously-treated,-PD-L1-positive,-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:49.878Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/Lancet-2017-Rittmeyer-Atezolizumab-versus-docetaxel-in-patients-with-previously-treated-non-small-cell-lung-cancer-(OAK)-a-phase-3, 2026-07-02T09:20:49.903Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/Lancet-2019-Mok-Pembrolizumab-versus-chemotherapy-for-previously-untreated,-PD-L1-expressing,-locally-advanced-or-metastatic 2026-07-02T09:20:49.895Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/Lancet-2021-Felip-Adjuvant-atezolizumab-after-adjuvant-chemotherapy-in-resected-stage-IB-IIIA-non-small-cell-lung-cancer-(IMpower010)-a 2026-07-02T09:20:49.873Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/Lancet-2022-Saji-Segmentectomy-versus-lobectomy-in-small-sized-peripheral-NSCLC-JCOG0802-WJOG4607L 2026-07-02T09:20:54.689Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/Lancet-2024-Spicer-Neoadjuvant-pembrolizumab-plus-chemotherapy-followed-by-adjuvant-pembrolizumab-compared-with-neoadjuvant-chemotherapy 2026-07-02T09:20:49.925Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/Lancet-2025-Xiong-Ivonescimab-versus-pembrolizumab-for-PD-L1-positive-non-small-cell-lung-cancer-(harmoni-2)-a-randomised,-double-blind, 2026-07-02T09:20:49.890Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/Lancet-2026-Lu-Ivonescimab-plus-chemotherapy-versus-tislelizumab-plus-chemotherapy-in-advanced-squamous-non-small-cell-lung-cancer 2026-07-02T09:20:49.921Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/Lancet-2026-Xiong-Sacituzumab-tirumotecan-plus-pembrolizumab-versus-pembrolizumab-in-PD-L1-positive-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:49.934Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2005-Montero-Docetaxel-for-treatment-of-solid-tumours-a-systematic-review-of-clinical-data 2026-07-02T09:20:49.886Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2006-Douillard-Adjuvant-vinorelbine-plus-cisplatin-versus-observation-in-patients-with-completely-resected-stage-IB-IIIA 2026-07-02T09:20:54.693Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2012-Atagi-Thoracic-radiotherapy-with-or-without-daily-low-dose-carboplatin-in-elderly-patients-with-non-small-cell-lung-cancer-a 2026-07-02T09:20:49.914Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2012-Paz-Ares-Maintenance-therapy-with-pemetrexed-plus-best-supportive-care-versus-placebo-plus-best-supportive-care-after-induction 2026-07-02T09:20:49.854Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2014-Reck-Docetaxel-plus-nintedanib-versus-docetaxel-plus-placebo-in-patients-with-previously-treated-non-small-cell-lung-cancer 2026-07-02T09:20:49.847Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2015-Bradley-Standard-dose-versus-high-dose-conformal-radiotherapy-with-concurrent-and-consolidation-carboplatin-plus-paclitaxel 2026-07-02T09:20:49.855Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2015-Golden-Local-radiotherapy-and-granulocyte-macrophage-colony-stimulating-factor-to-generate-abscopal-responses-in-patients-with 2026-07-02T09:20:49.901Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2015-Rizvi-Activity-and-safety-of-nivolumab,-an-anti-PD-1-immune-checkpoint-inhibitor,-for-patients-with-advanced,-refractory 2026-07-02T09:20:49.849Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2015-Shukuya-Nedaplatin-plus-docetaxel-versus-cisplatin-plus-docetaxel-for-advanced-or-relapsed-squamous-cell-carcinoma-of-the-lung 2026-07-02T09:20:49.936Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2015-Soria-Afatinib-versus-erlotinib-as-second-line-treatment-of-patients-with-advanced-squamous-cell-carcinoma-of-the-lung 2026-07-02T09:20:49.901Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2015-Thatcher-Necitumumab-plus-gemcitabine-and-cisplatin-versus-gemcitabine-and-cisplatin-alone-as-first-line-therapy-in-patients 2026-07-02T09:20:49.910Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2015-Weber-Nivolumab-versus-chemotherapy-in-patients-with-advanced-melanoma-who-progressed-after-anti-ctla-4-treatment-(checkmate 2026-07-02T09:20:49.891Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2016-Antonia-Safety-and-antitumour-activity-of-durvalumab-plus-tremelimumab-in-non-small-cell-lung-cancer-a-multicentre,-phase-1b 2026-07-02T09:20:49.901Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2016-Gomez-Local-consolidative-therapy-versus-maintenance-therapy-or-observation-for-patients-with-oligometastatic-non-small-cell 2026-07-02T09:20:49.897Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2016-Langer-Carboplatin-and-pemetrexed-with-or-without-pembrolizumab-for-advanced,-non-squamous-non-small-cell-lung-cancer-a 2026-07-02T09:20:49.863Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2016-Weber-Sequential-administration-of-nivolumab-and-ipilimumab-with-a-planned-switch-in-patients-with-advanced-melanoma 2026-07-02T09:20:49.846Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2017-Hellmann-Nivolumab-plus-ipilimumab-as-first-line-treatment-for-advanced-non-small-cell-lung-cancer-(CheckMate-012)-results-of-an 2026-07-02T09:20:49.844Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2017-Shaverdian-Previous-radiotherapy-and-the-clinical-activity-and-toxicity-of-pembrolizumab-in-the-treatment-of-non-small-cell-lung 2026-07-02T09:20:49.870Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2017-Wakelee-Adjuvant-chemotherapy-with-or-without-bevacizumab-in-patients-with-resected-non-small-cell-lung-cancer-(E1505)-an 2026-07-02T09:20:49.909Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2018-Herbst-Cetuximab-plus-carboplatin-and-paclitaxel-with-or-without-bevacizumab-versus-carboplatin-and-paclitaxel-with-or-without 2026-07-02T09:20:49.922Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2019-West-Atezolizumab-in-combination-with-carboplatin-plus-nab-paclitaxel-chemotherapy-compared-with-chemotherapy-alone-as 2026-07-02T09:20:49.854Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2020-Garassino-Patient-reported-outcomes-following-pembrolizumab-or-placebo-plus-pemetrexed-and-platinum-in-patients-with-previously 2026-07-02T09:20:49.894Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2020-Goldberg-Pembrolizumab-for-management-of-patients-with-NSCLC-and-brain-metastases-long-term-results-and-biomarker-analysis-from 2026-07-02T09:20:54.721Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2021-Paz-Ares-First-line-nivolumab-plus-ipilimumab-combined-with-two-cycles-of-chemotherapy-in-patients-with-non-small-cell-lung 2026-07-02T09:20:49.849Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2022-Naranbhai-HLA-a03-and-response-to-immune-checkpoint-blockade-in-cancer-an-epidemiological-biomarker-study 2026-07-02T09:20:49.933Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2022-OBrien-Pembrolizumab-versus-placebo-as-adjuvant-therapy-for-completely-resected-stage-IB-IIIA-non-small-cell-lung-cancer 2026-07-02T09:20:49.849Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetOncol-2025-DiFederico-Long-term-overall-survival-with-dual-CTLA-4-and-PD-L1-or-PD-1-blockade-and-biomarker-based-subgroup-analyses-in 2026-07-02T09:20:49.937Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LancetRespirMed-2020-Middleton-Pembrolizumab-in-patients-with-non-small-cell-lung-cancer-of-performance-status-2-(PePS2)-a-single-arm,-phase-2-trial 2026-07-02T09:20:49.893Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2005-Alam-Compliance-with-post-operative-adjuvant-chemotherapy-in-non-small-cell-lung-cancer.-an-analysis-of-national-cancer 2026-07-02T09:20:49.863Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2010-Kim-A-phase-II-study-of-pemetrexed-and-carboplatin-as-a-salvage-therapy-for-platinum-pretreated-patients-with-non-small 2026-07-02T09:20:49.923Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2011-Bennouna-Impact-of-histology-on-survival-of-resected-non-small-cell-lung-cancer-(NSCLC)-receiving-adjuvant-chemotherapy-subgroup 2026-07-02T09:20:49.915Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2012-Ohguri-Re-irradiation-plus-regional-hyperthermia-for-recurrent-non-small-cell-lung-cancer-a-potential-modality-for-inducing 2026-07-02T09:20:49.935Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2013-Hoang-Histology-based-analysis-of-E1594 2026-07-02T09:20:49.880Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2013-Satouchi-Efficacy-and-safety-of-weekly-nab-paclitaxel-plus-carboplatin-in-patients-with-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:49.919Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2015-Cooper-PD-L1-expression-is-a-favorable-prognostic-factor-in-early-stage-non-small-cell-carcinoma 2026-07-02T09:20:49.915Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2015-Kim-Clinicopathological-analysis-of-PD-L1-and-PD-L2-expression-in-pulmonary-squamous-cell-carcinoma-comparison-with 2026-07-02T09:20:49.911Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2016-Dudnik-Intracranial-response-to-nivolumab-in-NSCLC-patients-with-untreated-or-progressing-CNS-metastases 2026-07-02T09:20:49.915Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2016-Sakata-Phase-II-trial-of-weekly-nab-paclitaxel-for-previously-treated-advanced-non-small-cell-lung-cancer-kumamoto-thoracic 2026-07-02T09:20:49.850Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2016-Yoh-A-randomized,-double-blind,-phase-II-study-of-ramucirumab-plus-docetaxel-vs-placebo-plus-docetaxel-in-japanese-patients 2026-07-02T09:20:49.869Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2017-Fujimoto-A-pilot-trial-of-nivolumab-treatment-for-advanced-non-small-cell-lung-cancer-patients-with-mild-idiopathic-interstitial 2026-07-02T09:20:54.741Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2017-Paz-Ares-Treatment-outcomes-by-histology-in-REVEL-A-randomized-phase-III-trial-of-ramucirumab-plus-docetaxel-for-advanced 2026-07-02T09:20:49.862Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2017-Reck-Outcomes-in-patients-with-aggressive-or-refractory-disease-from-REVEL-A-randomized-phase-III-study-of-docetaxel-with 2026-07-02T09:20:49.897Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2018-Kawano-Phase-III-study-of-carboplatin-plus-nab-paclitaxel-and-concurrent-radiotherapy-for-patients-with-locally-advanced 2026-07-02T09:20:49.878Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2019-Assoun-Association-of-TP53-mutations-with-response-and-longer-survival-under-immune-checkpoint-inhibitors-in-advanced 2026-07-02T09:20:49.930Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2019-Crino-Nivolumab-and-brain-metastases-in-patients-with-advanced-non-squamous-non-small-cell-lung-cancer 2026-07-02T09:20:49.858Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2019-Galli-Efficacy-and-safety-of-immunotherapy-in-elderly-patients-with-non-small-cell-lung-cancer 2026-07-02T09:20:49.913Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2019-Gubens-Pembrolizumab-in-combination-with-ipilimumab-as-second-line-or-later-therapy-for-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:49.868Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2019-Nosaki-Safety-and-efficacy-of-pembrolizumab-monotherapy-in-elderly-patients-with-PD-L1-positive-advanced-non-small-cell-lung 2026-07-02T09:20:49.860Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2019-Oyanagi-Predictive-value-of-serum-protein-levels-in-patients-with-advanced-non-small-cell-lung-cancer-treated-with-nivolumab 2026-07-02T09:20:49.845Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2019-Park-A-phase-ib-study-of-the-combination-of-afatinib-and-ruxolitinib-in-EGFR-mutant-NSCLC-with-progression-on-EGFR-TKIs 2026-07-02T09:20:49.919Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2019-Takano-Improvement-in-the-survival-of-patients-with-stage-IV-non-small-cell-lung-cancer-experience-in-a-single-institutional 2026-07-02T09:20:49.923Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2019-Wang-Erratum-to-the-metastatic-site-does-not-influence-PD-L1-expression-in-advanced-non-small-cell-lung-carcinoma 2026-07-02T09:20:49.846Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2020-DallOlio-ECOG-performance-status-2-as-a-prognostic-factor-in-patients-with-advanced-non-small-cell-lung-cancer-treated-with 2026-07-02T09:20:49.922Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2021-Abbar-Definitions,-outcomes,-and-management-of-hyperprogression-in-patients-with-non-small-cell-lung-cancer-treated-with 2026-07-02T09:20:49.880Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2021-Eichhorn-Neoadjuvant-anti-programmed-death-1-immunotherapy-by-pembrolizumab-in-resectable-non-small-cell-lung-cancer-first 2026-07-02T09:20:49.847Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2021-Faivre-Finn-Impact-of-prior-chemoradiotherapy-related-variables-on-outcomes-with-durvalumab-in-unresectable-stage-III-NSCLC 2026-07-02T09:20:49.919Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2021-Forest-Heterogeneity-of-PD-L1-expression-in-lung-adenocarcinoma-metastasis-is-related-to-histopathological-subtypes 2026-07-02T09:20:49.851Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2021-Garon-Safety-of-pemetrexed-plus-platinum-in-combination-with-pembrolizumab-for-metastatic-nonsquamous-non-small-cell-lung 2026-07-02T09:20:49.859Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2021-Lobefaro-Immunotherapy-in-advanced-non-small-cell-lung-cancer-patients-with-poor-performance-status-the-role-of 2026-07-02T09:20:49.867Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2021-Park-Impact-of-subsequent-immune-checkpoint-inhibitor-treatment-on-overall-survival-with-avelumab-vs-docetaxel-in 2026-07-02T09:20:49.853Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/LungCancer-2026-Shiraishi-Final-overall-survival-analysis-of-the-APPLE-study-atezolizumab-and-platinum-pemetrexed-with-or-without-bevacizumab-for 2026-07-02T09:20:49.919Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/Medicina(Kaunas)-2021-Kaira-Clinical-effectiveness-of-immune-checkpoint-inhibitors-in-non-small-cell-lung-cancer-with-a-poor-performance-status 2026-07-02T09:20:54.769Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ModPathol-2021-Huang-A-pan-cancer-analysis-of-PD-L1-immunohistochemistry-and-gene-amplification,-tumor-mutation-burden-and-microsatellite 2026-07-02T09:20:49.929Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/MolCancerTher-2017-Goodman-Tumor-mutational-burden-as-an-independent-predictor-of-response-to-immunotherapy-in-diverse-cancers 2026-07-02T09:20:49.888Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2002-Schiller-Comparison-of-four-chemotherapy-regimens-for-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:49.887Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2004-Arriagada-Cisplatin-based-adjuvant-chemotherapy-in-patients-with-completely-resected-non-small-cell-lung-cancer 2026-07-02T09:20:49.880Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2004-Kato-A-randomized-trial-of-adjuvant-chemotherapy-with-uracil-tegafur-for-adenocarcinoma-of-the-lung 2026-07-02T09:20:49.937Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2005-Winton-Vinorelbine-plus-cisplatin-vs.-observation-in-resected-non-small-cell-lung-cancer 2026-07-02T09:20:49.913Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2006-Sandler-Paclitaxel-carboplatin-alone-or-with-bevacizumab-for-non-small-cell-lung-cancer 2026-07-02T09:20:49.925Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2012-Brahmer-Safety-and-activity-of-anti-PD-L1-antibody-in-patients-with-advanced-cancer 2026-07-02T09:20:49.890Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2015-Borghaei-Nivolumab-versus-docetaxel-in-advanced-nonsquamous-non-small-cell-lung-cancer 2026-07-02T09:20:49.857Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2015-Brahmer-Nivolumab-versus-docetaxel-in-advanced-squamous-cell-non-small-cell-lung-cancer 2026-07-02T09:20:49.886Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2015-Garon-Pembrolizumab-for-the-treatment-of-non-small-cell-lung-cancer 2026-07-02T09:20:49.909Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2015-Larkin-Combined-nivolumab-and-ipilimumab-or-monotherapy-in-untreated-melanoma 2026-07-02T09:20:49.903Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2015-Le-PD-1-blockade-in-tumors-with-mismatch-repair-deficiency 2026-07-02T09:20:49.844Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2016-Reck-Pembrolizumab-versus-chemotherapy-for-PD-L1-positive-non-small-cell-lung-cancer 2026-07-02T09:20:49.847Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2017-Antonia-Durvalumab-after-chemoradiotherapy-in-stage-III-non-small-cell-lung-cancer 2026-07-02T09:20:54.785Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2017-Carbone-First-line-nivolumab-in-stage-IV-or-recurrent-non-small-cell-lung-cancer 2026-07-02T09:20:49.883Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2017-Yarchoan-Tumor-mutational-burden-and-response-rate-to-PD-1-inhibition 2026-07-02T09:20:49.918Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2018-Antonia-Overall-survival-with-durvalumab-after-chemoradiotherapy-in-stage-III-NSCLC 2026-07-02T09:20:49.881Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2018-Forde-Neoadjuvant-PD-1-blockade-in-resectable-lung-cancer 2026-07-02T09:20:49.845Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2018-Gandhi-Pembrolizumab-plus-chemotherapy-in-metastatic-non-small-cell-lung-cancer 2026-07-02T09:20:49.922Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2018-Hellmann-Nivolumab-plus-ipilimumab-in-lung-cancer-with-a-high-tumor-mutational-burden 2026-07-02T09:20:49.912Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2018-Paz-Ares-Pembrolizumab-plus-chemotherapy-for-squamous-non-small-cell-lung-cancer 2026-07-02T09:20:49.924Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2018-Socinski-Atezolizumab-for-first-line-treatment-of-metastatic-nonsquamous-NSCLC 2026-07-02T09:20:49.904Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2019-Hellmann-Nivolumab-plus-ipilimumab-in-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:49.875Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2019-Rauer-Treatment-of-progressive-multifocal-leukoencephalopathy-with-pembrolizumab 2026-07-02T09:20:49.933Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2019-Walter-Treatment-of-progressive-multifocal-leukoencephalopathy-with-nivolumab 2026-07-02T09:20:49.924Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2020-Herbst-Atezolizumab-for-first-line-treatment-of-PD-L1-selected-patients-with-NSCLC 2026-07-02T09:20:49.931Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2022-Forde-Neoadjuvant-nivolumab-plus-chemotherapy-in-resectable-lung-cancer 2026-07-02T09:20:49.872Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2023-Heymach-Perioperative-durvalumab-for-resectable-non-small-cell-lung-cancer 2026-07-02T09:20:49.936Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NEnglJMed-2023-Wakelee-Perioperative-pembrolizumab-for-early-stage-non-small-cell-lung-cancer 2026-07-02T09:20:49.914Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NatBiotechnol-2018-Jarchum-Putting-a-number-on-neoepitope-quality 2026-07-02T09:20:49.906Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NatCancer-2026-Provencio-Clinical-outcomes-with-perioperative-nivolumab-by-nodal-status-in-patients-with-stage-III-resectable-NSCLC-phase-3 2026-07-02T09:20:49.876Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NatGenet-2019-Samstein-Tumor-mutational-load-predicts-survival-after-immunotherapy-across-multiple-cancer-types 2026-07-02T09:20:49.889Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NatMed-2021-Wang-Toward-personalized-treatment-approaches-for-non-small-cell-lung-cancer 2026-07-02T09:20:49.866Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NatMed-2026-Huang-Time-of-day-immunochemotherapy-in-non-small-cell-lung-cancer-a-randomized-phase-3-trial 2026-07-02T09:20:49.871Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/NatRevCancer-2018-Ngwa-Using-immunotherapy-to-boost-the-abscopal-effect 2026-07-02T09:20:49.904Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/OncoImmunology-2020-Barlesi-Effectiveness-and-safety-of-nivolumab-in-the-treatment-of-lung-cancer-patients-in-france-preliminary-results-from-the 2026-07-02T09:20:49.934Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/OncoImmunology-2025-Barlesi-Final-3-year-results-from-the-EVIDENS-study,-an-observational-study-of-nivolumab-in-non-small-cell-lung-cancer 2026-07-02T09:20:49.884Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/OncoTargetsTher-2014-Aprile-Ramucirumab-Preclinical-research-and-clinical-development 2026-07-02T09:20:49.896Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/Oncologist-2009-Scagliotti-The-differential-efficacy-of-pemetrexed-according-to-NSCLC-histology-a-review-of-two-phase-III-studies 2026-07-02T09:20:49.911Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/Oncotarget-2015-Campesato-Comprehensive-cancer-gene-panels-can-be-used-to-estimate-mutational-load-and-predict-clinical-benefit-to-PD-1-blockade 2026-07-02T09:20:49.916Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/RadiolOncol-2017-Janzic-PD-L1-expression-in-squamous-cell-carcinoma-and-adenocarcinoma-of-the-lung 2026-07-02T09:20:49.864Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/RespirRes-2019-Arimura-Comparison-of-tumor-cell-numbers-and-22c3-PD-L1-expression-between-cryobiopsy-and-transbronchial-biopsy-with 2026-07-02T09:20:49.854Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/SciRep-2026-Cengiz-Comparison-of-flat-dose-versus-weight-based-dose-nivolumab-treatment-in-NSCLC-patients 2026-07-02T09:20:49.887Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/Science-2018-Cristescu-Pan-tumor-genomic-biomarkers-for-PD-1-checkpoint-blockade-based-immunotherapy 2026-07-02T09:20:49.891Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/Science-2018-Zitvogel-The-microbiome-in-cancer-immunotherapy-Diagnostic-tools-and-therapeutic-strategies 2026-07-02T09:20:49.886Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/SpringerPlus-2015-Imai-Comparison-of-platinum-combination-re-challenge-therapy-and-docetaxel-monotherapy-in-non-small-cell-lung-cancer 2026-07-02T09:20:49.898Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/ThoracCancer-2019-Shiono-Improved-efficacy-of-ramucirumab-plus-docetaxel-after-nivolumab-failure-in-previously-treated-non-small-cell-lung 2026-07-02T09:20:49.907Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/TranslLungCancerRes-2021-Facchinetti-First-line-immunotherapy-in-non-small-cell-lung-cancer-patients-with-poor-performance-status-a-systematic-review-and 2026-07-02T09:20:49.897Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-negative/TumourBiol-2017-Fiala-Thyroid-transcription-factor-1-expression-is-associated-with-outcome-of-patients-with-non-squamous-non-small-cell-lung 2026-07-02T09:20:49.874Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/AmJSurgPathol-2019-Perret-SMARCA4-deficient-thoracic-sarcomas-clinicopathologic-study-of-30-cases-with-an-emphasis-on-their-nosology-and 2026-07-02T09:20:50.044Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/AnnOncol-2019-Hong-Larotrectinib-in-adult-patients-with-solid-tumours-a-multi-centre,-open-label,-phase-I-dose-escalation-study 2026-07-02T09:20:50.031Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/AnnOncol-2019-Schrock-Tumor-mutational-burden-is-predictive-of-response-to-immune-checkpoint-inhibitors-in-MSI-high-metastatic-colorectal 2026-07-02T09:20:50.063Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/AnnOncol-2020-Mazieres-Vemurafenib-in-non-small-cell-lung-cancer-patients-with-BRAFV600-and-BRAFnonV600-mutations 2026-07-02T09:20:50.020Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/CancerCell-2019-Liao-KRAS-IRF2-axis-drives-immune-suppression-and-immune-therapy-resistance-in-colorectal-cancer 2026-07-02T09:20:50.065Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/CancerCell-2024-Tong-Adeno-to-squamous-transition-drives-resistance-to-KRAS-inhibition-in-LKB1-mutant-lung-cancer 2026-07-02T09:20:50.023Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/CancerDiscov-2015-Doebele-An-oncogenic-NTRK-fusion-in-a-patient-with-soft-tissue-sarcoma-with-response-to-the-tropomyosin-related-kinase 2026-07-02T09:20:50.023Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/CancerDiscov-2015-Skoulidis-Co-occurring-genomic-alterations-define-major-subsets-of-KRAS-mutant-lung-adenocarcinoma-with-distinct-biology,-immune 2026-07-02T09:20:50.038Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/CancerDiscov-2015-Vaishnavi-TRKing-down-an-old-oncogene-in-a-new-era-of-targeted-therapy 2026-07-02T09:20:50.052Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/CancerDiscov-2016-Trusolino-Oncogenic-MET-as-an-effective-therapeutic-target-in-non-small-cell-lung-cancer-resistant-to-EGFR-inhibitors-the-rise-of 2026-07-02T09:20:50.034Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/CancerDiscov-2018-Subbiah-Precision-targeted-therapy-with-BLU-667-for-RET-driven-cancers 2026-07-02T09:20:50.037Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/CancerDiscov-2019-Kitajima-Suppression-of-STING-Associated-with-LKB1-Loss-in-KRAS-Driven-Lung-Cancer 2026-07-02T09:20:50.034Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/CancerDiscov-2020-Li-In-vivo-epigenetic-CRISPR-screen-identifies-Asf1a-as-an-immunotherapeutic-target-in-KRAS-mutant-lung-adenocarcinoma 2026-07-02T09:20:50.059Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/CancerDrugResist-2020-Liu-RET-kinase-alterations-in-targeted-cancer-therapy 2026-07-02T09:20:50.056Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/CancerRes-2019-Roman-Inhibitor-of-differentiation-1-sustains-mutant-KRAS-driven-progression,-maintenance,-and-metastasis-of-lung 2026-07-02T09:20:50.062Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/CancerRes-2019-Solomon-Detection-of-NTRK-fusions-Merits-and-limitations-of-current-diagnostic-platforms 2026-07-02T09:20:50.061Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/CancerRes-2024-Park-Proteogenomic-characterization-reveals-estrogen-signaling-as-a-target-for-never-smoker-lung-adenocarcinoma-patients 2026-07-02T09:20:50.024Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/CancerTreatRev-2010-Bronte-Driver-mutations-and-differential-sensitivity-to-targeted-therapies-a-new-approach-to-the-treatment-of-lung 2026-07-02T09:20:50.018Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/Cell-2019-Huang-A-tumor-agnostic-NTRK-(TRK)-inhibitor 2026-07-02T09:20:50.019Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/Cell-2020-Kim-Targeting-KRAS(G12C)-from-inhibitory-mechanism-to-modulation-of-antitumor-effects-in-patients 2026-07-02T09:20:50.030Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/Cell-2026-Wang-Farnesylation-driven-KRAS-phase-separation-promotes-colon-tumor-growth 2026-07-02T09:20:50.042Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/ClinCancerRes-2013-Cardarella-Clinical,-pathologic,-and-biologic-features-associated-with-BRAF-mutations-in-non-small-cell-lung-cancer 2026-07-02T09:20:50.056Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/ClinCancerRes-2014-Nakaoku-Druggable-oncogene-fusions-in-invasive-mucinous-lung-adenocarcinoma 2026-07-02T09:20:50.040Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/ClinCancerRes-2014-Vasan-A-RAS-renaissance-emerging-targeted-therapies-for-KRAS-mutated-non-small-cell-lung-cancer 2026-07-02T09:20:50.062Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/ClinCancerRes-2015-Fernandez-Cuesta-Molecular-pathways-targeting-NRG1-fusions-in-lung-cancer 2026-07-02T09:20:50.060Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/ClinCancerRes-2015-Tolcher-Antitumor-activity-in-RAS-driven-tumors-by-blocking-AKT-and-MEK 2026-07-02T09:20:50.021Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/ClinCancerRes-2018-Arbour-Effects-of-co-occurring-genomic-alterations-on-outcomes-in-patients-with-KRAS-mutant-non-small-cell-lung-cancer 2026-07-02T09:20:50.062Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/ClinCancerRes-2018-Wang-Mutant-LKB1-confers-enhanced-radiosensitization-in-combination-with-trametinib-in-KRAS-mutant-non-small-cell-lung-cancer 2026-07-02T09:20:54.841Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/ClinCancerRes-2019-Jonna-Detection-of-NRG1-gene-fusions-in-solid-tumors 2026-07-02T09:20:50.051Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/ClinCancerRes-2020-Recondo-Molecular-mechanisms-of-acquired-resistance-to-MET-tyrosine-kinase-inhibitors-in-patients-with-MET-exon-14-mutant-NSCLC 2026-07-02T09:20:50.021Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/ClinCancerRes-2021-Arbour-Treatment-outcomes-and-clinical-characteristics-of-patients-with-KRAS-G12C-mutant-non-small-cell-lung-cancer 2026-07-02T09:20:50.032Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/ClinCancerRes-2021-Jones-KRAS-G12C-mutation-is-associated-with-increased-risk-of-recurrence-in-surgically-resected-lung-adenocarcinoma 2026-07-02T09:20:50.053Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/ClinCancerRes-2021-Solanki-Cell-type-specific-adaptive-signaling-responses-to-KRASG12C-inhibition 2026-07-02T09:20:50.063Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/ClinCancerRes-2022-Le-Tepotinib-efficacy-and-safety-in-patients-with-MET-exon-14-skipping-NSCLC-outcomes-in-patient-subgroups-from-the-VISION 2026-07-02T09:20:50.020Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/ClinCancerRes-2026-Ruge-Molecular-and-clinical-characteristics-of-patients-with-NSCLC-harboring-KRAS-Q61-mutations-to-assess-therapeutic-responses 2026-07-02T09:20:50.046Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/ClinLungCancer-2026-Kropf-Sanchen-A-retrospective,-multicenter-analysis-within-the-national-network-genomic-medicine-lung-cancer-in-germany-to-detect-RET 2026-07-02T09:20:50.065Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/CritRevOncolHematol-2026-Canaslan-From-G12C-to-pan-RAS-the-expanding-therapeutic-landscape-of-KRAS-mutant-NSCLC 2026-07-02T09:20:50.053Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/CritRevOncolHematol-2026-Vitale-Targeting-KRAS-G12C-in-non-small-cell-lung-cancer-breakthrough-inhibitors-and-combination-approaches 2026-07-02T09:20:50.030Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/FrontOncol-2026-Liang-KRASG12C-inhibitors-versus-chemotherapy-alone-for-KRASG12C-mutated-non-small-cell-lung-cancer-a-pooled-analysis-of 2026-07-02T09:20:50.057Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/JAMA-2014-Kris-Using-multiplexed-assay-of-oncogenic-drives-in-lung-cancer 2026-07-02T09:20:50.059Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/JBiolChem-2014-Kahlert-Identification-of-double-stranded-genomic-DNA-spanning-all-chromosomes-with-mutated-KRAS-and-p53-DNA-in-the-serum 2026-07-02T09:20:50.047Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/JCOPrecisOncol-2019-Stein-Dual-checkpoint-inhibition-an-approach-for-STK11-and-KRAS-co-mutated-lung-adenocarcinoma 2026-07-02T09:20:50.041Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/JCOPrecisOncol-2020-Lee-Combined-CDK4-6-and-PD1-inhibition-in-refractory-SMARCA4-deficient-SCLC-of-the-ovary 2026-07-02T09:20:50.021Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/JClinOncol-2011-Marchetti-Clinical-features-and-outcome-of-patients-with-non-small-cell-lung-cancer-harboring-BRAF-mutations 2026-07-02T09:20:50.054Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/JClinOncol-2011-Paik-Clinical-characteristics-of-patients-with-lung-adenocarcinomas-harboring-BRAF-mutations 2026-07-02T09:20:50.018Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/JClinOncol-2014-Johnson-Recent-clinical-advances-in-lung-cancer-management 2026-07-02T09:20:50.018Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/JClinOncol-2016-Awad-MET-exon-14-mutations-in-non-small-cell-lung-cancer-are-associated-with-advanced-age-and-stage-dependent-MET-genomic 2026-07-02T09:20:50.032Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/JClinOncol-2016-Liu-Next-generation-sequencing-of-pulmonary-sarcomatoid-carcinoma-reveals-high-frequency-of-actionable-MET-gene-mutations 2026-07-02T09:20:50.039Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/JClinOncol-2017-Hyman-AKT-inhibition-in-solid-tumors-with-AKT1-mutations 2026-07-02T09:20:50.066Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/JClinOncol-2026-Sharma-Phase-I-study-of-telisotuzumab-adizutecan-(temab-A,-ABBV-400),-a-novel-c-met-antibody-drug-conjugate,-in-patients-with 2026-07-02T09:20:50.035Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/JImmunotherCancer-2021-Zhang-Multiomics-analysis-reveals-a-distinct-response-mechanism-in-multiple-primary-lung-adenocarcinoma-after-neoadjuvant 2026-07-02T09:20:50.055Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/JMedChem-2016-Menichincheri-Discovery-of-entrectinib-A-new-3-aminoindazole-as-a-potent-anaplastic-lymphoma-kinase-(ALK),-c-ros-oncogene-1-kinase 2026-07-02T09:20:50.055Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/JNatlCancerCent-2026-He-Study-of-the-blood-brain-barrier-penetrating-KRAS-G12C-inhibitor-JMKX1899-in-KRAS-G12C-mutated-NSCLC-with-brain 2026-07-02T09:20:50.031Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/JThoracOncol-2015-Farago-Durable-clinical-response-to-entrectinib-in-NTRK1-rearranged-non-small-cell-lung-cancer 2026-07-02T09:20:50.022Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/JThoracOncol-2016-Schrock-Characterization-of-298-patients-with-lung-cancer-harboring-MET-exon-14-skipping-alterations 2026-07-02T09:20:50.064Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/JThoracOncol-2021-Finn-Prognostic-impact-of-KRAS-G12C-mutation-in-patients-with-NSCLC-results-from-the-european-thoracic-oncology-platform 2026-07-02T09:20:50.059Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/LancetOncol-2016-Planchard-Dabrafenib-in-patients-with-BRAF(V600E)-positive-advanced-non-small-cell-lung-cancer-a-single-arm,-multicentre, 2026-07-02T09:20:50.056Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/LancetOncol-2017-Planchard-Dabrafenib-plus-trametinib-in-patients-with-previously-untreated-BRAFV600E-mutant-metastatic-non-small-cell-lung-cancer 2026-07-02T09:20:50.035Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/LancetOncol-2020-Doebele-Entrectinib-in-patients-with-advanced-or-metastatic-NTRK-fusion-positive-solid-tumours-integrated-analysis-of-three 2026-07-02T09:20:50.040Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/LancetOncol-2020-Hong-Larotrectinib-in-patients-with-TRK-fusion-positive-solid-tumours-a-pooled-analysis-of-three-phase-12-clinical-trials 2026-07-02T09:20:50.035Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/LungCancer-2013-Kim-Personalized-therapy-on-the-horizon-for-squamous-cell-carcinoma-of-the-lung 2026-07-02T09:20:50.019Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/LungCancer-2021-Sebastian-KRAS-G12C-mutated-advanced-non-small-cell-lung-cancer-A-real-world-cohort-from-the-german-prospective,-observational, 2026-07-02T09:20:50.029Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/LungCancer-2021-Wong-MET-exon-14-skipping-mutation-positive-non-small-cell-lung-cancer-response-to-systemic-therapy 2026-07-02T09:20:50.030Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/LungCancer-2026-Zhao-Clinical-outcomes-and-tumor-immune-microenvironment-in-SMARCA4-deficient-NSCLC-A-real-world-retrospective-study 2026-07-02T09:20:50.065Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/Med-2026-Luo-Nsclc-five-trials-to-watch 2026-07-02T09:20:50.021Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/ModPathol-2021-Kishikawa-Diffuse-expression-of-MUC6-defines-a-distinct-clinicopathological-subset-of-pulmonary-invasive-mucinous-adenocarcinoma 2026-07-02T09:20:50.057Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/NEnglJMed-2018-Drilon-Efficacy-of-larotrectinib-in-TRK-fusion-positive-cancers-in-adults-and-children 2026-07-02T09:20:50.064Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/NEnglJMed-2020-Drilon-Efficacy-of-selpercatinib-in-RET-fusion-positive-non-small-cell-lung-cancer 2026-07-02T09:20:50.041Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/NEnglJMed-2020-Hong-KRASG12C-inhibition-with-sotorasib-in-advanced-solid-tumors 2026-07-02T09:20:50.039Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/NEnglJMed-2020-Paik-Tepotinib-in-non-small-cell-lung-cancer-with-MET-exon-14-skipping-mutations 2026-07-02T09:20:50.033Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/NEnglJMed-2020-Wolf-Capmatinib-in-MET-exon-14-mutated-or-MET-amplified-non-small-cell-lung-cancer 2026-07-02T09:20:50.036Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/NEnglJMed-2021-Skoulidis-Sotorasib-for-lung-cancers-with-KRAS-p.g12c-mutation 2026-07-02T09:20:50.023Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/NEnglJMed-2023-Zhou-First-line-selpercatinib-or-chemotherapy-and-pembrolizumab-in-RET-fusion-positive-NSCLC 2026-07-02T09:20:50.058Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/NEnglJMed-2026-Park-Setidegrasib-in-advanced-non-small-cell-lung-cancer-and-pancreatic-cancer 2026-07-02T09:20:50.022Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/NEnglJMed-2026-Wu-Selpercatinib-in-early-stage-RET-fusion-positive-non-small-cell-lung-cancer 2026-07-02T09:20:50.037Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/NatCommun-2018-Nakaoku-A-secondary-RET-mutation-in-the-activation-loop-conferring-resistance-to-vandetanib 2026-07-02T09:20:54.901Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/NatCommun-2019-Xue-SMARCA4-loss-is-synthetic-lethal-with-CDK46-inhibition-in-non-small-cell-lung-cancer 2026-07-02T09:20:50.022Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/NatCommun-2026-Tishina-Oncogenic-KRAS-driven-type-I-interferon-signalling-primes-pancreatic-cancer-for-necroptosis 2026-07-02T09:20:50.038Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/NatGenet-2021-Zhang-Genomic-and-evolutionary-classification-of-lung-cancer-in-never-smokers 2026-07-02T09:20:50.054Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/NatMed-2012-Kohno-KIF5B-RET-fusions-in-lung-adenocarcinoma 2026-07-02T09:20:50.019Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/NatMed-2012-Lipson-Identification-of-new-ALK-and-RET-gene-fusions-from-colorectal-and-lung-cancer-biopsies 2026-07-02T09:20:50.060Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/NatMed-2012-Takeuchi-RET,-ROS1-and-ALK-fusions-in-lung-cancer 2026-07-02T09:20:50.020Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/NatMed-2013-Vaishnavi-Oncogenic-and-drug-sensitive-NTRK1-rearrangements-in-lung-cancer 2026-07-02T09:20:50.029Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/NatMed-2017-Zehir-Mutational-landscape-of-metastatic-cancer-revealed-from-prospective-clinical-sequencing-of-10,000-patients 2026-07-02T09:20:50.033Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/NatMed-2020-Drilon-Antitumor-activity-of-crizotinib-in-lung-cancers-harboring-a-MET-exon-14-alteration 2026-07-02T09:20:50.061Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/NatMed-2022-Hallin-Anti-tumor-efficacy-of-a-potent-and-selective-non-covalent-KRASG12D-inhibitor 2026-07-02T09:20:50.039Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/NatRevCancer-2021-OLeary-Tracing-the-origins-of-KRAS-oncogene-addiction 2026-07-02T09:20:50.032Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/NatRevClinOncol-2018-Cocco-NTRK-fusion-positive-cancers-and-TRK-inhibitor-therapy 2026-07-02T09:20:50.028Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/Nature-2009-Barbie-Systematic-RNA-interference-reveals-that-oncogenic-KRAS-driven-cancers-require-TBK1 2026-07-02T09:20:50.019Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/Nature-2013-Hatzivassiliou-Mechanism-of-MEK-inhibition-determines-efficacy-in-mutant-KRAS-versus-BRAF-driven-cancers 2026-07-02T09:20:50.042Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/OncoTargetsTher-2020-Bylicki-Targeting-the-MET-signaling-pathway-in-NSCLC 2026-07-02T09:20:50.060Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/Oncotarget-2017-Inamura-Association-of-tumor-TROP2-expression-with-prognosis-varies-among-lung-cancer-subtypes 2026-07-02T09:20:50.030Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/PLoSONE-2019-Lung-MET-exon-14-skipping-mutations-and-gene-amplification-in-a-Taiwanese-lung-cancer-population 2026-07-02T09:20:50.050Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/ProcNatlAcadSciUSA-2014-Lin-Mapping-the-molecular-determinants-of-BRAF-oncogene-dependence-in-human-lung-cancer 2026-07-02T09:20:50.064Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/ProcNatlAcadSciUSA-2020-Kessler-The-hanging-heart-How-KRAS-lures-its-prey-to-the-membrane 2026-07-02T09:20:50.031Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/SciTranslMed-2017-Plenker-Drugging-the-catalytically-inactive-state-of-RET-kinase-in-RET-rearranged-tumors 2026-07-02T09:20:50.061Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/TrendsCancer-2023-Zeissig-Next-batter-up!-targeting-cancers-with-KRAS-G12D-mutations 2026-07-02T09:20:50.023Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-Driver-Other/TrendsCancer-2026-Caswell-Lung-cancer-in-never-smokers-from-early-detection-to-prevention 2026-07-02T09:20:50.035Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ActaPharmSinB-2015-Huang-Mechanisms-of-resistance-to-EGFR-tyrosine-kinase-inhibitors 2026-07-02T09:20:49.048Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnnOncol-2008-Lee-Phase-II-study-of-erlotinib-as-a-salvage-treatment-for-non-small-cell-lung-cancer-patients-after-failure-of-gefitinib 2026-07-02T09:20:49.069Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnnOncol-2008-Zucali-Role-of-cMET-expression-in-non-small-cell-lung-cancer-patients-treated-with-EGFR-tyrosine-kinase-inhibitors 2026-07-02T09:20:49.101Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnnOncol-2013-Inoue-Updated-overall-survival-results-from-a-randomized-phase-III-trial-comparing-gefitinib-with-carboplatin-paclitaxel-for 2026-07-02T09:20:49.058Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnnOncol-2013-Lee-Primary-resistance-to-epidermal-growth-factor-receptor-(EGFR)-tyrosine-kinase-inhibitors-(TKIs)-in-patients-with 2026-07-02T09:20:49.105Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnnOncol-2014-Azuma-Association-of-PD-L1-overexpression-with-activating-EGFR-mutations-in-surgically-resected-nonsmall-cell-lung-cancer 2026-07-02T09:20:49.045Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnnOncol-2014-Beau-Faller-Rare-EGFR-exon-18-and-exon-20-mutations-in-non-small-cell-lung-cancer-on-10-117-patients-a-multicentre-observational 2026-07-02T09:20:49.140Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnnOncol-2014-Mok-Randomized-phase-II-study-of-two-intercalated-combinations-of-eribulin-mesylate-and-erlotinib-in-patients-with 2026-07-02T09:20:49.027Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnnOncol-2014-Ono-Mutant-allele-frequency-predicts-the-efficacy-of-EGFR-TKIs-in-lung-adenocarcinoma-harboring-the-L858R-mutation 2026-07-02T09:20:49.126Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnnOncol-2014-Yu-Poor-response-to-erlotinib-in-patients-with-tumors-containing-baseline-EGFR-T790M-mutations-found-by-routine-clinical 2026-07-02T09:20:49.083Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnnOncol-2015-Planchard-EGFR-independent-mechanisms-of-acquired-resistance-to-AZD9291-in-EGFR-T790M-positive-NSCLC-patients 2026-07-02T09:20:49.099Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnnOncol-2015-Sugawara-Randomized-phase-II-study-of-concurrent-versus-sequential-alternating-gefitinib-and-chemotherapy-in-previously 2026-07-02T09:20:49.046Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnnOncol-2015-Trivedi-Immune-biomarkers-of-anti-EGFR-monoclonal-antibody-therapy 2026-07-02T09:20:49.132Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnnOncol-2017-Haratani-Tumor-immune-microenvironment-and-nivolumab-efficacy-in-EGFR-mutation-positive-non-small-cell-lung-cancer-based-on 2026-07-02T09:20:49.107Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnnOncol-2017-Martinez-Marti-Dual-MET-and-ERBB-inhibition-overcomes-intratumor-plasticity-in-osimertinib-resistant-advanced-non-small-cell-lung 2026-07-02T09:20:49.051Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnnOncol-2017-Mayo-de-Las-Casas-Large-scale,-prospective-screening-of-EGFR-mutations-in-the-blood-of-advanced-NSCLC-patients-to-guide-treatment 2026-07-02T09:20:49.056Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnnOncol-2017-Paz-Ares-Afatinib-versus-gefitinib-in-patients-with-EGFR-mutation-positive-advanced-non-small-cell-lung-cancer-overall-survival 2026-07-02T09:20:49.086Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnnOncol-2017-Remon-Osimertinib-benefit-in-EGFR-mutant-NSCLC-patients-with-T790M-mutation-detected-by-circulating-tumour-DNA 2026-07-02T09:20:49.070Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnnOncol-2018-Bonomi-Predictive-biomarkers-for-response-to-EGFR-directed-monoclonal-antibodies-for-advanced-squamous-cell-lung-cancer 2026-07-02T09:20:49.136Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnnOncol-2018-Guibert-Amplicon-based-next-generation-sequencing-of-plasma-cell-free-DNA-for-detection-of-driver-and-resistance-mutations-in 2026-07-02T09:20:49.109Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnnOncol-2018-Kunimasa-Heterogeneity-of-EGFR-mutant-clones-and-PD-L1-highly-expressing-clones-affects-treatment-efficacy-of-EGFR-TKI-and-PD-1 2026-07-02T09:20:49.074Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnnOncol-2018-Ricordel-Molecular-mechanisms-of-acquired-resistance-to-third-generation-EGFR-TKIs-in-EGFR-T790M-mutant-lung-cancer 2026-07-02T09:20:49.036Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnnOncol-2018-Taniguchi-Programmed-death-ligand-1-expression-in-uncommon-epidermal-growth-factor-receptor-mutation-positive-non-small-cell-lung 2026-07-02T09:20:49.031Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnnOncol-2018-Westover-Mechanisms-of-acquired-resistance-to-first-and-second-generation-EGFR-tyrosine-kinase-inhibitors 2026-07-02T09:20:49.063Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnnOncol-2018-Yoshida-Nivolumab-in-non-small-cell-lung-cancer-with-EGFR-mutation 2026-07-02T09:20:49.131Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnnOncol-2019-Hastings-EGFR-mutation-subtypes-and-response-to-immune-checkpoint-blockade-treatment-in-non-small-cell-lung-cancer 2026-07-02T09:20:49.027Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnnOncol-2020-Park-A-phase-II,-multicenter,-two-cohort-study-of-160-mg-osimertinib-in-EGFR-T790M-positive-non-small-cell-lung-cancer 2026-07-02T09:20:49.067Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnticancerRes-2007-Uramoto-A-new-mechanism-for-primary-resistance-to-gefitinib-in-lung-adenocarcinoma-the-role-of-a-novel-G796A-mutation-in-exon 2026-07-02T09:20:49.059Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnticancerRes-2013-Koyama-Clinical-significance-of-erlotinib-monotherapy-for-gefitinib-resistant-non-small-cell-lung-cancer-with-EGFR-mutations 2026-07-02T09:20:49.032Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/AnticancerRes-2018-Watanabe-Phase-I-study-evaluating-the-combination-of-afatinib-with-carboplatin-and-pemetrexed-after-first-line-EGFR-TKIs 2026-07-02T09:20:49.063Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/BMCCancer-2011-Watanabe-Clinical-responses-to-EGFR-tyrosine-kinase-inhibitor-retreatment-in-non-small-cell-lung-cancer-patients-who-benefited 2026-07-02T09:20:49.094Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/BiochemBiophysResCommun-2015-Lin-EGFR-TKI-down-regulates-PD-L1-in-EGFR-mutant-NSCLC-through-inhibiting-NF-kappab 2026-07-02T09:20:49.094Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/BrJCancer-2007-Pallis-'Classical'-but-not-'other'-mutations-of-EGFR-kinase-domain-are-associated-with-clinical-outcome-in-gefitinib-treated 2026-07-02T09:20:49.088Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/BrJCancer-2019-Leonetti-Resistance-mechanisms-to-osimertinib-in-EGFR-mutated-non-small-cell-lung-cancer 2026-07-02T09:20:49.116Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/Cancer-2026-Passiglia-Amivantamab-in-advanced-non-small-cell-lung-cancer-with-epidermal-growth-factor-receptor-exon-20-insertion-mutations 2026-07-02T09:20:49.117Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerCell-2007-Yun-Structures-of-lung-cancer-derived-EGFR-mutants-and-inhibitor-complexes-mechanism-of-activation-and-insights-into 2026-07-02T09:20:49.057Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerCell-2010-Turke-Preexistence-and-clonal-selection-of-MET-amplification-in-EGFR-mutant-NSCLC 2026-07-02T09:20:49.046Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerCell-2014-Arteaga-ERBB-receptors-from-oncogene-discovery-to-basic-science-to-mechanism-based-cancer-therapeutics 2026-07-02T09:20:49.134Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerCell-2018-Lee-Targeting-PKCdelta-as-a-therapeutic-strategy-against-heterogeneous-mechanisms-of-EGFR-inhibitor-resistance-in 2026-07-02T09:20:49.057Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerCell-2021-Tanaka-Targeting-aurora-B-kinase-prevents-and-overcomes-resistance-to-EGFR-inhibitors-in-lung-cancer-by-enhancing-BIM-and 2026-07-02T09:20:49.054Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerCell-2026-Vuong-Hypoxia-shapes-both-therapeutic-response-and-resistance-in-metastatic-clear-cell-renal-cell-carcinoma 2026-07-02T09:20:49.118Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerChemotherPharmacol-2012-Togashi-Cerebrospinal-fluid-concentration-of-gefitinib-and-erlotinib-in-patients-with-non-small-cell-lung-cancer 2026-07-02T09:20:49.152Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerDiscov-2012-Ercan-Reactivation-of-ERK-signaling-causes-resistance-to-EGFR-kinase-inhibitors 2026-07-02T09:20:49.072Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerDiscov-2012-Takezawa-HER2-amplification-a-potential-mechanism-of-acquired-resistance-to-EGFR-inhibition-in-EGFR-mutant-lung-cancers-that 2026-07-02T09:20:49.143Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerDiscov-2013-Akbay-Activation-of-the-PD-1-pathway-contributes-to-immune-escape-in-EGFR-driven-lung-tumors 2026-07-02T09:20:49.044Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerDiscov-2013-Walter-Discovery-of-a-mutant-selective-covalent-inhibitor-of-EGFR-that-overcomes-T790M-mediated-resistance-in-NSCLC 2026-07-02T09:20:49.038Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerDiscov-2014-Cross-AZD9291,-an-irreversible-EGFR-TKI,-overcomes-T790M-mediated-resistance-to-EGFR-inhibitors-in-lung-cancer 2026-07-02T09:20:49.124Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerDiscov-2014-Janjigian-Dual-inhibition-of-EGFR-with-afatinib-and-cetuximab-in-kinase-inhibitor-resistant-EGFR-mutant-lung-cancer-with-and 2026-07-02T09:20:49.042Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerDiscov-2014-deBruin-Reduced-NF1-expression-confers-resistance-to-EGFR-inhibition-in-lung-cancer 2026-07-02T09:20:49.141Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerDiscov-2018-Piotrowska-Landscape-of-acquired-resistance-to-osimertinib-in-EGFR-mutant-NSCLC-and-clinical-validation-of-combined-EGFR-and-RET 2026-07-02T09:20:49.062Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerDiscov-2020-Yun-Antitumor-activity-of-amivantamab-(JNJ-61186372),-an-EGFR-MET-bispecific-antibody,-in-diverse-models-of-EGFR-exon-20 2026-07-02T09:20:49.144Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerDiscov-2026-Piotrowska-ELIOS-A-multicenter,-molecular-profiling-study-of-patients-with-EGFR-mutant-advanced-non-small-cell-lung-cancer-treated 2026-07-02T09:20:49.100Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerMetastasisRev-2012-Suda-Acquired-resistance-mechanisms-to-tyrosine-kinase-inhibitors-in-lung-cancer-with-activating-epidermal-growth-factor 2026-07-02T09:20:49.073Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerRes-2004-Kosaka-Mutations-of-the-epidermal-growth-factor-receptor-gene-in-lung-cancer-biological-and-clinical-implications 2026-07-02T09:20:49.102Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerRes-2005-Thomson-Epithelial-to-mesenchymal-transition-is-a-determinant-of-sensitivity-of-non-small-cell-lung-carcinoma-cell-lines-and 2026-07-02T09:20:49.070Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerRes-2006-Inukai-Presence-of-epidermal-growth-factor-receptor-gene-T790M-mutation-as-a-minor-clone-in-non-small-cell-lung-cancer 2026-07-02T09:20:49.100Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerRes-2006-Witta-Restoring-E-cadherin-expression-increases-sensitivity-to-epidermal-growth-factor-receptor-inhibitors-in-lung-cancer 2026-07-02T09:20:49.147Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerRes-2007-Yu-Resistance-to-an-irreversible-epidermal-growth-factor-receptor-(EGFR)-inhibitor-in-EGFR-mutant-lung-cancer-reveals 2026-07-02T09:20:49.140Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerRes-2011-Sasaki-A-novel-ALK-secondary-mutation-and-EGFR-signaling-cause-resistance-to-ALK-kinase-inhibitors 2026-07-02T09:20:49.116Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerRes-2013-Nakagawa-EGFR-TKI-resistance-due-to-BIM-polymorphism-can-be-circumvented-in-combination-with-HDAC-inhibition 2026-07-02T09:20:49.137Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerRes-2014-Nakayama-Beta-catenin-contributes-to-lung-tumor-development-induced-by-EGFR-mutations 2026-07-02T09:20:49.098Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerRes-2014-Rho-MET-and-AXL-inhibitor-NPS-1034-exerts-efficacy-against-lung-cancer-cells-resistant-to-EGFR-kinase-inhibitors-because-of-MET-or-AXL-activation 2026-07-02T09:20:49.043Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerRes-2015-Soucheray-Intratumoral-heterogeneity-in-EGFR-mutant-NSCLC-results-in-divergent-resistance-mechanisms-in-response-to-EGFR-tyrosine 2026-07-02T09:20:49.097Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerRes-2016-Jia-EGF816-exerts-anticancer-effects-in-non-small-cell-lung-cancer-by-irreversibly-and-selectively-targeting-primary-and 2026-07-02T09:20:49.050Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerRes-2017-Kosaka-Response-heterogeneity-of-EGFR-and-HER2-exon-20-insertions-to-covalent-EGFR-and-HER2-inhibitors 2026-07-02T09:20:49.032Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerRes-2017-Nukaga-Amplification-of-EGFR-wild-type-alleles-in-non-small-cell-lung-cancer-cells-confers-acquired-resistance-to 2026-07-02T09:20:49.062Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerRes-2017-Vaishnavi-EGFR-mediates-responses-to-small-molecule-drugs-targeting-oncogenic-fusion-kinases 2026-07-02T09:20:49.131Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerRes-2021-Kashima-Single-cell-analyses-reveal-diverse-mechanisms-of-resistance-to-EGFR-tyrosine-kinase-inhibitors-in-lung-cancer 2026-07-02T09:20:55.013Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerSci-2016-Kobayashi-Not-all-epidermal-growth-factor-receptor-mutations-in-lung-cancer-are-created-equal-perspectives-for-individualized 2026-07-02T09:20:49.130Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerSci-2020-Nishio-Ramucirumab-or-placebo-plus-erlotinib-in-EGFR-mutated,-metastatic-non-small-cell-lung-cancer-east-asian-subset-of-RELAY 2026-07-02T09:20:49.072Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerTreatRev-2014-Rolfo-Novel-therapeutic-strategies-for-patients-with-NSCLC-that-do-not-respond-to-treatment-with-EGFR-inhibitors 2026-07-02T09:20:49.102Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerTreatRev-2018-Lim-Acquired-resistance-to-EGFR-targeted-therapy-in-non-small-cell-lung-cancer-mechanisms-and-therapeutic-strategies 2026-07-02T09:20:49.069Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CancerTreatRev-2026-Zhao-Perioperative-strategies-for-resectable-EGFR-mutant-NSCLC-evidence-hierarchy-and-clinical-decision-making 2026-07-02T09:20:49.150Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/Cell-2010-Lemmon-Cell-signaling-by-receptor-tyrosine-kinases 2026-07-02T09:20:49.071Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CellRepMed-2022-Soltis-Proteogenomic-analysis-of-lung-adenocarcinoma-reveals-tumor-heterogeneity,-survival-determinants,-and-therapeutically 2026-07-02T09:20:49.043Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2005-Yauch-Epithelial-versus-mesenchymal-phenotype-determines-in-vitro-sensitivity-and-predicts-clinical-activity-of-erlotinib-in 2026-07-02T09:20:49.061Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2006-Balak-Novel-D761Y-and-common-secondary-T790M-mutation-in-EGFR-mutant-lung-adenocarcinoma-with-acquired-resistance 2026-07-02T09:20:49.149Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2006-Kimura-Detection-of-epidermal-growth-factor-receptor-mutations-in-serum-as-a-predictor-of-the-response-to-gefitinib-in 2026-07-02T09:20:49.140Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2006-Kosaka-Analysis-of-epidermal-growth-factor-receptor-gene-mutation-in-patients-with-non-small-cell-lung-cancer-and-acquired 2026-07-02T09:20:49.034Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2006-Riely-Clinical-course-of-patients-with-non-small-cell-lung-cancer-and-epidermal-growth-factor-receptor-exon-19-and-exon-21 2026-07-02T09:20:49.110Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2007-Pao-Epidermal-growth-factor-receptor-mutation-testing-in-lung-cancer-searching-for-the-ideal-method 2026-07-02T09:20:49.138Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2010-Heon-Development-of-central-nervous-system-metastases-in-patients-with-advanced-non-small-cell-lung-cancer-and-somatic-EGFR 2026-07-02T09:20:49.150Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2011-Arcila-Rebiopsy-of-lung-cancer-patients-with-acquired-resistance-to-EGFR-inhibitors-and-enhanced-detection-of-the-T790M 2026-07-02T09:20:49.039Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2011-Oxnard-Acquired-resistance-to-EGFR-tyrosine-kinase-inhibitors-in-EGFR-mutant-lung-cancer-distinct-natural-history-of-patients 2026-07-02T09:20:49.100Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2011-Wu-Effectiveness-of-tyrosine-kinase-inhibitors-on-uncommon-epidermal-growth-factor-receptor-mutations-of-unknown-clinical 2026-07-02T09:20:49.121Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2012-Heon-The-impact-of-initial-gefitinib-or-erlotinib-versus-chemotherapy-on-central-nervous-system-progression-in-advanced 2026-07-02T09:20:49.096Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2013-Byers-An-epithelial-mesenchymal-transition-gene-signature-predicts-resistance-to-EGFR-and-PI3K-inhibitors-and-identifies-axl 2026-07-02T09:20:49.028Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2013-Byun-USP8-is-a-novel-target-for-overcoming-gefitinib-resistance-in-lung-cancer 2026-07-02T09:20:49.095Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2013-Yu-Analysis-of-tumor-specimens-at-the-time-of-acquired-resistance-to-EGFR-TKI-therapy-in-155-patients-with-EGFR-mutant 2026-07-02T09:20:49.056Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2015-Corte-SMO-gene-amplification-and-activation-of-the-hedgehog-pathway-as-novel-mechanisms-of-resistance-to-anti-EGFR-in-human-lung-cancer 2026-07-02T09:20:49.045Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2015-Kobayashi-EGFR-exon-18-mutations-in-lung-cancer-molecular-predictors-of-augmented-sensitivity-to-afatinib-or-neratinib-as 2026-07-02T09:20:49.113Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2015-Lara-Phase-II-study-of-the-AKT-inhibitor-MK-2206-plus-erlotinib-in-patients-with-advanced-non-small-cell-lung-cancer-who 2026-07-02T09:20:49.029Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2016-Ballard-Preclinical-comparison-of-osimertinib-with-other-EGFR-TKIs-in-EGFR-mutant-NSCLC-brain-metastases-models,-and-early 2026-07-02T09:20:49.028Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2016-Gainor-EGFR-mutations-and-ALK-rearrangements-are-associated-with-low-response-rates-to-PD-1-pathway-blockade-in-NSCLC 2026-07-02T09:20:49.042Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2016-Karlovich-Assessment-of-EGFR-mutation-status-in-matched-plasma-and-tumor-tissue-of-NSCLC-patients-from-a-phase-I-study-of 2026-07-02T09:20:49.096Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2016-Thompson-Detection-of-therapeutically-targetable-driver-and-resistance-mutations-in-lung-cancer-patients-by-next-generation 2026-07-02T09:20:49.099Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2017-Shi-Overcoming-acquired-resistance-to-AZD9291,-A-third-generation-EGFR-inhibitor,-through-modulation-of-MEKERK-dependent 2026-07-02T09:20:49.118Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2017-Wang-Progression-of-EGFR-mutant-lung-adenocarcinoma-is-driven-by-alveolar-macrophages 2026-07-02T09:20:49.064Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2017-Yu-A-phase-I,-dose-escalation-study-of-oral-ASP8273-in-patients-with-non-small-cell-lung-cancers-with-epidermal-growth 2026-07-02T09:20:49.149Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2018-Yang-Investigating-novel-resistance-mechanisms-to-third-generation-EGFR-tyrosine-kinase-inhibitor-osimertinib-in-non-small 2026-07-02T09:20:49.036Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2019-Brown-On-target-resistance-to-the-mutant-selective-EGFR-inhibitor-osimertinib-can-develop-in-an-allele-specific-manner 2026-07-02T09:20:49.145Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2019-Offin-Tumor-mutation-burden-and-efficacy-of-EGFR-tyrosine-kinase-inhibitors-in-patients-with-EGFR-mutant-lung-cancers 2026-07-02T09:20:49.065Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2020-Schoenfeld-Tumor-analyses-reveal-squamous-transformation-and-off-target-alterations-as-early-resistance-mechanisms-to-first-line 2026-07-02T09:20:49.073Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2020-Xing-Biomarkers-of-osimertinib-response-in-patients-with-refractory,-EGFR-T790M-positive-non-small-cell-lung-cancer-and 2026-07-02T09:20:49.047Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinCancerRes-2021-Choudhury-Response-to-standard-therapies-and-comprehensive-genomic-analysis-for-patients-with-lung-adenocarcinoma-with-EGFR-exon 2026-07-02T09:20:49.124Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinLungCancer-2012-Koizumi-Prospective-study-of-gefitinib-readministration-after-chemotherapy-in-patients-with-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:49.143Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinLungCancer-2015-Matikas-Current-and-future-approaches-in-the-management-of-non-small-cell-lung-cancer-patients-with-resistance-to-EGFR-TKIs 2026-07-02T09:20:49.151Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ClinLungCancer-2026-Lu-Characteristics-and-clinical-outcomes-of-de-novo-and-acquired-uncommon-compound-EGFR-mutations-in-patients-with 2026-07-02T09:20:49.130Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CritRevOncolHematol-2014-Bronte-Are-erlotinib-and-gefitinib-interchangeable,-opposite-or-complementary-for-non-small-cell-lung-cancer-treatment 2026-07-02T09:20:49.052Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/CurrDrugTargets-2010-Li-Intercalation-of-erlotinib-and-pemetrexed-in-the-treatment-of-non-small-cell-lung-cancer 2026-07-02T09:20:49.041Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ESMOOpen-2018-Oizumi-Updated-survival-outcomes-of-NEJ005TCOG0902-a-randomised-phase-II-study-of-concurrent-versus-sequential-alternating 2026-07-02T09:20:49.099Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/EurJCancer-2011-Becker-Retreatment-with-erlotinib-regain-of-TKI-sensitivity-following-a-drug-holiday-for-patients-with-NSCLC-who-initially 2026-07-02T09:20:49.041Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/EurJCancer-2017-Lin-An-increase-in-BAG-1-by-PD-L1-confers-resistance-to-tyrosine-kinase-inhibitor-in-non-small-cell-lung-cancer-via 2026-07-02T09:20:49.058Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/EurJCancer-2024-Watanabe-A-phase-II-study-of-atezolizumab-with-bevacizumab,-carboplatin,-and-paclitaxel-for-patients-with-EGFR-mutated-NSCLC 2026-07-02T09:20:49.036Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/FrontImmunol-2026-Niu-Efficacy-and-mechanisms-of-immune-checkpoint-inhibitors-in-late-stage-EGFR-mutated-non-small-cell-lung-cancer-following 2026-07-02T09:20:49.065Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/FrontOncol-2026-Kim-Paired-ctDNA-analysis-reveals-diverse-resistance-mechanisms-to-mobocertinib-in-EGFR-exon-20-insertion-NSCLC 2026-07-02T09:20:49.125Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/IntJOncol-2016-Zhang-EGFR-pathway-is-involved-in-the-regulation-of-PD-L1-expression-via-the-IL-6-JAK-STAT3-signaling-pathway-in-EGFR-mutated-NSCLC 2026-07-02T09:20:49.138Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JAMA-2003-Kris-Efficacy-of-gefitinib,-an-inhibitor-of-the-epidermal-growth-factor-receptor-tyrosine-kinase,-in-symptomatic-patients 2026-07-02T09:20:49.049Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JAMA-2026-HARMONi-A-Bispecific-antibody-ivonescimab-added-to-chemotherapy-in-EGFR-variant-non-small-cell-lung-cancer-the-HARMONi-A 2026-07-02T09:20:49.044Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JAMAOncol-2018-Oshima-EGFR-TKI-associated-interstitial-pneumonitis-in-nivolumab-treated-patients-with-non-small-cell-lung-cancer 2026-07-02T09:20:49.132Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JAMAOncol-2018-Oxnard-Assessment-of-resistance-mechanisms-and-clinical-implications-in-patients-with-EGFR-T790M-positive-lung-cancer-and 2026-07-02T09:20:49.055Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JAMAOncol-2021-Akamatsu-Efficacy-of-osimertinib-plus-bevacizumab-vs-osimertinib-in-patients-with-EGFR-T790M-mutated-non-small-cell-lung-cancer 2026-07-02T09:20:49.111Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JCancerResClinOncol-2014-Tang-Different-treatment-orders-achieved-similar-clinical-results-a-retrospective-study-for-retreatment-of-epidermal-growth 2026-07-02T09:20:49.109Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinInvest-2018-Gong-TNF-driven-adaptive-response-mediates-resistance-to-EGFR-inhibition-in-lung-cancer 2026-07-02T09:20:49.098Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2003-Fukuoka-Multi-institutional-randomized-phase-II-trial-of-gefitinib-for-previously-treated-patients-with-advanced-non-small-cell 2026-07-02T09:20:49.092Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2004-Giaccone-Gefitinib-in-combination-with-gemcitabine-and-cisplatin-in-advanced-non-small-cell-lung-cancer-a-phase-III-trial-INTACT 2026-07-02T09:20:49.131Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2005-Herbst-TRIBUTE-a-phase-III-trial-of-erlotinib-hydrochloride-(OSI-774)-combined-with-carboplatin-and-paclitaxel-chemotherapy-in 2026-07-02T09:20:49.046Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2007-Cho-Phase-II-study-of-erlotinib-in-advanced-non-small-cell-lung-cancer-after-failure-of-gefitinib 2026-07-02T09:20:49.145Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2007-Suehisa-Epidermal-growth-factor-receptor-mutation-status-and-adjuvant-chemotherapy-with-uracil-tegafur-for-adenocarcinoma-of 2026-07-02T09:20:49.028Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2008-Costa-Differential-responses-to-erlotinib-in-epidermal-growth-factor-receptor-(EGFR)-mutated-lung-cancers-with-acquired 2026-07-02T09:20:49.127Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2008-Sequist-First-line-gefitinib-in-patients-with-advanced-non-small-cell-lung-cancer-harboring-somatic-EGFR-mutations 2026-07-02T09:20:49.112Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2010-Jackman-Clinical-definition-of-acquired-resistance-to-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors-in 2026-07-02T09:20:49.149Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2012-Han-First-SIGNAL-first-line-single-agent-iressa-versus-gemcitabine-and-cisplatin-trial-in-never-smokers-with-adenocarcinoma 2026-07-02T09:20:49.037Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2012-Su-Pretreatment-epidermal-growth-factor-receptor-(EGFR)-T790M-mutation-predicts-shorter-EGFR-tyrosine-kinase-inhibitor 2026-07-02T09:20:49.054Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2013-Sequist-Phase-III-study-of-afatinib-or-cisplatin-plus-pemetrexed-in-patients-with-metastatic-lung-adenocarcinoma-with-EGFR 2026-07-02T09:20:49.112Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2014-Kawaguchi-Randomized-phase-III-trial-of-erlotinib-versus-docetaxel-as-second-or-third-line-therapy-in-patients-with-advanced 2026-07-02T09:20:49.147Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2015-Johnson-Phase-III-study-of-HSP90-inhibitor-AUY922-and-erlotinib-for-EGFR-mutant-lung-cancer-with-acquired-resistance-to 2026-07-02T09:20:49.127Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2015-Kelly-Adjuvant-erlotinib-versus-placebo-in-patients-with-stage-IB-IIIA-non-small-cell-lung-cancer-(RADIANT)-A-randomized, 2026-07-02T09:20:49.041Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2015-Lee-Impact-of-specific-epidermal-growth-factor-receptor-(EGFR)-mutations-and-clinical-characteristics-on-outcomes-after 2026-07-02T09:20:49.075Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2016-Oxnard-Association-between-plasma-genotyping-and-outcomes-of-treatment-with-osimertinib-(AZD9291)-in-advanced-non-small-cell 2026-07-02T09:20:49.113Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2016-Urata-Gefitinib-vs-erlotinib-for-EGFR-mutant-NSCLC-Phase-3-WJOG5108L 2026-07-02T09:20:49.035Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2017-Magnuson-Management-of-brain-metastases-in-tyrosine-kinase-inhibitor-naive-epidermal-growth-factor-receptor-mutant 2026-07-02T09:20:49.118Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2017-Mok-Gefitinib-plus-chemotherapy-versus-chemotherapy-in-epidermal-growth-factor-receptor-mutation-positive-non-small-cell 2026-07-02T09:20:49.065Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2017-Yang-Osimertinib-in-pretreated-T790M-positive-advanced-non-small-cell-lung-cancer-AURA-study-phase-II-extension-component 2026-07-02T09:20:49.112Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2018-Ramalingam-Osimertinib-as-first-line-treatment-of-EGFR-mutation-positive-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:49.062Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2018-Reungwetwattana-CNS-response-to-osimertinib-versus-standard-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors-in-patients 2026-07-02T09:20:49.066Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2018-Wu-CNS-efficacy-of-osimertinib-in-patients-with-T790M-positive-advanced-non-small-cell-lung-cancer-data-from-a-randomized 2026-07-02T09:20:49.069Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2020-Cho-Osimertinib-for-patients-with-non-small-cell-lung-cancer-harboring-uncommon-EGFR-mutations-A-multicenter,-open-label, 2026-07-02T09:20:49.042Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2020-Goldberg-Randomized-trial-of-afatinib-plus-cetuximab-versus-afatinib-alone-for-first-line-treatment-of-EGFR-mutant 2026-07-02T09:20:49.030Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2020-Hosomi-Gefitinib-alone-versus-gefitinib-plus-chemotherapy-for-non-small-cell-lung-cancer-with-mutated-epidermal-growth-factor 2026-07-02T09:20:49.123Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2020-Yang-Osimertinib-in-patients-with-epidermal-growth-factor-receptor-mutation-positive-non-small-cell-lung-cancer-and 2026-07-02T09:20:49.095Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JClinOncol-2021-Park-Amivantamab-in-EGFR-exon-20-insertion-mutated-non-small-cell-lung-cancer-progressing-on-platinum-chemotherapy-initial 2026-07-02T09:20:49.040Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JNatlCancerInst-2005-Shigematsu-Clinical-and-biological-features-associated-with-epidermal-growth-factor-receptor-gene-mutations-in-lung-cancers 2026-07-02T09:20:49.091Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JNatlCancerInst-2014-Gao-Selective-antitumor-activity-of-ibrutinib-in-EGFR-mutant-non-small-cell-lung-cancer-cells 2026-07-02T09:20:49.040Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JNatlCancerInst-2017-Chaib-Coactivation-of-STAT3-and-YAP1-pathway-in-EGFR-mutant-NSCLC 2026-07-02T09:20:49.043Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JTOClinResRep-2020-Haratake-Optimizing-sequential-treatment-with-EGFR-tyrosine-kinase-inhibitor-with-a-simulation-of-the-T790M-mutation-rate-in 2026-07-02T09:20:49.150Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JThoracOncol-2008-Wong-Evidence-for-disease-control-with-erlotinib-after-gefitinib-failure-in-typical-gefitinib-sensitive-asian-patients-with 2026-07-02T09:20:49.041Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JThoracOncol-2010-Kaira-Pulmonary-pleomorphic-carcinoma-a-clinicopathological-study-including-EGFR-mutation-analysis 2026-07-02T09:20:49.033Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JThoracOncol-2010-Price-Phase-II-trial-of-gefitinib-and-everolimus-in-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:49.110Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JThoracOncol-2010-Takeda-De-novo-resistance-to-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors-in-EGFR-mutation-positive-patients 2026-07-02T09:20:49.060Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JThoracOncol-2013-Kobayashi-Compound-EGFR-mutations-and-response-to-EGFR-tyrosine-kinase-inhibitors 2026-07-02T09:20:49.145Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JThoracOncol-2014-Shin-EGFR-mutation-and-brain-metastasis-in-pulmonary-adenocarcinomas 2026-07-02T09:20:49.116Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JThoracOncol-2014-Watanabe-Effectiveness-of-gefitinib-against-non-small-cell-lung-cancer-with-the-uncommon-EGFR-mutations-G719X-and-L861Q 2026-07-02T09:20:49.151Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JThoracOncol-2015-Chen-Upregulation-of-PD-L1-by-EGFR-activation-mediates-the-immune-escape-in-EGFR-driven-NSCLC-implication-for-optional 2026-07-02T09:20:49.107Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JThoracOncol-2015-Chiu-Epidermal-growth-factor-receptor-tyrosine-kinase-inhibitor-treatment-response-in-advanced-lung-adenocarcinomas-with 2026-07-02T09:20:49.040Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JThoracOncol-2015-Hoffknecht-Efficacy-of-the-irreversible-ErbB-family-blocker-afatinib-in-epidermal-growth-factor-receptor-(EGFR)-tyrosine-kinase 2026-07-02T09:20:49.072Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JThoracOncol-2015-Scheffler-Spatial-tumor-heterogeneity-in-lung-cancer-with-acquired-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitor 2026-07-02T09:20:49.075Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JThoracOncol-2015-Tseng-Dynamic-plasma-EGFR-mutation-status-as-a-predictor-of-EGFR-TKI-efficacy-in-patients-with-EGFR-mutant-lung-adenocarcinoma 2026-07-02T09:20:49.055Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JThoracOncol-2017-Lee-Checkpoint-inhibitors-in-metastatic-EGFR-mutated-non-small-cell-lung-Cancer-A-meta-analysis 2026-07-02T09:20:49.092Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JThoracOncol-2017-Wang-Lung-adenocarcinoma-harboring-EGFR-T790M-and-in-trans-C797S-responds-to-combination-therapy-of-first-and 2026-07-02T09:20:49.121Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JThoracOncol-2018-Garassino-Italian-nivolumab-expanded-access-program-in-nonsquamous-non-small-cell-lung-cancer-patients-results-in-never-smokers 2026-07-02T09:20:49.049Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JThoracOncol-2018-Gettinger-Nivolumab-plus-erlotinib-in-patients-with-EGFR-mutant-advanced-NSCLC 2026-07-02T09:20:49.093Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JThoracOncol-2018-Lisberg-A-phase-II-study-of-pembrolizumab-in-EGFR-mutant,-PD-l1+,-tyrosine-kinase-inhibitor-naive-patients-with-advanced-NSCLC 2026-07-02T09:20:49.055Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JThoracOncol-2018-Minari-Concurrent-acquired-BRAF-V600E-mutation-and-MET-amplification-as-resistance-mechanism-of-first-line-osimertinib 2026-07-02T09:20:49.033Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JThoracOncol-2018-Shibahara-Intrinsic-and-extrinsic-regulation-of-PD-L2-expression-in-oncogene-driven-non-small-cell-lung-cancer 2026-07-02T09:20:49.061Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JThoracOncol-2018-Su-Strong-programmed-death-ligand-1-expression-predicts-poor-response-and-de-novo-resistance-to-EGFR-tyrosine-kinase 2026-07-02T09:20:55.169Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JThoracOncol-2018-Uchibori-Identification-of-mutation-accumulation-as-resistance-mechanism-emerging-in-first-line-osimertinib-treatment 2026-07-02T09:20:49.030Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JThoracOncol-2020-Ahn-Osimertinib-for-patients-with-leptomeningeal-metastases-associated-with-EGFR-T790M-positive-advanced-NSCLC-the-AURA 2026-07-02T09:20:49.093Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JThoracOncol-2021-Aredo-Durvalumab-for-stage-III-EGFR-mutated-NSCLC-after-definitive-chemoradiotherapy 2026-07-02T09:20:49.066Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JThoracOncol-2021-Shields-Selpercatinib-overcomes-CCDC6-RET-mediated-resistance-to-osimertinib 2026-07-02T09:20:49.061Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JThoracOncol-2022-Nogami-IMpower150-final-exploratory-analyses-for-atezolizumab-plus-bevacizumab-and-chemotherapy-in-key-NSCLC-patient-subgroups 2026-07-02T09:20:49.082Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JpnJClinOncol-2012-Takeda-Clinical-impact-of-switching-to-a-second-EGFR-TKI-after-a-severe-AE-related-to-a-first-EGFR-TKI-in-EGFR-mutated-NSCLC 2026-07-02T09:20:49.071Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/JpnJClinOncol-2019-Ohe-Osimertinib-versus-standard-of-care-EGFR-TKI-as-first-line-treatment-for-EGFRm-advanced-NSCLC-FLAURA-japanese-subset 2026-07-02T09:20:49.142Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/Lancet-2005-Thatcher-Gefitinib-plus-best-supportive-care-in-previously-treated-patients-with-refractory-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:49.111Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/Lancet-2008-Kim-Gefitinib-versus-docetaxel-in-previously-treated-non-small-cell-lung-cancer-(INTEREST)-a-randomised-phase-III-trial 2026-07-02T09:20:49.039Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/Lancet-2013-Rosell-Genetics-and-biomarkers-in-personalisation-of-lung-cancer-treatment 2026-07-02T09:20:49.114Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LancetOncol-2008-Linardou-Assessment-of-somatic-k-RAS-mutations-as-a-mechanism-associated-with-resistance-to-EGFR-targeted-agents-a-systematic 2026-07-02T09:20:49.049Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LancetOncol-2010-Cappuzzo-Erlotinib-as-maintenance-treatment-in-advanced-non-small-cell-lung-cancer-a-multicentre,-randomised,-placebo-controlled 2026-07-02T09:20:49.029Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LancetOncol-2010-Mitsudomi-Gefitinib-versus-cisplatin-plus-docetaxel-in-patients-with-non-small-cell-lung-cancer-harbouring-mutations-of-the 2026-07-02T09:20:49.117Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LancetOncol-2011-Zhou-Erlotinib-versus-chemotherapy-as-first-line-treatment-for-patients-with-advanced-EGFR-mutation-positive-non-small-cell 2026-07-02T09:20:49.126Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LancetOncol-2012-Ciuleanu-Efficacy-and-safety-of-erlotinib-versus-chemotherapy-in-second-line-treatment-of-patients-with-advanced,-non-small-cell 2026-07-02T09:20:49.051Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LancetOncol-2012-Lee-First-line-erlotinib-in-patients-with-advanced-non-small-cell-lung-cancer-unsuitable-for-chemotherapy-(TOPICAL)-a 2026-07-02T09:20:49.085Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LancetOncol-2012-Miller-Afatinib-versus-placebo-for-patients-with-advanced,-metastatic-non-small-cell-lung-cancer-after-failure-of-erlotinib, 2026-07-02T09:20:49.044Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LancetOncol-2012-Rosell-Erlotinib-versus-standard-chemotherapy-as-first-line-treatment-for-european-patients-with-advanced-EGFR 2026-07-02T09:20:49.142Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LancetOncol-2012-Yang-Afatinib-for-patients-with-lung-adenocarcinoma-and-epidermal-growth-factor-receptor-mutations-(LUX-lung-2)-a-phase-2 2026-07-02T09:20:49.048Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LancetOncol-2012-Zhang-Gefitinib-versus-placebo-as-maintenance-therapy-in-patients-with-locally-advanced-or-metastatic-non-small-cell-lung 2026-07-02T09:20:49.067Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LancetOncol-2014-Seto-Erlotinib-alone-or-with-bevacizumab-as-first-line-therapy-in-patients-with-advanced-non-squamous-non-small-cell-lung 2026-07-02T09:20:49.053Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LancetOncol-2014-Wu-Afatinib-versus-cisplatin-plus-gemcitabine-for-first-line-treatment-of-asian-patients-with-advanced-non-small-cell-lung 2026-07-02T09:20:49.103Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LancetOncol-2015-Soria-Gefitinib-plus-chemotherapy-versus-placebo-plus-chemotherapy-in-EGFR-mutation-positive-non-small-cell-lung-cancer-after 2026-07-02T09:20:49.039Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LancetOncol-2015-Tan-Treatment-approaches-for-EGFR-inhibitor-resistant-patients-with-non-small-cell-lung-cancer 2026-07-02T09:20:49.055Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LancetOncol-2015-Yang-Afatinib-versus-cisplatin-based-chemotherapy-for-EGFR-mutation-positive-lung-adenocarcinoma-(LUX-lung-3-and-LUX-lung-6) 2026-07-02T09:20:49.123Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LancetOncol-2015-Yang-Clinical-activity-of-afatinib-in-patients-with-advanced-non-small-cell-lung-cancer-harbouring-uncommon-EGFR-mutations-a 2026-07-02T09:20:49.063Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LancetOncol-2016-Goss-Osimertinib-for-pretreated-EGFR-Thr790Met-positive-advanced-non-small-cell-lung-cancer-(AURA2)-a-multicentre, 2026-07-02T09:20:49.030Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LancetOncol-2016-Park-Afatinib-versus-gefitinib-as-first-line-treatment-of-patients-with-EGFR-mutation-positive-non-small-cell-lung-cancer 2026-07-02T09:20:49.032Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LancetOncol-2017-Wu-Dacomitinib-versus-gefitinib-as-first-line-treatment-for-patients-with-EGFR-mutation-positive-non-small-cell-lung 2026-07-02T09:20:55.209Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LancetOncol-2018-Zhong-Gefitinib-versus-vinorelbine-plus-cisplatin-as-adjuvant-treatment-for-stage-II-IIIA-(N1-N2)-EGFR-mutant-NSCLC 2026-07-02T09:20:49.034Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LancetOncol-2019-Nakagawa-Ramucirumab-plus-erlotinib-in-patients-with-untreated,-EGFR-mutated,-advanced-non-small-cell-lung-cancer-(RELAY)-a 2026-07-02T09:20:49.103Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LancetOncol-2020-Sequist-Osimertinib-plus-savolitinib-in-patients-with-EGFR-mutation-positive,-MET-amplified,-non-small-cell-lung-cancer-after 2026-07-02T09:20:49.120Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LancetOncol-2026-Li-Aumolertinib-with-or-without-chemotherapy-in-EGFR-mutated-advanced-non-small-cell-lung-cancer-(AENEAS2)-an-open-label, 2026-07-02T09:20:49.053Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LancetRespirMed-2017-Ahn-Activity-and-safety-of-AZD3759-in-EGFR-mutant-non-small-cell-lung-cancer-with-CNS-metastases-(BLOOM)-a-phase-1, 2026-07-02T09:20:49.138Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LancetRespirMed-2017-Rosell-Erlotinib-and-bevacizumab-in-patients-with-advanced-non-small-cell-lung-cancer-and-activating-EGFR-mutations-(BELIEF) 2026-07-02T09:20:49.136Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LancetRespirMed-2019-Reck-Atezolizumab-plus-bevacizumab-and-chemotherapy-in-non-small-cell-lung-cancer-(IMpower150)-key-subgroup-analyses-of 2026-07-02T09:20:49.074Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LungCancer-2009-Sim-Erlotinib-after-gefitinib-failure-in-female-never-smoker-asian-patients-with-pulmonary-adenocarcinoma 2026-07-02T09:20:49.047Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LungCancer-2010-Tomizawa-Effect-of-gefitinib-re-challenge-to-initial-gefitinib-responder-with-non-small-cell-lung-cancer-followed-by-chemotherapy 2026-07-02T09:20:49.060Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LungCancer-2012-Oh-Retreatment-of-gefitinib-in-patients-with-non-small-cell-lung-cancer-who-previously-controlled-to-gefitinib-a 2026-07-02T09:20:49.122Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LungCancer-2012-Yamaguchi-Analysis-of-EGFR,-KRAS-and-P53-mutations-in-lung-cancer-using-cells-in-the-curette-lavage-fluid-obtained-by-bronchoscopy 2026-07-02T09:20:49.052Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LungCancer-2015-Fukuhara-Factors-associated-with-a-poor-response-to-gefitinib-in-the-NEJ002-study-smoking-and-the-L858R-mutation 2026-07-02T09:20:49.037Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LungCancer-2015-Kogo-Transformation-to-large-cell-neuroendocrine-carcinoma-as-acquired-resistance-mechanism-of-EGFR-tyrosine-kinase-inhibitor 2026-07-02T09:20:49.135Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LungCancer-2015-Lee-Pemetrexed-plus-platinum-versus-pemetrexed-alone-in-non-small-cell-lung-cancer-patients-who-have-progressed-after 2026-07-02T09:20:49.066Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LungCancer-2017-OKane-Uncommon-EGFR-mutations-in-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:49.032Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LungCancer-2017-Soo-Significance-of-immune-checkpoint-proteins-in-EGFR-mutant-non-small-cell-lung-cancer 2026-07-02T09:20:49.133Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LungCancer-2018-Baldacci-MET-amplification-increases-the-metastatic-spread-of-EGFR-mutated-NSCLC 2026-07-02T09:20:49.127Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LungCancer-2018-Soo-Immune-checkpoint-inhibitors-in-epidermal-growth-factor-receptor-mutant-non-small-cell-lung-cancer-current 2026-07-02T09:20:49.057Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LungCancer-2018-Yoneshima-PD-L1-expression-in-lung-adenocarcinoma-harboring-EGFR-mutations-or-ALK-rearrangements 2026-07-02T09:20:49.097Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LungCancer-2019-Akamatsu-Clinical-significance-of-monitoring-EGFR-mutation-in-plasma-using-multiplexed-digital-PCR-in-EGFR-mutated-patients 2026-07-02T09:20:49.139Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LungCancer-2019-Ichihara-Re-administration-of-osimertinib-in-osimertinib-acquired-resistant-non-small-cell-lung-cancer 2026-07-02T09:20:49.068Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LungCancer-2019-Schuler-First-line-afatinib-for-advanced-EGFRm+-NSCLC-analysis-of-long-term-responders-in-the-LUX-lung-3,-6,-and-7-trials 2026-07-02T09:20:49.133Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LungCancer-2019-Vad-Nielsen-Cause-and-effect-relationship-between-FGFR1-expression-and-epithelial-mesenchymal-transition-in-EGFR-mutated-non-small 2026-07-02T09:20:49.059Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LungCancer-2020-Lin-Complex-EGFR-mutations-with-secondary-T790M-mutation-confer-shorter-osimertinib-progression-free-survival-and-overall 2026-07-02T09:20:49.106Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LungCancer-2020-Zhou-Survival-outcomes-and-symptomatic-central-nervous-system-(CNS)-metastasis-in-EGFR-mutant-advanced-non-small-cell-lung 2026-07-02T09:20:49.138Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LungCancer-2021-Hirose-Extensive-functional-evaluation-of-exon-20-insertion-mutations-of-EGFR 2026-07-02T09:20:49.033Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LungCancer-2026-Okamoto-Durvalumab-plus-etoposide-platinum-in-patients-with-epidermal-growth-factor-receptor-(EGFR)-mutated-advanced-NSCLC-and 2026-07-02T09:20:49.055Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/LungCancer-2026-Wang-Vebreltinib-plus-EGFR-TKI-for-EGFR-mutated-NSCLC-with-MET-driven-resistance-A-real-world-study-of-chinese-patients 2026-07-02T09:20:49.104Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/MolCancerTher-2017-Kobayashi-Characterization-of-EGFR-T790M,-L792F,-and-C797S-mutations-as-mechanisms-of-acquired-resistance-to-afatinib-in-lung 2026-07-02T09:20:49.035Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/MolCancerTher-2017-Watanabe-T790M-selective-EGFR-TKI-combined-with-dasatinib-as-an-optimal-strategy-for-overcoming-EGFR-TKI-resistance-in 2026-07-02T09:20:49.115Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/MolCancerTher-2020-Floch-Osimertinib-exerts-antitumor-activity-in-various-preclinical-NSCLC-models-harboring-the-uncommon-EGFR-mutations-G719X-or-L861Q-or-S768I 2026-07-02T09:20:49.152Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/MolCell-2016-Guernet-CRISPR-Barcoding-for-intratumor-genetic-heterogeneity-modeling-and-functional-analysis-of-oncogenic-driver-mutations 2026-07-02T09:20:49.060Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NEnglJMed-2004-Lynch-Activating-mutations-in-the-epidermal-growth-factor-receptor-underlying-responsiveness-of-non-small-cell-lung-cancer-to 2026-07-02T09:20:49.064Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NEnglJMed-2005-Kobayashi-EGFR-mutation-and-resistance-of-non-small-cell-lung-cancer-to-gefitinib 2026-07-02T09:20:49.051Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NEnglJMed-2005-Shepherd-Erlotinib-in-previously-treated-non-small-cell-lung-cancer 2026-07-02T09:20:49.147Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NEnglJMed-2005-Shih-EGFR-mutation-conferring-primary-resistance-to-gefitinib-in-non-small-cell-lung-cancer 2026-07-02T09:20:49.077Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NEnglJMed-2006-Zakowski-EGFR-mutations-in-small-cell-lung-cancers-in-patients-who-have-never-smoked 2026-07-02T09:20:49.067Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NEnglJMed-2008-Maheswaran-Detection-of-mutations-in-EGFR-in-circulating-lung-cancer-cells 2026-07-02T09:20:49.148Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NEnglJMed-2009-Mok-Gefitinib-or-carboplatin-paclitaxel-in-pulmonary-adenocarcinoma 2026-07-02T09:20:49.042Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NEnglJMed-2009-Rosell-Screening-for-epidermal-growth-factor-receptor-mutations-in-lung-cancer 2026-07-02T09:20:49.037Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NEnglJMed-2010-Maemondo-Gefitinib-or-chemotherapy-for-non-small-cell-lung-cancer-with-mutated-EGFR 2026-07-02T09:20:49.031Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NEnglJMed-2015-Janne-AZD9291-in-EGFR-inhibitor-resistant-non-small-cell-lung-cancer 2026-07-02T09:20:49.050Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NEnglJMed-2015-Sequist-Rociletinib-in-EGFR-mutated-non-small-cell-lung-cancer 2026-07-02T09:20:49.134Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NEnglJMed-2017-Mok-Osimertinib-or-platinum-pemetrexed-in-EGFR-T790M-positive-lung-cancer 2026-07-02T09:20:49.047Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NEnglJMed-2018-Soria-Osimertinib-in-untreated-EGFR-mutated-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:49.034Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NEnglJMed-2020-Ramalingam-Overall-survival-with-osimertinib-in-untreated,-EGFR-mutated-advanced-NSCLC 2026-07-02T09:20:49.080Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NEnglJMed-2020-Wu-Osimertinib-in-resected-EGFR-mutated-non-small-cell-lung-cancer 2026-07-02T09:20:49.128Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NEnglJMed-2023-Zhou-Amivantamab-plus-chemotherapy-in-NSCLC-with-EGFR-exon-20-insertions 2026-07-02T09:20:49.068Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NEnglJMed-2024-Cho-Amivantamab-plus-lazertinib-in-previously-untreated-EGFR-Mutated-advanced-NSCLC 2026-07-02T09:20:49.056Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NEnglJMed-2025-Yang-Overall-survival-with-amivantamab-lazertinib-in-EGFR-Mutated-advanced-NSCLC 2026-07-02T09:20:49.045Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NEnglJMed-2026-Janne-Survival-with-osimertinib-plus-chemotherapy-in-EGFR-mutated-advanced-nsclc 2026-07-02T09:20:49.040Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NEnglJMed-2026-Zhou-First-line-sunvozertinib-in-NSCLC-with 2026-07-02T09:20:49.058Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NatBiotechnol-2022-Chang-Identifying-transcriptional-programs-underlying-cancer-drug-response-with-TraCe-seq 2026-07-02T09:20:49.054Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NatCommun-2015-Niederst-RB-loss-in-resistant-EGFR-mutant-lung-adenocarcinomas-that-transform-to-small-cell-lung-cancer 2026-07-02T09:20:49.139Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NatCommun-2016-Chabon-Circulating-tumour-DNA-profiling-reveals-heterogeneity-of-EGFR-inhibitor-resistance-mechanisms-in-lung-cancer-patients 2026-07-02T09:20:49.039Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NatCommun-2016-Shiraishi-Association-of-variations-in-HLA-class-II-and-other-loci-with-susceptibility-to-EGFR-mutated-lung-adenocarcinoma 2026-07-02T09:20:49.125Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NatCommun-2017-Jacobsen-Convergent-Akt-activation-drives-acquired-EGFR-inhibitor-resistance-in-lung-cancer 2026-07-02T09:20:49.035Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NatCommun-2017-Uchibori-Brigatinib-combined-with-anti-EGFR-antibody-overcomes-osimertinib-resistance-in-EGFR-mutated-non-small-cell-lung-cancer 2026-07-02T09:20:49.096Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NatGenet-2005-Bell-Inherited-susceptibility-to-lung-cancer-may-be-associated-with-the-T790M-drug-resistance-mutation-in-EGFR 2026-07-02T09:20:49.033Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NatGenet-2012-Zhang-Activation-of-the-AXL-kinase-causes-resistance-to-EGFR-targeted-therapy-in-lung-cancer 2026-07-02T09:20:49.129Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NatGenet-2017-Blakely-Evolution-and-clinical-impact-of-co-occurring-genetic-alterations-in-advanced-stage-EGFR-mutant-lung-cancers 2026-07-02T09:20:49.074Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NatMed-2015-Thress-Acquired-EGFR-C797S-mutation-mediates-resistance-to-AZD9291-in-non-small-cell-lung-cancer-harboring-EGFR-T790M 2026-07-02T09:20:49.076Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NatMed-2016-Hata-Tumor-cells-can-follow-distinct-evolutionary-paths-to-become-resistant-to-epidermal-growth-factor-receptor-inhibition 2026-07-02T09:20:49.091Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NatRevCancer-2007-Sharma-Epidermal-growth-factor-receptor-mutations-in-lung-cancer 2026-07-02T09:20:49.059Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NatRevCancer-2021-Kumagai-Antitumour-immunity-regulated-by-aberrant-ERBB-family-signalling 2026-07-02T09:20:49.068Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NatRevClinOncol-2026-Remon-Unresectable-stage-III-non-small-cell-lung-cancer-state-of-the-art-and-challenges 2026-07-02T09:20:49.135Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NatRevClinOncol-2026-Zhao-Navigating-the-landscape-of-EGFR-TKI-resistance-in-EGFR-mutant-NSCLC-mechanisms-and-evolving-treatment-approaches 2026-07-02T09:20:49.136Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/NatRevMolCellBiol-2001-yarden-Untangling-the-ErbB-signalling-network 2026-07-02T09:20:49.142Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/Nature-2016-Jia-Overcoming-EGFR(T790M)-and-EGFR(C797S)-resistance-with-mutant-selective-allosteric-inhibitors 2026-07-02T09:20:49.070Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/Nature-2021-Robichaux-Structure-based-classification-predicts-drug-response-in-EGFR-mutant-NSCLC 2026-07-02T09:20:49.075Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/OncoImmunology-2017-Dong-EGFR-mutation-correlates-with-uninflamed-phenotype-and-weak-immunogenicity,-causing-impaired-response-to-PD-1-blockade 2026-07-02T09:20:49.098Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/Oncogene-2008-Li-BIBW2992,-an-irreversible-EGFRHER2-inhibitor-highly-effective-in-preclinical-lung-cancer-models 2026-07-02T09:20:49.122Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/OncolLett-2014-Yamaguchi-Acquired-resistance-L747S-mutation-in-an-EGFR-TKI-naive-patients 2026-07-02T09:20:49.031Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/Oncologist-2018-Ahluwalia-Epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors-for-central-nervous-system-metastases-from-non-small-cell 2026-07-02T09:20:49.029Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/Oncotarget-2018-Tung-PD-L1-confers-resistance-to-EGFR-mutation-independent-tyrosine-kinase-inhibitors-in-non-small-cell-lung-cancer-via 2026-07-02T09:20:49.034Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/PLoSMed-2005-Pao-Acquired-resistance-of-lung-adenocarcinomas-to-gefitinib-or-erlotinib-is-associated-with-a-second-mutation-in-the-EGFR 2026-07-02T09:20:49.108Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/PLoSMed-2005-Pao-KRAS-mutations-and-primary-resistance-of-lung-adenocarcinomas-to-gefitinib-or-erlotinib 2026-07-02T09:20:49.070Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/PLoSMed-2007-Costa-BIM-mediates-EGFR-tyrosine-kinase-inhibitor-induced-apoptosis-in-lung-cancers-with-oncogenic-EGFR-mutations 2026-07-02T09:20:49.103Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ProcNatlAcadSciUSA-2004-Pao-EGF-receptor-gene-mutations-are-common-in-lung-cancers-from-never-smokers-and-are-associated-with-sensitivity-of-tumors 2026-07-02T09:20:49.094Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ProcNatlAcadSciUSA-2005-Kwak-Irreversible-inhibitors-of-the-EGF-receptor-may-circumvent-acquired-resistance-to-gefitinib 2026-07-02T09:20:49.048Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ProcNatlAcadSciUSA-2007-Bean-MET-amplification-occurs-with-or-without-T790M-mutations-in-EGFR-mutant-lung-tumors-with-acquired-resistance-to 2026-07-02T09:20:49.114Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ProcNatlAcadSciUSA-2019-Ikemura-Molecular-dynamics-simulation-guided-drug-sensitivity-prediction-for-lung-cancer-with-rare-EGFR-mutations 2026-07-02T09:20:49.115Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/RespirInvestig-2019-Asao-Resistance-to-molecularly-targeted-therapy-in-non-small-cell-lung-cancer 2026-07-02T09:20:49.090Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/SciImmunol-2020-Sugiyama-Blockade-of-EGFR-improves-responsiveness-to-PD-1-blockade-in-EGFR-mutated-non-small-cell-lung-cancer 2026-07-02T09:20:49.046Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/SciRep-2017-Fan-Effects-of-icotinib-with-and-without-radiation-therapy-on-patients-with-EGFR-mutant-non-small-cell-lung-cancer-and 2026-07-02T09:20:49.064Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/SciSignal-2013-Meyer-The-receptor-AXL-diversifies-EGFR-signaling-and-limits-the-response-to-EGFR-targeted-inhibitors-in-triple-negative 2026-07-02T09:20:49.030Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/SciSignal-2016-Gao-JAK2-inhibition-sensitizes-resistant-EGFR-mutant-lung-adenocarcinoma-to-tyrosine-kinase-inhibitors 2026-07-02T09:20:49.038Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/SciSignal-2017-Brand-RETRACTED-the-receptor-tyrosine-kinase-AXL-mediates-nuclear-translocation-of-the-epidermal-growth-factor-receptor 2026-07-02T09:20:49.043Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/SciTranslMed-2011-Sequist-Genotypic-and-histological-evolution-of-lung-cancers-acquiring-resistance-to-EGFR-inhibitors 2026-07-02T09:20:49.128Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/SciTranslMed-2013-Yasuda-Structural,-biochemical,-and-clinical-characterization-of-epidermal-growth-factor-receptor-(EGFR)-exon-20-insertion 2026-07-02T09:20:49.137Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/SciTranslMed-2017-Kohsaka-A-method-of-high-throughput-functional-evaluation-of-EGFR-gene-variants-of-unknown-significance-in-cancer 2026-07-02T09:20:49.108Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/SciTranslMed-2017-Nilsson-Stress-hormones-promote-EGFR-inhibitor-resistance-in-NSCLC-implications-for-combinations-with-beta-blockers 2026-07-02T09:20:49.105Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/Science-2004-Paez-EGFR-mutations-in-lung-cancer-correlation-with-clinical-response-to-gefitinib-therapy 2026-07-02T09:20:49.051Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/Science-2004-Sordella-Gefitinib-sensitizing-EGFR-mutations-in-lung-cancer-activate-anti-apoptotic-pathways 2026-07-02T09:20:49.047Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/Science-2007-Engelman-MET-amplification-leads-to-gefitinib-resistance-in-lung-cancer-by-activating-ERBB3-signaling 2026-07-02T09:20:49.119Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/SeminOncol-2014-Carnio-Extending-survival-of-stage-IV-non-small-cell-lung-cancer 2026-07-02T09:20:49.037Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-EGFR/ThrombosRes-2018-Young-Venous-thromboembolism-with-EGFR-monoclonal-antibody-necitumumab-in-stage-IV-non-small-cell-lung-cancer-A-retrospective 2026-07-02T09:20:49.092Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-HER2/AnnOncol-2015-Kris-Targeting-HER2-aberrations-as-actionable-drivers-in-lung-cancers-phase-II-trial-of-the-pan-HER-tyrosine-kinase 2026-07-02T09:20:49.153Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-HER2/AnnOncol-2019-Wang-HER2-exon-20-insertions-in-non-small-cell-lung-cancer-are-sensitive-to-the-irreversible-pan-HER-receptor-tyrosine 2026-07-02T09:20:49.152Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-HER2/AnnOncol-2026-Ruan-Preclinical-characterization-and-phase-1-results-of-TQB2102,-a-first-in-class-HER2-biparatopic-antibody-drug-conjugate, 2026-07-02T09:20:49.155Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-HER2/CancerCell-2026-Tillman-Reimagining-HER2-therapy-bridging-oncogene-addiction-and-immune-modulation 2026-07-02T09:20:49.158Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-HER2/CancerRes-2021-Han-Targeting-HER2-exon-20-insertion-mutant-lung-adenocarcinoma-with-a-novel-tyrosine-kinase-inhibitor-mobocertinib 2026-07-02T09:20:49.158Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-HER2/ClinCancerRes-2019-Peters-Trastuzumab-emtansine-(T-DM1)-in-patients-with-previously-treated-HER2-overexpressing-metastatic-non-small-cell-lung 2026-07-02T09:20:49.153Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-HER2/JAMAOncol-2018-Goss-Association-of-ERBB-mutations-with-clinical-outcomes-of-afatinib-or-erlotinib-treated-patients-with-lung-squamous-cell 2026-07-02T09:20:49.156Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-HER2/JClinOncol-2023-Goto-Trastuzumab-deruxtecan-in-patients-with-HER2-mutant-metastatic-non-small-cell-lung-cancer-primary-results-from-the 2026-07-02T09:20:49.155Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-HER2/JClinOncol-2023-Yu-HERTHENA-lung01,-a-phase-II-trial-of-patritumab-deruxtecan-(HER3-DXd)-in-epidermal-growth-factor-receptor-mutated 2026-07-02T09:20:49.158Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-HER2/JThoracOncol-2020-Zhao-Conformational-landscapes-of-HER2-exon-20-insertions-explain-their-sensitivity-to-kinase-inhibitors-in-lung 2026-07-02T09:20:49.154Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-HER2/LancetOncol-2024-Smit-Trastuzumab-deruxtecan-in-patients-with-metastatic-non-small-cell-lung-cancer-(destiny-lung01)-primary-results-of-the 2026-07-02T09:20:49.154Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-HER2/NEnglJMed-2022-Li-Trastuzumab-deruxtecan-in-HER2-mutant-non-small-cell-lung-cancer 2026-07-02T09:20:49.153Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-HER2/NEnglJMed-2026-Shitara-Zanidatamab-with-and-without-tislelizumab-in-HER2-positive-gastroesophageal-cancer 2026-07-02T09:20:49.157Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-HER2/NPJBreastCancer-2026-Terao-Risk-factors-and-metastatic-sites-in-HER2-positive-breast-cancer-with-pathological-complete-response 2026-07-02T09:20:49.157Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-HER2/NatRevClinOncol-2022-Friedlaender-EGFR-and-HER2-exon-20-insertions-in-solid-tumours-from-biology-to-treatment 2026-07-02T09:20:49.156Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-HER2/Nature-2004-Stephens-Lung-cancer-intragenic-ERBB2-kinase-mutations-in-tumours 2026-07-02T09:20:49.153Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-HER2/Nature-2018-Hyman-HER-kinase-inhibition-in-patients-with-HER2-and-HER3-mutant-cancers 2026-07-02T09:20:49.155Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/AAPSJ-2020-Parrott-Physiologically-based-absorption-modelling-to-explore-the-impact-of-food-and-gastric-pH-changes-on-the-pharmacokinetics 2026-07-02T09:20:50.117Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/AnnOncol-2013-Kim-The-frequency-and-impact-of-ROS1-rearrangement-on-clinical-outcomes-in-never-smokers-with-lung-adenocarcinoma 2026-07-02T09:20:50.115Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/AnnOncol-2019-Moro-Sibilot-Crizotinib-in-c-MET-or-ROS1-positive-NSCLC-results-of-the-AcSe-phase-II-trial 2026-07-02T09:20:50.101Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/AnnOncol-2019-Shaw-Crizotinib-in-ROS1-rearranged-advanced-non-small-cell-lung-cancer-(NSCLC)-updated-results,-including-overall-survival, 2026-07-02T09:20:50.117Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/CancerCell-2026-Ma-JYP0322,-a-highly-selective-and-brain-penetrant-ROS1-inhibitor,-overcomes-ROS1G2032R-resistance-mutation-in-NSCLC 2026-07-02T09:20:50.111Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/CancerChemotherPharmacol-2019-Roys-Resistance-mechanisms-and-potent-targeted-therapies-of-ROS1-positive-lung-cancer 2026-07-02T09:20:50.108Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/CancerDiscov-2017-Drilon-Safety-and-antitumor-activity-of-the-multitargeted-pan-TRK,-ROS1,-and-ALK-inhibitor-entrectinib-combined-results-from 2026-07-02T09:20:50.100Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/CancerRes-2019-Neel-Differential-subcellular-localization-regulates-oncogenic-signaling-by-ROS1-kinase-fusion-proteins 2026-07-02T09:20:50.098Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/Cancers-2020-DAngelo-Focus-on-ROS1-positive-non-small-cell-lung-cancer-(NSCLC)-crizotinib,-resistance-mechanisms-and-the-newer-generation-of 2026-07-02T09:20:50.104Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/ClinCancerRes-2012-Davies-Identifying-and-targeting-ROS1-gene-fusions-in-non-small-cell-lung-cancer 2026-07-02T09:20:50.109Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/ClinCancerRes-2013-Davies-Molecular-pathways-ROS1-fusion-proteins-in-cancer 2026-07-02T09:20:50.099Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/ClinCancerRes-2015-Song-Molecular-changes-associated-with-acquired-resistance-to-crizotinib-in-ROS1-rearranged-non-small-cell-lung-cancer 2026-07-02T09:20:50.119Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/ClinCancerRes-2016-Facchinetti-Crizotinib-resistant-ROS1-mutations-reveal-a-predictive-kinase-inhibitor-sensitivity-model-for-ROS1-and-ALK-rearranged 2026-07-02T09:20:50.108Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/ClinCancerRes-2019-Landi-Crizotinib-in-MET-deregulated-or-ROS1-rearranged-pretreated-non-small-cell-lung-cancer-(METROS)-A-phase-II, 2026-07-02T09:20:50.112Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/ClinCancerRes-2020-Papadopoulos-U.S.-phase-I-first-in-human-study-of-taletrectinib-(DS-6051bab-106),-a-ROS1TRK-inhibitor,-in-patients-with-advanced 2026-07-02T09:20:50.106Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/ClinCancerRes-2020-Yun-Repotrectinib-exhibits-potent-antitumor-activity-in-treatment-naive-and-solvent-front-mutant-ROS1-rearranged-non-small 2026-07-02T09:20:50.117Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/ClinCancerRes-2021-Lin-Spectrum-of-mechanisms-of-resistance-to-crizotinib-and-lorlatinib-in-ROS1-fusion-positive-lung-cancer 2026-07-02T09:20:50.114Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/ClinLungCancer-2019-Yu-Multiple-biomarker-testing-tissue-consumption-and-completion-rates-with-single-gene-tests-and-investigational-use-of 2026-07-02T09:20:55.365Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/InvestNewDrugs-2020-Ku-Entrectinib-resistance-mechanisms-in-ROS1-rearranged-non-small-cell-lung-cancer 2026-07-02T09:20:50.118Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/JCOOncolPract-2021-Almquist-The-road-less-traveled-A-guide-to-metastatic-ROS1-rearranged-non-small-cell-lung-cancer 2026-07-02T09:20:50.112Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/JCOPrecisOncol-2017-Gainor-Patterns-of-metastatic-spread-and-mechanisms-of-resistance-to-crizotinib-in-ROS1-positive-non-small-cell-lung-cancer 2026-07-02T09:20:50.116Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/JCOPrecisOncol-2020-Mezquita-Clinical-relevance-of-an-amplicon-based-liquid-biopsy-for-detecting-ALK-and-ROS1-fusion-and-resistance-mutations-in 2026-07-02T09:20:50.113Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/JClinOncol-2012-Bergethon-ROS1-rearrangements-define-a-unique-molecular-class-of-lung-cancers 2026-07-02T09:20:50.104Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/JClinOncol-2012-Janne-ROS1-rearrangements-in-lung-cancer-a-new-genomic-subset-of-lung-adenocarcinoma 2026-07-02T09:20:50.116Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/JClinOncol-2012-Komiya-Response-to-crizotinib-in-ROS1-rearranged-non-small-cell-lung-cancer 2026-07-02T09:20:50.101Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/JClinOncol-2015-Mazieres-Crizotinib-therapy-for-advanced-lung-adenocarcinoma-and-a-ROS1-rearrangement-results-from-the-EUROS1-cohort 2026-07-02T09:20:50.115Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/JClinOncol-2017-Lim-Open-label,-multicenter,-phase-II-study-of-ceritinib-in-patients-with-non-small-cell-lung-cancer-harboring-ROS1 2026-07-02T09:20:50.102Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/JClinOncol-2018-Wu-Phase-II-study-of-crizotinib-in-east-asian-patients-with-ROS1-positive-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:50.098Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/JClinOncol-2021-Dziadziuszko-Updated-integrated-analysis-of-the-efficacy-and-safety-of-entrectinib-in-locally-advanced-or-metastatic-ROS1 2026-07-02T09:20:50.107Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/JClinPathol-2017-Pal-ROS1-corrected 2026-07-02T09:20:50.118Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/JTOClinResRep-2021-Ou-Efficacy-of-taletrectinib-(AB-106ds-6051b)-in-ROS1+-NSCLC-an-updated-pooled-analysis-of-U.S.-and-japan-phase-1-studies 2026-07-02T09:20:50.097Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/JThoracOncol-2012-Chin-Targeting-ROS1-with-anaplastic-lymphoma-kinase-inhibitors-a-promising-therapeutic-strategy-for-a-newly-defined 2026-07-02T09:20:50.114Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/JThoracOncol-2017-Lin-Recent-advances-in-targeting-ROS1-in-lung-cancer 2026-07-02T09:20:50.111Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/JThoracOncol-2018-Li-Efficacy-of-crizotinib-among-different-types-of-ROS1-fusion-partners-in-patients-with-ROS1-rearranged-non-small-cell 2026-07-02T09:20:50.100Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/JThoracOncol-2018-Park-Characteristics-and-outcome-of-ROS1-positive-non-small-cell-lung-cancer-patients-in-routine-clinical-practice 2026-07-02T09:20:50.102Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/JThoracOncol-2018-Patil-The-incidence-of-brain-metastases-in-stage-IV-ROS1-rearranged-non-small-cell-lung-cancer-and-rate-of-central-nervous 2026-07-02T09:20:50.113Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/JThoracOncol-2019-Hofman-Multicenter-evaluation-of-a-novel-ROS1-IHC-assay-SP384-for-detection-of-ROS1-rearragements-in-a-large-cohort-of-lung-adenocarcinoma-patients 2026-07-02T09:20:50.105Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/JThoracOncol-2019-Michels-Safety-and-efficacy-of-crizotinib-in-patients-with-advanced-or-metastatic-ROS1-rearranged-lung-cancer-(EUCROSS)-A 2026-07-02T09:20:50.099Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/JThoracOncol-2019-Sun-Tumor-heterogeneity-and-testing-discrepancy-confound-ROS1-detection-in-NSCLC 2026-07-02T09:20:50.118Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/JThoracOncol-2020-Zhu-An-international-real-world-analysis-of-the-efficacy-and-safety-of-lorlatinib-through-early-or-expanded-access-programs 2026-07-02T09:20:50.104Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/LancetOncol-2018-Solomon-Lorlatinib-in-patients-with-ALK-positive-non-small-cell-lung-cancer-results-from-a-global-phase-2-study 2026-07-02T09:20:50.100Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/LancetOncol-2019-Shaw-Lorlatinib-in-advanced-ROS1-positive-non-small-cell-lung-cancer-a-multicentre,-open-label,-single-arm,-phase-1-2-trial 2026-07-02T09:20:50.110Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/LancetOncol-2020-Drilon-Entrectinib-in-ROS1-fusion-positive-non-small-cell-lung-cancer-integrated-analysis-of-three-phase-1-2-trials 2026-07-02T09:20:50.110Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/LungCancer-2019-Ou-CNS-metastasis-in-ROS1+-NSCLC-an-urgent-call-to-action,-to-understand,-and-to-overcome 2026-07-02T09:20:50.109Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/LungCancer-2026-Itchins-Real-world-treatment-sequencing-and-survival-in-ROS1-rearranged-NSCLC-across-evolving-treatment-eras-findings-from-the 2026-07-02T09:20:50.099Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/MolCancerTher-2016-Ardini-Entrectinib,-a-pan-TRK,-ROS1,-and-ALK-inhibitor-with-activity-in-multiple-molecularly-defined-cancer-indications 2026-07-02T09:20:50.103Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/NEnglJMed-2013-Awad-Acquired-resistance-to-crizotinib-from-a-mutation-in-CD74-ROS1 2026-07-02T09:20:50.105Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/NEnglJMed-2014-Shaw-Crizotinib-in-ROS1-rearranged-non-small-cell-lung-cancer 2026-07-02T09:20:50.107Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/NEnglJMed-2024-Drilon-Repotrectinib-in-ROS1-fusion-positive-non-small-cell-lung-cancer 2026-07-02T09:20:50.115Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/NatCommun-2019-Katayama-The-new-generation-selective-ROS1NTRK-inhibitor-DS-6051b-overcomes-crizotinib-resistant-ROS1-G2032R-mutation-in 2026-07-02T09:20:50.114Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/OncoTargetsTher-2017-Zhao-Response-to-crizotinib-in-a-lung-adenocarcinoma-patient-harboring-a-novel-SLC34A2-ROS1-fusion-variant 2026-07-02T09:20:50.107Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/Oncologist-2013-Gainor-Novel-targets-in-non-small-cell-lung-cancer-ROS1-and-RET-fusions 2026-07-02T09:20:50.110Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/Oncotarget-2018-Fujiwara-Safety-and-pharmacokinetics-of-DS-6051b-in-japanese-patients-with-non-small-cell-lung-cancer-harboring-ROS1-fusions-a 2026-07-02T09:20:50.106Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/ProcNatlAcadSciUSA-2015-Zou-PF-06463922-is-a-potent-and-selective-next-generation-ROS1ALK-inhibitor-capable-of-blocking-crizotinib-resistant-ROS1 2026-07-02T09:20:50.113Z https://research-2ry.pages.dev/Summary/Clinical-NSCLC-ROS1/SciRep-2017-Ogura-TKI-addicted-ROS1-rearranged-cells-are-destined-to-survival-or-death-by-the-intensity-of-ROS1-kinase-activity 2026-07-02T09:20:50.107Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/AnnOncol-2015-Rosenthal-Phase-I-dose-escalating-trial-of-escherichia-coli-purine-nucleoside-phosphorylase-and-fludarabine-gene-therapy-for 2026-07-02T09:20:49.610Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/AnnOncol-2026-Garrido-Castro-SACI-IO-HR+-A-randomized-phase-II-trial-of-sacituzumab-govitecan-with-or-without-pembrolizumab-in-patients-with 2026-07-02T09:20:49.586Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/BMJ-2015-Butterfield-Cancer-vaccines 2026-07-02T09:20:49.567Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/BioProtocol-2026-Kubo-Cite-as-kubo,-N.-et-al.-(2026).-A-feeder-cell-free-system-for-chimeric-antigen-receptor-gene-transduction-into 2026-07-02T09:20:49.604Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/Blood-2002-Haynes-Single-chain-antigen-recognition-receptors-that-costimulate-potent-rejection-of-established-experimental-tumors 2026-07-02T09:20:49.593Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/Blood-2005-Moeller-Adoptive-transfer-of-gene-engineered-CD4+-helper-T-cells-induces-potent-primary-and-secondary-tumor-rejection 2026-07-02T09:20:49.568Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/Blood-2008-Till-Adoptive-immunotherapy-for-indolent-non-hodgkin-lymphoma-and-mantle-cell-lymphoma-using-genetically-modified-autologous 2026-07-02T09:20:49.564Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/Blood-2010-Kochenderfer-Eradication-of-B-lineage-cells-and-regression-of-lymphoma-in-a-patient-treated-with-autologous-T-cells-genetically 2026-07-02T09:20:49.579Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/Blood-2011-Brentjens-Safety-and-persistence-of-adoptively-transferred-autologous-CD19-targeted-T-cells-in-patients-with-relapsed-or 2026-07-02T09:20:49.568Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/Blood-2011-Louis-Antitumor-activity-and-long-term-fate-of-chimeric-antigen-receptor-positive-T-cells-in-patients-with-neuroblastoma 2026-07-02T09:20:49.579Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/Blood-2012-Pegram-Tumor-targeted-T-cells-modified-to-secrete-IL-12-eradicate-systemic-tumors-without-need-for-prior-conditioning 2026-07-02T09:20:49.585Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/Blood-2012-Till-CD20-specific-adoptive-immunotherapy-for-lymphoma-using-a-chimeric-antigen-receptor-with-both-CD28-and-4-1bb-domains 2026-07-02T09:20:49.609Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/CancerCell-2015-Zhao-Structural-design-of-engineered-costimulation-determines-tumor-rejection-kinetics-and-persistence-of-CAR-T-cells 2026-07-02T09:20:49.566Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/CancerCell-2024-Sarnaik-Tumor-infiltrating-lymphocytes-a-new-hope 2026-07-02T09:20:49.608Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/CancerCell-2026-Chen-Overcoming-functional-and-translational-challenges-of-cellular-immunotherapies-for-solid-tumors 2026-07-02T09:20:49.587Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/CancerCell-2026-Planchard-Efficacy,-safety,-and-biomarker-analysis-of-datopotamab-deruxtecan-in-advanced-non-small-cell-lung-cancer-ICARUS-LUNG01 2026-07-02T09:20:49.577Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/CancerDiscov-2015-Sotillo-Convergence-of-acquired-mutations-and-alternative-splicing-of-CD19-enables-resistance-to-CART-19-immunotherapy 2026-07-02T09:20:49.585Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/CancerDiscov-2016-Morello-Mesothelin-targeted-CARs-driving-T-cells-to-solid-tumors 2026-07-02T09:20:49.573Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/CancerDiscov-2024-Schoenfeld-Lifileucel,-an-autologous-tumor-infiltrating-lymphocyte-monotherapy,-in-patients-with-advanced-non-small-cell-lung 2026-07-02T09:20:49.601Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/CancerDiscov-2026-Jee-Deconvolving-SARS-CoV-2-mRNA-vaccine-impact-on-immunotherapy-related-survival 2026-07-02T09:20:49.592Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/CancerImmunolImmunother-2014-Guest-Definition-and-application-of-good-manufacturing-process-compliant-production-of-CEA-specific-chimeric-antigen-receptor 2026-07-02T09:20:49.565Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/CancerImmunolRes-2014-Beatty-Mesothelin-specific-chimeric-antigen-receptor-mRNA-engineered-T-cells-induce-anti-tumor-activity-in-solid-malignancies 2026-07-02T09:20:49.565Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/CancerImmunolRes-2015-Frigault-Identification-of-chimeric-antigen-receptors-that-mediate-constitutive-or-inducible-proliferation-of-T-cells 2026-07-02T09:20:49.592Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/CancerImmunolRes-2019-Evgin-Suboptimal-T-cell-therapy-drives-a-tumor-cell-mutator-phenotype-that-promotes-escape-from-first-line-treatment 2026-07-02T09:20:49.582Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/CancerRes-2007-Moeller-Sustained-antigen-specific-antitumor-recall-response-mediated-by-gene-modified-CD4+-T-helper-1-and-CD8+-T-cells 2026-07-02T09:20:49.570Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/CancerRes-2013-Chang-A-chimeric-receptor-with-NKG2D-specificity-enhances-natural-killer-cell-activation-and-killing-of-tumor-cells 2026-07-02T09:20:49.590Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/Cell-2017-Ribas-Oncolytic-virotherapy-promotes-intratumoral-T-cell-infiltration-and-improves-anti-PD-1-immunotherapy 2026-07-02T09:20:49.600Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/Cell-2020-Ott-A-phase-ib-trial-of-personalized-neoantigen-therapy-plus-anti-PD-1-in-patients-with-advanced-melanoma,-non-small-cell 2026-07-02T09:20:49.609Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/Cell-2021-Johnson-The-immunostimulatory-RNA-RN7SL1-enables-CAR-T-cells-to-enhance-autonomous-and-endogenous-immune-function 2026-07-02T09:20:49.574Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/Cell-2026-Amor-CAR-T-targets-AI-takes-the-wheel 2026-07-02T09:20:49.606Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/Cell-2026-Baker-AI-driven-discovery-of-GPNMB-CAR-T-cells-as-a-multi-cancer-therapy 2026-07-02T09:20:49.597Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/Cell-2026-Conilh-Navigating-the-clinical-progress-of-antibody-drug-conjugates-emerging-opportunities-and-remaining-challenges 2026-07-02T09:20:49.606Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/Cell-2026-Freeburg-The-critical-role-of-the-endogenous-immune-compartment-after-CAR-T-cell-therapy-in-recurrent-GBM 2026-07-02T09:20:49.599Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/CellRepMed-2026-Bajgain-Engineering-functionality-optimized-fully-human-B7-H3-CAR-T-cells-for-enhanced-solid-tumor-therapy 2026-07-02T09:20:49.570Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/CellRepPhysSci-2025-Zhou-Challenges-and-opportunities-for-lysosome-targeting-chimeras 2026-07-02T09:20:49.606Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/CellStemCell-2013-Nishimura-Generation-of-rejuvenated-antigen-specific-T-cells-by-reprogramming-to-pluripotency-and-redifferentiation 2026-07-02T09:20:49.595Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/CellStemCell-2015-Themeli-New-cell-sources-for-T-cell-engineering-and-adoptive-immunotherapy 2026-07-02T09:20:49.576Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/ClinCancerRes-2006-Kershaw-A-phase-I-study-on-adoptive-immunotherapy-using-gene-modified-T-cells-for-ovarian-cancer 2026-07-02T09:20:49.610Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/ClinCancerRes-2012-Tamada-Redirecting-gene-modified-T-cells-toward-various-cancer-types-using-tagged-antibodies 2026-07-02T09:20:49.606Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/ClinCancerRes-2013-Hudecek-Receptor-affinity-and-extracellular-domain-modifications-affect-tumor-recognition-by-ROR1-specific-chimeric-antigen 2026-07-02T09:20:49.576Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/ClinCancerRes-2013-Morales-Kastresana-Better-performance-of-CARs-deprived-of-the-PD-1-brake 2026-07-02T09:20:49.583Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/ClinCancerRes-2014-Moon-Multifactorial-T-cell-hypofunction-that-is-reversible-can-limit-the-efficacy-of-chimeric-antigen-receptor-transduced 2026-07-02T09:20:49.571Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/ClinCancerRes-2014-Sampson-EGFRvIII-mCAR-modified-T-cell-therapy-cures-mice-with-established-intracerebral-glioma-and-generates-host-immunity 2026-07-02T09:20:49.590Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/ClinCancerRes-2015-Brown-Bioactivity-and-safety-of-IL13Ralpha2-redirected-chimeric-antigen-receptor-CD8+-T-cells-in-patients-with-recurrent 2026-07-02T09:20:49.572Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/ClinCancerRes-2015-Kageyama-Adoptive-transfer-of-MAGE-A4-T-cell-receptor-gene-transduced-lymphocytes-in-patients-with-recurrent-esophageal-cancer 2026-07-02T09:20:49.569Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/ClinCancerRes-2015-Katz-Phase-I-hepatic-immunotherapy-for-metastases-study-of-intra-arterial-chimeric-antigen-receptor-modified-T-cell-therapy 2026-07-02T09:20:49.587Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/ClinCancerRes-2017-Tolcher-Phase-ib-study-of-utomilumab-(PF-05082566),-a-4-1bbcd137-agonist,-in-combination-with-pembrolizumab-(MK-3475)-in 2026-07-02T09:20:49.591Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/ClinCancerRes-2018-Strauss-Phase-I-trial-of-M7824-(MSB0011359C),-a-bifunctional-fusion-protein-targeting-PD-L1-and-TGFbeta,-in-advanced-solid 2026-07-02T09:20:49.597Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/ClinCancerRes-2019-Suryadevara-Preventing-lck-Activation-in-CAR-T-Cells-confers-Treg-Resistance-but-requires-4-1BB-Signaling-for-them-to-persist-and-treat-solid-tumors-in-nonlymphodepleted-hosts 2026-07-02T09:20:49.595Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/CurrOpinImmunol-2015-Jensen-Designing-chimeric-antigen-receptors-to-effectively-and-safely-target-tumors 2026-07-02T09:20:49.579Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/FrontImmunol-2026-Pham-Adapter-based-allogeneic-CAR-t-cells-to-overcome-antigen-escape-in-solid-tumors 2026-07-02T09:20:49.607Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/FrontImmunol-2026-Zhan-Ionizing-radiation-enhances-CAR-T-cell-infiltration-and-efficacy-in-solid-tumors 2026-07-02T09:20:49.583Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/FrontOncol-2026-Chen-Evolution-and-recent-advances-in-antibody-drug-conjugate-therapy-for-lung-cancer-a-comprehensive-systematic-review 2026-07-02T09:20:49.593Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/JClinInvest-2016-Cherkassky-Human-CAR-T-cells-with-cell-intrinsic-PD-1-checkpoint-blockade-resist-tumor-mediated-inhibition 2026-07-02T09:20:49.590Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/JClinInvest-2016-Hegde-Tandem-CAR-T-cells-targeting-HER2-and-IL13Ralpha2-mitigate-tumor-antigen-escape 2026-07-02T09:20:49.603Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/JClinInvest-2019-Barrett-Improving-CAR-T-cell-immunotherapy-mediated-remissions-for-pediatric-leukemia 2026-07-02T09:20:49.610Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/JClinInvest-2019-Kellish-Oncolytic-virotherapy-for-small-cell-lung-cancer-induces-immune-infiltration-and-prolongs-survival 2026-07-02T09:20:49.606Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/JClinOncol-2015-Andtbacka-Talimogene-laherparepvec-improves-durable-response-rate-in-patients-with-advanced-melanoma 2026-07-02T09:20:49.594Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/JClinOncol-2015-Curran-Chimeric-antigen-receptor-T-cells-for-cancer-immunotherapy 2026-07-02T09:20:49.586Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/JClinOncol-2016-Brudno-Allogeneic-T-cells-that-express-an-anti-CD19-chimeric-antigen-receptor-induce-remissions-of-B-cell-malignancies-that 2026-07-02T09:20:49.612Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/JClinOncol-2020-Cappell-Long-term-follow-up-of-anti-CD19-chimeric-antigen-receptor-T-cell-therapy 2026-07-02T09:20:49.563Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/JClinOncol-2026-Peters-First-in-human,-phase-I-study-of-sigvotatug-vedotin,-an-integrin-beta-6-directed-antibody-drug-conjugate-results-from 2026-07-02T09:20:49.570Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/JClinOncol-2026-Qi-Guanylyl-cyclase-2c-targeted-chimeric-antigen-receptor-T-cell-therapy-in-patients-with-metastatic-colorectal-cancer 2026-07-02T09:20:49.587Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/JExpMed-2026-Abrahimi-Intravesical-mesothelin-based-CAR-T-cells-targeting-MUC16-effectively-control-bladder-cancer-in-preclinical-models 2026-07-02T09:20:49.589Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/JHematolOncol-2026-Li-Nanotechnology-enhanced-CAR-T-therapy-strategies-in-cancer,-aging,-and-autoimmune-diseases 2026-07-02T09:20:49.596Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/JImmunotherCancer-2026-Volpe-Membrane-bound-TRAIL-armoring-augments-CAR-T-cells-in-mesothelin-positive-solid-malignancies 2026-07-02T09:20:49.605Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/Lancet-2015-Lee-T-cells-expressing-CD19-chimeric-antigen-receptors-for-acute-lymphoblastic-leukaemia-in-children-and-young-adults-a 2026-07-02T09:20:49.605Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/LancetRegHealthEur-2026-Moreno-Advances-in-cell-therapy-for-solid-tumours-european-perspective-and-future-directions 2026-07-02T09:20:49.578Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/Leukemia-2016-Sommermeyer-Chimeric-antigen-receptor-modified-T-cells-derived-from-defined-CD8+-and-CD4+-subsets-confer-superior-antitumor 2026-07-02T09:20:49.611Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/Leukemia-2017-Monjezi-Enhanced-CAR-T-cell-engineering-using-non-viral-sleeping-beauty-transposition-from-minicircle-vectors 2026-07-02T09:20:49.564Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/LungCancer-2026-Hofman-New-biomarkers-for-antibody-drug-conjugates-in-lung-cancer-the-pathologist's-perspective 2026-07-02T09:20:49.574Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/MethodMolBiol-2026-Yasunaga-Bispecifc-antibodies-methods-and-protocols 2026-07-02T09:20:49.574Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/MolCancer-2026-Li-Antibody-drug-conjugates-in-breast-cancer-from-mechanism-to-revolutionizing-clinical-practice 2026-07-02T09:20:49.580Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/MolTher-2005-Pule-A-chimeric-T-cell-antigen-receptor-that-augments-cytokine-release-and-supports-clonal-expansion-of-primary-human-T-cells 2026-07-02T09:20:49.573Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/MolTher-2007-Park-Adoptive-transfer-of-chimeric-antigen-receptor-re-directed-cytolytic-T-lymphocyte-clones-in-patients-with-neuroblastoma 2026-07-02T09:20:49.604Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/MolTher-2009-Milone-Chimeric-receptors-containing-CD137-signal-transduction-domains-mediate-enhanced-survival-of-T-cells-and-increased 2026-07-02T09:20:49.598Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/MolTher-2011-Parkhurst-T-cells-targeting-carcinoembryonic-antigen-can-mediate-regression-of-metastatic-colorectal-cancer-but-induce-severe 2026-07-02T09:20:49.568Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NEnglJMed-2011-DiStasi-Inducible-apoptosis-as-a-safety-switch-for-adoptive-cell-therapy 2026-07-02T09:20:49.594Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NEnglJMed-2011-Porter-Chimeric-antigen-receptor-modified-T-cells-in-chronic-lymphoid-leukemia 2026-07-02T09:20:49.571Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NEnglJMed-2013-Grupp-Chimeric-antigen-receptor-modified-T-cells-for-acute-lymphoid-leukemia 2026-07-02T09:20:49.588Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NEnglJMed-2014-Maude-Chimeric-antigen-receptor-T-cells-for-sustained-remissions-in-leukemia 2026-07-02T09:20:49.581Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NEnglJMed-2015-Garfall-Chimeric-antigen-receptor-T-cells-against-CD19-for-multiple-myeloma 2026-07-02T09:20:49.605Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NEnglJMed-2016-Brown-Regression-of-glioblastoma-after-chimeric-antigen-receptor-T-cell-therapy 2026-07-02T09:20:49.596Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NEnglJMed-2016-Tran-T-cell-transfer-therapy-targeting-mutant-KRAS-in-cancer 2026-07-02T09:20:49.608Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NEnglJMed-2017-Neelapu-Axicabtagene-ciloleucel-CAR-T-cell-therapy-in-refractory-large-B-cell-lymphoma 2026-07-02T09:20:49.594Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NEnglJMed-2018-June-Chimeric-antigen-receptor-therapy 2026-07-02T09:20:49.612Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatBiotechnol-2002-Maher-Human-T-lymphocyte-cytotoxicity-and-proliferation-directed-by-a-single-chimeric-TCRzeta-cd28-receptor 2026-07-02T09:20:49.569Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatBiotechnol-2018-Tang-Enhancing-T-cell-therapy-through-TCR-signaling-responsive-nanoparticle-drug-delivery 2026-07-02T09:20:55.501Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatBiotechnol-2020-Giordano-Attianese-A-computationally-designed-chimeric-antigen-receptor-provides-a-small-molecule-safety-switch-for-T-cell-therapy 2026-07-02T09:20:49.575Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatBiotechnol-2020-Klichinsky-Human-chimeric-antigen-receptor-macrophages-for-cancer-immunotherapy 2026-07-02T09:20:49.582Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatCancer-2021-Hirabayashi-Dual-targeting-CAR-T-cells-with-optimal-costimulation-and-metabolic-fitness-enhance-antitumor-activity-and-prevent 2026-07-02T09:20:49.598Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatCancer-2021-King-Peoples-Splitting-signals-drives-CARs-further 2026-07-02T09:20:49.564Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatCancer-2021-Milone-Engineering-enhanced-CAR-T-cells-for-improved-cancer-therapy 2026-07-02T09:20:49.563Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatCancer-2023-Mandal-Structural-surfaceomics-reveals-an-AML-specific-conformation-of-integrin-beta2-as-a-CAR-T-cellular-therapy-target 2026-07-02T09:20:49.610Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatCancer-2026-Kong-Iron-mediated-ferroptosis-impairs-CAR-T-cell-function-and-antitumor-efficacy 2026-07-02T09:20:49.575Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatCancer-2026-Navarre-Tumor-irradiation-promotes-antigen-dressing-of-dendritic-cells-to-enhance-CAR-T-cell-persistence-and-efficacy-in-lung 2026-07-02T09:20:49.565Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatChemBiol-2022-Gardner-Engineering-CAR-T-cells-to-activate-small-molecule-drugs-in-situ 2026-07-02T09:20:49.604Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatMed-2003-Brentjens-Eradication-of-systemic-B-cell-tumors-by-genetically-targeted-human-T-lymphocytes-co-stimulated-by-CD80-and 2026-07-02T09:20:49.584Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatMed-2008-Pule-Virus-specific-T-cells-engineered-to-coexpress-tumor-specific-receptors-persistence-and-antitumor-activity-in 2026-07-02T09:20:49.580Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatMed-2015-Caruana-Heparanase-promotes-tumor-infiltration-and-antitumor-activity-of-CAR-redirected-T-lymphocytes 2026-07-02T09:20:49.583Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatMed-2015-Rapoport-NY-ESO-1-specific-TCR-engineered-T-cells-mediate-sustained-antigen-specific-antitumor-effects-in-myeloma 2026-07-02T09:20:49.567Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatMed-2021-Creelan-Tumor-infiltrating-lymphocyte-treatment-for-anti-PD-1-resistant-metastatic-lung-cancer-a-phase-1-trial 2026-07-02T09:20:49.592Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatMed-2021-Hu-Personal-neoantigen-vaccines-induce-persistent-memory-T-cell-responses-and-epitope-spreading-in-patients-with-melanoma 2026-07-02T09:20:49.589Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatMed-2026-Schett-Resetting-autoimmune-disease-with-CAR-cell-therapies 2026-07-02T09:20:49.587Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatMed-2026-Wermke-MAGE-A4MAGE-A8-targeted-TCR-based-bispecific-T-cell-engager-in-recurrent-andor-refractory-solid-tumors-a-phase-1-trial 2026-07-02T09:20:49.577Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatRevBioeng-2026-Jewell-Trial-design-of-CAR-t-cell-therapy-for-autoimmune-diseases 2026-07-02T09:20:49.594Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatRevCancer-2008-Rosenberg-Adoptive-cell-transfer-a-clinical-path-to-effective-cancer-immunotherapy 2026-07-02T09:20:55.525Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatRevCancer-2015-Larson-Radioimmunotherapy-of-human-tumours 2026-07-02T09:20:49.563Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatRevCancer-2021-Larson-Recent-advances-and-discoveries-in-the-mechanisms-and-functions-of-CAR-T-cells 2026-07-02T09:20:55.531Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatRevClinOncol-2014-Melero-Therapeutic-vaccines-for-cancer-an-overview-of-clinical-trials 2026-07-02T09:20:49.571Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatRevClinOncol-2016-Jackson-Driving-CAR-T-cells-forward 2026-07-02T09:20:49.602Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatRevClinOncol-2016-Khalil-The-future-of-cancer-treatment-immunomodulation,-CARs-and-combination-immunotherapy 2026-07-02T09:20:49.607Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatRevClinOncol-2021-Blass-Advances-in-the-development-of-personalized-neoantigen-based-therapeutic-cancer-vaccines 2026-07-02T09:20:49.612Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatRevClinOncol-2021-Kaufman-Advancing-oncolytic-virus-therapy-by-understanding-the-biology 2026-07-02T09:20:49.609Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatRevClinOncol-2021-Mikkilineni-CAR-T-cell-therapies-for-patients-with-multiple-myeloma 2026-07-02T09:20:49.599Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatRevClinOncol-2021-Wagner-Immunogenicity-of-CAR-T-cells-in-cancer-therapy 2026-07-02T09:20:49.605Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatRevImmunol-2005-Kershaw-Supernatural-T-cells-Genetic-modification-of-T-cells-for-cancer-therapy 2026-07-02T09:20:49.584Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatRevImmunol-2026-Krishna-Hallmarks-and-correlates-of-effective-adoptive-cell-immunotherapy-for-cancer 2026-07-02T09:20:49.591Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatRevImmunol-2026-Wu-Programming-the-immunological-properties-of-mRNA-vaccines-for-cancer 2026-07-02T09:20:49.611Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/NatRevMolCellBiol-2026-Andersson-Rolf-New-developments-and-applications-of-human-organoids 2026-07-02T09:20:49.584Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/ProcNatlAcadSciUSA-2004-Brockstedt-Listeria-based-cancer-vaccines-that-segregate-immunogenicity-from-toxicity 2026-07-02T09:20:49.593Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/SciChinaLifeSci-2016-You-Phase-1-clinical-trial-demonstrated-that-MUC1-positive-metastatic-seminal-vesicle-cancer-can-be-effectively-eradicated 2026-07-02T09:20:49.581Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/SciTranslMed-2011-Kalos-T-cells-with-chimeric-antigen-receptors-have-potent-antitumor-effects-and-can-establish-memory-in-patients-with 2026-07-02T09:20:49.601Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/SciTranslMed-2013-Brentjens-CD19-targeted-T-cells-rapidly-induce-molecular-remissions-in-adults-with-chemotherapy-refractory-acute-lymphoblastic 2026-07-02T09:20:49.601Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/SciTranslMed-2014-Adusumilli-Regional-delivery-of-mesothelin-targeted-CAR-T-cell-therapy-generates-potent-and-long-lasting-CD4-dependent-tumor 2026-07-02T09:20:49.569Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/SciTranslMed-2014-Davila-Efficacy-and-toxicity-management-of-19-28z-CAR-T-cell-therapy-in-B-cell-acute-lymphoblastic-leukemia 2026-07-02T09:20:49.567Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/SciTranslMed-2015-Johnson-Rational-development-and-characterization-of-humanized-anti-EGFR-variant-III-chimeric-antigen-receptor-T-cells-for 2026-07-02T09:20:49.602Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/SciTranslMed-2015-Porter-Chimeric-antigen-receptor-T-cells-persist-and-induce-sustained-remissions-in-relapsed-refractory-chronic-lymphocytic 2026-07-02T09:20:49.608Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/SciTranslMed-2020-Marquez-Rodas-Intratumoral-nanoplexed-poly-I-C-BO-112-in-combination-with-systemic-anti-PD-1-for-patients-with-anti-PD-1-refractory 2026-07-02T09:20:49.597Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/SciTranslMed-2026-Horowitz-Cd39+cd49a+cd103+-cytotoxic-tissue-resident-natural-killer-cells-infiltrate-and-control-solid-epithelial-tumor-growth 2026-07-02T09:20:49.612Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/Science-2006-Morgan-Cancer-regression-in-patients-after-transfer-of-genetically-engineered-lymphocytes 2026-07-02T09:20:49.567Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/Science-2013-McNutt-Cancer-immunotherapy 2026-07-02T09:20:49.588Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/Science-2018-June-CAR-T-cell-immunotherapy-for-human-cancer 2026-07-02T09:20:49.598Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/Science-2018-Sahin-Personalized-vaccines-for-cancer-immunotherapy 2026-07-02T09:20:49.575Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/Science-2020-Stadtmauer-CRISPR-engineered-T-cells-in-patients-with-refractory-cancer 2026-07-02T09:20:49.581Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/TrendsCancer-2026-Aalipour-In-vivo-CAR-t-cell-engineering-design-principles-and-open-questions 2026-07-02T09:20:49.562Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/TrendsCancer-2026-High-Lgr5-from-stem-cell-marker-to-therapeutic-target 2026-07-02T09:20:49.589Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/TrendsCancer-2026-Madsen-Driving-CAR-therapies-beyond-t-cells 2026-07-02T09:20:49.596Z https://research-2ry.pages.dev/Summary/Clinical-Novel-modalities/npjPrecisOncol-2026-Nicholas-Immunopeptidomics-guided-identification-of-functional-neoantigens-in-non-small-cell-lung-cancer 2026-07-02T09:20:49.602Z https://research-2ry.pages.dev/Summary/Clinical-Others/AmRevRespirDis-1993-DeGracia-Diagnostic-value-of-bronchoalveolar-lavage-in-peripheral-lung-cancer 2026-07-02T09:20:49.614Z https://research-2ry.pages.dev/Summary/Clinical-Others/AnnThoracCardiovascSurg-2012-Sakaguchi-Successful-resection-of-mediastinal-seminoma-evaluated-the-response-to-induction-chemotherapy-with 2026-07-02T09:20:49.615Z https://research-2ry.pages.dev/Summary/Clinical-Others/ClinCancerRes-2026-Cowzer-Molecular-and-clinical-determinants-of-targeted-therapy-treatment-in-biliary-tract-cancer 2026-07-02T09:20:49.614Z https://research-2ry.pages.dev/Summary/Clinical-Others/ClinCancerRes-2026-Medina-AI-based-pathology-classifier-predicts-sensitivity-to-enzalutamide-in-metastatic-hormone-sensitive-prostate-cancer-A 2026-07-02T09:20:49.619Z https://research-2ry.pages.dev/Summary/Clinical-Others/ClinCancerRes-2026-Poussaint-And-young-adult-patients-with-recurrent-CNS-tumors-and-newly-diagnosed-DIPG 2026-07-02T09:20:49.622Z https://research-2ry.pages.dev/Summary/Clinical-Others/ClinLungCancer-2018-Yanagawa-Radiologic-pathologic-correlation-of-solid-portions-on-thin-section-CT-images-in-lung-adenocarcinoma-A-multicenter-study 2026-07-02T09:20:49.618Z https://research-2ry.pages.dev/Summary/Clinical-Others/EurJCardiothoracSurg-2021-Nakagawa-Pattern-of-recurrence-of-pN2-non-small-cell-lung-cancer-should-postoperative-radiotherapy-be-reconsidered 2026-07-02T09:20:49.622Z https://research-2ry.pages.dev/Summary/Clinical-Others/FrontImmunol-2026-Li-Effect-of-histology-on-the-efficacy-of-first-line-immune-checkpoint-inhibitors-in-advanced-non-small-cell-lung-cancer-a 2026-07-02T09:20:49.621Z https://research-2ry.pages.dev/Summary/Clinical-Others/IntJRadiatOncolBiolPhys-2026-Zhu-Low-dose-SBRT-based-radiotherapy-followed-by-pembrolizumab-and-chemotherapy-for-potentially-resectable-NSCLC-A-phase-ib 2026-07-02T09:20:49.621Z https://research-2ry.pages.dev/Summary/Clinical-Others/JCOPrecisOncol-2026-Lovly-Real-world-patient-characteristics,-mutational-landscape,-and-outcomes-in-AdvancedMetastatic 2026-07-02T09:20:55.573Z https://research-2ry.pages.dev/Summary/Clinical-Others/JClinOncol-2015-Kochenderfer-Chemotherapy-refractory-diffuse-large-b-cell-lymphoma-and-indolent-b-cell-malignancies-can-be-effectively-treated-with 2026-07-02T09:20:49.613Z https://research-2ry.pages.dev/Summary/Clinical-Others/JHepatol-2026-Lombardi-A-myeloid-immunosuppressive-phenotype-defines-primary-refractoriness-to-atezolizumab-plus-bevacizumab-in-hepatocellular 2026-07-02T09:20:49.617Z https://research-2ry.pages.dev/Summary/Clinical-Others/JImmunotherCancer-2026-Naing-Phase-1-multicenter-study-of-the-NKG2A-targeting-antibody-S095029-as-a-single-agent-and-in-combination-with-anti-pd-1 2026-07-02T09:20:49.616Z https://research-2ry.pages.dev/Summary/Clinical-Others/JImmunotherCancer-2026-Rohrberg-First-in-human-study-of-lomvastomig,-a-PD-1-TIM-3-bispecific-antibody,-in-patients-with-advanced-andor-metastatic-solid 2026-07-02T09:20:49.617Z https://research-2ry.pages.dev/Summary/Clinical-Others/JImmunotherCancer-2026-Roulleaux-Dugage-VEGF-A-blockade-overcomes-liver-metastases-resistance-to-chemoimmunotherapy-in-patients-with-advanced-non-squamous-NSCLC 2026-07-02T09:20:49.615Z https://research-2ry.pages.dev/Summary/Clinical-Others/JThoracOncol-2026-Baramidze-Cemiplimab-plus-chemotherapy-versus-chemotherapy-in-advanced-NSCLC-5-year-results-from-phase-3-EMPOWER-lung-3-part-2 2026-07-02T09:20:49.618Z https://research-2ry.pages.dev/Summary/Clinical-Others/LancetOncol-2026-Fan-Novel-strategies-to-overcome-the-blood-brain-barrier-in-triple-negative-breast-cancer-brain-metastases 2026-07-02T09:20:49.614Z https://research-2ry.pages.dev/Summary/Clinical-Others/NEnglJMed-2019-Larkin-Five-year-survival-with-combined-nivolumab-and-ipilimumab-in-advanced-melanoma 2026-07-02T09:20:49.619Z https://research-2ry.pages.dev/Summary/Clinical-Others/NatCancer-2026-Chu-Integrated-proteogenomic-and-metabolomic-profiling-of-acute-myeloid-leukemias-to-identify-molecular-subtypes-and 2026-07-02T09:20:49.616Z https://research-2ry.pages.dev/Summary/Clinical-Others/NatMed-2026-Vishwanath-General-purpose-large-language-models-outperform-specialized-clinical-AI-tools-on-medical-benchmarks 2026-07-02T09:20:49.616Z https://research-2ry.pages.dev/Summary/Clinical-Others/NatRevCancer-2026-Chadwick-Striking-the-right-balance-with-type-i-interferon-signalling-in-cancer 2026-07-02T09:20:49.614Z https://research-2ry.pages.dev/Summary/Clinical-Others/NatRevCancer-2026-Luo-N6-Methyladenosine-an-RNA-modification-as-a-central-regulator-of-cancer 2026-07-02T09:20:49.617Z https://research-2ry.pages.dev/Summary/Clinical-Others/NatRevMolCellBiol-2026-Liu-Regulation-and-function-of-specialized-membrane-protrusions-in-intercellular-communication 2026-07-02T09:20:49.615Z https://research-2ry.pages.dev/Summary/Clinical-Others/Nature-2026-Tselikas-Safety-and-efficacy-of-intratumoural-anti-ctla4-with-intravenous-anti-pd1 2026-07-02T09:20:49.621Z https://research-2ry.pages.dev/Summary/Clinical-Others/Oncologist-2026-Mahmud-Biomarker-testing-patterns-among-patients-newly-diagnosed-with-metastatic-non-small-cell-lung-prostate-and-bladder-cancer 2026-07-02T09:20:49.619Z https://research-2ry.pages.dev/Summary/Clinical-Others/Thorax-2009-Hung-Post-recurrence-survival-in-completely-resected-stage-I-non-small-cell-lung-cancer-with-local-recurrence 2026-07-02T09:20:49.613Z https://research-2ry.pages.dev/Summary/Clinical-Others/Thorax-2010-Hung-Prognostic-factors-of-postrecurrence-survival-in-completely-resected-stage-I-non-small-cell-lung-cancer-with-distant 2026-07-02T09:20:49.618Z https://research-2ry.pages.dev/Summary/Clinical-Respiratory-diseases/CellRepMed-2026-Matralis-An-aerosolized-dual-action-autotaxin-inhibitor-PPARgamma-agonist-for-the-treatment-of-pulmonary-fibrosis 2026-07-02T09:20:49.321Z https://research-2ry.pages.dev/Summary/Clinical-Respiratory-diseases/Chest-1992-VanVyve-Comparison-between-bronchial-and-alveolar-samples-of-bronchoalveolar-lavage-fluid-in-asthma 2026-07-02T09:20:49.324Z https://research-2ry.pages.dev/Summary/Clinical-Respiratory-diseases/EurRespirJ-2004-Holz-Lung-fibroblasts-from-patients-with-emphysema-show-a-reduced-proliferation-rate-in-culture 2026-07-02T09:20:49.322Z https://research-2ry.pages.dev/Summary/Clinical-Respiratory-diseases/Immunohorizons-2026-Hansen-Nasal-humoral-immunity-the-first-line-of-protection-against-respiratory-pathogens 2026-07-02T09:20:49.319Z https://research-2ry.pages.dev/Summary/Clinical-Respiratory-diseases/JCIInsight-2026-Crawford-Mesenchyme-derived-inflammation-during-the-saccular-stage-recruits 2026-07-02T09:20:49.323Z https://research-2ry.pages.dev/Summary/Clinical-Respiratory-diseases/JClinInvest-2026-Rosas-Macropinocytosis-inhibition-attenuates-pro-fibrotic-responses-in-lung-fibroblasts-and-pulmonary-fibrosis-models 2026-07-02T09:20:49.324Z https://research-2ry.pages.dev/Summary/Clinical-Respiratory-diseases/JClinInvest-2026-Velu-Interstitial-lung-disease-and-the-STING-pathway 2026-07-02T09:20:49.323Z https://research-2ry.pages.dev/Summary/Clinical-Respiratory-diseases/LancetRespirMed-2026-Lee-Non-invasive-respiratory-supports-and-criteria-for-intubation-in-randomised-trials-of-acute-hypoxaemic-respiratory 2026-07-02T09:20:49.321Z https://research-2ry.pages.dev/Summary/Clinical-Respiratory-diseases/LungCancer-2019-Fujimoto-Nivolumab-for-advanced-non-small-cell-lung-cancer-patients-with-mild-idiopathic-interstitial-pneumonia-A-multicenter, 2026-07-02T09:20:49.323Z https://research-2ry.pages.dev/Summary/Clinical-Respiratory-diseases/NEnglJMed-2023-Dequin-Hydrocortisone-in-severe-community-acquired-pneumonia 2026-07-02T09:20:49.321Z https://research-2ry.pages.dev/Summary/Clinical-Respiratory-diseases/NEnglJMed-2026-Rosenfield-Ultrasound-facilitated,-catheter-directed-fibrinolysis-for-acute-pulmonary-embolism 2026-07-02T09:20:49.320Z https://research-2ry.pages.dev/Summary/Clinical-Respiratory-diseases/PulmCirc-2016-Chang-Versican-accumulates-in-vascular-lesions-in-pulmonary-arterial-hypertension 2026-07-02T09:20:49.324Z https://research-2ry.pages.dev/Summary/Clinical-Respiratory-diseases/Respiration-2018-Hetzel-Transbronchial-cryobiopsies-for-the-diagnosis-of-diffuse-parenchymal-lung-diseases-expert-statement-from-the-cryobiopsy 2026-07-02T09:20:49.324Z https://research-2ry.pages.dev/Summary/Clinical-Respiratory-diseases/SciTranslMed-2026-Ziehr-Lactate-transport-inhibition-therapeutically-reprograms-fibroblast-metabolism-in-experimental-pulmonary-fibrosis 2026-07-02T09:20:49.319Z https://research-2ry.pages.dev/Summary/Clinical-Respiratory-diseases/Thorax-1997-Jolliet-Nitric-oxide-and-prostacyclin-as-test-agents-of-vasoreactivity-in-severe-precapillary-pulmonary-hypertension-predictive 2026-07-02T09:20:49.320Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/ActaOncol-2019-Bahij-Outcome-of-treatment-in-patients-with-small-cell-lung-cancer-in-poor-performance-status 2026-07-02T09:20:49.399Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/ActaOncol-2020-Noronha-The-role-of-chemotherapy-in-patients-with-small-cell-lung-cancer-and-poor-performance-status 2026-07-02T09:20:49.374Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/AdvRadiatOncol-2023-Doshita-Incidence-and-treatment-outcome-of-radiation-pneumonitis-in-patients-with-limited-stage-small-cell-lung-cancer-treated 2026-07-02T09:20:49.400Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/AmJCancerRes-2015-Yamane-Programmed-cell-death-protein-1-and-programmed-death-ligand-1-are-expressed-on-the-surface-of-some-small-cell-lung 2026-07-02T09:20:49.337Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/AmJClinOncol-1992-Kudoh-Weekly-dose-intensive-chemotherapy-in-patients-with-small-cell-lung-cancer-a-pilot-study 2026-07-02T09:20:49.370Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/AnnCancerResTher-2018-Yamaguchi-Clinical-benefit-of-chemotherapy-for-SCLC-patients-with-extremely-poor-performance-status 2026-07-02T09:20:49.396Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/AnnOncol-1997-Maestu-Pretreatment-prognostic-factors-for-survival-in-small-cell-lung-cancer-a-new-prognostic-index-and-validation-of-three 2026-07-02T09:20:49.379Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/AnnOncol-2002-Hanna-Maintenance-daily-oral-etoposide-versus-no-further-therapy-following-induction-chemotherapy-with-etoposide-plus 2026-07-02T09:20:49.397Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/AnnOncol-2005-Ohe-Phase-I-II-study-of-amrubicin-and-cisplatin-in-previously-untreated-patients-with-extensive-stage-small-cell-lung-cancer 2026-07-02T09:20:49.332Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/AnnOncol-2006-Okamoto-EGFR-mutation-in-gefitinib-responsive-small-cell-lung-cancer 2026-07-02T09:20:49.376Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/AnnOncol-2013-Reck-Ipilimumab-in-combination-with-paclitaxel-and-carboplatin-as-first-line-therapy-in-extensive-disease-small-cell-lung 2026-07-02T09:20:49.328Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/AnnOncol-2019-Tay-Prognostic-value-of-circulating-tumour-cells-in-limited-stage-small-cell-lung-cancer-analysis-of-the-concurrent 2026-07-02T09:20:49.337Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/AnnOncol-2019-Weiss-Myelopreservation-with-the-CDK46-inhibitor-trilaciclib-in-patients-with-small-cell-lung-cancer-receiving-first-line 2026-07-02T09:20:49.398Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/AnnOncol-2020-Mansfield-Safety-and-patient-reported-outcomes-of-atezolizumab,-carboplatin,-and-etoposide-in-extensive-stage-small-cell-lung 2026-07-02T09:20:49.328Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/AnnOncol-2021-Dingemans-Small-cell-lung-cancer-ESMO-clinical-practice-guidelines-for-diagnosis,-treatment-and-follow-up 2026-07-02T09:20:49.339Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/AnnOncol-2021-Spigel-Second-line-nivolumab-in-relapsed-small-cell-lung-cancer-CheckMate-331 2026-07-02T09:20:49.354Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/AnnPalliatMed-2021-Jones-Factors-associated-with-survival-in-small-cell-lung-cancer-an-analysis-of-real-world-national-audit,-chemotherapy-and 2026-07-02T09:20:49.386Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/BMCCancer-2016-Oh-Belotecancisplatin-versus-etoposidecisplatin-in-previously-untreated-patients-with-extensive-stage-small-cell-lung 2026-07-02T09:20:49.374Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/BMCCancer-2022-Asao-A-phase-II-study-of-carboplatin-and-etoposide-plus-durvalumab-for-previously-untreated-extensive-stage-small-cell-lung 2026-07-02T09:20:49.326Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/BiochemBiophysRep-2021-Ohara-SCLC-J1-a-novel-small-cell-lung-cancer-cell-line 2026-07-02T09:20:49.355Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/BrJCancer-1991-Wolf-Analysis-of-prognostic-factors-in-766-patients-with-small-cell-lung-cancer-(SCLC)-the-role-of-sex-as-a-predictor-for 2026-07-02T09:20:49.352Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/BrJCancer-1999-Lassen-Early-death-during-chemotherapy-in-patients-with-small-cell-lung-cancer-derivation-of-a-prognostic-index-for-toxic 2026-07-02T09:20:49.397Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/BrJCancer-2001-Frasci-A-weekly-regimen-of-cisplatin,-paclitaxel-and-topotecan-with-granulocyte-colony-stimulating-factor-support-for-patients 2026-07-02T09:20:49.393Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/BrJCancer-2001-Sambrook-A-national-survey-of-the-chemotherapy-regimens-used-to-treat-small-cell-lung-cancer-(SCLC)-in-the-united-kingdom 2026-07-02T09:20:49.402Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/BrJCancer-2001-Sculier-A-three-arm-phase-III-randomised-trial-assessing,-in-patients-with-extensive-disease-small-cell-lung-cancer, 2026-07-02T09:20:49.385Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/BrJCancer-2007-Okamoto-Randomised-phase-III-trial-of-carboplatin-plus-etoposide-vs-split-doses-of-cisplatin-plus-etoposide-in-elderly-or 2026-07-02T09:20:49.380Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/Cancer-1993-Livingston-Prolonged,-alternating-chemotherapy-for-extensive-small-cell-lung-cancer.-A-southwest-oncology-group-study 2026-07-02T09:20:49.354Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/Cancer-2000-Paesmans-Prognostic-factors-for-patients-with-small-cell-lung-carcinoma-analysis-of-a-series-of-763-patients-included-in-4 2026-07-02T09:20:49.348Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/Cancer-2004-Hainsworth-Weekly-combination-chemotherapy-with-docetaxel-and-gemcitabine-as-first-line-treatment-for-elderly-patients-and 2026-07-02T09:20:49.396Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/Cancer-2009-Foster-Prognostic-factors-differ-by-tumor-stage-for-small-cell-lung-cancer-a-pooled-analysis-of-north-central-cancer-treatment 2026-07-02T09:20:49.380Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/Cancer-2014-Amini-Progress-in-the-management-of-LD-SCLC 2026-07-02T09:20:49.374Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/Cancer-2023-Agarwal-Chemoimmunotherapy-in-patients-with-extensive-stage-small-cell-lung-cancer-and-a-poor-performance-status 2026-07-02T09:20:49.375Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/Cancer-2026-Sethakorn-The-future-promise-of-antibody-drug-conjugates-in-extensive-stage-small-cell-lung-cancer 2026-07-02T09:20:49.350Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CancerCell-2018-Hellmann-Tumor-mutational-burden-and-efficacy-of-nivolumab-monotherapy-and-in-combination-with-ipilimumab-in-small-cell-lung 2026-07-02T09:20:49.391Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CancerCell-2020-Zhang-CDK7-inhibition-potentiates-genome-instability-triggering-anti-tumor-immunity-in-small-cell-lung-cancer 2026-07-02T09:20:49.389Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CancerCell-2021-Chan-Signatures-of-plasticity,-metastasis,-and-immunosuppression-in-an-atlas-of-human-small-cell-lung-cancer 2026-07-02T09:20:49.386Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CancerCell-2021-Frese-Small-cell-lung-cancer-enters-the-era-of-precision-medicine 2026-07-02T09:20:49.331Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CancerCell-2021-Gay-Patterns-of-transcription-factor-programs-and-immune-pathway-activation-define-four-major-subtypes-of-SCLC-with-distinct-therapeutic-vulnerabilities 2026-07-02T09:20:49.373Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CancerCell-2024-Duplaquet-Mammalian-swisnf-complex-activity-regulates-POU2F3-and-constitutes-a-targetable-dependency-in-small-cell-lung-cancer 2026-07-02T09:20:49.353Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CancerCell-2026-Campisi-Vascular-STING-activation-facilitates-NK-cell-anti-tumor-immunity-in-small-cell-lung-cancer 2026-07-02T09:20:49.330Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CancerChemotherPharmacol-2012-Hong-Phase-II-study-of-combined-belotecan-and-cisplatin-as-first-line-chemotherapy-in-patients-with-extensive-disease-of 2026-07-02T09:20:49.327Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CancerChemotherPharmacol-2014-Ikeda-A-phase-II-study-of-amrubicin-and-carboplatin-for-previously-untreated-patients-with-extensive-disease-small-cell-lung 2026-07-02T09:20:49.341Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CancerCommun(Lond)-2026-Hao-Serplulimab-plus-chemotherapy,-with-or-without-HLX04,-versus-chemotherapy-as-first-line-treatment-for-nonsquamous-NSCLC 2026-07-02T09:20:49.385Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CancerDiscov-2018-Yang-Intertumoral-heterogeneity-in-SCLC-is-influenced-by-the-cell-type-of-origin 2026-07-02T09:20:49.387Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CancerDiscov-2019-Hiatt-Delivering-a-STINGing-blow-to-small-cell-lung-cancer-via-synergistic-inhibition-of-DNA-damage-response-and 2026-07-02T09:20:49.336Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CancerDiscov-2019-Sen-Targeting-DNA-damage-response-promotes-antitumor-immunity-through-STING-mediated-T-cell-activation-in-small-cell-lung 2026-07-02T09:20:49.370Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CancerDiscov-2025-Rekhtman-Chromothripsis-mediated-small-cell-lung-carcinoma 2026-07-02T09:20:49.363Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CancerRes-2018-Meder-Combined-VEGF-and-PD-L1-blockade-displays-synergistic-treatment-effects-in-an-autochthonous-mouse-model-of-small-cell 2026-07-02T09:20:49.350Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CancerRes-2021-Schaff-Fragmentation-of-small-cell-lung-cancer-regulatory-states-in-heterotypic-microenvironments 2026-07-02T09:20:49.354Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CancerRes-2021-Zhu-Evasion-of-innate-immunity-contributes-to-small-cell-lung-cancer-progression-and-metastasis 2026-07-02T09:20:49.399Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CancerResTreat-2023-Lee-A-randomized-phase-II-study-of-irinotecan-plus-cisplatin-with-or-without-simvastatin-in-ever-smokers-with-extended 2026-07-02T09:20:49.388Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CancerResTreat-2024-Choi-The-real-world-outcome-of-first-line-atezolizumab-in-extensive-stage-small-cell-lung-cancer-A-multicenter-prospective 2026-07-02T09:20:55.665Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CancerTreatRev-2007-Pijls-Johannesma-Timing-of-chest-radiotherapy-in-patients-with-limited-stage-small-cell-lung-cancer-a-systematic-review-and 2026-07-02T09:20:49.388Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CaseRepOncol-2019-Aida-Small-cell-lung-cancer-treatment-of-newly-diagnosed-patients-with-poor-performance-status 2026-07-02T09:20:49.398Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/Cell-2024-Liu-Proteogenomic-characterization-of-small-cell-lung-cancer-identifies-biological-insights-and-subtype-specific-therapeutic-strategies 2026-07-02T09:20:49.365Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/Cell-2026-Trotta-Excessive-vascular-integrity-restricts-anti-tumor-immunity 2026-07-02T09:20:49.370Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CellRep-2016-Borromeo-ASCL1-and-NEUROD1-reveal-heterogeneity-in-pulmonary-neuroendocrine-tumors-and-regulate-distinct-genetic-programs 2026-07-02T09:20:49.343Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CellRep-2020-Tlemsani-SCLC-CellMiner-A-resource-for-small-cell-lung-cancer-cell-line-genomics-and-pharmacology-based-on-genomic-signatures 2026-07-02T09:20:49.328Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CellRepMed-2026-Wang-Spatial-multi-omics-unveils-the-monoclonal-origin,-neuroendocrine-plasticity,-and-microenvironment-niches-in-combined 2026-07-02T09:20:49.381Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/Chest-1994-Lad-A-prospective-randomized-trial-to-determine-the-benefit-of-surgical-resection-of-residual-disease-following-response-of 2026-07-02T09:20:49.346Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/ClinCancerRes-2000-Eerola-A-high-number-of-tumor-infiltrating-lymphocytes-are-associated-with-a-small-tumor-size,-low-tumor-stage,-and-a 2026-07-02T09:20:49.379Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/ClinCancerRes-2001-Kelly-Cisplatin,-etoposide,-and-paclitaxel-with-granulocyte-colony-stimulating-factor-in-untreated-patients-with 2026-07-02T09:20:49.325Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/ClinCancerRes-2008-Koyama-Reciprocal-CD4+-T-cell-balance-of-effector-CD62Llow-CD4+-and-CD62LhighCD25+-CD4+-regulatory-T-cells-in-small-cell-lung 2026-07-02T09:20:49.402Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/ClinCancerRes-2017-George-Genomic-amplification-of-CD274-(PD-L1)-in-small-cell-lung-cancer 2026-07-02T09:20:49.363Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/ClinCancerRes-2017-Gray-Therapy-of-small-cell-lung-cancer-(SCLC)-with-a-topoisomerase-I-inhibiting-antibody-drug-conjugate-(ADC)-targeting 2026-07-02T09:20:49.344Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/ClinCancerRes-2019-Atrafi-A-phase-I-dose-escalation-study-of-veliparib-combined-with-carboplatin-and-etoposide-in-patients-with-extensive-stage 2026-07-02T09:20:49.349Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/ClinCancerRes-2019-Morgensztern-Efficacy-and-safety-of-rovalpituzumab-tesirine-in-third-line-and-beyond-patients-with-DLL3-expressing, 2026-07-02T09:20:49.372Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/ClinCancerRes-2019-Su-Inferring-the-evolution-and-progression-of-small-cell-lung-cancer-by-single-cell-sequencing-of-circulating-tumor-cells 2026-07-02T09:20:49.352Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/ClinCancerRes-2021-Giffin-AMG-757,-a-half-life-extended,-DLL3-targeted-bispecific-T-cell-engager,-shows-high-potency-and-sensitivity-in 2026-07-02T09:20:49.351Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/ClinLungCancer-2017-Okuma-Comparison-of-amrubicin-and-weekly-CisplatinEtoposideIrinotecan-in-patients-with-relapsed-small-cell-lung-cancer 2026-07-02T09:20:49.347Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/ClinLungCancer-2020-Friedlaender-The-role-of-performance-status-in-small-cell-lung-cancer-in-the-era-of-immune-checkpoint-inhibitors 2026-07-02T09:20:49.347Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/ClinLungCancer-2020-Rittberg-Effect-of-hospitalization-during-first-chemotherapy-and-performance-status-on-small-cell-lung-cancer-outcomes 2026-07-02T09:20:49.340Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/ClinLungCancer-2021-Weiss-Effects-of-trilaciclib-on-chemotherapy-induced-myelosuppression-and-patient-reported-outcomes-in-patients-with 2026-07-02T09:20:49.389Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/ClinOncol(RCollRadiol)-2003-Mackay-A-phase-II-study-of-carboplatin-and-vinorelbine-in-patients-with-poor-prognosis-small-cell-lung-cancer 2026-07-02T09:20:49.369Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CochraneDatabaseSystRev-2013-Pelayo-Chemotherapy-versus-best-supportive-care-for-ED-SCLC 2026-07-02T09:20:49.378Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CritRevOncolHematol-2026-Guan-Overcoming-immunotherapy-resistance-in-extensive-stage-small-cell-lung-cancer-insights-into-mechanisms-and-therapeutic 2026-07-02T09:20:49.385Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/CurrTreatOptionsOncol-2026-Dai-Addressing-unmet-needs-in-the-management-of-small-cell-lung-cancer-treatment-of-brain-metastases,-quality-of-life,-and 2026-07-02T09:20:49.370Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/EurJCancer-2018-Bonanno-The-role-of-immune-microenvironment-in-small-cell-lung-cancer-distribution-of-PD-L1-expression-and-prognostic-role-of 2026-07-02T09:20:49.364Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/EurJCancer-2024-Falchero-Real-life-nationwide-characteristics-and-outcomes-of-small-cell-lung-cancer-over-the-last-20-years-impact-of 2026-07-02T09:20:49.376Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/EurJCardiothoracSurg-1998-Rea-Long-term-results-of-surgery-and-chemotherapy-in-small-cell-lung-cancer 2026-07-02T09:20:49.358Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/EurRespirJ-2007-Sculier-Chemotherapy-improves-low-performance-status-lung-cancer-patients 2026-07-02T09:20:49.375Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/FrontImmunol-2026-Zhang-First-line-serplulimab-plus-chemotherapy-versus-chemotherapy-alone-in-small-cell-lung-cancer-patients-with-brain 2026-07-02T09:20:49.367Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/FrontOncol-2022-Rittberg-Real-world-eligibility-for-platinum-doublet-plus-immune-checkpoint-inhibitors-in-extensive-stage-small-cell-lung-cancer 2026-07-02T09:20:49.383Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/FrontPharmacol-2026-Liu-Cost-effectiveness-of-tarlatamab-versus-chemotherapy-for-patients-with-small-cell-lung-cancer-after-platinum-based 2026-07-02T09:20:49.360Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/IntJCancer-2021-Daniel-Trilaciclib-prior-to-chemotherapy-and-atezolizumab-in-patients-with-newly-diagnosed-extensive-stage-small-cell-lung 2026-07-02T09:20:49.336Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/IntJRadiatOncolBiolPhys-2022-Li-Comprehensive-next-generation-sequencing-reveals-novel-predictive-biomarkers-of-recurrence-and-thoracic-toxicity-risks 2026-07-02T09:20:49.351Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/InvestNewDrugs-2007-Yana-Phase-II-study-of-amrubicin-in-previously-untreated-patients-with-extensive-disease-small-cell-lung-cancer-west-japan 2026-07-02T09:20:49.330Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/InvestNewDrugs-2017-Igawa-Phase-II-study-of-amrubicin-monotherapy-in-elderly-or-poor-risk-patients-with-extensive-disease-of-small-cell-lung 2026-07-02T09:20:49.393Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JAMAOncol-2026-Liu-First-line-serplulimab-in-extensive-stage-small-cell-lung-cancer-secondary-analysis-of-the-ASTRUM-005-phase-3 2026-07-02T09:20:49.356Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JCOGlobOncol-2025-Li-Durvalumab-in-limited-stage-small-cell-lung-cancer-clinical-triumph-and-toward-sustainable-value 2026-07-02T09:20:49.341Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JCardiothoracSurg-2009-Koletsis-Current-role-of-surgery-in-small-cell-lung-carcinoma 2026-07-02T09:20:49.326Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-1985-Friess-Effect-of-initial-resection-of-small-cell-carcinoma-of-the-lung-a-review-of-southwest-oncology-group-study-7628 2026-07-02T09:20:49.353Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-1987-Smith-Carboplatin-(paraplatin;-JM8)-and-etoposide-(VP-16)-as-first-line-combination-therapy-for-small-cell-lung-cancer 2026-07-02T09:20:49.362Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-1988-Shepherd-Adjuvant-chemotherapy-following-surgical-resection-for-small-cell-carcinoma-of-the-lung 2026-07-02T09:20:49.367Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-1990-Jett-Treatment-of-limited-stage-small-cell-lung-cancer-with-cyclophosphamide,-doxorubicin,-and-vincristine-with-or-without 2026-07-02T09:20:49.389Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-1992-Roth-Randomized-study-of-cyclophosphamide,-doxorubicin,-and-vincristine-versus-etoposide-and-cisplatin-versus-alternation-of 2026-07-02T09:20:49.345Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-1992-Warde-Does-thoracic-irradiation-improve-survival-and-local-control-in-limited-stage-small-cell-carcinoma-of-the-lung-A 2026-07-02T09:20:49.361Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-1993-Murray-Importance-of-timing-for-thoracic-irradiation-in-the-combined-modality-treatment-of-limited-stage-small-cell-lung 2026-07-02T09:20:49.333Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-1995-Lassen-Long-term-survival-in-small-cell-lung-cancer-posttreatment-characteristics-in-patients-surviving-5-to-18+-years-an 2026-07-02T09:20:49.335Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-1997-Gregor-Randomized-trial-of-alternating-versus-sequential-radiotherapychemotherapy-in-limited-disease-patients-with-small-cell 2026-07-02T09:20:49.327Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-1998-Westeel-New-combination-of-the-old-drugs-for-elderly-patients-with-small-cell-lung-cancer-a-phase-II-study-of-the-PAVE-regimen 2026-07-02T09:20:49.336Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-1999-Bonner-Phase-III-comparison-of-twice-daily-split-course-irradiation-versus-once-daily-irradiation-for-patients-with-limited 2026-07-02T09:20:49.359Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-1999-Okamoto-Phase-II-study-of-area-under-the-plasma-concentration-versus-time-curve-based-carboplatin-plus-standard-dose 2026-07-02T09:20:49.350Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-1999-vonPawel-Topotecan-versus-cyclophosphamide,-doxorubicin,-and-vincristine-for-the-treatment-of-recurrent-small-cell-lung-cancer 2026-07-02T09:20:49.334Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2001-Schiller-Topotecan-versus-observation-after-cisplatin-plus-etoposide-in-extensive-stage-small-cell-lung-cancer-E7593-a-phase-III 2026-07-02T09:20:49.388Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2004-Neubauer-Results-of-a-phase-II-study-of-weekly-paclitaxel-plus-carboplatin-in-patients-with-extensive-small-cell-lung-cancer 2026-07-02T09:20:49.349Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2006-Cronenberger-Role-of-chemotherapy-(CT)-in-performance-status-3-and-4-small-cell-lung-cancer-(SCLC)-patients 2026-07-02T09:20:49.341Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2006-Eckardt-Open-label,-multicenter,-randomized,-phase-III-study-comparing-oral-topotecancisplatin-versus-etoposidecisplatin-as 2026-07-02T09:20:49.373Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2006-Hanna-Randomized-phase-III-trial-comparing-irinotecancisplatin-with-etoposidecisplatin-in-patients-with-previously-untreated 2026-07-02T09:20:49.333Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2006-OBrien-Phase-III-trial-comparing-supportive-care-alone-with-supportive-care-with-oral-topotecan-in-patients-with-relapsed 2026-07-02T09:20:49.382Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2006-Onoda-Phase-II-trial-of-amrubicin-for-treatment-of-refractory-or-relapsed-small-cell-lung-cancer-thoracic-oncology-research 2026-07-02T09:20:49.373Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2006-Spiro-Early-compared-with-late-radiotherapy-in-combined-modality-treatment-for-limited-disease-small-cell-lung-cancer-a 2026-07-02T09:20:49.367Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2007-Eckardt-Phase-III-study-of-oral-compared-with-intravenous-topotecan-as-second-line-therapy-in-small-cell-lung-cancer 2026-07-02T09:20:49.372Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2008-Hermes-Irinotecan-plus-carboplatin-versus-oral-etoposide-plus-carboplatin-in-extensive-small-cell-lung-cancer-a-randomized 2026-07-02T09:20:49.399Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2008-Inoue-Randomized-phase-II-trial-comparing-amrubicin-with-topotecan-in-patients-with-previously-treated-small-cell-lung-cancer 2026-07-02T09:20:49.334Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2008-Kenmotsu-Clinical-significance-of-chemotherapy-for-small-cell-lung-cancer-(SCLC)-with-ECOG-performance-status-(PS)-3-4 2026-07-02T09:20:49.365Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2009-Horn-Phase-II-study-of-cisplatin-plus-etoposide-and-bevacizumab-for-previously-untreated,-extensive-stage-small-cell-lung 2026-07-02T09:20:49.330Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2009-Lara-Phase-III-trial-of-irinotecancisplatin-compared-with-etoposidecisplatin-in-extensive-stage-small-cell-lung-cancer 2026-07-02T09:20:49.371Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2009-Socinski-Phase-III-study-of-pemetrexed-plus-carboplatin-compared-with-etoposide-plus-carboplatin-in-chemotherapy-naive-patients 2026-07-02T09:20:49.343Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2010-Ettinger-Phase-II-study-of-amrubicin-as-second-line-therapy-in-patients-with-platinum-refractory-small-cell-lung-cancer 2026-07-02T09:20:49.369Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2011-Jotte-Randomized-phase-II-trial-of-single-agent-amrubicin-or-topotecan-as-second-line-treatment-in-patients-with-small-cell 2026-07-02T09:20:49.394Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2012-Rossi-Carboplatin-or-cisplatin-based-chemotherapy-in-first-line-treatment-of-small-cell-lung-cancer-the-COCIS-meta-analysis 2026-07-02T09:20:49.331Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2013-Montella-Evaluation-of-elderly-patients-with-extended-disease-small-cell-lung-cancer 2026-07-02T09:20:49.348Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2014-Satouchi-Phase-III-study-comparing-amrubicin-plus-cisplatin-with-irinotecan-plus-cisplatin-in-the-treatment-of-extensive-disease 2026-07-02T09:20:49.387Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2014-vonPawel-Randomized-phase-III-trial-of-amrubicin-versus-topotecan-as-second-line-treatment-for-patients-with-small-cell-lung 2026-07-02T09:20:49.328Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2015-Leighl-Sunitinib-the-next-advance-in-small-cell-lung-cancer 2026-07-02T09:20:49.400Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2016-Reck-Phase-III-randomized-trial-of-ipilimumab-plus-etoposide-and-platinum-versus-placebo-plus-etoposide-and-platinum-in 2026-07-02T09:20:49.342Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2017-Jalal-Carboplatin-and-etoposide-with-or-without-palifosfamide-in-untreated-extensive-stage-small-cell-lung-cancer-A 2026-07-02T09:20:49.362Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2017-Ott-Pembrolizumab-in-patients-with-extensive-stage-small-cell-lung-cancer-results-from-the-phase-ib-KEYNOTE-028-study 2026-07-02T09:20:49.351Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2017-Tiseo-Italian,-multicenter,-phase-III,-randomized-study-of-cisplatin-plus-etoposide-with-or-without-bevacizumab-as-first-line 2026-07-02T09:20:49.396Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2020-Rudin-Pembrolizumab-or-placebo-plus-etoposide-and-platinum-as-first-line-therapy-for-extensive-stage-small-cell-lung-cancer 2026-07-02T09:20:49.357Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2021-Liu-Updated-overall-survival-and-PD-L1-subgroup-analysis-of-patients-with-extensive-stage-small-cell-lung-cancer-treated 2026-07-02T09:20:49.355Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2021-Owonikoko-Nivolumab-and-ipilimumab-as-maintenance-therapy-in-extensive-disease-small-cell-lung-cancer-CheckMate-451 2026-07-02T09:20:49.365Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2021-Rodriguez-Randomized-phase-III-trial-of-prophylactic-cranial-irradiation-with-or-without-hippocampal-avoidance-for-small-cell 2026-07-02T09:20:49.341Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JClinOncol-2023-Khurshid-Systemic-therapy-for-small-cell-lung-cancer-ASCO-ontario-health-(cancer-care-ontario)-guideline 2026-07-02T09:20:49.364Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JHematolOncol-2019-Tian-Potential-immune-escape-mechanisms-underlying-the-distinct-clinical-outcome-of-immune-checkpoint-blockades-in-small 2026-07-02T09:20:49.350Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JImmunotherCancer-2019-Ricciuti-Use-of-targeted-next-generation-sequencing-to-characterize-tumor-mutational-burden-and-efficacy-of-immune-checkpoint 2026-07-02T09:20:49.338Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JImmunotherCancer-2020-Lai-CDK46-inhibition-enhances-antitumor-efficacy-of-chemotherapy-and-immune-checkpoint-inhibitor-combinations-in 2026-07-02T09:20:49.384Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JNatlCancerInst-2001-Pujol-Etoposide-plus-cisplatin-with-or-without-the-combination-of-4'-epidoxorubicin-plus-cyclophosphamide-in-treatment-of 2026-07-02T09:20:49.335Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JTOClinResRep-2021-Elegbede-A-real-world-evaluation-of-atezolizumab-plus-platinum-etoposide-chemotherapy-in-patients-with-extensive-stage-SCLC-in 2026-07-02T09:20:49.340Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JTOClinResRep-2025-Miyauchi-J-TAIL-2-A-prospective,-observational-study-of-atezolizumab-combined-with-carboplatin-and-etoposide-in-patients-with 2026-07-02T09:20:49.381Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JThoracCardiovascSurg-2005-Tsuchiya-Phase-II-trial-of-postoperative-adjuvant-cisplatin-and-etoposide-in-patients-with-completely-resected-stage-I-IIIa 2026-07-02T09:20:49.373Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JThoracOncol-2007-Shepherd-The-international-association-for-the-study-of-lung-cancer-lung-cancer-staging-project-proposals-regarding-the-clinical 2026-07-02T09:20:49.353Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JThoracOncol-2008-Sculier-The-impact-of-additional-prognostic-factors-on-survival-and-their-relationship-with-the-anatomical-extent-of-disease 2026-07-02T09:20:49.345Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JThoracOncol-2010-Jiang-A-meta-analysis-of-randomized-controlled-trials-comparing-irinotecanplatinum-with-etoposideplatinum-in-patients-with 2026-07-02T09:20:49.379Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JThoracOncol-2010-Lima-Camptothecins-compared-with-etoposide-in-combination-with-platinum-analog-in-extensive-stage-small-cell-lung-cancer 2026-07-02T09:20:49.333Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JThoracOncol-2010-Noguchi-A-retrospective-analysis-of-clinical-outcomes-of-patients-older-than-or-equal-to-80-years-with-small-cell-lung-cancer 2026-07-02T09:20:49.358Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JThoracOncol-2012-Fink-Topotecancisplatin-compared-with-cisplatinetoposide-as-first-line-treatment-for-patients-with-extensive-disease 2026-07-02T09:20:49.332Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JThoracOncol-2012-Owonikoko-A-systematic-analysis-of-efficacy-of-second-line-chemotherapy-in-sensitive-and-refractory-small-cell-lung-cancer 2026-07-02T09:20:49.339Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JThoracOncol-2013-Isobe-Evaluation-of-novel-orthotopic-nude-mouse-models-for-human-small-cell-lung-cancer 2026-07-02T09:20:49.390Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JThoracOncol-2015-Ishii-Significance-of-programmed-cell-death-ligand-1-expression-and-its-association-with-survival-in-patients-with-small-cell 2026-07-02T09:20:49.391Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JThoracOncol-2016-Arriola-Outcome-and-biomarker-analysis-from-a-multicenter-phase-2-study-of-ipilimumab-in-combination-with-carboplatin-and 2026-07-02T09:20:49.360Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JThoracOncol-2018-Araujo-Treatment-of-patients-with-poor-performance-status-(ECOG3-4) 2026-07-02T09:20:49.326Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JThoracOncol-2018-Gadgeel-Phase-II-study-of-maintenance-pembrolizumab-in-patients-with-extensive-stage-small-cell-lung-cancer-(SCLC) 2026-07-02T09:20:49.395Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JThoracOncol-2018-Kim-Association-of-PD-L1-expression-with-tumor-infiltrating-immune-cells-and-mutation-burden-in-high-grade-neuroendocrine 2026-07-02T09:20:49.334Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JThoracOncol-2019-Muppa-Immune-cell-infiltration-may-be-a-key-determinant-of-long-term-survival-in-small-cell-lung-cancer 2026-07-02T09:20:49.390Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JThoracOncol-2019-Park-DNA-damage-response-and-repair-pathway-alteration-and-its-association-with-tumor-mutation-burden-and-platinum-based-chemotherapy-in-SCLC 2026-07-02T09:20:49.377Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JThoracOncol-2019-Ready-Third-line-nivolumab-monotherapy-in-recurrent-SCLC-CheckMate-032 2026-07-02T09:20:49.360Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JThoracOncol-2020-Baine-SCLC-subtypes-defined-by-ASCL1,-NEUROD1,-POU2F3,-and-YAP1-A-comprehensive-immunohistochemical-and-histopathologic 2026-07-02T09:20:49.357Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JThoracOncol-2020-Chung-Pembrolizumab-after-two-or-more-lines-of-previous-therapy-in-patients-with-recurrent-or-metastatic-SCLC-results-from 2026-07-02T09:20:49.359Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JThoracOncol-2020-Ready-Nivolumab-monotherapy-and-nivolumab-plus-ipilimumab-in-recurrent-small-cell-lung-cancer-results-from-the-CheckMate-032 2026-07-02T09:20:49.392Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JThoracOncol-2020-Welsh-Phase-I-trial-of-pembrolizumab-and-radiation-therapy-after-induction-chemotherapy-for-extensive-stage-small-cell-lung 2026-07-02T09:20:49.325Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JThoracOncol-2021-Malhotra-A-phase-1-2-study-of-rovalpituzumab-tesirine-in-combination-with-nivolumab-plus-or-minus-ipilimumab-in-patients-with 2026-07-02T09:20:49.365Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JThoracOncol-2021-Owonikoko-YAP1-expression-in-SCLC-defines-a-distinct-subtype-with-T-cell-inflamed-phenotype 2026-07-02T09:20:49.339Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JThoracOncol-2022-Redin-YES1-is-a-druggable-oncogenic-target-in-SCLC 2026-07-02T09:20:49.390Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JpnJClinOncol-1996-Sakuragi-Retrospective-analysis-of-the-treatment-of-patients-with-small-cell-lung-cancer-showing-poor-performance-status 2026-07-02T09:20:49.343Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JpnJClinOncol-1997-Kawahara-Prognostic-factors-and-prognostic-staging-system-for-small-cell-lung-cancer 2026-07-02T09:20:49.371Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JpnJClinOncol-2014-Harada-A-phase-III-trial-of-irinotecan-plus-amrubicin-supported-with-G-CSF-for-extended-small-cell-lung-cancer 2026-07-02T09:20:49.355Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/JpnJClinOncol-2015-Asao-Phase-II-study-of-amrubicin-at-a-dose-of-45-mgm2-in-patients-with-previously-treated-small-cell-lung-cancer 2026-07-02T09:20:49.359Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/Lancet-1966-Comparetive-trial-of-surgery-and-radiotherapy-for-SCLC 2026-07-02T09:20:49.361Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/Lancet-1996-Girling-Comparison-of-oral-etoposide-and-standard-intravenous-multidrug-chemotherapy-for-small-cell-lung-cancer-a-stopped 2026-07-02T09:20:49.367Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/Lancet-2011-vanMeerbeeck-Small-cell-lung-cancer 2026-07-02T09:20:49.384Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/Lancet-2015-Slotman-Use-of-thoracic-radiotherapy-for-extensive-stage-small-cell-lung-cancer-a-phase-3-randomised-controlled-trial 2026-07-02T09:20:49.368Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/Lancet-2019-Paz-Ares-Durvalumab-plus-platinum-etoposide-versus-platinum-etoposide-in-first-line-treatment-of-extensive-stage-small-cell-lung 2026-07-02T09:20:55.809Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/Lancet-2025-Paz-Ares-Efficacy-and-safety-of-first-line-maintenance-therapy-with-lurbinectedin-plus-atezolizumab-in-extensive-stage 2026-07-02T09:20:49.329Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/LancetOncol-2014-Kubota-Etoposide-and-cisplatin-versus-irinotecan-and-cisplatin-in-patients-with-limited-stage-small-cell-lung-cancer-treated 2026-07-02T09:20:49.343Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/LancetOncol-2016-Antonia-Nivolumab-alone-and-nivolumab-plus-ipilimumab-in-recurrent-small-cell-lung-cancer-(CheckMate-032)-a-multicentre, 2026-07-02T09:20:49.386Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/LancetOncol-2016-Goto-Combined-chemotherapy-with-cisplatin,-etoposide,-and-irinotecan-versus-topotecan-alone-as-second-line-treatment-for 2026-07-02T09:20:49.375Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/LancetOncol-2017-Takahashi-Prophylactic-cranial-irradiation-versus-observation-in-patients-with-extensive-disease-small-cell-lung-cancer-a 2026-07-02T09:20:49.349Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/LancetOncol-2020-Baize-Carboplatin-plus-etoposide-versus-topotecan-as-second-line-treatment-for-patients-with-sensitive-relapsed-SCLC 2026-07-02T09:20:49.347Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/LancetOncol-2020-Trigo-Lurbinectedin-as-second-line-treatment-for-patients-with-small-cell-lung-cancer-a-single-arm,-open-label,-phase-2 2026-07-02T09:20:49.342Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/LancetOncol-2021-Goldman-Durvalumab,-with-or-without-tremelimumab,-plus-platinum-etoposide-versus-platinum-etoposide-alone-in-first-line 2026-07-02T09:20:49.329Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/LancetOncol-2025-Paulson-Safety-and-activity-of-tarlatamab-in-combination-with-a-PD-L1-inhibitor-as-first-line-maintenance-therapy-after 2026-07-02T09:20:49.371Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/LancetRespirMed-2025-Asao-Durvalumab,-carboplatin,-and-etoposide-in-patients-who-are-treatment-naive-with-extensive-stage-small-cell-lung-cancer 2026-07-02T09:20:49.382Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/LancetRespirMed-2025-Reguart-Rethinking-immunotherapy-in-patients-with-SCLC-with-poor-performance-status 2026-07-02T09:20:49.326Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/LungCancer(Auckl)-2016-Minami-Retrospective-analysis-of-outcomes-and-prognostic-factors-of-chemotherapy-for-small-cell-lung-cancer 2026-07-02T09:20:49.393Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/LungCancer-2003-Weinmann-Treatment-of-lung-cancer-in-elderly-part-II-small-cell-lung-cancer 2026-07-02T09:20:49.383Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/LungCancer-2006-Sohn-A-phase-II-trial-of-fractionated-irinotecan-plus-carboplatin-for-previously-untreated-extensive-disease-small-cell-lung 2026-07-02T09:20:49.357Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/LungCancer-2008-Kim-Combination-chemotherapy-with-irinotecan-and-cisplatin-in-elderly-patients-with-extensive-stage-small-cell-lung-cancer 2026-07-02T09:20:49.348Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/LungCancer-2014-Murakami-A-single-arm-confirmatory-study-of-amrubicin-therapy-in-patients-with-refractory-small-cell-lung-cancer-japan-clinical 2026-07-02T09:20:49.394Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/LungCancer-2014-Wakuda-Molecular-profiling-of-small-cell-lung-cancer-in-a-japanese-cohort 2026-07-02T09:20:49.376Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/LungCancer-2017-Tsuruoka-PD-L1-expression-in-neuroendocrine-tumors-of-the-lung 2026-07-02T09:20:49.368Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/LungCancer-2019-Kim-A-phase-II-study-of-pembrolizumab-and-paclitaxel-in-patients-with-relapsed-or-refractory-small-cell-lung-cancer 2026-07-02T09:20:49.346Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/LungCancer-2019-Lattuca-Truc-Trends-in-response-rate-and-survival-in-small-cell-lung-cancer-patients-between-1997-and-2017 2026-07-02T09:20:49.362Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/LungCancer-2020-Subbiah-Antitumor-activity-of-lurbinectedin-in-second-line-small-cell-lung-cancer-patients-who-are-candidates-for-re-challenge 2026-07-02T09:20:49.401Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/LungCancer-2022-Sagie-Real-world-evidence-for-immunotherapy-in-the-first-line-setting-in-small-cell-lung-cancer 2026-07-02T09:20:49.363Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/MedOncol-2005-Han-A-phase-II-study-of-dose-intensified-weekly-concomitant-administration-of-cisplatin-and-irinotecan-in-chemonaive 2026-07-02T09:20:49.355Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/NEnglJMed-1992-Pignon-A-meta-analysis-of-thoracic-radiotherapy-for-small-cell-lung-cancer 2026-07-02T09:20:49.337Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/NEnglJMed-1999-Turrisi-Twice-daily-compared-with-once-daily-thoracic-radiotherapy-in-limited-small-cell-lung-cancer-treated-concurrently-with 2026-07-02T09:20:49.369Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/NEnglJMed-2002-Noda-Irinotecan-plus-cisplatin-compared-with-etoposide-plus-cisplatin-for-extensive-small-cell-lung-cancer 2026-07-02T09:20:49.340Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/NEnglJMed-2007-Slotman-Prophylactic-cranial-irradiation-in-extensive-small-cell-lung-cancer 2026-07-02T09:20:49.329Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/NEnglJMed-2018-Horn-First-line-atezolizumab-plus-chemotherapy-in-extensive-stage-small-cell-lung-cancer 2026-07-02T09:20:49.342Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/NEnglJMed-2024-Cheng-Durvalumab-after-chemoradiotherapy-in-limited-stage-small-cell-lung-cancer 2026-07-02T09:20:49.377Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/NEnglJMed-2025-Mountzios-Tarlatamab-in-small-cell-lung-cancer-after-platinum-based-chemotherapy 2026-07-02T09:20:49.375Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/NatCancer-2020-Simpson-A-biobank-of-small-cell-lung-cancer-CDX-models-elucidates-inter-and-intratumoral-phenotypic-heterogeneity 2026-07-02T09:20:49.369Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/NatCancer-2022-Chemi-CfDNA-methylome-profiling-for-detection-and-subtyping-of-small-cell-lung-cancers 2026-07-02T09:20:49.335Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/NatGenet-2012-Rudin-Comprehensive-genomic-analysis-identifies-SOX2-as-a-frequently-amplified-gene-in-small-cell-lung-cancer 2026-07-02T09:20:49.332Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/NatMed-2017-Carter-Molecular-analysis-of-circulating-tumor-cells-identifies-distinct-copy-number-profiles-in-patients-with-chemosensitive 2026-07-02T09:20:49.368Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/NatMed-2026-Byers-SEZ6-targeting-antibody-drug-conjugate-ABBV-706-in-advanced-small-cell-lung-cancer-and-solid-tumors-a-phase-1-trial 2026-07-02T09:20:49.346Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/NatRevCancer-2019-Rudin-Molecular-subtypes-of-small-cell-lung-cancer-a-synthesis-of-human-and-mouse-model-data 2026-07-02T09:20:49.327Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/NatRevClinOncol-2017-Sabari-Unravelling-the-biology-of-SCLC-implications-for-therapy 2026-07-02T09:20:49.387Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/NatRevClinOncol-2020-Iams-Immunotherapeutic-approaches-for-small-cell-lung-cancer 2026-07-02T09:20:49.362Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/NatRevDisPrimers-2021-Rudin-Small-cell-lung-cancer 2026-07-02T09:20:49.338Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/Nature-2010-Pleasance-A-small-cell-lung-cancer-genome-with-complex-signatures-of-tobacco-exposure 2026-07-02T09:20:49.378Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/Nature-2015-George-Comprehensive-genomic-profiles-of-small-cell-lung-cancer 2026-07-02T09:20:49.378Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/Oncogene-2015-Poirier-DNA-methylation-in-small-cell-lung-cancer-defines-distinct-disease-subtypes-and-correlates-with-high-expression-of-EZH2 2026-07-02T09:20:49.344Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/Oncologist-2026-Sun-Phase-I-study-of-Y101D,-a-bispecific-antibody-targeting-PD-L1-and-TGF-beta-in-patients-with-advanced-solid-tumors 2026-07-02T09:20:49.380Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/Oncology-2005-Frasci-Weekly-dose-dense-cisplatin-epirubicin-paclitaxel-administration-with-granulocyte-colony-stimulating-factor-support 2026-07-02T09:20:49.325Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/Oncology-2018-Igawa-Efficacy-of-platinum-based-chemotherapy-for-relapsed-small-cell-lung-cancer-after-amrubicin-monotherapy-in-elderly 2026-07-02T09:20:49.381Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/SciTranslMed-2015-Saunders-A-DLL3-targeted-antibody-drug-conjugate-eradicates-high-grade-pulmonary-neuroendocrine-tumor-initiating-cells-in-vivo 2026-07-02T09:20:49.384Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/SeminOncol-2014-Pillai-Small-cell-lung-cancer-therapies-and-targets 2026-07-02T09:20:49.391Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/SeminThoracCardiovascSurg-2006-Anraku-Surgery-for-small-cell-lung-cancer 2026-07-02T09:20:49.358Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/SignalTransductTargetTher-2026-Zhao-Sintilimab-plus-concurrent-chemoradiotherapy-for-treatment-of-locally-advanced-small-cell-lung-cancer-(SINCE-01)-a 2026-07-02T09:20:49.356Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/SupportCareCancer-2012-Baldotto-Palliative-care-in-poor-performance-status-small-cell-lung-cancer-patients-is-there-a-mandatory-role-for-chemotherapy 2026-07-02T09:20:49.377Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/ThoracCancer-2018-Igawa-Comparison-of-carboplatin-plus-etoposide-with-amrubicin-monotherapy-for-extensive-disease-small-cell-lung-cancer-in-the 2026-07-02T09:20:49.349Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/ThoracCancer-2023-Mamesaya-Efficacy-and-safety-of-carboplatin-and-etoposide-in-older-extensive-stage-small-cell-lung-cancer-patients-with-a-poor 2026-07-02T09:20:49.356Z https://research-2ry.pages.dev/Summary/Clinical-SCLC/TranslLungCancerRes-2018-Zhang-Small-cell-lung-cancer-tumors-and-preclinical-models-display-heterogeneity-of-neuroendocrine-phenotypes 2026-07-02T09:20:49.339Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/AnnOncol-2013-Park-Prospective-analysis-of-quality-of-life-in-elderly-patients-treated-with-adjuvant-chemotherapy-for-non-small-cell-lung 2026-07-02T09:20:49.408Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/Cancer-1948-Karnofsky-The-use-of-the-nitrogen-mustards-in-the-palliative-treatment-of-carcinoma 2026-07-02T09:20:49.410Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/Cancer-2018-Katakami-Anamorelin-(ONO-7643)-for-the-treatment-of-patients-with-non-small-cell-lung-cancer-and-cachexia-results-from-a 2026-07-02T09:20:49.408Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/CancerControl-2015-Watkins-Transfusion-indications-for-patients-with-cancer 2026-07-02T09:20:49.410Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/CancerRes-2021-Koyanagi-Pronociceptive-roles-of-schwann-cell-derived-galectin-3-in-taxane-induced-peripheral-neuropathy 2026-07-02T09:20:49.404Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/Chest-2013-Brunelli-Physiologic-evaluation-of-the-patient-with-lung-cancer-being-considered-for-resectional-surgery-diagnosis-and 2026-07-02T09:20:49.403Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/ClinCancerRes-2018-Turner-Pembrolizumab-exposure-response-assessments-challenged-by-association-of-cancer-cachexia-and-catabolic-clearance 2026-07-02T09:20:49.405Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/CritCareMed-2012-McCurdy-Oncologic-emergencies 2026-07-02T09:20:49.403Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/Diagnostics-2022-Tanaka-Prognostic-nutritional-index-and-lung-immune-prognostic-index-as-prognostic-predictors-for-combination-therapies-of 2026-07-02T09:20:49.406Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/ESMOOpen-2018-Horinouchi-Oral-rehydration-solution-(OS-1)-as-a-substitute-of-intravenous-hydration-after-cisplatin-administration-in-patients 2026-07-02T09:20:49.410Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/ESMOOpen-2021-Arends-Cancer-cachexia-in-adult-patients-ESMO-clinical-practice-guidelines 2026-07-02T09:20:49.406Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/HematolOncolClinNorthAm-2010-Sun-Optimal-management-of-malignant-epidural-spinal-cord-compression 2026-07-02T09:20:49.411Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/IntJClinOncol-2011-Hahn-A-case-of-acute-aortic-thrombosis-after-cisplatin-based-chemotherapy 2026-07-02T09:20:49.402Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/IntJRadiatOncolBiolPhys-2012-Loblaw-A-2011-updated-systematic-review-and-clinical-practice-guideline-for-the-management-of-malignant-extradural-spinal-cord 2026-07-02T09:20:49.405Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/IntensiveCareMed-2026-Prescott-Surviving-sepsis-campaign-international-guidelines-for-management-of-sepsis-and-septic-shock-2026 2026-07-02T09:20:49.406Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/InternMed-2013-Ito-Acute-aortic-thrombosis-during-cisplatin-based-chemotherapy-for-gastric-cancer 2026-07-02T09:20:49.405Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/JAMA-2013-Smith-Effect-of-duloxetine-on-pain,-function,-and-quality-of-life-among-patients-with-chemotherapy-induced-painful-peripheral 2026-07-02T09:20:49.407Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/JAMAOncol-2020-Blayney-Efficacy-of-plinabulin-vs-pegfilgrastim-for-prevention-of-chemotherapy-induced-neutropenia-in-adults-with-non-small 2026-07-02T09:20:49.403Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/JCachexiaSarcopeniaMuscle-2014-vonHaehling-Prevalence,-incidence-and-clinical-impact-of-cachexia-facts-and-numbers-update-2014 2026-07-02T09:20:49.409Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/JClinOncol-1992-Bach-Metastatic-spinal-cord-compression-secondary-to-lung-cancer 2026-07-02T09:20:49.407Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/JClinOncol-2020-Roeland-Management-of-cancer-cachexia-ASCO-guideline 2026-07-02T09:20:49.412Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/JClinOncol-2020-Scott-Performance-status-in-cancer-not-broken,-but-time-for-an-upgrade 2026-07-02T09:20:49.408Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/JClinOncol-2021-Griggs-Appropriate-systemic-therapy-dosing-for-obese-adult-patients-with-cancer-ASCO-guideline-update 2026-07-02T09:20:49.406Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/JNatlCancerInst-1993-Aaronson-The-EORTC-QLQ-C30-a-quality-of-life-instrument-for-use-in-international-clinical-trials-in-oncology 2026-07-02T09:20:49.409Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/JNatlComprCancNetw-2014-Gajra-Management-of-patients-with-lung-cancer-and-poor-performance-status 2026-07-02T09:20:49.407Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/JPainSymptomManage-2007-Teunissen-Symptom-prevalence-in-patients-with-incurable-cancer-a-systematic-review 2026-07-02T09:20:49.411Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/JThoracOncol-2008-Yu-Superior-vena-cava-syndrome-a-proposed-classification-system-and-algorithm-for-management 2026-07-02T09:20:49.408Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/LancetNeurol-2008-Cole-Metastatic-epidural-spinal-cord-compression 2026-07-02T09:20:49.405Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/MayoClinProc-2010-Pelosof-Paraneoplastic-syndromes-an-approach-to-diagnosis-and-treatment 2026-07-02T09:20:49.403Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/NatRevCancer-2014-Argiles-Cancer-cachexia-Understanding-the-molecular-basis 2026-07-02T09:20:49.411Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/Oncologist-2007-Lenz-Management-and-preparedness-for-infusion-and-hypersensitivity-reactions 2026-07-02T09:20:49.411Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/Oncotarget-2018-Hata-Docetaxel-plus-ramucirumab-with-primary-prophylactic-pegylated-granulocyte-colony-stimulating-factor-for-pretreated 2026-07-02T09:20:49.412Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/SupportCareCancer-2016-Takayama-Anamorelin-(ONO-7643)-in-japanese-patients-with-non-small-cell-lung-cancer-and-cachexia-results-of-a-randomized-phase-2 2026-07-02T09:20:49.410Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/SupportCareCancer-2016-Takayama-Quality-of-life-and-survival-survey-of-cancer-cachexia-in-advanced-non-small-cell-lung-cancer-patients-japan-nutrition 2026-07-02T09:20:49.404Z https://research-2ry.pages.dev/Summary/Clinical-Supportive-care/TranslLungCancerRes-2026-Lin-International-consensus-on-severe-lung-cancer-the-second-edition 2026-07-02T09:20:49.407Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/AmJClinOncol-2002-Koizumi-Chemotherapy-for-advanced-thymic-carcinoma-clinical-response-to-cisplatin,-doxorubicin,-vincristine,-and 2026-07-02T09:20:49.820Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/AnnOncol-2015-Hirai-A-multicenter-phase-II-study-of-carboplatin-and-paclitaxel-for-advanced-thymic-carcinoma-WJOG4207L 2026-07-02T09:20:49.834Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/AnnOncol-2015-Serpico-Available-evidence-and-new-biological-perspectives-on-medical-treatment-of-advanced-thymic-epithelial-tumors 2026-07-02T09:20:49.833Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/AnnOncol-2024-Proto-Efficacy-and-safety-of-ramucirumab-plus-carboplatin-and-paclitaxel-in-untreated-metastatic-thymic-carcinoma-RELEVENT 2026-07-02T09:20:49.837Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/AnnThoracSurg-2003-Kondo-Therapy-for-thymic-epithelial-tumors-a-clinical-study-of-1,320-patients-from-japan 2026-07-02T09:20:49.833Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/AnnThoracSurg-2006-Detterbeck-Clinical-value-of-the-WHO-classification-system-of-thymoma 2026-07-02T09:20:49.824Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/AnnThoracSurg-2013-Weksler-Thymic-carcinoma-A-multivariate-analysis-of-factors-predictive-of-survival-in-290-patients 2026-07-02T09:20:49.833Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/AnnuRevImmunol-2008-Rodewald-Thymus-organogenesis 2026-07-02T09:20:55.925Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/AnticancerRes-2014-Hirai-Results-of-S-1-based-chemotherapy-for-platinum-(and-antrathycline)-refractory-advanced-thymic-carcinoma 2026-07-02T09:20:49.826Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/BrJCancer-2009-Kunitoh-A-phase-II-trial-of-dose-dense-chemotherapy-in-patients-with-disseminated-thymoma-report-of-a-japan-clinical-oncology 2026-07-02T09:20:49.834Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/BrJCancer-2010-Kunitoh-A-phase-II-trial-of-dose-dense-chemotherapy,-followed-by-surgical-resection-andor-thoracic-radiotherapy,-in-locally 2026-07-02T09:20:49.832Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/BrJCancer-2022-Bocchialini-Tumour-immune-microenvironment-in-resected-thymic-carcinomas-as-a-predictor-of-clinical-outcome 2026-07-02T09:20:49.826Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/Cancer-1981-Masaoka-Follow-up-study-of-thymomas-with-special-reference-to-their-clinical-stages 2026-07-02T09:20:49.832Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/Cancer-2002-Okumura-The-world-health-organization-histologic-classification-system-reflects-the-oncologic-behavior-of-thymoma-a-clinical 2026-07-02T09:20:49.826Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/Cancer-2003-Takeda-Primary-germ-cell-tumors-in-the-mediastinum-a-50-year-experience-at-a-single-japanese-institution 2026-07-02T09:20:49.830Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/Cancer-2015-Omasa-Postoperative-radiotherapy-is-effective-for-thymic-carcinoma-but-not-for-thymoma-in-stage-II-and-III-thymic-epithelial 2026-07-02T09:20:49.837Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/CancerCell-2018-Radovich-The-integrated-genomic-landscape-of-thymic-epithelial-tumors 2026-07-02T09:20:49.820Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/CancerChemotherPharmacol-2012-Palmieri-Imatinib-Thymic-carcinoma 2026-07-02T09:20:49.828Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/CancerMed-2020-Okuma-Phase-II-trial-of-S-1-treatment-as-palliative-intent-chemotherapy-for-previously-treated-advanced-thymic-carcinoma 2026-07-02T09:20:49.832Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/CancerRes-2017-Conforti-Therapeutic-effects-of-XPO1-inhibition-in-thymic-epithelial-tumors 2026-07-02T09:20:49.819Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/Cancers-2021-Kaira-Perspective-of-immune-checkpoint-inhibitors-in-thymic-carcinoma 2026-07-02T09:20:49.840Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/Cancers-2024-Rajan-Immunotherapy-for-thymomas-and-thymic-carcinomas-Current-status-and-future-directions 2026-07-02T09:20:49.828Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/Carcinogenesis-2017-Saito-The-genomic-and-epigenomic-landscape-in-thymic-carcinoma 2026-07-02T09:20:49.831Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/CellRepMed-2021-He-Molecular-predictors-of-response-to-pembrolizumab-in-thymic-carcinoma 2026-07-02T09:20:49.836Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/Chest-2005-Duwe-Tumors-of-the-mediastinum 2026-07-02T09:20:49.838Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/ClinCancerRes-2009-Girard-Comprehensive-genomic-analysis-reveals-clinically-relevant-molecular-distinctions-between-thymic-carcinomas-and-thymomas 2026-07-02T09:20:49.819Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/ClinCancerRes-2016-Yokoyama-Prognostic-value-of-programmed-death-ligand-1-and-programmed-death-1-expression-in-thymic-carcinoma 2026-07-02T09:20:49.840Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/ClinCancerRes-2017-Lee-Genomic-analysis-of-thymic-epithelial-tumors-identifies-novel-subtypes-associated-with-distinct-clinical-features 2026-07-02T09:20:49.839Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/ClinCancerRes-2019-Kim-The-first-week-proliferative-response-of-peripheral-blood-PD-1+cd8+-T-cells-predicts-the-response-to-anti-PD-1-therapy 2026-07-02T09:20:49.821Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/ClinLungCancer-2023-Asao-Study-design-and-rationale-for-marble-study-A-phase-II-trial-of-atezolizumab-(MPDL3280A)-plus-carboplatin-and 2026-07-02T09:20:49.834Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/ClinLungCancer-2024-Ardeshir-Larijani-Trop-2-expression-and-its-impact-on-survival-in-thymic-epithelial-tumors-brief-report 2026-07-02T09:20:49.823Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/ESMOOpen-2023-Girard-Efficacy-and-safety-of-nivolumab-for-patients-with-pre-treated-type-B3-thymoma-and-thymic-carcinoma-results-from-the 2026-07-02T09:20:49.831Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/ESMORareCancers-2025-Imbimbo-Thymic-epithelial-tumors-What's-newa-and-what's-next 2026-07-02T09:20:49.822Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/EurJCancer-2008-deJong-Thymic-epithelial-tumours-a-population-based-study-of-the-incidence,-diagnostic-procedures-and-therapy 2026-07-02T09:20:49.834Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/EurJCancer-2019-Katsuya-Single-arm,-multicentre,-phase-II-trial-of-nivolumab-for-unresectable-or-recurrent-thymic-carcinoma-PRIMER-study 2026-07-02T09:20:49.838Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/EurJCardiothoracSurg-2002-Rios-Prognostic-factors-in-thymic-epithelial-neoplasms 2026-07-02T09:20:49.836Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/ExpertRevAnticancerTher-2025-Masui-An-update-on-the-therapeutic-options-for-metastatic-thymomas-and-thymic-carcinomas 2026-07-02T09:20:49.841Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/FrontImmunol-2024-Perrino-Autoimmunity-in-thymic-epithelial-tumors-a-not-yet-clarified-pathologic-paradigm-associated-with-several-unmet-clinical 2026-07-02T09:20:49.817Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/FrontOncol-2022-Katsuya-Comprehensive-biomarker-analysis-from-phase-II-study-of-nivolumab-in-patients-with-thymic-carcinoma 2026-07-02T09:20:49.830Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/Histopathology-2014-Strobel-Corticomedullary-differentiation-and-maturational-arrest-in-thymomas 2026-07-02T09:20:49.822Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/IntJCancer-2003-Engels-Malignant-thymoma-in-the-united-states-demographic-patterns-in-incidence-and-associations-with-subsequent-malignancies 2026-07-02T09:20:49.840Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/JClinOncol-2002-Bokemeyer-Extragonadal-germ-cell-tumors-of-the-mediastinum-and-retroperitoneum-results-from-an-international-analysis 2026-07-02T09:20:49.839Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/JClinOncol-2011-Kelly-Thymic-malignancies-from-clinical-management-to-targeted-therapies 2026-07-02T09:20:49.824Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/JClinOncol-2011-Lemma-Phase-II-study-of-carboplatin-and-paclitaxel-in-advanced-thymoma-and-thymic-carcinoma 2026-07-02T09:20:49.818Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/JClinOncol-2019-Cho-Pembrolizumab-for-patients-with-refractory-or-relapsed-thymic-epithelial-tumor-an-open-label-phase-II-trial 2026-07-02T09:20:49.826Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/JImmunotherCancer-2019-Rajan-Efficacy-and-tolerability-of-anti-programmed-death-ligand-1-(PD-L1)-antibody-(avelumab)-treatment-in-advanced-thymoma 2026-07-02T09:20:49.838Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/JNatlComprCancNetw-2025-Riely-Thymomas-and-thymic-carcinomas,-version-2.2025,-NCCN-clinical-practice-guidelines-in-oncology 2026-07-02T09:20:49.818Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/JThoracCardiovascSurg-2009-Huang-Comparison-of-patterns-of-relapse-in-thymic-carcinoma-and-thymoma 2026-07-02T09:20:49.829Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/JThoracCardiovascSurg-2015-Ahmad-Thymic-carcinoma-outcomes-and-prognosis-Results-of-an-international-analysis 2026-07-02T09:20:49.840Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/JThoracDis-2018-Napieralska-Primary-mediastinal-seminoma 2026-07-02T09:20:49.821Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/JThoracOncol-2009-Falkson-The-management-of-thymoma-a-systematic-review-and-practice-guideline 2026-07-02T09:20:49.838Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/JThoracOncol-2010-Masaoka-Staging-system-of-thymoma 2026-07-02T09:20:55.981Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/JThoracOncol-2011-Agatsuma-Combination-chemotherapy-with-doxorubicin,-vincristine,-cyclophosphamide,-and-platinum-compounds-for-advanced-thymic 2026-07-02T09:20:49.825Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/JThoracOncol-2011-Kaira-Expression-of-excision-repair-cross-complementation-group-1,-breast-cancer-susceptibility-1,-and-beta-III-tubulin-in 2026-07-02T09:20:49.811Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/JThoracOncol-2014-Inoue-Phase-II-study-of-amrubicin-combined-with-carboplatin-for-thymic-carcinoma-and-invasive-thymoma-north-japan-lung-cancer 2026-07-02T09:20:49.836Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/JThoracOncol-2014-Marx-ITMIG-consensus-statement-on-the-use-of-the-WHO-histological-classification-of-thymoma-and-thymic-carcinoma-refined 2026-07-02T09:20:49.828Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/JThoracOncol-2014-Weksler-Alterations-of-the-immune-system-in-thymic-malignancies 2026-07-02T09:20:49.835Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/JThoracOncol-2015-Moreira-Massively-parallel-sequencing-identifies-recurrent-mutations-in-TP53-in-thymic-carcinoma-associated-with-poor-prognosis 2026-07-02T09:20:49.824Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/JThoracOncol-2015-Padda-Diffuse-high-intensity-PD-L1-staining-in-thymic-epithelial-tumors 2026-07-02T09:20:49.839Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/JThoracOncol-2015-Weis-The-impact-of-thymoma-histotype-on-prognosis-in-a-worldwide-database 2026-07-02T09:20:49.827Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/JThoracOncol-2021-Giaccone-Durable-response-in-patients-with-thymic-carcinoma-treated-with-pembrolizumab-after-prolonged-follow-up 2026-07-02T09:20:49.831Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/JThoracOncol-2021-Rajan-Immunotherapy-for-thymic-cancers-A-convoluted-path-toward-a-cherished-goal 2026-07-02T09:20:49.827Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/JThoracOncol-2021-Yamada-A-tuft-cell-like-signature-is-highly-prevalent-in-thymic-squamous-cell-carcinoma-and-delineates-new-molecular-subsets 2026-07-02T09:20:49.823Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/JThoracOncol-2022-Marx-The-2021-WHO-classification-of-tumors-of-the-thymus-and-mediastinum-what-is-new-in-thymic-epithelial,-germ-cell,-and 2026-07-02T09:20:49.837Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/JThoracOncol-2023-Ruffini-The-international-association-for-the-study-of-lung-cancer-thymic-epithelial-tumors-staging-project-proposal-for-a 2026-07-02T09:20:49.830Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/JpnJClinOncol-2004-Sakurai-Management-of-primary-malignant-germ-cell-tumor-of-the-mediastinum 2026-07-02T09:20:49.820Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/JpnJClinOncol-2011-Otani-Burden-on-oncologists-when-communicating-the-discontinuation-of-anticancer-treatment 2026-07-02T09:20:49.823Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/LancetOncol-2015-Thomas-Sunitinib-in-patients-with-chemotherapy-refractory-thymoma-and-thymic-carcinoma-an-open-label-phase-2-trial 2026-07-02T09:20:49.812Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/LancetOncol-2018-Giaccone-Pembrolizumab-in-patients-with-thymic-carcinoma-a-single-arm,-single-centre,-phase-2-study 2026-07-02T09:20:49.832Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/LancetOncol-2020-Sato-Lenvatinib-in-patients-with-advanced-or-metastatic-thymic-carcinoma-(REMORA)-a-multicentre,-phase-2-trial 2026-07-02T09:20:49.825Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/LancetOncol-2022-Conforti-Avelumab-plus-axitinib-in-unresectable-or-metastatic-type-B3-thymomas-and-thymic-carcinomas-(CAVEATT)-a-single-arm, 2026-07-02T09:20:49.839Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/LancetOncol-2025-Shukuya-Activity-and-safety-of-atezolizumab-plus-carboplatin-and-paclitaxel-in-patients-with-advanced-or-recurrent-thymic 2026-07-02T09:20:49.812Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/LungCancer-2008-Srirajaskanthan-A-review-of-thymic-tumours 2026-07-02T09:20:49.840Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/LungCancer-2008-Yoh-Mutational-status-of-EGFR-and-KIT-in-thymoma-and-thymic-carcinoma 2026-07-02T09:20:49.833Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/LungCancer-2011-Okuma-Cisplatin-and-irinotecan-combination-chemotherapy-for-advanced-thymic-carcinoma-evaluation-of-efficacy-and-toxicity 2026-07-02T09:20:49.821Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/LungCancer-2012-Abramyuk-Quantitative-modifications-of-TNM-staging,-clinical-staging-and-therapeutic-intent-by-FDG-PETCT-in-patients-with-non 2026-07-02T09:20:49.831Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/LungCancer-2014-Shitara-Genetic-profiling-of-thymic-carcinoma-using-targeted-next-generation-sequencing 2026-07-02T09:20:49.835Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/LungCancer-2015-Katsuya-Immunohistochemical-status-of-PD-L1-in-thymoma-and-thymic-carcinoma 2026-07-02T09:20:49.825Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/LungCancer-2016-Asao-Medical-treatment-involving-investigational-drugs-and-genetic-profile-of-thymic-carcinoma 2026-07-02T09:20:49.820Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/LungCancer-2023-Yeung-High-levels-of-expression-of-Trop-2-in-thymic-epithelial-tumors 2026-07-02T09:20:49.811Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/Med-2025-Mohrmann-Genomic-landscape-and-molecularly-informed-therapy-in-thymic-carcinoma-and-other-advanced-thymic-epithelial-tumors 2026-07-02T09:20:49.828Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/MedOncol-2014-Syrios-Advances-in-thymic-carcinoma-diagnosis-and-treatment-a-review-of-literature 2026-07-02T09:20:49.823Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/NEnglJMed-2004-Strobel-Thymic-carcinoma-with-overexpression-of-mutated-KIT-and-the-response-to-imatinib 2026-07-02T09:20:49.812Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/NatCommun-2020-Alvarez-Quilon-Endogenous-topoisomerase-II-mediated-DNA-breaks-drive-thymic-cancer-predisposition-linked-to-ATM-deficiency 2026-07-02T09:20:49.822Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/NatCommun-2022-Xin-The-immune-landscape-of-human-thymic-epithelial-tumors 2026-07-02T09:20:49.829Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/NatCommun-2022-Yasumizu-Myasthenia-gravis-specific-aberrant-neuromuscular-gene-expression-by-medullary-thymic-epithelial-cells-in-thymoma 2026-07-02T09:20:49.822Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/NatGenet-2014-Petrini-A-specific-missense-mutation-in-GTF2I-occurs-at-high-frequency-in-thymic-epithelial-tumors 2026-07-02T09:20:49.835Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/Oncologist-2018-Ko-Prognostic-factors-and-efficacy-of-first-line-chemotherapy-in-patients-with-advanced-thymic-carcinoma-A-retrospective 2026-07-02T09:20:49.812Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/Oncologist-2020-Tateishi-Clinical-outcomes-of-second-line-chemotherapy-in-patients-with-previously-treated-advanced-thymic-carcinoma-A 2026-07-02T09:20:49.841Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/Oncologist-2024-Nabel-Single-cell-sequencing-illuminates-thymic-development-an-updated-framework-for-understanding-thymic-epithelial-tumors 2026-07-02T09:20:49.829Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/PLoSONE-2019-Hsu-Trends-in-the-incidence-of-thymoma,-thymic-carcinoma,-and-thymic-neuroendocrine-tumor-in-the-United-States 2026-07-02T09:20:49.817Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/SciRep-2014-Wang-Mutations-of-epigenetic-regulatory-genes-are-common-in-thymic-carcinomas 2026-07-02T09:20:49.831Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/SeminDiagnPathol-2022-Prays-Molecular-landscape-of-thymic-epithelial-tumors 2026-07-02T09:20:49.832Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/SeminImmunol-2023-Li-Thymus-aging-and-immune-reconstitution,-progresses-and-challenges 2026-07-02T09:20:49.835Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/ThoracSurgClin-2019-Thapa-The-role-of-the-thymus-in-the-immune-response 2026-07-02T09:20:49.818Z https://research-2ry.pages.dev/Summary/Clinical-Thymic/TrendsCancer-2023-Caruso-Thymic-expression-of-immune-checkpoint-molecules-and-their-implication-for-response-to-immunotherapies 2026-07-02T09:20:56.033Z https://research-2ry.pages.dev/Summary/Clinical-irAE/AnnInternMed-2018-Abdel-Wahab-Use-of-immune-checkpoint-inhibitors-in-the-treatment-of-patients-with-cancer-and-preexisting-autoimmune-disease 2026-07-02T09:20:49.631Z https://research-2ry.pages.dev/Summary/Clinical-irAE/AnnOncol-2015-Naidoo-Toxicities-of-the-anti-PD-1-and-anti-PD-L1-immune-checkpoint-antibodies 2026-07-02T09:20:49.643Z https://research-2ry.pages.dev/Summary/Clinical-irAE/AnnOncol-2017-Menzies-Anti-PD-1-therapy-in-patients-with-advanced-melanoma-and-preexisting-autoimmune-disorders-or-major-toxicity-with 2026-07-02T09:20:49.626Z https://research-2ry.pages.dev/Summary/Clinical-irAE/AnnRheumDis-2021-Kostine-EULAR-points-to-consider-for-the-diagnosis-and-management-of-rheumatic-immune-related-adverse-events-due-to-cancer 2026-07-02T09:20:49.632Z https://research-2ry.pages.dev/Summary/Clinical-irAE/ArthritisRheumatol-2019-Tison-Safety-and-efficacy-of-immune-checkpoint-inhibitors-in-patients-with-cancer-and-preexisting-autoimmune-disease-A 2026-07-02T09:20:49.644Z https://research-2ry.pages.dev/Summary/Clinical-irAE/AutoimmunRev-2017-Giat-Cancer-and-autoimmune-diseases 2026-07-02T09:20:49.638Z https://research-2ry.pages.dev/Summary/Clinical-irAE/Blood-2012-Kochenderfer-B-cell-depletion-and-remissions-of-malignancy-along-with-cytokine-associated-toxicity-in-a-clinical-trial-of-anti-CD19 2026-07-02T09:20:49.640Z https://research-2ry.pages.dev/Summary/Clinical-irAE/Blood-2016-Brudno-Toxicities-of-chimeric-antigen-receptor-T-cells-recognition-and-management 2026-07-02T09:20:49.643Z https://research-2ry.pages.dev/Summary/Clinical-irAE/CancerDiscov-2016-Teachey-Identification-of-predictive-biomarkers-for-cytokine-release-syndrome-after-chimeric-antigen-receptor-T-cell-therapy 2026-07-02T09:20:49.626Z https://research-2ry.pages.dev/Summary/Clinical-irAE/CancerImmunolImmunother-2019-Kehl-Pre-existing-autoimmune-disease-and-the-risk-of-immune-related-adverse-events-among-patients-receiving-checkpoint 2026-07-02T09:20:49.644Z https://research-2ry.pages.dev/Summary/Clinical-irAE/CancerImmunolRes-2013-Maus-T-cells-expressing-chimeric-antigen-receptors-can-cause-anaphylaxis-in-humans 2026-07-02T09:20:49.623Z https://research-2ry.pages.dev/Summary/Clinical-irAE/CancerImmunolRes-2018-Santini-Safety-and-efficacy-of-re-treating-with-immunotherapy-after-immune-related-adverse-events-in-patients-with-NSCLC 2026-07-02T09:20:49.640Z https://research-2ry.pages.dev/Summary/Clinical-irAE/CancerSci-2021-Sata-Treatment-and-relapse-of-interstitial-lung-disease-in-nivolumab-treated-patients-with-non-small-cell-lung-cancer 2026-07-02T09:20:49.637Z https://research-2ry.pages.dev/Summary/Clinical-irAE/CaseRepOncol-2019-Cybulska-Stopa-Immune-related-pancytopenia-induced-by-anti-PD-1-therapy-interrupt-or-continue-treatment-the-role-of 2026-07-02T09:20:49.641Z https://research-2ry.pages.dev/Summary/Clinical-irAE/CaseRepOncol-2019-Ni-AIHA-and-pancytopenia-as-complications-of-pembrolizumab-therapy-for-metastatic-melanoma-a-case-report 2026-07-02T09:20:49.642Z https://research-2ry.pages.dev/Summary/Clinical-irAE/ClinLungCancer-2023-Aung-Safety-and-efficacy-of-immune-checkpoint-inhibitors-in-cancer-patients-and-preexisting-autoimmune-disease-A-systematic 2026-07-02T09:20:49.639Z https://research-2ry.pages.dev/Summary/Clinical-irAE/ESMOOpen-2017-Varricchi-Cardiotoxicity-of-immune-checkpoint-inhibitors 2026-07-02T09:20:49.634Z https://research-2ry.pages.dev/Summary/Clinical-irAE/ESMOOpen-2023-Castelo-Branco-Challenges-and-knowledge-gaps-with-immune-checkpoint-inhibitors-monotherapy-in-the-management-of-patients-with 2026-07-02T09:20:49.628Z https://research-2ry.pages.dev/Summary/Clinical-irAE/EurJCancer-2016-Michot-Immune-related-adverse-events-with-immune-checkpoint-blockade-a-comprehensive-review 2026-07-02T09:20:49.637Z https://research-2ry.pages.dev/Summary/Clinical-irAE/EurJCancer-2017-Michot-Immune-related-bone-marrow-failure-following-anti-PD1-therapy 2026-07-02T09:20:49.642Z https://research-2ry.pages.dev/Summary/Clinical-irAE/EurJCancer-2018-Danlos-Safety-and-efficacy-of-anti-programmed-death-1-antibodies-in-patients-with-cancer-and-pre-existing-autoimmune-or 2026-07-02T09:20:49.634Z https://research-2ry.pages.dev/Summary/Clinical-irAE/EurJCancer-2020-Michot-The-2016-2019-ImmunoTOX-assessment-board-report-of-collaborative-management-of-immune-related-adverse-events,-an 2026-07-02T09:20:49.630Z https://research-2ry.pages.dev/Summary/Clinical-irAE/EurJCancer-2021-Fujimoto-Pembrolizumab-plus-chemotherapy-induced-pneumonitis-in-chemo-naive-patients-with-non-squamous-non-small-cell-lung 2026-07-02T09:20:49.633Z https://research-2ry.pages.dev/Summary/Clinical-irAE/EurJCancer-2022-Panhaleux-Anti-programmed-death-ligand-1-immunotherapies-in-cancer-patients-with-pre-existing-systemic-sclerosis-A-postmarketed 2026-07-02T09:20:49.633Z https://research-2ry.pages.dev/Summary/Clinical-irAE/FrontOncol-2020-Hommes-Biomarkers-of-checkpoint-inhibitor-induced-immune-related-adverse-events-A-comprehensive-review 2026-07-02T09:20:49.632Z https://research-2ry.pages.dev/Summary/Clinical-irAE/InvestNewDrugs-2018-Fujii-Incidence-of-immune-related-adverse-events-and-its-association-with-treatment-outcomes-the-MD-anderson-cancer-center 2026-07-02T09:20:49.630Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JAMAOncol-2016-Friedman-Treatment-of-the-immune-related-adverse-effects-of-immune-checkpoint-inhibitors-A-review 2026-07-02T09:20:49.631Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JAMAOncol-2016-Johnson-Ipilimumab-therapy-in-patients-with-advanced-melanoma-and-preexisting-autoimmune-disorders 2026-07-02T09:20:49.631Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JAMAOncol-2016-Khan-Prevalence-of-autoimmune-disease-among-patients-with-lung-cancer-implications-for-immunotherapy-treatment-options 2026-07-02T09:20:49.629Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JAMAOncol-2018-Haratani-Association-of-immune-related-adverse-events-with-nivolumab-efficacy-in-non-small-cell-lung-cancer 2026-07-02T09:20:49.641Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JAMAOncol-2019-Toi-Profiling-preexisting-antibodies-in-patients-treated-with-anti-PD-1-therapy-for-advanced-non-small-cell-lung-cancer 2026-07-02T09:20:49.636Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JAMAOncol-2020-Shankar-Multisystem-immune-related-adverse-events-associated-with-immune-checkpoint-inhibitors-for-treatment-of-non-small-cell 2026-07-02T09:20:49.638Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JAMAOncol-2021-Nebhan-Clinical-outcomes-and-toxic-effects-of-single-agent-immune-checkpoint-inhibitors-among-patients-aged-80-years-or-older 2026-07-02T09:20:49.642Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JAMAOncol-2022-Han-Association-between-toxic-effects-and-survival-in-patients-with-cancer-and-autoimmune-disease-treated-with-checkpoint-inhibitor-immunotherapy 2026-07-02T09:20:49.639Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JAMAOncol-2023-Socinski-Association-of-immune-related-adverse-events-with-efficacy-of-atezolizumab-in-patients-with-non-small-cell-lung-cancer 2026-07-02T09:20:49.626Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JCOOncolPract-2021-Stock-Martineau-Challenges-of-immunotherapy-in-stage-IV-non-small-cell-lung-cancer 2026-07-02T09:20:49.641Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JClinInvest-2019-Suresh-The-alveolar-immune-cell-landscape-is-dysregulated-in-checkpoint-inhibitor-pneumonitis 2026-07-02T09:20:49.631Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JClinOncol-2012-Weber-Management-of-immune-related-adverse-events-and-kinetics-of-response-with-ipilimumab 2026-07-02T09:20:49.623Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JClinOncol-2015-Chiou-Pseudoprogression-and-immune-related-response-in-solid-tumors 2026-07-02T09:20:49.624Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JClinOncol-2018-Leonardi-Safety-of-PD-1-pathway-inhibitors-among-patients-with-NSCLC-and-preexisting-autoimmune-disease 2026-07-02T09:20:49.633Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JClinOncol-2020-Abu-Sbeih-Immune-checkpoint-inhibitor-therapy-in-patients-with-preexisting-inflammatory-bowel-disease 2026-07-02T09:20:49.625Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JCrohnsColitis-2017-Coutzac-Colon-immune-related-adverse-events-anti-CTLA-4-and-anti-PD-1-blockade-induce-distinct-immunopathological-entities 2026-07-02T09:20:49.640Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JDtschDermatolGes-2011-Kahler-Treatment-and-side-effect-management-of-CTLA-4-antibody-therapy-in-metastatic-melanoma 2026-07-02T09:20:49.623Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JImmunotherCancer-2019-Xing-Incidence-rates-of-immune-related-adverse-events-and-their-correlation-with-response-in-advanced-solid-tumours-treated 2026-07-02T09:20:49.624Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JImmunotherCancer-2020-Bender-Increased-rates-of-immunosuppressive-treatment-and-hospitalization-after-checkpoint-inhibitor-therapy-in-cancer 2026-07-02T09:20:49.628Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JImmunotherCancer-2020-Boland-Immunotherapy-to-treat-malignancy-in-patients-with-pre-existing-autoimmunity 2026-07-02T09:20:49.625Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JImmunotherCancer-2020-Martinez-Safety-and-efficacy-of-immune-checkpoint-inhibitors-in-advanced-urological-cancers-with-pre-existing-autoimmune 2026-07-02T09:20:49.635Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JImmunotherCancer-2021-Brahmer-Society-for-immunotherapy-of-cancer-(SITC)-clinical-practice-guideline-on-immune-checkpoint-inhibitor-related-adverse 2026-07-02T09:20:49.634Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JImmunotherCancer-2021-Brown-Combination-anti-PD1-and-ipilimumab-therapy-in-patients-with-advanced-melanoma-and-pre-existing-autoimmune-disorders 2026-07-02T09:20:49.639Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JImmunotherCancer-2021-Halle-Immune-checkpoint-inhibitors-in-patients-with-pre-existing-psoriasis-Safety-and-efficacy 2026-07-02T09:20:56.093Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JImmunotherCancer-2022-Govindan-Society-for-immunotherapy-of-cancer-(SITC)-clinical-practice-guideline-on-immunotherapy-for-the-treatment-of-lung 2026-07-02T09:20:49.627Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JImmunotherCancer-2023-Naidoo-SITC-consensus-definitions-for-immune-checkpoint-inhibitor-associated-immune-related-adverse-events-(irAEs)-terminology 2026-07-02T09:20:49.630Z https://research-2ry.pages.dev/Summary/Clinical-irAE/JNephrol-2015-Cosmai-Renal-toxicity-of-anticancer-agents-targeting-HER2-and-EGFR 2026-07-02T09:20:49.643Z https://research-2ry.pages.dev/Summary/Clinical-irAE/LancetOncol-2021-Zhou-Treatment-related-adverse-events-of-PD-1-and-PD-L1-inhibitor-based-combination-therapies-in-clinical-trials-a 2026-07-02T09:20:49.644Z https://research-2ry.pages.dev/Summary/Clinical-irAE/LungCancer-2018-Khan-How-does-autoimmune-disease-impact-treatment-and-outcomes-among-patients-with-lung-cancer-A-national-SEER-Medicare-analysis 2026-07-02T09:20:49.632Z https://research-2ry.pages.dev/Summary/Clinical-irAE/LungCancer-2018-Tokumo-Nivolumab-induced-severe-pancytopenia-in-a-patient-with-lung-adenocarcinoma 2026-07-02T09:20:49.624Z https://research-2ry.pages.dev/Summary/Clinical-irAE/LungCancer-2019-Yoneshima-Safety-and-efficacy-of-PD-1-inhibitors-in-non-small-cell-lung-cancer-patients-positive-for-antinuclear-antibodies 2026-07-02T09:20:49.635Z https://research-2ry.pages.dev/Summary/Clinical-irAE/LungCancer-2024-Asao-Risk-and-survival-of-patients-with-non-small-cell-lung-cancer-and-pre-existing-autoimmune-disorders-receiving-immune 2026-07-02T09:20:49.628Z https://research-2ry.pages.dev/Summary/Clinical-irAE/MolTher-2010-Morgan-Case-report-of-a-serious-adverse-event-following-the-administration-of-T-cells-transduced-with-a-chimeric-antigen 2026-07-02T09:20:49.627Z https://research-2ry.pages.dev/Summary/Clinical-irAE/NEnglJMed-2006-Suntharalingam-Cytokine-storm-in-a-phase-1-trial-of-the-anti-CD28-monoclonal-antibody-TGN1412 2026-07-02T09:20:49.634Z https://research-2ry.pages.dev/Summary/Clinical-irAE/NEnglJMed-2016-Johnson-Fulminant-myocarditis-with-combination-immune-checkpoint-blockade 2026-07-02T09:20:49.629Z https://research-2ry.pages.dev/Summary/Clinical-irAE/NEnglJMed-2018-Postow-Immune-related-adverse-events-associated-with-immune-checkpoint-blockade 2026-07-02T09:20:49.629Z https://research-2ry.pages.dev/Summary/Clinical-irAE/NatRevCancer-2026-Schneider-Microbiota-and-immune-related-adverse-events-in-cancer-immunotherapy 2026-07-02T09:20:49.636Z https://research-2ry.pages.dev/Summary/Clinical-irAE/NatRevClinOncol-2020-Edfahani-Moving-towards-personalized-treatments-of-immune-related-adverse-events 2026-07-02T09:20:49.635Z https://research-2ry.pages.dev/Summary/Clinical-irAE/NatRevRheumatol-2022-Tison-Immune-checkpoint-inhibitor-use-in-patients-with-cancer-and-pre-existing-autoimmune-diseases 2026-07-02T09:20:49.637Z https://research-2ry.pages.dev/Summary/Clinical-irAE/Oncologist-2019-Cortellini-Clinical-outcomes-of-patients-with-advanced-cancer-and-pre-existing-autoimmune-diseases-treated-with-anti-programmed 2026-07-02T09:20:49.636Z https://research-2ry.pages.dev/_Index 2026-07-02T09:20:46.467Z https://research-2ry.pages.dev/_Recent-summary-list 2026-07-02T09:20:46.467Z https://research-2ry.pages.dev/_Resummary-list 2026-07-02T09:20:46.459Z https://research-2ry.pages.dev/ 2026-07-02T09:20:46.126Z